<SEC-DOCUMENT>0001129928-21-000013.txt : 20210305
<SEC-HEADER>0001129928-21-000013.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210305150355
ACCESSION NUMBER:		0001129928-21-000013
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210305
DATE AS OF CHANGE:		20210305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		21718126

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf-20201231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb,d:d25010cc8f2d484d8b4b3c9949ddb687--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:oncyf="http://www.oncolyticsbiotech.com/20201231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>oncyf-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xLTEtMS0xLTA_7b90dd63-d16a-40ef-8795-aa204f246f41">ONCOLYTICS BIOTECH INC</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8yLTEtMS0xLTA_c72cc472-8e1d-4e8d-8431-b32f29881b2d">0001129928</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8zLTEtMS0xLTA_16dde344-46df-4871-a923-8a9d9a835622">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF80LTEtMS0xLTA_138b1a64-f61e-41db-8210-6debb132b2a6">Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF81LTEtMS0xLTA_0aa9acd9-dcc3-429f-86ef-e872f142fff5">20-F</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF82LTEtMS0xLTA_f2dbb72e-9c3f-4b45-ba05-118b4957396b">12/31/2020</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF83LTEtMS0xLTA_dca360cf-e793-42a5-b9ae-66ff06e4a521">2020</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF84LTEtMS0xLTA_83e799bc-9302-4bc6-acd8-a0f93705b6d6">FY</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF85LTEtMS0xLTA_61e28688-3889-4e4a-abff-6ff810a06569">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMS0yLTEtMS0w_1b4fa9be-edc7-431c-a1a2-6de0af6b0c75">46,166,980</ix:nonFraction><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMi0xLTEtMS0w_903e5243-605a-4749-8c53-5273877baf01">false</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMy0xLTEtMS0w_08550afd-28ba-439c-8ed0-7d8f3015639c">false</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNS0xLTEtMS0w_a65158a2-4336-4a96-8ee5-6a6349a629d7">No</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNi0xLTEtMS0w_40179f7f-8fea-48c1-b89c-5002d04436e3">No</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNy0xLTEtMS0w_556f2a03-0068-41cf-8b12-ca33263e138b">Yes</ix:nonNumeric><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt:booleantrue" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xOC0xLTEtMS00MDI1_8f4b2ad4-c40d-483f-9006-891dc89773c0">TRUE</ix:nonNumeric><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjEvZnJhZzozYmEyNzNmN2Q0NDA0MWQ3YWQ1NWEzYjk1OTBmMGRhMS90YWJsZTpkNDhlMTU0ZGQ0OTc0OWYwOTc2MDFlZWVjYTJjZmE2Ny90YWJsZXJhbmdlOmQ0OGUxNTRkZDQ5NzQ5ZjA5NzYwMWVlZWNhMmNmYTY3XzItMS0xLTEtMA_f7e1050e-d5da-4b3b-90be-566665b866f9"></ix:nonFraction><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjEvZnJhZzozYmEyNzNmN2Q0NDA0MWQ3YWQ1NWEzYjk1OTBmMGRhMS90YWJsZTpkNDhlMTU0ZGQ0OTc0OWYwOTc2MDFlZWVjYTJjZmE2Ny90YWJsZXJhbmdlOmQ0OGUxNTRkZDQ5NzQ5ZjA5NzYwMWVlZWNhMmNmYTY3XzItMi0xLTEtMA_c97862c6-4e03-4c8f-8275-baf511609e5b"></ix:nonFraction><ix:nonNumeric contextRef="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927" name="oncyf:SharePurchaseAgreementConsecutiveTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362">P5D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i24bbb67471bf4b8a92598ca24be99b9c_D20180522-20180522" decimals="INF" name="oncyf:StockholdersEquityNoteStockSplitConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjkvZnJhZzplNTIzMTI1ODkwMDE0ODRjYTAzMTgzNDYzMTEzOGRjMi90YWJsZToyNzZmMGY2ODY1ZDc0M2RkYjA1MGU4OWEyODNlOTcxNy90YWJsZXJhbmdlOjI3NmYwZjY4NjVkNzQzZGRiMDUwZTg5YTI4M2U5NzE3XzEtMS0xLTEtMA_1b11f56f-d74c-481d-89ab-a97c4b003f9b">0.105263157894737</ix:nonFraction><ix:nonNumeric contextRef="i1a6ff11f5e994a3ba6d29746ff0a9970_D20200101-20201231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1Mg_cd3e7b72-8b81-4fad-847f-5db8340cf26d">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE0NTA_028b8dc4-7e4a-4f5f-b344-5ed3a29ae30d">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4Mjk_c9939d36-c1bf-4c0e-9451-a1e30a1ffc57">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="oncyf-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i15a34dc52087401598ad74c4d7ac44b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>oncyf:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i32c78d9692194534851ffc8c75765b43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6d2dc50163e54e6db20f3ccf3ba816f0_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id935cd2438124cedb738b9f24443737b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6435e19e015d4b808b125677fa352829_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60063ff60dff4605b4e8b5483faadde5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906da6928e2f4d77ba1644f365f7df40_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e26aa497764738a8d24ee240e72834_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i094c62fa747f4899aeca008f52c1fa6b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa6d8dd8f6146b78474b69d14555dcc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709c9ca13b8045cd8feecfcbfced3580_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb8127fce9e04a639cbec7243495cd9f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id770e57addee4de3aced4720a0bad691_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b8081505894c88a322be3d879c0edb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150aa4258e9c4a31b2082f36f70929ac_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d71b0468ef40768a5f915151140251_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21916c58eb054ab08a45ae978142cd8f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962cc14c35434620bd55808cd2ba8d73_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f0a2ff107346a1969c67caf312a512_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7a8f3213d645b8a8fa1b6364129806_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25846079a5ed4549a9e8ad780e2b2d07_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486bc14f55c74a9d826bd06a228146ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab548591894744e4b55cfc4ab2de9220_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf74771c263472a9fbac91516305b93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1683597bdf444baa0a2c591f2efc8c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae50a49b8984e75aee582dcff0d7703_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a319f8e847b4b4bb642fd9d86aa5225_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a43f0a866349d8bc5f0b63f8d0e784_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562af6df16fd49e5b90954aeea2d4aea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b9cc93c17f4804b0117d1b5087e203_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3a4fc591144d32b93f7d833c2d6c8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf2ec1b8b034942a3533ec514919b05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76695d2971ca43c4829d183db3ebe53d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914f2dfba8874652a9bc67c5190a974e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie624bde674254422be5db7d03183d08e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146d8b2a85a9470192da0785eb8a6240_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c164267fc04f55a74c61c77cf6e840_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6090088661d04f81ad4934969e730d18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc3c9e5c988498783bbc9fa6d366285_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c0248efb984ca8b2400ce4a3fa18cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4f5982efe94fd9bfde6746d570342d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7eb63a1dc564425a34c178e971918c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53aacee4c85d4d55b6cf4d4273d55c08_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23b49ebdb2744409fa1b9c0240e0941_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0091234801409c93750ab9a547e561_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591759eeeca54189b9eeaf5b33f1ebf0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aec3edd676f499ab586efe1570a2ae3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iacdf4b3e43034c8187484f366189cec0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4fe19e601e24c888cb45375f76fb410_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d52a25ccdf40d1a3e77fa4d8cedd50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>oncyf:plan</xbrli:measure></xbrli:unit><xbrli:context id="ib06e365abc0d41b58a7b3cdfa48a3679_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6986d4b1f04f6a904bdd51c5d79c18_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c148463e6434c3aaafd2ff899545a17_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa4f6a1ffb546c5a334dd8511ac2d42_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4655f1fa7ede498fae573a51a97ed506_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56533e258a8349e2b1036c892d892ccf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cea8db44544431e891019dff150dd98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee202aacf30f4366b9853640242782a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257b3f18166343278211f238c2dd1391_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a7de3dc38546928f9df260409a9610_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i975b34c09afa4efca073be66a065bf73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c222353eac842659f464fd34266ded9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268d98dd221747dd8a4a11bc620dd8f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie83afaabad954ec4895f2c369a9d6f75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99ca2509feb4a0ea2f8357c20cae1ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3cd77a1b7d43c5a6cd445b718cdf8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71bcd083c6824318a0e66fc53b430792_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b6f7f3189d49abb49de0e01b7e44ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f6d1b20ef4741adb4cf59f9baae80d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f34c507c5a459a8a88148e94bf32e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0cebabc5f343b080b31d7829dc92c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af37e2b626f4990a2de0594206009fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95589ae338604bb095806c15a829cbe2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5608138db81c4378b9e3057d7fe8a191_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f507765d834457c84f195dc7edc1f22_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd208fddb4e4c54a4009d5ed906ab60_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib110db811cd046fbac2029260a02467b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1656f7c240ef4a678ed77b1775d078d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd46cf77bd84410f9d1ab54ec16f5575_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b47ea4e17640a387dc2928c713393c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a02a4f770f476189f841381bc8b9d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c686540959c4e5c86fbde52e38211d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f643d6a99d44ee996c4b204e5c8cef1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4736152495f44911a78b2700c5477e6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ba725d95a6450888552f6a4b9c7cda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca8fc2742454766b4a9bee74b6996c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e12d3e53584943aba148ce1dd9619c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fe6774bf5c4a27849fb882fbafeedf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2870641ce4c84e3b8447a0c27f0e300d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic591edc2e85b4d218e8613fe7eab62f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d577f40a6943b58f48867c0d5abfc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14cbb33f0a794897ae108913ed8cf4f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27cde419036d4d169847c09cbecf4717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie74dd4d434d245e2a524758edc8a73b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2fdee1c89e4724bc66d086bb390c86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32873cbf8ad4247a3aa058d3a8c0f0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e06eabd4bba416db2a6ea0aae6fdcf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9345d7396c654329be1b09069b9f5e75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125186a4e4e54e67bb5d103d16aec302_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic411ea96f38e4c2a8f99ab7b026cebf3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6977c19ac3804e89bd0cdabd80283dd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee20efa67c54f03b5de8025f70b242c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="renewal"><xbrli:measure>oncyf:renewal</xbrli:measure></xbrli:unit><xbrli:context id="ide6d8e3c655c4d70ab1c6f8d0cc12aed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0538bd9470324b8389be50058e5cf219_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1546a2edd29843b68c4ba7b149c00e10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2a68a929fc4eb59d764ac865a75d38_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-17</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47b4b76e637454fa2794190496a94ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7073102f39754418a48b29815277781f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>oncyf:year</xbrli:measure></xbrli:unit><xbrli:context id="idded585e6408411a94c46d5d947389d3_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f79d8de4290471c8bd4630bf062b395_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2ce693bb1e4e538d5f9509be7279ff_D20180101-20180521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3cc312234b04ffe88d045cec709e645_I20180521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9699ac58b344404a871327fc97617f6_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1b8fc753754267b5ee38bbe8188c69_D20180523-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-23</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia523aae440294924869d91f14d20ba80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ce7a75633844d5a5c8538827785c0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e853028eaf4f4687a1425b818892a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20080a94d52341bf8043af636627ec2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50194a1104f0447dbe8bdab6b84fb381_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86af6651ee84454ba8d1a822e9eb52bf_I20160225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971a344a7f6e456094ca126adf0186ff_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if769c8e2f8534ccc947473705accee72_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-05</xbrli:startDate><xbrli:endDate>2018-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bfe04f75e74d34a9bcbec045406bbb_I20180605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7797595a0e345bd82875cde18a102f6_I20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-27</xbrli:startDate><xbrli:endDate>2018-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cec20e510e74bd3b6a829215e7e1186_I20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida04d93b266c4c888708cd83f197cba6_D20180927-20180927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-27</xbrli:startDate><xbrli:endDate>2018-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694e083ddd244a1590868a988368affb_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c90e3a44c2a4d788944653b7f87451b_D20181024-20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-24</xbrli:startDate><xbrli:endDate>2018-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562f369a1b84407798feac1b05faee8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d73158ebeb4204a27888336398e6ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b7d32d88cd49f39016f010737d5836_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id181bdb06f844a62bdf467f41ba1dd43_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170cc49c63b04227a02de91e6163db24_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862c5b4961c74a48a39f058918e7d03e_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc96efef1fbb4efcb5325460bb72a700_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47812f018f2f4cef9ae9380e51b482b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15e7713f103e4177900f7c2683516777_I20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9fe4ea63e045e096465e2bfb11ba95_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7326a67f5024a94b5c25675622288c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363f02f84b6946e8a01f345e20f5224d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef329fa905d4c3185e2177c3e6dee42_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65287d01f32c419ba89f7f594cd47caf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24bbb67471bf4b8a92598ca24be99b9c_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ef05068a8440d6a4ba5000646081ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib21db9d5af5b44628e536172b106e636_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93af58043e324a92a840919953931d39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d6c1efdf1b45f6902ca44f7d279adc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48739a7cd7d84144a5f4e605f94af42e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4c186a1a8848be9fc5a892d41b0be2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1865037223514d83939793fbf4bc69ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib597056817fd4c54bf70bc918648c2e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d5b6c5f2e84005a152b1904fe0c190_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8643920cc194ebb907287f7a4b18747_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58518506fee64ab482067aea42680848_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36557f93937d4dfb8b9c2f7b122eec39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0895434d6a7f4a60aa00d05659a746fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f893a9adab4729a2352e2afd1e63c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e98e8622faf479ca1780f0865b894c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f71c7cf6714950bc9da0b9936fb3bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b192cb3fe24ee0bb059e2280534d09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc681ffda9640f2a837978353fda2e8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6ff11f5e994a3ba6d29746ff0a9970_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc04adeb60ac4cd197686969029179ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c471998cb54e5198f60c7e8a879104_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a75edaede244932b30bf68f09001b73_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda3a9497dd94381bf80f0a2b9616cad_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5661766048540b6a4217ef7021adea7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be04968d7ac45418925f2727fd67f7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff34051430c94f87baaf766281ba7412_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2899ca476be7407391ff311c63456837_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bdbb4f6a5e46ceb26e20c137bccd91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fe69759d8547afa04be2fd7beb55b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0330059b7334744a4426087fd12ceff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd64c7e97d84e4588d426a71091008b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf7891a1e984661bf760a99c195c570_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ad307898ce427b8790187e5e3b200c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d89438e9834962b588ec713f9cd690_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3f0138f46c4695ad37fbc8f2fdd536_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf141931e3d34eaa866f4acef645b42c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed0ad348c7d44b8a47c4217a6d28e36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a469cc0b8945629f3b38ad881e0e5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09469d6bdcf47b6bcfcf25aee7cb4b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ac27a554b240599f9bd777a1fc6041_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca105778fa3488ab4fcac5815684208_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eca0e1194124e76a337dbb158229685_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b678dac805480d81678cec8ff97f34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a1e703d63441b4bd16a9d814bd0759_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60114d1ecfaa437a904d6c5f10744623_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060c05e904e543c0b502d08304c1d52c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0824dc040346089bbc41d9b1bc5c4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e526825a3a4c41ad8c2653148296cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7656abe4911c4cfdb005eaabc3cad80c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0965b8657ffb499a9cb5db812656c63f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id63c5c00c60c4df1a2140b12e0626f97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23653b0174744934a761bcc2fb2c6c28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157e9a3c5d344966b0455389eb83448b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa85527afb2a4cf99bce5e48d4143c65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10628d338fe649f8be7f5a4c729aff30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e7b2e1b5084522b265069419c11268_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a4b9c9d6c38474ebcd1343720d274a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6adeb07951ec41eb8fba6df6d47342b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0637845ec63458e85e2cbae28f8f5d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c77b28bdcf1403cb5d35cd988bdcfe7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ad5f87e7304d85bd63633afc56fe8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871337f4238f4abd9e90092d1f02384e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iababe61944e54b2c9ceccc57bf2faecf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie482d3a1b82148c1bd56712a715af083_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7801864cfd79494a9a797845cc05d6ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab3c42e6c6fd41feb4b54f0b9082e910_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79faad7289cd45f58106ae2fdd652ec1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e6aac06972419c9ec828611697e6f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8378abfb369e439497cb8d7d53a35bf7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if898df29e89b4ec3a60df1b042af3863_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5cacf4383b8479f8cf65a36c967cae1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9020465658f74f4fbde6469e191a8c40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a02e778e8c84e928734637cf208bd4f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf277f3b07e54dbb8e328eacdafdddbd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4063dfdc87384c3e85d8174c150d31b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931661a623914b388fdfa5f4e409ccaf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0bf7d64d344c48bd924d075e96c40f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658b28d872bd41568deaa26495694e07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878f5c4c5d6f4d41947cf6fb9d21cfdf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1ca5e55ba34078871b684db87e823e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15589c7e1a2b491aa913407d6863f338_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16bc392d6f74d4dbbf71003e9881f32_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a004d3e9c7446896d6d5d1956caf96_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcb30c64a054057ae8268e11a956cf5_I20200612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b52d8638644519af44304507a14d80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269daa67eeae4597bc0a7db7539e1081_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c5734d8c674bc1ad227ce90090ae8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ic994dbffe9564855820d86ebe9bc1885_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieacddbbb17314a6bbe19b73efcd83368_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b307c503b264545a9529c655c522919_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61dbf81b2c67488eabed83aa307e45c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia846c8c806434b23ad5a6d843024e310_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640ad69a2bed48779ac6bb4eb9764cd1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137e70b443b146e3bd028f654a8470d4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1dda167e3394214b8a7f2f4ef0d20bb_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For fiscal year ended</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2020</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>For the transition period from ____ to ____</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Date of event requiring this shell company report:</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: 001-38512</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Province of Alberta, Canada</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kirk Look</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite 210, 1167 Kensington Crescent, N.W. Calgary, Alberta, T2N 1X7</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tel: (403) 670-7377</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-mail: info@oncolytics.ca</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:29.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares, no par value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONCY</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: 46,166,980 common shares as at December&#160;31, 2020</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;U.S. GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Financial Reporting Standards as issued&#160;&#160;by the International Accounting Standards Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_16">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_19">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_22">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_25">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_25">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_28">&#160;Item 4A.    Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_28">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_31">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_31">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_34">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_34">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_37">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_37">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_40">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_40">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_43">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_43">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_46">&#160;Item 10.&#160;&#160;&#160; Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_46">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_49">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_49">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_52">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_52">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_58">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_58">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_61">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_61">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_64">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_64">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_67">&#160;Item 16.     [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_67">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_70">&#160;Item 16A. &#160;Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_70">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_73">&#160;Item 16B.&#160;&#160; Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_73">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_76">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_76">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_79">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_79">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_82">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_82">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_85">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_85">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_88">&#160;Item 16G.&#160; Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_88">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_91">&#160;Item 16H.   Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_91">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_97">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_97">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_100">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_100">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_103">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_103">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_106">&#160;Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_106">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_109">&#160;Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id25010cc8f2d484d8b4b3c9949ddb687_109">F1 - F31</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this annual report on Form 20-F to the terms &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;the Company&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;We do not assume responsibility for the accuracy and completeness of these statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This list is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements.&#160;Additional discussion of the risks summarized below and other risks that we face, can be found under &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; and should be carefully considered, together with other information in this annual report on Form 20-F and our other filings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to all of our products, including pelareorep, being in the research and development stage and requiring further development and testing before they can be marketed commercially;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks inherent in pharmaceutical research and development;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to timing and possible delays in our clinical trials;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to develop our products for use in combination with third-party drugs, including immune checkpoint inhibitors;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding our estimated market opportunities;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our operations being adversely impacted by the COVID-19 pandemic;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to toxicity, undesirable side effects and adverse safety events;  </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our lack of operating revenues and history of losses;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to obtain additional financing to fund future research and development of our products and to meet ongoing capital requirements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate fluctuations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our pharmaceutical products being subject to intense regulatory approval processes in the United States and other foreign jurisdictions;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to being subject to government manufacturing and testing regulations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to some of our clinical trials being conducted in countries outside of the United States;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our reliance on patents and proprietary rights to protect our technology;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to development in patent law;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the extremely competitive biotechnology industry and if our competitors develop and market products that are more effective, our business could be adversely impacted;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to potential products liability claims;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to future legal proceedings and any finding of liability or damages;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our new products not being accepted by the medical community or consumers;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our technologies becoming obsolete;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our dependence on third-party relationships for research, clinical trials, manufacturing, raw materials and other third-party arrangements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our license, development, supply and distribution agreement (the &#8220;Licensing Agreement&#8221;) with Adlai Nortye Biopharma Co. Ltd. (&#8220;Adlai&#8221;);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to negative developments in the field of immuno-oncology;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to potential increases in the cost of director and officer liability insurance;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our dependence on key employees and collaborators;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to Barbados law, including those relating to the enforcement of judgments obtained in Canada or the United States;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the effect of changes in the law on our corporate structure;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to data privacy laws;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our information technology systems and security breaches;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our compliance with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sarbanes-Oxley Act of 2002, as amended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. civil liabilities may not be enforceable against us, or certain of our directors or officers named in this Form 20-F; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our status as a foreign private issuer;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk related to&#160;possible &#8220;passive foreign investment company&#8221; status; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our common shares, such as volatility of market price, potential dilution and no cash dividend in the foreseeable future. &#160;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">[RESERVED] </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this Annual Report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results or cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome.&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or we may abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of our clinical trials may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply, storage, distribution or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size and nature of the subject population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proximity of subjects to clinical sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The eligibility criteria for the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design of the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing clinical trials; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 30, 2018, the federal Right to Try Act was signed into law. The law, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates available to eligible patients as a result of the Right to Try Act, new and emerging legislation regarding expanded access to unapproved drugs could negatively impact enrollment in our clinical trials and our business in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In several of our current and planned studies, pelareorep is being or will be administered in combination with immune checkpoint inhibitors (ICIs), a class of drugs intended to stop tumor cells from interfering with the ability of the patient&#8217;s immune system to attack their tumor. We have entered into agreements with Pfizer and Roche to supply their ICIs, avelumab and atezolizumab, respectively, for use in our ongoing and upcoming Oncolytics-sponsored studies. Specifically, avelumab is being used in our currently enrolling Phase 2 study in breast cancer (BRACELET study), and atezolizumab is being used in our ongoing window-of-opportunity study in breast cancer (AWARE study) and will be used in our ongoing upcoming Phase 1/2 study in gastrointestinal cancer (GOBLET study). In addition, other ICIs are being used in combination with pelareorep in ongoing investigator-sponsored studies including retifanlimab (Incyte) in a Phase 2 study in breast cancer (IRENE study) and nivolumab (BMS) in a Phase 1 study in myeloma.  Additionally, we may enter into future agreements for the supply ICIs for use in connection with the development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to develop pelareorep for use in combination with ICIs depends on our ability to access ICIs for use in our clinical trials on commercially reasonable terms.  We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all.  Any failure to maintain or enter into new successful commercial relationships or the expense of purchasing checkpoint blockade therapies in the market may delay our development timelines, increase our costs, and jeopardize our ability to develop pelareorep as a commercially viable therapy.  If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any current or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing appropriate ICIs. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of an alternative appropriate ICI or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, the development of pelareorep for use in combination with ICIs may present challenges that are not faced for single agent product candidates. Developments related to the other product may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our product development strategy, including determining indications on which to focus in preclinical or clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, the acceptance of such data by the medical community and patient access, product pricing and reimbursement, any limitations on populations and indications in approved product labeling, as well as the approval of new or competing medicines. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). COVID-19 has had a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets. In March 2020, we transitioned our workforce to a remote working arrangement to protect the health and safety of our employees and in accordance with enhanced health and safety protocols consistent with guidelines issued by local health authorities. Clinical trial activities, including patient enrollment and site activation, were not materially delayed due to COVID-19. To date, COVID-19 has not had a material impact on our financial condition, liquidity or longer-term strategic development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may cause more significant disruptions to our business and greater impacts to our results of operations will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak (including future potential waves or cycles), travel restrictions and social distancing, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the COVID-19 pandemic worsens or continues for a prolonged period of time, particularly in regions where we or our collaborators and suppliers do business, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical research and other business activities, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption to and delays in preclinical research activities due to an extended closure or reduced capacity of lab facilities; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling patients in our ongoing and planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients discontinuing their treatment or follow-up visits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in supply, logistics or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical research, initiate or complete our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers and strategic partners; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in resources that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, restrictions on travel, or prolonged stay-at-home or similar working arrangements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approvals from regulatory authorities to initiate our planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and incur unexpected costs, or require us to discontinue clinical trials altogether; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators (including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to our strategic partners&#8217; operations, which could delay the development of our product candidates in certain geographical regions and thereby affect the timing of development and commercial milestone payments and royalties on potential future product sales we may receive; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to recruit preclinical research, clinical, regulatory and other professional staff on the timeframe required to support our research and development programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 could result in the continued significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. Such financial market volatility may continue and the value of our common shares may be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the effects of COVID-19 on our business. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To date, pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with pelareorep as it continues through its clinical development, including when co-administered with approved products. As with many pharmaceutical and biological products, treatment with our product candidate may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release, and may exacerbate known adverse events associated with co-administered approved products. If our product candidates or similar products or product candidate under development by third parties demonstrate unacceptable adverse events, or unacceptably exacerbate adverse events associated with co-administered approved products, we may be required to halt or delay further clinical development of our product candidate. The FDA, the EMA or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate for any or all targeted indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidate to understand its side effect profiles, both for our planned clinical trials and upon any commercialization. Inadequate training in recognizing or managing the potential side effects of our product candidate could result in adverse effects to patients, including death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if our product candidate receives marketing approval, and we or others later identify undesirable side effects caused or exacerbated by such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reputations may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2020, we had an accumulated deficit of $367.1 million and we incurred net losses of $22.5 million, $33.1 million and $17.0 million for the years ended December&#160;31, 2020, 2019, and 2018, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. We anticipate that we will continue to incur significant losses during 2021 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash and cash equivalents of $31.2 million. Working capital was approximately $31.6 million.&#160;We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore we are exposed to foreign currency exchange rate fluctuations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the U.S. dollar, the Euro and the British pound (&#8220;GBP&#8221;).&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party credit risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain third-party reimbursement for the cost of our product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have conducted, and may in the future choose to conduct, clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deem clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any clinical trials we may conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and proprietary rights to protect our technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">know-how, the value of our technology and products could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patented technology, we rely upon unpatented proprietary technology, processes and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants and third parties as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developments in patent law could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, authorities in the United States, the European Union and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Also, case law may have a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">substantial impact on the way patents are prosecuted, examined and litigated. This also affects the scope of protection that is available in a specific jurisdiction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developments of patent law in other jurisdictions may impact our business. For example, it is currently not clear what impact the planned introduction of the Unified Patent Court in the European Union will have. Patents that are valid and enforceable under the current system may be considered invalid and/or unenforceable under the new system. Also patents may be invalidated not just in one single jurisdiction, but across all countries of the European Union in one single trial. Also the effect the impending withdrawal of the United Kingdom from the European Union ("Brexit") has on the patent system, in particular in connection with aforementioned Unified Patent Court, bears certain risks and uncertainties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology industry is extremely competitive and if our competitors develop and market products that are more effective, safer or less expensive than our products, our business could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition and have substantially greater financial, manufacturing, technical, marketing, drug development and human resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies and human clinical trials of new pharmaceutical products, obtaining regulatory approvals and manufacturing and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development or commercialization expenses incurred with respect to any such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition and results of operations, possibly materially.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited manufacturing experience and intend to rely on third parties to commercially manufacture our products, if and when developed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products may not be accepted by the medical community or consumers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely rely on third parties to market our products, assuming that they receive regulatory approvals. If we rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived ease of use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage or reimbursement by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding marketing and distribution support; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution or use restrictions imposed by regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there can be no assurance that physicians, patients or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by Health Canada, the FDA and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technologies may become obsolete.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not currently own or operate any manufacturing facilities. We rely on a contract manufacturer to source suitable raw materials and produce sufficient quantities of pelareorep for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. The process of manufacturing our pelareorep is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the third-party manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure by our third-party manufacturers to comply with applicable regulatory and quality standards or any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to third-party manufacturers, we rely on other third parties to store, monitor and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on contract manufacture and testing facilities to source required materials for production and evaluation of pelareorep as well as testing of clinical trial-related samples. As a result, we have less control over the supply timing and cost of these materials than if we sourced these materials directly. In addition, these are often specialized materials and third-party suppliers may also encounter challenges in producing, testing, or distributing materials that can impact delivery quantities and timeframes. If we are unable to arrange for sufficient supply or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. If we are unable to arrange for appropriate testing materials or they are not available in a timely manner, we may be unable to execute some clinical trial testing or we may be delayed in doing so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to monitor, support, conduct and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on entities outside of our control, which may include clinical and research consultants, academic institutions and contract research organizations ("CROs"), to perform, monitor, support, conduct and oversee preclinical studies and clinical trials of pelareorep. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our products. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our CROs fail to comply with applicable regulatory regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or we may be required to perform additional clinical trials before approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs is terminated, we may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of immuno-oncology could damage public perception of pelareorep and negatively affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The commercial success of pelareorep depends in part on public acceptance of the use of cancer immunotherapies including ICIs. Adverse events in clinical trials of pelareorep or in clinical trials of similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future including in connection with competitor therapies, could result in decreased acceptance of and demand for pelareorep. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to pelareorep or to competitors&#8217; products, pelareorep may not be accepted by the general public or the medical community, and potential clinical trial participants may be discouraged from enrolling in our trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pelareorep is an oncolytic virus and, as such, adverse developments related vaccines for viral diseases or in clinical trials of other virus-based oncolytic immunotherapy products may result in a disproportionately negative effect on the perception of pelareorep compared to other products in the field of immuno-oncology that are not based on viruses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of pelareorep. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars&#160;or health epidemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires. An outbreak of infectious disease, a pandemic or a similar public health threat, such as the COVID-19 pandemic, or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key employees and collaborators.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Intense competition for attracting key skill-sets may limit our ability to retain and motivate key personnel on acceptable terms. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. The loss of key employees and/or key collaborators may affect the speed and success of product development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Barbados, which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Barbados in Barbados based on the civil liabilities provisions of applicable securities laws. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law could adversely affect our business and corporate structure.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that changes will not occur in corporate, tax, property and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may obtain health information from third that is subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization and data protection outside of the U.S., such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our products and product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with data protection laws and regulations both within and outside of the U.S. could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">damage from industrial espionage attacks, malware or other cyber attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted and our business reputation could be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. In addition, as a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the Company is a Canadian Company and some of its directors and officers are resident outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a Canadian company, with its principal place of business in Canada. Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the U.S. Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of U.S. courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the U.S. federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;U.S. Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f) and 16 of the U.S. Exchange Act pursuant to Rule&#160;3a12-3 of the U.S. Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were to lose our foreign private issuer status under U.S. federal securities law, we would likely incur additional expenses associated with compliance with the U.S. securities law applicable to U.S. domestic issuers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, as discussed above under the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, we are exempt from certain provisions of the U.S. federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during the tax year ended December&#160;31, 2020, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a U.S. holder&#8217;s holding period of the Common Shares, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the shareholder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with respect to the Common Shares.&#160;A U.S. holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;However, U.S. holders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply U.S. holders with information that such U.S. holders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. holder wishes to make a QEF Election. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, U.S. holders may not be able to make a QEF Election with respect to their Common Shares. A U.S. holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material United States Federal Income Tax Considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;Each U.S. holder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our Common Shares </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility of market price of the Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential dilution of present and prospective shareholdings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company does not intend to pay cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition and capital requirements, restrictions in financing agreements, business opportunities and conditions and other factors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_25"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was formed under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located at 210, 1167 Kensington Cres. NW, Calgary, Alberta, Canada, T2N 1X7, telephone (403) 670-7377. Our agent for service in the U.S. is Registered Agent Solutions, Inc., 9E Lookerman Street, Suite 311, Dover, Delaware 19901.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. The filings are also contained on the Company&#8217;s website at https://www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts related to pelareorep, a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts.&#160;We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially viable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our potential product for human use, pelareorep, an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological malignancies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Scientific Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s anti-tumor activity is based on three modes of action which are complementary but not interdependent (Figure 1): </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Research and Development highlights</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and translational research to date indicates the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has anticancer effects in a variety of animal models demonstrating that it can reduce tumor burden and prolong survival in these models. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticancer effects in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy, radiotherapy, and other targeted cancer therapies, highlighting the beneficial adjuvant or anticancer immune-boosting properties of pelareorep.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A toxic dose of pelareorep has not been reached/established in animal models and infection presents with minimal side-effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data to date indicate the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More than 1,400 patients have been enrolled in clinical studies conducted in countries including the U.S., Canada and EU. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (IV) administration.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When combined with chemotherapy or immunotherapy, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of these agents.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efficacy analysis from clinical studies show that treatment with pelareorep can improve the outcome of cancer patients in a variety of potential tumor targets: </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a randomized Phase 2 study with 74 metastatic breast cancer (mBC) patients, known as IND 213, treatment with pelareorep plus paclitaxel versus paclitaxel alone demonstrated a statistically significant improvement in overall survival: 17.4 months versus 10.4 months, respectively (HR = 0.65; 80% CI 0.46&#8211;0.91; p=0.1). In a post hoc subgroup analysis, the OS improved with pelareorep plus paclitaxel in estrogen receptor-positive; human epidermal growth factor receptor 2 negative (ER+; HER2-) patients: 21.0 months versus 10.8 months, respectively (HR = 0.60; p=0.1). In patients that were ER+, progesterone receptor-positive, and HER2- (ER+;PgR+;HER2-) the median OS further improved with pelareorep plus paclitaxel: 21.8 months versus 10.8 months (HR = 0.36; p= 0.003)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a single-arm study with gemcitabine plus pelareorep, in first-line patients with pancreatic ductal adenocarcinoma (PDAC), known as REO 017, the median OS was 10 months with a 1 year and 2-year survival of 45% and 24%, respectively. For a single-arm study, these results were encouraging relative to 20&#8211;22% and 2&#8211;5%, landmark 1-year and 2-year survival, respectively for PDAC patients treated with gemcitabine alone from two different phase 3 studies.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a two-arm Phase 2 randomized study (NCI 8601), patients with PDAC were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs. 9% in the control arm. Biomarker studies from this clinical trial identified the immunomodulatory CEA cell adhesion molecule 6 (CEACAM6/CD66c) as a potential receptor for specific viral subtypes, where altered CEACAM6 levels may be predictive for pelareorep sensitivity. Specifically, when comparing extraordinary responders in the test arm to those with poor outcomes, low levels of CEACAM6 mRNA expression were associated with prolonged progression-free survival in pela-treated patients (10.32 months in CEACAM6 low versus 7.75 months in CEACAM6 high patients, p=0.05), importantly this effect was not seen in the control arm.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biomarker data from an ongoing window-of-opportunity study in early breast cancer (AWARE-1) demonstrates that pelareorep can replicate at high levels in breast cancer tissue following intravenous delivery. Viral replication, in turn, promotes the recruitment of tumor-infiltrating lymphocytes (mainly CD8+cells) and upregulates the expression of PD-L1, creating a tumor microenvironment poised to respond to checkpoint blockade therapy.   </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Mechanism of Action</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. Proposed mechanism of action for pelareorep</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="oncyf-20201231_g1.jpg" alt="oncyf-20201231_g1.jpg" style="height:358px;margin-bottom:5pt;vertical-align:text-bottom;width:446px"/></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PKR). In non-cancer cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was originally established that selective lysis with reovirus was mediated by tumor cells with an activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not just restricted to cells with an active RAS pathway, oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and or chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Innate Immunity</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and clinical studies provide compelling evidence that pelareorep functions as a systemically-delivered immunogenic agent which acts locally at the site of the tumor. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak of pro-inflammatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cytokines. NK cells within reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover,  peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Adaptive Immunity</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptive anti-tumor immunity allows for elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increases overall survival. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines. In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following its therapeutic administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these immunological events, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments and initiate adaptive anti-tumor immunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Pelareorep primes an anti-cancer immune response</span></div><div style="margin-bottom:8pt"><img src="oncyf-20201231_g2.jpg" alt="oncyf-20201231_g2.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:513px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development Plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our current clinical development program centers on the role of pelareorep in immuno-oncology mechanisms, particularly in combination with key immune checkpoint inhibitors and potentially other immune-based therapies. Our primary focus is to demonstrate enhanced antitumor efficacy with high profile checkpoint inhibitors, as we believe this may be the most immediately impactful clinical data and the most expeditious path to approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with different classes of immunotherapies. Therefore, as our clinical development program evolves and delivers additional data, we will consider appropriate expansion of our plan to investigate potential opportunities with such immunotherapies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020, we presented preliminary results at multiple conferences from our AWARE-1 study, which received regulatory approval in 2019 and examined the use of pelareorep and atezolizumab&#160;(Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;in a breast cancer window-of-opportunity study. The preliminary results demonstrated that pelareorep mediated priming of the tumor microenvironment for checkpoint blockade therapy. In the second quarter of 2020, we began enrollment in our BRACELET-1 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1&#160;and Paclitaxel) study, for which we initiated start-up activities in the second half of 2019. The BRACELET-1 study will essentially repeat our IND 213 trial in mBC in patients that are hormone receptor-positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-), with the addition of a third arm that includes pelareorep, paclitaxel and avelumab (Bavencio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Efficacy analysis of our IND213 trial is described in "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Research and Development highlights" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above. In the third quarter of 2020, we dosed our first patient in our investigator-sponsored multi-center trial known as IRENE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCMGA00012, and the oncolytic virus pela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep in metastatic triple-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gative breast cancer). This trial will investigate pelareorep in combination with Incyte&#8217;s anti-PD-1, retifanlimab (INCMGA00012) in triple-negative breast cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to breast cancer, we also announced a platform study known as GOBLET (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1) in the third quarter of 2020. GOBLET will examine combination therapy with pelareorep and atezolizumab (Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a variety of gastrointestinal indications in four cohorts: (1) Patients with first-line locally advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC); (2) Patients with first-line metastatic colorectal cancer (mCRC), limited to microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors; (3) Patients with third-line mCRC independent of microsatellite instability (MSI)/dMMR status; and (4) Patients with &#8805; second-line locally advanced/metastatic unresectable squamous cell carcinoma of the anal canal (SCCA) of viral or non-viral origin after prior systemic chemotherapy. We expect to begin enrollment in the second quarter of 2021.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, our pancreatic cancer study combination study</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was ongoing in 2020. This study is an extension of our phase 1 study investigating pelareorep in combination with chemotherapy and pembrolizumab (Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In 2019, we published our first data set related to the phase 1 study, in the journal of Clinical Cancer Research, demonstrating the safety and tolerability of this combination treatment regime and showed encouraging clinical efficacy with one patient achieving a partial response (six-month duration) and two patients with stable disease (lasting 126 and 221 days). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Trade Secrets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions and proprietary rights of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. We believe there will continue to be significant litigation in the industry regarding patent and other intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we have 377 issued patents including 40 issued in the U.S. and 17 in Canada. We also have 12 patents pending in the U.S., Canada, and other jurisdictions, but we cannot be certain whether any given patent application filed by us will result in the issuance of a patent or if any given patent issued to us will later be challenged and invalidated. Nor can we be certain whether any given patent that may be issued to us will provide any significant proprietary protection to our product and business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings may also be necessary to enforce or defend our proprietary rights and patents. In Europe, patents can be revoked through opposition or nullity proceedings. In the United States patents may be revoked or invalidated in court actions or challenged in interference, post-grant review, inter partes review, derivation or re-examination proceedings by the United States Patent and Trademark Office ("USPTO"). Such litigation or proceedings could result in substantial cost or distraction to us, resulting in an adverse decision as to our or our licensors&#8217; patent applications and patents.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on not infringing the patents or proprietary rights of others and not breaching licenses granted or that may be granted to us. Competitors may have filed patent applications, obtained patents, may in the future file patent applications, and/or obtain patents relevant to our product and technologies.&#160;&#160;We are not aware of competing intellectual property relating to our pelareorep project at this time.&#160;While we currently believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future.&#160;&#160;Litigation to defend our position could be costly and time consuming. We also cannot be certain that we will be successful. We may be required to obtain a license from a prevailing party in order to continue the portion of our business that relates to the proceeding. We may also be required to obtain licenses to other third-party technologies necessary in order to market our products. Such licenses may not be available to us on acceptable terms, or on any terms, and we may have to discontinue that portion of our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to license any technologies required to commercialize our technologies or products at reasonable cost may have a material adverse effect on our business, results of operations, financial condition, cash flow and future prospects. We are not currently involved in any litigation concerning our competitors&#8217; patent applications and patents. We may be involved in such litigation in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of the employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Strategy</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to develop and market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;We intend to achieve our business strategy by focusing on these key areas:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human subjects;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establish collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this Annual Report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early-stage human trials and our most recent data in HR+/HER2- mBC patients, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;It is not possible to predict, based upon studies in animals, or early-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;There are no assurances that the particular result expected by us will occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we do not intend to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution or manufacturing capabilities.&#160;We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;The drug approval process in Canada is regulated by Health Canada.&#160;&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;).&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submit marketing materials before being allowed to market pharmaceutical products.&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our pharmaceutical product in Canada, the United States, Europe and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pre-Pharmacological Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease model and has any adverse toxicology in a disease model.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Investigational New Drug Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - An Investigational New Drug (IND) Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmacological Studies&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or Phase 1 Clinical Trials)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Therapeutic Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">New Drug Submission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Approvals</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all. If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Marketing Regulations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="i32c78d9692194534851ffc8c75765b43_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:ConcentrationRiskNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yNS9mcmFnOjVjODBlODlhZGFiMTRkNzQ5ZWUyMGY2NGFkZTQxYjI1L3RleHRyZWdpb246NWM4MGU4OWFkYWIxNGQ3NDllZTIwZjY0YWRlNDFiMjVfNzY5NjU4MTQ1NzYxOA_f172b17d-cb70-464f-aba0-f921ca15a36c">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies, and foreign, state and federal civil and criminal investigations, fines and prosecutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Government Regulations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Competition </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">According to estimates for 2021 from the American Cancer Society, more than 1.9 million Americans are expected to be diagnosed with cancer in the year, and approximately 608,570 Americans are expected to die of cancer.&#160;Cancer is the second most common cause of death in the U.S., exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in 2 and 1 in 3, respectively (Source: American Cancer Society's Cancer Facts &amp; Figures 2021). The prevalence of breast cancer in the United States in 2017 was 3.6 million, of which there were 68% (2.4 million) patients with HR+/HER2- subtype. It was projected that there will be 114,438 patients with HR+/HER2- mBc. (Source: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">https://seer.cancer.gov/statfacts/html/breast.html (accessed Feb 24, 2021); https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed Feb 24, 2021); Marriotto et al. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer, Epidemiology, Biomarkers &amp; Prevention May 18, 2017. https://cebp.aacrjournals.org/content/cebp/26/6/809.full.pdf)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of this disease state are also significant.&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2021 that The National Cancer Institute estimated that the 2015 direct medical costs for cancer were $183 billion and are projected to increase to $246 billion by 2030. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face substantial competition in the development of products for cancer and other diseases. This competition from other manufacturers of the same types of products and from manufacturers of different types of products designed for the same uses is expected to continue in both U.S. and international markets.&#160;&#160;Oncolytic virus therapies, our primary focus area, are rapidly evolving areas in the biotechnology industry and are expected to undergo many changes in the coming years as a result of technological advances. We are currently aware of a number of groups that are developing oncolytic virus therapies including early-stage and established biotechnology companies, pharmaceutical companies, academic institutions, government agencies and research institutions. We face competition from all of these groups in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. It is possible that our competitors could achieve earlier market commercialization, could have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">superior patent protection, or could have safer, more effective or more cost-effective products. These factors could render our potential products less competitive, which could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Marketing Strategy</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;&#160;Our management and consultants have relevant experience with the partnering process.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality of Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have not been materially impacted by seasonality.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2020, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;In addition, Oncolytics Biotech (U.S.) Inc., a Delaware corporation, is a material wholly-owned subsidiary of OBB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, U.S. and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of pelareorep, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2021 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.&#160;&#160;Investors are cautioned against placing undue reliance on forward-looking statements.&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2020 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2020 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Research and Development, Patents, and Licenses, etc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" for information on the Company&#8217;s research and development policies.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Trend Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures.&#160;&#160;The amount and timing of expenditures and availability of capital resources vary substantially from period to period, depending on the level of research and development activity being undertaken at any one time and the availability of funding from investors and prospective commercial partners. See our 2020 MD&amp;A in Exhibit 15.1 for our comparative discussion on our expenditures between 2018 - 2020 and our expectations for 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and places of residence of all our directors and senior management as at December&#160;31, 2020, as well as the positions and offices held by such persons and their principal occupations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr style="height:164pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown, MBA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Brown is the Managing Partner at Accelera Canada Ltd., a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of the HBSPCA, Cardiol Therapeutics, Oncolytics Biotech Inc, and Sernova Corp. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph. She most recently completed the Institute of Corporate Directors Designation (ICD.D).</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td></tr><tr style="height:113pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016, prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td></tr><tr style="height:243pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro<br/>California, USA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro has more than 25 years of biopharmaceutical commercialization and business development experience. He has held executive and senior-level positions at leading pharmaceutical and biotechnology companies, working on initiatives across both developed and emerging markets globally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and Prevacid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and Epogen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;before joining MedImmune to lead marketing efforts for the FluMist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. de Guttadauro has a Bachelor of Science degree in engineering from the United States Military Academy at West Point.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr style="height:123pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman, P.Eng., PMP, MBT Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:213pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas C. Heineman, MD, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Clinical Development and Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Heineman brings more than 20 years of experience leading clinical development programs to Oncolytics, including 14 years in the biopharmaceutical industry.  Most recently, Dr. Heineman served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman&#8217;s experience further extends into big pharma and academia, as he has previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine.<br/><br/>Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in several specialties, including Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:123pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr style="height:213pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer, MBA, CPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vinkeveen, The Netherlands</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Kruimer has over 30 years experience in accounting, corporate finance, and strategy, in senior management positions in private and publicly listed life science companies. Mr. Kruimer served as CFO and Executive Committee Member of Crucell from 1998 through 2011, when Crucell was acquired by JNJ. During his tenure, he led financing activities of the company and contributed to Crucell's strategic acquisition of Swiss-based Berna Biotech. Currently, Mr. Kruimer serves as independent director and Chairman of the Audit Committee for Zealand Pharma (Nasdaq: ZEAL), and Chairman of the Board of BioInvent AB (OMXS: BINV). He is a director of Advent Int. Global Investments and advisor to private equity firm Karmijn Kapitaal Investments. Previously, he was CFO of SkylineDx, a DNA diagnostics company and Chairman of ProFibrix through its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013. Mr. Kruimer held various executive board positions on an interim basis. Prior to Crucell, Mr. Kruimer held senior executive positions at TIP Europe, a GE Capital company and Continental Can Europe. He was a consultant with McKinsey and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from Harvard, a BA in accounting and finance from University of Massachusetts and is a CPA in New York State.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2019</span></td></tr><tr style="height:92pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look, CA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:152pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                            Pennsylvania, USA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mr. Pisano has served as a Director/Chairman of several publicly traded companies in the US and Canada and has more than 30 years of experience as a pharmaceutical industry executive. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td></tr><tr style="height:143pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William G. Rice, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California, USA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. From 2003 to 2013, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University Laney Graduate School and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr style="height:102pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, USA and Munich, Germany</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Governance Committee.&#160;Dr. Rice is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Science and Technology Committee. Dr. Seizinger is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Compensation, Audit, Governance and Science and Technology Committees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at March&#160;1, 2021, the directors and senior management as a group beneficially owned, directly or indirectly, 677,068 of our common shares, representing 1.17% of the issued and outstanding common shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;In accordance with the Alberta Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers are related by blood, marriage or adoption to any other director or officer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or senior management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt"> Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid in 2020 to each director.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Based Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Based Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan Compensation<br/>($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Value<br/>($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other Compensation<br/>($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,294</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,912</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,206</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,758</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,162</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,920</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,477</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,541</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,724</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,877</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,601</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Rice</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,162</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,188</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd Seizinger</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,835</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,992</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;N/A </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,827</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors are paid fees in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.2732.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The value of share-based and option based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 audited consolidated financial statements.  </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Ms. Brown elected to receive US$15,000 (25%) of her annual retainer in restricted share awards. </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Kruimer elected to receive US$7,500 (14%) of his annual retainer in restricted share awards.  </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr.&#160;Pisano elected to receive US$40,625 (50%) of his annual retainer in restricted share awards.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Dr.&#160;Seizinger elected to receive US$24,000 (40%) of his annual retainer in restricted share awards.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Management </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid to our senior management in 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:105.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:59pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>$</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540,750</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,970</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,657</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489,377</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,550</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526,642</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,758</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,950</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,126,900</span></td></tr><tr style="height:48pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Head of Clinical Development and Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,200</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,507</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,294</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,992</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640,993</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Rita Laeufle</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(6)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,916</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279,758</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593,674</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,960</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,314</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,941</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,247</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">903,462</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421,314</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,625</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,378</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738,317</span></td></tr><tr style="height:41pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael Moore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(7)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vice President, Investor Relations &amp; Corporate Communications</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,604</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,279</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,883</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The value of share and option based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 audited consolidated financial statements.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The dollar amounts set forth under this column are related to contributions to the senior management's respective retirement savings plan and amounts provided for health care benefits by the Company. With regards to Dr. Laeufle and Mr. Moore, the amount also included severance payments of $265,558 and $183,145, respectively. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid salaries, bonuses and other compensation in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.2732.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Dr. Heineman was appointed as the Global Head of Clinical Development and Operations on August 3, 2020. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Dr. Laeufle ceased to hold the position of Chief Medical Officer effective July 31, 2020.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Mr. Moore ceased to hold the position of Vice President, Investor Relations &amp; Corporate Communications on June 4, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with each member of the Company's senior management (each an "Employment Agreement").&#160;The following base salaries for 2021 were approved by the Board of Directors:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:298.50pt"><tr><td style="width:1.0pt"></td><td style="width:193.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Salary<br/>$</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look, C.A.<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Clinical Development and Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;U.S. Employees are paid in U.S. Dollars and salaries above for those U.S. employees are presented in U.S. dollars. All other employees are paid in Canadian Dollars and salaries above for those Canadian employees are presented in Canadian dollars. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, each member of the Company's senior management is entitled to additional benefits and performance-based bonuses.&#160;As well, the Employment Agreements provide that each member of the Company's senior management is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company.&#160;Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not provide pension plan benefits to its senior management and employees. The Company does not currently have a stock appreciation rights plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Employment or Change of Control </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects amounts payable to the each member of the Company's senior management based on their respective Employment Agreements assuming that their employment was terminated on December 31, 2020 without cause or due to a change of control of the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:381.75pt"><tr><td style="width:1.0pt"></td><td style="width:180.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination without Cause Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227,884&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look, C.A.<br/>Chief Financial Officer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Clinical Development and Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2020, all options granted to senior management had fully vested except for the options granted on March 8, 2018, December 13, 2019, August 1, 2020 and December 11, 2020. As a result, all members of senior management shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated unless otherwise approved by the Board of Directors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On a change of control of the Company, senior management shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">U.S. Employees are paid in U.S. Dollars and are presented in U.S. dollars.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Dr. Heineman's probation period, per the terms of his Employment Agreement, expires 6 months following his appointment.   </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Corporation Since</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiration of Current Term of Office</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown, BSc, MBA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer, MBA, CPA<br/>Vinkeveen, Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA<br/>New Jersey, USA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William G. Rice, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD<br/>New Jersey, USA and Munich Germany</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2021 Annual General Meeting of the Shareholders</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Contracts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each director who is not a salaried employee of the Company is entitled to the following fees:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Retainer </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each director receives a base retainer of US$40,000. In addition to the base retainer directors are eligible to receive the following additional fees depending on committee involvement:</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Retainers (USD):</span></div><div style="margin-bottom:17pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:79.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.663%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board chair</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee chair</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance &amp; Compensation Committee chair</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science &amp; Technology Committee chair</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Audit Committee</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Governance, Compensation or Science &amp; Technology  Committee</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors, annually, may opt to take up to 100% of their respective annual retainer in restricted share awards. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the combined retainer, in 2020, the Corporation granted US$30,000 of restricted share awards that vested immediately.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also grant to directors, from time to time, stock options in accordance with the Option Plan and the reimbursement of any reasonable expenses incurred by them while acting in their directors' capacity.&#160;During the year ended December 31, 2020, total compensation of $741,760 was paid to the independent directors which consisted of fee payments of $368,114, share-based awards of $373,646 and option based awards of nil . </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed a compensation committee (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its compensation practices and provide recommendations to the committee with respect to compensation for directors and senior management. The Corporation did not retain an external compensation advisor for the year-ended December 31, 2020. The Compensation Committee has retained Radford, An Aon Hewitt Corporation as a specialist consultant to assist with the benchmarking of officer compensation for 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage senior management of the Company to take inappropriate or excessive risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Corporation&#8217;s corporate trading policy, insiders (including senior management and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, the following guidelines were employed by the Board in granting bonuses, Options and Share Awards to the Corporation&#8217;s executive and senior officers. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Bonus, Option Grants and Share Award Grants </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 50% of his base salary and the Chief Financial Officer is eligible for a cash bonus of up to 40% of his/her base salary and the other senior officers are eligible for a cash bonus of up to 30% of their respective base salaries. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee Mandate </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Policy Statement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain a Compensation Committee (the "Committee"), composed entirely of independent directors, to assist the Board of Directors of the Corporation (the "Board") in carrying out its responsibility for the Corporation&#8217;s human resources and compensation policies and processes.  The Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board, including administrative support.  If determined necessary by the Committee, it will have the discretion to investigate and conduct reviews of any human resource or compensation matter including the standing authority to retain experts and special counsel.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Composition of Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Committee shall consist of a minimum of three (3) directors.  The Board shall appoint the members (&#8220;Members&#8221;) of the Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Committee to be the Chair of the Committee, or delegate such authority to appoint the Chair of the Committee to the Committee.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Chair of the Committee shall be responsible for the leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Each director appointed to the Committee by the Board shall be an outside director who is unrelated.  An outside, unrelated director is a director who meets the requirements of NASDAQ Rule 5605 (a)(2) and 5605(d)(2) and National Instrument 58-101 who is independent of management and is free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to be independent of management and to act with a view to the best interests of the Corporation, including, but not limited to the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Corporation to such director and whether such director is affiliated with the Corporation, a subsidiary of the Corporation or an affiliate of a subsidiary of the Corporation other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the then current legislation, rules, policies and instruments of applicable regulatory authorities.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Each Member shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Chair of the Board shall be an ex officio Member of the committee. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Meetings of the Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Committee shall meet a minimum of twice per year at such time and place as may be designated by the Chair of the Committee and whenever a meeting is requested by the Board, a Member of the Committee, or the Chief Executive Officer of the Corporation (the "CEO"). </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Notice of each meeting of the Committee shall be given to each Member of the Committee.  The CEO shall attend each meeting of the Committee whenever requested to do so by a Member of the Committee.  The CEO may not be present during voting or deliberations on his or her compensation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Notice of a meeting of the Committee shall:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">be in writing, including by electronic communication facilities;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">state the nature of the business to be transacted at the meeting in reasonable detail;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Committee may permit.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">A quorum for the transaction of business at a meeting of the Committee shall consist of a majority of the Members of the Committee.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">A Member or Members of the Committee may participate in a meeting of the Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">In the absence of the Chair of the Committee, the Members of the Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall be the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Minutes shall be kept of all meetings of the Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Committee shall be distributed to members of the Committee, to other members of the Board and, with the exception of &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in camera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; items, to the Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Duties and Responsibilities of the Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Committee&#8217;s primary duties and responsibilities are to review and make recommendations to the Board in respect of:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">human resource policies, practices and structures (to monitor consistency with the Corporation&#8217;s goals and near and long-term strategies, support of operational effectiveness and efficiency, and maximization of human resources potential);</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">compensation policies and guidelines;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">management incentive and perquisite plans and any non-standard remuneration plans;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">senior management, executive and officer appointments and their compensation;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">management succession plans, management training and development plans, termination policies and termination arrangements; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">Board compensation matters.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">In carrying out its duties and responsibilities, the Committee shall:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually assess and make a recommendation to the Board with regard to the competitiveness and appropriateness of the compensation package of the CEO, all other officers of the Corporation and such other key employees of the Corporation or any subsidiary of the Corporation as may be identified by the CEO and approved by the Committee (collectively, the "Designated Employees");</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually review the performance goals and criteria for the CEO and evaluate the performance of the CEO against such goals and criteria and recommend to the Board the amount of regular and incentive compensation to be paid to the CEO;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually, review and make a recommendation to the Board regarding the CEO&#8217;s performance evaluation of Designated Employees and the CEO&#8217;s recommendations with respect to the amount of regular and incentive compensation to be paid to such Designated Employees;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review and make a recommendation to the Board regarding any employment contracts or arrangements with each of the Designated Employees, including any retiring allowance arrangements or any similar arrangements to take effect in the event of a termination of employment;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">periodically, review the compensation philosophy statement of the Corporation and make recommendations for change to the Board as considered necessary;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">from time to time, review and make recommendations to the Board in respect of the design, benefit provisions, investment options and text of applicable pension, retirement and savings plans or related matters;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually, in conjunction with the Corporation&#8217;s general and administrative budget, review and make recommendations to the Board regarding compensation guidelines for the forthcoming budget period;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">viii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">when requested by the CEO, review and make recommendations to the Board regarding short term incentive or reward plans and, to the extent delegated by the Board, approve awards to eligible participants;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ix.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review and make recommendations to the Board regarding incentive stock option plans or any other long term incentive plans and to the extent delegated by the Board, approve grants to participants and the magnitude and terms of their participation;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">as required, fulfill the obligations assigned to the Committee pursuant to any other employee benefit plans approved by the Board;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually, prepare or review the report on executive compensation required to be disclosed in the Corporation&#8217;s information circular or any other human resource or compensation matter required to be publicly disclosed by the Corporation;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">annually, review and make a recommendation to the Board regarding the compensation of the Board of Directors;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xiii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">as determined in the sole discretion of the Committee, retain independent advice in respect of human resources and compensation matters from a compensation consultant, legal counsel or other advisor (the &#8220;Advisor&#8221;) and, if deemed necessary by the Committee, meet separately with the Advisor; the Committee shall be directly responsible for the appointment, compensation and oversight of the work of the Advisor retained by the Committee; </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xiv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">select, or receive advice from, an Advisor to the Committee, other than in-house legal counsel, after taking into consideration the following factors:</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.73pt">the provision of other services to the Corporation by the entity that employs the Advisor ;</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.96pt">the amount of fees received from the Corporation by the entity that employs the Advisor, as a percentage of the total revenue of the entity that employs the Advisor;</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:7.19pt">the policies and procedures of the entity that employs the Advisor that are designed to prevent conflicts of interest;</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:7.73pt">any business or personal relationship of the Advisor with a member of the Board;</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any stock of the Corporation owned by the Advisor; and</span></div><div style="padding-left:144pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:7.73pt">any business or personal relationship of the Advisor or the entity employing the Advisor with an executive officer of the Corporation;</span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">provided however, none of the above factors shall prevent the Committee from retaining any Advisor as the Committee deems appropriate, in its sole discretion, after consideration of the above factors. </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">review and consider the implications of the risks associated with the Corporation&#8217;s compensation policies and practices, specifically, situations that could potentially encourage an insider to expose the Corporation to inappropriate or excessive risks; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">xvi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:20.73pt">assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">In addition to the foregoing, the Committee shall undertake on behalf of the Board such other initiatives as may be necessary or desirable to assist the Board in discharging its responsibility for the Corporation&#8217;s human resources development, performance evaluation, compensation and succession planning programs are in place and operating effectively.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">External Advisors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If, in order to properly discharge its function, duties and responsibilities, it is necessary, in the opinion of the Committee that the Committee obtains the advice and counsel of external advisors, the Chair shall, at the request of the Committee, engage the necessary experts. The Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel, and other advisor retained by the Committee.  The Corporation will provide adequate funding, as determined by the Committee, for payment of such external advisors. The Committee will only engage a compensation consultant, legal counsel or other external advisor after taking into consideration the factors set forth in NASDAQ Rule 5605 (d)(3)(D) (See Appendix A). The Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Committee&#8217;s regular reports to the Board.  The Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Date of Mandate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Mandate was last reviewed, amended and approved by the Board on March 4, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">       Audit Committee </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, Mr. Kruimer and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;Each Audit Committee member is financially literate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee Mandate </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Policy Statement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is the policy of Oncolytics Biotech Inc. (the "Corporation") to establish and maintain an Audit Committee, composed entirely of independent directors, to assist the Board of Directors (the "Board") in carrying out their oversight responsibility for the Corporation&#8217;s internal controls, financial reporting and financial risk management processes.  The Audit Committee will be provided with resources commensurate with the duties and responsibilities assigned to it by the Board including administrative support.  If determined necessary by the Audit Committee, it will have the discretion to institute investigations of improprieties, or suspected improprieties within the scope of its responsibilities, including the standing authority to retain special counsel or experts.  In the event of a conflict of interest or potential conflict of interest involving one or more of the directors or members of management, the Audit Committee may modify the procedures and requirements set out in this Mandate restrict communication and sharing of information to independent directors or otherwise take reasonable measures to manage the conflict of interest or potential conflict of interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Composition of the Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Audit Committee shall consist of a minimum of three (3) directors.   The Board shall appoint the members (&#8220;Members&#8221;) of the Audit Committee and may seek the advice and assistance of the Governance Committee in identifying qualified candidates.  The Board shall appoint one Member of the Audit Committee to be the Chair of the Audit Committee, or delegate such authority to appoint the Chair of the Audit Committee to the Audit Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Chair of the Committee shall be responsible for leadership of the Committee, including preparing or approving the agenda, presiding over the meetings, and making committee assignments.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Each director appointed to the Audit Committee by the Board shall be an outside director who is unrelated and independent.  An outside, unrelated and independent director is a director who meets the requirements of NASDAQ Rule 5605(a)(2) and National Instrument 52-110. A director appointed to the audit committee shall also meet the requirements of NASDAQ Rule 5605(c)(2) and Rule 10A-3(b)(1) of the United States Securities Exchange Act of 1934, as amended. Such director shall be independent of management and free from any interest, any business or other relationship which could, or could reasonably be perceived, to materially interfere with the director&#8217;s ability to act with a view to the best interests of the Corporation, other than interests and relationships arising from shareholding.  In determining whether a director is independent of management, the Board shall make reference to the abovementioned rules and any applicable revisions thereto, and any additional relevant and then current legislation, rules, policies and instruments of applicable regulatory authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Each Member of the Audit Committee shall be financially literate.  In order to be financially literate, a director must be, at a minimum, able to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. At least one Member shall have accounting or related financial management expertise, meaning the ability to analyze and interpret a full set of financial statements, including the notes attached thereto, in accordance with generally accepted accounting principles and shall be a &#8220;financial expert&#8221; as defined in Item 407 of Regulation S-K promulgated by the U.S. Securities and Exchange Commission and &#8220;financially sophisticated&#8221; as defined in NASDAQ Rule 5605(c)(2).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">In determining whether a Member of the Audit Committee is financially literate or has accounting or related financial expertise, reference shall be made to the then current legislation, rules, policies and instruments of applicable regulatory authorities. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">Each Member of the Audit Committee shall be appointed by the Board annually at the next scheduled meeting of the Board following the AGM.  The Members will be appointed to hold office until the next annual general meeting of shareholders or until their successors are appointed. The Board may remove a Member at any time and may fill any vacancy occurring on the Audit Committee.  A Member may resign at any time and a Member will automatically cease to be a Member upon ceasing to be a director.   </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Chair of the Board shall be an ex officio Member of the committee.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Meetings of the Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Audit Committee shall convene a minimum of four times each year at such times and places as may be designated by the Chair of the Audit Committee and whenever a meeting is requested by the Board, a Member of the Audit Committee, the auditors, or senior management of the Corporation.  Scheduled meetings of the Audit Committee shall correspond with the review of the year-end and quarterly financial statements and management discussion and analysis.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Notice of each meeting of the Audit Committee shall be given to each Member of the Audit Committee.  The auditors are entitled to attend meetings that pertain to the quarterly and year end financial reporting and, if there are any other meetings, only at the request of the Audit Committee.  </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Notice of a meeting of the Audit Committee shall:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">be in writing, including by electronic communication facilities;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">state the nature of the business to be transacted at the meeting in reasonable detail;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">to the extent practicable, be accompanied by copies of documentation to be considered at the meeting; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">be given at least two business days prior to the time stipulated for the meeting or such shorter period as the Members of the Audit Committee may permit.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">A quorum for the transaction of business at a meeting of the Audit Committee shall consist of a majority of the Members of the Audit Committee.  However, it shall be the practice of the Audit Committee to require review, and, if necessary, approval of certain important matters by all Members of the Audit Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">A Member or Members of the Audit Committee may participate in a meeting of the Audit Committee by means of such telephonic, electronic or other communication facilities, as permits all persons participating in the meeting to communicate adequately with each other.  A Member participating in such a meeting by any such means is deemed to be present at the meeting.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">In the absence of the Chair of the Audit Committee, the Members of the Audit Committee shall choose one of the Members present to be Chair of the meeting.  If the Board has appointed a Corporate Secretary, the Corporate Secretary shall act as the secretary of the meeting.  If the Board has not appointed a Corporate Secretary, the Members of the Committee shall choose one of the persons present to be the secretary of the meeting or may have another person who is not a Member of the Committee present to record the minutes of the meeting.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">A member of the Board, senior management of the Corporation, external auditors and other parties may attend meetings of the Audit Committee; however the Audit Committee (i) shall, at a meeting attended by the external auditor, meet with them independent of other individuals other than the Audit Committee; (ii) may exclude: (A) management, (B) directors who are not independent directors, or (C) any party that has a conflict of interest or potential conflict of interest, from part or all of a meeting of the Audit Committee if reasonably necessary for the Audit Committee to properly discharge its responsibilities; and (iii) may meet separately with management.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Chief Executive Officer and the Chief Financial Officer shall each attend meetings of the Audit Committee when requested to do so by a Member of the Audit Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.73pt">Minutes shall be kept of all meetings of the Audit Committee and shall be signed by the Chair and the secretary of the meeting.  Minutes of the meetings of the Audit Committee shall be distributed to Members of the Audit Committee, to other members of the Board and, with the exception of &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in camera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; items, to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer and Chief Financial Officer.  Notwithstanding the foregoing, distribution of minutes of meetings or parts thereof may be restricted to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Duties and Responsibilities of the Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Audit Committee&#8217;s primary duties and responsibilities are to:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">identify and monitor the management of the principal risks that could impact the financial reporting of the Corporation;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">monitor the integrity of the Corporation&#8217;s financial reporting process and system of internal controls regarding financial reporting and accounting compliance;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">monitor the independence and performance of the Corporation&#8217;s external auditors. This will include receipt, review and evaluation, at least annually, of a formal written statement from the independent auditors confirming their independence, and qualifications, including their compliance with the requirements of the relevant oversight boards and actively engage in a dialogue with the auditors with respect to any disclosed relationships or services that may impact objectivity and independence of the auditors and take, or recommend that the full board take, appropriate action to oversee the independence of the external auditors;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">deal directly with the external auditors to pre-approve external audit plans, other services (if any) and fees;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">directly oversee the external audit process and results (in addition to items described in Section 4(d) below);</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">provide an avenue of communication among the external auditors, management and the Board; </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">carry out a review designed to ensure that an effective "whistle blowing" procedure exists to permit stakeholders to express any concerns to an appropriately independent individual;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">viii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">pre-approve any related party transactions to be entered into by the Company, and ensure appropriate disclosure thereof;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ix.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">ensure financial disclosure incorporates inclusion of any material correcting adjustments required by the external auditors; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">require and ensure that the external auditors are directly responsible to the Audit Committee, to whom they report.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall have the authority to:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">inspect any and all of the books and records of the Corporation and its affiliates;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">discuss with the management of the Corporation and its affiliates, any affected party and the external auditors, such accounts, records and other matters as any Member of the Audit Committee considers necessary and appropriate;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">engage independent counsel and other advisors as it determines necessary to carry out its duties.  The Audit Committee shall keep the Board apprised of both the selection of experts and the expert&#8217;s findings through the Audit Committee&#8217;s regular reports to the Board.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary; </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">communicate directly with the external auditors; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">set and pay the compensation for (A) any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review, or attest services for the Corporation, (b) any advisors employed by the Audit Committee, and (C) ordinary administrative expenses of the Audit Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Audit Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review the audit plan with the Corporation&#8217;s external auditors and with management;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review with the independent auditors the matters required to be discussed relating to the conduct of the audit, including (a) the proposed scope of their examination, with emphasis on accounting and financial areas where the Committee, the independent auditors or management believes special attention should be directed; (b) the results of their audit, including their audit findings report and resulting letter, if any, of recommendations for management; (c) their evaluation of the adequacy and effectiveness of the Company&#8217;s internal controls over financial reporting; (d) significant areas of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:108pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">disagreement, if any, with management; (e) co-operation received from management in the conduct of the audit; (f) significant accounting, reporting, regulatory or industry developments affecting the Company; and (g) any proposed changes in major accounting policies or principles proposed or contemplated by the independent auditors or management, the presentation and impact of material risks and uncertainties and key estimates and judgements of management that may be material to financial reporting;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review with management and with the external auditors material financial reporting issues arising during the most recent fiscal period and the resolution or proposed resolution of such issues;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review any problems experienced or concerns expressed by the external auditors in performing an audit, including any restrictions imposed by management or material accounting issues on which there was a disagreement with management;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review with senior management the process of identifying, monitoring and reporting the principal risks affecting financial reporting;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review audited annual financial statements (including management discussion and analysis) and related documents in conjunction with the report of the external auditors and obtain an explanation from management of all material variances between comparative reporting periods. Without restricting the generality of the foregoing, the committee will discuss with management and the independent auditors to the extent required, any issues and disclosure requirements regarding (a) the use of &#8220;pro forma&#8221; or &#8220;adjusted&#8221; non-GAAP information, as well as financial information and earnings guidance provided to analysts and rating agencies, (b) any off balance sheet arrangements, and (c) any going concern qualification.</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">consider and review with management, the internal control memorandum or management letter containing the recommendations of the external auditors and management&#8217;s response, if any, including an evaluation of the adequacy and effectiveness of the internal financial controls of the Corporation and subsequent follow-up to any identified weaknesses;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">viii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review with financial management and the external auditors the quarterly unaudited financial statements, management discussion and analysis, letter to shareholders and press release (all to be considered the &#8220;Quarterly Financial Reports&#8221;) and recommend the Quarterly Financial Reports to the Board for approval by the Board before release to the public;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ix.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">before release, review and if appropriate, recommend for approval by the Board, all public disclosure documents containing audited or unaudited financial information, including any prospectuses, financial statements, including the notes thereto, annual reports, annual information forms, management discussion and analysis and press releases; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">x.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">oversee, any of the financial affairs of the Corporation or its affiliates, and, if deemed appropriate, make recommendations to the Board, external auditors or management.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">The Audit Committee shall:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">evaluate the independence and performance of the external auditors;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">recommend the nomination of the external auditors to the Board for appointment by the shareholders at the Corporation&#8217;s annual general meeting;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt"> recommend the discharge of the external auditor when circumstances warrant;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">monitor the rotation of the audit partner of the external auditors as required by applicable law or regulations;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-25.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">consider the recommendations of management in respect of the appointment of the external auditors;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">pre-approve all non-audit services to be provided to the Corporation or its subsidiary entities by its external auditors, or the external auditors of affiliates of the Corporation subject to the over-riding principle that the external auditors are not permitted to be retained by the Corporation to perform specifically listed categories of non-audit services as set forth by the Securities and Exchange Commission as well as internal audit outsourcing services, financial information systems work and expert services.  Notwithstanding, the foregoing the pre-approval of non-audit services may be delegated to a Member of the Audit Committee, with any decisions of the Member with the delegated authority reporting to the Audit Committee at the next scheduled meeting;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">vii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">approve the engagement letter for non-audit services to be provided by the external auditors or affiliates, together with estimated fees, and considering the potential impact of such services on the independence of the external auditors;</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-33.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">viii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">when there is to be a change of external auditors, review all issues and provide documentation related to the change, including the information to be included in the Notice of Change of Auditors and documentation required pursuant to the then current legislation, rules, policies and instruments of applicable regulatory authorities and the planned steps for an orderly transition period; and</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-28.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ix.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">review all reportable events, including disagreements, unresolved issues and consultations, as defined by applicable securities policies, on a routine basis, whether or not there is to be a change of external auditors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">The Audit Committee shall inquire into and determine the appropriate resolution of any conflict of interest in respect of audit or financial matters, which are directed to the Audit Committee.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall review the Corporation&#8217;s accounting and reporting of revenues, costs, liabilities and contingencies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall establish and maintain procedures for:</span></div><div style="padding-left:108pt;text-align:justify;text-indent:-23.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls, or auditing matters; and </span></div><div style="padding-left:108pt;text-align:justify;text-indent:-26.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:18pt">the confidential, anonymous submission by employees of the Corporation or concerns regarding questionable accounting or auditing matters.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.73pt">The Audit Committee shall review and approve the Corporation's hiring policies regarding partners and employees and former partners and employees of the present and former external auditors.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">j.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.73pt">The Audit Committee shall review with the Corporation's legal counsel, on no less than an annual basis, any legal matter that could have a material impact on the Corporation's financial statements, and any inquiries received from regulators, or government agencies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">k.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall review with management and the Corporation&#8217;s external auditors, on no less than an annual basis, any taxation matters that could have a material impact on the Corporation&#8217;s financial statements.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">l.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.73pt">The Audit Committee, through the Chair, shall receive notice from management of any instance of non-trivial fraud or other failure or weakness of the control system promptly upon management becoming aware of such.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">m.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:7.73pt">The Audit Committee shall review and approve the signing authority for the Corporation at least annually or when a change is required. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">The Audit Committee shall assess, on an annual basis, the adequacy of this Mandate and the performance of the Audit Committee.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Committee shall, at the earliest opportunity after each meeting, report to the Board the results of its activities and any reviews undertaken and make recommendations to the Board as deemed appropriate.  The Audit Committee may restrict such reports to independent directors in the event of a conflict of interest or potential conflict of interest or if otherwise necessary for the Audit Committee to properly discharge its responsibilities, but only for as long as is reasonably necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">Date of Mandate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Mandate was last reviewed and approved by the Board on March 4, 2021.  </span></div><div style="text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.78pt">Employees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:384.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Activity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:346.50pt"><tr><td style="width:1.0pt"></td><td style="width:231.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic location</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the share ownership and options held of our directors and officers as of March&#160;1, 2021. Common shares, stock options and exercise prices for all periods have been adjusted retroactively for the Share Consolidation. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"><tr><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>Ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry Date</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Officers</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 27, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 19, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 17, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 19, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas Heineman</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 3, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.96</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.24</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 12, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"><tr><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>Ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry Date</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 9, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 28, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 7, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Rice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd Seizinger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL:</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Less than 1% ownership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on 52,083,924 common shares issued and outstanding on March&#160;1, 2021. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Options granted to acquire common shares. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of 57,804,242.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the restricted share units held by our directors as of March&#160;1, 2021. Restricted share awards have been adjusted retroactively for the Share Consolidation. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:399.75pt"><tr><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:76.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Vested and Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Vested and Undistributed</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Unvested</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,725)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Rice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd Seizinger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554,472)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the restricted share units held by our officers as of March&#160;1, 2021. Restricted share awards have been adjusted retroactively for the Share Consolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:319.50pt"><tr><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Vested and Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs Unvested</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,315)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,315)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the performance share units held by our officers as of March&#160;1, 2021. Performance share awards have been adjusted retroactively for the Share Consolidation. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:338.25pt"><tr><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:78.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs Vested and Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PSUs Vested and Undistributed</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Coffey</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two share-based compensation plans: the Stock Option Plan and the Share Award Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Stock Option Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Corporation (including the Share Award Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Corporation or any subsidiary of the Corporation (such persons being &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options are generally granted for a term expiring on the tenth anniversary of the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant.  The Stock Option Plan provides that if the expiration date of an Option occurs during a &#8220;blackout period&#8221; or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change of control of the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day following the change of control.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;changing the provisions relating to the manner of exercise of Options; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increases the number of Common Shares reserved for issuance under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permits awards other than Options to be made under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;changes the insider participation limitation at any time under the Stock Option Plan; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;amends the amending provision of the Stock Option Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with PSAs, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Corporation&#8217;s performance compared to identified operational or financial targets and the Corporation&#8217;s shareholder return.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis). The Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the such blackout period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cessation Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change the insider participation limit under the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;change the amendment provisions of the Share Award Plan.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_37"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not directly or indirectly owned or controlled by another corporation(s) or by any foreign government. To the knowledge of our directors and senior officers, as at March&#160;5, 2021, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in the United States </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates, as of February&#160;26, 2021, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S.&#160;addresses, the portion of the outstanding common shares held by U.S.&#160;holders of record, and the percentage of common shares held by U.S.&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Holders of Record</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Common Shares Issued and Outstanding<br/>&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of U.S.&#160;Holders of Record</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares Held by U.S.&#160;Holders of Record</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Common Shares Held by U.S.&#160;Holders of Record&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,083,924</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,933,581&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.35&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;5, 2021, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Control by Others</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation, any foreign government, or any other natural or legal person, severally or jointly.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment contracts with each of our senior management members (see Item 6).&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the fiscal year ended December 31, 2020 up to March&#160;5, 2021, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Consolidated Statements and Other Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report are filed under Item 18.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company do not know of any material, active or pending, legal proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends on its common shares.&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Significant Changes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Offering and Listing Details</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares are traded on the TSX and on the Nasdaq Capital Market under the symbol ONC and ONCY, respectively. Between November 5, 2015 and June 1, 2018, our Common Shares were quoted for trading on the OTCQX International ("OTCQX") under the symbols ONCYF and ONCYD, after our Common Shares were delisted from the Nasdaq on November 5, 2015. On June 1, 2018, our Common Shares were approved for listing and commenced trading on the Nasdaq Capital Market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Plan of Distribution</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Markets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbol &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Selling Shareholders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Dilution</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Expenses of the Issue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; ADDITIONAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Articles of Continuance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights, Preferences and Dividends Attaching to Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a distribution of assets on a winding-up, dissolution or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro&#160;rata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other classes of shares are currently permitted to be issued.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action Necessary to Change the Rights of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual and Special Meetings of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the U.S..&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the Rights to Own Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Share Ownership</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 10&#160;days from the day on which the change takes place.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Provisions of Articles and By-laws</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Articles or By-laws:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring disclosure of share ownership; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada presently has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities, except as discussed below in Section E, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizing documents on the right of foreigners to hold or vote securities of our company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may require review and approval by the Minister of Industry (Canada) of certain acquisitions of &#8220;control&#8221; of our company by a &#8220;non-Canadian&#8221;. The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the company. &#8220;Non-Canadian&#8221; generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust or joint venture that is ultimately controlled by non-Canadians.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is, as of the date of this Annual Report, a summary of the principal Canadian federal income tax considerations under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the regulations thereunder (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) generally applicable to an investor who acquires as beneficial owner Common Shares pursuant to the Offering and who, for the purposes of the Tax Act and the Regulations and at all relevant times deals at arm&#8217;s length with the Corporation and the Agent, is not affiliated with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporation or the Agent, is not exempt from tax under Part I of the Tax Act, and who acquires and holds the Common Shares, as capital property (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Generally, the Common Shares will be considered to be capital property to a Holder provided that the Holder does not hold the Common Shares in the course of carrying on a business as part of an adventure or concern in the nature of trade.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business in Canada and elsewhere. Such Holders should consult their own tax advisors with respect to an investment in Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the Tax Act and the Regulations in force as of the date hereof and counsel&#8217;s understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) published in writing by the CRA prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act and the Regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Proposals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative or judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations, which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing practices of the CRA.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to their particular circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the Common Shares (including dividends, adjusted cost base and proceeds of disposition) must, to the extent such amounts are not in Canadian dollars, be converted into Canadian dollars based on an exchange rate determined in accordance with the Tax Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Corporation are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend, unless such rate is reduced by the terms of an applicable tax treaty. For example, under the Canada-United States Tax Convention (1980), as amended (the &#8220;Treaty&#8221;), the rate of withholding tax on dividends paid or credited to a  Non-Resident Holder who is a beneficial owner of dividends and who is a resident of the United States for purposes of the Treaty and who is entitled to the benefits of the Treaty  is generally limited to 15% of the gross amount of the dividend. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dispositions of Common Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a disposition (or a deemed disposition) of a Common Share (other than to the Corporation unless purchased by the Corporation in the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Non-Resident Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of such Common Shares, net of any reasonable costs of disposition, are greater (or are less) than the adjusted cost base of such Common Share to the Non-Resident Holder.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, unless the Common Share constitutes &#8220;taxable Canadian property&#8221; and is not &#8220;treaty-protected property&#8221; (each as defined under the Tax Act) of the Non-Resident Holder at the time of disposition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes the NASDAQ and TSX), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Resident Holder at that time, unless at any time during the 60 month period immediately preceding the disposition the following two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length, and (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident Holder did not deal at arm&#8217;s length held a membership interest directly or indirectly through one or more partnerships, owned 25% or more of the issued shares of any class or series of shares of the Corporation; and (ii) more than 50% of the fair market value of such shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), (c) &#8220;timber resource properties&#8221; (as defined in the Tax Act) or (d) an option in respect of, an interest in, or for civil law a right in any of the foregoing property, whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the Tax Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Scope of this Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">U.S. Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an individual who is a citizen or resident of the United States;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are required to accelerate the recognition of any item of gross income with respect to Common Shares as a result of such income being recognized on an applicable financial statement; or (i) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Corporation. This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Tax Act; (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &#8220;taxable Canadian property&#8221; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Passive Foreign Investment Company Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">PFIC Status of the Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Corporation believes that it was classified as a PFIC during the tax year ended December 31, 2019, and based on current business plans and financial expectations, the Corporation expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Corporation as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Corporation (or any subsidiary of the Corporation) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Corporation and each subsidiary of the Corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In any year in which the Corporation is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Corporation generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Corporation is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Corporation&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;). &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For purposes of the PFIC income test and PFIC asset test described above, if the Corporation owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Corporation will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Corporation from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under certain attribution rules, if the Corporation is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Corporation&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Corporation or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Default PFIC Rules Under Section 1291 of the Code</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Corporation and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Corporation is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Corporation will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Corporation ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Corporation was a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">QEF Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Corporation, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Corporation, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Corporation is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Corporation. However, for any tax year in which the Corporation is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a timely and effective QEF Election with respect to the Corporation generally (a) may receive a tax-free distribution from the Corporation to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Corporation that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Corporation was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Corporation ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Corporation is not a PFIC. Accordingly, if the Corporation becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Corporation qualifies as a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Corporation: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Corporation owns more than 50% of such subsidiary&#8217;s total aggregate voting power and (b) for each year in which the Corporation is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Corporation and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Corporation may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Corporation will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Corporation can provide no assurances that such Subsidiary PFIC will provide such information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Corporation does not provide the required information with regard to the Corporation or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Mark-to-Market Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this matter. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Corporation is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Corporation is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Other PFIC Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain additional adverse rules may apply with respect to a U.S. Holder if the Corporation is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Rules Applicable to the Ownership and Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Distributions on Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Corporation is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below). However, the Corporation may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Corporation with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Subject to applicable limitations and provided the Corporation is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities market, dividends paid by the Corporation to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Corporation not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sale or Other Taxable Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder&#8217;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Additional Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Receipt of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign Tax Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the PFIC rules discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Backup Withholding and Information Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Not Applicable</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statements by Experts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at https://www.sec.gov. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (https://www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 4 &#8211; &#8220;Information on the Company&#8221; and Note 17 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our audited consolidated financial statements beginning on page F-1 of this annual report on Form 20-F.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions. </span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Debt Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Warrants and Rights</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Other Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">American Depository Shares</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Common Shares are not represented by American Depository Receipts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_55"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modification of Instruments Defining Rights of Security Holders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modification or Issuance of Other Class of Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withdrawal or Substitution of Security</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Trustee or Paying Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Evaluation of Disclosures and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with  IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;&#160;Based on this assessment, management believes that, as of December 31, 2020, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ernst &amp; Young LLP, the registered public accounting firm that audited the financial statements included in this annual report on Form 20-F, has issued an attestation report on management's assessment of the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Attestation Report of the Registered Public Accounting Firms</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Auditor Attestation Report is included in the Ernst &amp; Young LLP Independent Auditor's Report, included in the Company's financial statements, beginning on page F-1 of this annual report on Form 20-F. </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Changes in Internal Controls over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 .&#160; [RESERVED]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah Brown and Leonard Kruimer is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act.</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B.&#160; CODE OF ETHICS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted a Code of Ethics for our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer and Controller.&#160;&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at https://www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 210 &#8211; 1167 Kensington Crescent, NW, Calgary, Alberta, Canada, T2N 1X7, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no amendments to our Code of Ethics during the fiscal year ended December 31, 2020. We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees and Services</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the financial years ended December 31, 2020 and 2019, Ernst &amp; Young LLP received the following fees:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:183.75pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Audit Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit fees were for professional services rendered by Ernst &amp; Young, LLP for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements, accounting consultations, assistance with prospectus filings and matters relating to the provision of a consent letter for various filings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Audit-Related Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Tax Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax fees were for tax return preparations, scientific research and development return and other tax consultation fees.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">All Other Fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NASDAQ CORPORATE GOVERNANCE</span></div><div style="margin-top:3.4pt;padding-left:4.5pt;padding-right:333pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Meeting Quorum Requirement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws. Our quorum requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_94"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17. FINANCIAL STATEMENTS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18 FINANCIAL STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements appear on pages F-1 through F-31.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19. EXHIBITS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NUMBER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Constating Documents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Articles of Incorporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-laws</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21exdescriptionofsecurit.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex41august2013hagerman.htm">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex42hagermandec2015.htm">Amending Agreement, dated December 1, 2015 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex443deguttadauro.htm">Employment Agreement, dated June 29, 2017 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex47hagermanamendment2019.htm">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex48kirklook2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex49coffey2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex410guttadauroamendment20.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex413hagermanamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex414lookamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex415coffeyamendment2020.htm">Amending Agreement, dated January 1, 2020 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex412employmentagreementth.htm">Employment Agreement, dated August 3, 2020 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex413mattcoffeyamendment-e.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex414kirklookamendment-emp.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex415allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex416andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex417thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex80subsidiaries2020.htm">List of subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex121ceocertification2020.htm">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex122cfocertification2020.htm">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex131ceocertification2020.htm">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex132cfocertification2020.htm">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2020mda.htm">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex152ey2020consent.htm">Consent of Ernst &amp; Young LLP</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (XBRL-Related Documents)</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* - Denotes management contract or agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Previously filed with the SEC on Form 20-F dated June 14, 2002.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Previously filed with the SEC on Form 20-F dated March 19, 2018.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Previously filed with the SEC on Form 20-F dated March 6, 2020.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;5, 2021 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">/s/ Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December&#160;31, 2020 and 2019</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) and all other information in the Annual Report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the Annual Report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, an independent firm of Charter Professional Accountants, has been engaged, as approved by a vote of the shareholders' at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinions on the following: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the Company's consolidated financial statements as at and for the year ended December 31, 2020; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the effectiveness of the Company's internal control over financial reporting as at December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young have full and free access to our Board of Directors and its Committees to discuss audit, financial reporting and related matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following report is provided by management in respect of the company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management is responsible for establishing and maintaining adequate internal control over the company&#8217;s financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has used the Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework (2013) in Internal Control - Integrated Framework to evaluate the effectiveness of the company&#8217;s internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has assessed the effectiveness of the company&#8217;s internal control over financial reporting as at December 31, 2020, and has concluded that such internal control over financial reporting was effective as of that date. Additionally, based on this assessment, management determined that there were no material weaknesses in internal control over financial reporting as at December 31, 2020. Because of inherent limitations, systems of internal control over financial reporting may not prevent or detect misstatements and even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The effectiveness of the company&#8217;s internal control over financial reporting as at December 31, 2020 has been audited by Ernst &amp; Young, independent auditor, as stated in their report which appears herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc.: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinion on the Consolidated Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related consolidated statements of loss, comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2020 and 2019, and its financial performance and cash flows for each of the three years in the period ended December 31, 2020, in conformity with International Financial Reporting Standards  as issued by the International Accounting Standards Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated March 4, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:150%">Critical Audit Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="oncyf-20201231_g3.jpg" alt="oncyf-20201231_g3.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 1999.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calgary, Canada</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2021</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Oncolytics Biotech Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, Oncolytics Biotech Inc.  maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020 based on the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of Oncolytics Biotech Inc. as of December 31, 2020 and 2019, the related consolidated statements of loss, comprehensive loss shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes, and our report dated March 4, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="oncyf-20201231_g3.jpg" alt="oncyf-20201231_g3.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calgary, Canada</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2021</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:402.00pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMtMi0xLTEtMA_64405755-bebe-4d22-9660-2f3ad1fcdd8f">31,219,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMtMy0xLTEtMA_5e18efc1-06f3-4f34-b228-63e0e472463a">14,148,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzQtMi0xLTEtMA_3be87b92-16ed-4608-929e-702a28680d3b">89,661</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzQtMy0xLTEtMA_0fb2c4e2-981f-4aa0-85e9-d2128fa53d20">2,068,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzUtMi0xLTEtMA_08f871eb-a20b-4bb7-a9b8-1503d79a9e97">2,427,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzUtMy0xLTEtMA_7346ca66-0ceb-4205-a824-62b81410e88e">2,713,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzYtMi0xLTEtMA_ef6581ef-73ca-44cb-8595-f7bdc81387a1">33,736,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzYtMy0xLTEtMA_b1b43a25-58ba-40b4-9ecc-810adab65bfa">18,930,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzgtMi0xLTEtMA_7233f138-1f45-4d02-9d5a-8f9c93fb4721">236,664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzgtMy0xLTEtMA_8ca6ee37-86fa-4be7-bd79-53eb9e3cf6b6">296,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzktMi0xLTEtMA_e9a20665-a749-4393-a485-8fc3f4371ae3">372,468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzktMy0xLTEtMA_4a46aed4-c635-40c6-9ac7-669ace0a78dc">430,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEwLTItMS0xLTA_69d50322-4db1-40f5-bbdf-f02b9c79503d">609,132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEwLTMtMS0xLTA_b49c7296-c3e1-4972-b195-5bd9b06eb2fe">727,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEyLTItMS0xLTA_84dc94dc-ee82-4a0b-beea-b241dd8e0e53">34,345,567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEyLTMtMS0xLTA_9c164841-2fa2-42b6-a142-77532dac7f08">19,657,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity (Deficit) </span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE1LTItMS0xLTA_2a481be5-5d82-4da3-b8c4-20655825becc">1,805,015</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE1LTMtMS0xLTA_a4311029-0d25-472e-937a-db3cbff8800e">3,173,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE3LTItMS0xLTA_69e51115-8ac2-4aee-b8c0-50ed67bf1112">123,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE3LTMtMS0xLTA_eba9dbca-865b-4082-87c6-dff353f610b9">847,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE4LTItMS0xLTA_bf250e40-61bb-4a00-aa5d-5efd1899734d">248,885</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE4LTMtMS0xLTA_2b997d94-c432-4bcd-8a1c-d3040c0c8105">339,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE5LTItMS0xLTA_b9a189bf-6381-43a7-90a6-dd740c8123ed">531,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE5LTMtMS0xLTA_d621617f-4ee8-48e7-b088-6bf042d83b8c">8,508,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIwLTItMS0xLTA_775e9670-fcbf-436c-bc9d-024cf2ff9e81">2,709,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIwLTMtMS0xLTA_1b9e66e7-2a28-46c1-887b-db7ab04ff882">12,869,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIyLTItMS0xLTA_94ea7d5a-95a7-4d27-b8b9-b6d453aa8061">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIyLTMtMS0xLTA_897bf93f-2ee0-46fc-8648-43cdb90fe280">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI0LTItMS0xLTA_97d15e02-a5ef-44ed-9984-2cce73db9a09">153,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI0LTMtMS0xLTA_d7632190-de4d-471f-93d5-97eaa4a954fe">166,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI1LTItMS0xLTA_f2f00026-1ac8-4f00-baed-0f18081facce">6,883,461</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI1LTMtMS0xLTA_ebb10218-1354-406d-9202-df20d4092ba6">6,896,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI3LTItMS0xLTA_55abe7b6-4286-4fba-9882-90975d9cccd5">9,592,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI3LTMtMS0xLTA_7624de08-e0ae-4ec5-a55a-9bd6fefe0ecb">19,765,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13, 14 and 19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity (deficit) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized: unlimited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued: December&#160;31, 2020 &#8211; <ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDlhMGQxNjEyZTg0NmMwYTZhOGE4YzM2YzlmMzA3ZV83Njk2NTgxMzk0NjEw_8c46a6cd-8463-4c60-ac1a-c46c05aab9a7">46,166,980</ix:nonFraction> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2019 &#8211; <ix:nonFraction unitRef="shares" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDlhMGQxNjEyZTg0NmMwYTZhOGE4YzM2YzlmMzA3ZV83Njk2NTgxMzk0NjA2_52b9b535-dd71-4682-a1d3-11277c711716">32,198,453</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTItMS0xLTA_ae0ee2ca-6a6a-4bf2-8960-c06b66cfdc76">356,824,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTMtMS0xLTA_395f91ca-cec4-4964-8c84-80e5bd94c369">311,077,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsandRightsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMxLTItMS0xLTA_f0e6f903-93b6-48e2-a861-c8902869f316">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsandRightsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMxLTMtMS0xLTA_cad801bb-1ec7-4b3f-a4e7-445c93b2584e">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionalPaidinCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMyLTItMS0xLTA_9f881a94-850b-4a83-ad86-0472c5f7570c">31,022,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionalPaidinCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMyLTMtMS0xLTA_2f37e57c-d655-44da-af17-264609ec4bd4">29,338,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMzLTItMS0xLTA_f37bd02a-4c06-4846-9072-98fe4d397d92">400,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMzLTMtMS0xLTA_51318a64-ba6c-4021-bb6c-36b23dadb352">464,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM0LTItMS0xLTA_0de66544-4f0c-4e5c-8b70-4a9590e33bb6">367,111,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM0LTMtMS0xLTA_3eb3b3e1-1e7c-4ca7-88e7-920459713c6e">344,606,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total shareholders&#8217; equity (deficit) </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM1LTItMS0xLTA_01e77329-bb5c-44f7-b663-a35b69f809b3">24,752,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM1LTMtMS0xLTA_46bfcb2d-5fe8-4ae5-991b-2a84cd66e9d7">107,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total liabilities and shareholders' equity (deficit) </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM2LTItMS0xLTA_50c2b4a7-0912-4bce-aee0-8595e95173e3">34,345,567</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM2LTMtMS0xLTA_b4695163-2ffe-4a6a-9b9f-541cc9b9d9f0">19,657,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="padding-left:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:46.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;On behalf of the Board:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Angela Holtham</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Wayne Pisano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Director&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Director&#160;&#160;&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:499.50pt"><tr><td style="width:1.0pt"></td><td style="width:229.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10, 21, 22, 24</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtMi0xLTEtMA_57bc22e2-a3ca-483e-84c3-44f01f23966d">12,944,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtMy0xLTEtMA_94792b5b-b78c-439c-ad69-a5e2d80c63b2">10,817,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtNC0xLTEtMA_3a564d04-a807-4c1c-ab47-996b264cd6b1">10,027,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10, 21, 22</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtMi0xLTEtMA_38650c75-4de3-487a-ad68-3d1c8727da8c">12,514,496</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtMy0xLTEtMA_add6e8de-7f9b-4a13-93a6-df7581abc54d">9,558,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtNC0xLTEtMA_7d14e9b6-8f38-4db0-82a2-7c5805c7071e">7,244,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before the following</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtMi0xLTEtMA_55a7bf01-0780-4ec1-9301-6e6865c2e453">25,459,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtMy0xLTEtMA_2dd2f8b4-b95d-4e88-9c8a-593260f4d6af">20,376,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtNC0xLTEtMA_61af5e48-0615-4ef0-b922-b49bbcbeb8a3">17,272,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtMi0xLTEtMA_afdd6306-55c6-4f57-8a8f-7427cc49555f">3,491,928</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtMy0xLTEtMA_dc65d2fa-23da-4c9f-bdb8-e5ad7c508dcc">12,608,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtNC0xLTEtMA_ca7fd50c-beac-40c7-8357-e5db53718a3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign exchange (loss) gain</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">21, 24</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMi0xLTEtMTU1_b7eb8744-6c7a-453b-a977-526ef739f3e7">659,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMy0xLTEtMTU1_2db2332d-f0a3-4cc6-b24d-184a5345cdb4">316,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctNC0xLTEtMTU1_0e733e35-e57d-405a-b067-8d56fb5f176f">610,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMi0xLTEtMA_7b03ccbd-09b8-48ef-ab69-4faf0cdf6374">121,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMy0xLTEtMA_853cba08-b10b-41c8-8c3d-c446109b2a8a">179,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctNC0xLTEtMA_d53cd991-e38f-4e6b-aded-c2f022701ac8">173,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtMi0xLTEtMA_95f666c6-359b-47fa-830d-01984cc85fdd">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtMy0xLTEtMA_0ebc737b-c8ea-47f8-87b2-5f771cd18d4b">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtNC0xLTEtMA_28a2ee46-9df6-4a1f-b665-4bf368a6b1d1">16,489,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">15</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktMi0xLTEtMA_5f5419e9-0eea-4e12-85ef-7c595909afc9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktMy0xLTEtMA_2f0d664e-daf9-436b-b11e-681da5d80c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktNC0xLTEtMA_b7013568-2414-4b7f-89a8-99d403dc7078">548,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTItMS0xLTA_760e7445-aabb-43fb-85be-ec8ad61708c4">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTMtMS0xLTA_3228fa69-dfd6-442f-b978-12d821e8a745">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTQtMS0xLTA_5c265eab-173e-4178-817a-df912223f07a">17,037,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other comprehensive (loss) income items that may be<br/>  reclassified to net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTItMS0xLTA_1f4a4e87-bb09-49fc-a875-6896be8e185b">63,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTMtMS0xLTA_f4a65354-036e-49cf-aca4-b30e94f13021">143,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTQtMS0xLTA_9a7e1ab5-9cd8-4f77-8e7c-75adae9e0ab5">233,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTItMS0xLTA_b18228df-9e27-47f1-8fbc-b186ff2ef07f">22,568,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTMtMS0xLTA_658d24ed-8e5b-4e04-a5e8-b18ee1cb4d38">33,266,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTQtMS0xLTA_b49afd0c-6e15-456c-9f5d-aa64a7a30803">16,803,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Basic and diluted loss per common share</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTItMS0xLTA_1fb4d9bf-c357-4fb3-b824-24cd37027f77">0.56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTMtMS0xLTA_989861e2-0f53-4cd7-ab47-936dff26ae11">1.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="2" sign="-" name="ifrs-full:BasicAndDilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTQtMS0xLTA_6e182e74-6c30-486f-a91e-a17412d32b3f">1.06</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTItMS0xLTA_b699c798-4092-4168-8a8c-be31ebbce2c5"><ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTItMS0xLTA_cbd5b67f-10ad-4a47-8d21-fd68013d5cc5">40,338,789</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTMtMS0xLTA_52da9c68-ff2c-439a-a459-0d9c2e4f6434"><ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTMtMS0xLTA_a5a1ce02-c5f5-4447-8d8d-fb50605bba93">22,137,990</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTQtMS0xLTA_817edb81-9af4-49ec-aa91-752a02aeaf95"><ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTQtMS0xLTA_cc4b8b70-3a1c-4afa-b993-6aa5a2e73f3b">16,016,366</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:693.00pt"><tr><td style="width:1.0pt"></td><td style="width:232.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:89.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2017</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6d2dc50163e54e6db20f3ccf3ba816f0_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtMi0xLTEtMA_4920b968-f97d-41c4-a035-0888534b4e6a">271,710,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id935cd2438124cedb738b9f24443737b_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtMy0xLTEtMA_a7992a82-049d-476d-baae-33b2720f3d93">3,617,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6435e19e015d4b808b125677fa352829_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNC0xLTEtMA_459b4cb2-f5c9-4699-96e1-74d6bf7b4819">27,028,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i60063ff60dff4605b4e8b5483faadde5_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNS0xLTEtMA_f328674e-96c6-40a2-bd99-2a4233920cfd">373,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i906da6928e2f4d77ba1644f365f7df40_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNi0xLTEtMA_6c9a6934-e67f-4a1a-95db-2740f1fe63a0">294,446,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69e26aa497764738a8d24ee240e72834_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNy0xLTEtMA_d6a5f119-a707-42af-b947-d8b84b66e7f4">8,283,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i094c62fa747f4899aeca008f52c1fa6b_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNS0xLTEtMA_c8b36b52-d20a-40d3-8818-525765a9d3cb">233,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="idaa6d8dd8f6146b78474b69d14555dcc_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNi0xLTEtMA_ea0ab1c5-62ea-487a-bbaa-1b4d83033efb">17,037,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNy0xLTEtMA_5e0de05b-a51a-411e-9266-99a92f0ceb35">16,803,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i709c9ca13b8045cd8feecfcbfced3580_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEwLTItMS0xLTA_446a8805-1124-4798-afac-08662d029b7a">620,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEwLTctMS0xLTA_9015addd-477a-4874-bc8e-bdb2eef560c7">620,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="idb8127fce9e04a639cbec7243495cd9f_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzExLTItMS0xLTA_4cda03e3-c31f-4aaa-a96f-ed878499b05c">11,606,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id770e57addee4de3aced4720a0bad691_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzExLTctMS0xLTA_21c3a690-905a-44d0-bf63-9e0d464cf4cc">11,606,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i17b8081505894c88a322be3d879c0edb_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEyLTItMS0xLTA_cdb049cb-4821-4aab-8244-3209d83b08e5">3,314,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i150aa4258e9c4a31b2082f36f70929ac_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEyLTctMS0xLTA_229499ee-5e18-4adf-a386-dc01499414c0">3,314,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTItMS0xLTA_9d34b997-46b2-4e55-8274-e1ee62ecf3ef">197,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTQtMS0xLTA_4adcf98c-5648-46ea-9dd5-47952ae6536e">73,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTctMS0xLTA_6213643c-8942-4412-b98d-51771d2b2017">123,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTItMS0xLTA_76d59992-5723-432b-8d15-e59649fe3e77">109,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTQtMS0xLTA_ab99acb7-9046-4452-80d6-3edfbf61f36d">109,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTctMS0xLTA_347954c1-fea8-407e-9bbd-b2aaaed27aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTItMS0xLTA_259e2422-573c-416f-850d-c971f96d228e">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i99d71b0468ef40768a5f915151140251_D20180101-20181231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTMtMS0xLTA_25f40e75-72ab-45ef-a00a-158df871098b">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTctMS0xLTA_cf50ba4f-1f28-414b-b20c-b681025377c3">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE2LTQtMS0xLTA_2dbf7b0d-2291-4994-9558-954c9a594394">1,415,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE2LTctMS0xLTA_57897687-cfab-404e-89a8-e59576bf6b22">1,415,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE3LTItMS0xLTA_a34c4abc-f54e-4256-81e0-20cf3ad94067">2,366,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE3LTctMS0xLTA_a6373285-3d98-4c7d-9b4d-429e7774e7cf">2,366,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i21916c58eb054ab08a45ae978142cd8f_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTItMS0xLTA_b9adea68-7e5b-4974-8bfc-4a509e84a41a">285,193,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i962cc14c35434620bd55808cd2ba8d73_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTMtMS0xLTA_8ea3ca9c-3ebf-4e72-ae5c-b4ad540faae6">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i51f0a2ff107346a1969c67caf312a512_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTQtMS0xLTA_b5bc5bfb-beee-45e8-9bc7-02cd639ecb64">28,260,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icf7a8f3213d645b8a8fa1b6364129806_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTUtMS0xLTA_f3c19ccf-93f2-4229-ae36-56430219e273">607,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i25846079a5ed4549a9e8ad780e2b2d07_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTYtMS0xLTA_c6b2d2f6-cf09-4ddb-a1f4-7ef4ffcde2a1">311,483,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTctMS0xLTA_449fd1a3-71b8-41d6-b343-c600f9ca99f1">6,195,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i486bc14f55c74a9d826bd06a228146ed_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTUtMS0xLTA_02069ba5-ef45-4295-a6d7-8e963d51d0c6">143,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="iab548591894744e4b55cfc4ab2de9220_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTYtMS0xLTA_2f172b05-e7f6-4be3-b5ba-363c4f0d5b99">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTctMS0xLTA_2b5acd32-585c-4e2c-ac55-5ef9c90dcea1">33,266,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTItMS0xLTA_4b2122e3-07fc-4ade-bbf0-945707cb42fc">391,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTQtMS0xLTA_908995c9-a670-4769-8335-dbb5599ab2b7">391,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTctMS0xLTA_aace9646-2ed8-49fc-9adf-9ada5896362f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iedf74771c263472a9fbac91516305b93_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIxLTItMS0xLTA_81275335-f618-4fa5-a0ec-028922c73193">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3e1683597bdf444baa0a2c591f2efc8c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIxLTctMS0xLTA_262094cd-86b4-4d4e-95d9-003c988cd5eb">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaae50a49b8984e75aee582dcff0d7703_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIyLTItMS0xLTA_328a8279-6132-431a-9129-54f24eff1338">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIyLTctMS0xLTA_9fe828fc-7ab1-496e-9215-993e5f84384e">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0a319f8e847b4b4bb642fd9d86aa5225_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIzLTItMS0xLTA_d872c0d5-896d-4bb6-9e3a-7609fcaf757c">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIzLTctMS0xLTA_8e1e8b4f-b0cb-4d3a-a9c6-66ab4a1fe0ad">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8, 9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI0LTItMS0xLTA_2789dd8b-b92c-4534-93fe-816053ea2660">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI0LTctMS0xLTA_a2b757f5-1c9f-48e3-bc3b-263b77464556">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI1LTQtMS0xLTA_7afb1ce4-7481-4001-ab57-c0bfdc095c09">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI1LTctMS0xLTA_7e5671fc-43c9-475c-9a4e-9ac207cac04b">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI2LTItMS0xLTA_a7ae45bf-327c-4945-b96e-b3b74761aed3">854,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI2LTctMS0xLTA_fcc7efba-61d3-400e-bd24-76eff25f01c8">854,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i29a43f0a866349d8bc5f0b63f8d0e784_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTItMS0xLTA_ce42aee8-5904-4638-9b62-878df76bd13b">311,077,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i562af6df16fd49e5b90954aeea2d4aea_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTMtMS0xLTA_3b7ebe78-a829-4677-b4ae-60e09be4ec50">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96b9cc93c17f4804b0117d1b5087e203_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTQtMS0xLTA_f78814d2-6d48-44a7-8a27-202b2f09d267">29,338,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1a3a4fc591144d32b93f7d833c2d6c8b_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTUtMS0xLTA_ee7a0165-b4b0-4feb-86eb-c7cb94037733">464,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ibdf2ec1b8b034942a3533ec514919b05_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTYtMS0xLTA_f54ed513-8ec1-4dfe-a12b-88f40ef4cf8a">344,606,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTctMS0xLTA_d8ea68ad-ec6d-4623-87d7-f58449621f1b">107,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i76695d2971ca43c4829d183db3ebe53d_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTUtMS0xLTE4OA_021ee140-e40a-43ec-8cdc-cfd377e8f819">63,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i914f2dfba8874652a9bc67c5190a974e_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTYtMS0xLTE4OA_46212bda-9d30-48d5-9f7e-28baec540e70">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTctMS0xLTE4OA_cea47115-727b-4ea4-bc76-7a5f4cdbab19">22,568,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTItMS0xLTE4OA_e785f5a1-4291-483b-a8b0-188af22d5ac1">385,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTQtMS0xLTE4OA_ca6c9a3f-29d0-40b3-9c73-195e70173dae">143,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTctMS0xLTE4OA_2024aaf2-533c-4a83-9bb6-acbc660096b8">241,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTItMS0xLTE4OA_1d01b14e-0096-4525-b88d-e9b8891bd5aa">732,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTQtMS0xLTE4OA_3cae49d0-942b-4db6-af9d-620c9119503d">732,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTctMS0xLTE4OA_5095c31f-ef09-45b0-a3ab-627204252b40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie624bde674254422be5db7d03183d08e_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMxLTItMS0xLTE4OA_1b313b21-e1fb-4431-b6b0-0de7043f317c">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMxLTctMS0xLTE4OA_49051eba-5724-49fb-9b96-c9448e29006e">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8, 9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMyLTItMS0xLTE4OA_1affbf32-698d-4a47-afed-ce5375c7ba7d">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMyLTctMS0xLTE4OA_7a34e01a-49a0-4a82-9f54-fc9d78ba40ca">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMzLTQtMS0xLTE4OA_2520a124-65a8-4549-a900-04483d03c6d0">2,558,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMzLTctMS0xLTE4OA_9c5872d2-e1a8-44bd-bcad-d3ac518a228d">2,558,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM0LTItMS0xLTE4OA_787626ab-f6b6-4842-9342-f191152b8dfd">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM0LTctMS0xLTE4OA_6f5df0b5-1484-43dc-9fa9-5c862a1647c4">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i146d8b2a85a9470192da0785eb8a6240_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTItMS0xLTE4OA_11f69422-8a1c-4522-9ebb-7bb7249aab71">356,824,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i60c164267fc04f55a74c61c77cf6e840_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTMtMS0xLTE4OA_ea4c9a81-349f-4cf3-9d7b-7233194b4249">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6090088661d04f81ad4934969e730d18_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTQtMS0xLTE4OA_4c7c31d6-4c01-4e35-b639-e38015474d8c">31,022,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iacc3c9e5c988498783bbc9fa6d366285_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTUtMS0xLTE4OA_aeea22da-7055-49b2-a286-8d5a8ed3174a">400,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i99c0248efb984ca8b2400ce4a3fa18cb_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTYtMS0xLTE4OA_355711a2-7770-4d31-becb-ced1cb64ebb9">367,111,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTctMS0xLTE4OA_41faab44-fec1-454d-8b0c-a12a5f881aca">24,752,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:485.25pt"><tr><td style="width:1.0pt"></td><td style="width:232.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtMi0xLTEtMA_6e40f2ff-d25f-40de-9ae7-98fdd0101132">22,505,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtMy0xLTEtMA_df5759a4-37fc-4043-9847-e2b67bcefa1f">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtNC0xLTEtMA_9075bc31-c570-47fa-a5f2-06ab8e6b0823">17,037,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6, 21</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtMi0xLTEtMA_92c63fc9-85f2-4144-8cfb-125f5b59aa9c">88,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtMy0xLTEtMA_718abb14-157f-4497-8fd0-496e37fed1d7">122,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtNC0xLTEtMA_535e4ba9-33e6-40f4-b44a-11ee082485ef">95,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7, 21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtMi0xLTEtMA_28f736e2-3457-474b-aea4-fcd0a96c881e">357,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtMy0xLTEtMA_9fe9f2f6-d664-4af1-a6e0-7abf2c6306a0">362,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtNC0xLTEtMA_7f91e387-8e22-4118-8b34-89aa286b1bc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10, 21, 22</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtMi0xLTEtMA_56ed7286-cace-4b1b-964d-7f2443fd11b7">2,558,974</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtMy0xLTEtMA_f3553364-790c-4f55-b145-accd127e5806">1,470,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtNC0xLTEtMA_b5e858e6-c746-498c-978c-b92dc8abd97f">1,415,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctMi0xLTEtMA_43a7060f-67b4-44ae-b467-eeec27b9ebc9">68,526</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctMy0xLTEtMA_f7feef5e-3ca8-4ae6-a9b5-a9ceeaab9218">94,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctNC0xLTEtMA_671758f2-a3d2-414b-be3d-10d951f14454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtMi0xLTEtMA_e62d5638-3c02-4baa-ad9a-4d308e2f3c1f">645,078</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtMy0xLTEtMA_03810734-5ca5-47d9-8a4c-3f302a2120dd">353,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtNC0xLTEtMA_e241ceee-b3f9-410a-afc9-9ddc915db3ce">374,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onerous lease contract</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktMi0xLTEtMA_3416480d-23f5-432f-b277-69e00cac855c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktMy0xLTEtMA_988f847d-71e7-4265-96c0-49b2b151ea0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktNC0xLTEtMA_b318fdee-cf42-46aa-bd73-af97f2ec1a6b">67,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization - lease incentive liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">21</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTItMS0xLTA_0b25e2f0-971e-4f03-8126-aaa2abfe7ba0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTMtMS0xLTA_67d5f1e8-add3-4ece-9d96-d89e18918266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTQtMS0xLTA_649a70ba-5820-4648-957d-91a3c890641d">8,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTItMS0xLTA_ec3dd849-aa53-4914-85bc-1903502f3e10">3,491,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTMtMS0xLTA_63a2d649-0806-4e94-a90e-0d1320b8b3f3">12,608,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTQtMS0xLTA_d8b1c07d-62e9-4603-ad5e-c26c7ece7e4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">18</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTItMS0xLTA_908f88de-10b2-4005-868a-4f210c102bdc">209,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTMtMS0xLTA_aa3740f9-c337-4897-9b11-c3a4e87db88f">1,795,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTQtMS0xLTA_5780bff5-f7df-4a5c-a3aa-2a5c49f4d20b">3,904,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTItMS0xLTA_19967308-7729-4b69-af87-5d09b6167d41">22,068,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTMtMS0xLTA_85b559f2-4517-4a6a-930a-ed15dae4fd2e">19,906,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTQtMS0xLTA_ccf81870-9263-4562-807b-391f427f6e10">11,920,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTItMS0xLTA_81bb4d40-3a9f-4f30-8744-2e83b71c7a54">29,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTMtMS0xLTA_1d99bd7c-8437-4b77-a575-00b57fa2ca4d">10,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTQtMS0xLTA_9709ebd8-a0a9-482a-a4c0-eb95e7868c6d">107,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTItMS0xLTA_25b26a82-e385-4da4-9890-1e64912407c3">29,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTMtMS0xLTA_c81d9e62-fcd6-4d6e-b522-8af1a451d3de">10,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTQtMS0xLTA_ea1ea46a-5903-4416-ae1b-313c63a40ee0">107,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTItMS0xLTA_cdb6081b-5e35-4e0e-befc-c2ef687dde07">241,922</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTMtMS0xLTA_18b29d89-c7d0-489e-abd2-234161a3003f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTQtMS0xLTA_d546a8a4-33fe-465f-bebc-4257654bedbf">123,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8, 9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0c4f5982efe94fd9bfde6746d570342d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTItMS0xLTA_7aaadf36-2b35-42da-a2fd-e0a5940a91fc">1,696,460</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie7eb63a1dc564425a34c178e971918c4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTMtMS0xLTA_51d9ca67-9e94-47d7-9dd3-ce8192412797">3,465,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i53aacee4c85d4d55b6cf4d4273d55c08_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTQtMS0xLTA_8fbd20a0-4060-41db-ad62-82e9add0e339">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie23b49ebdb2744409fa1b9c0240e0941_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTItMS0xLTA_600bb8c4-b3e0-4a0d-8601-f78ca990b28a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1e0091234801409c93750ab9a547e561_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTMtMS0xLTA_79e56023-807f-4345-8682-e96289fd4616">5,360,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i591759eeeca54189b9eeaf5b33f1ebf0_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTQtMS0xLTA_c0d2256d-4cc7-4c1f-8aab-4117b461a393">2,533,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "At the Market" equity distribution  agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTItMS0xLTA_621dae4c-3365-4484-a79d-168ac5cf5685">38,296,146</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTMtMS0xLTA_ecbf6489-fdd8-4b7f-a9f5-6ae2bf614c82">8,131,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTQtMS0xLTA_007a3cbd-b583-4f8f-bb1b-ce5bca406278">451,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7aec3edd676f499ab586efe1570a2ae3_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTItMS0xLTA_c42e85a0-8854-477e-95f3-1afba42c73e1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTMtMS0xLTA_18acac83-15f7-4676-a4d1-d46c7e744a35">4,505,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id770e57addee4de3aced4720a0bad691_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTQtMS0xLTA_d4acfaff-7be8-4f58-9389-bd8f21040d6a">10,188,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTItMS0xLTA_332cf8ab-feaf-478e-b2d8-c8d358beec0d">460,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTMtMS0xLTA_2d6ff412-f88b-41cb-9535-28b72d0bb851">447,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:CashOutflowForLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTQtMS0xLTA_7b8f09ed-565d-4723-856c-ea3c2ebc6c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTItMS0xLTA_d3322e3f-5509-415f-8ec9-b5a93f2915dc">39,773,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTMtMS0xLTA_cde6cf54-fab7-42ac-be5c-97c3a118702c">21,015,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTQtMS0xLTA_1659b0ae-9219-47ba-857a-adcdbec9a18d">13,299,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase in cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTItMS0xLTA_5db094c9-19a7-4bb7-bd97-e5100b7f0ea4">17,676,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTMtMS0xLTA_42d34b24-3162-463f-af67-6f99a7bab65b">1,098,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTQtMS0xLTA_fad8860b-4b67-4d3b-b169-3c72a535d27c">1,271,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTItMS0xLTA_f2179b6f-8eaa-4a16-9350-e0f101386acf">14,148,021</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTMtMS0xLTA_0c4eb03c-4080-4956-b61d-2206e80d59e6">13,699,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69e26aa497764738a8d24ee240e72834_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTQtMS0xLTA_98ec0741-2a19-48db-8695-ba2c0919327e">11,836,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTItMS0xLTA_a8b880f8-1c5b-4cc1-8693-b58b3c6d66c4">604,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTMtMS0xLTA_e7822abe-6741-4328-8154-653a589f87b7">650,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTQtMS0xLTA_dfcecdfd-7a7a-4ce7-bc43-979ee243cac3">592,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTItMS0xLTA_592d0919-b4e5-4f5d-a4a4-2dca95820426">31,219,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTMtMS0xLTA_ae2ca62a-8763-4924-b9a1-2e05d9efc74c">14,148,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTQtMS0xLTA_4118a5af-7be1-48e6-8d00-8a01efb31c7e">13,699,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_136"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzkvZnJhZzplNDUwY2JhY2E3NTg0MTcxOTc2NmU4MjIyMGZkMDI2NS90ZXh0cmVnaW9uOmU0NTBjYmFjYTc1ODQxNzE5NzY2ZTgyMjIwZmQwMjY1XzE1NjY_11010276-28dd-4d40-95b9-4cc24a8de942" continuedAt="if59dd7ceeb46498ea7b9883a3f460cd0" escape="true">Incorporation and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="if59dd7ceeb46498ea7b9883a3f460cd0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;4, 2021. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDIvZnJhZzo4OGVjNjU1MGU1MGM0NTEyYTg1YjZiNzIyNWI2ZDZkYS90ZXh0cmVnaW9uOjg4ZWM2NTUwZTUwYzQ1MTJhODViNmI3MjI1YjZkNmRhXzEzODE_0bdf0446-d493-4209-ab78-36b8299b1e77" continuedAt="icfabb10ad9c8419d9d68f9bbdeea6ea8" escape="true">Basis of Financial Statement Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="icfabb10ad9c8419d9d68f9bbdeea6ea8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (U.S.) Inc., and Oncolytics Biotech (U.K.) Ltd. and are presented in Canadian dollars, our functional currency.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 3: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDMz_55c41236-093b-4778-b83b-1c499f45dc30" continuedAt="i83e3893168b249039f49b103fc7e9eee" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i83e3893168b249039f49b103fc7e9eee" continuedAt="iad8a9fcc556041e6867039db89a79eff"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDI4_aa5e59e4-3f77-48c8-ac36-f71cf4eca122" escape="true">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ix:nonNumeric>  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="iad8a9fcc556041e6867039db89a79eff" continuedAt="i2ee518ac65bd443f9550a48297a869b4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDIx_429a699e-ceb0-488f-b8d4-8b7644dcf32a" continuedAt="i01f60c019cd3492a81e2a67784f76996" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments ("IFRS 9")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01f60c019cd3492a81e2a67784f76996">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDIw_3b2bccfc-88f4-461d-af7a-4b7e5f5ad699" escape="true">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.</ix:nonNumeric>  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDE2_1ab72101-793f-4f91-b950-b50c48b43e1f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzcxNDY4MjU2MDcxMTI_cff13d3b-1dc0-40e6-9389-804ba5d24783" continuedAt="i9ec38838b21741288594a818b510f507" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ec38838b21741288594a818b510f507">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDA4_b95cc2fa-3bd3-4633-94d7-223281a41b39" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDE3_36328cd6-97f4-4d1c-8085-19ceaa962669" continuedAt="ifc7cff0a8f7146b1a322862ea7cf3b91" escape="true">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i2ee518ac65bd443f9550a48297a869b4" continuedAt="i7d3178f72be543eaba58e5860387e117"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc7cff0a8f7146b1a322862ea7cf3b91" continuedAt="ibd156fa963a5427aa4aabb05fcb3047d">transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd156fa963a5427aa4aabb05fcb3047d">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ix:continuation>  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss per common share</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDAz_79de8b3c-cdd5-429f-979b-6bf3fe7c5210" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property and equipment </span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDM3_dd48ee65-952f-4c46-8462-71f3983e2f7f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDA0_7d3fd11d-05f3-486e-81a5-db293ada21f8" continuedAt="ieb0cdb98ebec4dcbadcf9e84f2112701" escape="true">Depreciation is recorded using the declining balance method at the following annual rates:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ieb0cdb98ebec4dcbadcf9e84f2112701" continuedAt="i77ad38e93b904c0287e1e713e6392e0a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"></td><td style="width:47.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacdf4b3e43034c8187484f366189cec0_D20200101-20201231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzAtMS0xLTEtMA_40228936-6d34-41db-bee3-78cf6a5e10c8">20</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4fe19e601e24c888cb45375f76fb410_D20200101-20201231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzEtMS0xLTEtMA_fcc05c5b-a405-4e7a-bebf-1b5b93a4ff80">20</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02d52a25ccdf40d1a3e77fa4d8cedd50_D20200101-20201231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzItMS0xLTEtMA_fef5808d-2de5-4ace-a51c-8cb711796da3">30</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDM5_85b0f2cd-2448-4c9f-ab4e-08e329d609a7" continuedAt="i2e4652f2da9b450caeb45d4b39fe4e6c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i7d3178f72be543eaba58e5860387e117" continuedAt="i736fc508c5334fb4bcb845151f758156"><ix:continuation id="i2e4652f2da9b450caeb45d4b39fe4e6c" continuedAt="ib99f49e1596c47dbb46d0e26f33794bf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib99f49e1596c47dbb46d0e26f33794bf">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDMx_f7521531-b04b-43b8-94d4-1b42d366c6d0" continuedAt="i200a9cf72be5459b889d6eeaf7612511" escape="true">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i200a9cf72be5459b889d6eeaf7612511">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDEy_e5abccf7-b2ab-4788-a9f6-941916c4768b" continuedAt="i61ee8bca0c784101a06971573e7bb46c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i736fc508c5334fb4bcb845151f758156" continuedAt="i1ef7358d89d7439e8974342d399428a4"><ix:continuation id="i61ee8bca0c784101a06971573e7bb46c"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share-based payments </span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDQ2_372ae9c1-9c44-4de1-a2c7-ed7550bec51c" continuedAt="i596079b8eb39418e9bd440b3c1a2b262" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:NumberOfStockOptionPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzE1NzA3_188ae0a5-e06f-4448-8fb7-33bafd030d4f">one</ix:nonFraction> stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt-sec:duryear" name="oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzE2MjE3_eb4e5601-98a1-4817-abfd-79abb915623c">10</ix:nonNumeric> years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ef7358d89d7439e8974342d399428a4"><ix:continuation id="i596079b8eb39418e9bd440b3c1a2b262">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_148"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDgvZnJhZzo3ZTVlNGI5NGMwNzA0NmRmOTIwMzcxZjgwNGRiNmExNi90ZXh0cmVnaW9uOjdlNWU0Yjk0YzA3MDQ2ZGY5MjAzNzFmODA0ZGI2YTE2XzUyNzE_16e7937a-77e9-4860-b022-9947c2ce5b81" continuedAt="i5766e36babb3433da71e70916a7e97bc" escape="true">Significant Judgments, Estimates and Assumptions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5766e36babb3433da71e70916a7e97bc" continuedAt="if7db411d1258405183f441ca52d022ae"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2020, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based payments </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="if7db411d1258405183f441ca52d022ae"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</span></div></ix:continuation><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIyMA_bf458bca-01c2-4e93-9b6c-9a3683588c00" continuedAt="idc0535d3f3804eec9991a3810985ebe1" escape="true">Cash Equivalents </ix:nonNumeric></span></div><ix:continuation id="idc0535d3f3804eec9991a3810985ebe1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzEyOA_4f5bf3df-c367-4bde-a86a-e9736b60ca41">30,361,591</ix:nonFraction> (December&#160;31, 2019 &#8211; $<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzEzNw_78f4b94e-cda5-4cbd-8d2c-109e10c48a67">13,058,092</ix:nonFraction>).&#160;&#160;The current annual interest rate earned on these deposits is <ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="4" name="oncyf:CashEquivalentsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIwNA_26253451-c818-4029-a6f2-80dfaa8c91a0">0.36</ix:nonFraction>% (December&#160;31, 2019 &#8211; <ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="4" name="oncyf:CashEquivalentsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIxMw_ff9afb26-10d9-40bb-ab4e-f7022934fbf7">1.17</ix:nonFraction>%).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_154"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90ZXh0cmVnaW9uOjk0M2VhMTI5NTQxNzQ4YTZhZDJkYmI1MDU2MDE1MWQzXzQ2_8a3684b5-f895-4945-b42c-7b31eadc828c" continuedAt="i2acbeb476e724253b2fe742ea2da392f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i2acbeb476e724253b2fe742ea2da392f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><ix:continuation id="i77ad38e93b904c0287e1e713e6392e0a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:121.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:69.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib06e365abc0d41b58a7b3cdfa48a3679_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMS0xLTEtMA_f63468e7-48fa-4db6-ab9b-62d1e172fe90">60,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b6986d4b1f04f6a904bdd51c5d79c18_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMi0xLTEtMA_f4b4f796-74a0-440d-ae55-33ed3f52e6d7">345,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2c148463e6434c3aaafd2ff899545a17_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMy0xLTEtMA_dc77e472-a9e3-45f5-8f33-8fb773eb7bcc">247,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaaa4f6a1ffb546c5a334dd8511ac2d42_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNC0xLTEtMA_a8694212-6ee9-4341-ba76-6ee23018c2e6">105,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4655f1fa7ede498fae573a51a97ed506_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNS0xLTEtMA_8c0abf7a-7930-48b9-a8f1-1af4843f68a7">498,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i56533e258a8349e2b1036c892d892ccf_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNi0xLTEtMA_281fcd68-9f5c-4182-9966-9aa7b3753444">1,257,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2cea8db44544431e891019dff150dd98_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMS0xLTEtMA_129c2db3-8d90-42da-9a25-8814b09e3387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee202aacf30f4366b9853640242782a2_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMi0xLTEtMA_6f68b397-3cb0-4b38-b16c-1a95eaf0bed2">7,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i257b3f18166343278211f238c2dd1391_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMy0xLTEtMA_3370db88-a223-4087-93a5-5efae639194b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNC0xLTEtMA_96206589-5235-4b42-9195-cb53128828ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNS0xLTEtMA_f6b00fee-a954-4b5d-b5bc-8de7b632cfd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNi0xLTEtMA_2ef946c4-c4d3-49ad-9fd5-80c72c896e03">7,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2cea8db44544431e891019dff150dd98_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMS0xLTEtMA_2eb18046-cd33-40a2-aac1-2c5c26de65e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee202aacf30f4366b9853640242782a2_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMi0xLTEtMA_7288948d-d2ca-4fa1-bae6-8710e4f7c273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i257b3f18166343278211f238c2dd1391_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMy0xLTEtMA_6fdf1b96-2190-4b85-bc57-5a94c86fb9dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNC0xLTEtMA_e380d782-8992-46cd-b55b-3312eb7b9965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNS0xLTEtMA_a3a067a6-55d7-4ecc-a900-80f426e03b80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNi0xLTEtMA_dc1d6b59-6226-41c3-9d6d-b4b0ccd10a61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia8a7de3dc38546928f9df260409a9610_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMS0xLTEtMzEx_6879b832-c19f-45fd-8e98-4df96af7887a">60,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i975b34c09afa4efca073be66a065bf73_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMi0xLTEtMzEx_254d16cc-935e-44d7-8c69-7d275d6442ab">352,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8c222353eac842659f464fd34266ded9_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMy0xLTEtMzEx_a13d6f45-3d2e-4f3e-adc6-0e11543aaf5e">247,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i268d98dd221747dd8a4a11bc620dd8f8_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNC0xLTEtMzEx_5c39b590-9e8c-43f2-b633-f7dcee8ada31">105,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie83afaabad954ec4895f2c369a9d6f75_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNS0xLTEtMzEx_8c1d9135-5140-493a-80c5-e511fda1696e">498,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia99ca2509feb4a0ea2f8357c20cae1ae_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNi0xLTEtMzEx_11e2dfc0-4c9c-4c9a-8cb4-29f46352b960">1,264,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMS0xLTEtMzE1_6e2dad10-a558-4b24-8d7c-03ee44d7c44b">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMi0xLTEtMzE1_7cc8d8e8-3135-49f2-a836-4c1154b5b7f1">27,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMy0xLTEtMzE1_b8e7cb88-6b1f-40d0-bd0a-3462bc8f1a72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNC0xLTEtMzE1_45184add-b0e7-4677-9d66-1fa48601d855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNS0xLTEtMzE1_2dc17a07-f500-4481-be96-b6b657e9e60b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNi0xLTEtMzE1_bdebcd19-8c25-4ba5-85d8-350e0d037b2a">28,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTEtMS0xLTMxNQ_7e2177a7-ad9e-416b-9799-84ecb4596c13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTItMS0xLTMxNQ_4eef2496-9e43-4d33-a898-3afc6bc913c4">15,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTMtMS0xLTMxNQ_61a6c87c-b3a9-4056-aabf-f589cc60d5f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTQtMS0xLTMxNQ_37c8352f-3527-497f-ab09-d9fdda6f428b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTUtMS0xLTMxNQ_cdc991d4-8a03-4e43-a41f-6aea331f2f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTYtMS0xLTMxNQ_c7d185ab-f15c-469d-a772-49d1ad3516dc">15,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="idc3cd77a1b7d43c5a6cd445b718cdf8d_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMS0xLTEtMA_fc07482d-8b1d-41c5-a5a9-623fda740326">61,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i71bcd083c6824318a0e66fc53b430792_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMi0xLTEtMA_ec8e5cf1-00bc-4e7a-8897-488e17c599ea">365,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i89b6f7f3189d49abb49de0e01b7e44ce_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMy0xLTEtMA_84b902ba-37ba-4b98-8102-f6c90a6072b6">247,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8f6d1b20ef4741adb4cf59f9baae80d7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNC0xLTEtMA_cf321c03-2c18-4164-b988-ffcaad5d5664">105,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i06f34c507c5a459a8a88148e94bf32e9_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNS0xLTEtMA_c5e49906-427c-48e1-ab0d-06edd3fa2b11">498,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifd0cebabc5f343b080b31d7829dc92c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNi0xLTEtMA_9d4ed25e-67bf-44dd-a6b1-f51f04bfd1ec">1,278,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1af37e2b626f4990a2de0594206009fc_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTEtMS0xLTA_babaa8ac-30f9-4f31-bc13-7362047ebcec">24,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i95589ae338604bb095806c15a829cbe2_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTItMS0xLTA_19531485-5178-4d9a-b7c3-f0ea2b59d976">174,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5608138db81c4378b9e3057d7fe8a191_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTMtMS0xLTA_f89c8a1f-25c4-4bdc-9c31-c4cdfe8daeaa">157,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9f507765d834457c84f195dc7edc1f22_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTQtMS0xLTA_4f751a93-b8bd-422f-9639-ce6c47dc3656">72,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icdd208fddb4e4c54a4009d5ed906ab60_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTUtMS0xLTA_0ac22abe-3093-4734-89ea-5210748e1e5c">414,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib110db811cd046fbac2029260a02467b_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTYtMS0xLTA_dde44c5b-b460-4012-af38-d243843dbb3e">844,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTEtMS0xLTA_4e3f4301-7b37-402d-91fb-2f0529b5ea9a">20,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTItMS0xLTA_ee79c064-59ce-4d45-884a-ad3dc7b0156d">49,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTMtMS0xLTA_b2e7a056-b26f-4f5a-b284-8acb5b82fabe">14,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTQtMS0xLTA_96e50a15-8eb8-4514-9a02-f7f5c43c2100">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTUtMS0xLTA_6646064d-2549-4b45-8f71-7b63d2aecb1a">33,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTYtMS0xLTA_4ef43370-543d-421a-a2f1-ad46e4bd64d1">122,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTEtMS0xLTA_e75fc082-59d7-4d25-876e-42faa0376cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTItMS0xLTA_21d4c5ba-7fc6-4d91-a1e8-593d3fab02d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTMtMS0xLTA_4b46b4e8-0de4-4b45-8424-3f9c00803eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTQtMS0xLTA_bfb8c13a-12b1-4949-a395-6474ac50b5f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTUtMS0xLTA_cb06b8c8-c00e-458c-b01a-cad3be6a869d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTYtMS0xLTA_b4d3bbcc-acee-4497-924e-c698c5d9597b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1656f7c240ef4a678ed77b1775d078d4_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTEtMS0xLTMyMw_64f1666a-da46-4bfa-a4ca-33380735965e">44,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="idd46cf77bd84410f9d1ab54ec16f5575_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTItMS0xLTMyMw_f93f222d-e53f-4f17-9ef8-9926415a84bf">224,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i17b47ea4e17640a387dc2928c713393c_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTMtMS0xLTMyMw_cf9a30bf-841e-4ff0-87b2-d366df6ab2a7">172,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i53a02a4f770f476189f841381bc8b9d0_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTQtMS0xLTMyMw_1e6c42f7-f760-48aa-842d-c20105b89427">78,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1c686540959c4e5c86fbde52e38211d9_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTUtMS0xLTMyMw_4646e971-781e-4b00-adef-0026da456a92">448,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7f643d6a99d44ee996c4b204e5c8cef1_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTYtMS0xLTMyMw_fbdef112-9eca-4281-b346-ee015027930d">967,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTEtMS0xLTMyMw_9e112183-63ea-4516-8b83-9e1e7afa831c">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTItMS0xLTMyMw_9e6e358b-71dd-4dd0-9b02-74134f2c5972">40,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4736152495f44911a78b2700c5477e6f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTMtMS0xLTMyMw_81d9ed97-e556-445f-bdfa-03072d13e8a1">7,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTQtMS0xLTMyMw_a794a8d9-72dd-4224-8c7e-a8b70c3ad5c3">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTUtMS0xLTMyMw_707e7ad8-f0e3-4c4e-bf60-ccdb97d7f207">33,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTYtMS0xLTMyMw_a6604176-14d9-462f-b79d-5e88de9d2a21">88,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTEtMS0xLTMyMw_61e78301-dbe4-42e9-a98c-b61a6ac8ec4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTItMS0xLTMyMw_58d5aa86-006f-4845-b915-e8321d076ab0">15,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4736152495f44911a78b2700c5477e6f_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTMtMS0xLTMyMw_5a8d6019-1f1b-4aa6-9dd1-8a0531a0e33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTQtMS0xLTMyMw_6bb1a64a-43f4-41f5-8dee-fdb224151b51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTUtMS0xLTMyMw_0d59f5c5-bbe0-462f-be34-7d26c525925d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTYtMS0xLTMyMw_e14b5ace-9b1a-4be3-95a4-08d9a0e3ff67">15,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i93ba725d95a6450888552f6a4b9c7cda_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTEtMS0xLTA_3b640467-e7b1-4a4e-b781-a6132e7ee73c">47,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2ca8fc2742454766b4a9bee74b6996c3_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTItMS0xLTA_59f1f9c2-a3e1-40f9-b77d-d8c2504fb925">248,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i80e12d3e53584943aba148ce1dd9619c_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTMtMS0xLTA_57bc8d05-cc30-487e-bf35-e92002a017ab">180,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i89fe6774bf5c4a27849fb882fbafeedf_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTQtMS0xLTA_0a4ebedd-7c88-45ad-9f32-55e0ed4961ff">82,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2870641ce4c84e3b8447a0c27f0e300d_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTUtMS0xLTA_b317f0f8-5409-4144-8ec1-3332de36abb7">481,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic591edc2e85b4d218e8613fe7eab62f3_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTYtMS0xLTA_99ecd810-5e74-4e36-a8e6-f3174f089a81">1,041,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i85d577f40a6943b58f48867c0d5abfc3_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTEtMS0xLTA_4cf2c249-60a4-43c3-88c1-ad041a5f98b9">13,862</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i14cbb33f0a794897ae108913ed8cf4f6_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTItMS0xLTA_6f7bddf3-c34f-4b05-b9b0-ba28a42a484e">116,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i27cde419036d4d169847c09cbecf4717_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTMtMS0xLTA_5b87f7cd-adad-491e-8ba4-a4c565f73d1e">67,033</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie74dd4d434d245e2a524758edc8a73b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTQtMS0xLTA_2d4187ee-9ffc-4195-84e7-9cf1f6faf5ba">22,739</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaa2fdee1c89e4724bc66d086bb390c86_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTUtMS0xLTA_56406d8e-111d-455e-b6eb-208547c5ae4c">16,426</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTYtMS0xLTA_3d2a7f57-259d-45cc-bde0-af8a6c4b3e03">236,664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if32873cbf8ad4247a3aa058d3a8c0f0f_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTEtMS0xLTA_6d64fe8e-c800-4db0-8fbf-ea0df3618f4c">15,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1e06eabd4bba416db2a6ea0aae6fdcf7_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTItMS0xLTA_5187595e-0db4-43a6-8456-10e865d14ce6">128,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9345d7396c654329be1b09069b9f5e75_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTMtMS0xLTA_186c53d4-32cc-4f05-9182-72a339f2a56c">75,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i125186a4e4e54e67bb5d103d16aec302_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTQtMS0xLTA_9fcf9311-bdaa-4586-b328-d182d97aacfe">27,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic411ea96f38e4c2a8f99ab7b026cebf3_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTUtMS0xLTA_8f18a7ce-87ed-4f3b-82d1-78e14ad73886">50,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTYtMS0xLTA_3249ca9b-f784-492c-bcbf-78290a8d9a0a">296,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3NQ_a70988b6-2392-45b3-83bd-dc20268e7938" continuedAt="i9c6e3a58b3404ecaaefd9f5448964cc3" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9c6e3a58b3404ecaaefd9f5448964cc3" continuedAt="i9217d3d61b964ffd9b79ea9aa9dcfcc6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between <ix:nonNumeric contextRef="i6977c19ac3804e89bd0cdabd80283dd4_D20200101-20201231" format="ixt-sec:duryear" name="oncyf:OperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzEwNg_3fc25119-1030-4c26-aebe-423d93d0e3cd">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i7ee20efa67c54f03b5de8025f70b242c_D20200101-20201231" format="ixt-sec:duryear" name="oncyf:OperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzExMg_a82e4e9c-9cbf-4985-a271-6452cf298f91">5</ix:nonNumeric> years. We currently do not have leases with variable lease payments, residual value guarantees, or leases not yet commenced to which we are committed. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was <ix:nonFraction unitRef="number" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzUxMw_75c71c87-377a-4926-8683-7b65113bd27f">15</ix:nonFraction>%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we entered into an office space lease for one of our subsidiaries. We recognized a $<ix:nonFraction unitRef="usd" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0Xzc2OTY1ODEzOTU5Mjc_ba0ef9f4-7ae2-4efc-a700-28ed0fa0dcc0">297,373</ix:nonFraction> right-of-use asset and a lease liability of the same amount. The lease provided for <ix:nonFraction unitRef="renewal" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt-sec:numwordsen" name="oncyf:NumberOfRenewals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0Xzc2OTY1ODEzOTU5OTY_f4ab2fc6-4374-4d1d-b219-769773456b65">one</ix:nonFraction> extension option that we were not reasonably certain to exercise at lease commencement date.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i9217d3d61b964ffd9b79ea9aa9dcfcc6"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3Nw_3ed818f4-1a18-4a1e-84b4-ae0aa3322247" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right-of-use assets               </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:280.50pt"><tr><td style="width:1.0pt"></td><td style="width:223.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzEtMS0xLTEtMA_c3ec2b07-dd29-4984-b7a2-4c12193f936f">808,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMzc2_f1b69f8b-b80a-41f1-b5ec-458738b283ee">362,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzMtMS0xLTEtMzc2_b421cf52-91f6-4b26-a2f1-bb973ccd5112">14,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzQtMS0xLTEtMzc2_076d6d89-eebd-497c-bb97-cc40e74069de">430,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMzQw_d66a73eb-119a-4287-8c51-8b7a65f4dfc0">297,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMA_7cce76ca-ecec-43db-8d03-c7765b1c3b09">357,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzMtMS0xLTEtMA_f8a841e8-0525-4e9f-8414-a7a4bd1cf44c">1,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzQtMS0xLTEtMA_a164fcc0-4a93-4020-9273-c3942a89d594">372,468</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzcxNDY4MjU1ODIxMTY_dae1dd70-6ec0-4417-921e-d2069d351e55" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease liabilities                  </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:279.00pt"><tr><td style="width:1.0pt"></td><td style="width:222.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzEtMS0xLTEtMA_2df6585f-b6f2-44a5-83a1-0983c9b2a786">882,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtNDEw_ea35e61b-92db-46e2-baea-cf9e46e18413">447,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzMtMS0xLTEtNDEw_86b9b932-a15c-4df5-9ff1-488f6d39b468">94,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:GainsLossesfromForeignExchangeImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzQtMS0xLTEtNDEw_8b204ba4-e1fb-4fe3-8298-eb83200c3fce">23,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzUtMS0xLTEtNDEw_cde8c58a-658e-4ffa-9612-5463a0301a31">506,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtMzUx_ad1a24f2-cf64-448e-9f49-b6884f20e60c">297,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashOutflowForLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtMA_66c70e17-1176-4566-b2bc-88ade648effb">460,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzMtMS0xLTEtMA_4c0086ac-00d7-4c8c-9d5e-a7f12ea3a2f8">68,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:GainsLossesfromForeignExchangeImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzQtMS0xLTEtMA_3cbc9064-d181-490b-b015-248b9169077d">9,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzUtMS0xLTEtMA_3a7a8ebd-a91e-4e1f-9211-2b67bfb7c54f">402,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3Mw_565ca4a6-c7b5-4767-b2d6-5bf896133503" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ide6d8e3c655c4d70ab1c6f8d0cc12aed_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzItMS0xLTEtMA_7cf3be35-4711-41dd-a675-7ec8fe57e71e">286,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0538bd9470324b8389be50058e5cf219_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzMtMS0xLTEtMA_bfc0e287-06ac-42c4-8c1b-6134685d1cb4">172,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1546a2edd29843b68c4ba7b149c00e10_I20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:GrossLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzQtMS0xLTEtMA_e85ebeaa-9dfe-4b0e-b535-f6e636de7e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzUtMS0xLTEtMA_3fc86354-030b-4b86-a890-53636ed55b46">458,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_160"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIzMjM_6283e4dc-c186-4e2f-9156-9b44c2fa420e" continuedAt="i6762d253563e4894aeb833351ad4d645" escape="true">Warrant Derivative</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6762d253563e4894aeb833351ad4d645"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5Xzk4_77d77e39-ce22-40b8-b412-31bb8f27ec1f">4,619,773</ix:nonFraction> units were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE0MA_bc8b5662-b292-44f2-b966-177cbc7c8e87">0.81</ix:nonFraction> per unit for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE3NA_5ce8db8d-d8c8-4e32-af6b-db4124afc9db">3,742,016</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:CommonSharesPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE5Nw_7f3743bb-a69a-474c-be78-ac17d86cfec8">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:CommonSharesPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIxNw_b3eeab08-3215-4da7-ab94-e3df8b4d28f7">one</ix:nonFraction> common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzMzMQ_ae41af16-8b4e-4147-80fc-245074457514">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzM3MQ_bcb00696-df73-46d6-901b-902fbddeff9e">0.90</ix:nonFraction> until August 16, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzkyNQ_0be3c5a3-717a-43ff-bbd3-11b04ef691cf">0.90</ix:nonFraction> meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIzMjU_a93ecc2d-675b-483e-a24a-0bf9e2098660" continuedAt="i6faccb114d964a7399ec0b9735841a02" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:385.50pt"><tr><td style="width:1.0pt"></td><td style="width:192.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued, August 16, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassOfWarrantOrRightOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzEtMS0xLTEtMA_3f21d302-ccce-4d5e-b127-52acf5b9a2a5">4,619,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzEtMi0xLTEtMA_23104e2c-9692-4eed-a879-0a2e214035ae">1,657,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMS0xLTEtNDI3_77d7f15e-7c24-4fc9-9b09-831a58628619">2,935,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMi0xLTEtNDI3_1d2c2ab5-1795-4e95-9a57-9fe6ff9e9ce7">5,687,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzMtMi0xLTEtNDI3_c804f5a0-fc65-412b-b094-8c964ddbb549">12,608,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:GainsLossesfromForeignExchangeImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzQtMi0xLTEtNDI3_261ba3b7-ad6c-4d84-bb0a-0f7d3f13bafb">70,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassOfWarrantOrRightOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMS0xLTEtNDI3_f7a7d97e-fb60-4e64-a3d1-1fe08fdd080e">1,684,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMi0xLTEtNDI3_9fb6642b-c649-451a-bd1a-74c2ac19f0b7">8,508,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMS0xLTEtMA_c6a16b71-31c8-4a09-8af8-010869a928c4">1,418,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMi0xLTEtMA_f7310157-d325-4619-8b80-55a449de2762">4,636,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzMtMi0xLTEtMA_6b761612-8de4-497b-bede-ff8f322669f2">3,491,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GainsLossesfromForeignExchangeImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzQtMi0xLTEtMA_b5a3de63-e8c2-4151-98cc-773a2a29ee94">150,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7073102f39754418a48b29815277781f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassOfWarrantOrRightOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMS0xLTEtMA_0f83c0b4-e6a1-49b9-b6e4-9417e973a924">265,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7073102f39754418a48b29815277781f_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMi0xLTEtMA_a740cf09-f96f-4915-8f53-f6f323c8460f">531,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received cash proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromWarrantExercises1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE2Nzc_84d1915b-9527-4940-855d-4773e4f628a6">1,276,532</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromWarrantExercises1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5Xzc2OTY1ODEzOTcwMjg_400147b8-90fc-45a7-83e0-d3a08c53e4cf">2,642,082</ix:nonFraction>) with respect to the warrants exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6faccb114d964a7399ec0b9735841a02"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions: </span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"><tr><td style="width:1.0pt"></td><td style="width:202.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="i7073102f39754418a48b29815277781f_I20201231" decimals="2" name="oncyf:FairValueofWarrantIssuedPerWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzEtMS0xLTEtMA_79ed952d-03e4-4d2a-82cc-f4fdc71718ad">1.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231" decimals="2" name="oncyf:FairValueofWarrantIssuedPerWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzEtMi0xLTEtMA_11d674d3-a399-4e0a-8262-48d2ca2daf63">3.89</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="2" name="oncyf:WarrantIssuedUnderlyingSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzItMS0xLTEtMA_82dac367-e5f6-430d-acc0-d9f84a78d5e7">2.38</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="2" name="oncyf:WarrantIssuedUnderlyingSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzItMi0xLTEtMA_78110400-3aa1-4e88-8918-42060b19b9e6">4.76</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzMtMS0xLTEtMA_21567185-acd1-4bf8-8e46-c95b51945df2">0.10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzMtMi0xLTEtMA_020ccb48-ddd1-4185-b12f-518ff9305751">1.59</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzQtMS0xLTEtMA_bb3aa4eb-b89a-4177-8271-ce462975083f">1.0</ix:nonFraction> year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzQtMi0xLTEtMA_80c288ca-1850-41cb-b4cd-75c3f2d8b2f1">1.0</ix:nonFraction> year</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzUtMS0xLTEtMA_dbc918ff-4bed-4948-acef-f9f52e7a60eb">90.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzUtMi0xLTEtMA_e4fc69dd-695f-4cc8-99da-050da6857fe0">90.00</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:DividendYieldPercent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzYtMS0xLTEtMA_84219dfd-a300-4d04-99c2-5269f35dd690">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:DividendYieldPercent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzYtMi0xLTEtMA_9f7e583b-deaf-4813-aef8-45ae2d80c44a">Nil</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_166"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDU_c1ffda84-76bf-412c-8064-49e0c3dd8661" continuedAt="i9aeeab3c54774beb994fc44f7f734fc5" escape="true">Share Capital</ix:nonNumeric></span></div><ix:continuation id="i9aeeab3c54774beb994fc44f7f734fc5" continuedAt="ia050a5fd479849c2aad1f688de5a171e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Consolidation:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we completed the consolidation of our common shares on the basis of <ix:nonFraction unitRef="shares" contextRef="idded585e6408411a94c46d5d947389d3_I20180522" decimals="1" name="oncyf:ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzIwOA_2b4a321c-6d0f-44c7-a26a-d8dd28dae5a0">9.5</ix:nonFraction> pre-consolidation common shares for each <ix:nonFraction unitRef="shares" contextRef="idded585e6408411a94c46d5d947389d3_I20180522" decimals="0" format="ixt-sec:numwordsen" name="oncyf:ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDI_c063c697-f919-442e-ac5a-ffd16ed43c3a">one</ix:nonFraction> post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. </span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDY_8f74f050-e733-44e7-beef-45a4ca9794f7" continuedAt="i32257d2b43964355bb9a87d0a8390f7d" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"><tr><td style="width:1.0pt"></td><td style="width:309.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f79d8de4290471c8bd4630bf062b395_I20171231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzctMS0xLTEtMA_2d125eb1-2d5b-48db-abd7-5692d4b04512">141,805,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7f79d8de4290471c8bd4630bf062b395_I20171231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzctMi0xLTEtMA_9df22bd0-9551-41ce-bd9f-83756432ab42">271,710,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzgtMS0xLTEtMA_e189d131-4f0c-4af3-afaf-d340f6f61ae2">519,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzgtMi0xLTEtMA_4227786b-bde4-46ea-865e-d9267a3dfe00">553,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ife2ce693bb1e4e538d5f9509be7279ff_D20180101-20180521" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzktMi0xLTEtMA_3b4d4fda-4fe2-4474-b1a5-f3549c10c33d">33,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEwLTEtMS0xLTA_d0c21f72-daba-4f68-a976-a5bdb287772f">71,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEwLTItMS0xLTA_30f45a6c-cfb4-47c7-9e25-2894cbd8769a">38,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - pre-consolidation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3cc312234b04ffe88d045cec709e645_I20180521" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzExLTEtMS0xLTA_d6a087a8-7717-465b-a663-4cba01176b1d">142,396,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic3cc312234b04ffe88d045cec709e645_I20180521" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzExLTItMS0xLTA_c42ecf40-2c31-4b3e-8051-03cf2632d5e4">272,268,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - post-consolidation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEyLTEtMS0xLTA_b284cd4b-5c72-47b9-9731-3ce7bd45e147">14,988,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEyLTItMS0xLTA_97cf8a98-b9a3-4c80-88af-a98483d62d19">272,268,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEzLTEtMS0xLTA_959300ab-0ce8-467e-83e6-25c77e7c44db">1,532,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEzLTItMS0xLTA_1c778c6c-5d8e-42e9-a8de-d32eecbdaf9d">11,606,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrants exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(see "&#8212; Equity Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231" decimals="INF" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE0LTEtMS0xLTA_396d28e9-0d81-454e-90e6-6d850407ec27">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE0LTItMS0xLTA_8499d33f-75c7-4803-a4cc-50315b22ee83">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9699ac58b344404a871327fc97617f6_D20180523-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE1LTEtMS0xLTA_8da4fe48-e2b6-4f12-98aa-c6dbcb13d276">34,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id9699ac58b344404a871327fc97617f6_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE1LTItMS0xLTA_0d0f4aa6-081d-44d7-8f03-44bd1bd78f69">158,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE2LTEtMS0xLTA_961004fc-a158-4b05-9a6b-e8ef1a85c0eb">28,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE2LTItMS0xLTA_e6335eb8-29e3-4f29-b5a5-2b9045f8afd0">109,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE3LTEtMS0xLTA_75d8158e-abc5-4844-bd09-7b8fa3c27c76">797,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE3LTItMS0xLTA_3ec32ca7-2392-43b7-9569-fe36238c7213">3,314,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE4LTEtMS0xLTA_16ff9a5b-c21f-4d71-9d45-e4a33df8a3b4">18,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE4LTItMS0xLTA_e0c5e576-4cc5-4b93-91c6-b0742e5c8cb4">66,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i9c1b8fc753754267b5ee38bbe8188c69_D20180523-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE5LTItMS0xLTA_e1e4ac64-056f-4a49-a7ce-726149035eaf">2,333,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIwLTEtMS0xLTA_6c59dfb7-ead2-4076-b5f5-f52473a04e65">17,399,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIwLTItMS0xLTA_c9a2084a-1f4f-4d99-bda9-5552053e292a">285,193,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia523aae440294924869d91f14d20ba80_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIxLTEtMS0xLTA_8cd0f0c6-9b93-4c1a-972b-a1338379adcd">323,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia523aae440294924869d91f14d20ba80_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIxLTItMS0xLTA_108589a0-588f-4379-8562-0985df6d6dd9">391,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIyLTEtMS0xLTA_5cbec77f-743d-4e81-adb6-95e6c9f2157a">2,494,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIyLTItMS0xLTA_508a9715-db53-458c-822a-5b7d81aac777">5,403,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTEtMS0xLTA_99cc10f6-e74c-4718-8476-c826dcc571e7">4,425,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTItMS0xLTA_d268cf0f-b025-4000-aae8-f85df41cabc5">8,476,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTEtMS0xLTA_989b201a-7bad-4045-a5e1-3b90b5a3a51b">4,619,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTItMS0xLTA_3ccc8189-4dd6-44a9-b261-1f4e80e22ae4">3,314,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTEtMS0xLTA_6a0ccb12-af04-40d9-87ef-1439125611c8">2,935,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTItMS0xLTA_4d0f4e61-4cee-490d-b3de-56ed933a4326">9,152,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i42ce7a75633844d5a5c8538827785c0d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTItMS0xLTA_f9f0645a-373f-46d1-a320-180c813190a6">854,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3e853028eaf4f4687a1425b818892a2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTEtMS0xLTA_21e3a452-6ded-4e14-9290-620ef1dc7d5c">32,198,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia3e853028eaf4f4687a1425b818892a2_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTItMS0xLTA_1f761d83-dc3e-4758-8922-d2fbf404a3b4">311,077,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20080a94d52341bf8043af636627ec2f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTEtMS0xLTQ3Ng_a0e73f64-4e72-426f-9748-7b89da2b89be">133,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i20080a94d52341bf8043af636627ec2f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTItMS0xLTQ3Ng_2c2d3421-62b1-4696-bfd2-7e7da235aa4b">385,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTEtMS0xLTQ3Ng_b0bcb7e7-021b-49cd-999c-e4cac4bcae54">234,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTItMS0xLTQ3Ng_608375a8-c1a7-4e4d-9a8c-d277cb4063e7">732,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTEtMS0xLTQ3Ng_8e70e3f4-1790-4ea6-baf2-b425eb6d8a6b">12,182,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTItMS0xLTQ3Ng_793db5ba-0988-4894-966e-72d49947e469">40,037,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTEtMS0xLTQ3Ng_8b54a26c-14ee-40c8-b57c-2bbe2abad22b">1,418,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTItMS0xLTQ3Ng_ac70a0cc-015e-4a59-8cf6-6da7786dca4b">6,332,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i50194a1104f0447dbe8bdab6b84fb381_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTItMS0xLTQ3Ng_e586e5ca-8113-41cd-bc9b-c10bcaa687f2">1,741,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI4LTEtMS0xLTQ3Mg_d149ca27-1a55-418c-844b-a13924eaa685">46,166,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI4LTItMS0xLTQ3Mg_2280c07b-0e98-4200-9f2f-c026f79e45de">356,824,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $<ix:nonFraction unitRef="usd" contextRef="i86af6651ee84454ba8d1a822e9eb52bf_I20160225" decimals="INF" format="ixt:numdotdecimal" name="oncyf:SharePurchaseAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzkxNw_d5909ca6-f373-4d8e-a3f5-44450a07376f">4.6</ix:nonFraction> million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold <ix:nonFraction unitRef="shares" contextRef="i971a344a7f6e456094ca126adf0186ff_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzEzMTY_7b6f0819-170a-498b-a2d9-d6927bcfb49c">519,500</ix:nonFraction> pre-consolidation common shares (approximately <ix:nonFraction unitRef="shares" contextRef="if769c8e2f8534ccc947473705accee72_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzEzNTk_fb61bbce-d4eb-4114-84c2-5fa2eb3efb0e">54,684</ix:nonFraction> post-consolidation common shares) for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzE1MDc_6340fbf4-1a24-4e37-98df-597d5501c39a">553,650</ix:nonFraction>. We incurred share issue costs of $<ix:nonFraction unitRef="cad" contextRef="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzE1NTg_5e0cb2e5-23ad-4dfe-8963-a12d56db35d7">33,335</ix:nonFraction>. This sales agreement expired on March 16, 2018. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="ia050a5fd479849c2aad1f688de5a171e" continuedAt="i3cdb7c648e8c46eb9cb345a21c95a69f"><ix:continuation id="i32257d2b43964355bb9a87d0a8390f7d"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 5, 2018, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzI5NjU_e0791905-038c-41cf-ae73-8a0f893c4559">1,532,278</ix:nonFraction> common shares were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i15bfe04f75e74d34a9bcbec045406bbb_I20180605" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwMTc_9ae93348-59e4-43ef-8249-decbba2faa2b">5.83</ix:nonFraction> per share for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwNTQ_c101232c-99ea-49f7-a1c0-16ffe52cf15f">8,933,181</ix:nonFraction>. We incurred share issue costs of $<ix:nonFraction unitRef="cad" contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwOTE_3f33d9cd-9647-400a-9081-0dab5b4d0114">1,418,356</ix:nonFraction>.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$<ix:nonFraction unitRef="usd" contextRef="ic7797595a0e345bd82875cde18a102f6_I20180927" decimals="INF" format="ixt:numdotdecimal" name="oncyf:SharePurchaseAgreementAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMzMzY_df684ccf-0707-4cfb-8f25-c5963659b661">26,000,000</ix:nonFraction> worth of common shares to LPC over the <ix:nonNumeric contextRef="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927" format="ixt-sec:durmonth" name="oncyf:SharePurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMzNzg_6067afa8-3315-4aa5-9bbb-c7e258884028">30</ix:nonNumeric>-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i2cec20e510e74bd3b6a829215e7e1186_I20180927" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzM5ODU_823adc1b-a921-4862-9a44-eb6a7ebfd759">1.00</ix:nonFraction> per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362">five</span> immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to <ix:nonFraction unitRef="number" contextRef="ida04d93b266c4c888708cd83f197cba6_D20180927-20180927" decimals="INF" name="oncyf:NumberofSharesOutstandingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQyODA_e3099c09-d8b9-405d-b835-c5ab07e763d7">19.99</ix:nonFraction>% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold <ix:nonFraction unitRef="shares" contextRef="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4MTI_8bc084f7-3e8e-470d-a1bf-f883d276c504">nil</ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI1Nzg_e19dc257-b465-454e-8da6-115af0bd956e">2,477,665</ix:nonFraction>; 2018 - <ix:nonFraction unitRef="shares" contextRef="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ2NDQ_6cf58c12-0b98-46fd-af8a-05fc12c571ee">678,182</ix:nonFraction>) common shares for gross proceeds of <ix:nonFraction unitRef="usd" contextRef="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NDA_1ea18ece-7056-4bf7-b3c9-19e122e83895">nil</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4MjU_5bb20e2d-5774-4705-8d06-7d4d6eb80e68">4,055,725</ix:nonFraction>;  2018 - US$<ix:nonFraction unitRef="usd" contextRef="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ2OTc_199c3923-d7d6-417a-bbe4-e688b0d10124">2,055,207</ix:nonFraction>) and issued <ix:nonFraction unitRef="shares" contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NTc_40313e61-32e0-4382-82f7-9e068cdeb8ea">nil</ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NDc_8ef39272-cda2-43bc-b4b0-3aab05914e20">17,278</ix:nonFraction>; 2018 - <ix:nonFraction unitRef="shares" contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ3MjE_b5b3a477-726b-4b0c-ade8-eb5287208729">119,509</ix:nonFraction>) commitment shares. The commitment shares were fair valued at <ix:nonFraction unitRef="usd" contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4ODA_17dd70be-3aa8-496b-b4a1-7a236cb7a876">nil</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4Njc_8a882312-86cc-4265-8da9-337415a53abe">29,758</ix:nonFraction>; 2018 - US$<ix:nonFraction unitRef="usd" contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ3OTk_6658c8a1-9851-4117-8e82-495aa7997ba9">483,690</ix:nonFraction>) and were recorded as share issue costs in addition to cash share issue costs of <ix:nonFraction unitRef="cad" contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4OTc_fe048b7e-a763-428f-a754-f6069c999f3a">nil</ix:nonFraction> (2019 - $<ix:nonFraction unitRef="cad" contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4ODc_bba1cf95-b3bf-4f72-952e-6b85986de2ea">3,757</ix:nonFraction>; 2018 - $<ix:nonFraction unitRef="cad" contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ4OTI_56d78fab-fc76-403e-9102-14586c74572c">208,726</ix:nonFraction>).  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="i694e083ddd244a1590868a988368affb_I20181024" decimals="INF" format="ixt:numdotdecimal" name="oncyf:SharePurchaseAgreementAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc2Mzk_81fd26bb-0d3d-4cdf-b2a7-0b129dcd1cc5">30,000,000</ix:nonFraction> over a <ix:nonNumeric contextRef="i4c90e3a44c2a4d788944653b7f87451b_D20181024-20181024" format="ixt-sec:durwordsen" name="oncyf:SharePurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTU0MTk_5c7fc285-9608-46a1-8a66-386a9e6957eb">19-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold <ix:nonFraction unitRef="shares" contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NTE_2b2393af-9972-4363-bd70-51dc8d5f84fb">6,741,518</ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NjI_67ac93ad-290c-48cd-9c30-5e08e43e52e2">4,425,040</ix:nonFraction>; 2018 - <ix:nonFraction unitRef="shares" contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NzM_c93f0a82-2836-4ca6-9a66-5cb920f074be">18,002</ix:nonFraction>) common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MTQ_dafff168-7881-4d5d-992b-9806cecec0f9">17,538,342</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MjU_e5b11c5b-6228-438c-a7e1-48375e3e8bcf">6,390,691</ix:nonFraction>; 2018 - US$<ix:nonFraction unitRef="usd" contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MzY_9a3bb6c2-d267-4840-9441-85c32a2751f9">50,046</ix:nonFraction>) at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i562f369a1b84407798feac1b05faee8a_I20201231" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDgyMzg_2838dcf9-e222-4cf6-a064-67588a75abe0">2.42</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="i05d73158ebeb4204a27888336398e6ce_I20191231" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxMzI_02ab7a42-db1b-47d0-a40b-6bf99fb167e1">1.70</ix:nonFraction>; 2018 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="ib2b7d32d88cd49f39016f010737d5836_I20181231" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyMDI_4ab06a76-72fb-431b-ba83-65fb1ae7f64a">2.85</ix:nonFraction>). We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ShareIssueRelatedCostCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwNzY_76d51f91-b44e-4bec-b058-49c046867067">526,150</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ShareIssueRelatedCostCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxNTQ_b8de1e08-ecc1-4c8e-a765-a74da7b34cf7">191,721</ix:nonFraction>; 2018 - US$<ix:nonFraction unitRef="usd" contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ShareIssueRelatedCostCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyMjI_dc79bfae-726a-4eec-ae52-fafc12ab2898">1,501</ix:nonFraction>), proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxMTI_ec283241-8688-4e5e-a42e-3e864758f157">17,012,192</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxODM_6edf8015-3e88-42fe-93f3-0d156e04bbda">6,198,970</ix:nonFraction>; 2018 - US$<ix:nonFraction unitRef="usd" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyNDY_e41d43c1-c7c4-476f-ae5f-58a3e54eb466">48,545</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4NzU_189030f8-e633-451f-a683-e8d6a123a182">856,754</ix:nonFraction> (2019 - $<ix:nonFraction unitRef="cad" contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4ODY_0e792f39-13fa-4f4f-9a96-15215f1c9f0b">344,834</ix:nonFraction>; 2018 - $<ix:nonFraction unitRef="cad" contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4OTc_6f7f19d8-d194-47de-80a5-a0649bcc15cf">135,000</ix:nonFraction>). This sales agreement expired on June 4, 2020. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM3Njg_abff922c-fdde-4fb8-8df1-cdfbf9cecd70">4,619,773</ix:nonFraction> units were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4MTM_3450663c-a130-4950-be86-40af49ff18b3">0.81</ix:nonFraction> per unit for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4NTA_05a43499-4728-4409-b6f7-fceca15f77d1">3,742,016</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:CommonSharesPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4NzQ_0e04033b-140e-4477-94ef-54dbc3ef13b4">one</ix:nonFraction> common share with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5MTQ_da8bb534-98a7-4282-8c63-b43db6c27d81">0.54</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:CommonSharesPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5MjI_8456757e-62dd-4f82-86e5-14a0212abd76">one</ix:nonFraction> common share purchase warrant with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5Nzk_dd673414-79cc-4ed6-af85-753e1e794866">0.27</ix:nonFraction>. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQxMjE_1fb0497e-38c1-4fd0-a966-eb5295bda0e8">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQxNjQ_958cf725-693a-4757-8b04-32d161de8c21">0.90</ix:nonFraction> until August 16, 2024. We incurred transaction costs of $<ix:nonFraction unitRef="cad" contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyMjQ_c53e29fb-b624-480a-a671-30f93f8c726a">699,427</ix:nonFraction> of which $<ix:nonFraction unitRef="cad" contextRef="id181bdb06f844a62bdf467f41ba1dd43_D20190816-20190816" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyMzc_8828c980-ddd7-4b60-a9f7-774ae893b781">466,284</ix:nonFraction> were allocated to share issue costs and $<ix:nonFraction unitRef="cad" contextRef="i170cc49c63b04227a02de91e6163db24_D20190816-20190816" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyODE_6f8a3cc8-b932-4251-b2d4-0fda76fc0a37">233,143</ix:nonFraction> were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $<ix:nonFraction unitRef="cad" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0MzM_db971cd9-1b1a-4323-91f3-6daf6d4c0b99">4,636,317</ix:nonFraction> (2019 - <ix:nonFraction unitRef="cad" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ1OTE_1d2c2ab5-1795-4e95-9a57-9fe6ff9e9ce7">5,687,003</ix:nonFraction>) in addition to gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromWarrantExercises1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0NzI_84d1915b-9527-4940-855d-4773e4f628a6">1,276,532</ix:nonFraction> (2019 - US$<ix:nonFraction unitRef="usd" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromWarrantExercises1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ2MDQ_400147b8-90fc-45a7-83e0-d3a08c53e4cf">2,642,082</ix:nonFraction>) for the <ix:nonFraction unitRef="shares" contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0ODQ_dc40ab8e-efaf-4790-b4ac-a05722472752">1,418,369</ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ2MTg_77d7f15e-7c24-4fc9-9b09-831a58628619">2,935,647</ix:nonFraction>) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$<ix:nonFraction unitRef="usd" contextRef="i862c5b4961c74a48a39f058918e7d03e_I20200615" decimals="INF" format="ixt:numdotdecimal" name="oncyf:SharePurchaseAgreementAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUwMjk_c3d67c73-8b8f-4619-8c13-06d520300d17">40,000,000</ix:nonFraction> over a <ix:nonNumeric contextRef="idc96efef1fbb4efcb5325460bb72a700_D20200615-20200615" format="ixt-sec:durwordsen" name="oncyf:SharePurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTUzOTc_bab7d943-2479-4acc-98c9-ffcef39862df">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold <ix:nonFraction unitRef="shares" contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUyNTM_aeb9e9a2-7424-43a0-be49-0ae946b18733">5,441,014</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUyOTM_3565178c-25b8-4c5c-87b9-634f9df85e4c">12,628,775</ix:nonFraction> at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i47812f018f2f4cef9ae9380e51b482b5_I20201231" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDgyNzM_525d9866-5728-42c8-9797-af23b8dcf48a">2.11</ix:nonFraction>. We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ShareIssueRelatedCostCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwMjk_1962b80d-b8b5-4ae8-9865-1103ef5b0b9c">378,863</ix:nonFraction>, proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwNTU_aa9f7e06-487c-4e6e-922b-c89175f78bcf">12,249,911</ix:nonFraction>. In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUzMzI_2fbd4440-fdcf-4a45-8acb-164454f7558b">884,886</ix:nonFraction>.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i3cdb7c648e8c46eb9cb345a21c95a69f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601" decimals="INF" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYyNzU_f21d2f2b-0800-46ef-9843-c3805a499412">16,445,000</ix:nonFraction> units were sold for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYyODc_c7f1b4a9-3abc-4176-aa58-90e696e42a37">11,511,500</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i15e7713f103e4177900f7c2683516777_I20170601" decimals="0" format="ixt-sec:numwordsen" name="oncyf:CommonSharesPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MjQ_497767e6-bbac-4dea-ae52-49eccc979e90">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="i15e7713f103e4177900f7c2683516777_I20170601" decimals="0" format="ixt-sec:numwordsen" name="oncyf:CommonSharePurchaseWarrantPerUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MzI_3c213f56-ea3a-488f-b34f-37fe0e66f919">one</ix:nonFraction> common share purchase warrant. Following the Share Consolidation, <ix:nonFraction unitRef="shares" contextRef="i15e7713f103e4177900f7c2683516777_I20170601" decimals="1" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYzMTM_b16d046e-5440-4fe5-86ce-99be3a2a01fa">9.5</ix:nonFraction> common share purchase warrants entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i15e7713f103e4177900f7c2683516777_I20170601" decimals="0" format="ixt-sec:numwordsen" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0NDA_2eeff204-58f5-4c2d-801a-7ab6b0c20d56">one</ix:nonFraction> common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $<ix:nonFraction unitRef="cadPerShare" contextRef="i15e7713f103e4177900f7c2683516777_I20170601" decimals="3" name="oncyf:SharesIssuedWarrantPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYzMjA_2699e90e-71ee-4301-89f1-ef9845c1a9fe">9.025</ix:nonFraction>. These warrants were classified as equity. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzYzMTY_0624b97e-906c-47d1-8219-b4cf686bc128" continuedAt="iebca887249034398bf6585c875bed3e4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba9fe4ea63e045e096465e2bfb11ba95_I20171231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMS0xLTEtMjA5NA_e22c9341-7438-4575-b171-b12591f9b189">16,445,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i69e26aa497764738a8d24ee240e72834_I20171231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMi0xLTEtMjA5NA_d909afd7-60e6-4edc-a840-f5a9b8177833">3,617,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrant exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib7326a67f5024a94b5c25675622288c0_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMS0xLTEtMjA5NA_2dd218ad-c139-4715-8393-15ffe1023820">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMi0xLTEtMjA5NA_56c21122-2f69-45bb-8068-df4485473a67">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i363f02f84b6946e8a01f345e20f5224d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzMtMS0xLTEtMjA5NA_de0962b0-d46d-4b62-9767-e3c214ed5f73">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzMtMi0xLTEtMjA5NA_cfe4492a-c58e-4c9b-909d-421f5625477e">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ef329fa905d4c3185e2177c3e6dee42_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMS0xLTEtMTA3Mw_55474f9c-a783-4b36-b700-954b2965e8e6">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMi0xLTEtMTA3Mw_c2362081-fa17-4392-8a3c-e05182261ac0">3,617,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65287d01f32c419ba89f7f594cd47caf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMS0xLTEtMTA3Mw_6b8a55bc-a821-470b-af9d-494cda57f893">16,443,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:WarrantsAndRightsOutstanding1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMi0xLTEtMTA3Mw_d2dc79ac-7e9a-4f4b-92d0-f1788a519b6f">3,617,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="iebca887249034398bf6585c875bed3e4" continuedAt="ib585881fe18d47f082b77548de65c4d2">(1) Exercisable into <ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzYyOTE_668ffa31-0207-4dc3-b5e7-7ad530f53976">1,730,894</ix:nonFraction> common shares.</ix:continuation></span></div><div><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_172"></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0ODI_26957c8d-7de3-4ca1-8990-ac4bb4c87258" continuedAt="i0754cccf59554d0cb970b5eabe981e39" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i0754cccf59554d0cb970b5eabe981e39" continuedAt="ic8af8cede64d4a35a929dc81285269f4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI1MDM_532b27fa-244f-4652-b005-70b1084193b9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:488.25pt"><tr><td style="width:1.0pt"></td><td style="width:117.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMS0xLTEtMA_5f946737-41bc-4074-83dd-226052d2ba23">2,246,947</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMi0xLTEtMA_12575a4c-cf62-4d55-a095-869dbd57ce90">5.31</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMy0xLTEtMA_2b824a30-ee8f-4805-8c3b-9a143a0c724d">1,249,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNC0xLTEtMA_6bb0d3fb-1e3b-4365-8f2b-4fa86c156a58">8.73</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69e26aa497764738a8d24ee240e72834_I20171231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNS0xLTEtMA_f45de674-2f9b-44a6-9610-39fc6039b34d">647,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i69e26aa497764738a8d24ee240e72834_I20171231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNi0xLTEtMA_12ad862c-cb7d-4fd6-841b-e4ae114dc834">13.20</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMS0xLTEtMA_2e8db598-4083-401e-b5bc-931772b71cdd">1,817,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMi0xLTEtMA_34ab3409-cec2-469b-97a4-5bd76ce377b1">3.19</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMy0xLTEtMA_0f3fb612-59af-4998-880d-cf0501d5455f">1,020,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNC0xLTEtMA_e929b930-3617-4b87-85a4-84883fad0cc4">1.42</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNS0xLTEtMA_6964455f-f138-4b29-9f4e-0843b84309b1">750,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNi0xLTEtMA_4665f626-8f3e-43b3-b3af-4ad9dae77278">4.97</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMS0xLTEtMA_7e09dbec-ca7e-4cf7-9256-2d93d4eb31e3">141,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMi0xLTEtMA_a7e5af57-2923-42f8-9e9c-a8e755e26658">3.84</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMy0xLTEtMA_416ffc55-df0f-4b1d-920d-f7880664b649">12,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNC0xLTEtMA_308895ae-4b49-42bc-99da-d03760281727">11.35</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNS0xLTEtMA_ac276d4e-7cd7-4043-9b5d-22d0b376f771">105,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNi0xLTEtMA_3e009ba0-4c34-4e82-aa9d-8676753a0760">11.67</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMS0xLTEtMA_51bd4913-3e39-4cf2-88a4-f90d43fe4c9d">25,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMi0xLTEtMA_f110f78b-815a-4969-9e5a-96abd92530ce">62.49</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMy0xLTEtMA_a64283b1-4f9e-4fed-8cde-b06ac6d30b75">9,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNC0xLTEtMA_c70f7fda-1b9a-41aa-9354-c6e8c89fcf78">29.07</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNS0xLTEtMA_640b66ca-ccaf-4eb2-8e62-620ab340c5f3">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNi0xLTEtMA_4e53478f-d57c-4967-9d17-0960c79d1c21">13.78</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMS0xLTEtMA_e434de26-49b0-4368-95a5-ae0a0def1cd7">133,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMi0xLTEtMA_76d2bdde-427b-4487-b248-5f65bc1b0ee2">1.81</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMy0xLTEtMA_d9e5232b-dc8f-434d-bee7-b8b851f9b323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="2" format="ixt:zerodash" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNC0xLTEtMA_7b2f1e2d-5e14-4deb-b337-8516491d88e0">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNS0xLTEtMA_961fd5f5-fa96-402a-8bd5-6bbeb215ab33">41,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNi0xLTEtMA_c7efa9a2-89cf-4693-9c98-210e672476d1">2.96</ix:nonFraction></span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the<br/>  year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMS0xLTEtMA_9da81ba6-152d-4ff9-b40b-ba73b8b808ec">3,764,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMi0xLTEtMA_f6ec9ab7-f5d4-4a5c-ae3b-07b177eb0506">4.08</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMy0xLTEtMA_3e22da26-4a15-42e7-9346-8241ba986a63">2,246,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNC0xLTEtMA_7cfe5e20-6338-4231-8535-e08ae1f33898">5.31</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNS0xLTEtMA_9e5ac20d-1da5-4991-a1af-61460ef33678">1,249,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNi0xLTEtMA_7bb7a6e2-456b-43d8-9960-be759076a8c9">8.73</ix:nonFraction></span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMS0xLTEtMA_12b8d786-c293-4adf-b001-2309aed88105">2,164,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMi0xLTEtMA_1871ea8c-f11c-42f2-b8a4-36d0337a4d68">4.84</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMy0xLTEtMA_8f8d2159-cbc0-4833-a885-b5848cdbbe00">1,327,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNC0xLTEtMA_4fdc7868-6f0c-4e81-b6c1-78df9b04dad0">7.22</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNS0xLTEtMA_c9930baf-1756-4593-a219-b3f26e7bfadd">777,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNi0xLTEtMA_1f2de527-0190-48bd-a8c3-0188bce1a9cf">11.04</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="ic8af8cede64d4a35a929dc81285269f4" continuedAt="id7899a933db04f6f8ddd66b86ab2c83a"><ix:continuation id="ib585881fe18d47f082b77548de65c4d2"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0ODQ_bf7ea6dc-a3ac-4bf5-8c11-6f52f0a243c5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:135.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="ia5ef05068a8440d6a4ba5000646081ad_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYTkyNzMxMzE2MjQ1NDE5MjA5YTg1OGJkZTEzOTgxXzc2OTY1ODEzOTQ0NTQ_0494590e-acb6-403f-b95a-e8ab48c1639c">0.54</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="ib21db9d5af5b44628e536172b106e636_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYTkyNzMxMzE2MjQ1NDE5MjA5YTg1OGJkZTEzOTgxXzc2OTY1ODEzOTQ0NjI_7a9783bc-5ffd-446b-aa0f-cc08ea748a1e">1.79</ix:nonFraction></span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93af58043e324a92a840919953931d39_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMS0xLTEtMA_d6fad68b-e32c-4eda-9399-b0baeaa06c54">808,333</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie2d6c1efdf1b45f6902ca44f7d279adc_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMi0xLTEtMA_c5e6d6db-18d6-47e7-98cd-33c44fd27319">3.03</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i93af58043e324a92a840919953931d39_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMy0xLTEtMA_8e043ea8-8cf3-4a41-afb7-b998eb5284ee">1.39</ix:nonFraction></span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93af58043e324a92a840919953931d39_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtNC0xLTEtMA_ea84ea8a-cc0a-48b2-be1d-12c8c9c6f537">545,009</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i93af58043e324a92a840919953931d39_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtNS0xLTEtMA_19f26616-6759-4ee4-a0af-9b02d79fc097">1.37</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i48739a7cd7d84144a5f4e605f94af42e_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTA1OWZmZDRhOTQ5OWViMjc2MTU1Y2FlYjhkNzA3Xzc2OTY1ODEzOTQ0NTQ_448df9ae-a088-44c0-a3a2-e882aedfda22">1.80</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i7f4c186a1a8848be9fc5a892d41b0be2_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTA1OWZmZDRhOTQ5OWViMjc2MTU1Y2FlYjhkNzA3Xzc2OTY1ODEzOTQ0NjI_4b3d006c-def6-4709-b86d-4fe63cf42e55">3.01</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMS0xLTEtMA_eabbab86-727c-4ce6-8d13-5ae8589694e7">459,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1865037223514d83939793fbf4bc69ec_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMi0xLTEtMA_26da5352-4584-4af3-b20e-ac8384d8bc38">4.49</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMy0xLTEtMA_239f52be-7672-422b-8c25-0d0f9540b3ae">2.66</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItNC0xLTEtMA_6965a74a-1bc1-4ec3-8ea3-00cff2fff406">289,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItNS0xLTEtMA_523d8ae7-acd8-4341-ae12-c982ea5891d6">2.68</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="ib597056817fd4c54bf70bc918648c2e4_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmJiMDkwMDdjNDJmNDQzMGNhZDA0ZGI0OTNlYzMzOGFkXzc2OTY1ODEzOTQ0NTQ_c58f31ec-bbf0-4f9c-adad-6ac54a5b4154">3.02</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i34d5b6c5f2e84005a152b1904fe0c190_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmJiMDkwMDdjNDJmNDQzMGNhZDA0ZGI0OTNlYzMzOGFkXzc2OTY1ODEzOTQ0NjI_4b52ebf3-f34f-4126-8d3c-4675bf9c18cb">3.90</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8643920cc194ebb907287f7a4b18747_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMS0xLTEtMA_fdb0e4ce-db8e-4384-a39c-2267bbb1ff81">1,834,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58518506fee64ab482067aea42680848_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMi0xLTEtMA_5984111a-3735-4a99-9b6b-c771b409fdfb">3.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="id8643920cc194ebb907287f7a4b18747_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMy0xLTEtMA_381ae3d0-2b2c-47e6-8917-0524c12c16ce">3.21</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8643920cc194ebb907287f7a4b18747_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtNC0xLTEtMA_03b463d0-0c5d-4880-83f8-0829f89c45ad">769,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="id8643920cc194ebb907287f7a4b18747_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtNS0xLTEtMA_3c2d64fa-2829-4acb-b5c6-c84692b27eda">3.26</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i36557f93937d4dfb8b9c2f7b122eec39_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU3MGVmN2YyYjY3OTQ4OGU4MWY2NjFlMzkwMzg3YzJlXzc2OTY1ODEzOTQ0NTQ_4122973c-53f2-41d8-a9ee-61ad083ffe5c">3.91</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i0895434d6a7f4a60aa00d05659a746fb_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU3MGVmN2YyYjY3OTQ4OGU4MWY2NjFlMzkwMzg3YzJlXzc2OTY1ODEzOTQ0NjI_55b56665-d0d2-4f53-8e0a-4d3484fde46d">7.41</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMS0xLTEtMA_f3688eba-9aaf-4b26-bd69-9c7d54f8f281">493,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e98e8622faf479ca1780f0865b894c1_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMi0xLTEtMA_bcdd658f-7b26-44e8-9f0b-c8677307c343">2.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMy0xLTEtMA_bbeaf72d-cb70-46c0-8d2b-89659411727b">6.13</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtNC0xLTEtMA_0271604a-e143-4c57-b55d-46db216d228c">392,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtNS0xLTEtMA_32b05ea9-7932-4fc1-95f1-6e59e2208dd8">6.02</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i88f71c7cf6714950bc9da0b9936fb3bc_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjRlNTkwODczZmM0MDQ3M2FhMWYxYTMwODU2YjJlMGVkXzc2OTY1ODEzOTQ0NTU_75572ca3-1571-4a7e-9545-729282e40e45">7.42</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i43b192cb3fe24ee0bb059e2280534d09_I20201231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjRlNTkwODczZmM0MDQ3M2FhMWYxYTMwODU2YjJlMGVkXzc2OTY1ODEzOTQ0NjQ_2f375d55-d412-4441-9027-3b44327f8d29">52.63</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMS0xLTEtMA_4af1148d-55c0-4705-8769-f6608ca7dd1c">168,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fc681ffda9640f2a837978353fda2e8_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMi0xLTEtMA_4b921482-dfd5-456b-bba4-187ad3a38b19">2.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMy0xLTEtMA_d39fe179-d033-4540-9a46-e198a498223d">24.32</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtNC0xLTEtMA_29de37dd-7981-45fb-a2b3-2c0673cf76a0">168,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtNS0xLTEtMA_10ef9192-ae60-4021-9d03-21f6206c0a9d">24.32</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMS0xLTEtMA_d7e467d3-5bfe-4af4-8988-9b8e1e486c92">3,764,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMi0xLTEtMA_120ad387-218d-49d0-bd3b-2cabb4d1b9c0">3.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMy0xLTEtMA_6c4e9ee8-71a8-422f-98ec-d4d677386a17">4.08</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtNC0xLTEtMA_5e97b545-3e5d-48ac-80c0-d347e385e91c">2,164,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtNS0xLTEtMA_8120a537-7755-430d-9287-fc230d0ff969">4.84</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-exercisable options vest annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1Mg_cd3e7b72-8b81-4fad-847f-5db8340cf26d">one</span> to <ix:nonNumeric contextRef="idc04adeb60ac4cd197686969029179ea_D20200101-20201231" format="ixt-sec:durwordsen" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1OA_25612117-0b98-4f8a-af90-0cb098b0f0ae">three years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0OTE_a9456ef0-df70-4569-9ab2-75812fada8b2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:348.00pt"><tr><td style="width:1.0pt"></td><td style="width:181.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMS0xLTEtMA_b0c8d902-7aa3-4177-a404-c121eeae9ac7">0.34</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMi0xLTEtMA_1ed2779d-1d2b-48c2-b4fd-ab6e3e97aa45">1.62</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMy0xLTEtMA_ba099eba-784a-4369-aa0e-a0d1ad575285">2.02</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMS0xLTEtMA_ac07650d-375a-4135-a685-100c4eeeacec">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMi0xLTEtMA_8ac3ad05-ba7e-41fe-b731-f1c56900c279">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMy0xLTEtMA_21ce61de-7bff-4295-9b49-9dcc03652984">3.0</ix:nonFraction> years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMS0xLTEtMA_10f9145f-733b-4859-af6b-c01f9953c288">110.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMi0xLTEtMA_502208cd-f0e4-454b-b136-abb9c9c0fc0b">97.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMy0xLTEtMA_61a6cf84-f220-43be-ae11-fc7b5a01e2bd">81.15</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="4" name="oncyf:ExpectedForfeitureShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMS0xLTEtMA_383c68d2-8816-4c30-a603-7a44a6191537">3.67</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="4" name="oncyf:ExpectedForfeitureShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMi0xLTEtMA_921f015e-e02e-4a88-923f-ab7fd0ff7ae8">3.67</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="4" name="oncyf:ExpectedForfeitureShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMy0xLTEtMA_dd8dc09a-0822-4f86-94b6-e5b5dfa945a9">3.67</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMS0xLTEtMA_52ade50c-4051-4945-be19-716e16622044">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMi0xLTEtMA_cd1bb686-0f80-46df-bc43-362dd4593976">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMy0xLTEtMA_dd0f5910-b61d-423e-9072-35e53fe9f454">Nil</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMS0xLTEtMA_e5db8d55-78c8-4a96-9f78-4ab6f480d22b">2.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMi0xLTEtMA_ca31a80a-1e4f-492e-b911-aad18996951f">0.87</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMy0xLTEtMA_70c5c38c-ece4-4745-b183-83d0be97d61c">2.67</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE0NTA_028b8dc4-7e4a-4f5f-b344-5ed3a29ae30d">three</span> year period. <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0Nzc_fd7a1a4d-8fa0-44fc-965b-57c311174b3e" continuedAt="ifdd467a801504023a2dcfa5a682baad5" escape="true">The following RSUs are outstanding at December&#160;31:</ix:nonNumeric></span></div><ix:continuation id="ifdd467a801504023a2dcfa5a682baad5" continuedAt="i9d10e3bb82a54848b89d7e29906def63"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"></td><td style="width:199.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMS0xLTEtMA_c3324679-bd9f-49cb-a4ab-a91c96738ae7">209,657</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a75edaede244932b30bf68f09001b73_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMi0xLTEtMA_b2ebdf1c-3027-48e0-9037-54afe7d2419f">260,755</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibda3a9497dd94381bf80f0a2b9616cad_I20171231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMy0xLTEtMA_c568a241-4824-404d-833e-d2ea93e58e69">190,407</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMS0xLTEtMA_ece2965d-790d-403d-96dc-f9dad5a59315">154,923</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMi0xLTEtMA_f5e69ee6-2166-4eb1-b76b-41a6ec8a507b">270,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMy0xLTEtMA_10efeb50-1415-46df-88fd-f43625971324">102,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMS0xLTEtMA_e549ad42-eb29-4bdd-a87e-ebaf0528b125">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMi0xLTEtMA_07eb41f3-64cd-4760-a24b-9cb6723961cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMy0xLTEtMA_684fa783-c16a-4cf1-b67e-f62e471bb36e">4,210</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMS0xLTEtMA_fe658722-3b0c-4e02-95aa-ea47280fe25f">229,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMi0xLTEtMA_d5008b85-ed60-4e83-bc79-1df128c275a5">321,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMy0xLTEtMA_6cd620c0-7ddb-4a17-aa17-861a40ed0f64">28,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9be04968d7ac45418925f2727fd67f7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMS0xLTEtMA_76674d6d-e511-4d6e-9a5b-b7fe2e6f7c04">134,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMi0xLTEtMA_6f1c2d09-e31a-43bf-88a5-ded17613b90d">209,657</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a75edaede244932b30bf68f09001b73_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMy0xLTEtMA_d5ca453c-ac0d-4997-88cd-b05f1c91b58b">260,755</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">         (1) The weighted average fair value of the RSUs granted was $<ix:nonFraction unitRef="cad" contextRef="i9be04968d7ac45418925f2727fd67f7f_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1Njc_d1f35bdb-7a82-43a5-8241-6c47f3ae3d2c">2.41</ix:nonFraction> in 2020 (2019 - $<ix:nonFraction unitRef="cad" contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1ODI_84cba693-7e36-4c27-9bb3-233d8e43f343">0.80</ix:nonFraction> ; 2018 - $<ix:nonFraction unitRef="cad" contextRef="i5a75edaede244932b30bf68f09001b73_I20181231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1OTI_bd6af722-7a71-4321-b956-c0f720be4174">3.35</ix:nonFraction>).</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="id7899a933db04f6f8ddd66b86ab2c83a" continuedAt="i1ec1671b25264f05a86fb213028fce94"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also issued PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after <ix:nonNumeric contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231" format="ixt-sec:duryear" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4MTE_f833a0c3-a387-4267-ae26-956ad3274438">3</ix:nonNumeric> years or vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4Mjk_c9939d36-c1bf-4c0e-9451-a1e30a1ffc57">three</span> year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary.<ix:continuation id="i9d10e3bb82a54848b89d7e29906def63" continuedAt="idb82461a1a994e399d34873588cb1c8d"> The following PSUs are outstanding at December&#160;31:</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="idb82461a1a994e399d34873588cb1c8d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"><tr><td style="width:1.0pt"></td><td style="width:204.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff34051430c94f87baaf766281ba7412_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMS0xLTEtMA_61d2f9e5-7adb-43cc-bf44-c25cd4a35a41">61,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMi0xLTEtMA_f16a240d-1865-49a3-844d-5f740c84b488">63,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2899ca476be7407391ff311c63456837_I20171231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMy0xLTEtMA_09ffe0a5-623e-4ec0-a3d5-2aa8ff83417a">94,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMS0xLTEtMA_f6218389-da80-4563-abd7-fbe719b8aec2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMi0xLTEtMA_bcd147c5-68bf-44e8-a7fe-185fa2d99de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMy0xLTEtMA_acb80aa0-1f7e-421e-b9e0-520aef35e4c7">31,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMS0xLTEtMA_c49202f4-0c64-4cc4-a62d-e476c30ff94b">4,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMi0xLTEtMA_401934e3-e0f1-45fb-95b9-4c2a3585c15f">2,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMy0xLTEtMA_8fa7104f-8efe-4920-8133-8659dd7dc07b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67bdbb4f6a5e46ceb26e20c137bccd91_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMS0xLTEtMA_c2394d95-fa70-42e0-b862-664d3be31d4c">56,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff34051430c94f87baaf766281ba7412_I20191231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMi0xLTEtMA_cda7d3d8-eb60-4f07-9bfe-14ec72c5d1f7">61,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMy0xLTEtMA_131935d9-08dd-4f2b-a0fc-4d05d159ebaf">63,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ec1671b25264f05a86fb213028fce94">We have reserved <ix:nonFraction unitRef="shares" contextRef="ie5fe69759d8547afa04be2fd7beb55b4_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzIyODI_6c0dcd9e-a33c-40db-8a72-b6faff294189">4,616,698</ix:nonFraction> common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NTQ_41eda25e-a1b3-4899-8edc-c0858a81091b">2,558,974</ix:nonFraction> (2019 - $<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NjM_c8c35165-622b-48cf-a46e-049a1d385757">1,470,153</ix:nonFraction>; 2018 - $<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NzI_8418b651-c1a3-4129-b4c2-896365a7cfb1">1,415,833</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzQxNQ_362f7d5f-7466-4b23-bcd9-2dcbee1ff7e1" continuedAt="i7bdf08ce2ec34ba68bc4f79e8e8c931d" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i7bdf08ce2ec34ba68bc4f79e8e8c931d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2020 of <ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE4OA_b699c798-4092-4168-8a8c-be31ebbce2c5"><ix:nonFraction unitRef="shares" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE4OA_cbd5b67f-10ad-4a47-8d21-fd68013d5cc5">40,338,789</ix:nonFraction></ix:nonFraction> (2019 - <ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE5Nw_52da9c68-ff2c-439a-a459-0d9c2e4f6434"><ix:nonFraction unitRef="shares" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE5Nw_a5a1ce02-c5f5-4447-8d8d-fb50605bba93">22,137,990</ix:nonFraction></ix:nonFraction>; 2018 - <ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzIwNg_817edb81-9af4-49ec-aa91-752a02aeaf95"><ix:nonFraction unitRef="shares" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzIwNg_cc4b8b70-3a1c-4afa-b993-6aa5a2e73f3b">16,016,366</ix:nonFraction></ix:nonFraction>). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzEyMTY_1e4eb6aa-1670-4df7-8c2a-852f96d8646c" continuedAt="ib5bc3cdbc80c49bca448fc4d4519adc9" escape="true">Contract Liability and Receivable</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib5bc3cdbc80c49bca448fc4d4519adc9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzEyMTk_517fb237-b74f-4842-9a12-c76cb47d4bd0" escape="true"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at December 31, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next <ix:nonFraction unitRef="year" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:ContractLiabilityRecognitionPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzExOTQ_b0d7db65-19ae-4a15-96ba-9eb980cf5b8e">five</ix:nonFraction> years, is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"><tr><td style="width:1.0pt"></td><td style="width:175.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:78.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzEtMS0xLTEtMA_4e56abb0-34ce-494c-9aee-c7522931f004">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzEtMi0xLTEtMA_ec7c380d-8d59-4928-88f8-28e7343aedb5">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzItMS0xLTEtMA_9006e707-3c2a-49b6-a5c7-82d45c2d56dd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:RevenueFromContractsWithCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzItMi0xLTEtMA_d6c4dd76-5ede-4388-905a-6a59ef92b3a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzMtMS0xLTEtMA_d78fbd04-0311-4e03-8b63-62c1da319382">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzMtMi0xLTEtMA_33d4103e-aa25-4a9c-987e-16d37ad9f9e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzQtMS0xLTEtMA_cfba1e94-3be9-4d23-96c5-0e7aeac03680">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzQtMi0xLTEtMA_aa940519-3a31-4667-a502-975076bd28e2">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzYtMS0xLTEtMA_6d29287f-2f93-4c3e-9d17-cab3fbd6fcdf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzYtMi0xLTEtMA_44a19391-a3e3-4f6a-a1aa-889d79f8836d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzctMS0xLTEtMA_d8ae2179-a57a-41c7-b4e8-750ec0ba34ea">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzctMi0xLTEtMA_d6bd36ab-a51d-4583-92a2-9ffb5a5cfd35">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzgtMS0xLTEtMA_187df005-bb22-48bd-9374-72f34a1b40a0">6,730,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzgtMi0xLTEtMA_9462f62c-9bd3-4961-85c1-547a00f9c9cc">6,730,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_184"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 13: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzEyMjM_61b57c0e-2a72-4a20-862a-c8faecbff16c" continuedAt="i0765da352c1144f4ba41e23f7c51be72" escape="true">Commitments</ix:nonNumeric></span></div><ix:continuation id="i0765da352c1144f4ba41e23f7c51be72"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:PurchaseObligation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY2_b339a7dc-a367-4bba-b0b3-c3aa17faead0">9,360,653</ix:nonFraction> for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" format="ixt-sec:durwordsen" name="oncyf:PurchaseObligationCommitmentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzc2OTY1ODEzOTU4NDM_c12d854b-66a3-4feb-ac59-5b5b3d934367">two years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December 31, 2020, we recorded <ix:nonFraction unitRef="usd" contextRef="ia0330059b7334744a4426087fd12ceff_I20201231" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:OtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzUwMQ_7214e03c-59d2-4969-b89c-582ebc3296f8">nil</ix:nonFraction> (December&#160;31, 2019 - US$<ix:nonFraction unitRef="usd" contextRef="i5fd64c7e97d84e4588d426a71091008b_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzUxMA_fb012471-a522-40b5-be2c-80c964e39663">1,500,000</ix:nonFraction>) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$<ix:nonFraction unitRef="cad" contextRef="ia0330059b7334744a4426087fd12ceff_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY2Mw_0a8e0225-e942-441c-879d-358bf4b9e386">97,381</ix:nonFraction> (December&#160;31, 2019 - US$<ix:nonFraction unitRef="cad" contextRef="i5fd64c7e97d84e4588d426a71091008b_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY3Mg_bfa69cc3-2388-4420-97b8-35148c0b5625">652,306</ix:nonFraction>) in other liabilities representing future trial costs to be incurred.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:FundedandRoyaltyRepayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzk1Mg_17b93d0a-d6fe-4ea3-87ed-dcaa4f6e3b3d">400,000</ix:nonFraction> plus an overhead repayment of $<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:OverheadRepayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzk4NQ_1932423c-7d5e-4942-9555-d17cfb6b2383">100,000</ix:nonFraction>, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) <ix:nonFraction unitRef="number" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" name="oncyf:AnnualContingentPaymentGrossSalesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzExMTY_f3c5d176-b90f-4568-ba4d-f185a8164ab4">5</ix:nonFraction>% of gross sales of a specified product; or (b) $<ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:AnnualContingentPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzExNjU_cb357b3d-1909-4418-a27f-7ad20ac1c864">100,000</ix:nonFraction> per annum once sales of a specified product commence.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 14: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzIwNTc_dd60c969-3304-4434-b1b0-060dfec5c8c1" continuedAt="i2b75d3660ebc43579564ded8938b0619" escape="true">Contingencies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2b75d3660ebc43579564ded8938b0619" continuedAt="ief2efc27ad61440296d9b70b32155a85"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumption Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, a milestone payment was still outstanding for $<ix:nonFraction unitRef="cad" contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzM4MQ_39c0bb2b-3b59-4e12-90ec-5ab4f1a5a05c">1.0</ix:nonFraction> million, due within <ix:nonNumeric contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231" format="ixt-sec:durday" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzM5Ng_229f07c1-4903-470c-849a-a16c4d71aca7">90</ix:nonNumeric> days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders <ix:nonFraction unitRef="number" contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzExMDU_0519be78-5368-40aa-97b3-a3d1f4bdc1d1">10.75</ix:nonFraction>% (2019 - <ix:nonFraction unitRef="number" contextRef="iedf7891a1e984661bf760a99c195c570_D20190101-20191231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzExMTQ_f8ebb128-33b2-49eb-9b2e-4aa9c275029e">10.75</ix:nonFraction>%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of <ix:nonFraction unitRef="number" contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzEzNzU_0b35968f-4341-4291-ba89-5fd665f50cb0">2.15</ix:nonFraction>% (2019 - <ix:nonFraction unitRef="number" contextRef="iedf7891a1e984661bf760a99c195c570_D20190101-20191231" decimals="INF" name="oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzEzODQ_bc5a34b0-f6dc-4271-9d55-eb00347b6baa">2.15</ix:nonFraction>%) of Net Sales received for such products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRI &#8220;Work in Kind&#8221; Contribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ief2efc27ad61440296d9b70b32155a85">We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of <ix:nonFraction unitRef="number" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="INF" name="oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzE4NDE_a204041a-15c7-44d2-a32c-8801e605a9a4">0.5</ix:nonFraction>% of Sales Revenue or $<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="oncyf:ContingentRoyaltyPaymentAnnualMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzE4NjQ_a39681db-40dd-441a-9022-46eb738bbe65">20,000</ix:nonFraction> per year until December 31, 2028.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_193"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 15: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNjc_0210a72d-b816-4721-8b4f-7190dabc4706" continuedAt="i934e1eb7a29f4ace816cbf57d2a9ce4a" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i934e1eb7a29f4ace816cbf57d2a9ce4a" continuedAt="i6ebd01a75af1402094194e461a015a71"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNzI_a36ebb1c-36c8-4477-93ed-e303d85e54b5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:437.25pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMS0xLTEtMA_69584d96-7537-4b10-9231-05aacd455a8d">22,505,057</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMi0xLTEtMA_7b6db189-df81-4393-882a-e45c19f2f784">33,122,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMy0xLTEtMA_a9992191-0a1f-4a15-b500-3e53ceb6b305">16,489,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMS0xLTEtMA_bec4509f-4c49-449b-b4a8-a9903624f83b">24.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMi0xLTEtMA_59e4e482-6979-40f5-bdc9-7e4a1b9c990d">26.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMy0xLTEtMA_1cd95616-4820-4086-9ccf-1f11fef08c6e">27.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMS0xLTEtMA_e7024e37-15db-434e-a245-017a71eef2b6">5,401,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMi0xLTEtMA_81470e7b-826c-4558-9f81-73934171fb2c">8,777,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMy0xLTEtMA_bbcf544a-e709-44cb-be25-a6c4b3bf99d5">4,452,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMS0xLTEtMA_bf192926-83b5-4471-bb56-b6ba82259deb">3,237,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMi0xLTEtMA_1111fe22-e60e-493c-839d-77ded6aa028e">3,088,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMy0xLTEtMA_e36d2c06-7ceb-4dde-a7ff-1330d41ea409">3,312,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfStockBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMS0xLTEtMA_7b7b28c6-b01d-4bc4-9751-0a1dce0480e4">614,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfStockBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMi0xLTEtMA_6c007329-6b4a-4092-af08-4adf7618c0a6">389,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfStockBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMy0xLTEtMA_4d6a8362-79b2-47bc-a120-8459e755f23d">382,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMS0xLTEtMA_936671aa-9b89-4b2c-a222-f78c60070c48">838,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMi0xLTEtMA_764a676e-98a2-4a78-ae80-740953d12134">3,341,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMy0xLTEtMA_c1d384cf-523e-45d2-8984-633510d7f798">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMS0xLTEtMA_dc221704-38a7-4578-b142-120b6a4fb59c">96,028</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMi0xLTEtMA_f6925983-6bc6-49e5-a07e-b18a62a9a804">3,758,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMy0xLTEtMA_18a2f997-c373-43c7-b602-c5a03ea1e8d5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfTaxPools" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMS0xLTEtMA_e71ac777-9ba9-4a29-a798-1cc905dd84d9">20,711</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfTaxPools" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMi0xLTEtMA_99a55f66-3150-477e-8179-786183340905">11,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:TaxEffectOfTaxPools" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMy0xLTEtMA_22a707b3-a297-4de7-804e-39e9c1aa5199">238,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMS0xLTEtMA_466eeeae-ea54-4bec-a840-bbd3e41ae91f">108,945</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMi0xLTEtMA_112ee8ec-705b-443e-88f6-450e2c6101d1">149,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMy0xLTEtMA_ab548204-38dc-49ed-937c-efcf2aed7744">35,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to <br/>  be recovered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTEtMS0xLTA_12d497fa-50a0-4997-bbce-b59234d16848">2,161,541</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTItMS0xLTA_f105cf9d-4fc6-4389-9126-111bbec205ae">1,961,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTMtMS0xLTA_3a2f10f1-9cbd-47f0-bfad-1220aa3b4f4a">1,579,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTEtMS0xLTA_0b78bcb1-d3da-4be2-bfda-3f852cfe4846">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTItMS0xLTA_2bbda7b7-36dc-4c22-857d-45ec07dadb1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTMtMS0xLTA_b7686fac-8e9f-4312-a640-3368f8373fd7">548,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment in respect to prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTEtMS0xLTA_ebbeed72-0c43-48f2-b518-8b93e945dbd4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTItMS0xLTA_31871b42-30d6-4d7e-94f3-29916d5dbeb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTMtMS0xLTA_c65739a7-50d2-46fd-b3eb-0a7949392196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTEtMS0xLTA_2b2e06eb-bead-4bcc-87b1-be84e77759d2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTItMS0xLTA_b2fdaf92-4933-4e28-9adb-46d15784f2dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTMtMS0xLTA_912daa62-1a78-4dfa-87ff-370b7e72bc24">548,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNjQ_6cb98a82-fb44-4534-80a4-b9d5af0ea114" continuedAt="i5c24a99a9d3542ab9fad0990f771fa85" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-capital losses for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.853%"><tr><td style="width:1.0%"></td><td style="width:35.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i36ad307898ce427b8790187e5e3b200c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEtMS0xLTEtMA_bcac7bd7-61b5-4772-9542-a8a4d92b8453">9,809,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i54d89438e9834962b588ec713f9cd690_I20201231" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzItMS0xLTEtMA_3f7a276b-bb8b-4cac-8e7e-958acb5b959c">12,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifd3f0138f46c4695ad37fbc8f2fdd536_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzMtMS0xLTEtMA_c872ed86-4293-4883-9a72-7cee7ca89082">4,009,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibf141931e3d34eaa866f4acef645b42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzQtMS0xLTEtMA_bd88a448-dd86-460c-9725-84ca27e04507">4,774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifed0ad348c7d44b8a47c4217a6d28e36_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzUtMS0xLTEtMA_0e3a98ef-33e7-4ad7-9b36-179b09163c4f">4,343,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i38a469cc0b8945629f3b38ad881e0e5f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzYtMS0xLTEtMA_e77586d1-4b80-41af-aa08-835c04d3b9c7">2,873,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia09469d6bdcf47b6bcfcf25aee7cb4b7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzctMS0xLTEtMA_2da74d0c-f55f-4fd6-829f-5c70735a2b76">2,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i39ac27a554b240599f9bd777a1fc6041_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzgtMS0xLTEtMA_1b43d2d5-3200-43ee-8629-87dcf9dd0afc">2,472,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7ca105778fa3488ab4fcac5815684208_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzktMS0xLTEtMA_490539bc-bf00-4487-8c2a-328c1c8add6a">3,125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8eca0e1194124e76a337dbb158229685_I20201231" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEwLTEtMS0xLTA_867a4364-a569-462e-ac7d-b9983e8f0d6c">6,430,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if6b678dac805480d81678cec8ff97f34_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzExLTEtMS0xLTA_8cd0769e-19e9-48b7-a672-c2d8bc024fe6">4,812,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id2a1e703d63441b4bd16a9d814bd0759_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEyLTEtMS0xLTA_b3551c9c-0e4a-403e-89a7-02f6395c2c16">5,056,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i60114d1ecfaa437a904d6c5f10744623_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEzLTEtMS0xLTA_4d7e2810-1925-4853-ad23-533f01ca3c09">6,864,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i060c05e904e543c0b502d08304c1d52c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzE0LTEtMS0xLTI4NjQ_a25f2361-55cf-465a-a977-3e9ddfe83077">9,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibd0824dc040346089bbc41d9b1bc5c4b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzE0LTEtMS0xLTA_4635772b-6aec-4f84-bff5-555de198c3fd">78,994,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i6ebd01a75af1402094194e461a015a71"><ix:continuation id="i5c24a99a9d3542ab9fad0990f771fa85" continuedAt="if9582a1a8c9345378570a011ce423861"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:142.50pt"><tr><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i12e526825a3a4c41ad8c2653148296cd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzItMS0xLTEtMA_aca6f729-c45a-4758-ac2c-82f04699d9d4">471,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7656abe4911c4cfdb005eaabc3cad80c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzMtMS0xLTEtMA_2d2f8250-cd21-4093-a9ba-9d0dbf2b2863">465,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0965b8657ffb499a9cb5db812656c63f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzQtMS0xLTEtMA_e42defd8-1cfe-477a-af9a-25b9e9ffe6bc">361,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id63c5c00c60c4df1a2140b12e0626f97_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzUtMS0xLTEtMA_ca7a4165-c81e-47eb-ac4d-548fabfd0c90">228,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i23653b0174744934a761bcc2fb2c6c28_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzYtMS0xLTEtMA_810a4653-95a9-4ed6-8b4a-5c95cc645879">271,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i157e9a3c5d344966b0455389eb83448b_I20201231" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzctMS0xLTEtMA_90b50cd3-b8ca-46a0-965d-5d1a713566aa">520,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaa85527afb2a4cf99bce5e48d4143c65_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzgtMS0xLTEtMA_a037ece9-36f9-4074-b468-ad02adf79a5f">596,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i10628d338fe649f8be7f5a4c729aff30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzktMS0xLTEtMA_c945de69-8512-4fc8-8542-2c9d538fdf19">622,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i94e7b2e1b5084522b265069419c11268_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEwLTEtMS0xLTA_3cd5af40-f4d0-44ee-b8ed-24ee886fef1a">173,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4a4b9c9d6c38474ebcd1343720d274a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzExLTEtMS0xLTA_a26614d1-59e7-43ac-81af-6a0e65a9246e">91,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6adeb07951ec41eb8fba6df6d47342b2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEyLTEtMS0xLTA_f0acff0f-90f4-4edc-8d7b-ddf4549361e7">114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id0637845ec63458e85e2cbae28f8f5d1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEzLTEtMS0xLTA_f4c5ca7e-d7b6-4840-9804-1676913d8084">381,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7c77b28bdcf1403cb5d35cd988bdcfe7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE0LTEtMS0xLTA_77597496-fb75-4790-88ec-eb2442f271ae">487,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie9ad5f87e7304d85bd63633afc56fe8a_I20201231" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE1LTEtMS0xLTA_aa9a1785-88c1-41bd-a84d-14aff2768f67">270,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i871337f4238f4abd9e90092d1f02384e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE2LTEtMS0xLTA_d3b0b3d8-02ee-4d52-8b0f-3df7553b4099">183,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iababe61944e54b2c9ceccc57bf2faecf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE3LTEtMS0xLTA_fee26d29-f493-40a4-b946-3c348013e523">41,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie482d3a1b82148c1bd56712a715af083_I20201231" decimals="-1" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE4LTEtMS0xLTA_470204be-70ca-4595-9599-a19957e8497c">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7801864cfd79494a9a797845cc05d6ef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE5LTEtMS0xLTA_ce696c45-cfaa-45c0-aa93-2fc16f41a70d">22,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iab3c42e6c6fd41feb4b54f0b9082e910_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE5LTEtMS0xLTI4NzI_bbdd883e-23a5-473a-ab10-451e20e64437">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzIwLTEtMS0xLTA_7fa0316a-f6df-480c-abe3-830162d9748f">5,304,980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately $<ix:nonFraction unitRef="cad" contextRef="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzYzMg_00386e26-d806-47ef-b6f5-16086e17f29f">27,660,000</ix:nonFraction>.&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</span></div><ix:continuation id="if9582a1a8c9345378570a011ce423861"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:459.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i79faad7289cd45f58106ae2fdd652ec1_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMS0xLTEtMA_7075a683-f2ed-4c92-a115-dd39ec36a996">21,487,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i56e6aac06972419c9ec828611697e6f7_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMi0xLTEtMA_d6d91640-0c2d-4208-83f1-ad78b3036026">19,625,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8378abfb369e439497cb8d7d53a35bf7_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMy0xLTEtMA_47be8576-b5b3-4836-a4f9-093ede8375b8">20,664,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMS0xLTEtMA_4291c6c1-9f75-4916-a145-1a6c815a75bf">6,362,152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if898df29e89b4ec3a60df1b042af3863_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMi0xLTEtMA_af3544fc-e4de-4eb4-9cbf-ba161a1b5a0e">6,338,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic5cacf4383b8479f8cf65a36c967cae1_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMy0xLTEtMA_2e74ef8f-d211-4bcc-8c7b-19f92e207756">7,406,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9020465658f74f4fbde6469e191a8c40_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMS0xLTEtMA_46a97c42-8d28-43ca-bb9b-859cd3533730">4,068,105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1a02e778e8c84e928734637cf208bd4f_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMi0xLTEtMA_36566421-b9b8-49ed-914a-abe2034943d0">4,222,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibf277f3b07e54dbb8e328eacdafdddbd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMy0xLTEtMA_6b184969-35e3-45ac-aadb-c7e28cc050fa">3,988,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4063dfdc87384c3e85d8174c150d31b8_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMS0xLTEtMA_aae4d09d-084e-442c-9bce-7896ad255b24">1,927,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i931661a623914b388fdfa5f4e409ccaf_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMi0xLTEtMA_78b3a175-946e-4381-ba57-5328ac821e77">1,908,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b0bf7d64d344c48bd924d075e96c40f_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMy0xLTEtMA_1a249c03-9c9f-4256-97a4-4b257289ecef">1,949,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i658b28d872bd41568deaa26495694e07_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMS0xLTEtMA_436e6989-964f-4715-af19-04930ff67ae2">689,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i878f5c4c5d6f4d41947cf6fb9d21cfdf_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMi0xLTEtMA_bb8c3218-861c-4724-a2bb-2d4ac5a9e3d0">611,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7b1ca5e55ba34078871b684db87e823e_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMy0xLTEtMA_0963b320-63f3-4e8f-bf13-bfcd7f2701e1">696,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15589c7e1a2b491aa913407d6863f338_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMS0xLTEtMA_eaba6a38-becb-4428-8629-0589d6cee79b">6,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia16bc392d6f74d4dbbf71003e9881f32_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMi0xLTEtMA_1659df29-a6c1-4b22-ab1e-a5bddfe4dc5e">6,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i17a004d3e9c7446896d6d5d1956caf96_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMy0xLTEtMA_5b34631b-8668-4511-a928-5add265ca2cb">7,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMS0xLTEtMA_f081910e-02b2-4afa-b36a-2306c4097303">34,541,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMi0xLTEtMA_655c33be-e13e-41ec-8938-4a72505a7faa">32,712,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMy0xLTEtMA_c48bc7fd-712d-4baa-ae73-d8ae019df012">34,712,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzM2OTM_35f02ddc-f1c4-44ea-a4f9-d4894e4305f8" continuedAt="iad9f52a04d114ea9945e7bc7926bf61a" escape="true">Capital Disclosures</ix:nonNumeric></span></div><ix:continuation id="iad9f52a04d114ea9945e7bc7926bf61a" continuedAt="ia6f8b9e9357142c1a03ce83500919efe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="ia6f8b9e9357142c1a03ce83500919efe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:DisclosureOfCapitalComponentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzM2ODk_61bbb545-90ca-4d09-bb95-d0c6e976f504" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:70.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzEtMS0xLTEtMA_64405755-bebe-4d22-9660-2f3ad1fcdd8f">31,219,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzEtMi0xLTEtMA_5e18efc1-06f3-4f34-b228-63e0e472463a">14,148,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzItMS0xLTEtMA_01e77329-bb5c-44f7-b663-a35b69f809b3">24,752,993</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzItMi0xLTEtMA_46bfcb2d-5fe8-4ae5-991b-2a84cd66e9d7">107,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On  June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $<ix:nonFraction unitRef="cad" contextRef="i8dcb30c64a054057ae8268e11a956cf5_I20200612" decimals="INF" format="ixt:numdotdecimal" name="oncyf:EquityAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzE4NzQ_ffcbdbad-65c9-407b-9a6f-723f88f4f705">150,000,000</ix:nonFraction> of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 9). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 17: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzM3MjM_bd6f77de-6e79-439e-b837-0026866400df" continuedAt="i8196f09a7d92497492bd8c106cc3477c" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i8196f09a7d92497492bd8c106cc3477c" continuedAt="i6f3e8420b132477690fae21f3e777d12"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at December&#160;31, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2020, the fair value of our warrant derivative was $<ix:nonFraction unitRef="cad" contextRef="i84b52d8638644519af44304507a14d80_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzU1NQ_70f98ff8-1cfd-4e64-a646-b7c51c6921a4">531,228</ix:nonFraction> (December&#160;31, 2019 - $<ix:nonFraction unitRef="cad" contextRef="i269daa67eeae4597bc0a7db7539e1081_I20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzU2NA_d2f5d115-1d05-42e1-8533-275fce5aeba7">8,508,764</ix:nonFraction>).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="i6f3e8420b132477690fae21f3e777d12"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $<ix:nonFraction unitRef="cad" contextRef="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231" decimals="INF" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI2NjU_0be186dd-6d22-464e-a00e-dfa967da6e67">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $<ix:nonFraction unitRef="cad" contextRef="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI4MDg_c1bb2b07-9e69-4e25-960b-8c313d5aac5f">172,000</ix:nonFraction>.&#160;&#160;The impact of a $<ix:nonFraction unitRef="cad" contextRef="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231" decimals="INF" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI4Mjk_24307a2b-2461-4303-a474-f6c46ad925b7">0.10</ix:nonFraction> increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $<ix:nonFraction unitRef="cad" contextRef="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI5NzQ_72654c58-d9af-4ccb-81bf-315585dc4b06">20,000</ix:nonFraction>. The impact of a $<ix:nonFraction unitRef="cad" contextRef="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231" decimals="INF" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI5OTQ_223206ed-2e34-4b0b-a373-40bd8627031b">0.10</ix:nonFraction> increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $<ix:nonFraction unitRef="cad" contextRef="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzMxMzA_181b7b78-c352-463e-86a2-15d98c28d7f6">3,000</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzM3Mjc_0185bbf0-e51c-4627-ad82-325a29c2c81d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:466.50pt"><tr><td style="width:1.0pt"></td><td style="width:165.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollars <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br/>&#8364;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMS0xLTEtMA_b824bc0b-824e-4182-a938-de6f8d76cd66">23,134,113</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMi0xLTEtMA_82002a43-e316-4753-99c5-f96ff63688af">26,768</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMy0xLTEtMA_7a33c355-f380-4ea1-9ebe-df131285b5d9">37,347</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMS0xLTEtMA_1f1db766-c24c-4ef9-a6e2-5d2ce70cc81e">455,588</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMi0xLTEtMA_67cf6c86-2d49-42bf-9129-71c842dc6f70">2,244</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231" decimals="0" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMy0xLTEtMA_1687fef3-f0c3-495e-81dc-4ff6a0c9569e">930</ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMS0xLTEtMA_7cd75859-bd8f-4441-82cb-2bcd072468dc">417,238</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMi0xLTEtMA_d39dd597-86bd-41fa-a554-c61279f719b6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMy0xLTEtMA_6ad11780-0ce6-45cd-ab35-dff76a0dc0a9">&#8212;</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:BalanceHeldInForeignCurrencyNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMS0xLTEtMA_d3c7e8da-d817-4845-b3c2-96ed41723c45">22,261,287</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:BalanceHeldInForeignCurrencyNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMi0xLTEtMA_e7d9cd8a-f1d9-422e-8c0f-f149867397ed">24,524</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:BalanceHeldInForeignCurrencyNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMy0xLTEtMA_d0ce85bd-e5a7-4942-beb7-2864ac5e38db">36,417</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_202"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 18: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEyNw_d6d17c8e-adbb-4348-9a7d-2ba97f762577" continuedAt="if2f52e45e02f42c5955acede0d64cfdd" escape="true">Additional Cash Flow Disclosures</ix:nonNumeric></span></div><ix:continuation id="if2f52e45e02f42c5955acede0d64cfdd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:CashFlowOperatingCapital1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEzMw_f697809f-bd45-4cc5-a44c-132012eceef4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"><tr><td style="width:1.0pt"></td><td style="width:292.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMS0xLTEtMA_ad1e0f01-44ec-4898-9747-80b59cd98aae">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMi0xLTEtMA_475fce69-cc7d-4c7f-be27-99fa02239ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMy0xLTEtMA_54c8112c-8d8a-4133-a5cf-5654ff9e031a">4,767,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMS0xLTEtMA_ac01a17a-b19a-4be0-929e-5427fd02c633">1,979,111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMi0xLTEtMA_b639fd77-c26a-423b-8a56-ee64491ca1c1">2,017,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMy0xLTEtMA_9c0a92d8-35da-467d-a0c2-cbd125c87a7d">13,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseinPrepaidExpense1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMS0xLTEtMA_a2c99176-9624-4940-b470-d83b09c04065">286,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseinPrepaidExpense1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMi0xLTEtMA_a5562b41-c3e0-42fc-ad52-e5c9a2a58d9b">2,012,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseinPrepaidExpense1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMy0xLTEtMA_fc9c798c-b5aa-416d-9986-ecebac77166c">475,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMS0xLTEtMA_e4300af4-f24b-4dd4-9cc5-070e89b2fb69">1,368,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMi0xLTEtMA_5dc05f14-a8e9-4991-99e3-0d9debfba487">1,347,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMy0xLTEtMA_ed5838ca-afb6-432a-9b8e-ad3bde6898ef">1,858,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMS0xLTEtMA_05bc28ae-9f59-4cdd-b1db-2489fe8b43ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMi0xLTEtMA_7296c259-18af-4493-855b-6bd9f5841888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMy0xLTEtMA_24b78e2c-ad65-417c-a9d7-a9b9081ec937">547,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMS0xLTEtMA_2eeb157d-abd1-498e-aca6-43ab4859eaa4">723,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMi0xLTEtMA_d6973c22-c9e1-4b45-bd21-b827b632bc26">807,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMy0xLTEtMA_5053055a-8e10-4f10-801e-2415394d4210">27,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMS0xLTEtMA_ba93b8ad-e384-46c6-a6e1-ac8234ec3cf7">35,710</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMi0xLTEtMA_860df08d-8f72-4636-9b95-764e6c20c907">78,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMy0xLTEtMA_d90b87d2-9b6e-4525-8971-cc2fd3e52780">14,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMS0xLTEtMA_d2d0e86b-6ed9-4396-9ed0-e441050a9b08">209,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMi0xLTEtMA_a9c4f9db-ce28-4ad2-8e81-e31d4aac15cd">1,795,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMy0xLTEtMA_b552675b-f025-4526-82e5-482588c08b9f">3,904,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEyNA_7de16553-1728-41c9-8374-41e557e1eb20" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"></td><td style="width:255.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromInterestReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMS0xLTEtMA_da49ca6c-cac6-4859-bd77-76d82e14a755">189,720</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromInterestReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMi0xLTEtMA_92ac1876-6ca8-42e8-ab40-e0010dd7594b">274,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:ProceedsfromInterestReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMy0xLTEtMA_f51493af-d8f1-411c-9f42-e67af81bebc4">173,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMS0xLTEtMA_a7064b21-d2d5-437e-abd6-7f05507f4a6a">12,080</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMi0xLTEtMA_1b635ede-4824-4933-95ef-67cfd2529a76">5,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidRefund" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMy0xLTEtMA_816af1a0-ed64-4be8-84f3-9b3833c8998f">15,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_205"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 19: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDUvZnJhZzoyZjQyYjA1NzM4NzI0YzU1YTM4YjJhOWU4OGM3NTk2ZC90ZXh0cmVnaW9uOjJmNDJiMDU3Mzg3MjRjNTVhMzhiMmE5ZTg4Yzc1OTZkXzExNjU_8b12d836-dd72-4938-9008-2aa6e212405c" continuedAt="i4b2559c11912411eaf789679118a1bc4" escape="true">Indemnification of Officers and Directors</ix:nonNumeric></span></div><ix:continuation id="i4b2559c11912411eaf789679118a1bc4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 20: <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:DisclosureOfEconomicDependenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDgvZnJhZzphMDVlZmRlOTI5NjU0NGYzYTRmNjJkZWM1ZDE2ZjEwOC90ZXh0cmVnaW9uOmEwNWVmZGU5Mjk2NTQ0ZjNhNGY2MmRlYzVkMTZmMTA4XzY0MQ_ff32c5fd-799e-4bca-a57c-d673a9877bdc" continuedAt="id7aea4b5bad9462f84301d3b564a6037" escape="true">Economic Dependence</ix:nonNumeric></span></div><ix:continuation id="id7aea4b5bad9462f84301d3b564a6037"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="i32c78d9692194534851ffc8c75765b43_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="oncyf:ConcentrationRiskNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDgvZnJhZzphMDVlZmRlOTI5NjU0NGYzYTRmNjJkZWM1ZDE2ZjEwOC90ZXh0cmVnaW9uOmEwNWVmZGU5Mjk2NTQ0ZjNhNGY2MmRlYzVkMTZmMTA4XzExMA_f172b17d-cb70-464f-aba0-f921ca15a36c">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_211"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 21:  <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90ZXh0cmVnaW9uOmMwZDFlYWMyODk4MTQyZjliNTZiMzZmYWM5YWM3MGQyXzYxNg_5f66eb49-734f-4c64-997e-522445d5f00d" continuedAt="i4872f4ab7a42408d8821e9f195f7b613" escape="true">Other Expenses and Adjustments</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4872f4ab7a42408d8821e9f195f7b613" continuedAt="iea413a54039c41caa0d87b73ad17c5de">The following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><ix:continuation id="iea413a54039c41caa0d87b73ad17c5de"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="oncyf:OtherExpensesAndAdjustmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90ZXh0cmVnaW9uOmMwZDFlYWMyODk4MTQyZjliNTZiMzZmYWM5YWM3MGQyXzYxMg_d5d1e4b5-2de2-446b-a411-f73343277732" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieacddbbb17314a6bbe19b73efcd83368_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMS0xLTEtMA_aff33383-9239-430b-adfd-28c92770bce8">1,043,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4b307c503b264545a9529c655c522919_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMi0xLTEtMA_d8bed02e-3c54-49af-bd05-bf57ec318877">561,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i61dbf81b2c67488eabed83aa307e45c0_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMy0xLTEtMA_11ff8f95-5e5e-49d7-a39f-7075361c3baf">680,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMS0xLTEtMA_5020c850-e1f0-41e1-b957-f090f782d39a">88,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMi0xLTEtMA_4923512d-398c-4827-bcc0-f9d91ccba2a7">122,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AmortisationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMy0xLTEtMA_e4453c85-5191-4dc4-b987-4e84bddfb874">95,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMS0xLTEtMA_d3615ae9-4b4d-487e-beec-ed534be6c7e1">357,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMi0xLTEtMA_56e35934-c53b-42ba-aaff-314fbc54c269">362,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:DepreciationRightofuseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMy0xLTEtMA_4d215bf0-5bd1-4d7c-ac24-b8bf4f6a62a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMS0xLTEtMA_2395577a-e701-49d3-9521-c9be856ff03e">1,515,601</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMi0xLTEtMA_c6bd9120-7fa2-4b03-8a61-920f91d91163">908,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMy0xLTEtMA_7ef64c1f-7e93-4adb-9076-94a1db907a8d">735,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia846c8c806434b23ad5a6d843024e310_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTEtMS0xLTA_6f4673f1-2a00-45bf-b3bc-c55c7eb96c2c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i640ad69a2bed48779ac6bb4eb9764cd1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTItMS0xLTA_950a45d9-fbf0-49eb-a8c5-4480a22eb22b">233,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i137e70b443b146e3bd028f654a8470d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:ShareIssueRelatedCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTMtMS0xLTA_ed9beef2-c247-4f9f-ab2b-4b03f2c26c40">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onerous lease contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTEtMS0xLTA_5c03039f-60f0-4a57-afe1-40d630315cfb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTItMS0xLTA_fd35f238-c18b-4c10-a530-035065207ca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForProvisions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTMtMS0xLTA_497cc169-4e02-4938-8799-ac4e9e3d3d93">67,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization - lease incentive liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTEtMS0xLTA_52ff1f45-cfe3-4a4e-b0aa-4ac646b38c0e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231" decimals="0" format="ixt:zerodash" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTItMS0xLTA_2a76c241-ad0a-4ba8-b657-1af6143915d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="oncyf:AdjustmentsforLeaseAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTMtMS0xLTA_4afc7dca-1e53-44e9-999a-80feaeeb48fc">8,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_214"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 22:  <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90ZXh0cmVnaW9uOjU5MWQ2Nzk5NzI5ODQ5Y2RiY2FiYzI1YWI5ZGU3YTQzXzY1OQ_bcc59207-0868-4483-a4ab-b6d860027a03" continuedAt="idd9f99f273f34a6aaeb01d825cdb1d9b" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idd9f99f273f34a6aaeb01d825cdb1d9b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90ZXh0cmVnaW9uOjU5MWQ2Nzk5NzI5ODQ5Y2RiY2FiYzI1YWI5ZGU3YTQzXzY1NQ_bd61000b-7350-407d-9987-89a4d6b3b31d" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:390.00pt"><tr><td style="width:1.0pt"></td><td style="width:223.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMS0xLTEtMA_e6271ab0-1f7d-4c8a-8071-ae8bcddfb24d">3,514,527</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMi0xLTEtMA_47a85dd2-1d1c-4aee-b12c-b332c8e02a74">3,786,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMy0xLTEtMA_2550f1f9-d39c-4253-af20-f5e52cc633f4">2,680,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMS0xLTEtMA_dec8cc5a-5ad6-44f8-a09f-3c8369396ed7">495,175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMi0xLTEtMA_3e1fe349-6efe-4606-a263-aa0801ab3a11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMy0xLTEtMA_18007caf-872c-4bb1-a94e-072f95a7d89b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMS0xLTEtMA_03abee2a-ce0a-4fd3-9447-e6e21e519994">1,757,723</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMi0xLTEtMA_bd14bb6c-23f1-4eb1-8eb9-7180adb1a9c0">1,123,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMy0xLTEtMA_605230cc-6223-4f2c-bcd1-adf9660d37a3">1,067,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMS0xLTEtMA_255799d9-41aa-435e-beb9-c3c91714b34b">5,767,425</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMi0xLTEtMA_06afb528-ac3e-466c-a579-eec707353ef8">4,910,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMy0xLTEtMA_502376c0-df31-4646-a55c-ecbf2a08fe89">3,747,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_217"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020 </span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 23:  <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzM4OA_aa408f9e-32cd-453b-99cc-6d13a81cf9c5" continuedAt="i8a8f184aed754747bcc84209cd6fb2c9" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a8f184aed754747bcc84209cd6fb2c9">Between January 1, 2021 and March 4, 2021, through our June 2020 ATM equity distribution agreement, we issued <ix:nonFraction unitRef="shares" contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304" decimals="0" format="ixt:numdotdecimal" name="oncyf:IssueOfEquityShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU1ODI_2ac4f9cc-a616-4c79-97c0-a2558576f686">5,685,097</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304" decimals="0" format="ixt:numdotdecimal" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU1OTM_e83a6056-0efe-44b9-ba71-f0cae6d55a43">18,503,188</ix:nonFraction> at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="id1dda167e3394214b8a7f2f4ef0d20bb_I20210304" decimals="INF" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU3MzM_8b30f59c-96b3-4d56-ace8-4e94855d4027">2.85</ix:nonFraction>. We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304" decimals="0" format="ixt:numdotdecimal" name="oncyf:ShareIssueRelatedCostCommissions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU5NjM_83ad8d8b-90ed-4bb0-b7b4-e9f8c043bd06">555,096</ix:nonFraction>, proceeds of US$<ix:nonFraction unitRef="usd" contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTYwNDI_58f38b13-c624-4513-8646-6df1ce8490c6">17,948,092</ix:nonFraction>.</ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="id25010cc8f2d484d8b4b3c9949ddb687_1863"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Note 24:  <ix:nonNumeric contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231" name="ifrs-full:DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODYzL2ZyYWc6MDBlZmViYTA0N2NjNGEzYmJlMTRkNzFhNTgwN2QxZDEvdGV4dHJlZ2lvbjowMGVmZWJhMDQ3Y2M0YTNiYmUxNGQ3MWE1ODA3ZDFkMV83MTQ2ODI1NTgwODI1_1eb7ff8f-be43-4740-adb0-3bc6288ae77b" continuedAt="iad87eebcd09740c5b4380c22b1fbcd06" escape="true">Comparative Figures</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad87eebcd09740c5b4380c22b1fbcd06">Reclassification was made to prior period's figure to conform to the current period's presentation.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21exdescriptionofsecurit.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib983e62227cf486b872d58f3e3a9876e_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXHIBIT 2.1</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March&#160;4, 2021, we have 52,083,924 Common Shares issued and outstanding. After giving effect to the exercise or distribution of all outstanding options to acquire Common Shares, all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan and Common Share purchase warrants, we would have 57,804,242 Common Shares issued and outstanding. As at March&#160;4, 2021, we have 16,443,500 (exercisable into 1,730,894 common shares) Common Share purchase warrants issued in 2017 (the &#8220;2017 Warrants&#8221;) and 110,572 Common Share purchase warrants issued in 2019 (the &#8220;2019 Warrants&#8221;) outstanding. 9.5 2017 Warrant entitles the holder to purchase one Common Share until June 1, 2022, at an exercise price of $9.05. The 2017 Warrants are subject to acceleration if the volume weighted average price of the Common Shares equals or exceeds $23.75 for a period of 15 consecutive trading dates. Each 2019 Warrant entitles the holder to purchase one Common Share until August 16, 2024, at an exercise price of US$0.90. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>3
<FILENAME>ex412employmentagreementth.htm
<DESCRIPTION>EX-4.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6ce2ab7c59124912ac8c57ab6fef5b03_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT         </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS EMPLOYMENT AGREEMENT (&#8220;Agreement&#8221;), effective August 3, 2020 (&#8220;Effective Date&#8221;), is made between Oncolytics Biotech (U.S.), Inc., (&#8220;Employer&#8221; or the &#8220;Company&#8221;), and Thomas C. Heineman, M.D., Ph.D. (&#8220;Employee&#8221;).  Employee and the Company are sometimes referred to herein as the &#8220;Parties.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.67pt">Employer is in the business (the &#8220;Business&#8221;) of developing pharmaceutical products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.67pt">Employer desires to obtain the services of Employee as its Global Head of Clinical Development and Operations, in which capacity Employee has access to Employer&#8217;s Confidential Information (as hereinafter defined), and to obtain assurance that Employee will protect Employer&#8217;s Confidential Information during the term of employment and for a reasonable period of time after termination of employment pursuant to this Agreement, and Employee is willing to agree to these terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.01pt">Employee desires to be assured of the salary, bonus opportunity and other benefits in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in consideration of the mutual covenants in this Agreement, and other good and valuable consideration, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Employer hereby employs Employee, and Employee agrees to be employed as Global Head of Clinical Development and Operations.  Employee will perform the duties of Global Head of Clinical Development and Operations for Employer, its parent corporation, Oncolytics Biotech Inc. and other affiliated corporations.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee will report initially to the President of Employer.  Changes may be made from time to time by Employer in its sole discretion to the duties, reporting relationships and title of Employee.  Employee will devote full time and attention to the duties on Exhibit A to this Agreement.  Notwithstanding the foregoing, Employee may, with the written approval of the President of the Employer, undertake consulting work, whether personally or through a corporation controlled by Employee, provided that such consulting work does not interfere with or conflict with the performance of Employee&#8217;s duties and obligations under this Agreement.  Employee will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer&#8217;s Employee Handbook and Company Policy Manual. Employee will perform all of Employee&#8217;s responsibilities in compliance with all applicable laws and will ensure that the operations that Employee manages are in compliance with all applicable laws.  During Employee&#8217;s employment, Employee will not engage in any other business activity which, in the reasonable judgment of the President of Employer, conflicts with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the duties of Employee under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Term of Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of employment (&#8220;Term&#8221;) will not be for a definite period, but rather continue indefinitely until terminated in accordance with the terms and conditions of this Agreement.  The first 6 months following the Effective Date will be a probation period (the &#8220;Probation Period&#8221;).  Not less than 2 weeks prior to the end of the Probation Period, Employer will notify Employee in writing either that Employee&#8217;s employment is being continued or that Employee&#8217;s employment is being terminated at the completion of the Probation Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the duration of Employee&#8217;s employment under this Agreement, the Employee will be entitled to compensation which will be computed and paid pursuant to the following subparagraphs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.Base Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Employer will pay to Employee a base salary (&#8220;Base Salary&#8221;) at an annual rate of $400,000, payable in equal installments on the fifteenth and last day of each month, subject to withholdings and deductions as required or permitted by law.  Employee&#8217;s Base Salary will be reviewed annually by the President of Employer and may be adjusted in the sole discretion of Employer based on such review, but will not be reduced by Employer unless a material adverse change in the financial condition or operations of Employer has occurred or unless Employee&#8217;s responsibilities are altered to reflect less responsibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.Incentive Bonus.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee will participate in Employer&#8217;s annual incentive bonus plan under which Employee may earn an annual incentive bonus.  The terms of the annual incentive bonus plan, including the criteria upon which Employee can earn the maximum bonus, will be determined annually by Employer&#8217;s Board of Directors or its President if so delegated.  For 2020, Employee may earn an annual incentive of up to 30% of Employee&#8217;s then Base Salary, pro-rated based on the portion of the year from the Effective Date to December 31, 2020.  Employee may also participate in other bonus or incentive plans adopted by Employer that are applicable to Employee&#8217;s position, as they may be changed from time to time, but nothing herein shall require the adoption or maintenance of any such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.68pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iii.Incentive Stock Options.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Upon commencement of employment, Employer will grant to Employee an incentive stock option to purchase 70,000 shares of Employer's Common Stock. The Stock Options will be priced at the time of the grant with 50% vesting on the first anniversary of employment, 25% vesting on the second anniversary of employment and the remaining 25% vesting on the third anniversary of employment.  All Stock Option are pursuant and subject to the Stock Plan and Incentive Share Award Plan (&#34;the Plans&#34;) of Oncolytics Biotech Inc. attached together as Exhibit C to this agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Other Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.Certain Benefits.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Employee will be eligible to participate in all employee benefit programs as outlined in Exhibit B.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.Vacations, Holidays and Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the duration of Employee&#8217;s employment hereunder, Employee will be provided such holidays and sick leave as Employer makes available to its management level employees generally.  Employee will be entitled to 20 business days paid vacation per year of service and in addition to traditional U.S. holidays. Employer will reimburse Employee in accordance with company policies and procedures for reasonable expenses necessarily incurred in the performance of duties hereunder against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.68pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iii.Right of Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  By accepting this Agreement, Employee consents to a deduction from any amounts Employer owes Employee from time to time (including amounts owed to Employee as wages or other compensation, a bonus, fringe benefits, or vacation pay, as well as any other amounts owed to Employee by Employer), to the extent of the amounts Employee owes to Employer.  Whether or not Employer elects to make any set-off in whole or in part, if Employer does not recover by means of set-off the full amount Employee owes it, calculated as set forth above, Employee agrees to pay immediately upon Employer&#8217;s demand, the unpaid balance to Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Termination Or Discharge By Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.For Cause.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employer will have the right to immediately terminate Employee&#8217;s services and this Agreement for Cause.  &#8220;Cause&#8221; means the Employer&#8217;s belief that any of the following has occurred&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employee&#8217;s breach of this Agreement by Employee, including, without limitation, breach of Employee&#8217;s covenants in Sections 7, 8, 9 and 10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employee&#8217;s failure to perform Employee&#8217;s duties for the Company in a competent and effective manner as judged in good faith by either the Chief Executive Officer of the Company or the Company&#8217;s Board of Directors in their sole discretion. Employee shall be given written notice of Employee&#8217;s failure to perform Employee&#8217;s duties and 30 days in which to cure such failure. Employee shall be entitled to only one notice and cure opportunity over the course of Employee&#8217;s employment with the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employee&#8217;s material violation of any statutory or common law duty of loyalty to Employer and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employee&#8217;s commission of a felony.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employer&#8217;s reasonable belief that Employee engaged in a violation of any statute, rule or regulation, any of which in the judgment of Employer is harmful to the Business or to Employer&#8217;s reputation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employer&#8217;s reasonable belief that Employee engaged in unethical practices, dishonesty or disloyalty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Employer&#8217;s lack of funding sufficient to support Employee&#8217;s position.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon termination of Employee&#8217;s employment hereunder for Cause or upon the death or disability of Employee, Employee will have no rights to any unvested benefits or any other compensation or payments after the termination date or the last day of the month in which Employee&#8217;s death or disability occurred, respectively.  For purposes of this Agreement, &#8220;disability&#8221; means the incapacity or inability of Employee, whether due to accident, sickness or otherwise, as determined by a medical doctor acceptable to the Board of Directors of Employer and confirmed in writing by such doctor, to perform the essential functions of Employee&#8217;s position under this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue hardship on Employer will be required) for an aggregate of 90 days during any period of 180 consecutive days, or such longer period as may be required under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.Without Cause.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Employer may terminate Employee&#8217;s employment under this Agreement without Cause and without advance notice&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Employer will continue to pay, as severance pay, Employee&#8217;s Base Salary at the rate in effect on the termination date through the date that is&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">if the Employee&#8217;s employment is terminated after the Employee has completed the Probation Period but prior to the first anniversary of the Effective Date, 1 month from the termination date&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">if the Employee&#8217;s employment is terminated after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, 2 months from the termination date&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">if the Employee&#8217;s employment is terminated after the second anniversary of the Effective Date but prior to the fifth anniversary of the Effective Date, 4 months from the termination date&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">if the Employee&#8217;s employment is terminated after the fifth anniversary of the Effective Date, 6 months from the termination date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Employer will be entitled to offset any severance pay otherwise payable to Employee by the amount of any compensation or consulting fees being paid to Employee by another party while severance pay would otherwise be payable.  Employee shall only be entitled to such severance pay if Employee signs (and then Employee does not rescind, as may be permitted by law) a general release of claims in favor of Employer in a form acceptable to Employer, provided, however, that such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">release of claims shall only require Employee to release Employer from claims relating directly to Employee&#8217;s employment and the termination thereof, and shall not require Employee to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company.  Such payments will be at usual and customary pay intervals of Employer and will be subject to all appropriate deductions and withholdings.  Upon termination, Employee will have no rights to any unvested benefits or any other compensation or payments except as stated in this paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.68pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding Section 5.2, if there is a change of control of Oncolytics Biotech Inc., as defined herein, and if this Agreement is terminated by Employer at any time within one (1) year following the change of control other than pursuant to Section 5.1, Employee shall be entitled to severance payment equal to the Employee&#8217;s Base Salary for 12 months.  For the purposes of this Section 5.3, &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics Biotech Inc., or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc., or will result in a person acquiring sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.68pt">Termination By Employee.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee may terminate Employee&#8217;s employment under this Agreement for any reason provided that Employee gives Employer at least 30 days&#8217; notice in writing.  Employer may, at its option, accelerate such termination date to any date at least two weeks after Employee&#8217;s notice of termination.  Employer may also, at its option, relieve Employee of all duties and authority after notice of termination has been provided.  All compensation, payments and unvested benefits will cease on the termination date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Delivery of Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Upon termination of this Agreement or upon request of the Company, Employee shall deliver to the Company all property, documents and materials pertaining to the Company&#8217;s Business including, but not limited to, memoranda, notes, records, drawings, manuals, disks, copies, representations, extracts, summaries and analyses, all inventory, demonstration units, and any other property, documents or media of the Company, and all equipment belonging to the Company, including but not limited to corporate cards, access cards, office keys, office equipment, laptop and desktop computers, cell phones and other wireless devices, thumb drives, zip drives and all other media storage devices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Employee recognizes that Employer&#8217;s Business and continued success depend upon the use and protection of confidential and proprietary business information, including, without limitation, the information and technology developed by or available through licenses to Employer, to which Employee has access (all such information being &#8220;Confidential Information&#8221;).  For purposes of this Agreement, the phrase &#8220;Confidential Information&#8221; includes, for Employer and its current </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or future subsidiaries and affiliates, without limitation, and whether or not specifically designated as confidential or proprietary&#58; all business plans and marketing strategies&#59; information concerning existing and prospective markets and customers&#59; financial information&#59; information concerning the development of new products and services&#59; information concerning any personnel of Employer (including, without limitation, skills and compensation information)&#59; and technical and non-technical data related to software programs, designs, specifications, compilations, inventions, improvements, methods, processes, procedures and techniques&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the phrase does not include information that (a)&#160;was lawfully in Employee&#8217;s possession prior to disclosure of such information by Employer&#59; (b)&#160;was, or at any time becomes, available in the public domain other than through a violation of this Agreement&#59; (c)&#160;is documented by Employee as having been developed by Employee outside the scope of Employee&#8217;s employment and independently&#59; or (d)&#160;is furnished to Employee by a third party not under an obligation of confidentiality to Employer.  Employee agrees that during Employee&#8217;s employment and after termination of employment irrespective of cause, Employee will use Confidential Information only for the benefit of Employer and will not directly or indirectly use or divulge, or permit others to use or divulge, any Confidential Information for any reason, except as authorized by Employer.  Employee&#8217;s obligation under this Agreement is in addition to any obligations Employee has under state or federal law.  Employee agrees to deliver to Employer immediately upon termination of Employee&#8217;s employment, or at any time Employer so requests, all tangible items containing any Confidential Information (including, without limitation, all memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes taken by or provided to Employee, and any other documents or items of a confidential nature belonging to Employer) whether in hard copy, electronic, or other format, together with all copies of such material in Employee&#8217;s possession or control.  Employee agrees that in the course of Employee&#8217;s employment with Employer, Employee will not violate in any way the rights that any entity has with regard to trade secrets or proprietary or confidential information.  Employee&#8217;s obligations under this Section&#160;8 are indefinite in term and shall survive the termination of this Agreement.  However, Employee further understands that nothing in this Agreement prohibits Employee from reporting to any governmental authority information concerning possible violations of law or regulation and that Employee may disclose Confidential Information to a government official or to an attorney and use it in certain court proceedings without fear of prosecution or liability, provided Employee files any document containing Confidential Information under seal and does not disclose the Confidential Information, except pursuant to court order.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.34pt">Work Product and Copyrights.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee agrees that all right, title and interest in and to the materials resulting from the performance of Employee&#8217;s duties at Employer and all copies thereof, including works in progress, in whatever media, (the &#8220;Work&#8221;), will be and remain in Employer upon their creation.  Employee will mark all Work with Employer&#8217;s copyright or other proprietary notice as directed by Employer.  Employee further agrees&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent that any portion of the Work constitutes a work protectable under the copyright laws of the United States (the &#8220;Copyright Law&#8221;), that all such Work will be considered a &#8220;work made for hire&#8221; as such term is used and defined in the Copyright Law, and that Employer will be considered the &#8220;author&#8221; of such portion of the Work and the sole and exclusive owner throughout the world of such copyright&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any portion of the Work does not qualify as a &#8220;work made for hire&#8221; as such term is used and defined in the Copyright Law, that Employee hereby assigns and agrees to assign to Employer, without further consideration, all right, title and interest in and to such Work or in any such portion of such Work and any copyright in such Work and further agrees to execute and deliver to Employer, upon request, appropriate assignments of such Work and copyright in such Work and such other documents and instruments as Employer may request to fully and completely assign such Work and copyright in such Work to Employer, its successors or nominees, and that Employee appoints Employer as attorney-in-fact to execute and deliver any such documents on Employee&#8217;s behalf in the event Employee should fail or refuse to do so within a reasonable period following Employer&#8217;s request&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.68pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To waive and agree not to assert any moral rights Employee may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.67pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining copyright registrations with respect to such Works.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.34pt">Inventions and Patents.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement, &#8220;Inventions&#8221; includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours.  Employee agrees that all Inventions conceived or made by Employee during the period of employment with Employer belong to Employer, provided they grow out of Employee&#8217;s work with Employer or are related in some manner to the Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies.  Accordingly, Employee will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Make adequate written records of such Inventions, which records will be Employer&#8217;s property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assign to Employer, at its request, and does hereby assign to Employer, any rights Employee may have to such Inventions for the U.S. and all foreign countries&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:46.68pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining patents registrations with respect to such Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee further agrees that Employee will promptly disclose in writing to Employer during the term of Employee&#8217;s employment and for 1 year thereafter, all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inventions whether developed during the time of such employment or thereafter (whether or not Employer has rights in such Inventions) so that Employee&#8217;s rights and Employer&#8217;s rights in such Inventions can be determined.  Except as set forth on the initialed Exhibit D (List of Inventions) to this Agreement, if any, Employee represents and warrants that Employee has no Inventions, software, writings or other works of authorship useful to Employer in the normal course of the Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NOTICE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;  This Section&#160;10 does not apply to Inventions for which no equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on Employee&#8217;s own time, unless&#58;  (a) the Invention relates (i) directly to the business of Employer or (ii) to Employer&#8217;s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Employee for Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accordance with California Labor Code Section 2870, Employee is notified that&#58;</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-27.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Relate at the time of conception or reduction to practice of the invention to the Employer&#8217;s Business, or actual or demonstrably anticipated research or development of the employer&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">k.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding other provisions of this Agreement regarding dispute resolution, Employee agrees that Employee&#8217;s violation of any of Sections 7, 8, 9 or 10 of this Agreement would cause Employer irreparable harm which would not be adequately compensated by monetary damages and that an injunction may be granted by any court or courts having jurisdiction, restraining Employee from violation of the terms of this Agreement, upon any breach or threatened breach of Employee of the obligations set forth in any of Sections 7, 8, 9 or 10.  The preceding sentence shall not be construed to limit Employer from any other relief or damages to which it may be entitled as a result of Employee&#8217;s breach of any provision of this Agreement, including Sections 7, 8, 9 or 10.  Employee also agrees that a violation of any of Sections 7, 8, 9 or 10 would entitle Employer, in addition to all other remedies available at law or equity, to recover from Employee any and all funds, including, without limitation, wages, salary and profits, which will be held by Employee in constructive trust for Employer, received by Employee in connection with such violation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">l.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.34pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Except for the right of Employer and Employee to seek injunctive relief in court, any controversy, claim or dispute of any type arising out of or relating to Employee&#8217;s employment or the provisions of this Agreement shall be resolved in accordance with this Section&#160;12 regarding resolution of disputes, which will be the sole and exclusive procedure for the resolution of any disputes.  This Agreement shall be enforced in accordance with the Federal Arbitration Act, the enforcement provisions of which are incorporated by this reference.  Matters subject to these provisions include, without limitation, claims or disputes based on statute, contract, common law and tort and will include, for example, matters pertaining to termination, discrimination, harassment, compensation and benefits.  Matters to be resolved under these procedures also include claims and disputes arising out of statutes such as the Fair Labor Standards Act, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, and any state laws related to employment.  Nothing in this provision is intended to restrict Employee from submitting any matter to an administrative agency with jurisdiction over such matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">i.Mediation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Employer and Employee will make a good faith attempt to resolve any and all claims and disputes by submitting them to mediation in San Diego, California before resorting to arbitration or any other dispute resolution procedure.  The mediation of any claim or dispute must be conducted in accordance with the then-current JAMS procedures for the resolution of employment disputes by mediation, by a mediator who has had both training and experience as a mediator of general employment and commercial matters.  If the parties to this Agreement cannot agree on a mediator, then the mediator will be selected by JAMS in accordance with JAMS&#8217; strike list method.  Within thirty (30) days after the selection of the mediator, Employer and Employee and their respective attorneys will meet with the mediator for one mediation session of at least four hours.  If the claim or dispute cannot be settled during such mediation session or mutually agreed continuation of the session, either Employer or Employee may give the mediator and the other party to the claim or dispute written notice declaring the end of the mediation process.  All discussions connected with this mediation provision will be confidential and treated as compromise and settlement discussions.  Nothing disclosed in such discussions, which is not independently discoverable, may be used for any purpose in any later proceeding.  The mediator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:50.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ii.Arbitration.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any claim or dispute has not been resolved in accordance with Section&#160;12.1, then the claim or dispute will be determined by arbitration in accordance with the then-current JAMS employment arbitration rules and procedures, except as modified herein.  The arbitration will be conducted by a sole neutral arbitrator who has had both training and experience as an arbitrator of general employment and commercial matters and who is and for at least ten (10) years has been, a partner, a shareholder, or a member in a law firm.  If Employer and Employee cannot agree on an arbitrator, then the arbitrator will be selected by JAMS in accordance with Rule 15 of the JAMS employment arbitration rules and procedures.  No person who has served as a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mediator under the mediation provision, however, may be selected as the arbitrator for the same claim or dispute.  Reasonable discovery will be permitted and the arbitrator may decide any issue as to discovery.  The arbitrator may decide any issue as to whether or as to the extent to which any dispute is subject to the dispute resolution provisions in Section&#160;12 and the arbitrator may award any relief permitted by law.  The arbitrator must base the arbitration award on the provisions of Section&#160;12 and applicable law and must render the award in writing, including an explanation of the reasons for the award.  Judgment upon the award may be entered by any court having jurisdiction of the matter, and the decision of the arbitrator will be final and binding.  The statute of limitations applicable to the commencement of a lawsuit will apply to the commencement of an arbitration under Section&#160;12.2.  The arbitrator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">m.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.01pt">Fees Related to Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise agreed, the prevailing party will be entitled to its costs and attorneys&#8217; fees incurred in any litigation or dispute relating to the interpretation or enforcement of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">n.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Disclosure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Employee agrees fully and completely to reveal the terms of this Agreement to any future employer or potential employer of Employee and authorizes Employer, at its election, to make such disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">o.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Representation of Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Employee represents and warrants to Employer that Employee is free to enter into this Agreement and has no contract, commitment, arrangement or understanding to or with any party that restrains or is in conflict with Employee&#8217;s performance of the covenants, services and duties provided for in this Agreement.  Employee agrees to indemnify Employer and to hold it harmless against any and all liabilities or claims arising out of any unauthorized act or acts by Employee that, the foregoing representation and warranty to the contrary notwithstanding, are in violation, or constitute a breach, of any such contract, commitment, arrangement or understanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">p.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Conditions of Employment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Employer&#8217;s obligations to Employee under this Agreement are conditioned upon Employee&#8217;s timely compliance with requirements of the United States immigration laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">q.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Assignability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During Employee&#8217;s employment, this Agreement may not be assigned by either party without the written consent of the other&#59; provided, however, that Employer may assign its rights and obligations under this Agreement without Employee&#8217;s consent to a successor by sale, merger or liquidation, if such successor carries on the Business substantially in the form in which it is being conducted at the time of the sale, merger or liquidation.  This Agreement is binding upon Employee, Employee&#8217;s heirs, personal representatives and permitted assigns and on Employer, its successors and assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">r.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.01pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Any notices required or permitted to be given hereunder are sufficient if in writing and delivered by hand, by facsimile, by registered or certified mail, or by overnight courier, to Employee at 1011 Scarlett Way, Encinitas, California, 92024 or to the President of Employer at 4660 La Jolla Village Drive, Suite 850, San Diego, California, 92122 with a copy sent to Oncolytics Biotech Inc., 210, 1167 Kensington Crescent N.W, Calgary, Alberta, Canada T2N 1X7.  Notices shall be deemed to have been given (i) upon delivery, if delivered by hand, (ii) seven days after mailing, if mailed, (iii) one business day after delivery, if delivered by courier, and (iv) one business day following receipt of an appropriate electronic confirmation, if by facsimile.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">s.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any provision of this Agreement or compliance by any of the parties with any provision of this Agreement constitutes a violation of any law, or is or becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable or void, shall be deemed modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision will be enforced to the fullest extent permitted by law.  The Parties shall engage in good faith negotiations to modify and replace any provision which is declared invalid or unenforceable with a valid and enforceable provision, the economic effect of which comes as close as possible to that of the invalid or unenforceable provision which it replaces.  If such modification is not possible, said provision, to the extent that it is in violation of law, unenforceable or void, shall be deemed severable from the remaining provisions of this Agreement, which provisions will remain binding on the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">t.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.68pt">Waivers.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder will operate as a waiver thereof&#59; nor will any single or partial waiver of a breach of any provision of this Agreement operate or be construed as a waiver of any subsequent breach&#59; nor will any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">u.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25.34pt">Governing Law.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided in Section&#160;12 above, the validity, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the conflicts of law provisions of such laws.  The courts of the state of California shall have exclusive jurisdiction of any lawsuit arising from or relating to Employee&#8217;s employment with, or termination from, Employer, or arising from or relating to this Agreement.  Employee consents to such venue and personal jurisdiction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">v.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">409A Savings Clause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties intend that payments or benefits payable under this Agreement not be subject to the additional tax imposed pursuant to Section 409A of the Code (&#8220;Section 409A&#8221;), and the provisions of this Agreement shall be construed and administered in accordance with such intent. To the extent such potential payments or benefits could become subject to Section 409A, the parties shall cooperate to amend this Agreement with the goal of giving Executive the economic benefits described herein in a manner that does not result in such tax being imposed. If </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the parties are unable to agree on a mutually acceptable amendment, the Company may, without Executive&#8217;s consent and in such manner as it deems appropriate or desirable, amend or modify this Agreement or delay the payment of any amounts hereunder to the minimum extent necessary to meet the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">w.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:23.34pt">Counterparts.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This agreement may be executed in counterpart in different places, at different times and on different dates, and in that case all executed counterparts taken together collectively constitute a single binding agreement. Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">x.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Costs and Fees Related to Negotiation and Execution of Agreement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each Party Shall be responsible for the payment of its own costs and expenses, including legal fees and expenses, in connection with the negotiation and execution of this Agreement.  Neither Party will be liable for the payment of any commissions or compensation in the nature of finders' fees or brokers' fees, gratuity or other similar thing or amount in consideration of the other Party entering into this Agreement to any broker, agent or third party acting on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">y.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This instrument contains the entire agreement of the parties with respect to the relationship between Employee and Employer and supersedes all prior agreements and understandings, and there are no other representations or agreements other than as stated in this Agreement related to the terms and conditions of Employee&#8217;s employment.  This Agreement may be changed only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought, and any such modification will be signed by the President of Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the parties have duly signed and delivered this Agreement as of the day and year first above written.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Oncolytics Biotech (U.S.), Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Andrew de Guttadauro</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Gilles L. Gosselin</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Director </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EMPLOYEE</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Thomas C. Heineman</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Print Name&#58;  Thomas C. Heineman, M.D., Ph.D.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INITIAL DUTIES AND RESPONSIBILITIES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee shall have primary responsibility for the execution of the existing clinical trial strategy, contribute to the Company&#8217;s future clinical development strategy, and manage the clinical studies being conducted by or supported by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Employee will manage operational and logistical tasks of clinical development to ensure efficient execution of trials, ensuring all activities occur in compliance with the appropriate regulations in the relevant jurisdictions. The Employee shall co-ordinate the efforts of internal and external resources to ensure quality and efficiency in patient recruitment, trial site selection and performance, for optimal execution of the clinical trial program.  The Employee will also be expected to provide strategic opinions on the overall clinical development strategy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Membership to the global team, contributing to the development of the clinical programs and decision making in relation to the clinical development strategy. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Applying a sound understanding of disease targets, market needs and regulatory issues in advising the clinical development pathways. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Assisting in defining the Company&#8217;s clinical development strategy and providing expert medical expertise and direction in its implementation, including acting as a medical monitor, thus ensuring the successful progression of the company&#8217;s products through clinical development. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Overseeing the planning, design, organization and conduct of clinical trials and ensuring the delivery of clinical development activities on time and on budget. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ensuring that the company is accessing valuable expertise through external networks where appropriate, managing trials with appropriate use of CROs and building effective, long term relationships with appropriate KOLs. </font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Playing an appropriate part in business and corporate development, bringing drug development expertise to decision making and providing expert input to the strategic management of the company&#8217;s portfolio.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Maintaining current awareness of developments and competitor activity in the medical fields relevant to the company.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Provide day to day leadership and guidance to the clinical group on all operational issues and have managerial responsibility for their effectiveness.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Prepares manuscripts, posters, and other scientific communications and makes presentations at scientific meetings.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Coach, mentor, and develop the team to maximize resources. </font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Recommend training programs as appropriate and required.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Ensure clinical study reports, annual reports, investigator brochures, and other required reports are prepared in an accurate and timely manner.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Participate in the assessment and cost-effective management of external vendors, including CROs and CRAs</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Develop, as required, and ensure compliance with all SOPs and applicable regulatory standards</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Enhance the overall effectiveness of the clinical operations team</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Participate in marketing application planning and execution </font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Perform other duties as assigned from time to time.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BENEFITS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Physical Fitness Benefit&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employee is entitled to the Physical Fitness Benefit in the amount of Seven Hundred and Fifty ($750.00) United States Dollars per annum to use towards an item or service that promotes physical activity&#59; the details of which are outlined in the Company Policy Manual.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deferred Compensation&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The employer will match the employee contribution up to 4% of the employee&#8217;s base salary or the annual compensation limit set by the IRS, whichever is lower. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Health Care Benefit&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee shall, if qualified to do so, be entitled to access the health care menu sponsored by the employer. The menu includes&#58;</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.89pt">Plans for which the employer will contribute towards the premium at 100% for the employee and at 75% for the dependents&#58;</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Medical HMO for California based employees</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Medical PPO</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Medical HSA</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Dental PPO</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Vision PPO</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.89pt">Insurance contributed at 100% of the premium for&#58;</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Life Insurance and AD&#38;D</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Short Term Disability</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Long Term Disability</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.89pt">Voluntary life insurance may be added for the employer and&#47;or the dependents at the employee&#8217;s expense</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further details are outlined in the Enrollment Guide.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STOCK OPTION PLAN AND INCENTIVE SHARE AWARD PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED STOCK OPTION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. The Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has adopted this Stock Option Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) governing the issuance of Options (as defined herein) of the Corporation to Eligible Persons (as defined herein).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. Purpose</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of this Plan is to advance the interests of the Corporation by encouraging the Directors, Officers, Employees and Consultants to acquire Shares, thereby (i) increasing the proprietary interests of such persons in the Corporation&#59; (ii) aligning the interests of such persons with the interests of the Corporation&#8217;s shareholders generally&#59; (iii) encouraging such persons to remain associated with the Corporation&#59; and (iv) furnishing such persons with an additional incentive in their efforts on behalf of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">associate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 4 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which together with such person&#8217;s then owned Shares, if any, represent more than 50 percent (50%) of the Corporation&#8217;s then outstanding Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) the sale, lease or other disposition of all or substantially all of the assets of the Corporation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii) a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation&#8217;s assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an individual or Consultant Corporation, other than a Director, Officer or Employee, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) is engaged to provide on an ongoing </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) provides the services under a written contract for an initial, renewable or extended period of twelve months or more&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consultant Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means for an individual consultant, a company or partnership of which the individual is an employee, shareholder or partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a director of the Corporation or any subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eligible Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Director, Officer, Employee or Consultant of the Corporation or its subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a person who would be considered an &#8216;employee&#8217; under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Toronto Stock Exchange and such other stock exchange(s) on which the Shares are then listed and posted for trading from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">insider participation limit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Market Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the closing price of the Shares on the TSX (or, if the Shares are not then listed and posted for trading on the TSX or are then listed and posted for trading on more than one Exchange, on such Exchange on which the Shares are then listed and posted for trading as may be selected for such purpose by the Board acting reasonably and in good faith) on the last trading date prior to the date of grant of an Option hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n) &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; means any Director who is not also an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an option to purchase Shares granted pursuant to this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each of the Eligible Persons granted an Option pursuant to this Plan and their heirs, executors and administrators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means this Stock Option Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Security Based Compensation Arrangement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means common shares in the capital of the Corporation and shall be deemed to include any other listed securities that may be acquired by a Participant upon the exercise of an Option the terms of which have been modified in accordance with Section 17.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Canada), as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TSX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Toronto Stock Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TSX Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the policies included in the TSX Company Manual.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Administration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Subject to the terms and conditions set forth herein and the TSX Policies, the Board is authorized to provide for the granting, exercise and method of exercise of Options, all on such terms (which may vary between Options granted from time to time) as it shall determine. In addition, the Board shall have the authority to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) construe and interpret this Plan and all option agreements entered into hereunder,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) prescribe, amend and rescind rules and regulations relating to this Plan&#59; And</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) make all other determinations necessary or advisable for the administration of this Plan. All determinations and interpretations made by the Board shall be binding on all Participants and on their legal, personal representatives and beneficiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) Options shall be evidenced by an agreement, signed on behalf of the Corporation and by the person to whom an Option is granted, which agreement shall be in such form as the Board shall approve or authorize from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. Shares Subject to this Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) Subject to Section 17, the securities that may be acquired by Participants under this Plan shall consist of authorized but unissued Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) The number of Shares reserved for issuance under this Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed ten percent (10%) of the total number of issued and outstanding Shares from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) If any Option granted under this Plan shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Shares to which such Option relates shall be available for the purposes of the granting of Options under this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Maintenance of Sufficient Capital</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Corporation shall at all times during the term of this Plan ensure that the number of Shares it is authorized to issue shall be sufficient to satisfy the requirements of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. Eligibility and Participation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may from time to time, in its discretion, grant an Option to any Eligible Person, upon such terms, conditions and limitations as the Board may determine, including the terms, conditions and limitations set forth herein, provided that Options granted to any Participant shall be approved by the shareholders of the Corporation if the TSX Policies or the requirements of any other Exchange on which the Shares are listed require such approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. Exercise Price</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exercise Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time that the Option is granted. No Option shall be granted with an Exercise Price at a discount to the Market Price.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. Number of Optioned Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a Participant shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one Participant under this Plan or any other Security Based Compensation Arrangement, shall not exceed five percent (5%) of the total number of issued and outstanding Shares (calculated on a non-diluted basis).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. Term</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The period during which an Option may be exercised (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Option Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be determined by the Board at the time the Option is granted, subject to any vesting limitations which may be imposed by the Board in its sole unfettered discretion at the time such Option is granted, provided that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) no Option shall be exercisable for a period exceeding ten (10) years from the date the Option is granted&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) the Option Period shall be automatically reduced in accordance with Sections 12 and 13 upon the occurrence of any of the events referred to therein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) no Option in respect of which shareholder approval is required under the TSX Policies or the requirements of any other Exchange on which the Shares are then listed shall be exercisable until such time as the Option has been approved by the shareholders of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, if the Option Period of an Option expires during a Blackout Period (as defined below) or within five (5) business days after a Blackout Period, such Option Period shall be deemed to be extended to the date which is the tenth (10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) business day after the last day of the applicable Black Out Period. For the purposes of this Plan, Blackout Period means, with respect to an Option, any period </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">during which the holder of such Option is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. Method of Exercise of Option</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) Except as set forth in Sections 12 and 13 or as otherwise determined by the Board, no Option may be exercised unless the holder of such Option is, at the time the Option is exercised, an Eligible Person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Options may be exercised in whole or in part and may be exercised on a cumulative basis where a vesting limitation has been imposed at the time of grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) Any Participant (or his legal, personal representative) wishing to exercise an Option shall deliver to the Corporation, at its principal office in the City of Calgary, Alberta&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) a written notice expressing the intention of such Participant (or his legal, personal representative) to exercise his Option and specifying the number of Shares in respect of which the Option is exercised&#59; and (ii) a cash payment, cheque or bank draft, representing the full purchase price of the Shares in respect of which the Option is exercised. For greater certainty, the Corporation shall not provide financial assistance in regards to the exercise of an Option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) Upon the exercise of an Option as aforesaid, the Corporation shall use its reasonable efforts to forthwith deliver, or cause the registrar and transfer agent of the Shares to deliver, to the relevant Participant (or his legal, personal representative) or to the order thereof, a certificate representing the aggregate number of fully paid and non-assessable Shares as the Participant (or his legal, personal representative) shall have then paid for.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) In order to fulfill the Corporation&#8217;s obligations under the Tax Act in respect of withholding and remittance on account of tax payable by Participants on the exercise of Options under this Section 11, the Corporation shall advise each Participant, on receiving such Participant&#8217;s notice of intention to exercise, of the amount of such remittance (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Remittance Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) required under the Tax Act. Prior to the delivery of the Shares, the Corporation may, in its sole discretion&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) require the Participant to pay to the Corporation, as an additional amount on the exercise of their Options, the Remittance Amount&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) withhold from any remuneration or consideration payable to the Participant an amount equal to the Remittance Amount&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) retain and sell on behalf of the Participant such number of Shares to obtain proceeds from the sale of such shares on the principal stock exchange on which the common shares are traded sufficient to satisfy the Remittance Amount&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) any combination of the above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon receipt or payment of this amount in the manner described above, the Corporation shall in accordance with Section 11(d) issue to the Participant the Shares (or in the case of subsection 11(d)(iii), the remaining Shares) for which the Option was exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) Notwithstanding anything else contained herein, each Participant shall be responsible for the payment of all applicable taxes, including, but not limited to, income taxes payable in connection with the exercise of any Options under this Plan and the Corporation, its Directors, Officers, Employees and agents shall bear no liability in connection with the payment of such taxes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. Ceasing to be an Eligible Person</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a Participant providing otherwise, if any Participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the Participant, such Participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5&#58;00 p.m. (Calgary time) on the earlier of the date of the expiration of the Option Period and the ninetieth (90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day after the date such Participant ceases to be an Eligible Person as to the then vested portion of the Option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Option Agreements under which Options have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither the selection of any person as a Participant nor the granting of an Option to any Participant under this Plan shall (i) confer upon such Participant any right to continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be, or (ii) be construed as a guarantee that the Participant will continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised by a Participant that has ceased to be an Eligible Person, in the case of Options held by non-management Directors, by not more than one (1) year, and in the case of Options held by other persons, by not more than three (3) years, but in no case longer than the original expiry date of the Options established at the time of grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13. Death or Permanent Disability of a Participant</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a Participant providing otherwise, if in the event of the death or permanent disability of a Participant, any Option previously granted to such Participant shall be exercisable until the end of the Option </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Period or until the expiration of 12 months after the date of death or permanent disability of such Participant, whichever is earlier, and then only&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) by the person or persons to whom the Participant&#8217;s rights under the Option shall pass by the Participant&#8217;s will or applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) to the extent that he was entitled to exercise the Option as at the date of the Participant&#8217;s death or permanent disability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14. Change of Control</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision hereof, in the event of a Change of Control, all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or this Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following the Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15. Transferability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All benefits, rights and Options accruing to any Participant in accordance with the terms and conditions of this Plan shall not be transferable or assignable unless specifically provided herein. The Corporation shall not recognize any attempted exercise of any purported assignee of a Participant. During the lifetime of a Participant any Options granted hereunder may only be exercised by the Participant and in the event of the death or permanent disability of a Participant, by the person or persons to whom the Participant&#8217;s rights under the Option pass by the Participant&#8217;s will or applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16. Amendment and Termination of Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) The Board may, at any time, suspend or terminate this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Subject to Section 16(c) and 16(d), the Board may, at any time and from time to time, amend this Plan or any Option, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation (provided that no such amendment may be made that will materially prejudice the rights of any Participant under any Option previously granted to the Participant without consent by such Participant) including without limitation&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) to amend, modify or terminate this Plan with respect to all Shares in respect of Options which have not yet been granted thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) to make any amendment of a &#8220;housekeeping nature&#8221;, including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan or any Option&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) to change the provisions relating to the manner of exercise of Options, including changing or adding any form of financial assistance provided by the Corporation or adding or amending provisions relating to a cashless exercise of Options&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Shares from this Plan reserve&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) to make any addition to, deletion from or alteration of the provisions of this Plan or any Option that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) Notwithstanding Section 16(b), the Board may not, without approval of the holders of a majority of Shares present and voting in person or by proxy at a meeting of holders of Shares, amend this Plan or any Option to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) increase the number of Shares reserved for issuance pursuant to this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) extend eligibility to participate in this Plan to persons other than Eligible Persons&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) permit Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) permit awards other than Options to be made under this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) amend or delete Section 10(a) to extend the term of any Option beyond the Option Period of such Option or allow for such Option to be exercisable for a period exceeding ten (10) years from the date the Option is granted, or extend any Option benefitting an insider other than as otherwise provided for under this Plan&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) reduce the Exercise Price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same option-holder with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a lower Exercise Price will be considered an amendment to reduce the Exercise Price of an Option)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii) change the insider participation limitation under this Plan&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii) amend this Section 16.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) Notwithstanding Section 16(b), no amendment or revision to this Plan or any Option pursuant to Section 16(b) shall in any manner materially adversely affect the rights of any Participant under any Options granted under this Plan prior to such amendment or revision without such Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17. Necessary Approvals</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) The obligation of the Corporation to issue and deliver Shares in accordance with this Plan is subject to applicable securities legislation and to the receipt of any approvals that may be required from any regulatory authority or any Exchange on which the Shares are then listed. If Shares cannot be issued to a Participant upon the exercise of an Option for any reason whatsoever, the obligation of the Corporation to issue such Shares shall terminate and any funds paid to the Corporation in connection with the exercise of such Option will be returned to the relevant Participant as soon as practicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Without obtaining the approval of the shareholders of the Corporation in accordance with the TSX Policies or the requirements of any other Exchange on which the Shares are then listed, no Options shall be granted pursuant to this Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) a number of Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Shares at any time&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the issuance within a one year period to insiders, of a number of Shares exceeding ten percent (10%) of the number of outstanding Shares&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Shares exceeding five percent (5%) of the number of outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) The total annual grant of Options to any one Non-Employee Director cannot exceed a grant value of $150,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18. Stock Exchange Rules</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Plan and any option agreements entered into hereunder shall comply with the TSX Policies and the requirements of any other Exchange on which the Shares are then listed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19. Right to Issue Other Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Corporation shall not by virtue of this Plan be in any way restricted from declaring and paying stock dividends, issuing further Shares, varying or amending its share capital or corporate structure or conducting its business in any way whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20. Notice</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice required to be given by this Plan shall be in writing and shall be given by registered mail, postage prepaid or delivered by courier or by facsimile or email transmission addressed, if to the Corporation, at its principal address in Calgary, Alberta (being currently 210, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7), Attention&#58; Chief Financial Officer&#59; or if to a Participant, to such Participant at his address as it appears on the books of the Corporation or in the event of the address of any such Participant not so appearing then to the last known address of such Participant&#59; or if to any other person, to the last known address of such person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21. Gender</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whenever used herein words importing the masculine gender shall include the feminine and neuter genders and vice versa.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22. Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Plan will be governed by and construed in accordance with the laws of the Province of Alberta.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;DATED&#58; May 4, 2017&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><div id="i6ce2ab7c59124912ac8c57ab6fef5b03_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED INCENTIVE SHARE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has adopted this Incentive Share Award Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) governing the issuance of&#58; (i) Restricted Share Awards to Eligible Persons&#59; and (ii) Performance Share Awards to Employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purposes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The principal purposes of the Plan are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to retain and attract qualified directors, officers, employees and consultants for the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to promote ownership of common shares of the Corporation by such directors, officers, employees and consultants and to encourage such persons to remain in the employ or service of the Corporation and put forth maximum efforts for the success of the affairs of the Corporation&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to focus management of the Corporation on operating and financial performance and total long-term shareholder return.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Where used herein, the following terms shall have the following meanings, respectively&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Black-Out Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any period during which the holder of a Share Award is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 3 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each day other than a Saturday, Sunday, a statutory holiday in Alberta or any day on which the principal chartered banks located in Calgary, Alberta are not open for business during normal business hours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cessation Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, in respect of a Participant, the last day of active employment or service of the Participant with the Corporation, regardless of the reason for the cessation of employment or service and regardless of whether any or any adequate or proper advance notice of termination or resignation is provided in respect of such cessation of employment or service.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which together with such person's then owned Shares, if any, represent more than 50 percent (50%) of the Corporation's then outstanding Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the sale, lease or other disposition of all or substantially all of the assets of the Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a bona fide reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation's assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; means an individual or Consultant Corporation, other than an Employee or a Non- Employee Director, that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is engaged to provide on an ongoing bona fide basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provides the services under a written contract for an initial, renewable or extended period of twelve months or more&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consultant Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; means for an individual consultant, a company or partnership of which the individual is an employee, shareholder or partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Eligible Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an Employee, a Non-Employee Director or a Consultant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; means a persons who would be considered an 'employee' under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the TSX and such other stock exchange(s) on which the Shares are then listed and posted for trading from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the grant date for a Share Award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">insider participation limit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issue Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which Shares are issued to a Participant in respect of a Share Award following completion of the applicable Vesting Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any director of the Corporation (including, for greater certainty, any subsidiary of the Corporation) who is not also an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34; means an officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an Eligible Person to whom a Share Award has been granted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Criteria</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any performance-related measures or criteria as determined by the Board in its sole discretion at Grant Date to be taken into consideration over the Vesting Period of a Performance Share Award for purposes of determining the applicable Vesting Percentage, which measures or criteria may include, the Corporation&#8217; performance compared to identified operational or financial targets, the Corporation&#8217; shareholder return, and any such other performance-related measures or criteria matters as the Board may determine, in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an award to an Employee under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in accordance with Section 5 hereof, based upon achieving the applicable Performance Criteria and subject to adjustment in accordance with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an award to an Eligible Person under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined in accordance with Section 5 hereof, subject to adjustment in accordance with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Security Based Compensation Arrangement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean a common share in the capital of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Performance Share Award or Restricted Share Award, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 5 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shareholder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a holder of Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TSX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Toronto Stock Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TSX Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the policies included in the TSX Company Manual.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(y) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vested</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the applicable Vesting Period having been completed and additionally in the case of Performance Share Awards, the applicable Performance Criteria in relation to a whole or percentage of the number of Shares covered by such Performance Share Award determined by the Board having been met, where &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (or any applicable derivative term) has a comparable meaning.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(z) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting Percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the percentage of outstanding Performance Share Awards that will vest based upon the relative achievement of the Performance Criteria for such award during the Vesting Period, where such percentage will range from 0 percent to 100 percent reflecting the Board&#8217;s determination, in its sole discretion, of the achievement of the Performance Criteria.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aa) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period over which Share Awards granted under the Plan shall vest in accordance with Section 5(b)(i), subject to adjustment or modification pursuant to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Administration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation. The Board shall have the authority in its sole and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">absolute discretion to administer the Plan and to exercise all the powers and authorities either specifically granted to it under the Plan or necessary or advisable in the administration of the Plan including, without limitation, the authority to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">grant Restricted Share Awards to Eligible Persons and Performance Share Awards to Employees&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determine the Grant Date for Share Awards&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determine the Eligible Persons who may participate in this Plan and designate any officer or employee of the Corporation as being an Employee under this Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determine Performance Criteria applicable to any Performance Share Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">approve the form and determine the terms and provisions of Share Award Agreements (which need not be identical) entered into in connection with Share Awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interpret the Plan and the Share Award Agreements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prescribe, amend and rescind rules and regulations relating to the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determine whether and the extent to which adjustments shall be made pursuant to the Plan&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">make all other determinations deemed necessary or advisable for the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For greater certainty and without limiting the discretion conferred on the Board pursuant to this Section 3, the Board&#8217;s decision to approve the grant of a Share Award in any period shall not require the Board to approve the grant of a Share Award to any Participant in any other period&#59; nor shall the Board&#8217;s decision with respect to the amount or terms and conditions of a Share Award in any period require it to approve the grant of a Share Award of the same or similar amount or with the same or similar terms and conditions to any Participant in any other period. The Board shall not be precluded from approving the grant of a Share Award to any Participant solely because such Participant may previously have been granted a Share Award under this Plan or any other Security Based Compensation Arrangement. No Participant has any claim or right to be granted a Share Award. There is no obligation for uniformity of treatment of Non-Employee Directors, Employees or Consultants, or any group of Non-Employee Directors, Employees or Consultants.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any interpretation, rule, regulation, determination or other act of the Board hereunder shall be made in its sole discretion and shall be final and conclusively binding upon the Corporation and all persons affected by the Plan. No member of the Board shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">liable for any action or determination made in good faith pursuant to the Plan or any instrument of grant evidencing any Share Award awarded under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reservation of Shares&#59; Participation Limits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares reserved for issuance under the Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed 10% of the total number of issued and outstanding Shares from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares issuable to Insiders at any time, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares issued to Insiders, within any one-year period, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares reserved for issuance under all Security Based Compensation Arrangements of the Corporation to any one Participant shall not exceed 5% of the total number of issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this Plan, Performance Share Awards may only be granted to Employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Share Awards that are vested and redeemed, or are cancelled, terminated or expire prior to the settlement of all or a portion thereof, shall result in the Shares that were reserved for issuance thereunder being available for a subsequent grant of Share Awards pursuant to this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The maximum number of Shares that may be reserved for issuance to Non-Employee Directors pursuant to Restricted Share Awards under the Plan is 1% of the Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Shares reserved for issuance to such Non-Employee Director under any other Security Based Compensation Arrangement, and the total annual grant of Restricted Share Awards to any one Non-Employee Director cannot exceed a grant value of $150,000 (less the amount awarded to such Non-Employee Director in the year pursuant to any other Security Based Compensation Arrangement).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terms and Conditions of Share Awards</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Share Award granted under the Plan shall be subject to the terms and conditions of the Plan and evidenced by a written agreement between the Corporation and the Participant or an award letter from the Corporation to the Participant (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which agreement shall comply with, and be subject to, the requirements of the Exchange and the following terms and conditions (and with such other terms and conditions as the Board, in its discretion, shall establish)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Number of Share Awards </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- The Board may determine the number of Share Awards to be awarded to a Participant in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vesting of Share Awards </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board, the Vesting Period in respect of Share Awards granted hereunder shall be three (3) years from the Grant Date of such Share Awards. The Board may, in its sole discretion, accelerate the vesting of all or any Share Awards at any time and from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon vesting, each Restricted Share Award and each Performance Share Award (following application of the applicable Vesting Percentage) so vested will entitle the holder to receive one Share (subject to adjustment in accordance with the terms of this Plan) on the applicable Issue Date. For greater certainty, a Participant shall have no right to receive any Shares or other consideration in respect of any Performance Share Awards other than for the Vesting Percentage of such Performance Share Awards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board shall determine the Performance Criteria for each grant of Performance Share Awards at the time of the grant of the award and, the Board shall, as soon as reasonably practicable following the completion of the Vesting Period applicable to a particular grant of Performance Share Awards determine, in its sole discretion, the applicable &#8220;Vesting Percentage&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this Plan, no term or condition of a grant of Share Awards hereunder or any Share Award Agreement may have the effect of causing any Shares to be issued pursuant to any Share Award under the Plan to a Participant in satisfaction of such Participant&#8217;s Performance Share Awards under the Plan (or any portion thereof) to occur after December 31 in the third (3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) calendar year following the calendar year in respect of which such Share Awards were granted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance of Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Shares that are issuable to the Participant on the Issue Date shall be issued from treasury as fully paid and non-assessable Shares. No fractional Shares will be issued and all fractional entitlements shall be rounded down to the nearest whole number.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Delivery of Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- The Issue Date shall occur as soon as practicable and in any event within 31 days following the completion of the Vesting Period applicable to a Share Award. Subject to the remainder of this Section 5(d), on the Issue Date, the Corporation will issue from treasury to the Participant that number of Shares to which the Participant is entitled to receive in respect of such Share Award in accordance with this Section 5, subject to Section 7 hereof, and sent by pre-paid mail or delivered to the Participant. Notwithstanding the foregoing, if on the Issue Date a Black-Out Period has been imposed upon a Participant which is still in effect, then the Issue Date shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">occur until the date which is the tenth (10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) business day after the last day of the applicable Black Out Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Unless otherwise determined by the Board in its sole discretion, upon a Change of Control, all unvested Share Awards shall become automatically vested (in the case of Performance Share Awards, with a deemed Vesting Percentage of 100). Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to Participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board Discretion </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Notwithstanding anything else in this Plan, the Board may, in its sole discretion, but subject to the limits described in Sections 4 and 9 hereof and any other applicable requirements of the Exchange or other regulatory authority&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">make any additional adjustments to the Vesting Percentage (in respect of any Performance Share Awards) or the number of Shares to be issued or delivered to a Participant in connection with any Share Award if, in the sole discretion of the Board, such adjustments are appropriate in the circumstances having regard to the principal purposes of the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">change the Issue Date (including amending the Vesting Period related thereto) for all or any Share Awards at any time and from time to time&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise amend or modify the terms and conditions regarding any grant of Share Awards or payments in respect of any Share Awards hereunder, provided, however, that no such amendment or modification may, without the consent of the affected Participant, impair or adversely affect a Share Award granted to the Participant under the Plan prior to the date of such amendment or modification.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect of Certain Changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- In the event&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of any change in the Shares through subdivision, consolidation, reclassification, recapitalization or similar transaction&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that any rights are granted to Shareholders to purchase Shares at prices substantially below fair market value, and such events do not constitute a Change of Control, then, in any such case, the Board may make such adjustments to the Plan, to any Share Awards and to any Share Award Agreements outstanding under the Plan as the Board may, in its sole discretion, consider appropriate in the circumstances to prevent dilution or enlargement of the rights granted to Participants hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ceasing to be an Eligible Person </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award Agreement pertaining to a particular Share Award or any written employment or other agreement governing a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant&#8217;s role as an Eligible Person, the following provisions shall apply in the event that a Participant ceases to be an Eligible Person&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Termination for Cause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211; If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Share Awards Agreements under which Share Awards have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Voluntary Resignation </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- If a Participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the Participant as set forth in Section 7(h)(iii), effective as of the date notice is given by the Participant of such resignation, unless otherwise determined by the Board, all outstanding Share Award Agreements under which Share Awards have been made to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by the Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Termination Upon Death or Permanent Disability or Retirement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211; Upon the death, permanent disability or retirement of a Participant (other than the early retirement of an Eligible Employee), all outstanding Share Award Agreements under which Share Awards have been made to such Participant prior to the Cessation Date shall immediately vest as of the Cessation Date, and the Issue Date in respect of all Share Awards held by such Participant shall be the earlier of&#58; (A) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day following the Cessation Date&#59; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Termination not for Cause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- If a Participant ceases to be an Eligible Person other than as set forth in Sections 7(h)(i), (ii) or (iii), effective as of the Cessation Date all Share Awards awarded to such Participant under any outstanding Share Award Agreements shall fully vest effective as of the Cessation Date, unless otherwise determined by the Board. On the applicable Issue Date in respect of such Share Awards, the Participant shall be entitled to receive the number of Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the Grant Date in respect of the applicable Share Award to the Cessation Date&#59; and (B) the denominator of which is the total number of days comprising the Vesting Period in respect of such Share Award. In such circumstances, the Vesting Percentage in respect of Performance Share Awards shall be determined as of the Cessation Date. The Issue Date in respect of any such Awards shall be the earlier of&#58; (A) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day following the Cessation Date&#59; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rights as a Shareholder </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Until the Shares underlying any Share Award have been issued in accordance with the terms of the Plan, the Participant to whom such Share Award has been made shall not possess any incidents of ownership of such Shares including, for greater certainty and without limitation, the right to exercise voting rights in respect of such Shares. Such Participant shall only be considered a Shareholder in respect of such Shares when such issuance has been entered upon the records of the duly authorized transfer agent of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ratification and Approval by Shareholders</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this Plan&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">no Shares may be issued pursuant to any Share Award until the Plan has been approved by the Shareholders at a duly called meeting of the Shareholders&#59; and </font><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any grants of Share Awards by the Board prior to the Plan being approved by the Shareholders must be ratified by the Shareholders at the meeting of the Shareholders at which the Shareholders approve the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Withholding Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When a Participant or other person becomes entitled to receive Shares under any Share Award, the Corporation shall have the right to require the Participant or such other person to remit to the Corporation an amount sufficient to satisfy any withholding tax requirements relating thereto. Unless otherwise prohibited by the Board or by applicable law, satisfaction of the withholding tax obligation may be accomplished by any of the following methods or by a combination of such methods&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the tendering by the Participant of cash payment to the Corporation in an amount equal to the total withholding tax obligation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the withholding or sale by the Corporation from the Shares otherwise due to the Participant, of such number of Shares having a value determined by the Corporation in its sole discretion, acting reasonably, equal to the amount of the total withholding tax obligation (and in the case of a treasury issuance of Shares to settle Share Awards hereunder, such sale of Shares shall be automatically made on or as soon as practicable after the applicable Issue Date for the purposes of satisfying withholding tax obligations, unless otherwise agreed to by the Corporation and the Participant)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the withholding by the Corporation from any cash payment otherwise due to the Participant of such amount of cash as is equal to the amount of the total withholding tax obligation&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any other method determined by the Corporation in its sole discretion, acting reasonably, provided, however, that the sum of any cash so paid or withheld and the value of any Shares so withheld or sold is, sufficient, in the reasonable estimation of the Corporation, to satisfy the total withholding tax obligation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Transferability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The right to receive Shares pursuant to a Share Award granted to a Participant may only be settled by such Participant personally or through the Participant&#8217;s personal representative or estate and no assignment, sale, transfer, pledge or charge of a Share Award, whether voluntary, involuntary, by operation of law or otherwise (except by will or the laws of descent and distribution), vests any interest or right in such Share Award whatsoever in any assignee or transferee and, immediately upon any assignment, sale, transfer, pledge or charge or attempt to assign, sell, transfer, pledge or charge, such Share Award shall terminate and be of no further force or effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment and Termination of Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may, at any time, suspend or terminate this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Section 9(c), the Board may, at any time and from time to time, amend this Plan or any Share Award, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation, including without limitation&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to amend, modify or terminate this Plan with respect to all Shares in respect of Share Awards which have not yet been granted thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to make any amendment of a &#34;housekeeping nature&#34;, including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan or any Share Award&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to make any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding Section 9(b), the Plan or any Share Award may not be amended without Shareholder approval to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">increase the number of Shares issuable pursuant to outstanding Share Awards at any time pursuant to Section 4 hereof&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">change the insider participation limitation under this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">expand the categories of individuals contained in the definition of &#34;Employee&#34; who are eligible to participate in the Plan&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amend this Section 9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, no amendment to the Plan or Share Awards granted pursuant to the Plan may be made without the consent of the Participant, if such amendment adversely alters or impairs the rights of any Participant in respect of any Share Award previously granted to such Participant under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect of Headings </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- The Section headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Legal Requirements </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- The Corporation shall not be obliged to issue any Shares if such issuance would violate any law or regulation or any rule of any government authority or Exchange. The Corporation, in its sole discretion, may postpone the issuance or delivery of Shares under any Share Award as the Board may consider appropriate, and may require any Participant to make such representations and furnish such information as it may consider appropriate in connection with the issuance or delivery of Shares in compliance with applicable laws, rules and regulations. The Corporation shall not be required to qualify for resale pursuant to a prospectus or similar document any Shares awarded under the Plan, provided that, if required, the Corporation shall notify the Exchange and any other appropriate regulatory bodies in Canada of the existence of the Plan and the granting of Share Awards hereunder in accordance with any such requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Right to Continued Employment </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Nothing in the Plan or in any Share Award Agreement entered into pursuant hereto shall confer upon any Participant the right to continue in the employ or service of the Corporation, to be entitled to any remuneration or benefits not set forth in the Plan or a Share Award Agreement or to interfere with or limit in any way the right of the Corporation to terminate Participant&#8217;s employment or service arrangement with the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- All expenses in connection with the Plan shall be borne by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governing Language </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-This Plan is drawn up in the English language and each notice, instrument, certificate or other communication to be given under or in connection with this Plan shall be in the English language. If this Plan or any notice, instrument, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">certificate or other communication is translated into any other language, the English language text shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Market Fluctuations </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- No amount will be paid to, or in respect of, a Participant under the Plan to compensate for a downward fluctuation in the price of Shares which impacts the Share Award, nor will any other form of benefit be conferred upon, or in respect of, a Participant for such purpose. The Corporation makes no representations or warranties to a Participant with respect to the Plan or the Share Awards whatsoever. In seeking the benefits of participation in the Plan, a Participant agrees to exclusively accept all risks associated with a decline in the market price of Shares and all other risks associated with the holding of Share Awards.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Any payments and benefits under the Plan to be paid in cash shall be determined in the lawful currency of Canada and paid in the local currency of the Participant&#8217;s country of residence using the currency exchange rate available to the Corporation at the time of payment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Participation is Voluntary&#59; No Additional Rights </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- Participation in the Plan shall be entirely voluntary and any decision by a Participant not to participate shall not affect any Participant&#8217;s employment or service with the Corporation. In such instance where a Participant provides notice in writing to the Corporation of his or her intent to not participate in a Share Award, such award shall be immediately terminated and the Participant shall not be eligible to receive any form of in lieu compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan shall be governed by, interpreted and construed in accordance with the laws in force in the Province of Alberta.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Plan shall take effect on May </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;4&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, 2017. The issuance of Shares under the Plan is subject to the acceptance of the Plan by the Exchange and any other relevant regulatory authorities and approval of the Shareholders.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF INVENTIONS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Halozyme&#58; PCT&#47;US19&#47;32537 </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble PH20 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Genocea&#58; PCT&#47;US 62&#47;855,309&#59; PCT&#47;US 62&#47;848,527 </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Methods of identifying and&#47;or selecting antigens that improve, increase and&#47;or stimulate immune control of a tumor or cancer and methods of administering the same </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">GSK&#58; EP 2 281 831 A3&#59; US20180008700A1 </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#323232;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compositions for use in and methods for protecting against Herpes Zoster (HZ)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4825-1831-5011&#92;3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>4
<FILENAME>ex413mattcoffeyamendment-e.htm
<DESCRIPTION>EX-4.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1b292274b2e2474b81c2af6c55fca3a4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.13</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDING AGREEMENT #2</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDING AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> day of January, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Matt Coffey</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019, amended by Amending Agreement #1 dated January 1, 2020 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)     Commencing January 1, 2021, Oncolytics shall pay to the Employee a salary of SIX HUNDRED THIRTY-SEVEN THOUSAND TWO HUNDRED ($637,200.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-SIX THOUSAND FIVE HUNDRED FIFTY DOLLARS ($26,550.00) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Brown</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair, Compensation Committee, Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">___&#47;s&#47; Matt Coffey____________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MATT COFFEY</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>5
<FILENAME>ex414kirklookamendment-emp.htm
<DESCRIPTION>EX-4.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7e32ec0489f34554bbb1cdf1c1881f5f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.14</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDING AGREEMENT #2</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDING AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> day of January, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kirk Look</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 amended by Amending Agreement #1 dated January 1, 2020 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)   Commencing January 1, 2021, Oncolytics shall pay to the Employee a salary of FOUR HUNDRED SEVENTY-THREE THOUSAND EIGHT HUNDRED ($473,800.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of NINETEEN THOUSAND SEVEN HUNDRED FORTY-ONE DOLLARS and SIXTY-SEVEN CENTS ($19,741.67) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">s&#47; Wayne Pisano</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">s&#47; Deborah Brown</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair, Compensation Committee, Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Kirk Look________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KIRK LOOK</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>6
<FILENAME>ex415allisonhagermanamendm.htm
<DESCRIPTION>EX-4.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia0ac9fe9ffae425785d17f0f530db2e2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.15</font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDING AGREEMENT                                             </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDING AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> day of January, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Allison Hagerman,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS Oncolytics and the Employee entered into an Employment Agreement dated August 1, 2013, which has been amended by amending agreements including that dated January 1, 2020 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS Oncolytics and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)     Commencing January 1, 2021, Oncolytics shall pay to the Employee a salary of THREE HUNDRED EIGHTY THOUSAND FIVE HUNDRED ($380,500.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of FIFTEEN THOUSAND EIGHT HUNDRED FIFTY-FOUR DOLLARS and SEVENTEEN CENTS ($15,854.17) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:0.12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair, Compensation Committee,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Director</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Allison Hagerman</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALLISON HAGERMAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>7
<FILENAME>ex416andrewdeguttadauroame.htm
<DESCRIPTION>EX-4.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i47fb681f610845bfbcf3679f64cc656f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.16</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDING AGREEMENT #4</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDING AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">day of January, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, as amended by Amending Agreement #1, Amending Agreement #2 and Amending Agreement #3 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS OBUS and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Amendment to the Employment Agreement</font></div><div style="padding-left:54pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2021, OBUS shall pay to the Employee a salary of THREE HUNDRED TWENTY-TWO THOUSAND NINE HUNDRED ($322,900.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of THIRTEEN THOUSAND FOUR HUNDRED FIFTY-FOUR UNITED STATES DOLLARS and SEVENTEEN CENTS ($13,454.17) on the 15th and last day of each month.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; Matt Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">__&#47;s&#47; Andrew de Guttadauro</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>8
<FILENAME>ex417thomasheinemanamendme.htm
<DESCRIPTION>EX-4.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4987d98e0514471d91e20e33c5540067_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 4.17</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDING AGREEMENT #1</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS AMENDING AGREEMENT </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">day of January, 2021</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective August 3, 2020, (the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Amendment to the Employment Agreement</font></div><div style="padding-left:54pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Employment Agreement Section 3.1 &#8211; Base Salary is amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commencing January 1, 2021, OBUS shall pay to the Employee a Base Salary at an annual rate of FOUR HUNDRED AND TEN THOUSAND ($410,000.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SEVENTEEN THOUSAND AND EIGHTY-THREE UNITED STATES DOLLARS and THIRTY-THREE CENTS ($17,083.33) on the 15th and last day of each month.</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:26.84pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:0.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">s&#47; Matt Coffey</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47; Thomas Heineman</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>9
<FILENAME>ex80subsidiaries2020.htm
<DESCRIPTION>EX-8.0
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6feedbaab3b440febebf0433cbc83993_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 8.0</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2020</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (Barbados) Inc.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (US) Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:8pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>10
<FILENAME>ex121ceocertification2020.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib05cb65eb11f4170b85f330532ab94f0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Matthew Coffey, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Matthew Coffey</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA<br>Chief Executive Officer<br>Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>11
<FILENAME>ex122cfocertification2020.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6ef66d45fcca4a1e88ccb08068338c8f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Kirk Look, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA<br>Chief Financial Officer<br>Principal Accounting and Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>12
<FILENAME>ex131ceocertification2020.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i47790d08e7f744e582e84a33f9e9d722_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">&#47;s&#47; Matthew Coffey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">_________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Dr. Matthew Coffey, PhD, MBA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;5, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>13
<FILENAME>ex132cfocertification2020.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5aafb6a416644688b1986a40bce7840f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">&#47;s&#47; Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Kirk Look, CA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Accounting and Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;5, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>14
<FILENAME>ex151-2020mda.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i70bf9ef902e1498280e11735f3f12e9e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="oncolyticslogotaglineblueaa.jpg" src="oncolyticslogotaglineblueaa.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">2020 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i70bf9ef902e1498280e11735f3f12e9e_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;4, 2021 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) should be read in conjunction with our 2020 audited consolidated financial statements and notes thereto, which have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). This MD&#38;A along with our consolidated financial statements for the year ended December&#160;31, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on March&#160;4, 2021. Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean Canadian dollars.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements, including&#58; our belief as to the potential and mode of action of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals, focus and objectives for the development of pelareorep&#59; the impact of the COVID-19 pandemic on our research and development activities, business operations and financial condition, our plans to mitigate any such impact&#59; the potential impact of the COVID-19 pandemic on stock markets and global economic activity&#59; our plan to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply&#59; our plans respecting regulatory approval for pelareorep&#59; our planned clinical development program, including the timing thereof&#59; our expectations as to the purpose, design, outcomes and benefits of our current or pending clinical trials involving pelareorep&#59; our expectations regarding enrollment under our various clinical trials&#59; our expectations respecting the delivery of additional clinical data and the timing thereof&#59; our anticipated milestones and catalysts&#59; our planned 2021 development activity for pelareorep&#59; our 2021 manufacturing program&#59; our anticipated 2021 expenses relating to clinical trials, manufacturing, intellectual property, research collaborations and other research and development and operating expenses&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; our anticipated cash usage in 2021&#59; our plans for funding our capital expenditure requirements&#59; our approach to credit rate, interest rate, foreign exchange and liquidity risk mitigation&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Forward-looking statements, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding among other things&#58; our ability to recruit and retain talented employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pelareorep Development Update For 2020</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we proactively manage all aspects of the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply, and our intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Potential Impact of COVID-19</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). In order to combat the spread of COVID-19, governments and businesses worldwide have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although COVID-19 has impacted our research and development activities, it has not caused a significant disruption to our business operations to date. In March 2020, we transitioned our workforce to a remote working arrangement to protect the health and safety of our employees and in accordance with enhanced health and safety protocols consistent with guidelines issued by local health authorities. Clinical trial activities by Oncolytics, including patient enrollment and site activation, were not materially delayed due to COVID-19. To date, COVID-19 has not had a material impact on our financial condition, liquidity or longer-term strategic development. The global outbreak of COVID-19 has also caused and may continue to cause significant fluctuations in stock markets, global economic activity and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may cause more significant disruptions to our business and greater impacts to our results of operations will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak (including future potential waves or cycles), travel restrictions and social distancing, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaborated with our investigators to ensure the safety of patients and employees, as well as the productivity of our clinical programs. We expect these measures will allow us to build on the positive momentum of the past year, despite any COVID-19-related challenges that may arise. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may impact clinical timelines.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ultimate objective of our clinical development plan is to obtain regulatory approval for pelareorep and is based on the compelling efficacy data from previous studies in breast, multiple myeloma, and selected gastrointestinal cancers. Our current clinical development program centers on the role of pelareorep in immuno-oncology mechanisms, particularly in combination with key immune checkpoint inhibitors and potentially other immune-based therapies. Our primary focus is to demonstrate enhanced antitumor efficacy with high profile checkpoint inhibitors, as we believe this may be the most immediately impactful clinical data and the most expeditious path to approval. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with different classes of immunotherapies. Therefore, as our clinical development program evolves and delivers additional data, we will consider appropriate expansion of our plan to investigate potential opportunities with such immunotherapies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">2020 Developments&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical studies aiding breast cancer program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for the treatment of hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+ &#47; HER2-) metastatic breast cancer (mBC). This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1 and Paclitaxel), is an open-label study planned to enroll 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab (Bavencio&#174;). PrECOG LLC, a leading cancer research network, is managing operations of the BRACELET-1 study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study will examine the expression of immune-related biomarkers to identify changes in T cell population between pretreatment and on-therapy biopsies and seek to confirm our previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1 and iRECIST. The safety of the combination will also be evaluated. Similar to the AWARE-1 study (see below), the results of this study may provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population where we presented compelling mBC survival data at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are designed to further de-risk our planned phase 3 registration study, hopefully permitting for a smaller study with a higher likelihood of clinical success. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we dosed our first patient, continued patient enrollment and treatment and study initiating activities including selecting and readying additional clinical trial sites.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study, which was announced in September 2018, from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which we are utilizing under our Master Clinical Supply Agreement with Roche. In 2019, we announced preliminary trial data demonstrating viral replication and promotion of inflammation following systemic administration of pelareorep when combined with Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study plans to enroll 38 patients. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy in breast cancer and to confirm biomarker data for breast cancer. The primary objective of this study is to supplement the existing randomized phase 2 results by providing key biomarker data points to enhance our probability of success in the phase 3 registration study. The results of this study may also provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we continued with patient enrollment, treatment and data analysis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also published the following electronic-posters (ePoster) with clinical data from our AWARE-1 window-of-opportunity breast cancer study. These data in the table below demonstrated the ability of pelareorep to promote a pro-inflammatory tumor microenvironment (TME) and provided a basis for the findings of a prior successful phase 2 trial (IND-213) that showed a near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- breast cancer patients. These data also highlighted the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep.  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description&#47;Conclusion</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Society for Medical<br>Oncology Breast<br>Cancer Virtual<br>Meeting</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key data and conclusions demonstrated&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Intravenous systemic administration resulted in tumor cell specific pelareorep replication</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">All patients treated with pelareorep demonstrated an increase in CD8+ T cells as confirmed in tumor biopsies (range of 1.6-fold to 11.2-fold increase)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">All patients treated with pelareorep experienced an increase in the number of PD-L1 positive cells in their tumors in as early as three weeks after beginning treatment (range of 1.3-fold to 11.0-fold increase)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Four out of six evaluated patients exhibited an increase in CelTIL, which is associated with favorable clinical response, the study's primary endpoint</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Peripheral T cell clonality correlated with changes in the TME and CelTIL, highlighting its potential as a compelling biomarker of pelareorep response in breast cancer</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Tumor-cell specific pelareorep replication was observed in all cohort-1 patients following systemic pelareorep administration</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">70% of cohort 1 patients saw an increase in CelTIL, the study's primary endpoint and a measure of tumor-associated cellularity and tumor-infiltrating lymphocytes that is associated with favorable clinical outcomes</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">On average, there was a 14-fold increase in intratumoral CD8+ T cells from baseline (pre-pelareorep administration) to surgery (21-days post-administration), with increases observed in all cohort-1 patients</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Pelareorep administration led to the generation and expansion of new T cell clones in the tumor and periphery, which included both anti-tumor and anti-viral clones</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 San Antonio Breast Cancer Symposium (SABCS)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key data and conclusions included&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">72% of evaluated patients (n&#61;18) saw an increase in CelTIL, the study's primary endpoint that is associated with favorable clinical outcomes</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">The maximum percentage increase in CelTIL (&#126;300%) was achieved in a cohort 2 patient receiving pelareorep in combination with checkpoint blockade therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">On average, there was a 105-fold increase in TME PD-L1 expression (n&#61;13) from baseline (pre-pelareorep administration) to surgery (21-days post-administration)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Tumor microenvironment PD-L1 expression increased in all evaluated patients (n&#61;13)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13pt">Preliminary imaging mass cytometry analysis showed pelareorep treatment promoted broad anti-tumor changes in the TME, including enhanced CD8+ T cell activation and the recruitment of memory T cells</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional checkpoint inhibitor combinations </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triple-negative breast cancer study combining pelareorep and retifanlimab  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we dosed the first patient in our investigator-sponsored trial (IST) managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCMGA00012 and the oncolytic virus pela</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep in metastatic triple-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gative breast cancer), will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). This single-arm, open-label, phase 2 study plans to enroll 25 patients and will be conducted at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRENE study represents an expansion of our lead breast cancer program into a new disease subtype (TNBC). In addition to investigating the safety and efficacy of pelareorep-anti-PD-1 combination treatment in TNBC patients, the study will also evaluate changes in PD-L1 expression and correlations between treatment outcomes and peripheral T cell clonality, a previously identified biomarker of pelareorep response that may enable the success of future pivotal studies by facilitating the patient selection process. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The phase 1&#47;2 trial, known as GOBLET (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1), will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The study is expected to be conducted at 25 centers in Germany. The primary endpoint of the study is safety, with overall response rate and blood-based biomarkers (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned for enrollment across four separate cohorts&#58; pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients, pelareorep in combination with atezolizumab in 2nd and 3rd line metastatic colorectal cancer patients that are diagnosed as MSI high (microsatellite instability), pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients, and pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we continued patient treatment in our IST supported by Merck Inc. (Merck), Northwestern University and Oncolytics. This study, an extension of our phase 1 study (REO 024), will investigate pelareorep in combination with Merck&#8217;s anti-PD1 checkpoint inhibitor Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to treat second-line pancreatic cancer patients. The study plans to enroll approximately 40 patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, we published an abstract on treatment tolerability and efficacy in pancreatic cancer patients treated with pelareorep, in combination with pembrolizumab (Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Preliminary data indicate that the combination of pelareorep and pembrolizumab resulted in tumor-specific replication, a high degree of T cell repertoire turnover, and the creation of new T cell clones in the peripheral blood during treatment. The treatment was found to be well tolerated, with most treatment-related adverse events being grade 1 or 2. One patient achieved a partial response and three achieved stable disease, with an overall disease control rate of 30% in evaluable patients. The study will not proceed to stage 2 in unselected patients, however further evaluation of the anti-tumor activity of pelareorep and anti-PD-1 therapy is now planned in biomarker defined pancreatic patients in a subsequent study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple myeloma study combining pelareorep and Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we continued patient enrollment and treatment of our IST with Emory University and the University of Utah investigating the combination of pelareorep and Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 40 - 50 relapsed or refractory myeloma patients.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional research collaborations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key studies that have been presented at scientific forums are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In January 2020, at the 2020 Gastrointestinal Cancers Symposium, we made a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In April 2020, we published positive clinical data in a peer-reviewed journal highlighting that the combination of FOLFIRI, bevacizumab and pelareorep was well tolerated, with promising efficacy signals in colorectal cancer patients with KRAS mutated tumors. The article, entitled &#34;Elucidation of Pelareorep Pharmacodynamics in a Phase I Trial in Patients with KRAS Mutated Colorectal Cancer,&#34;, was published on March 10, 2020, in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Molecular Cancer Therapeutics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13pt">In May 2020, at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, we published an ePoster with clinical proof-of-concept data from our phase 1b study in carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib (Kyprolis&#174;). Data presented in the ePoster demonstrated that the pelareorep-carfilzomib combination treatment resulted in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses. Key </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">findings included a 50% Overall Response Rate and 83% Clinical Benefit Rate in patients who failed carfilzomib, and T cell activation resulting in the 1st report of cytokine storm associated with tumor response in multiple myeloma.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In November 2020, at the 2020 Society of Neuro-Oncology Annual Meeting, we announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results showed a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.</font></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">Post 2020 Developments&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, at the CAR-TCR Summit Europe 2021, we published an ePoster, in collaboration with subject matter expert investigators at the Mayo Clinic, with data from a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors. The results show that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model, in stark contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. Efficacy of pelareorep-loaded CAR T cell therapy was further enhanced by boosting mice 8 days later with a single intravenous dose of pelareorep, generating highly persistent CAR T cells, inhibition of recurrent tumor growth, and ultimately tumor cures.</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2020, we completed a current good manufacturing practices (cGMP) production run and the associated release testing at audited manufacturing facilities, completed two product fills and continued distribution activities with the product supply. As well, we continued our activities to develop clinical and commercial production capabilities to fill pelareorep into vials, representing the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including The United States Food and Drug Administration (&#34;FDA&#34;), for product approval. </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2020, we had been issued 377 patents including 40 US and 17 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_22"></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 1,418,369 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$1,276,532.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538,342 at an average price of US$2.42. We received, net of commissions of US$526,150, proceeds of US$17,012,192. In total, we incurred share issue costs (including commissions) of $856,754. </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_28"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Impact</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had estimated that our cash requirements for 2020 to fund operations for the year would be between $23 - $25 million. Our actual cash usage for the year was $22,068,441 for operating activities, $29,305 for the acquisition of property and equipment </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $460,724 for the payment of office leases. Our net loss for the year was $22,505,057, which included a non-cash change in fair value of warrant derivative gain of $3,491,928 and a foreign exchange loss of $659,173 primarily due to unrealized translation loss on U.S. dollar denominated cash balances. </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended 2020 with cash and cash equivalents totaling $31,219,574 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Subsequent Events</font></div><div><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January 1, 2021 and March 4, 2021, through our June 2020 ATM equity distribution agreement, we issued 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$2.85. We received, net of commissions of US$555,096, proceeds of US$17,948,092.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Expected Pelareorep Development For 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned 2021 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our primary 2021 clinical objectives will focus on BRACELET-1 enrollment, the commencement of enrollment in our GOBLET platform study and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and possible other clinical development opportunities. While we are making every effort to maintain the timing of our future milestones, the full impact of the COVID-19 pandemic on these milestones is not known. Patient safety is our foremost concern and we will provide updates as they become known. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 manufacturing program includes product fills and the associated analytical testing, process development activities as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. We also intend to assess a process development plan investigating application of single-use equipment to our drug substance production process. These activities are consistent with our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently estimate the cash requirements to fund our operations for 2021 will be approximately $28 - $30 million but will depend on our ultimate clinical program.  (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_40"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Our Accounting Policies </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements we use IFRS as issued by the International Accounting Standards Board. IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available in selecting our accounting policies. Our selection of accounting policies, along with our estimates and assumptions affect the reported amounts of our assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Critical Accounting Policies </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets at the date of the financial statements and the reported amounts of expenses during the periods presented.  Significant estimates are used for, but not limited to, the treatment of our research and development expenditures, revenue recognition, the calculation of share-based compensation and warrant derivative (see Note 4 &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Judgments, Estimates and Assumptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;) of our audited consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with the Licensing Agreement with Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_46"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Significant Estimates </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based payments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black-Scholes valuation model (&#8220;Black-Scholes&#8221; or the &#8220;Model&#8221;) to calculate the fair value of our stock options. Black-Scholes is currently widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black-Scholes is the appropriate option pricing model to use for our stock options at this time. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and  inputs used for estimating fair value for stock options granted issued are disclosed in Note 10 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash share-based payment expense for the year of $2,558,974. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black-Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative are disclosed in Note 8 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded a non-cash change in fair value of warrant derivative for the year of  $3,491,928. However, given the above discussion, these amounts could have been different and still be in accordance with IFRS.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_55"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Selected Annual Information</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:439.50pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,505,057)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,037,225)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.56)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.50)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,345,567</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657,865&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,865,253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes&#58;</font></td></tr><tr style="height:21pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)  Included in consolidated net loss and loss per common share for 2020 is a non-cash change in fair value of warrant derivative gain of $3,491,928 (2019 - loss of $12,608,808&#59; 2018 - nil).</font></div></td></tr><tr style="height:21pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)  Included in consolidated net loss and loss per common share for 2020, 2019 , and 2018 are share-based payment expenses of $2,558,974, $1,470,153 and $1,415,833, respectively.</font></div></td></tr><tr style="height:20pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)   We issued 13,968,527 common shares for net cash proceeds of $40.2 million in 2020 (2019 - 14,798,704 common shares for net cash proceeds of $21.5 million&#59; 2018 - 2,472,909 common shares for net cash proceeds of $13.3 million).  </font></div></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)  We have not declared or paid any dividends since incorporation.</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i70bf9ef902e1498280e11735f3f12e9e_58"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year was $22,505,057 compared to $33,122,888 and $17,037,225 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. Net loss in 2020 included a non-cash change in fair value of warrant derivative gain of $3,491,928 (2019 - loss of $12,608,808&#59; 2018 - nil) and a foreign exchange loss of $659,173 (2019 - loss of $316,719&#59; 2018 - gain of $610,106). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:468.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 10pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,054,869</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,622&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938,911&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,384,172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776,288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073,726&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">906,657</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,991&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">317,757</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,966&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,622&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237,682</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,319,326&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,102,203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,043,373</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,541&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,944,510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,817,997&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027,994&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses include those costs associated with our clinical trial program which primarily included expenses related to the preparation and development of our multi-study breast cancer program and immunotherapy combinations. Included in clinical trial expenses are regulatory and consulting activities, contract research organization expenses, data management expenses and other costs associated with our clinical trial program.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:451.50pt"><tr><td style="width:1.0pt"></td><td style="width:280.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,054,869</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,622&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938,911&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, our clinical trial expenses were $3,054,869 compared to $2,189,622 and $2,938,911 for the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively. In all three years, our clinical trial program focused mainly on our breast cancer program. In 2020, these costs included continued patient enrollment and treatment as well as data analysis for our AWARE-1 study as well as our portion (net of Pfizer's contribution) of trial initiation activities and patient enrollment and treatment related to our BRACELET-1 study. In 2019, these costs included startup activities and patient enrollment and treatment for our AWARE-1 study as well as our portion (net of Pfizer's contribution) of trial initiation activities related to the BRACELET-1 study. We also incurred costs to complete our supporting regulatory documents and key opinion leader activities. In 2018, these costs included phase 3 development activities, activities related to obtaining the special protocol assessment from the FDA and our AWARE-1 study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in addition to activities related to our breast cancer program, we also incurred GOBLET study initiation expenses, costs related to our ongoing ISTs, data management consultant costs, and close-out costs related to our fully enrolled legacy clinical trials. In 2019 and 2018, in addition to activities related to our breast cancer program, we also incurred close-out costs related to our fully enrolled legacy clinical trials, patient enrollment and&#47;or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in combination with pelareorep. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our clinical trial expenses to increase in 2021 compared to 2020. During 2021, we will focus on BRACELET-1 enrollment, the commencement of enrollment in our GOBLET platform study and the assessment of our clinical data to help form the nature of our registration strategy, our path to approval and possible other clinical development opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development (&#8220;M&#38;P&#8221;)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M&#38;P expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, fill, label, packaging and storage costs and are net of any recoveries that are received from any R&#38;D collaborators. Process development expenses include costs associated with studies </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that examine components of our manufacturing and analytical processes looking for improvements and costs associated with the creation of our process validation master plan and related conformity testing. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:60.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,237,960</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535,632&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667,481&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">146,212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,656&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,245&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,384,172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776,288&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,073,726&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our M&#38;P expenses for 2020 were $3,384,172 compared to $3,776,288 and $2,073,726 for the years ending December&#160;31, 2019 and December&#160;31, 2018. In 2020, our product manufacturing costs primarily related to completion of a cGMP production run, two product fills and the associated consulting and testing expenses, as well as shipping and storage costs of our bulk and vialed product. In 2019, our product manufacturing costs primarily related to the completion of training and engineering production runs required to support our clinical development plan and the associated product testing, shipping and storage costs of our bulk and vialed product, and an ongoing product fill. In 2018, our product manufacturing activities mainly related to shipping and storage costs of our bulk and vialed product along with startup costs for a product fill and a production run. We also incurred costs related to relabeling activities in line with extended stability data. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development expenses for 2020 were $146,212 compared to $240,656 and $406,245 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. During 2020, our process development activities focused on  analytical development and stability studies. During 2019, our process development activities focused on analytic development studies. During 2018, our process development activities focused on analytic development and stability studies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our M&#38;P expenses for 2021 to increase compared to 2020. In 2021, we expect to fill products and perform the associated analytical testing, carry out process development activities as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. We also intend to assess a process development plan investigating application of single-use equipment to our drug substance production process. These activities are consistent with our process validation master plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:64.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">906,657</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,375&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,991&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for 2020 were $906,657 compared to $827,375 and $869,991 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. At the end of 2020, we had been issued over 377 patents including 40 U.S. and 17 Canadian patents, as well as issuances in other jurisdictions.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our intellectual property expenses will remain consistent in 2021 compared to 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research collaborations are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.549%"><tr><td style="width:1.0%"></td><td style="width:66.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaborations</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">317,757</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,966&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,622&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, our research collaboration expenses were $317,757 compared to $143,966 and $362,622 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. In 2020, 2019 and 2018, our research collaborations included studies investigating the interaction of the immune system with pelareorep, and biomarker studies.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research collaborations in 2021 will increase compared to 2020. We expect to complete our ongoing collaborative program carried over from 2020 and will continue to be selective in the types of new collaborations we enter into in 2021.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Research and Development Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and development expenses include compensation expenses for employees (excluding share-based payments), travel and other miscellaneous R&#38;D expenses.  </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:60.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,135,300</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096,231&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868,251&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,382</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,095&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Research and Development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,237,682</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,319,326&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,102,203&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Other Research and Development expenses were $4,237,682 compared to $3,319,326 and $3,102,203 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. Our Other Research and Development activities focused on supporting our clinical development program along with other third-party trials and clinical trials sponsored by Oncolytics. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in R&#38;D personnel-related expenses in 2020 compared to 2019 was due to an increase in headcount as we expanded our U.S. office, recruitment-related costs and a change in salary leve</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l, partly offset by personnel cost recovery from Pfizer related to BRACELET-1. The change in R&#38;D personnel-related expenses in 2019 compared to 2018 was due to the timing of filling open positions in our U.S. office and a change in salary level, partly offset by personnel cost recovery from Pfizer related to BRACELET-1.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses in 2020 compared to 2019 and 2018 was primarily due to decreased travel expenses as a result of COVID-19.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our Other Research and Development expenses to increase in 2021 compared to 2020 as we look to continue expanding our U.S. office. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:60.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,043,373</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,541&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash share-based payments for the year ending December&#160;31, 2020 were $1,043,373 compared to $561,420 and $680,541  for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. We incurred share-based payment expenses associated with the vesting of options and share awards to officers and employees. In the third quarter of 2020, we also recognized a recovery of share-based payment expenses as a result of changes in personnel and the forfeiture of unvested options.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:60.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,432,418</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,089,918&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041,226&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,120,290</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074,416&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,372,898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,957</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357,230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,515,601</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,514,496</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558,641&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,244,791&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public company-related expenses include costs associated with investor relations and business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we incurred public company-related expenses of $7,432,418 compared to $5,089,918 and $3,041,226 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. The change in public company-related expenses in 2020 compared to 2019 was due to increased directors and officers insurance premiums, increased investor relations and business development activities and the associated professional expenses. This is partly offset by decreased travel related expenses as a result of COVID-19 and transaction costs of $233,143 incurred in 2019 related to our August 2019 public offering (see Note 9 of our audited consolidated financial statements). The change in public company-related expenses in 2019 compared to 2018 was due to increased investor relations and business development activities, transaction costs of $233,143 related to our August 2019 public offering as discussed above, as well as increased insurance premiums. This is partly offset by lower professional fees, including legal fees and costs related to the special meeting of shareholders held in February 2018. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based payments), rent related to short-term leases, and other office-related costs. In 2020, we incurred office expenses of $3,120,290 compared to $3,074,416 and $3,372,898 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. The change in office expenses in 2020 compared to 2019 was primarily due to the timing of filling open positions in our U.S. office and a change in salary level. The change in office expenses in 2019 compared to 2018 was due to a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets and personnel cost recovery from Pfizer related to BRACELET-1, and is partly offset by change in salary level. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our non-cash share-based payment expenses were $1,515,601 compared to $908,733 and $735,292 for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. In 2020, 2019 and  2018, we incurred share-based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating expenses in 2021 to increase compared to 2020.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:60.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,491,928</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,608,808)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ending December&#160;31, 2020, we recognized a gain of $3,491,928 on the change in fair value of our warrant derivative compared to a loss of $12,608,808 and nil for the years ending December&#160;31, 2019 and December&#160;31, 2018, respectively. The change in fair value in 2020 was based on several factors including changes in market price of our shares to US$2.38 on December 31, 2020 from US$4.76 on December 31, 2019, and the revaluation on warrants exercised. The change in fair value in 2019 was based on several factors including changes in the market price of our shares to US$4.76 on December 31, 2019 from US$0.54 at warrant issuance, the revaluation on warrants exercised, as well as a decrease in the remaining term </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the warrants and changes in estimated future volatility of our common shares. The number of outstanding warrants was 265,757 and 1,684,126 as at December&#160;31, 2020 and December&#160;31, 2019, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange (Loss) Gain</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:60.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(659,173)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,719)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,106&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ending December&#160;31, 2020, our foreign exchange loss was $659,173 compared to a loss of $316,719 and a gain of $610,106 for the years ending December 31, 2019 and December&#160;31, 2018, respectively. The foreign exchange (loss) gain incurred in all three years was primarily due to unrealized translation (loss) gain on U.S. dollar denominated cash balances.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:166.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sept.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,329)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,749)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,827)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,402)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,529)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,254)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic (loss) earnings per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,346</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,242&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,553&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,461&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,220&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,214&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net (loss) income and (loss) earnings per common share between December 2020 and July 2019 are non-cash change in fair value of warrant derivative (loss) gain of $(213,168), $60,264, $(507,150), $4,151,982, $(12,486,310) and $(122,498), respectively. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There was no change in fair value of warrant derivative expense between June 2019 and January 2019.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in net (loss) income and (loss) earnings per common share between December 2020 and January 2019 are quarterly share-based payment expenses of $1,704,453, $201,076, $260,640, $392,805, $658,662, $250,384, $260,184 and $300,923, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Q1 2020 included the effect of dilutive warrant derivative, stock options and share awards. For all other periods presented, the effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 13,968,527 common shares for net cash proceeds of $40.2 million in 2020 (2019 - 14,798,704 common shares for net cash proceeds of $21.5 million).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i70bf9ef902e1498280e11735f3f12e9e_64"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Fourth Quarter</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statement of loss for the three-month periods ended December&#160;31, 2020 and 2019&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:372.00pt"><tr><td style="width:1.0pt"></td><td style="width:241.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the three-month periods ending December 31,</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,061,464</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696,443&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,010,894</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132,548&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,072,358)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,828,991)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213,168)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,486,310)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,052,531)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,279)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,385</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,938&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,328,672)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,401,642)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,328,672)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,401,642)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other comprehensive loss - translation adjustment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(144,433)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,754)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,473,105)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,458,396)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,108,936</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,200,947&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Fourth Quarter Review of Operations</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three-month period ended December&#160;31, 2020, our net loss was $9,328,672 compared to $19,401,642 for the three-month period ended December&#160;31, 2019. Net loss for the three-month period ended December&#160;31, 2020 included a non-cash change in fair value of warrant derivative loss of $213,168 (2019 - loss of $12,486,310) and a foreign exchange loss of $1,052,531 (2019 - loss of $114,279). </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:408.00pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,200,998</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,436&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,943</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,077&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,940</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,036&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,815</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,391&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,430,167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,083&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">817,601</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,420&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,061,464</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696,443&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:68.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,200,998</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581,436&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, our clinical trial expenses were $1,200,998 compared to $581,436 for the fourth quarter of 2019. In the fourth quarter of 2020, these activities mainly related to continued patient enrollment and treatment as well as data analysis for our AWARE-1 study and our portion (net of Pfizer's contribution) of patient enrollment and treatment related to our BRACELET-1 study. In the fourth quarter of 2019, these activities mainly related to patient enrollment and treatment for our AWARE-1 study and our portion (net of Pfizer's contribution) of trial initiation activities related to our BRACELET-1 study. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the activities related to our breast cancer program, in the fourth quarter of 2020, we also incurred trial initiation costs related to our GOBLET study, costs related to our ongoing ISTs and data management consulting costs. In the fourth quarter of 2019, our clinical activities also included costs related to patient enrollment and&#47;or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with pelareorep and close-out costs related to our fully enrolled legacy clinical trials. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &#38; Related Process Development Expenses (&#8220;M&#38;P&#8221;)</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:68.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product manufacturing expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">399,522</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,309&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,421</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">434,943</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,077&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, our M&#38;P expenses were $434,943 compared to $474,077 for the fourth quarter of 2019. During the fourth quarters of 2020 and 2019, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product, as well as costs related to a product fill and product test. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our process development activity for the fourth quarter of 2020 and 2019 related to analytic development studies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,940</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,036&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property expenses for the fourth quarter of 2020 were $106,940 compared to $68,036 for the fourth quarter of 2019. At the end of the fourth quarter of 2020, we had been issued over 377 patents including 40 U.S. and 17 Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaboration Expenses </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:69.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research collaboration expenses</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,815</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,391</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaboration expenses were $70,815 for the fourth quarter of 2020 compared to $41,391 for the fourth quarter of 2019.  During the fourth quarters of 2020 and 2019, our research collaborations were primarily focused on studies investigating the interaction of the immune system and pelareorep. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Research and Development Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,406,242</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219,536&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,925</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,430,167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295,083&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other research and development expenses were $1,430,167 in the fourth quarter of 2020 compared to $1,295,083 in the fourth quarter of 2019. Our R&#38;D personnel-related expenses increased in the fourth quarter of 2020 compared to the fourth quarter of 2019 primarily due to the timing of filling open positions in our U.S. office and a change in salary level.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other R&#38;D expenses in the fourth quarter of 2020 compared to the fourth quarter of 2019 was primarily due to decreased travel expenses as a result of COVID-19.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">817,601</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,420&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarters of 2020 and 2019, we incurred share-based payment expenses associated with the vesting of granted options and share awards to officers and employees.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:398.25pt"><tr><td style="width:1.0pt"></td><td style="width:280.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,037,925</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,590,135&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">978,484</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,988&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,437</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86,196</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,391&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">886,852</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,242&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,010,894</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132,548&#160;</font></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses for the fourth quarter of 2020 were $4,010,894 compared to $4,132,548 for the fourth quarter of 2019. Public company-related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. During the fourth quarter of 2020, our public company-related expenses were $2,037,925 compared to $2,590,135 for the fourth quarter of 2019. The change was primarily due to lower investor relation activities and lower travel related expenses as a result of COVID-19, partly offset by increased insurance premiums.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office expenses include compensation costs (excluding share-based payments), rent related to short-term leases, and other office-related costs. During the fourth quarter of 2020, our office expenses were $978,484 compared to $1,004,988 for the fourth quarter of 2019. The change in the fourth quarter of 2020 compared to the fourth quarter of 2019 was primarily due to the timing of filling open positions in our U.S. office and a change in salary level.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-cash share-based payment expenses in the fourth quarter of 2020 were $886,852 compared to $422,242 for the fourth quarter of 2019. We incurred share-based payment expenses associated with the vesting of granted options and share awards to officers, employees, consultants and independent board members.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(213,168)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,486,310)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a loss of $213,168 on the change in fair value of our warrant derivative compared to a loss of $12,486,310 for the fourth quarter of 2019. The change in fair value in 2020 was based on several factors including changes in the market price of our shares to US$2.38 on December 31, 2020 from US$1.69 on September 30, 2020. The change in fair value in 2019 was based on several factors including changes in the market price of our shares to US$4.76 on December 31, 2019 from US$0.57 on September 30, 2019, the revaluation on warrants exercised in the quarter, as well as a decrease in the remaining term of the warrants and changes in estimated future volatility of our common shares. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows. The number of outstanding warrants was 265,757 and 1,684,126 as at December&#160;31, 2020 and December&#160;31, 2019, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Loss</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:69.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,052,531)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,279)</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange loss was $1,052,531 for the fourth quarter of 2020 compared to a loss of $114,279 for the fourth quarter of 2019. The foreign exchange loss incurred in 2020 and 2019 was primarily due to unrealized translation loss on U.S. dollar denominated cash balance. </font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_70"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_73"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2020 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant exercise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 1,418,369 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$1,276,532.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538,342 at an average price of US$2.42. We received, net of commissions of US$526,150, proceeds of US$17,012,192. In total, we incurred share issue costs (including commissions) of $856,754.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_76"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">2019 Financing Activities </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public offering</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. Each common share purchase warrant entitles the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2019, 2,935,647 warrants were exercised for gross proceeds of US$2,642,082.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 U.S. &#34;at-the-market&#34; equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we sold 4,425,040 common shares for gross proceeds of US$6,390,691 at an average price of US$2.42. We received, net of commission of US$191,721, proceeds of US$6,198,970. In total, we incurred share issue costs of (including commissions) of $344,834.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Purchase Agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we sold 2,477,665 common shares for gross proceeds of US$4,055,725 and issued 17,278 commitment shares. The commitment shares were fair valued at US$29,758 and were recorded as share issue costs in addition to cash share issue costs of $3,757.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i70bf9ef902e1498280e11735f3f12e9e_79"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Liquidity</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020 and 2019, we had cash and cash equivalents and working capital positions as follows&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.777%"><tr><td style="width:1.0%"></td><td style="width:66.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br>$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br>$</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,219,574</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital position</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,558,550</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,570,105&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our cash and cash equivalent reflects the cash usage from our operating activities of $22.1 million and $0.5 million for the payment of office leases along with the cash provided by our financing activities of $40.2 million for the year ending December&#160;31, 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to maintain adequate cash reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection. To date, we have funded our operations mainly through the issue of additional capital via public and private offerings and through the exercise of warrants and stock options. In 2020, we were able to raise funds through our U.S. ATM. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. On June 12, 2020, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to 150 million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.   </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 9 of our audited consolidated financial statements). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ATM equity distribution agreement provide us with access to, subject to terms and conditions, US$40 million of which we have raised gross proceeds of approximately US$12.6 million at December&#160;31, 2020. We expect to continue to access our equity arrangement to help support our current clinical trial, manufacturing, intellectual property and collaboration programs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the expected cash usage from our operations in 2021 will be approximately $28 - $30 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources and access to additional cash resources through our equity arrangement to fund our presently planned operations into 2022. Factors that will affect our anticipated cash usage in 2021, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><div id="i70bf9ef902e1498280e11735f3f12e9e_82"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the following contractual obligations as at December&#160;31, 2020&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:28.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Obligations</font></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments Due by Period</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year<br>$</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2 -3 years</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years<br>$</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital lease obligations</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,509&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,003&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,360,653&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,240,435&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120,218&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long term obligations</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,819,165&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526,944&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,292,221&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to fund our capital expenditure requirements and commitments with existing working capital.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_85"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we had not entered into any off-balance sheet arrangements.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_88"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, we did not enter into any other related party transactions other than compensation paid to Key Management Personnel disclosed in Note 22 of our audited consolidated financial statements.  </font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_91"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and warrant derivative.&#160;As at December&#160;31, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2020, the fair value of our warrant derivative was $531,228 (December&#160;31, 2019 - $8,508,764).  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $172,000.&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $20,000. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at December&#160;31, 2020 are as follows&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:471.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollars </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br>&#8364;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,134,113</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,768</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,347</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,588)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,244)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,238)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,261,287</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,417</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_94"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 52,083,924 common shares outstanding at March&#160;4, 2021.  If all of our options, restricted share units and performance share units (3,878,852), common share purchase warrants with a $9.025 exercise price (16,443,500 warrants exercisable into 1,730,894 common shares) and common share purchase warrants with a US$0.90 exercise price (110,572), were exercised or were to vest, we would have 57,804,242 common shares outstanding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 annual report on Form 20-F will be available on www.sedar.com.</font></div><div style="text-align:justify"><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_97"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing timely material information relating to the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all error and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the design and operation of our internal control over financial reporting as of December&#160;31, 2020, and has concluded that such internal control over financial reporting is effective as of December&#160;31, 2020. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Controls over Financial Reporting</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><font><br></font></div><div id="i70bf9ef902e1498280e11735f3f12e9e_100"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Risk Factors Affecting Future Performance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risk Factors</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative.  It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful.  There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g. competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and&#47;or limited human testing may not be substantiated in larger, controlled clinical trials&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical and non-competitive&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling or manufacturing which may result in the discontinuation of research and other critical projects.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). COVID-19 has had a broad adverse impact on the global economy across many industries and has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business shutdowns, as well as significant volatility in global financial markets. In March 2020, we transitioned our workforce to a remote working arrangement to protect the health and safety of our employees and in accordance with to enhanced health and safety protocols consistent with guidelines issued by local health authorities. Clinical trial activities, including patient enrollment and site activation, were not materially delayed due to COVID-19. To date, COVID-19 has not had a material impact on our financial condition, liquidity or longer-term strategic development.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may cause more significant disruptions to our business and greater impacts to our results of operations will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak (including future potential waves or cycles), travel restrictions and social distancing, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease and to address its impact, including on financial markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the COVID-19 pandemic worsens or continues for a prolonged period of time, particularly in regions where we or our collaborators and suppliers do business, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical research and other business activities, including&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption to and delays in preclinical research activities due to an extended closure or reduced capacity of lab facilities&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling patients in our ongoing and planned clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients discontinuing their treatment or follow-up visits&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in supply, logistics or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical research, initiate or complete our clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others&#59; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and&#47;or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers and strategic partners&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in resources that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, restrictions on travel, or prolonged stay-at-home or similar working arrangements&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approvals from regulatory authorities to initiate our planned clinical trials&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and incur unexpected costs, or require us to discontinue clinical trials altogether&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators (including the FDA), ethics committees and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to our strategic partners&#8217; operations, which could delay the development of our product candidates in certain geographical regions and thereby affect the timing of development and commercial milestone payments and royalties on potential future product sales we may receive&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to recruit preclinical research, clinical, regulatory and other professional staff on the timeframe required to support our research and development programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 could result in the continued significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. Such financial market volatility may continue and the value of our common shares may be adversely impacted.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the effects of COVID-19 on our business. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating results.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions and criminal prosecutions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s cGMP and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money and effort in production and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions&#58; (i) restrict the release of the product&#59; (ii) suspend manufacturing of the specific lot of the product&#59; (iii) order a recall of the lot of the product&#59; or (iv) order a seizure of the lot of the product.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection and hazardous substance control, and may be subject to other present and future local, provincial, state, federal and foreign regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims, which are uninsured.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance&#59; however, it is possible this coverage may not provide full protection against all risks.&#160;&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition and future prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our technologies may become obsolete.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes and the emergence of new industry standards may render our products obsolete, less competitive or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our license, development, supply and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a Licensing Agreement with Adlai. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency and legal risks and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2020, we had an accumulated deficit of $367.1 million and we incurred net losses of $22.5 million, $33.1 million and $17.0 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively. We anticipate that we will continue to incur significant losses during 2021 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our pre-clinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting and enforcing our patent claims and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The cost of director and officer liability insurance may continue to increase substantially or may not be available to us and may affect our ability to retain quality directors and officers.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore are exposed to foreign currency exchange rate fluctuations.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our manufacturing, clinical, collaborative and consulting expenses in foreign currencies, primarily the U.S. dollar, the Euro and the British pound.&#160;&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions there may be an increase in our foreign exchange exposure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>15
<FILENAME>ex152ey2020consent.htm
<DESCRIPTION>EX-15.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iebd82f874f63481683f25ae70b1ce464_1"></div><div style="min-height:136.8pt;width:100%"><div><font><br></font></div><div style="margin-bottom:6pt"><img alt="eyheader1.jpg" src="eyheader1.jpg" style="height:106px;margin-bottom:5pt;vertical-align:text-bottom;width:93px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.721%"><tr><td style="width:1.0%"></td><td style="width:37.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">Ernst &#38; Young LLP</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">2200, 215 2nd St SW</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">Calgary, AB T2P 1M4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;Tel&#58; +1 403 206 5000</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;Fax&#58; +1 403 290 4265</font></div><div><font style="color:#666666;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:160%">&#160;ey.com&#47;ca</font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 15.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the use of our reports dated March 4, 2021 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) as at December 31, 2020 and 2019 and for each of the years in the three year period ended December 31, 2020 included as an exhibit to or incorporated by reference in the Annual Report (Form 20-F) for 2020.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also consent to the incorporation by reference in the Registration Statement on Form F-10 (Nos. 333-239025) and Registration Statements on Form S-8 (Nos. 333-171625 and 333-205708) of our report dated March 4, 2021 with respect to the consolidated financial statements of Oncolytics as at December 31, 2020 and 2019 and for each of the years in the three year period ended December 31, 2020 included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2020, as filed with the SEC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"><tr><td style="width:1.0%"></td><td style="width:26.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calgary, Alberta</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:46.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:324pt;text-indent:36pt"><font style="color:#666666;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">A member firm of Ernst &#38; Young Global Limited</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>eyheader1.jpg
<TEXT>
begin 644 eyheader1.jpg
M_]C_X  02D9)1@ ! 0$ 40!1  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !: $X# 2(  A$! Q$!_\0
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1#9YSG.<\YKI** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>oncolyticslogotaglineblueaa.jpg
<TEXT>
begin 644 oncolyticslogotaglineblueaa.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
M  <! 0$!             0(#! 4*"PD(!P;_Q !^$  ! P(# P8'!PP+"@D'
M 1D  0(#! 4&!Q$2(3$("1-!4? *%")A<8&1%7:AL;7!T1HC,C,W.%=WMM3A
M\189-#9"<W1UE;*S%R125G*6E[35UB4U5%588I2WTB8G*$-%@I,81$9'4X6E
MQ--C96:&DF1GAZ*FQN*#A,+%U__$ !T! 0 " @,! 0             '" $&
M @0% PG_Q !:$0 " 0("!@0%#P<*! 4%  ,  0(#$00A!08'$C%!$U%A<2(R
M-8&1%!<C0E)R<W2AL;*SP='P,U-B@I*3TA4D-$-4PL/3X?%C@Y2B%B5$5;1%
M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
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MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
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M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
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M1:XK(H
M
M
M
M
M
M
M
M
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MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
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M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
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M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
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M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
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M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
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M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
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MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
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M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
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M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
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MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
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MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
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M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
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M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
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MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
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MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
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MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
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M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
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MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
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M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
M           $% /X/,S,>RX0P[?,58BKH;98<.VJOO5WN%0[9AI+?;::2KJI
MW*O'8BB<K6(BN>[98U'.<C5Y7W."<LV[Y]YJ8CS$N;9Z6DKI4H,.6J=VKK/A
MFA?(RTT+F-<^-E0^)SZVO2-SFK7U=2U'RM8R639:\)IYQ)D;*7D]85N*+-+X
MC>\RWT<WVF!4BN%@PO5.C71LU2UU-?JVCE152D=:99(EBJH7+II]GF33LW>A
M-WP;NKBI8799JST%&6/JQM6KQM03XQP_.2RXU7GUJ"33\)E8ML.MGJC$+1M"
M5Z.&:=9I^#.NN,7U]"LE^G*2:O%  $M]RLNI$*?/POU]_< "61[6(KG+LM:B
MJY>&RB<5X+[?9O,/AR7#C\OR<!\N5[?=^.!]F<@/D;WK/G-3#67%FVXHKA(^
MY8@N3$VF6;"UN?"^\721=4V%5DT-OHE77;N=?10HU72(=4#*7*VR8)PS8L(X
M;H8K;8<-VNCM%IHH4:UD%%10MAB14:B(LCD:KYGJFU+*Y\KE5SU/&'F%.;B_
MN)Y8,Q+B2W+39C9C4]#=[ZVJB6.MLME1JSV/#<D;_*II:6.H=77&!S63MN53
M+!4^52,B@]XFIH5@VBZT>K\9T5*3>&PTG"G;Q9RO:=3MO;=B_<JZ\9EN=E^J
M/\G8+IJT+8K%QC.I=>%3I\:=+LM?>FL_"=O:HBB$0"/R3P      >.W/[?>E
M9N?R3"WY<89/8D\=N?V^]*S<_DF%ORXPR>SJ[Y0P/QO#?70-?UK\F:0^)XCZ
MJ1S.  7&7!%%E]_S@ &3(                                   ,K[_
M )C?*\%4^XOCO\8]1\@68VAC5Y\%4^XOCO\ &/4?(%F-H8J3KOY6Q_P[^C$N
MIL\\BZ.^+Q^=@ &JFY@         _/,W?WJ8G][]Y^3JD_0S\\S=_>IB?WOW
MGY.J3Z4?'C[Z/SH^.(_)S]Y+Z+./O4?;)?XV7^T<4BK4?;)?XV7^T<4B[-/Q
M4?G_ #\:7OF  <SB6E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1'($K_M$W\5)_44
MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
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MM-^[KX\/5\7J*Q%-^/83.F  9,@
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M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
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MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
M1/@/7Y '[6-R;/\ H]Y(_P"B? ?^P"</7CH<L%52Y+I(-<.V-RO\=A>(MGI"
MD^']1)<NRIUG*4U0:H=6O]K&Y-G_ $>\D?\ 1/@/_8 _:QN39_T>\D?]$^ _
M]@#UXZ']BJ_O*?W&?6,K_P!OI?N9?QG*4U0:H=6O]K&Y-G_1[R1_T3X#_P!@
M#]K&Y-G_ $>\D?\ 1/@/_8 ]>.A_8JO[RG]P]8RO_;Z7[F7\9RE-4&J'5K_:
MQN39_P!'O)'_ $3X#_V /VL;DV?]'O)'_1/@/_8 ]>.A_8JO[RG]P]8RO_;Z
M7[F7\9RE-4&J'5K_ &L;DV?]'O)'_1/@/_8 _:QN39_T>\D?]$^ _P#8 ]>.
MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
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M G3[(J$C.LJ-XH#+XLK(1 !@
M                                                   MRG)U%9_$
MIOX Y0XE-_$I=O?J*KNKT(45XKYT!Q+9_$M9.LNW]1;/ +"3J+&3BN[C])?O
M+.1=_?S@&,D,=+Q]IE).OT?,8Z8 QC^!BYC+R)Q[^<QDR<>_$ Q$R<=.^XQK
MTX^@RLG7Z#&R\?;\0!CI?G/'SGU\%-O')FQY-L[3K%588O\ &G6GBV(;?0R.
M1%W?6Z>Y3O<JJBHUKO7["R>8^).<=PBZ^Y YSVQC%EFERRQE4TL:::R5MLL=
M9=*%C=7,1'.K**!&JYR-1517:HBH>OJ_B>BQ^#J<-W$4G?A;PXIN_8FWV'B:
MRX;IM'XZE:[GA*Z2XW?1RLK=KR7:<T-?7Z_5O3AHB]G:BZ<"!*QR*B*G!=Z*
MG!45$5%X)QUUX)QX$Q<A?CT%$GQ?>  9 /VGDW8J?8\Q,!7=CNC6@QEAF=S]
M=-B)+S1LF?KOTV87O7@[739T37:;^+$S*Z2E<VJBW2TKFU,2[]TL#DEC7<J*
MFCV)O145OV2;T1#XXBETE.=-\)PE#]N+C]IV,)6Z.K2J+C3J0J+OA)27RHZR
M\-0R1$D8NK)$1[%[4<B.1==$7?M+N7U:(NRV_A[_  'YQE?>H[CAO#M?$Y7Q
MUECM52U[DV7.2:@@?Y2:KH[?O;JNGK/T6/C["E56.[*2ZI;O[.7^I?NA.\(>
M]3])EHU^8R42F,B^9#)0KP]1\CZF5B^8R$+N'?@8V/J+^$ RL:E_&O?T&-CZ
MB^C7>NG: 9"/J[]9>Q]98,X%\SB 7D:\"NWBI:Q]9=)Q7U %9O!>_4:P7A4/
MW&,#>_\ A^1Z\V?&KN7UFL'X5!]QC _O_A^2*\VO4?RK@?C$/M--VA>1=(_%
MIFAROT?$0(JI MHN"*5/B  9,    ^UN0)RY\6\GS,*@QSA9[JFG<V*@Q-AZ
M25T=!B:PK+MS6^J:BHQM5 JOGM-:J;=OK%5[56">ICD^*0=;&82G7I3HU8*=
M.I%QG%\XOC;M7%6S3LUF=K XVKAZL*]&;IU:4E.$ERE'A=<T^#7!K)Y'7)Y+
M7*;PGG!@:PY@8+N#*^QWVD25J;2)56^MC\BNM-RA1=JEN5NJ4?3U=/(B*US4
MD9M0R12/^AD.93S0G.E7?DWXW1MQ6KN666)ZJFAQE985?++0*GUJ+$]GIE>C
M'7*W1Z^-4[48MRH6+!TC9H8')TJ<"8[L^)K-;,06"XTUVLMXHJ>X6RY4<G2T
MU91U4;98)XG[ET>QR*K7HV1CM62-:]KFI5;7#52IHO$..<L-4;>'JVXQ]Q+D
MJD+I27/*2R=BXFHFN=+2^%4FXPQ5*,5B:5^$G=*<5QZ.=FX]6<6[J[_K@012
M)J)O0                 !JG^%A?<LRJ_&34_DG>S1?-Z#PL+[EF57XR:G\
MD[V:+Y9O9=Y)I_"UOILJ3M@\M5?@,/\ 08 !(I%H-FKP6+[N>,?Q;U?R]:#6
M5-FKP6+[N>,?Q;U?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4
MF*EK[_G+I@ &0               ""D%<B'YKG%F[8,!X6OV,<45\5LL&'+;
M4W6Z5LRM:V&FIHED<C4<K4?+*J)%!'M(LLSV1HNKCE3@Y248IRE)J,8I7;D\
MDDN;?)'"I44(RG)J,8IR<F[))9MM\$ES/A/G3><<L7)PRXJ\1S,IKGC"[I/;
ML#X<EE5J7.\+'NJZU&.2=EEM.TVKN4D>R^2-C:.![*BHB>WF79NYN8DQYB6\
MXPQ==JB]XCO];)772XU2IMS32.<K8XHV_6Z:EIXU;!2T<*=!301QPPM8UB[7
MTUSAO+CQ%R@<SKUCR]OG@MJO=;L(V&21708=PU3O7Q.BB8FC/'*M4\?N]3OD
MJJ^9[5<E-3T<,'P\6DU%U2AHW#*4XIXNLE*K/W,7XM&/4H\9<-Z6?!1M3W:'
MKK/2N*<:<G'!4&XT8/V\EDZSZW+VON899-NX &]$>   RE?) RMCLE;=*VCM
MEKHJRYW2XU,5';K;;J6>NN%?63JC(*2BHJ5DM35U,SG(D,%/%)*]RMV44^P>
M0YR LQN4#BIF&<!VO:IJ=T;L08FKTD@P_AJB>YFU47&K1JK+4JQZ.I;52)+<
M*Q?M<3(4EJ(NA3S=/-)Y8<G:UPS62WLQ!CF>G='=L>7BG@EN\_2[*RTEJ;HL
M=EM7DM8VDH5:Z9K4?635$FKFZ3K5KUA=&+<_+XFSM0A)>#?@ZCSW%U9;[Y*Q
MONINSW&:6:J)=!A+YXFI&7A6XQHK+I'UYJ"YMO(UGN07X,IC#%K*/$&=UVJL
M"6.1(YVX2LCJ2HQ?61[37)#<*^9E9:[%'(U521L4%RKD1-A%IGN;-'M[<ESD
M+949,VQELRYP5:,/HC42>XMA6MO=<]&=&LUPO=:ZHNE;,]GD/?/5.5S$1FZ-
M&M3ZWV=$]>O:3*TKWIW6[':1E[/6DJ5\J$+PI)<O!RWK=<FWVEG-7=2='Z-B
MN@H*56ROB*MI5I=\GXB[(I1[&3@ UDVXAH-"(          !@,2X8MMXHI[=
M=J"CN=!4L6.HHJ^EAK*69BIHK9:>=CXGIHJ_9-73JT7>9\E<FJ&5)K--IK@U
MQ7<<914DTTFGDTU=>AFMSRX_!M,H\P(ZZ\Y8RR95XMDZ69M+0L6LP/<IWHB[
M-987ZRVAS]%1E3A^IHX872RSU-LN$RMV-,GEH<W_ )I9!WIEIS$P]-0TE7+)
M'9L242NK,-7Q6;3]F@NK6]&RL5C7R.MM8VFN#&LDE2GDI6+(=7S9\Q^>9HY3
MX<QK8Z_#.+;';,1X?NL"T]PM-WI(:RBJ8UWM5T4K7;,L;M'P3QJR:GE:V:"2
M.5C7$AZM[2,;@W&%=O%8=9;M3.K%</ J/PW9<(S;7);JS47:T[*L!CE.IAXK
M!XEJZE33Z&<K/\I162OSE349<\^#Y>7-E<B*NY0&;^'<!1MG98X]J^8SN,*.
M;[G85MDL*5Z](FK6U%SJ)::T43&K'+XQ7)*QW103/BZEN$L*V^QVNW66TTD5
M#:[314MNM]' Q&0TM%10LIZ:"-K=$1D44;6(GKWGPKR$.;/RWY.[<8-P!2UK
M5QC>([C53W.9M764=!20K';K#35BM;.^UV^2:MGIF3O?*DM;.Y[W*[4]#D.E
MKSK6M*8F+I;T<-1ANTHR5I-O.<Y15TF\HI)NT8KK/2V>:F_R1A9*JJ;Q=:5Z
MTZ>:W(94X1DTFXI7EG9N4F[$0 :02"             -23;0 F537XY\_G;&
MY%89CP/@BK@FS5Q=13^+RL<V7]A=C>B128@JXT1R)<:ISU@L-+*K>DE;+<)&
MK!2-9/Z4<X3RV</9!Y87_,&]HRJJJ2%:/#=EZ3HYL08EJFN;:K6QVBK%3NG3
MQBX5:([Q*WP552V.66.*&7ER9W9UXES&Q;?<;XPN#[IB+$=?+<+C5+JV-KI%
M1(J6CB<K_%J&BAV::AIVO^L01,1RR2*^5\E[.M4%CJ_JK$1OA:$LHVRKUDKQ
MIOKIQR<^NRCUVB+:EKS_ "=1]1X:7\\Q$'>2:O0I7:E/X26<8+BLY<HW_-;A
M<*BKJ*BLJYYJNLJZB>KJZNID=-4U5752OGJ:JHF>KGRU%1-))+/*]5?))(][
ME57*I: %DXQLDK6MRZBJKDVVV[MW=\\[\7GGGV@ '(P!W[^T=^_S=N_3@>MW
M-A<T+C[E(72.OA63"^6E#6)!?,:U4"O\9? ]JU5JPO2R-V+G=MAW0R5+M+=:
MY7.?5.J98TH*CHZ1TG0PE*5>O4A3IPSWI_,K>$W)7LHIMG?T9HJOC:T,/AJ4
MJM6;RA'YY/@HKG)M)=9Y[9"\GW&F:&)J/!^ </7'$V(*U%D;16Z%9&TM(U\<
M<MPN52JMI[;;8'21LEK:N6*G9(^.'62IGAA?N4\@+P93">'4M^)L];BF,KVS
MHZEF!K5(Z#!]#,BL>R.\U:,CN.(Y(5:UCZ=CJ"SO^NQU%+<X'L<S8-Y(?(HR
MZR-PTS"^7>'J6T4TG0ONEQ5K)KU?:N%BL96WJYO3QFOG:CGI"V1Z04S'OCIH
MHFN<U?K)6^WV%?=9]IN)Q3E2P6]AL/PWLNGFNMS2M3B^48/>MQEG967U1V2X
M7"*-;'[F,Q.3=+/U-3>62@_RK5LY36[?A!6N_P"/P%@"QX8MM/9L.VBVV.TT
MC&1TMNM5%3T%'"QK48B,IZ:..-%V6M:K]%<Y&IJNX_LR"(1(PE)R;<FVWQ;=
MV^]\R8(044HQ2C%9**222ZDEDO,0T\Q$ P<B&A$     $-"( )53O\1\=\K/
MD%Y49VVMUKS&P?;;TYL;FT=W8Q:&_P!L>]$1)K9>J3HKA22,V&[FS+"]NL<L
M4D3Y(W?8Q*Y-3ZT,14I3C4I3G3G%WC.G+=DGWG6Q>#I5Z<J5:G"K3GE*%1*4
M6NYF@!SB'@XV/LLX;ABC*>LK\S,'TW2U,EFDIHDQW:*)KE>Y'TM#'#28F;!$
MFKI[734-;.UCD99W2:)-K9R1N8Y\;V.CDB>^*2-[7,DBEC56R12,<B/CDC<B
MMDC>UKV.16N:BHJ'9'<Q5[=W#V=]W;HNIX.\Z9S&&",^(*[%6%&6_!&:BQOE
M2]0P+%9L33,;JRGQ31TC%Z265R-8E\IX7W&G1=J5E<QJ0+,FJFU"<7"AI)N<
M;V6*]M'DNEBEX2ZYQ5TN,7Q()USV/0DIXC15H26;PCONOFW1DV[-\H2RY;RR
M1SE]0?L>?7)_QEEABBYX,QY8:S#V([3,Z.JHJM&OCEC15;%66^LB=)2W&WU+
M-)*6NHY9:>6)45CT5SV-_'/T+ZEX=_1VH3G2K1J1C.G*,H26]&46I*47PDFF
MTT^M9%>JU"I2G*G4C*,X/=E&2<91DN,7%I-/L:N  ?0^=AJ?8_(4Y;V,<@<P
MK9CS"51TC(I(Z3$=AFD>VVXGL#Y6K76NN8U=&S;"OEM=>C5DMU>R*J1LT734
M\_QP11=-%3BBZIQ3>F]-Z<%[%ZEWG7Q6$IUZ<Z-:*G3J1<9PEXLD^%WV/T/,
M[.$QM6A5A6HR<*M*2G3J1?A1FK6:ZU:Z:]LO!:LV=<KDO<I7"V;N![#C_!M<
MVNL=_I.FBU5$J:&J8O1UMLKX]56&NM]2U]-51+HK98U5-6.:I] :]O7Q]1S@
M>8OYS9^0V83L-8EKY(\K\?UE'2WQDLCUH\.7]=FDM^*XHU<L=+&^-T-NQ!4,
M:SI[?#0U%6[HK/3OBZ/%+-')&R2-[)(Y&MDCD8J.8]CT1S'M<W5KFO:J.1R*
MJ.1=4*H:WZLST9B^BLY4*EY4*CXRCQW6^#E#)2MV/*]BY>H^ME/2^#55M1Q%
M)*&)IQX*?*<5Q4)VNK\'>-W:Y<M33VDP!JR-T               !!>KOU*1
M(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DYYG[Z?._P!^$?R!926-
MC_\ 3L1\5_Q($,;;O)N&^-Q^JJ'F8 "Q!5X  /@N_P"XP^7XY,Z,G@UWWJF&
M/?7CW\JKB>]AX)^#7?>J88]]>/?RJN)[V%/]:_*6.^,U?I,O'J9Y*T?\5I?1
M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
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M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
M                        +6>9K&*][VL8Q%>][U1K6M:BN<Y[ET:UK6HK
ME<JZ-1%551$+ER[CP+\(.Y>K\H<G%PO8JI:?&^:,E5AVUK$_2HM6'HX$=B>^
M;GM<QT=--!9Z)S5VO=&[P3M;+!252-]#1.C)XS$T<-3\>K-175%<92?9%+>?
M8FN9Y>F]*TL%A:^*K?DZ,')I63D^$8QO[:4K)=YJD<^'SB=1GMFU7VZSU:OR
MYP!4U5BPG%&Z3H;O6Q*V"^8HGC5VP]]?6,GH[4NB+%9J:FE79EKJJ)/%Q5]/
MKTU]:HB:^Q"5K41$1$T1$T1---R</_V=$7L5%3CJ1+@:+T93P>'I8:DDJ=*"
MBDE9RE[:<G[IW;?:4=TQI6KCL35Q5=WG6FYSSNE'VE.'5&*M%=UP #T'\AYH
M'?J]6NO#Z=W%40=T[^;CQ37335-=3U1YIKFS[SRD<P&VV7QFWX PW)35F.;[
M$KHY&TLCE=!8;;-L.;[L7=K'L16K_>%"D]:YR2M@8_I:2Q]+"4:E>O)0A26]
M*_&ZX1MSDW9)<VTN9Z&B]&UL77I8>A!SJ5I*,;>+VN3Y12SD^4<SZ*YFGF<K
MGRA;LS%^+VU5JRALU:Z"LJ89'4U?B^XTST2:PV>5OEP4<;O(N]T9L/IM])2.
M6L>]]-T.\O<NK'A.R6O#6&K50V2PV6B@M]JM-NIV4U'04=.Q&1001,1&M:U$
M35=[GN5SWN>][E&767=CPE8;3AG#=LI+-8+%0T]LM5KH8VPTM%14L:100Q1I
MQT:FT][E=)+(KY97OE>][O[A&H54UKUJKZ4KN<VXT(M]#13\&*]U/@I5)9;S
MM^BK122N-J=J;A]$8=0@E/$S2>(Q%DI3EQW8<7&G#A&*>?C.\FV2HN_LU*A+
ML_K)C5S<5W)=B  !D               $%(@ \U><GYLK O*/P>^T7Z)MIQ5
M:XY)L(8UHXV^Z=BK=4<D%0BZ-N5EK=$@N=KJE<Q\3UJ:-]'<H:2NI^:QRHN3
M/BW)_'-[R^QM;UM]]LDK%56H_P 3N=OJ.D6@O-IFE:U:JUU\<3U@F8KT;-#4
M4TJI54]1%%US]GOP^(\D^=SYL"R\H[ 4D%-'24.8^'*:KJ<#W^5$B_OA[4EE
ML%SG:BO6RWB2*.*='(]*.H6*OB8KHGMDDC437:> J1PV(FY8.<LG)O\ F\I/
MQT_S?NXY)7<UG=.)]HVSZGI&D\5AH*..IQN]VR]412\22R]DMXDN+LH/*S7,
M=!_3XUP5=\-WBYX?Q!;:NSWRRUU1;;M:J^)8:RWU]*]8ZBFGC77>QZ+LO:KH
MY8U9-"^2&2.1W\P66C.,DG%III----._--<5]Y5*=-P<HR34HNS3333S33ZF
MGDT\TTT  <C@0<U%145$5%3147>BHN[14ZTW\-VO:= /P<SG$GYE9=R958HN
M'C.,\LJ*F@MTM3*KJN[X(:K:2U3N?(NU53V-W1VBKGVG/\7]SI:E$DFZ2;G^
MGU5R).51=LE<T\'9E6ATKG8=N:+=*-CW(RZX?KXWT5^M<[6JB2LJ;=-,^!DC
M7MBKX:*KC:V>EBD9JFN6KL=(X&I22731]DP\K9JI"+>[?W,XW@^]/DC<]1=9
MY:+TA2JMOH*CZ/$1ODZ4VEO6X;T)6G%]C7,ZTK5U34B?PV6^8=JQ9A^RXFL=
M2RML]_ME'=K951N:YL]%701U,#]6.<W:6.1$>C7.1KT<W:734_M]?C^8J7*+
MBVFK--IKFFLFGW%TH5%)*2=U)*2:S33X-/F3  P<P            07J[]2D
M2"]7?J4 AU>KYCER<\S]]/G?[\(_D"RG4;ZO5\QRY.>9^^GSO]^$?R!926-C
M_P#3L1\5_P 2!#&V[R;AOC<?JJAYF  L05>  #X+O^XP^7XY,Z,G@UWWJF&/
M?7CW\JKB>]AX)^#7?>J88]]>/?RJN)[V%/\ 6ORECOC-7Z3+QZF>2M'_ !6E
M]$  U\V8                              @I\@<NKD@6#//++$N7-_:V
M-EWI5EM-Q1NU-9;]2:RVF[T^Y=)*.J5NVFCFRT[YH)&OCE<QWV 2.0^V'Q$Z
M4X5:<G"I3DIPE'C&47=-><Z^+PM.O3G1JQ4Z=2+A.$E=2C)6DGWHX_.<&4]\
MP)BK$6"\344MOQ!A:\5UDNM+*Q[%;544KF]+#MHBS4M7#T5;15+$6&JHJBGJ
MX'R4\T<COS@W9?"8N;H]UK1!R@L*T*.N=@IZ2U9AQ4[/KM98&/;!:L0S-9']
M=DLLKHZ&NJ))6.9:98G2/=3T#>@TFN_?@6WU6T_#26#IXB-HRRA6BGE"LDE)
M=D9>-#]%]=RD^M^K=31>.JX:6\X+PZ$VGX=&3>Z[^V<<XSL\I+JL  ;&C5P?
M5G(GY7&(,C<R\-9DX>UFDLE6UEWM>TK8K[AZJ<V.\V:5VTUC'UE&C_$IW;24
M=PCI:QS)60.AD^4R*+HNOS)WU[.SJ/ABL-"M2G1J14H5(N%12S4H-6LER>;L
M^MI\CL83%5*%6G6I2<:E*<9TY1=G&:?C7YI632YNZX,[ 646;%CQUA>P8QPS
M6QW&PXCME)=[75Q*U4FI*R)LK$>C7.2.:)56&HB5=J*:.2)WE,<?I::_ :4?
M@RO.)+07.MY/F*JQWB=R2LOV7%742-Z.GN$>DM[PMM.\O2OB>^\VA-[&RTMU
MHU>DD]N@?NMM[H5#UGT#/1^,J8:5]Q/?HR?]91DWNN_6O%E^DFN1=K5+6*GI
M/!4L5&RFUNUH)_DZT4E)6>:4O&C^C)$X /"-F    !3<[=WXF&P3.<B&H]X3
M;SA+K-8J#(+"]?T5QQ+%!>,P)J=^DL&&XWJ^V8>5[=\7NW60MK;BC5:LEMH$
MH9.DIKG41+L>\LGE5X?R7RXQ/F-B14?18?H))J:A9(R.HO%UEUAMEGI%D7]T
M7"L=%!JC7K#&LL^S(V)6KRHLY\X<0Y@XMQ#CG%=9X]B3%-SJ+O=ZEJ*V-:F=
M41E/3-<^1T=#0P,AHJ"G621(**FIX=IRQ[1*>S#5EXK%>K*B]BPLEN1DKQJ5
MWXN7522WW^ENKKM#NUS6OU+A5@:4ETV,@W4:DKT\/%K>[I5?%CEXN^[\#\S7
MO]/7QZR []_F!8U%6;]?$ #OWZO;ZM5T1<C_ 'RXY9EW06^HJZBGHZ."2JJZ
MN>&EI*:%NW/45,\C8X((6<7232.;&QNBHYSD:NFITVN9TYN^DY/>4U%;*Z&-
MV.L5NI\08\KOLI$N4E.UE%8X)/LFT&'Z5WBD,6NR^MDN-<K6RUTIK0>#<\W$
MN-<8KGCBJBZ3"V!*UT&#:>HC7H[MC2-NCKJK5=L.IL,,D;-2_;D]V9H)OK4M
ML:LV^.U-WT$ [5-9^EJ1T=2E>%*TL3*+MOU/:TI+_A+.7)S?7%EDMCVJ/1TW
MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
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M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
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M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
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MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
MJ"9KHU@P_33JGNG-"]56*OOT[5N52Q=F2"&6DHW[3J9\DFSWX2KSBG[$,)TF
M1F%JU&XEQS1^Z.,)Z>5J26?!O3.C@H'JU=J&KQ/512Q,:J*K+515LCT8M52.
MDT5MR)HFY$W)V:)P33JW>=>'_6W3WLJU9Z.G+2->'AU4X8=-<*3NI5%S3G;=
MB[^*F^$RMFV36U5*L=%T9WA1:GB7'A*KDX4WR:IKPFK>.US@  3+ERX$%M@*
M#^LP)@6[XGO5HP[A^@GNE[OMPI;5:;?3M59JROK96PT\+-VY%>[621?(BB;)
M*]49&Y4Q*247)M**XR;244EX3E?DOF,P@Y248J\I-1C%*[E*7BJ-N;NEWGKA
MS(O-S2Y]YKTE5?**5^6^ JBBO>+I'1R)3W:JAEZ:T83;-Y+?^$ZB%9;K'$_I
MHK3'41(D4M7!41]*NEIVQ,9'&QD<<;&QLCC:UC&,8B-8QC6HC6L8U-EK41$1
M-$3<B'P+S:'(:M7)]RGP]@.D=#6WI(UNN+[TR%(G7K$U>B2W"=J:N>VAHM66
MRTP/55AMU'3I(KYW32R>@+5[\2J&N^LKTCC)2BWZGHN5/#KDXW\*I;KJM;V:
MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
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MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
M                    %)Y5*<G4 47\"FO!"H_@4UX(#E?+\=I23[)>_86T
MA<_PBW?P!Q+=_ L)$^ OW\"QDZ^_6 63DT5OI3X=3'2IQ+^3J]/SJ6,OS &,
MF[^PQ[^LR,R=_@,=)U@&,F^DQ<R=_@,M-Q[^8Q4W?V@&-DX^K3YSYQY6E)+4
M959H00,66:;+G'4,,2(BK)++A:ZLCCT7<NV]S6[*[EUT7<I]'2\?:?FF:UE6
MY87Q-;D255N&'KW0HD&G3ZUELJJ9.AU1R=+K+];16JFWLZIIJ=G!3W:U*754
M@_1)'5QT-ZA6C[JE->F+1RG:?[7'HJJG1LT5=^ODIOU]A6+*VO1::G<FB:P1
MNT3AHZ-J[N"Z)P3<7I==-/-=I0.2LVN<;)]?/[D  #B10M:UNU#,G;%(GM:J
M=_@U71%N2G,W5CT3K8Y/:BIZ.OBNY.)GD_-^/F,KBO/Z7:WRG5 R,NGCN"L(
M5>QT?C&&+!+L:JNSM6JET35415]:(O:B'ZW$I\G\AJ^)<LFLK+@U55M;@+"]
M2BJ_I55);12.1>D_AZHJ+M=:Z]6B)]81=12G'PW:]:/55FO^YE_,!54Z%&:X
M2I4Y+SP3,C%Q4R<2_-\!BX^/K3X>)DH3J';,M O?V&29Q3OU&,AX]^PR3%X>
MH R47S&1B7>GG,9"IDHNKT &0CW;B^C7AW\QCXT^!2_CZN_6 7S.!<Q?.6L?
M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
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M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
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MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
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ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
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M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
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M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
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MU7IJ&C<!%</4>&?IHP8 !XY[P
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MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
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MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
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M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
M @1(+])AL&O_ .$LW"*+DMWJ*1RM?5XRP/3TZ(USMN6.^1UCFJK45K$2GI9W
M[4BL:NQL(JR/C:[G8&^MX51C'Q/(K UFCD:V:]YKVMTL6WHLM!:L*8NJYWHQ
M'HLB1U[K6U=ICXV+(U7*R3H5-"DLMLIIVT5O>[Q%62[4E"/SQ:\Q4[;)5WM,
M;ON,-17G;G*WH:?G  )+(H!]2<AVBEJ,Y\J((6.DEDS"PDUC&_9.<MYI-$1/
MA[-#Y;/OCFL</K=.4CDA1;"O:_,;#M1(Q-K?#0U*UTZ^1Y:;,--(Y7(NRW35
MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
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M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
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MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
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M0<\/)9-Q<)-Q3_4E#+_<B #1B1
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MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
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M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
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M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
M         ""J1  /Q/E&9TVO+C F,<>WEVELPAAN[X@JF)(V)]2VV4,U3'10
M/<UZ>-5TS(Z.D:C'NDJ9X8VQO<K6N_:U=IW[]T-5KPH+EDQX=P#8,G+36HV\
M8]JH[SB*"";9E@PG9JEKH&5;8W*K8;O>HX(H63-:RI;;JQT3E\3EV?9U>T6\
M;C*&&BFU.I'?MRIQ:E4=^5H)_)UFOZTZ8A@,!B<3)I.G2ET?Z562<:<5VN;2
M-'O&V-;EB6]7C$=YE2HO&(+K<;Y=9TUV9;E=JR:X5KF-<YZLB6IGD6-NVY6,
M;&QJ(U#^9"=^KX.H%Q8P44HI64<EPX<EEU*R\S*-5)N4G*3O*7A2?6WQ=^+N
MT^( !R. [_#I\YO^^# 9'NP_D3=\6SQ[%1CS&%=6PN<Q4>ZVV2"&STRL>OV4
M$LT-3(Q$U1)'2]:Z)H#0TD\[XZ>D@EJJNHD9!2TL$:S35-5,YD5-3PQ,U>^:
M>5S8HV,3:D>Y&-17*B+UIN1/R?X\K,I,N\OF)'TN%<)V:V5[XEUCGN[:5DM[
MJF*B;VU5WEKJIO\ &H1+M<TBJ>!HX=/PL16WFN>[13^1RE'CU+SS/L4T8ZFD
M*^)E&ZPU#=C)\-ZL[*W:HJ:\[/J8 %>2T(            (+U=^I2)!>KOU*
M 0ZO5\QRY.>9^^GSO]^$?R!93J-]7J^8Y<G/,_?3YW^_"/Y LI+&Q_\ IV(^
M*_XD"&-MWDW#?&X_55#S, !8@J\  'P7?]QA\OQR9T9/!KOO5,,>^O'OY57$
M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
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MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
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M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
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MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
M>H>0#T4YLSG$\2<G#,.GQ3;(Y[IAFZ=!;\;88CEZ/W:L[955)Z/;7H&7NUK)
M)4VN2;8CE<LM#/-!!5/GA\ZP=3'8*EB:4Z%>"J4JD=V<7S79U-63BUFFDUFC
MN:.Q]7"UJ=>A.5.K3E>$H9-/J?)QE=J2>33=SKY9&9XX7S(PI9L:X,NU/></
M7ZDCK*"MIWI]B]/KE/41:[=-64LFU!5TDJ-EIYV/CD:BM/UU#F7\TUSM>)>3
M9B*2DJXZS$.65]J$?B/"\4C%J**I<C6>[^'EF>V*&Y1,:C:RB>Z.FND*-1SX
MJEC)CHUY!\H'"&9V%+3C3 ]\HK_AV\0=+25U'(C]E[7+'44E5%KTE)7T<[7T
MU;15#65%+41OBE8US2K.MNJ-;1=9JSGAIMNC6MQ3SW*G*-1<UE>UUU*X>I.N
M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
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MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
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MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
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M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
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M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
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MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
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M@!7!!%(@
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MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
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M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
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M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
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M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
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M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
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MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
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MJ
M4W.ZB#G$@ )'+U(15>I"373AQZP JZ;BDKM^A%SB1=V_K )5W:I\);N=J3.>
M4'.T )'N+5[R=[BS>X @]WPEF]Y.]Y9/?^@ DD<8Z5Y6E?W\Y8O=U %-[S&S
M2<2O+(8V5P!2D>8V=Y<2O]IC7OXKV@%.1W46+W]?#V[O/N15]B*O8FI5>[])
M_!YB8^M.%[%>,2WZL9066PV^JNETK'ZJVGHJ.)TTST1/*=)L-V(HT\J69\;&
M:.>UI]*=*4Y1C%;TIO=C%<;G&=11C*<K*$%O2E)VME?Y#PL\(!Y;*X$RWBRV
ML-:M/BK,A)*:X/IWHV>V8,@<B79Z*W5T<M[?L6:)^J.2BFN;F.CD\7>:/"(B
M;D31$X(G4FB;O0FFY$X>E3ZCY9G*HO6=&8^(\P+SK![JU;XK/;-I71V7#U*]
MT=GM+%UT6:"E5DM=,U&-J;A-65#(:>.1D$7RZ6RU.U?6CL#3I-+I9^R5GS<Y
M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
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M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
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MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
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M
M
M
M
M
M
M
M
M
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M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
M%QO[4[^HCOZU+;I/,.D\P!755[>_L&UY_@*'2>8EVE +G5O8-4ZD]I;;2DJK
MV@%RLFG8GH0D60M]I"57@%PK^PD5RE'I"19//[ "MM(2J_L+99"19/. 5UE\
MY25_J*"R%-7@%=9"FKU+=9/04'2>P N'/["@Z0H++WX%!TO?J *RO["@^0HN
ME[\"T=+W4 N'2H6KY"BYY0?( 5'R%L^4HOE+)\OJ *LDI:OD34I.D+.2?0 K
M22%B^0D>_KWH6SY._P"H B^3X"U=)Q7J(.=^H_&L\\^<)Y;89N.,,:7JFL5@
MMD>W/5U+M72R*GUFCHZ=FM16U]4_2*DH:2*>IJ)WM8R/1-WTI4I5)1ITXN4Y
M248I)MN3=DDEV\CY5Z\*4)5:LE"G"+E.4I*,8Q2NVV^"MS9_>8NQ?;+#:Z^]
M7RX4=HL]KI)JZY7.OG934='24[5?-/--(J-:UC>";W/?LQ,:Z1[6KHY\[)SP
MUTSAJ:O N JBLLV5]+421UE2Q9:6X8XDB=LMFKVILRTUA:J*^EM#W:U2N957
M%'JRGAB_#><YYUO$^?US6SV]E7AO+*WU"26O#3I&I5W>:%[W07?$KX))(YJE
M$<BTML9+)14#F)+]?JD94,\E>_M+!ZC[/HX7<Q6,BI8AVE"B[2C0ZG)\)5.:
MY1[9+*LFT/:;+&.>"P,G#"YQJ5HWOB.N,><::X.^<^R+\*"<.SAN]'#AYM"(
M!+)#%_DX   P   #T-YN#F^,0<H+&K;+2+56S"5G=3U.,L2Q0[;;;0R/79H*
M&62.2F?>[BC)(Z"&1LC88V25D\,D4#F2_C_(UY'F+L[\;V_!6$J=6NE<RHO=
M[GCD6UX;M#5=XQ<[E+&UVB[+7Q4%(Q'3W"M6*F@C=K(^/HL<DSDJ83R;P5;,
M$8/HT@H:':GK*U[&)77FZ2LC95W>Y3)Y<U74JQJ(KW/6"G9#2PJD$+$2/->]
M<XZ.I]!1DGBZJ\%<Z4'QF_TO<+GQ?"Q*.SG4*6E*W3XB+C@:3\)O^OFN%.'5
M%?ULO,LY7C^H92938?P-ARSX2PK;(+/8+#0PV^V6^G1=(8(6HFU-([62HJIW
M;4U753.=/55#WU$TCWO<J_IS&:DK(M-$1/1YD^;A\!D(XD0K)4J2G*4YMN4G
MO-MW;;YM\WVEM*5&%.$802C&*44DK))9))*R27<5(V<-V\O(HR6-GF+^.,XG
M,J11\._?0OV-)(V::%Y&SOV@$\;-?09"-G?L*<3._P Q>QL )F-["^8WAVDC
M&]9=,: 3L;U%TQOL)6-ZBX1 "=B:EPFY/.I*Q$]A43?O]@!,B:%1=R:=8:G6
MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
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MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
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M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
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MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
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M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
M           07Z/C(D%^CXP#RKY[3[UG.3WK2?ZU2G,%7BIT^N>T^]9SD]ZT
MG^M4IS!5XJ6'V0?T'$_&?\.)6+;AY0PGQ7_%F0 !+2^_YB%'P_:^B;N/@FG[
MS<YO?7ACY#JS;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I
M?6U  #43>@        #Q%\(L^]#S-_G++;_O2P6<VI>KOUJ=)7PBS[T/,W^<
MLMO^]+!9S:EZN_6I8K9%Y/K_ !N7U5(JUMK\IT?BL/IS(  E=\60X J:HJ+O
M145%3_*\GX-=5T5%5$5$U7R5 XV7'-7XYY>@<^[AE=I=5^)NN\P3SS#KY%:\
MB<U[NY]\@C919=XJN,CG2WJEA8O186O%6K5:^Z44#-+3<*B1)+E21I2U$DE?
M$V6JV[XUW>?KX<?5K\:^DXW-/4RPR1SP2RP3P2QSP3P2/AG@FA>V2&>":-S)
M89X96LDAEC>R2.1K9&.:]C5.@!S%O/&1YQ6FERMS'N4+<U+)0N2V7*=R0NQY
M9Z")NW6-1R-C?B&AA17W2GA59:RGB?=&QZ)5JV!-HNHSI.>/PD+4F][$T8K\
ME)_UD$L^C?&2MX,G?Q6]VR.RW: JL:>C<;4O62W<+6E+.M"/BTZC?];%.T'?
MPDK/-+>V2@46OX)WTX=]?I*Q#9.X  !#K]GSGQQSAGW#,V?>#B7Y-G/L?K]G
MSGQQSAGW#,V?>#B7Y-G.[HW^D8?X:E].)T=)_P!&Q'P%7ZN1R<:?[7'_ )#?
MZJ%8HT_VN/\ R&_U4*Q=)<$4%!N(^"6_NW/+^)P%_7Q0:=QN(^"6_NW/+^)P
M%_7Q0:-M(\D8GOI?61)!V7>6\'_S?JIFYVG%._4A4*:<4[]2%0JPOO\ G+C@
M &0   4N''X/6:M7A'7.9S8%PRW(_!=TDI<6XTMZ3XOKZ&5\578L'5#UB6@C
MGC5KJ>LQ0L<U&]S?KD=G;7;*PR5$$S=C?/G..SY>8-Q-CB_2-BM&%[+<;U6N
M<](]N.A@?,V!KU1R-DJ9$93Q*K51LDC55%3<<GKE%9\7_-#'6*LPL3U"U%ZQ
M9>*N[56NJ,I897)'06VG;M.2.CM5NCI;;1PHNL5-2Q-<Z21'2ODO9GJTL9BW
MB:L;T<+NR2:O&=5N\(M/BE9RDNR*=TV1'M:ULE@<''"4)..(QB<')>-2HQ_*
M-/DYI[D7E:\GQ2O^+(B)N1-$1$1$1-$1$1-$V4W-T14].]&JNRJD0"RM_F5^
M?#A;S9%4Y/B^]I+YK?BV?$!51-ZZ(B;U5>"(G%5\R=9!RHB*J[D1%557AHG%
M?0G6;>W,?\Q92WVGLN=&=-M=-:Y6Q7/!& JR)J4]QAD;#-;L38D8YZOEI'(J
MSVJR/8D50BTU?6N?!LT+_"U@U@P^CL.ZV(?93IKQZLK748]7:WE%9OD;!JUJ
MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
MV88BI9$END2.<V1,,V/I(:ZZ;V*Q+C+XI9V.^U55;+%+3&X'R6_!_P#DXY<P
MP37/",69-Z8UJ2W/,"."]T;Y$T57PX=DC;8(VN5$722@J7,77HWM1SD/:R@H
MHJ>*.G@CC@@@C9%!!"QL<444;49''%&Q$9'&QB(UC&(C6M31$1-"^*YZ?U_Q
M^.E)*IZFHWRI4'N9<M^:M*3MQS4>J/,M)JWLST;H^,7*E'%8A+PJV(2J6?53
M@[PA%<LG+KER/YO#>%+99Z2GH+1;:"UT%)$D-+16VCIJ*DIH6Z[,5/34T<4,
M,;=5T9&QK4U71$U/Z+OH3 TB3;;<G>_&^?SW?RDA1@HJT4HKDDK)>;@2IZ-"
MA/ V1-E[&O;V/:UR>Q=2Y!A*W#+N,M)JSS7:><7*-YIOD]9HMJY,49789BNM
M6C^DQ'AZWPX;Q$LK]5Z>2ZV6.CFKI6ZKL^Z/CL;5551BNT-8KER># XKL$%;
M?\CK\N,:*)))UP3B&:DM^(DC;M/6.S7I[Z:UW.1K=EL=)<EMDDB(]4KI971T
M[MY(D<FO=/G1?1U=9M.A]<=(X%KHL3.=.ZO1K2=6DUU;LLXKWCB^TU'3FHNC
M,>GTN&A"I;*O02I54^3<HJTNU34EV7L<Q[FM.;@O^;&?U!@#%N'KI:+/@N1V
M(,S*"\T%1;ZFAM5MJ6PPV6KIJN.-Z55^NG0VZ*E>U'RT27.L9%)3V^I1O34H
M*&&D@AIJ:&."GIH8Z>"&)J,CA@B:D<44;6IHUD;&HUK4T1&HB)P,?2X;H(:V
MJN4-%217"LBIX*RNCIXF5=7#1]+XK%4U+6MFGCIEGF\79(YR1))(C%3I':Y]
MO!#.M>M=72M6G4G&-.%*&["G%N45)YU)-Y7E-]BLDER/GJ5J;1T-1J4X2=6I
M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
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MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
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M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
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MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
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M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
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M+T*P  ,@
M
M
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M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
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M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
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MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
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MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
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M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
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M
M
M
M
M
M
M
M
M
M
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MJ(3
M
M
M
M
M
M
M
M
M
M                                    @J$0 4U9V$NRI6 !;D%34N%0
MIJP H[!#14\Z=^_65- #-REN] 5O9P*FGF)58@!35"FK$]!<:*0VNI4 4;E%
M&KV^TEW]B*5M$_7^@(WL4!JQ0T3T$%:G:GK*^RO82JGF!@H+%YB7H_25]CTA
M$7M]H!;]&2JQ2[W]:(O?SD%5$ZOB +/1>P@J>8NET\Y#< 6NB=A!6H7>SZ._
MJ'1^@ L]A!L(7O1>COZB'1^9/@ +/80;"%YT?F^(;'F +/80;"%WL>8CT?F^
M( L]A!L(7G1^9"/1>@ LT8A'1.PN^C]!#91.P MD3S$=E>PN-$[>_P !'=YP
M"WV%)TC*V[L4GU7L +;H_23)%YBOHOH]!#8[5 *>SIV(3:-)T;YB?3S?  4]
M/,A'1>W3T%78[=Q+HG: 4]CSZDZ)V$Z.1."$V]?,#-OQ<D1JD=W?]1-L=I,B
M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
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MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
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M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
M    #5[\*D^XQ@?\8$/R/7&T(:O?A4GW&,#_ (P(?D>N-IU)\K8#XQ#[33=H
M7D72/Q:?V&AF=$+P9G[V&E]_F,O[>B.=Z=$+P9G[V&E]_F,O[>B)GVM>2Z7Q
MNC]36(&V+>6)_$:_UV'-@U."$2"<$(E;RU8                      ((H
M!$$NN_S$5\P!$             @J^8 B"&I$       &K3X5?&BY0Y>JO5F"
MNFY%5-;%7HJHJ\-W5HJ.151=#:6-6KPJ_P"Y#E]^,!?D2N-JU(2>EL GP]41
M^9FF;0VUH32-FT_4T[-<N!HB'1,\&C^]<M7OVQM\J1G.S.B9X-']ZY:O?MC;
MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
M                     /YW$^)J.SVVX7:X2I!0VRCJKA63.5K6Q4U'"^HG
M>JO5K4V8XW+O<B:Z)JFI_1'A)X1!RJ/[F_)UOEHHJE8+_F;7T^!+6D:Z31V^
MLBGKL3U::*U\<<5@HJNA94L7^]Z^YV]=ZO:B^AHG1TL7BL/AH\:U6$.Y-J\N
MZ*O)]B9Y>FM)1P>$Q&*GXM"E.IRS<8MJ*OSE*T8];:1H*<KK/NJS2S0Q[F'5
MJJR8MQ-<;I"BN>Y([=MI2VBG9TFKTCI;534=-$QR_68HF1)N1I\Z]_F]/7IN
M5%\_4I$3J3S)YDW?0FOHU(([7AZ_-P7?_@KIOT=H[S;E+DT,-&E3A2IQM&G"
M,(1ZE"T8I>9?*42Q.)G6JU*LWO5*LYU)M<Y3E*4I>F7V'05\&9Y3RXNR)FP)
M75#IKIEA>ZNU4Z2.:Z5V'+S++>;2B:NZ1[**:HK[<Q>C;'#3T])3LU6-438X
MU3L]?H.<-X/'RIFY=<HBS6&OJ?%['FC2/P75K(_9@;?'=)6X4DE7_#J+HR2R
M4B(U5=67N#54:CG-Z/#4T\^_?ZRKNT;1#PNDZVZMVGB;8BF^5YOV1?MJ3MU-
M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
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M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
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M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
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MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
M-<QCR6O[J7*.P3'50=-8\"SMS O6VQ5A=)ARHAJ+%2O79=&JSX@=;IUBE3HZ
MFCHJN+1-51=K[PDSDM.QYR?Y,64-.DEZRJO4.*XWHUO2R8=JH'6K$]+TB_:X
M8Z:>CO<NB.622PP0HGEZI(.L&M/J;3.C\)O6@XS59)Y*6)M"AO+]'=4NZ9&>
MKFISQ.@=*8W=<JD73>'?-QPMYXA1]^I.+XYP]'/BPGBFNL=VM-\M<SZ>Z6.Z
M6Z\VRHC79?!<;5605]%.QR;VOAJ:>*1CFJBM5NO4=:_DJYZT.9V7."L?V]S'
M4V*\.VR\*V-%1D514TL:U<#6JKG-2"KZ:)&O7;:C/*T7<<C)?IW+U=6GP=>_
M?O-Z;P6GE4^[^7.,<IJ^9RW#+Z[P7RRH]Z?7L,XM?5R200M<]99%M-]H:_QE
M4:V"GI[O:88UU5[6^;M9T3TV"I8J*\+#32D_^'6:@W^K4W/-)OD>ML9TRZ..
MJ8.;M'&0O!<E5H1<[=7A0WTNV,5Q9M4@@G B5W+1     E50"8'\MC/&EIP[
M:JZ]WVY45HM%LIY*NX7*X5$=+1T=-$W:DFGJ)7-9&QJ=;G;U5&IJY41=/KEX
M^% R1UEPP]D#8H:BE@?+3?W0<4TSU@K7,5K756'L/-DCF=2*FVE-57EU/-.]
M6O6V0QHQU1[F@]7,9I&;AA:+FH^/4?@TH=\WE?\ 15Y/DC7=8=:L#HNFIXNM
M&%_$IQ\*K-_H4UF^]VBN;-RMZKNTU]7?OPXJ2)QW:^S3O]&J]ARE<W><LY0.
M.JB2?$N<./Y6R:M=0VG$5;AJU;*KJD;K7AJ2U4$S6:)L+403R(G&357*[YVH
M<_,>TLS*BEQYC>FJ(UVHYZ?%^(H)XG;*MU9+%<VR,=LJY-6.1=E5;KIJA(]'
M8[B'&\\91C*V:C3J32\]X_,B+*VW/"J5H8&M*-\FZM.,G^K9V?6KY/F=?E#Y
MLY9/W),SO>%BWY"KCG(\G;GI>4GEO4P/H<S+WBBVQ.:Z6S8[J),74U2U%T5J
MW"ZOEOT*HW:1GB]U;"Q%1TD3W-C1-E_)7G_, 9VY:8\P3C&B3+[,:NP#BF"@
MIJBI;-A?$]8MBK46FL5TD<V2FN$CD58K1=&1S3MT2WU5<])HX?#QVSG2&"J4
MJEH8BDJM.\Z+;E%;ZNYTWX226;:WDEFVL[;!H_:CHW'T:]%N>&KNA5W:=9+=
MF]R64*J\!OJ3W6WDD\KZ)-)]JB_BV?U4-D7P6C[Y;$?XD<8?EUE::W5(FD42
M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
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MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
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MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
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ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
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MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
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M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
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M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>oncyf-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.oncolyticsbiotech.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncorporationandNatureofOperations" roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations">
        <link:definition>2101101 - Disclosure - Incorporation and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofFinancialStatementPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation">
        <link:definition>2102102 - Disclosure - Basis of Financial Statement Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
        <link:definition>2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesandAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions">
        <link:definition>2108104 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalents" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents">
        <link:definition>2109105 - Disclosure - Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails">
        <link:definition>2410403 - Disclosure - Cash Equivalents - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment">
        <link:definition>2111106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables">
        <link:definition>2312302 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails">
        <link:definition>2413404 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>2114107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>2315303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>2416405 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails">
        <link:definition>2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivative" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative">
        <link:definition>2119108 - Disclosure - Warrant Derivative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeTables" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables">
        <link:definition>2320304 - Disclosure - Warrant Derivative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails">
        <link:definition>2421408 - Disclosure - Warrant Derivative - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
        <link:definition>2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
        <link:definition>2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>2124109 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>2325305 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalShareConsolidationNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails">
        <link:definition>2426411 - Disclosure - Share Capital - Share Consolidation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails">
        <link:definition>2427412 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails">
        <link:definition>2428413 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryofOutstandingWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails">
        <link:definition>2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalEquityWarrantsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails">
        <link:definition>2430415 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments">
        <link:definition>2131110 - Disclosure - Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables">
        <link:definition>2332306 - Disclosure - Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails">
        <link:definition>2433416 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails">
        <link:definition>2434417 - Disclosure - Share Based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
        <link:definition>2435418 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails">
        <link:definition>2436419 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails">
        <link:definition>2437420 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>2138111 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>2439421 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityandReceivable" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable">
        <link:definition>2140112 - Disclosure - Contract Liability and Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityandReceivableTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables">
        <link:definition>2341307 - Disclosure - Contract Liability and Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityandReceivableNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails">
        <link:definition>2442422 - Disclosure - Contract Liability and Receivable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails">
        <link:definition>2443423 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.oncolyticsbiotech.com/role/Commitments">
        <link:definition>2144113 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails">
        <link:definition>2445424 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.oncolyticsbiotech.com/role/Contingencies">
        <link:definition>2146114 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails">
        <link:definition>2447425 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>2148115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>2349308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2450426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNoncapitalLossesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails">
        <link:definition>2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails">
        <link:definition>2452428 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>2453429 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>2154116 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>2355309 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>2456430 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>2157117 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>2358310 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2459431 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
        <link:definition>2460432 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>2161118 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>2362311 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>2463433 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>2464434 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationofOfficersandDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors">
        <link:definition>2165119 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>2166120 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>2467435 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesandAdjustments" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments">
        <link:definition>2168121 - Disclosure - Other Expenses and Adjustments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesandAdjustmentsTables" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables">
        <link:definition>2369312 - Disclosure - Other Expenses and Adjustments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherExpensesandAdjustmentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails">
        <link:definition>2470436 - Disclosure - Other Expenses and Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>2171122 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>2372313 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2473437 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents">
        <link:definition>2174123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails">
        <link:definition>2475438 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComparativeFigures" roleURI="http://www.oncolyticsbiotech.com/role/ComparativeFigures">
        <link:definition>2176124 - Disclosure - Comparative Figures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="oncyf_TwentyThirtyTwoMember" abstract="true" name="TwentyThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementCanadianMember" abstract="true" name="SharesUnderAtthemarketAgreementCanadianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AnnualContingentPaymentGrossSalesPercent" abstract="false" name="AnnualContingentPaymentGrossSalesPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_ForeignExchangeImpactRightofUseAssets" abstract="false" name="ForeignExchangeImpactRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesUnderSharePurchaseAgreementMember" abstract="true" name="SharesUnderSharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementTerm" abstract="false" name="SharePurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" abstract="false" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" abstract="false" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementMember" abstract="true" name="SharesUnderAtthemarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentTerm" abstract="false" name="PurchaseObligationCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsLineItems" abstract="true" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommonSharePurchaseWarrantPerUnit" abstract="false" name="CommonSharePurchaseWarrantPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_SharesUnderIncentiveAwardPlanMember" abstract="true" name="SharesUnderIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_IssuedCapitalExcludingCommitmentSharesMember" abstract="true" name="IssuedCapitalExcludingCommitmentSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_InvestmentTaxCreditsMember" abstract="true" name="InvestmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ProceedsfromWarrantExercises1" abstract="false" name="ProceedsfromWarrantExercises1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TwentyTwentyNineMember" abstract="true" name="TwentyTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ConcentrationRiskNumber" abstract="false" name="ConcentrationRiskNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_CommitmentsAndContingencies1" abstract="false" name="CommitmentsAndContingencies1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" abstract="false" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" abstract="true" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" abstract="false" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_WarrantIssuedUnderlyingSharePrice" abstract="false" name="WarrantIssuedUnderlyingSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_AdjustmentsforLeaseAmortization" abstract="false" name="AdjustmentsforLeaseAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingMember" abstract="true" name="SharesPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureofincometaxAbstract" abstract="true" name="DisclosureofincometaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" abstract="false" name="ClassofWarrantorRightExercisePriceofWarrantsorRights2" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" abstract="true" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" abstract="false" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_AnnualContingentPayment" abstract="false" name="AnnualContingentPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ComparativeFiguresAbstract" abstract="true" name="ComparativeFiguresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyTwentyFourMember" abstract="true" name="TwentyTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantsAndRightsOutstanding1" abstract="false" name="WarrantsAndRightsOutstanding1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_StockholdersEquityNoteStockSplitConversionRatio" abstract="false" name="StockholdersEquityNoteStockSplitConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" abstract="false" name="CashEquivalentsAndShortTermInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_Statement1LineItems" abstract="true" name="Statement1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingEquityWarrantsMember" abstract="true" name="SharesPublicOfferingEquityWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Axis" abstract="true" name="ConcentrationRiskType1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" abstract="false" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_SYNSORBMember" abstract="true" name="SYNSORBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" abstract="false" name="AdjustmentsforDecreaseIncreaseinContractReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Currency1Table" abstract="true" name="Currency1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyTwentyThreeMember" abstract="true" name="TwentyTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderStockOptionPlanMember" abstract="true" name="SharesUnderStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DividendYieldPercent" abstract="false" name="DividendYieldPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CashEquivalentsInterestRate" abstract="false" name="CashEquivalentsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_ConcentrationRisk1Table" abstract="true" name="ConcentrationRisk1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommitmentsAbstract" abstract="true" name="CommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyMember" abstract="true" name="TwentyThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" abstract="false" name="ContingentRoyaltyPaymentPercentOfSalesRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" abstract="true" name="CashEquivalentsAndShortTermInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" abstract="true" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightWarrantsExercised" abstract="false" name="ClassofWarrantorRightWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_GainsLossesfromForeignExchangeImpact" abstract="false" name="GainsLossesfromForeignExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_ChangeInFairValueWarrantDerivativeRollForward" abstract="true" name="ChangeInFairValueWarrantDerivativeRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyThirtySixMember" abstract="true" name="TwentyThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_BalanceHeldInForeignCurrencyNet" abstract="false" name="BalanceHeldInForeignCurrencyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfTaxPools" abstract="false" name="TaxEffectOfTaxPools" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" abstract="true" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofWarrantsExercised" abstract="false" name="ClassofWarrantorRightNumberofWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_TwentyTwentySevenMember" abstract="true" name="TwentyTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_WarrantsandRightsOutstanding" abstract="false" name="WarrantsandRightsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ExpectedForfeitureShareOptionsGranted" abstract="false" name="ExpectedForfeitureShareOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_ShareIssueCostsMember" abstract="true" name="ShareIssueCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_NumberOfRenewals" abstract="false" name="NumberOfRenewals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_TwentyThirtyNineMember" abstract="true" name="TwentyThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ShareIssueRelatedCostCommissions" abstract="false" name="ShareIssueRelatedCostCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesIssuedWarrantPricePerShare" abstract="false" name="SharesIssuedWarrantPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingWarrantDerivativesMember" abstract="true" name="SharesPublicOfferingWarrantDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CommonSharesPerUnit" abstract="false" name="CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseinPrepaidExpense1" abstract="false" name="IncreaseDecreaseinPrepaidExpense1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesUnderCommonStockPurchaseAgreementMember" abstract="true" name="SharesUnderCommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1LineItems" abstract="true" name="ConcentrationRiskType1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" abstract="true" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OperatingExpensesMember" abstract="true" name="OperatingExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" abstract="false" name="AdjustmentsforIncreaseDecreaseinContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_GrossProceedsFromIssueOfOrdinaryShares" abstract="false" name="GrossProceedsFromIssueOfOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTable" abstract="true" name="OtherExpensesAndAdjustmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_EquityAuthorized" abstract="false" name="EquityAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OverheadRepayment" abstract="false" name="OverheadRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstandingRollForward" abstract="true" name="NumberOfWarrantsOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_TwentyFortyMember" abstract="true" name="TwentyFortyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyTwentyOneMember" abstract="true" name="TwentyTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_PurchaseObligation1" abstract="false" name="PurchaseObligation1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfSharebasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" abstract="false" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_TwentyTwentyTwoMember" abstract="true" name="TwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureofrelatedpartyAbstract" abstract="true" name="DisclosureofrelatedpartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" abstract="false" name="ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesIssuedPricePerShare1" abstract="false" name="SharesIssuedPricePerShare1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_RestrictedShareUnitsMember" abstract="true" name="RestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_CommitmentSharesMember" abstract="true" name="CommitmentSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TwentyThirtyOneMember" abstract="true" name="TwentyThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" abstract="true" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementConsecutiveTradingDays" abstract="false" name="SharePurchaseAgreementConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" abstract="false" name="CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_PerformanceShareUnitsMember" abstract="true" name="PerformanceShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ContingentRoyaltyPaymentAnnualMaximum" abstract="false" name="ContingentRoyaltyPaymentAnnualMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1Table" abstract="true" name="Statement1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" abstract="false" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_Currency1LineItems" abstract="true" name="Currency1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceAbstract" abstract="true" name="DisclosureOfEconomicDependenceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyThirtyFourMember" abstract="true" name="TwentyThirtyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_UnusedNetOperatingLossCarryForwardsMember" abstract="true" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" abstract="false" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_SupplierConcentrationRisk1Member" abstract="true" name="SupplierConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtySevenMember" abstract="true" name="TwentyThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TaxEffectOfStockBasedCompensation" abstract="false" name="TaxEffectOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_FundedandRoyaltyRepayment" abstract="false" name="FundedandRoyaltyRepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" abstract="true" name="WarrantDerivativeAndSharesUnderWarrantAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightOutstanding1" abstract="false" name="ClassOfWarrantOrRightOutstanding1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_SharesUnderWarrantAgreementMember" abstract="true" name="SharesUnderWarrantAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TwentyTwentyFiveMember" abstract="true" name="TwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ContingenciesAbstract" abstract="true" name="ContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyThirtyEightMember" abstract="true" name="TwentyThirtyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyThirtyThreeMember" abstract="true" name="TwentyThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_FairValueofWarrantIssuedPerWarrant" abstract="false" name="FairValueofWarrantIssuedPerWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="oncyf_DisclosureofeventsafterreportingperiodAbstract" abstract="true" name="DisclosureofeventsafterreportingperiodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_TwentyTwentyEightMember" abstract="true" name="TwentyTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Domain" abstract="true" name="ConcentrationRiskType1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" abstract="true" name="SharesUnderAtthemarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_UnusedCapitalLossCarryForwardNetMember" abstract="true" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementAmount" abstract="false" name="SharePurchaseAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ContractLiabilityRecognitionPeriod" abstract="false" name="ContractLiabilityRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_TwentyTwentySixMember" abstract="true" name="TwentyTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" abstract="false" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="oncyf_TwentyThirtyFiveMember" abstract="true" name="TwentyThirtyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" abstract="false" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_NumberofSharesOutstandingPercent" abstract="false" name="NumberofSharesOutstandingPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="oncyf_ProceedsfromInterestReceived" abstract="false" name="ProceedsfromInterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>oncyf-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_1876163e-38cd-4e37-a7d7-28a3abaf2054" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_89cb6065-dd85-4c61-b31b-0b86df116723" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1876163e-38cd-4e37-a7d7-28a3abaf2054" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_89cb6065-dd85-4c61-b31b-0b86df116723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_0dbd4322-6b2f-4d87-8527-26b76e5719f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_1876163e-38cd-4e37-a7d7-28a3abaf2054" xlink:to="loc_ifrs-full_RightofuseAssets_0dbd4322-6b2f-4d87-8527-26b76e5719f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_326317f3-e8a2-4c8a-b0b6-e7814eb36e3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_088fa96d-d2cf-462d-822a-a89d0001ffe2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_326317f3-e8a2-4c8a-b0b6-e7814eb36e3d" xlink:to="loc_ifrs-full_CurrentLiabilities_088fa96d-d2cf-462d-822a-a89d0001ffe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_379d4de7-bb2e-4de6-8295-23ccaaaf936a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_326317f3-e8a2-4c8a-b0b6-e7814eb36e3d" xlink:to="loc_ifrs-full_NoncurrentLiabilities_379d4de7-bb2e-4de6-8295-23ccaaaf936a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_a0198760-6fe1-44e3-968a-5f49d290805e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_16862466-7e21-48ab-86db-925f5908a177" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_a0198760-6fe1-44e3-968a-5f49d290805e" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_16862466-7e21-48ab-86db-925f5908a177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_e7baf236-a4a0-4eaa-882c-6d69a609919a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_a0198760-6fe1-44e3-968a-5f49d290805e" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_e7baf236-a4a0-4eaa-882c-6d69a609919a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_3d7a62ca-a603-4e4d-b2a3-1b709be0d826" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:to="loc_ifrs-full_IssuedCapital_3d7a62ca-a603-4e4d-b2a3-1b709be0d826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_aba4e9bd-4f69-46a3-9614-05f29139bf27" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_aba4e9bd-4f69-46a3-9614-05f29139bf27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_a5a41a8f-9fc8-48aa-bdc5-ddce322d61ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_a5a41a8f-9fc8-48aa-bdc5-ddce322d61ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_63dd91b0-be84-4634-b355-fc9c3ed8103e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_63dd91b0-be84-4634-b355-fc9c3ed8103e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_1d069ad6-56e4-49ba-a076-c1ce795b7d7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_2139a98f-ffcf-486f-b417-07cb0d1288d7" xlink:to="loc_ifrs-full_RetainedEarnings_1d069ad6-56e4-49ba-a076-c1ce795b7d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_351f1a37-1808-4106-9c37-2733c1b42fd5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5119f45c-4273-44e6-8f9e-fa2c1a2c6bd8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_351f1a37-1808-4106-9c37-2733c1b42fd5" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5119f45c-4273-44e6-8f9e-fa2c1a2c6bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_bb6d8eb1-aeed-4c8a-ab93-78adc11785be" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_351f1a37-1808-4106-9c37-2733c1b42fd5" xlink:to="loc_ifrs-full_OtherCurrentReceivables_bb6d8eb1-aeed-4c8a-ab93-78adc11785be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_7c3bb179-b591-4f94-9911-5f68f0e9ddd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_351f1a37-1808-4106-9c37-2733c1b42fd5" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_7c3bb179-b591-4f94-9911-5f68f0e9ddd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_4ec63e51-5b5b-49df-a890-4395f91e6c11" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_85da079a-edde-400a-8f53-b87f752d4d2d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_4ec63e51-5b5b-49df-a890-4395f91e6c11" xlink:to="loc_ifrs-full_Equity_85da079a-edde-400a-8f53-b87f752d4d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4e89575c-82c1-4d45-a6fd-4bf088c658ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_4ec63e51-5b5b-49df-a890-4395f91e6c11" xlink:to="loc_ifrs-full_Liabilities_4e89575c-82c1-4d45-a6fd-4bf088c658ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_fd63d2e7-a614-4de4-8512-258a2ca2bd9f" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_4ec63e51-5b5b-49df-a890-4395f91e6c11" xlink:to="loc_oncyf_CommitmentsAndContingencies1_fd63d2e7-a614-4de4-8512-258a2ca2bd9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_595eccab-4c7d-4934-8147-75abccd91f62" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_f293cce8-f772-4c83-a196-9e50be179e29" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_595eccab-4c7d-4934-8147-75abccd91f62" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_f293cce8-f772-4c83-a196-9e50be179e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_fbc8b272-f1f2-4a76-8765-71f4db806b29" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_595eccab-4c7d-4934-8147-75abccd91f62" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_fbc8b272-f1f2-4a76-8765-71f4db806b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_366b963b-26dc-4b8a-b688-7a29fd143a89" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_595eccab-4c7d-4934-8147-75abccd91f62" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_366b963b-26dc-4b8a-b688-7a29fd143a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_438c66d2-1544-477f-abd3-df6572975850" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_595eccab-4c7d-4934-8147-75abccd91f62" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_438c66d2-1544-477f-abd3-df6572975850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_d0a183c2-3506-47d6-9fea-14c60b0c0ca0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_63f9dc42-624b-487d-a400-77ac10a6f0d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d0a183c2-3506-47d6-9fea-14c60b0c0ca0" xlink:to="loc_ifrs-full_CurrentAssets_63f9dc42-624b-487d-a400-77ac10a6f0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_c3373cbd-28e0-4bbe-ae31-ba139769fcd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_d0a183c2-3506-47d6-9fea-14c60b0c0ca0" xlink:to="loc_ifrs-full_NoncurrentAssets_c3373cbd-28e0-4bbe-ae31-ba139769fcd9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_f2ea240f-25ce-4d4f-8d66-b14e860a5714" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d8dfe47d-7192-4d2e-b465-ea55c2017225" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f2ea240f-25ce-4d4f-8d66-b14e860a5714" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d8dfe47d-7192-4d2e-b465-ea55c2017225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_03b4156d-6b3e-4d8e-98fb-422390d8f4fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f2ea240f-25ce-4d4f-8d66-b14e860a5714" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_03b4156d-6b3e-4d8e-98fb-422390d8f4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_6ab062b3-f508-4fc5-872b-697fdd41173e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f2ea240f-25ce-4d4f-8d66-b14e860a5714" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_6ab062b3-f508-4fc5-872b-697fdd41173e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_87d80f45-2f5d-4b28-b1bd-96a066c98cf6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f2ea240f-25ce-4d4f-8d66-b14e860a5714" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_87d80f45-2f5d-4b28-b1bd-96a066c98cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3c234c0a-9464-472f-ac00-f7deadfe4402" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_27242ccc-8af4-4395-bf4d-0b4c1dcdcc20" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3c234c0a-9464-472f-ac00-f7deadfe4402" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_27242ccc-8af4-4395-bf4d-0b4c1dcdcc20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_63481be4-721a-4b75-a305-4cf80dfc6881" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3c234c0a-9464-472f-ac00-f7deadfe4402" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_63481be4-721a-4b75-a305-4cf80dfc6881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_fd12e4fe-4461-42cf-bbeb-ce26cb9fa22a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a056757e-ff9b-410b-8c51-34fc14722057" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_fd12e4fe-4461-42cf-bbeb-ce26cb9fa22a" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a056757e-ff9b-410b-8c51-34fc14722057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_b3e25e2e-b8b1-47d4-aca7-10c95006e410" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_fd12e4fe-4461-42cf-bbeb-ce26cb9fa22a" xlink:to="loc_ifrs-full_OperatingExpense_b3e25e2e-b8b1-47d4-aca7-10c95006e410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_31b00022-71a7-4629-ab8c-95e90a16c663" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_ef39f2bc-fb8f-4026-be49-4455d90b2664" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_31b00022-71a7-4629-ab8c-95e90a16c663" xlink:to="loc_ifrs-full_ProfitLoss_ef39f2bc-fb8f-4026-be49-4455d90b2664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ab4bb6ad-b1bb-4d49-8531-5f48ac294fc7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_31b00022-71a7-4629-ab8c-95e90a16c663" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ab4bb6ad-b1bb-4d49-8531-5f48ac294fc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5655b3fb-a5ed-46bc-9e26-1661bf3c8911" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_535f8356-647c-47a0-969f-fbe78cbbabee" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5655b3fb-a5ed-46bc-9e26-1661bf3c8911" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_535f8356-647c-47a0-969f-fbe78cbbabee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_501eb2e5-4b15-4710-9d4d-73e123c10c33" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5655b3fb-a5ed-46bc-9e26-1661bf3c8911" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_501eb2e5-4b15-4710-9d4d-73e123c10c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_e93f3712-1b53-4e30-8bc8-227f54cbb17c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5655b3fb-a5ed-46bc-9e26-1661bf3c8911" xlink:to="loc_ifrs-full_CashOutflowForLeases_e93f3712-1b53-4e30-8bc8-227f54cbb17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_e913ecce-eb03-4d6a-a9ff-4c66189efd3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_ProfitLoss_e913ecce-eb03-4d6a-a9ff-4c66189efd3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_bc1ffbf0-67c6-4382-97a3-ea595b1502c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_bc1ffbf0-67c6-4382-97a3-ea595b1502c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_024f777e-cb7c-4d51-8939-b4e5a6a2002c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_024f777e-cb7c-4d51-8939-b4e5a6a2002c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_b9797829-8c8d-47ad-9dcb-d31c204e18cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_b9797829-8c8d-47ad-9dcb-d31c204e18cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7ddeb5ca-49e1-4c36-8e19-6a8374f1ba4f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7ddeb5ca-49e1-4c36-8e19-6a8374f1ba4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0d1f2962-0169-46e0-9c0c-864e4402b10c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_0d1f2962-0169-46e0-9c0c-864e4402b10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_8fdc014a-951e-4fc8-b485-ebd503f34110" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_8fdc014a-951e-4fc8-b485-ebd503f34110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_ac6f16ca-b0d1-4d43-a706-88f0ba577bc4" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_ac6f16ca-b0d1-4d43-a706-88f0ba577bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_9512dff7-de2e-4564-be76-ca36d434bd7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_9512dff7-de2e-4564-be76-ca36d434bd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_cf5cf57b-58a0-4018-b20e-c52bc3c0db6b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ba8fa588-2744-4f96-8d49-5ef5a145fbce" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_cf5cf57b-58a0-4018-b20e-c52bc3c0db6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c9f99362-03c5-4774-a107-135d74dde032" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_5277a382-28e4-46e4-a579-5d0eea403feb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c9f99362-03c5-4774-a107-135d74dde032" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_5277a382-28e4-46e4-a579-5d0eea403feb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_8785fccc-a43e-404c-b2a7-35ea4d722bfa" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_c34d128b-7395-449a-a177-c22b01373a52" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_8785fccc-a43e-404c-b2a7-35ea4d722bfa" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_c34d128b-7395-449a-a177-c22b01373a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3a68eec6-f9da-440f-b016-f6e99a76a06e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_8785fccc-a43e-404c-b2a7-35ea4d722bfa" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3a68eec6-f9da-440f-b016-f6e99a76a06e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_0ed7a967-ac78-416b-a5c0-c72e2838f80b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_8785fccc-a43e-404c-b2a7-35ea4d722bfa" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_0ed7a967-ac78-416b-a5c0-c72e2838f80b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncorporationandNatureofOperations"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="simple" xlink:href="oncyf-20201231.xsd#BasisofFinancialStatementPresentation"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalents"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivative"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapital"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalShareConsolidationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShare"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivable"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6b145af9-76c7-4775-b1de-670ee26efac7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_c002f556-505e-4602-b34d-af25a5561e13" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_6b145af9-76c7-4775-b1de-670ee26efac7" xlink:to="loc_ifrs-full_CurrentContractLiabilities_c002f556-505e-4602-b34d-af25a5561e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_52b03ae0-e840-4ad8-88bb-cdcab1ccdbe9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_6b145af9-76c7-4775-b1de-670ee26efac7" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_52b03ae0-e840-4ad8-88bb-cdcab1ccdbe9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Commitments"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Contingencies"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_c773e733-c24c-400f-95e4-38e62b93bdcb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_c1cd4cbf-1596-446d-a7df-59b1e3269c49" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_c773e733-c24c-400f-95e4-38e62b93bdcb" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_c1cd4cbf-1596-446d-a7df-59b1e3269c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_a93ce732-ffbc-4708-bcd7-26759a5c435c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_c773e733-c24c-400f-95e4-38e62b93bdcb" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_a93ce732-ffbc-4708-bcd7-26759a5c435c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_4a6ea390-2b34-45ff-afbc-669ac00cd1ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_4a6ea390-2b34-45ff-afbc-669ac00cd1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_a7f81d29-47b4-4cc9-9ce2-c1f0a2bf2e68" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_a7f81d29-47b4-4cc9-9ce2-c1f0a2bf2e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_2eb8b02f-2dbc-4ff9-a82e-b2d962c00333" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_2eb8b02f-2dbc-4ff9-a82e-b2d962c00333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_069e7189-20a7-4025-abbb-1e6f1c2765ca" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_069e7189-20a7-4025-abbb-1e6f1c2765ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_3cc674f0-a8a0-4d42-a630-9d707ef6f574" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_3cc674f0-a8a0-4d42-a630-9d707ef6f574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_6f6febec-745a-4315-a9f9-6334e3e16366" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_oncyf_TaxEffectOfTaxPools_6f6febec-745a-4315-a9f9-6334e3e16366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_fcd44378-461c-4dae-b3fe-d5d8a0c6aca2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_fcd44378-461c-4dae-b3fe-d5d8a0c6aca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_ce05efc8-3128-4877-9fb7-14db727ce077" xlink:href="oncyf-20201231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_81a58599-889a-4294-96f3-5ddee364eddc" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_ce05efc8-3128-4877-9fb7-14db727ce077" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNoncapitalLossesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosures"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosures"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_927843d8-c75c-4ae6-989b-a07a5fe3b1b3" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_927843d8-c75c-4ae6-989b-a07a5fe3b1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_12da5905-a15b-4fb0-9038-0f9275957b53" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_12da5905-a15b-4fb0-9038-0f9275957b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_6e2c8277-f198-4f1f-9250-c6cf912551b5" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_6e2c8277-f198-4f1f-9250-c6cf912551b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_35f510b5-7052-47be-956d-20d487d83924" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_35f510b5-7052-47be-956d-20d487d83924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_d2f204cb-efb2-4331-8f02-e7df38824019" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_d2f204cb-efb2-4331-8f02-e7df38824019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_46288a52-7381-43fe-bcaf-1e56d5b2359f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_46288a52-7381-43fe-bcaf-1e56d5b2359f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_804c7b49-c2fc-4d27-9e0e-1b6a331ae547" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_89ecbe37-71ec-41a3-afc5-3a5a884b4092" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_804c7b49-c2fc-4d27-9e0e-1b6a331ae547" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependence"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependenceDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustments"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsTables"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_fb5930ce-2ee0-4bff-8e56-02b860e9e4d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_424cf730-a4cc-4e29-a74b-82920ab8b290" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fb5930ce-2ee0-4bff-8e56-02b860e9e4d0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_424cf730-a4cc-4e29-a74b-82920ab8b290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_b6574ac4-c766-463e-92a0-66610e2db1cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fb5930ce-2ee0-4bff-8e56-02b860e9e4d0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_b6574ac4-c766-463e-92a0-66610e2db1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_facf54be-2f5d-42da-b1f5-bcbaeeccb431" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fb5930ce-2ee0-4bff-8e56-02b860e9e4d0" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_facf54be-2f5d-42da-b1f5-bcbaeeccb431" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ComparativeFigures"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>oncyf-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended" id="i12eb8858251844e18cd694bf61eb3793_Cover"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended" id="i933d57fe657f416f8a91bb71e5b5a748_CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended" id="if4798984728444d3b2e2b42a636d2ac6_CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended" id="id62af1a18a4a49a58ebafb44c09ce759_CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended" id="i4aea149836684ebeb970b572a7f09fc3_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_165e26d5-b064-4676-b7f3-8319ecf353f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_Equity_165e26d5-b064-4676-b7f3-8319ecf353f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_aa566561-d2fa-4008-9f74-c23795009acc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_ComprehensiveIncome_aa566561-d2fa-4008-9f74-c23795009acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5a92da45-42f0-4404-95aa-1168d8be9629" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5a92da45-42f0-4404-95aa-1168d8be9629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a2839384-61d0-4d14-a936-c7d3a78eadbc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a2839384-61d0-4d14-a936-c7d3a78eadbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a55e30f1-ba55-44a6-9ef7-8ffe837d14c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IssueOfEquity_a55e30f1-ba55-44a6-9ef7-8ffe837d14c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_c4a6308c-6823-4bc6-8f87-ddceec7798b7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_c4a6308c-6823-4bc6-8f87-ddceec7798b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_d15ffb1b-f16a-4a88-8168-ecd41a8e95c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_d15ffb1b-f16a-4a88-8168-ecd41a8e95c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_d75cb7f5-927e-4de0-9ec1-6eaaa3e859b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_d75cb7f5-927e-4de0-9ec1-6eaaa3e859b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5e52051d-e38f-4f41-810b-b2ae4ecc9c37" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5b55c3fa-1b44-4678-a2ba-417612ed1572_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:to="loc_ifrs-full_EquityMember_5b55c3fa-1b44-4678-a2ba-417612ed1572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:to="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_fe8e09b0-4e2b-4ff9-9a8a-bd5ff3401bf8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_IssuedCapitalMember_fe8e09b0-4e2b-4ff9-9a8a-bd5ff3401bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_88f38712-0fe7-4f4c-8123-a3264b42c39d" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_oncyf_WarrantsMember_88f38712-0fe7-4f4c-8123-a3264b42c39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_46bdc37e-f65f-4b96-9d45-bdd1cb96f01e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_SharePremiumMember_46bdc37e-f65f-4b96-9d45-bdd1cb96f01e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_ccc7c1d7-156b-48cd-ba4a-72d44ca41e01" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_ccc7c1d7-156b-48cd-ba4a-72d44ca41e01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_e30221a0-7c75-4ecf-bd3b-33abe81ecd2e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_RetainedEarningsMember_e30221a0-7c75-4ecf-bd3b-33abe81ecd2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:to="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_57090ecb-de48-45f1-b2c5-bf5147022f65_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:to="loc_oncyf_SaleOfStockDomain_57090ecb-de48-45f1-b2c5-bf5147022f65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:to="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_27220ed4-0bfd-41e8-a2c5-6ad79ef441c3" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_27220ed4-0bfd-41e8-a2c5-6ad79ef441c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_9d63f8bf-e46e-4821-ad1f-42f52a232d01" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesPublicOfferingMember_9d63f8bf-e46e-4821-ad1f-42f52a232d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_e425ee8d-00b8-49f7-86f0-dc733a0ff7e0" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_e425ee8d-00b8-49f7-86f0-dc733a0ff7e0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i9e77a139c0484d9d8bac8902122faa2f_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:href="oncyf-20201231.xsd#oncyf_Statement1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9aad710e-252b-4671-a43b-be0a5dfba5fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_ProfitLoss_9aad710e-252b-4671-a43b-be0a5dfba5fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_29133675-2d99-424a-9fea-d5f491dc43fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_29133675-2d99-424a-9fea-d5f491dc43fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_610ca9ec-16a3-43b7-9870-82d931b5ee5a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_610ca9ec-16a3-43b7-9870-82d931b5ee5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_24d9ea8d-7381-4cd7-b362-55681ea93bea" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_24d9ea8d-7381-4cd7-b362-55681ea93bea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_aafd3988-b83e-4621-a5c3-31fbe1a2cb0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_aafd3988-b83e-4621-a5c3-31fbe1a2cb0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2cfc2cea-8c8d-443c-bf5e-8e0eff1ad8d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2cfc2cea-8c8d-443c-bf5e-8e0eff1ad8d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_5c4c9b91-54c1-4ef2-a3f6-87e1cf5189d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_5c4c9b91-54c1-4ef2-a3f6-87e1cf5189d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_1801ad11-e3f2-455b-a35d-b2c9ec369589" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_1801ad11-e3f2-455b-a35d-b2c9ec369589" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d0bab866-aaf4-4200-af61-6c1c5fcd50aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d0bab866-aaf4-4200-af61-6c1c5fcd50aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2736337c-db67-41c6-9b96-6bcc685373c5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2736337c-db67-41c6-9b96-6bcc685373c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_03a94fad-2350-46b3-8df0-09c4e40284cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_03a94fad-2350-46b3-8df0-09c4e40284cb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_abff5c9b-e055-4333-b8f1-ccfa9bf6dc50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_abff5c9b-e055-4333-b8f1-ccfa9bf6dc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_76f0fec8-22d8-4fd7-9c04-9880f0ee220d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_76f0fec8-22d8-4fd7-9c04-9880f0ee220d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_d022d4ce-4985-4e92-a093-1235e34387d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_d022d4ce-4985-4e92-a093-1235e34387d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_5c2573c0-ba72-4418-8cb6-8189f3f303af" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_5c2573c0-ba72-4418-8cb6-8189f3f303af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_6833fb3f-2cea-4798-ad16-6c404fef2d72" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_CashOutflowForLeases_6833fb3f-2cea-4798-ad16-6c404fef2d72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_51719c41-2876-4e17-9e0b-83a3795d9b06" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_51719c41-2876-4e17-9e0b-83a3795d9b06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2c4ec236-bf2d-41fd-abb3-d3175f16046d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2c4ec236-bf2d-41fd-abb3-d3175f16046d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3a54d39a-f301-4f5e-9e52-768838c6bb54" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3a54d39a-f301-4f5e-9e52-768838c6bb54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_556cbc91-f1cb-4746-ac3b-2cfe92e8bc7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_556cbc91-f1cb-4746-ac3b-2cfe92e8bc7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2dbb39fa-bb65-4203-9a40-bafeeac83537" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:href="oncyf-20201231.xsd#oncyf_Statement1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:to="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7e5f1528-78ba-4517-833a-3795bf543112_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:to="loc_oncyf_SaleOfStockDomain_7e5f1528-78ba-4517-833a-3795bf543112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:to="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_1e95e4d2-52d6-49eb-9d45-eaa15563f84e" xlink:href="oncyf-20201231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_1e95e4d2-52d6-49eb-9d45-eaa15563f84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_a3c1f24d-fec0-46cf-a6c2-23eb376a226e" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_a3c1f24d-fec0-46cf-a6c2-23eb376a226e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_43bb5b44-ccc5-46d1-ab23-884f3366e829" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_43bb5b44-ccc5-46d1-ab23-884f3366e829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_da2c218c-5772-4498-b8e8-4b57d617cf34" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesPublicOfferingMember_da2c218c-5772-4498-b8e8-4b57d617cf34" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncorporationandNatureofOperations"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="extended" id="iddb4b08ba4144f508b1ac66b84f85c35_IncorporationandNatureofOperations"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="simple" xlink:href="oncyf-20201231.xsd#BasisofFinancialStatementPresentation"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="extended" id="icb44305350bd4173bb39b026c23d9345_BasisofFinancialStatementPresentation"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ib8353a24db3245578d306d0c1f7d6982_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i5b31e7f730994f42b14052e3f4e5dbf2_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="if8d25f82cf9a4bf19eba943d94c92fcd_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended" id="if1406139690c4c19b92f4bbb76dc5af8_SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8e298fc0-3a0f-4cdb-a59b-02a8e9ffb730" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8e298fc0-3a0f-4cdb-a59b-02a8e9ffb730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_f2bfa472-131d-4f97-ac8f-07d8b12368a2_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_f2bfa472-131d-4f97-ac8f-07d8b12368a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_3f01a52f-cc29-40af-8c31-123ffc96ebeb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_ifrs-full_OfficeEquipmentMember_3f01a52f-cc29-40af-8c31-123ffc96ebeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_884622f7-51f5-455e-8e9b-2003084a2494" xlink:href="oncyf-20201231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_oncyf_MedicalEquipmentMember_884622f7-51f5-455e-8e9b-2003084a2494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_993d8e52-d437-46e4-b010-8bd153296f7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_ifrs-full_ComputerEquipmentMember_993d8e52-d437-46e4-b010-8bd153296f7c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i3ed827721edb4c16947ed4935b6302c8_SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended" id="if86843243cbb461086a6a2a82072dfb8_SignificantJudgmentsEstimatesandAssumptions"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalents"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended" id="i4f21850af3a24d649adc57ee1fccab55_CashEquivalents"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended" id="ie8805887ef3544e6a0f669edf9717e42_CashEquivalentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended" id="i7eb6432754e34f9bb5b789886186c176_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended" id="iaa84209a763b4924aa142543ff604c12_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="ic268695015e64073a86502998308192a_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_8d304126-889a-4656-ab9d-577a5cdb8f27" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_8d304126-889a-4656-ab9d-577a5cdb8f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_05fc3509-b79d-444e-b6f8-ad9b8e257321" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_05fc3509-b79d-444e-b6f8-ad9b8e257321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_f05ee5c0-75bc-49b8-93f2-f06b225693d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_f05ee5c0-75bc-49b8-93f2-f06b225693d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_b19e106b-f5a1-4d70-9d59-1a924ffe7aa2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_b19e106b-f5a1-4d70-9d59-1a924ffe7aa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9308c15b-c421-4110-ba20-45e55ffba603" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_b4b5fba7-724d-4282-bc74-e3df53d7eb0a_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_b4b5fba7-724d-4282-bc74-e3df53d7eb0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_54e65a46-c084-47b0-b2ab-6fd1ef02c7a5" xlink:href="oncyf-20201231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_oncyf_MedicalEquipmentMember_54e65a46-c084-47b0-b2ab-6fd1ef02c7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_025ccb32-f76c-4236-b2cc-22cdeffa933a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_025ccb32-f76c-4236-b2cc-22cdeffa933a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_6a0e1634-ca3f-405d-ae05-b720b43552ff" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_6a0e1634-ca3f-405d-ae05-b720b43552ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_16ce2c5f-2a99-49e7-8b3b-d3d299ce876d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_16ce2c5f-2a99-49e7-8b3b-d3d299ce876d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_28534278-2146-42b6-a153-6e875aa23a41" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_28534278-2146-42b6-a153-6e875aa23a41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_d1877001-1d44-4996-a88e-38286738ec98_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:to="loc_ifrs-full_CarryingAmountMember_d1877001-1d44-4996-a88e-38286738ec98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:to="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_276e3ba7-b6a2-4088-a6ad-969b364c0f9e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_276e3ba7-b6a2-4088-a6ad-969b364c0f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_f273d3fd-9d4f-4cec-927f-3e651751c62f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_f273d3fd-9d4f-4cec-927f-3e651751c62f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended" id="i796ce4affae44c9eb35511c6a70c426a_Leases"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended" id="i3e0d1914ecf9413fb7eeea87bd900882_LeasesTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ib1ffbb72340a48da96f499a3e6e1ef3a_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_338690ba-d63b-4977-a68f-2c749348e2e2" xlink:href="oncyf-20201231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_338690ba-d63b-4977-a68f-2c749348e2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_efd12763-a8ca-45c0-9677-8b926586c150" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_efd12763-a8ca-45c0-9677-8b926586c150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_49e48b3b-e4c7-4532-a95c-b5c3a2f2e97e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_ifrs-full_RightofuseAssets_49e48b3b-e4c7-4532-a95c-b5c3a2f2e97e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfRenewals_9fc9a535-7ecb-45c8-a198-b97e646e4a6c" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfRenewals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_oncyf_NumberOfRenewals_9fc9a535-7ecb-45c8-a198-b97e646e4a6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:to="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_533a0ddb-a18a-4239-beec-1136af7acb61_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:to="loc_srt_RangeMember_533a0ddb-a18a-4239-beec-1136af7acb61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:to="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_20e075f5-1474-4af1-820a-0704bb5f9e04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:to="loc_srt_MinimumMember_20e075f5-1474-4af1-820a-0704bb5f9e04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c15f783f-98eb-4576-950f-f85a2da04fc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:to="loc_srt_MaximumMember_c15f783f-98eb-4576-950f-f85a2da04fc7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended" id="id0968a8c0b2c495eb36353f7dd172144_LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended" id="id389e26718fc47c2b87fd9258d219b60_LeasesTotalUndiscountedLeaseLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_a4bc9b8e-83f9-4159-bfee-393d86f1faa7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_a4bc9b8e-83f9-4159-bfee-393d86f1faa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:to="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5c912107-0c03-48c9-8d20-a5486f7d866f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5c912107-0c03-48c9-8d20-a5486f7d866f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_c1cf829b-db28-4c7f-a8f1-21ff652139e7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_c1cf829b-db28-4c7f-a8f1-21ff652139e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_965b8dce-84c4-49ef-a33a-3256b798afbb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_965b8dce-84c4-49ef-a33a-3256b798afbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_138ad655-f7db-4cf8-9480-61a92ce5d9a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_138ad655-f7db-4cf8-9480-61a92ce5d9a2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivative"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended" id="ifa42778eb06a4f30bad370612ea2f2c9_WarrantDerivative"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended" id="i904e86c369574b769f673c688ee81faa_WarrantDerivativeTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended" id="i0099506f5b6b4dacaca196a45c837db3_WarrantDerivativeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_05be264e-532e-45d3-a620-4cf3ad975eba" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_IssueOfEquityShares_05be264e-532e-45d3-a620-4cf3ad975eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_84a56427-125b-4f86-8cd3-de4fd890713a" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_84a56427-125b-4f86-8cd3-de4fd890713a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_98c9b971-6922-410a-b482-8e9d97824cbd" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_98c9b971-6922-410a-b482-8e9d97824cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_882d4c1c-6616-401a-939b-1caa484530d3" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_CommonSharesPerUnit_882d4c1c-6616-401a-939b-1caa484530d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3c7d3155-ca82-483a-bc34-987e8c4c201b" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3c7d3155-ca82-483a-bc34-987e8c4c201b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_e0fbea44-d9a7-4871-850d-28bb081903ae" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_e0fbea44-d9a7-4871-850d-28bb081903ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_b8dac380-e909-4fdd-b631-8fcf6b8e9a96" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_b8dac380-e909-4fdd-b631-8fcf6b8e9a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_a85e5218-796b-4086-ac08-1b03501732f5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_a85e5218-796b-4086-ac08-1b03501732f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_403ffb8d-0909-40fc-8283-4a9abc575bc0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:to="loc_ifrs-full_IssuedCapitalMember_403ffb8d-0909-40fc-8283-4a9abc575bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:to="loc_ifrs-full_LiabilitiesMember_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:to="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_3f5bd074-cabb-4411-9734-33a2483d6839" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:to="loc_oncyf_WarrantsMember_3f5bd074-cabb-4411-9734-33a2483d6839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f2d7339c-e541-4fb7-9109-4e56f906d2d3_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:to="loc_oncyf_SaleOfStockDomain_f2d7339c-e541-4fb7-9109-4e56f906d2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:to="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_064d6353-b0a2-4f25-ba42-7c914dc1624d" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_064d6353-b0a2-4f25-ba42-7c914dc1624d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended" id="i3abe037dbafa4e39926da0246f7e58b3_WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_7c0dc729-7158-4a4c-b70e-1a57c0d0de9c" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_7c0dc729-7158-4a4c-b70e-1a57c0d0de9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_8d47be35-b565-49bc-9414-7ee4badd67de" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_8d47be35-b565-49bc-9414-7ee4badd67de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_d4d5ca92-c5b3-4cbd-9070-0636f763f796" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:href="oncyf-20201231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_bb03f61a-020d-4f04-a442-414bc869beb0" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_bb03f61a-020d-4f04-a442-414bc869beb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_4f9f5fa0-1c05-4974-a3bd-eb7f23dbeba8" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_4f9f5fa0-1c05-4974-a3bd-eb7f23dbeba8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_ca0fc4c4-a698-4b07-95c4-30783af4aca1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_ca0fc4c4-a698-4b07-95c4-30783af4aca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_c1576e38-da00-447c-9998-97922ecf42cb" xlink:href="oncyf-20201231.xsd#oncyf_GainsLossesfromForeignExchangeImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_c1576e38-da00-447c-9998-97922ecf42cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_23d6f000-406f-456c-9382-e6a60d6326bb" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a6489098-706c-4abb-afd7-39d8d89e67a0_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:to="loc_ifrs-full_LiabilitiesMember_a6489098-706c-4abb-afd7-39d8d89e67a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:to="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_cf48927f-9f45-4769-b431-fc077821decd" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:to="loc_oncyf_WarrantsMember_cf48927f-9f45-4769-b431-fc077821decd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended" id="i53e87ca67d7e4d29bb56043a5e8e3514_WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_a6abd04c-7b29-40d3-907e-cd661d5d59a0" xlink:href="oncyf-20201231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_a6abd04c-7b29-40d3-907e-cd661d5d59a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_38a7858e-41c0-47a5-a9e6-3c0b53892dbe" xlink:href="oncyf-20201231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_38a7858e-41c0-47a5-a9e6-3c0b53892dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_a59bf299-d95a-488d-a761-46aa92adffe1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_a59bf299-d95a-488d-a761-46aa92adffe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_621fc395-8129-4903-98ac-d358c84f326f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_621fc395-8129-4903-98ac-d358c84f326f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_5942e05a-8085-4e5e-84cb-293c2458e17f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_5942e05a-8085-4e5e-84cb-293c2458e17f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent_6275fcab-e63a-48af-bdc8-b661b99aa957" xlink:href="oncyf-20201231.xsd#oncyf_DividendYieldPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_DividendYieldPercent_6275fcab-e63a-48af-bdc8-b661b99aa957" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_ee77d422-4112-400d-8ea7-8e4633bf8fc7_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:to="loc_ifrs-full_LiabilitiesMember_ee77d422-4112-400d-8ea7-8e4633bf8fc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:to="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_566cbf07-1db1-4666-b950-62d0edb1ac1a" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:to="loc_oncyf_WarrantsMember_566cbf07-1db1-4666-b950-62d0edb1ac1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapital"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended" id="i66df7e42135e406f834b4bbe56e82931_ShareCapital"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended" id="i1ac1f7346bae4781874cdfffaa769b6b_ShareCapitalTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalShareConsolidationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="extended" id="ibfafd6c3b9a0435fa5a0b16708cc4c30_ShareCapitalShareConsolidationNarrativeDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended" id="id899927385584326a35b3c9130963b9b_ShareCapitalScheduleofShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_87fc0239-5681-44af-a203-9bb472c3151a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_NumberOfSharesIssued_87fc0239-5681-44af-a203-9bb472c3151a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_eb69d0f3-056b-42b6-83fc-b7c5efebbc39" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_oncyf_IssueOfEquityShares_eb69d0f3-056b-42b6-83fc-b7c5efebbc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_bc5f5b74-e9dc-47f9-8606-94476546e525" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_faa77c3d-9010-4794-b5de-8f240ae48bba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_Equity_faa77c3d-9010-4794-b5de-8f240ae48bba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_23c5bfe0-761a-4cad-8fee-63c173010396" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_IssueOfEquity_23c5bfe0-761a-4cad-8fee-63c173010396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_29a377ae-3fe2-49d5-9cb1-f17845bbe216" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_29a377ae-3fe2-49d5-9cb1-f17845bbe216" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b2687f57-d8f2-4481-962c-ec24527cdfff" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_c3268b85-3e6d-4d97-953b-cc1ee6daf769_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:to="loc_ifrs-full_RestatedMember_c3268b85-3e6d-4d97-953b-cc1ee6daf769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:to="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_311083bf-3698-4525-89c4-74833c73906f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:to="loc_ifrs-full_PreviouslyStatedMember_311083bf-3698-4525-89c4-74833c73906f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_cb180269-03b1-4ccf-bc71-ef8762e4faad_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_cb180269-03b1-4ccf-bc71-ef8762e4faad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f946280a-ff2f-43d8-b018-65928a425cc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:to="loc_ifrs-full_IssuedCapitalMember_f946280a-ff2f-43d8-b018-65928a425cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_73313b2d-1a5b-4681-a72f-c05249868dc2_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:to="loc_oncyf_SaleOfStockDomain_73313b2d-1a5b-4681-a72f-c05249868dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:to="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_4be32f07-5904-43b3-8615-c89b014a95f9" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_4be32f07-5904-43b3-8615-c89b014a95f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_6c1be2d6-809e-4db5-b2dd-c8f53de15d9a" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_6c1be2d6-809e-4db5-b2dd-c8f53de15d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_cb42d4d0-9b13-41d4-ade5-705267277dd5" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_cb42d4d0-9b13-41d4-ade5-705267277dd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_580817ed-e04f-4dbd-aae8-b5d24ae9e7d5" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_580817ed-e04f-4dbd-aae8-b5d24ae9e7d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_b024fb9b-732d-470f-9112-426bf9b07000" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_b024fb9b-732d-470f-9112-426bf9b07000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_b2ae3943-c8ad-40f8-b7e5-fc1f09f643d1" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_b2ae3943-c8ad-40f8-b7e5-fc1f09f643d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_372a5b51-388f-48b4-ac41-8fab869dd6d2" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderWarrantAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_372a5b51-388f-48b4-ac41-8fab869dd6d2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended" id="i5ab4c316e46348c9add2e93bafa28206_ShareCapitalScheduleofShareCapitalFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_e1a3e478-4e09-4cf7-b923-ac5bcee93255" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_e1a3e478-4e09-4cf7-b923-ac5bcee93255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_f3fdff62-1764-4282-bce2-d91fe0cea8b2" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_IssueOfEquityShares_f3fdff62-1764-4282-bce2-d91fe0cea8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a967c841-c5fc-45ea-95e5-c3080d5fa34f" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a967c841-c5fc-45ea-95e5-c3080d5fa34f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_32f69e41-3270-4aa7-a1d5-2a21cff2aea4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_32f69e41-3270-4aa7-a1d5-2a21cff2aea4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_55c46cb7-3fe2-417a-9951-415881b403b9" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_55c46cb7-3fe2-417a-9951-415881b403b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_f8ed1296-191f-4ed4-8e0c-cd7228caf806" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_f8ed1296-191f-4ed4-8e0c-cd7228caf806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays_ef6ef922-ca36-4e57-b2c0-421c42d3f65d" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays_ef6ef922-ca36-4e57-b2c0-421c42d3f65d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent_33b5a991-cb0a-499b-9b0a-ee4faa4c7040" xlink:href="oncyf-20201231.xsd#oncyf_NumberofSharesOutstandingPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_NumberofSharesOutstandingPercent_33b5a991-cb0a-499b-9b0a-ee4faa4c7040" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_d77d0211-00b2-4b29-b765-91899183a4eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_d77d0211-00b2-4b29-b765-91899183a4eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_feb30cdc-e53e-4bac-a8c0-4a6c343388a9" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_feb30cdc-e53e-4bac-a8c0-4a6c343388a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_371b02c1-60b4-4ada-a74e-a7c2eb81902f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_371b02c1-60b4-4ada-a74e-a7c2eb81902f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_84a6eb4f-9aeb-4202-8605-26d77acac47c" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_CommonSharesPerUnit_84a6eb4f-9aeb-4202-8605-26d77acac47c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_033e1c36-1372-41ec-8d48-f26d7eaf77e6" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_033e1c36-1372-41ec-8d48-f26d7eaf77e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_1ff520a9-b88a-455b-9a89-640c9d9b7f52" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_1ff520a9-b88a-455b-9a89-640c9d9b7f52" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_82ac26de-b87c-498e-83ac-18d181aec822" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_82ac26de-b87c-498e-83ac-18d181aec822" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_de468305-fad8-4c28-90f3-686991a6d7ca" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_de468305-fad8-4c28-90f3-686991a6d7ca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_091bd862-7b31-4cff-8382-2a77835646e0" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_091bd862-7b31-4cff-8382-2a77835646e0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_2812ed54-a406-45ea-afb7-8d3bc5f62c8a_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:to="loc_ifrs-full_LiabilitiesMember_2812ed54-a406-45ea-afb7-8d3bc5f62c8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:to="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_3b8f21b9-55d2-4b0e-a84f-53daa8ceb773" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:to="loc_oncyf_WarrantsMember_3b8f21b9-55d2-4b0e-a84f-53daa8ceb773" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14f730c0-fb40-46d0-95de-6b5b9bc8b63c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:to="loc_srt_RangeMember_14f730c0-fb40-46d0-95de-6b5b9bc8b63c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:to="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59d40f0d-698c-4bd7-b628-244c03d9e494" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:to="loc_srt_MinimumMember_59d40f0d-698c-4bd7-b628-244c03d9e494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c55e486d-693a-4747-8d92-c70a1fc0caf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:to="loc_srt_MaximumMember_c55e486d-693a-4747-8d92-c70a1fc0caf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_14119d35-8c6f-4f53-aa29-dbdd9fbe0553_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:to="loc_oncyf_SaleOfStockDomain_14119d35-8c6f-4f53-aa29-dbdd9fbe0553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:to="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_afc0d0e0-27d4-43b8-948d-c2903a5db9cb" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_afc0d0e0-27d4-43b8-948d-c2903a5db9cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_597b6a97-807f-4fb4-b676-4cf2e7340741" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesPublicOfferingMember_597b6a97-807f-4fb4-b676-4cf2e7340741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fa888703-0f22-47a9-8049-b0ee9f3a5d80" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fa888703-0f22-47a9-8049-b0ee9f3a5d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_e9b7130c-9ae5-4741-995e-80a404e6ba00" xlink:href="oncyf-20201231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_e9b7130c-9ae5-4741-995e-80a404e6ba00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_fa52a9e1-7373-41d4-8370-f9b9ff9427e4" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_fa52a9e1-7373-41d4-8370-f9b9ff9427e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_3a423b8b-e3bf-45bc-ab6a-5e3bffb7c42c" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_3a423b8b-e3bf-45bc-ab6a-5e3bffb7c42c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_26405459-47f8-4603-b830-6f344fa08b10_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:to="loc_ifrs-full_RestatedMember_26405459-47f8-4603-b830-6f344fa08b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:to="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_f61b1c4e-47a6-480f-aa67-96591948f952" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:to="loc_ifrs-full_PreviouslyStatedMember_f61b1c4e-47a6-480f-aa67-96591948f952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_e70d28a5-e4d1-4697-8b78-25b7505531d0_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_e70d28a5-e4d1-4697-8b78-25b7505531d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_efbcb054-88f8-4a54-a1a9-e5e7bc1e1453" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:to="loc_oncyf_WarrantsMember_efbcb054-88f8-4a54-a1a9-e5e7bc1e1453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:to="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember_f8600888-d76f-4446-bb4e-fbf739326c0a" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:to="loc_oncyf_CommitmentSharesMember_f8600888-d76f-4446-bb4e-fbf739326c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_fa857e28-368b-443a-ade6-a3f90aa6a25a" xlink:href="oncyf-20201231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:to="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_fa857e28-368b-443a-ade6-a3f90aa6a25a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_35ad4b4d-df1f-4fac-b476-0133fe9925bd_default" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_35ad4b4d-df1f-4fac-b476-0133fe9925bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_9eb4c08d-9224-4a4b-bb69-0827ad162fd9" xlink:href="oncyf-20201231.xsd#oncyf_OperatingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:to="loc_oncyf_OperatingExpensesMember_9eb4c08d-9224-4a4b-bb69-0827ad162fd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended" id="i0645b9709fb3470186067d7689636df9_ShareCapitalSummaryofOutstandingWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_4bbc3635-5db0-4559-ad41-f8161b2a5720" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_4bbc3635-5db0-4559-ad41-f8161b2a5720" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_9edd6e3f-f39b-4418-bb80-034f61946d6d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_9edd6e3f-f39b-4418-bb80-034f61946d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_c37225ad-2727-4f32-b6f6-1c7edb321acf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_028e410e-3ae8-4f15-9fb9-d35095a040a8" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_028e410e-3ae8-4f15-9fb9-d35095a040a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_44dd5904-dfea-4903-b68e-9c578e1d638e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_44dd5904-dfea-4903-b68e-9c578e1d638e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_045d9074-8feb-482f-a0b6-eef42beac98b" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_c57b2720-3262-411d-969a-2f105253cbeb" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_c57b2720-3262-411d-969a-2f105253cbeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_e5cb4430-a25f-4f12-9a66-749844aa4b19_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_e5cb4430-a25f-4f12-9a66-749844aa4b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_b6222d30-1de6-407e-84a2-cce5ab3ea5c9" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:to="loc_oncyf_WarrantsMember_b6222d30-1de6-407e-84a2-cce5ab3ea5c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended" id="i6115cbd4bf7e4b2cad6e29ab84fca029_ShareCapitalEquityWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b6b48405-44cb-4b05-bad0-bac4e18088a1" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_IssueOfEquityShares_b6b48405-44cb-4b05-bad0-bac4e18088a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_70fad9f1-7a50-49ba-987d-2c2135f55a64" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_70fad9f1-7a50-49ba-987d-2c2135f55a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_74701069-8d3c-41de-8514-445a3407a222" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_CommonSharesPerUnit_74701069-8d3c-41de-8514-445a3407a222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_cb5a86d8-e9ed-475f-8f8a-b24c4b311945" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_cb5a86d8-e9ed-475f-8f8a-b24c4b311945" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_569ee3b6-bf7d-4099-9dd8-e7930bb7b993" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_569ee3b6-bf7d-4099-9dd8-e7930bb7b993" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_688b7075-6f48-4017-a89f-723754bbdfcd" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_688b7075-6f48-4017-a89f-723754bbdfcd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_3cb21c21-dcea-4bb7-b28b-ff484c57fba3" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_3cb21c21-dcea-4bb7-b28b-ff484c57fba3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:to="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c1e3976c-db9e-4f4e-a5b4-4bbf53510117_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:to="loc_oncyf_SaleOfStockDomain_c1e3976c-db9e-4f4e-a5b4-4bbf53510117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:to="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_0ac40f1e-fe44-4c3c-a7c9-af35b7dd0920" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_0ac40f1e-fe44-4c3c-a7c9-af35b7dd0920" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended" id="ie465e940f26043d0b7efc8878456d65a_ShareBasedPayments"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="ib5ca6c6e21b147edb7e46d78b24c8a92_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended" id="ib1d61611900c4bde87b65539f2cb4a02_ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended" id="i308ba3afe7f24db29223179767724809_ShareBasedPaymentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_a1088ef9-f443-413d-9844-d0adf3499559" xlink:href="oncyf-20201231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_a1088ef9-f443-413d-9844-d0adf3499559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9a665cf0-49bb-4c9c-bb61-4d42758771be" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9a665cf0-49bb-4c9c-bb61-4d42758771be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_f4c2ab8f-0738-4a7a-9752-6e6e4a2ed026" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_f4c2ab8f-0738-4a7a-9752-6e6e4a2ed026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:to="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_25687628-b264-4055-8e89-d3be092e1729_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:to="loc_ifrs-full_RangesMember_25687628-b264-4055-8e89-d3be092e1729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:to="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_44e6b74f-1efd-4c83-b2a8-b1aa5254b4cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:to="loc_ifrs-full_BottomOfRangeMember_44e6b74f-1efd-4c83-b2a8-b1aa5254b4cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2a71710b-9b21-44df-9f92-bb7a3c1b4da6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:to="loc_ifrs-full_TopOfRangeMember_2a71710b-9b21-44df-9f92-bb7a3c1b4da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ae08b2a4-c271-4ba5-b2c7-ed5554aec426_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ae08b2a4-c271-4ba5-b2c7-ed5554aec426_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_5fc5b65b-5de2-4bef-bbf3-78195134f600" xlink:href="oncyf-20201231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_oncyf_RestrictedShareUnitsMember_5fc5b65b-5de2-4bef-bbf3-78195134f600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_567c6f12-2c13-4043-9429-31cc668280d3" xlink:href="oncyf-20201231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_oncyf_PerformanceShareUnitsMember_567c6f12-2c13-4043-9429-31cc668280d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_55eacfac-f3dc-432d-a016-410cc12df0fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_55eacfac-f3dc-432d-a016-410cc12df0fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended" id="ia8de6c67f185443c8bb458ce8305ae7d_ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_7fd6476b-8259-4898-b064-697e8f2a23bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_7fd6476b-8259-4898-b064-697e8f2a23bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_d8f649ed-e560-4475-8dda-9a964a076d2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_d8f649ed-e560-4475-8dda-9a964a076d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a6ec4601-4814-4e5a-bb86-7b5ed06b5534" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a6ec4601-4814-4e5a-bb86-7b5ed06b5534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8fb2190e-0d20-474f-bd22-ad31840a13d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8fb2190e-0d20-474f-bd22-ad31840a13d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_88e55d28-3d2d-4651-9129-3b37246770ce" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_88e55d28-3d2d-4651-9129-3b37246770ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_a8fe3579-7e5f-4c1e-a147-0dbd336138d1_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_a8fe3579-7e5f-4c1e-a147-0dbd336138d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_3e701bd1-c362-4d9a-8b7a-0efd811c60a7" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_3e701bd1-c362-4d9a-8b7a-0efd811c60a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_538d9ca3-2ae9-494e-88b1-e21082ad8073" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_538d9ca3-2ae9-494e-88b1-e21082ad8073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_2a579206-ef72-408d-ad40-5d92d3db299d" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_2a579206-ef72-408d-ad40-5d92d3db299d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_3926ec7a-0226-4029-a1c0-6440b9a152a7" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_3926ec7a-0226-4029-a1c0-6440b9a152a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_880c615e-fc3f-478a-bbe6-1f49c3224040" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_880c615e-fc3f-478a-bbe6-1f49c3224040" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_06255b07-265d-4f9d-85f3-436bb01877a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_06255b07-265d-4f9d-85f3-436bb01877a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f9d64ccf-932b-4399-90b1-236c0a558446" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f9d64ccf-932b-4399-90b1-236c0a558446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_f9d64ccf-932b-4399-90b1-236c0a558446_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_fb0dda0f-17dc-4bc6-a487-33518d0aaa31" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_230aa51a-9263-4fcf-9da9-fc18de4ac437" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_e55c2211-4930-4b0a-a20d-3dec99591110" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_50c0744b-8ad7-4379-8c74-3ca37d419598" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_998eae77-aa05-418f-9d98-3ec0856e7aff" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_9ed2ac17-5f8d-426d-88d0-153382c3edf1" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:to="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_57e3c2aa-40a7-489e-8222-ff806fb995a7_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:to="loc_ifrs-full_RangesMember_57e3c2aa-40a7-489e-8222-ff806fb995a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:to="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c289b053-a989-481d-89f0-23a518f31928" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:to="loc_ifrs-full_BottomOfRangeMember_c289b053-a989-481d-89f0-23a518f31928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e001809e-4377-4b5b-ba55-11daf2cc4c4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:to="loc_ifrs-full_TopOfRangeMember_e001809e-4377-4b5b-ba55-11daf2cc4c4a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended" id="i9924c4de2827477e9c17bca5902ed3e7_ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended" id="i1cb984966d544cd2b6fefd7fe257ea35_ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0d571e31-762a-459f-a2fb-a400610e092a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0d571e31-762a-459f-a2fb-a400610e092a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_8f1f7d33-2891-4b02-9a10-c32ae9fc44f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_8f1f7d33-2891-4b02-9a10-c32ae9fc44f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_9239e601-3877-4d3a-b760-a139441f2931" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_9239e601-3877-4d3a-b760-a139441f2931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_fb9cc2c8-468b-4104-8bdb-8a7740c7ec05" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_fb9cc2c8-468b-4104-8bdb-8a7740c7ec05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_db8aab07-b006-4f1d-8c17-7ea9a25faf4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_cd707a89-096b-4f9b-829a-0720c888fe50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_cd707a89-096b-4f9b-829a-0720c888fe50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_68a90b68-b826-46fd-8474-7ec20c3654b9_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_68a90b68-b826-46fd-8474-7ec20c3654b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_270985d3-22d8-4013-88a7-5ce874284fc3" xlink:href="oncyf-20201231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:to="loc_oncyf_RestrictedShareUnitsMember_270985d3-22d8-4013-88a7-5ce874284fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_eba9aa2f-4264-47ba-ad16-1ba44f48d5c3" xlink:href="oncyf-20201231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:to="loc_oncyf_PerformanceShareUnitsMember_eba9aa2f-4264-47ba-ad16-1ba44f48d5c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShare"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended" id="i388dadf8c00e4785a57bfd5a88f833e2_LossPerCommonShare"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended" id="i886412e8791f477e94b177b2eb557a44_LossPerCommonShareDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivable"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="extended" id="iecad0b8a383f428b9bf06a69e9c4f72c_ContractLiabilityandReceivable"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="extended" id="i293e4d3732274c13909afa2e799bf176_ContractLiabilityandReceivableTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="extended" id="i35dde8acbd65425a8647ec55b555c596_ContractLiabilityandReceivableNarrativeDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended" id="i24be11b61083412ab67d09325fe82916_ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Commitments"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended" id="i79a51a82145b4e6e89bf5252c5ff4637_Commitments"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended" id="i64ef8efae24b4f3ab1f11391e5b0a9ce_CommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_ef5118e9-f9e2-46fe-a931-ee3c58521d9f" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_PurchaseObligation1_ef5118e9-f9e2-46fe-a931-ee3c58521d9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_8fe07a6c-7875-4d71-aa82-92d772cb4502" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_8fe07a6c-7875-4d71-aa82-92d772cb4502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_bef765a2-4f05-46a0-bf3c-6ad566b55c39" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_ifrs-full_OtherReceivables_bef765a2-4f05-46a0-bf3c-6ad566b55c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_4d0193fa-73bc-43bb-95b3-5dc675cf2f5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_4d0193fa-73bc-43bb-95b3-5dc675cf2f5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_420c349b-9aed-46d9-9819-c218bc9bba6b" xlink:href="oncyf-20201231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_420c349b-9aed-46d9-9819-c218bc9bba6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment_7548651d-ca98-424b-b74c-450e13954d9c" xlink:href="oncyf-20201231.xsd#oncyf_OverheadRepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_OverheadRepayment_7548651d-ca98-424b-b74c-450e13954d9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_73ee628b-bbe1-46ad-b785-f6a6527e7a92" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_73ee628b-bbe1-46ad-b785-f6a6527e7a92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment_33a70db4-07d4-479e-b79a-a1d948fe87da" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_AnnualContingentPayment_33a70db4-07d4-479e-b79a-a1d948fe87da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_e0bf7f9b-c249-4d02-8001-1f40549d54bd_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:to="loc_ifrs-full_OtherProvisionsMember_e0bf7f9b-c249-4d02-8001-1f40549d54bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:to="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_78026b2e-183f-4972-8302-4093362591b9" xlink:href="oncyf-20201231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:to="loc_oncyf_CollaborationAgreementMember_78026b2e-183f-4972-8302-4093362591b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Contingencies"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended" id="iec0a997f7e464cc997e975e2f6f0db24_Contingencies"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended" id="if8a60c2a068640ddb91af37cce3b4401_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_67960efe-3318-4ac2-9120-3d0d9aae05d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_67960efe-3318-4ac2-9120-3d0d9aae05d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b37e1cf6-fc6a-4d8e-aa83-2fd3a01b5f97" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b37e1cf6-fc6a-4d8e-aa83-2fd3a01b5f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_78a81c81-ab0f-461d-8bd9-8125e6ee3b79" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_78a81c81-ab0f-461d-8bd9-8125e6ee3b79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_6a0f6630-5ec0-4f3d-bd0e-d06fc079031c" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_6a0f6630-5ec0-4f3d-bd0e-d06fc079031c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_a805cdb5-0281-42ee-ad25-9b7f339d2e9c" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_a805cdb5-0281-42ee-ad25-9b7f339d2e9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_925eb3c1-d333-453f-a287-60c855496114" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_925eb3c1-d333-453f-a287-60c855496114" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:to="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_c252d364-9bd9-41a3-84e5-94e79161a85b_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:to="loc_ifrs-full_CounterpartiesMember_c252d364-9bd9-41a3-84e5-94e79161a85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:to="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember_2691d3ef-7d4a-474c-9b77-70a4e1381390" xlink:href="oncyf-20201231.xsd#oncyf_SYNSORBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:to="loc_oncyf_SYNSORBMember_2691d3ef-7d4a-474c-9b77-70a4e1381390" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended" id="ied35ef7ba8f74b95949c54658e3e1bc0_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended" id="icb1a69e453034d1dbdc057f65bcc4d08_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended" id="i366de75eaf834e0b8859866b776df284_IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNoncapitalLossesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="extended" id="i4d2539248e154b15b8972ac90e60346b_IncomeTaxesSummaryofNoncapitalLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_124521e2-aff5-44b1-93ce-466f9f06ba3e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_124521e2-aff5-44b1-93ce-466f9f06ba3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:to="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_77a23f06-3a94-46e4-8a26-32977da838bc_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_77a23f06-3a94-46e4-8a26-32977da838bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_c4e45621-face-4c7f-bba7-7ebb9e656be9" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentySixMember_c4e45621-face-4c7f-bba7-7ebb9e656be9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_efe15a38-96dc-4a2d-885f-c27891b929f6" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentySevenMember_efe15a38-96dc-4a2d-885f-c27891b929f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_93f9040c-4458-44c5-8d6c-bc9e1d7749f3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentyNineMember_93f9040c-4458-44c5-8d6c-bc9e1d7749f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_65a0e18c-dd44-4025-ba28-f7690b94d6e5" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyMember_65a0e18c-dd44-4025-ba28-f7690b94d6e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_990dcff1-1e30-4f8f-b9df-7af74e5d84ee" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyOneMember_990dcff1-1e30-4f8f-b9df-7af74e5d84ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_790a1be9-187d-4a25-9175-45c15263c957" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyTwoMember_790a1be9-187d-4a25-9175-45c15263c957" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_d2f239b5-9870-477b-a0f0-b123853c3ef1" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyThreeMember_d2f239b5-9870-477b-a0f0-b123853c3ef1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_ece7433f-c06f-4da1-887e-a94db91783e5" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyFourMember_ece7433f-c06f-4da1-887e-a94db91783e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_5516d876-8217-4222-bb5c-bcdaacee592f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyFiveMember_5516d876-8217-4222-bb5c-bcdaacee592f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_a7514373-1722-48f6-be79-9b2e07330a01" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtySixMember_a7514373-1722-48f6-be79-9b2e07330a01" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_97b07a0f-4ba8-4bc0-b624-1cc537dda94f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtySevenMember_97b07a0f-4ba8-4bc0-b624-1cc537dda94f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_e5e5975a-7e28-48d2-befa-84de91759289" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyEightMember_e5e5975a-7e28-48d2-befa-84de91759289" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_83ba498e-d8ef-427e-9257-474da09e2721" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyNineMember_83ba498e-d8ef-427e-9257-474da09e2721" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember_def0ec65-588b-40f4-ba98-07c9b13ee3d7" xlink:href="oncyf-20201231.xsd#oncyf_TwentyFortyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyFortyMember_def0ec65-588b-40f4-ba98-07c9b13ee3d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_94194433-b1d9-442c-bcaa-96a814a00e3b_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_94194433-b1d9-442c-bcaa-96a814a00e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_f67f5ea6-15f5-46b3-b08d-d2138f9a2a7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_f67f5ea6-15f5-46b3-b08d-d2138f9a2a7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended" id="iee34c9df501341cfa96f1c4fa428cd1b_IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_279a8208-5cac-4db8-ae6c-dcc2e490945b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_279a8208-5cac-4db8-ae6c-dcc2e490945b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:to="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_33402a0a-d941-4ca9-abbd-ff15c0848c50_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_33402a0a-d941-4ca9-abbd-ff15c0848c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyOneMember_40439d50-91be-461a-8070-80558cbb3571" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyOneMember_40439d50-91be-461a-8070-80558cbb3571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_de551bb3-a136-4624-a09a-7adf4c6f5c08" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyTwoMember_de551bb3-a136-4624-a09a-7adf4c6f5c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_90aafb3c-d5d4-40ca-bdee-482fac98eb2a" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyThreeMember_90aafb3c-d5d4-40ca-bdee-482fac98eb2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_acbe2116-6ed2-4d52-8f88-da7048d1ca15" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyFourMember_acbe2116-6ed2-4d52-8f88-da7048d1ca15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_8de9a0a7-f8a6-45dc-afd0-3e6ffba37999" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyFiveMember_8de9a0a7-f8a6-45dc-afd0-3e6ffba37999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_963b153e-c62c-4e74-8fe3-d5a397d618c7" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentySixMember_963b153e-c62c-4e74-8fe3-d5a397d618c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_5d010a17-4b88-438a-9ce5-28097de86e1e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentySevenMember_5d010a17-4b88-438a-9ce5-28097de86e1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_3b4ca50e-b83d-46be-b0c5-88466fe899c0" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyEightMember_3b4ca50e-b83d-46be-b0c5-88466fe899c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_75184abf-0025-44df-9f77-55995548561e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyNineMember_75184abf-0025-44df-9f77-55995548561e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_630f3dcc-77dc-4462-8361-206ca425f55e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyMember_630f3dcc-77dc-4462-8361-206ca425f55e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_a0eec5c3-d607-4780-9a95-671f648f661e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyOneMember_a0eec5c3-d607-4780-9a95-671f648f661e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_8b5df3c3-1a02-4150-ac87-510b4a8eecd3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyTwoMember_8b5df3c3-1a02-4150-ac87-510b4a8eecd3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_a9fb5f85-e558-42b7-a86a-8be920d0e1e3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyThreeMember_a9fb5f85-e558-42b7-a86a-8be920d0e1e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_5473d11d-3d43-42a2-a28b-6ca45ea04b38" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyFourMember_5473d11d-3d43-42a2-a28b-6ca45ea04b38" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_3497ff37-8ed0-42dd-a9a7-097f3d23738f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyFiveMember_3497ff37-8ed0-42dd-a9a7-097f3d23738f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_607b046b-08ef-430e-b9ee-375b2f492a68" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtySixMember_607b046b-08ef-430e-b9ee-375b2f492a68" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_a8dbac40-9db3-4d9c-a850-35caee17c935" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtySevenMember_a8dbac40-9db3-4d9c-a850-35caee17c935" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_66bf1f32-5af3-47b1-badb-d0b904b1177d" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyEightMember_66bf1f32-5af3-47b1-badb-d0b904b1177d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_4f0891c2-ab72-438a-808b-023dea3cf022" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyNineMember_4f0891c2-ab72-438a-808b-023dea3cf022" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_72644335-c779-4367-bdeb-c62a83d0d219_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_72644335-c779-4367-bdeb-c62a83d0d219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_a1e65e5e-c16b-4856-a82a-4bac54bd0850" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_a1e65e5e-c16b-4856-a82a-4bac54bd0850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_a6e051f6-77a9-4e59-8652-02b431101bf2" xlink:href="oncyf-20201231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_a6e051f6-77a9-4e59-8652-02b431101bf2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended" id="i902b0cb3f8b44848ade0a6eb85322bc4_IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_2652c17a-a682-4da8-8e7a-fd306dfc360e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_2652c17a-a682-4da8-8e7a-fd306dfc360e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_83c77754-4d1a-49e1-b411-9a133b895861_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_83c77754-4d1a-49e1-b411-9a133b895861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_64b4342c-a075-490f-9eea-f23aca32dc27" xlink:href="oncyf-20201231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_64b4342c-a075-490f-9eea-f23aca32dc27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_c3c86c9a-64b9-4d68-babf-3a774ca69ae3" xlink:href="oncyf-20201231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_c3c86c9a-64b9-4d68-babf-3a774ca69ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_1f14e61c-cefd-4e2b-b366-d23b17fa70f4" xlink:href="oncyf-20201231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_1f14e61c-cefd-4e2b-b366-d23b17fa70f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_b80516d2-e8ec-4e94-8f08-dd38528fd941" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_b80516d2-e8ec-4e94-8f08-dd38528fd941" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_7305f29a-de4a-4b17-b987-c8143c46f03f" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_ShareIssueCostsMember_7305f29a-de4a-4b17-b987-c8143c46f03f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_3e9ca0ff-9249-45c6-a568-8abc21686e92" xlink:href="oncyf-20201231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_3e9ca0ff-9249-45c6-a568-8abc21686e92" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosures"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended" id="i326b1f1f589b45bc8462881d551320d6_CapitalDisclosures"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended" id="iae6f23b68da543cf8d34b9ec68b1250e_CapitalDisclosuresTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended" id="i8638322380f44d2c81625de90f895318_CapitalDisclosuresDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended" id="i3dab795968744b3eb119d9ff9a5af899_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i7e060e20a9b5418abf98774b92cf3201_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="iebca044eaf304426af7e0aedadd08f50_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_49a0f9a2-70a2-4a3b-a52e-7583280cfbd6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_49a0f9a2-70a2-4a3b-a52e-7583280cfbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_24cff1aa-f139-4d35-9876-be379b99e37d" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_24cff1aa-f139-4d35-9876-be379b99e37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_c65c35eb-0338-4e4a-9408-dccc66ef91bf" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_c65c35eb-0338-4e4a-9408-dccc66ef91bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_44d8110b-ad6a-4dcc-91ae-a63d3ae29904_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_44d8110b-ad6a-4dcc-91ae-a63d3ae29904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_6e7ec6ce-d800-4a2b-8b9f-bc0d2ff8ace1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_6e7ec6ce-d800-4a2b-8b9f-bc0d2ff8ace1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_3cd126c1-2a9f-46a6-afcf-d67936e5e63d_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:to="loc_ifrs-full_TypesOfRisksMember_3cd126c1-2a9f-46a6-afcf-d67936e5e63d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:to="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_01719fa3-bd1e-4a66-8b2c-52e23f6263e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:to="loc_ifrs-full_CurrencyRiskMember_01719fa3-bd1e-4a66-8b2c-52e23f6263e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_968c2172-460f-46b8-a2b3-54123a3a908c_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:to="loc_currency_AllCurrenciesDomain_968c2172-460f-46b8-a2b3-54123a3a908c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:to="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_7717dda7-0232-4d9d-a69e-ca1950163b96" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_USD_7717dda7-0232-4d9d-a69e-ca1950163b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_8cb03e27-9ac0-4b0f-b7d3-ff600ecec891" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_GBP_8cb03e27-9ac0-4b0f-b7d3-ff600ecec891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_387676b0-f9e5-4460-aa2b-b4dfca7a7fa8" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_EUR_387676b0-f9e5-4460-aa2b-b4dfca7a7fa8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended" id="ice6aef4efafc4509bc661106ed2ec5e6_FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:href="oncyf-20201231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_71e0505d-0dc0-426f-b227-01b18f5a0b20" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_71e0505d-0dc0-426f-b227-01b18f5a0b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_c7cc7871-e87c-4350-9b2a-69d3231d446f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_c7cc7871-e87c-4350-9b2a-69d3231d446f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_958a6393-f442-474a-a22c-d6c829c53c73" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_958a6393-f442-474a-a22c-d6c829c53c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_e75178b4-2321-4e40-8ea1-99c2ba34b4e0" xlink:href="oncyf-20201231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_e75178b4-2321-4e40-8ea1-99c2ba34b4e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:href="oncyf-20201231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:to="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_0d1c5e67-a55e-4aec-952f-93d41127173b_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:to="loc_currency_AllCurrenciesDomain_0d1c5e67-a55e-4aec-952f-93d41127173b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:to="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_b314c5ee-2755-4b8d-975c-d4a4f0231f1f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_USD_b314c5ee-2755-4b8d-975c-d4a4f0231f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_b0ba9927-8c2e-480b-b5a8-8d8eaf812a7e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_GBP_b0ba9927-8c2e-480b-b5a8-8d8eaf812a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_95de4f61-bb43-4e0c-bcee-bf86759191f8" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_EUR_95de4f61-bb43-4e0c-bcee-bf86759191f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosures"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended" id="ie3760e3d7a8f4f3ba9c1f70219bc7244_AdditionalCashFlowDisclosures"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended" id="i319815c0cde143ae85b2c85ea9852e3d_AdditionalCashFlowDisclosuresTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended" id="i2ca4d867ee314f14829e5b5688b6b5ae_AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended" id="iaf8d90f9a3c44af585a3925eb80fa80e_AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended" id="i2b88129231224a528d09a694090dfc50_IndemnificationofOfficersandDirectors"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependence"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended" id="ie0b083dee53a4060bcc545719b4fc14b_EconomicDependence"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependenceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended" id="i7e757f23b4324c58ad1fab1325778166_EconomicDependenceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_ec88068f-22aa-45bd-b540-375cb2dd69bc" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:to="loc_oncyf_ConcentrationRiskNumber_ec88068f-22aa-45bd-b540-375cb2dd69bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:to="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_29d0cf7a-95a4-47a8-8f70-ce02ce456709_default" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_29d0cf7a-95a4-47a8-8f70-ce02ce456709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_d86c5b6f-b40d-4913-96ef-9ca75e0dc811" xlink:href="oncyf-20201231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_d86c5b6f-b40d-4913-96ef-9ca75e0dc811" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustments"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="extended" id="if8d8415417a74d82a7e3146a6421032c_OtherExpensesandAdjustments"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="extended" id="i99df8019b1044347808ad78c29ecda7d_OtherExpensesandAdjustmentsTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="extended" id="i82ae3d5efcc84519b05a9fb7f352adc5_OtherExpensesandAdjustmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_bd681254-ed2a-4c90-b851-eb5b08104e69" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_bd681254-ed2a-4c90-b851-eb5b08104e69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_68fb6404-84a1-4d8a-ac8e-6d1aa541bb15" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_AmortisationExpense_68fb6404-84a1-4d8a-ac8e-6d1aa541bb15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_25dfb64f-85bd-4ee0-ae47-458823757dfc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_25dfb64f-85bd-4ee0-ae47-458823757dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_cd12c992-a13d-45a8-9816-6ea329a35760" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_cd12c992-a13d-45a8-9816-6ea329a35760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_51f9224f-b713-4ada-bf25-b49eb1f5be83" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_51f9224f-b713-4ada-bf25-b49eb1f5be83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_f24541b2-965e-4eb8-b176-1133082afb56" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_f24541b2-965e-4eb8-b176-1133082afb56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_f508518b-ae36-4d0f-9c93-2ce6bf8e1305_default" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_f508518b-ae36-4d0f-9c93-2ce6bf8e1305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_3930f3f7-6911-456e-a0be-f104d78022e2" xlink:href="oncyf-20201231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_3930f3f7-6911-456e-a0be-f104d78022e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_08c0e53c-9055-4fa0-b7b1-11f209c4b327" xlink:href="oncyf-20201231.xsd#oncyf_OperatingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:to="loc_oncyf_OperatingExpensesMember_08c0e53c-9055-4fa0-b7b1-11f209c4b327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:to="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_5d569d95-f082-4cfc-a375-372849acb51d_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:to="loc_oncyf_SaleOfStockDomain_5d569d95-f082-4cfc-a375-372849acb51d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:to="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_8e2d121a-91ee-40b1-b7a0-4ce06854127c" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:to="loc_oncyf_WarrantsMember_8e2d121a-91ee-40b1-b7a0-4ce06854127c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended" id="i0a2c085cb76b4551b50bd7671b5d0ad3_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsTables"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended" id="i8e7b3db17c5d4aa1914afa40014e6242_RelatedPartyTransactionsTables"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i8928b1211a6743df9f312baabefcab85_RelatedPartyTransactionsDetails"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended" id="i1b11acfac43b48088fe47dfc41880a19_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended" id="idbe1ecea051d4767b868b9fdc42a0de9_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_de4046cf-2e30-4cb9-9fa2-a236b885bf8f" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_IssueOfEquityShares_de4046cf-2e30-4cb9-9fa2-a236b885bf8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9d394e24-85b2-469f-b321-fb393e40d9f3" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9d394e24-85b2-469f-b321-fb393e40d9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_db84d54c-7bcc-43a6-ae2f-4b49a53ed945" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_db84d54c-7bcc-43a6-ae2f-4b49a53ed945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_64737c69-6769-4bf3-a8a5-40c4a021db35" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_64737c69-6769-4bf3-a8a5-40c4a021db35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_95ec954f-7f7b-4020-b34a-71b65555fff2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_95ec954f-7f7b-4020-b34a-71b65555fff2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_34ece79d-5e97-4247-97ef-1691410636ee_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_34ece79d-5e97-4247-97ef-1691410636ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8f340376-b123-4a99-8f85-511248d6b750" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8f340376-b123-4a99-8f85-511248d6b750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:to="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d_default" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:to="loc_oncyf_SaleOfStockDomain_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:to="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_d7f63653-ad2c-41ac-adb4-00f9dcc6e80e" xlink:href="oncyf-20201231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_d7f63653-ad2c-41ac-adb4-00f9dcc6e80e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ComparativeFigures"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="extended" id="ifcdb54dfc19c4f8db693bf54febea03a_ComparativeFigures"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>oncyf-20201231_g1.jpg
<TEXT>
begin 644 oncyf-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
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MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
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MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
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MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
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MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
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MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
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M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
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MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
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M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
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M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
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MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
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MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
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MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
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MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
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MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
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MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
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M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
M"EPBC&T \X'3\*^KP<Z>'@XTHV3;;MU;W/S/'9MC<744L;4E.44HJ[U48JRC
MZ(\K\>-\9?AC\-6UKP1>1W?BK6;J)6AO;47LMMIZQ2NZVEL 5=GG6%,JK!$)
M)VY++[!!\;;Q]%L=/U318H_%G]G0/JLUI:G[+#=F/$BKR=O/123@Y&3UKG?C
MUX7T75/%=OKFFZS]JUY;66V@:WW;1;G)+OUVLH8CY>23@9S@<+=?MG^ _@;>
MZMH?B&SOK:30 JS:K;V$EU&]QL5RA"ODE20"2IP1[5YF,QE+"UOK.*K<L9VB
MDVDK^7GH>GA?K&9X*.6X'"*52#<W.*;J23LE%[Z)[)+Y7NWA_P#!1?\ :DM?
MV$?V<[+Q\? &E>,O$E]J$>B:7%?XCMUN9UE<23X&YHHQ&QVC#,2!E02:^*[_
M /X*9_$_X[_#R32/&&O6MGI6H%7N;#3;"*Q2Z'40LR_,T0_NEB#QG-8O_!4S
M]NC2_P!NC5/"7A_POI.J6_A/P;>3ZA'<:B +K5;N5!&9/+4D1QH@PH)+'<Q.
M.!67\"OV7O\ A-O#ENVI7U[)=:HJ_8+"PA\QR?-53YAQNC7[^3M(.W@\BO&Q
M'US-,0\-E_O1MKK:ZZ_+H?LV09'E7!N3QS;BN"A4G)<O-'GE%]$K7Y96]YVL
MUUU6F>/$NBZXR^3;S7%T7'RKRJ#/7/8=ZZJQ\9Z=I:>7J.E_;-,N\"[MI(SY
M9DSRP'&#[@@\5R-U8#PSJ%Y86\,=K;6Y(DE1P3,1E0H[D'T[9.>E7;/Q1-/I
M4MIJ$,-U!,HRF?G0*, @^O _*OSS%<TJ_(H.+CHU=W\]_P C]\R^7M:"JTZC
MG"233OI9JZL>F:O\,=-^'OA+2M?AM)O%G@W5)Q=6C!V$L%VB-&BW" C<B;B-
MO&"%/H*7X5^*]=/BY[[0[;R+?5-1C>[MTNBL5C" 0"FX$LR# 7HQW$Y%;'[.
M_CZSB^'4GAVYM4NM*N[H.CLQ6:SEQ@LI&0P( RI';M7J'P7TWP?=_P!O+I$F
MI3:OX-D\[58ELV$<:A/.#1)MW2$J."NX,P*CGBOK(YMB<5A(8*M*\(;)K7YO
MKY/=7MMH?DF9<*Y=E68XC.*%/]_6TE*^C6ZLMH]%)))-Q4K7U,_P]'XL^'?B
M74+;X@>)[73Y-4A;4-,U2X@-CI^GVZR10QPO.0H%P9'4JF,D'&YJ[71_V2I]
M4\)ZI+=26$JZE+,^OF>X>WNM$5T:6&VC=U0P1%.#&!A<L<[@17S?_P %:?'F
MC^*/V4/AFOA>5K71_%^L3^)H(-LL4DS+G<\T4OSHPED.%8 *5/'%;_Q?^)OC
M[_@HG^S7X)\4>3'IH\*I?P:SI<4WEG5[F*.(FZ@3_EI^ZW#:YW*5< L"*]S#
M\4XK+L#+"Q:49=/56LGH^J:]-C\OS[@G"YOF5#-Y0;E2;497T3BT]87E&VDD
MTNKNY:'1^$OVQ? ^M?%OX1_$K4)XO!=]HMN- UBU)DN87BCW1Y655)8&*5A\
MPS\@ZUYM\??VY=<LOVQO&7_"A=+T/[1XQ,.DPZQ)I/VO4M810@V)YY*Q(TBY
M"HB9VJ3R*\/T'4=-DM?+V*50DA9R&$9!P>.S#ITS1I^N3>&-;75O"^H1:5XH
MT_\ TC3+N6(&)9E(."#P=R[EP>#NKR<PXLJXVG1P]2.M-<JEY7=K^2N>QPWX
M>PRW$XK$TU*7MI<[C]GFLM=-[M)G<?MSCXO?&;R=-^(.K7]JUK91/;66EW$<
M6FW*C(,Q2%RC.7# EB0I&/EQBN]_X)T_MS:#\+_"4G@'XV>+]074M,U"'4?"
M^JZXDEU'9@0M"4\W!,;1Y;#.6&V4C("BOD_XT?$+XP>-?&VDZUXJT2'156PQ
MH]S8V_V6TM[8-O.P*Q=2[2A\$Y82*?NXK&\0?%ZYURV^RZI:VFM6TBHKO=P#
M= PX+(4VMD^Y-9T8KDO4LV][:K[SV:>!G._L&^5/2ZY9?<[IZ;]-=S]=/C-K
MFG_#3P-)XMM[=M4AM=)EO-%U".(2Z?=2792 1Q3J^V1F55D92K?NXR00<Y\%
M^+%^G@#X0V/]EZ?J2^(O%%HEQ=.T$AF@AEBC:02[F9#+).K2[D5,*4& VXUX
M%^R]^WW;Z+9>#_ /Q&L(G^&OAJ4R6HLHR9+56<LVT?\ +:(DX()WJ&;&?NU]
M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
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MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
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MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
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MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
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MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
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MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
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MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
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MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
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MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
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MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
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MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
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'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>oncyf-20201231_g2.jpg
<TEXT>
begin 644 oncyf-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
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M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
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MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
MP52^ /[<6G>.O#7P\^$^B_ _XF23OXJ\3:!IWER6NM^8ZQ/?P3*J,RJ[1AHV
MC41&9 N\,6/Z?5^+_P#P:\_\$)/B9^P!X]\3?&CXS64/AGQ1KFC-X?T7PVMW
M'<W%I;231337%RT3-&KL8(0B*Q8 OO"G"U^T% 'Y0_\ !Q-\4_V"?@[K6CS?
MM(_#D_$+XK:I917&E6/ATR6^O"SC>6..6>XCFA5;8.\VU)F99&1L1OY9V_"_
M_!63_@I]^T9_P4"_X),ZWG]CN/X1?L_VT^D3)XCU6[:5[&WCFM5M3IZ216NY
M)))88UFBAD3RI)4'1G3I?^#JW_@D!\??CE^VRGQJ^'/@?Q!\2_".KZ#9:=<6
MWAZV?4-2TBX@)C*&TC!F>-]ZN'B5@"9-VP*"W)?"S]CG_@IM_P %B?@3I?PA
M^*EYKOPS^#GAW2?++^+?#T&AR:K<6>YK&&:W6*.]G8N(4WLHB5(1*=\H'F@'
M=?\ !C>Q'CK]I%<G:;#P\2/^VFHU^=__  5_\*V_CK_@O%\7M#O"XM-8^)'V
M&<H<,$EFB1L'UPQK[&_X-[_V1_VU_P#@G_\ \%-[7PA=?"WQ]X'\"^*+B"W\
M>ZC>^'5N-(DL[;=-&8M0*M;LY9S$#!*QQ/)@;EW)Y;_P4B_X)W_M >.?^"Z/
MC_Q=HGP+^,6L>$[SXE0W]OK5CX,U*XT^>W%Q$3,DZ0F-HP 3O#8P#S0!^P?_
M  <__"+PSX3_ .""GCK2=,T/3;#3?!,WA]=!MH(%6/2@NIVELHA&/DQ!+)'Q
M_"Y'<U\&?\&.LK#XL_M$)N;:VD:(2N>"1->X/ZG\Z_3C_@Y+^$?BSXZ?\$;?
MBOX7\$>&/$7C+Q-J,VBFTTC0].FU"^NA'K%E(_EPPJSMM1&8X!PJDG@$U\$_
M\&<_[(7Q9_9B^*/QVN/B5\+_ (B?#VWUC2M(CL)?$WAN\TE+UDFNRZQ&XC0.
M5#*2%SC<,]10!^[U?GS_ ,' 'CG]C#X7?!+1-6_:R\'6?C:\O!/9^%M,L4E7
MQ!>%&BFF6UFAEBDAC#+#YDAE1/G5&)\P(WZ#5^)O_!V[_P $K/C1^VAJ?PW^
M)?PI\,ZAX\LO!>E7FEZOH>ECSM2MPSB=+B&W^].&PR,L0:3*QX5@25 /$_BC
M_P %6?C)^U+_ ,$G/B%\/?@)^Q-<>&?V;-!\%7>D)XI\0:@TUM;:1 D_FWT0
M:.WBFNDC@>0B*2<QW #,9695;PG_ (,S&*_\%9=?P3\WPYU,'W_TW3JZ3]BK
M]G?_ (*=?MA?L\Z%^R[/8^-OA+\!X5DT76-1\5>%8=$:STF0*7@+3Q17EU&H
M$@2.$Y<SLDD@C ,7!_L+_P#!-W]NC_@EA_P5*T:S\%_#7QI;S7=\WAV^\5Z?
MX>_M7P_=Z+/<!9;G[4R/;Q#9"LZK*R2*R1ADRVQ@##_X.XO^4SOBC_L6]&_]
M)A7[??&_]GCPA\-?^#9/Q1X/TO0]/BT/2_@7/J,<'DKM>\323=_:FXYE-R/.
M+]=_/6OR;_X.A?V"/CI^T!_P5J\2>)/ ?P7^+/C;P[/H&DPQZIH'A#4-2LI'
M2W =!-#$R%E/! .0>M?MI^TQ\-?$>O?\$*/&GA&Q\/ZU>^++KX(7.DP:+!8R
MR:C->'0VB%LMNJF1IC)\@C"[MW&,\4 ?@S_P9O2LG_!7*_"LRA_ .J!@#]X?
M:+(X/X@'\*N?\'F7_*6;0?\ LG.F?^ENHUZ/_P &HO["WQN_9U_X*BW?B#X@
M_!SXJ>!=!;P3J5H-2\0^$[_2[,S//:%8_-GB1-[!6(7.2%/H:^@_^#K3_@BM
M\7_VR_C3X1^-GP?\-W7CB33?#H\.Z_HEC+&+ZW2":>XAN88F(,P;[0\;)&6<
M%(\(0S%0#]-/^",__*)G]F__ +)SHG_I%%7\YO\ P=Q?\IG?%'_8MZ-_Z3"O
MJW_@B/\ $K_@IIH/Q/\ @[\+=5\"?$;0_@3X#UFSM=:3Q1X2@T*2'16.# MS
M>0Q3S1PK&[*L+-("5C8E&C0>6?\ !T+^P1\=/V@/^"M7B3Q)X#^"_P 6?&WA
MV?0-)ACU30/"&H:E92.EN Z":&)D+*>" <@]: /V:_:;^(/Q8^%7_!"VU\0?
M VWURZ^*VF^ - ?P]%H^BKK-\\I6R5_+M&BE$I\II,@QM@9/&,C\5?\ AY9_
MP62_Z%S]H#_PQ-M_\J:_H^_9+T:\\-_LK?#/3M1M+JPU"P\*:7;7-M<Q-%-;
M2I9Q*\;HP!5E8$%2 000:] H _,'_@V]_:6_;)_:(_X7-_PUMIOQ T_^Q_[$
M_P"$4_X2?P)%X7\SS?[0^V>3LM+?S\>7:[L[]F4^[O\ F_!7PCHEA^T?_P '
M!UKIOQ(9+[3?%7QU-KK<.H%9X[F-];*-;2;\JT;#$6",;3C&*_LHK^>?_@O!
M_P &V/Q@NOVO]6^//[,^F3>(K?Q9JPUS4M%TR^BL-6\/:HS^9)=VQ9HP\;S#
MS,QL98Y')VE1N4 _93_@H=_P3X^#O_!03X'Z/X'^+UFB^&=)U>VO[!K>[33Y
M89T#1K#'+C*+(K%"J%2PP 1@5#X#_8)_9O\ V%_V0O&G@W3? _A'PA\'[C3K
MB\\5P:A(\]G=6J0GSYKR6X=WD B4Y>1B0JCG &/YU_CO'_P52_X*K^!-+^$O
MC[X?_&C5_#]K+'>FUU7P1%X4L[V:)F$<ES=R6]M'(5\T81Y-O[M7VEU+U^MW
M[-W_  16^*_PF_X(,?$K]GO7_B)=>(OBA\0='F^SK>ZO<7&D>'F$42V^E6S/
MGR[<+ J.R*%S*^ 5510!\>_LV?\ !7/X"_LZ_M2>,-#_ ."=_P"QKXN^)'BK
MQT\::OJ*75W:VBQ)< K+!;LEQ);6;/.P?>UI#%Y<)* +A?R;_P""O7BWXC>/
MO^"COQ0USXM> ])^&7Q"UB^MKW5O#6FNKP::9+.W>'++)(&E>$Q22-NRTDCD
MJA)1?HK]AO\ 9L_X*._\$POVA=?LOA%\&_BIX=\3>(K0Z)J,Y\&IJFCSJ4+Q
MN+R6*2RS$["19!+MWKM;<I>-NB_X*4?\$ OVV(M.T7XV>.-%USXS>//B-&U_
MXRM/#ML-4U3PY>;TCAMY(K;/GCR?+&ZUC:*(QNGW$21P#]7_ /@[$8O_ ,$/
MK%F)+'Q'H1)/?]W+7S=_P9!_!_P_-X6^.WCR;3[>;Q/#>Z;H=M>N@:2UM3'-
M-)'&>JB1_++8Z^4GI6S^W-\._P!JW]L#_@V?\/V/Q,\ ^/O$WQFNO&%A+_PC
M]CX4D&L0:; 'BBDEL[:+S%8JOF.70,&F((4 */1_^#/#]F'XE?LR? 7XTV?Q
M)^'GCGX>WFJZ_I\UE!XET&ZTF2\1;>0,\:W$:%U!(!*Y )H _'C_ (.4/#&G
M^$/^"W7QYL],L[>QMI-0TZ\:.% BF:?2;*>9\#^)Y9'<GN6)[U]L_P#!Y/XM
MU:YMOV5='DN+G^QU\*7M^$,I\N6Y862,Q7NP55^8]G..ISXM_P '$O\ P3R^
M/_QM_P""R7QG\4>"_@;\8?%WAG5)M*-EJ^B^#-1U"QO FCV,;^7-%"R/M='4
M[2<,K \@BOV1_P""U7_!&&;_ (*R?L*>!=,T6ZL_#_Q5^'5E'=>'YM10QPS^
M9;QK<V,[;2\:R&.,A@/E>)<C&Z@!W_!KK\(_"/A?_@B;\-;C2;'2[B;QHVJW
MWB&401EM1N?M]S;LL^!\^R&*.+#Y^2,#I7H'[#__  0J_90_8Z^(Z_$+X=>"
M;35/%UK>SS6FO7NJ2:@^FNS,&CMT#""'8&9!LC#A<J6(K\)/@9;_ /!57_@E
M#X'U'X3^ O /QGTGP_=/)>I::3X*A\76=A+)(%D>VNHH+J.)F,391)-O[PR;
M=SK)7V#_ ,&X7_!#C]I;X%_M:S?&[XSZIXK^&^C0R2W<OAY]>9M0\:WCI*JR
MZA'#(P,,;3RR8G/F-)CY=K,Q /S;_P"#B'7M6\8?\%R?C5]NM9M6NK?7;&QM
M+&1I)//ACLK5(85"$/M=0/E0AOG.#DYKZW_:H_X**?\ !0K]KW]DO7/@KXG_
M &$XK7P/K.G+IL4.G?!KQ/%)I"Q@>3+:;YWCBEA*J8VV$*5'!'%?3_\ P<I?
M\&Z_CC]LOXOR_'OX$Z?:ZYXNOK2&U\4>%S<16MQJ9A01QWEL\A6-I!"JH\;N
M"PB0IN;Y3\;ZC^T;_P %??B-\.'^",WA;X[1VL@FT:?4_P#A!%L;B>!8UC,1
MUG[.B[ (F*W"SAY#*V99 R@ 'T=_P9Z_LL_'#]ES]I'XQ0?$3X6?$KX>^&_$
M'AJS=)_$OAR]TF"\NX+HB-$,\2*[B.><X!R 3QSQ^5_['GP(T/\ :<_X+7>$
M? ?B>$77ASQ)\4FM]3MB,K=VPOW>2$\C D52A(Y <FOZ6?\ @@G^R'^TI^RK
M^S%=+^TQ\3O$'C'Q-K31'3O#VI:HNKGPI;IO/EO>'<\LSM)A@LKQ(D<:H3@X
M_#S_ ()N_P#!._\ : \#?\%T? 'B[6_@7\8M'\)V?Q*FO[C6K[P9J5OI\%N;
MB4B9YWA$:QD$'>6Q@CF@#^I_1/"&D^&M,T^RTW2].T^STF/RK&"VMDBBLTQM
MVQJH 08XPN!BM&BB@#^;?_@]S_Y/!^"__8G7/_I:]?6O_.F)_P!TX_\ <E7B
M?_!X+^QK\8/VF?VJ?A)J/PW^%/Q)^(.GZ;X4GMKNY\->&;W5H;64WCL(Y'MX
MW"L5(.TD''-?3_\ PSG\0O\ B$L_X5O_ ,('XR_X6)_P@/V/_A%_[%N?[:\_
M^T-_E?8]GG;]OS;=F<<XQ0!^>'_!EO\ !_P_XX_X*"?$#Q-JVGV]]JG@WP>9
M-'DF0-]AFN+J*)YDSTD\L.@8<A97'>N*_P"#Q?PKIWAS_@KK:W5C9V]K<:YX
M$TN^OWB0*UU.)[R'S'Q]YO+AB7)YP@':OJ7_ (,^OV-?C!^S-^U3\6]1^)'P
MI^)/P^T_4O"D%M:7/B7PS>Z3#=2B\1C'&]Q&@9@H)V@DXYKSS_@[,_8:^-G[
M1W_!3G1=?^'GP>^*7CS0HO 6G6;ZEX=\*7^J6B3K=WS-$98(G0.%="5SD!E.
M.10!^D_[._P \(Z3_P &NMGX;M]#T^'2=>^ \^MWL*0A1/>W.CM>2W!]9?M#
M^8'/(95(Q@8_'+_@SL_Y2]O_ -B-JO\ Z,M:_=SX,?"[Q-I?_!OSX?\ !=UX
M=UVW\80_ 2/1Y-"EL)4U*.^&@>5]E-N5\P3^9\GEE=V[Y<9XK\>/^#4[]A/X
MW_L[_P#!4Q_$/Q ^#?Q5\"Z!_P (;J=K_:?B'PE?Z99^<\EL5C\V>)4WMM;"
MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
M^Q!U3_THLJ^P/^"P/_!L=^T%^WY_P45^(GQ:\%^,OA?I?AGQ;)9/96NK:K?P
MWD0AL+>W?>L=I(@R\3$8<Y!!.#D  _=A=4MG("W$!). !(.:_)W_ (.I?^"F
M/QL_X)O^"/@O>?!KQE_PA]QXLOM6AU5O[*L[_P"U+#':&(8N8I N#(_W0"<\
MYP,?&_[)'_!H_P#M,? ?]JKX9^.-8\>?"*XTCP;XJTS7+Z*UUC4GGE@MKN*:
M145K-5+%8R "P!. 2!S7J/\ P?%_\DS_ &=?^PGKO_HJQH ^@_V./^"DWQH^
M*O\ P;3^//C_ *]XR^W?%K1=)\07-GKG]EV<?E26L\B0'R%B$!VJH&#&0>^:
M_.G]@G_@Y&_;=^-Z^+OA[X=AN/C5\7/%Z6L7A%!H%A#!X>CC\Y[VZ=+>*%9"
M4,(4S-Y2$%FS]UOJ+_@GG_RIN?%#_L ^*_\ TIFKYK_X,HK"&?\ X*%_$ZX>
M*-IX/A[*L<A7+1AM1LMP![9P/RH X73O^#B']O#_ ()X?M?S:%\=-4O-<N-'
MNXF\0>#O$6C6-KYL#@2?N)K>)3&6C?,<D;,ARI(=1BOO#_@Z+^./[1GCW]ES
MPOJGP;M]:N/V=?&O@<ZKXYGBTNTF@6&:2&6W,LLBM-$2C*?W;#WS7P!_P>"1
MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
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M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
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MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
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M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
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M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
M!WP9XNTY+O0X= TV:6331':RW,"S/ 9BSHTH#&3(+#!&!CXY_P"#<'PQJ'Q$
M_P""Z7PHO/#=K-'9Z?J6J:M.$&T6EDMC=!MV. "'2/'0EU'>LO\ X+TZ?#J_
M_!>;XQ6EQ&LMO=>*["&5#T=6M;0$'\#B@#]'OV!O^"DW_!03]OG_ (*._"OQ
MCJ'A_P <>"_V;_%WB(D06GA)5T,:6J2RA7O)(#))O5 OGEP"Y^3;D*/WPJGH
MVD6OA_1K33[&WAL[*QA2WMX(4"1P1HH5451P%    X %7* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S)_X+6?\
M&ZO_  ^ _:+\->/O^%N?\(!_PCWAV/0?L/\ PC7]I^?MN9Y_-W_:8MO^NV[=
MI^[G/.!^@WPA^%4/PR^!7A?P/=21ZQ;>'M!M-"FEE@"I?)#;I S-&2P <*25
M)(P<9-=A10!^%/QJ_P"#)?P[XW^+GB36O"/QTF\(^&=6U&:[TW1)/" O3I$$
MCEEMA-]M3S%C!VJQ0$@#.3DG];OB+^PWX'^/'[%5M\#?B-I\/B[PF-!L]$N]
MZ&!Y6MXHTCN8B"6AE5XUD4@DJ0.2,Y]HHH _ OXN?\&0%K>>,)IO GQ^GT_0
M9')CM=<\-"ZN[=>P,T,\:R$>OEI]*^X_^"0W_!N3\)_^"4_C%O'']L:E\2/B
M<;=[6#7=1M4M+?2HW7;(+2V5G\MW4E6D:1VVDJ"H9@WZ(T4 ?F;_ ,%L?^#=
M[_A\+\?_  KXZ_X6U_PK_P#X1GP^-"^Q?\(W_:?VC%Q-/YN_[3#M_P!;MVX/
MW<YYP/J;X9_L#?\ "N_^"6\/[-G_  E/VOR/ $_@?_A(?[/V;O-M'MOM/V?S
M#TW[MGF<XQNYS7T910!^5_\ P1P_X-IO^'3/[7,_Q2_X7'_PG?GZ!=:'_9O_
M  B_]FX\Z2%_-\W[7+]WR<;=G.[.1CG]4*** "O@W_@N'_P11_X?+>&?AUIW
M_"QO^%>?\(#=7USYG]A?VI]M^TK N,>?#LV^3G.3G=T&.?O*B@#X5_9Z_P""
M+W_"A_\ @C=XH_9+_P"%B_VI_P ))8:M9?\ "4?V'Y/V?[=*[[OLOGMNV;L8
M\T9QG(KS?_@B=_P;O?\ #GKX_P#BKQU_PMK_ (6!_P )-X?.A?8O^$;_ +,^
MSYN(9_-W_:9MW^JV[<#[V<\8/Z944 ?E/_P6#_X-F/\ AZY^V!)\5O\ A<G_
M  @^_1;32/[,_P"$6_M''D&0^9YOVN+[V_ILXQU.>/L;]H;_ ()^?\+Y_P""
M7UY^S=_PE?\ 9?VOP=8^$_\ A(/[.\[9]FCA3S_L_F+G=Y.=GF#&[[QQS])4
M4 ?FW_P1&_X-]_\ ASG\7?&OBK_A:W_"P?\ A,-'BTK[-_PCO]E_9-DXEW[O
MM,V[.,8P,=<GI7M'_!8O_@D1X2_X*^_L^:7X1U[7+[PGKOAF_;4M"UVUMENC
M9RLA22.2%F7S(G7;N4.AS&A##!!^O** /QO_ .";W_!I%H/[(_Q \5ZQ\1OB
MBOQ"T_Q1X7U/PG)I-AH9TU5M[Z'R99O.::1A(JEMFU1@X.3C%>-R_P#!DM>:
M)\3)+GP[^TE=:7X;D=E4MX8;^TXX&R&C+QW2(YQP6PH/)VCI7[Z44 ?B;^T_
M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
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MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
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M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
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M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
M@?-_\37Q6AS4P90.G(I6*678=_9_,^S&_P""V/B\?\R+X;_\#IO_ (FHG_X+
M<^+HO^9%\.?^!TW_ ,37QE*XYK-NG+R>PIV1/]GX?^7\_P#,^X$_X+=>+7_Y
MD7PY_P"!T_\ \322?\%N?%Z#CP)X;/\ V_S_ /Q-?$$).ZKGE;T%%A?V?A_Y
M?S_S/LX?\%P?&1_YD+PW_P"!\_\ \35ZR_X+5^+KKKX%\.CZ7\W^%?$<, ,E
M:5E\I':E83P.'_E_/_,^W+7_ (+(>++CKX)\/C_M]F_^)K1MO^"NGBB<?\B;
MX?'_ &^2_P#Q-?%FG'%;5G*%0&GRHB6!P_\ +^?^9]D6G_!5[Q-<'YO"&AK]
M+R7_ .)K6M/^"GWB*Y13_P (KHO/I=R?X5\<:=-N(KI]'DW)2Y3&6#H_RGU]
MX0_X*(ZUX@\165G/X<TJ&.ZD"%UN9"1D'H,5\^_M ?\ !=#QO\$OC9XB\)K\
M/_#-U#H]SY4,\E_.KS1E0RL0%P"0PZ<5B:-J!TS4K6XS@P2H_P"1!KY@_P""
ML&@?\(Y^U1%J4:XBU_2+>Z!QP60M$Q_)%HB%/!T74Y7'H?3%G_P<&^-;@#/P
M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
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M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
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M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
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M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
M\#7_ ,//&FK:%J<:1:CHMY+8W2(P91+&Y1@#W&1P>XKT#]E#XY:7\*K[Q)X?
M\56-UJ?@7QU8#3=;@M3BXM]I+17,0) ,D3$D ]0>.0 :.VM'FI^[KL_E=,X+
M1-2GT+4;6\LYI+6ZLI4GMYHFVO ZD,K*>Q! (->Z_L@?"=_VH/B]XFUOQ1!K
M'C'^P=,EUN[L(Y\7>O7.0L4!DR" [=3D<+@8%.\/_!GX*^#M>AUK5?BVOB7P
M_9R+<)H]CH-Q%J>H!2#Y#E\1QYQACG&,X(R"(_@[^TQX;\._'/QI=ZCH#>'O
M GQ"L9])N[#1^)-'A<@Q2Q=,NA7+8P"68@< 4$U)N4'[-.]M[6^7<]L\&?LX
MZU\>;Z\\,^+/@#IOPYMKFSF.E>(-'C,#Z7<(A:,3DR,)D8C:20.3T&<CQ7X3
M%D_8$^-"MM\Q-9T56QTR)6SBGWW@CX8^"-.U+4;SXSZQXRB^SR+I>E:-:7=I
M>3RE2(VF>;Y(U4X+#!)Y ]*J?LW>*?"FK? 'XC?#[Q+XGM_!]SXGN-/OK'4K
MJTDN+5FMW)>-A'E@2",'H>>XP9L8\LE%O6UX]'WUWNR/X0S?\:_/C2?36=#_
M /1K5X/;ZHD+A7=%STR0*]X^!/B/P3+\'?BM\-=;\9VWAM?$5_8W>DZW=6$T
MEI<K:RL2&1 70NN" ?7!Y&#S?P"_:HOOV6;[Q#8:#HW@_P 6V6I78*7FM:8\
MI=8BRJ\:[U*!P<E3DCC."#5&T)23GRK6Z\NB/-'OXMG^MC_[Z%4+R;?T.0>:
M^K8_^"H?B<X/_"O/A21QD?V-(,^V?-I_QW^ GA[]K;X=WGQ8^$MBMGK%F-_B
MSPC$ 9;23&6N(% &5."<*,,,D ,&6IN/ZQ)/][&R?6]_^&/D]+*XALHKMHI!
M;3.T:2D?*[* 6 /J 1GZUHV&6%;_ ,.;S3];\.7GAO6)ULX;F476GW;8\NWN
M ,%'/\*..-W13R>"2+7B+X6ZQX%0M>6<RP<'S=A  /0L.P/8\J>Q(YKBACHJ
MM["M[LF_=[27EY]UOUM:QWNC[BG'5=?)_P"7G^IL?#G]H36OAOH[Z+<1P>(?
M"EQG[1H>I#S;4@]2F<F-NX(XSR037>6GA3P[XE\/7WCKX7^(9M NM A,^HZ'
M=MFZL5) (#DXFMV)P,[B#QG&0/#;J#>M6/A7XRG^&?Q4T?6(AOABN4BNX6Y2
M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
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M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
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M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
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MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
MZU:N(O2J,\!5Z7,!<MI<D5:F3S<5E03^61DYS6K;2>9'23T HZHGEK]*S8Y]
MY&.]:FJ'.[O67:6KRW'2B7<3U-&VM_-')YJ[;60':FZ=9-&.E7TCV#WJ2T5I
M[-0F>A%86HR&&4\5T]TJB'W-<_J%H6E/>@F6I!IURQD'''2MJW@WC<1@5F:=
M!Y<@R.*W(,,M 1*%ZNP-M["N2U*\(F*Y[\UV>I($@;UQ7#:I'MN2?6JOJ3(U
M- N/,DK?MC\W-<YX:BWG.:Z9$VQBA;#CL-NAG/I6:9MLGO5J^OO(7:!UJJ L
MISW-#0P,Y?I1]GWC=U]JE:U8Q_*.:6*'R8_FZFET#4K_ &'< >F.E6+>W*KG
MO4MNRS#;Z5<BL\)2!(@A; J0OO6GO:\<5$,JV*I 5IH QSBHTMMW;%7_ "Q(
M#3?+"+1L!7%ID8JK=V'/RU<DN=@-0I<&3K2 JQ1-&>G2K3M\OM4@3<N=O-0W
M+;(\'J:=[ 4;UMR&L&ZC*2FNB\H,#FJ\FF^=SCBFB'J9NE0DSY[=*ZBQ.U,>
ME9=G8>0W2M"U.P'-&XXE?7;@K ?:N7GNV+'UKHM:_>JP%<V8\3$>E"=R9&EH
MD_F+@_6M9&Y-8^DV_P"\&!Q6Y%#SZFB^M@W+VF7'EL@KKM NV9UYKE-/@RPX
MKH-)S&PHNC&1W.GW.Y16BISMK!T24N,5OV@WBEN8R+%N=_6O/O\ @J%X:_X2
MW]B3PSK(&Z7PUK:1,?1)5DC/Z[*]#B0(U1_'WP]_PL+]A?XFZ2%WS6%K_:4(
MZG=$5ER/P1JDSVDI>:/R[TV#* BNAT>U)92!BL30F$BJ>QKI]-F6)151/3Y3
M?TR+RP*WM/N]A7!KFX+S$8-6K*^)/6J)?8]"TJ[R@YYK6*I=0X958>A%<?X?
MO3+&,FNDLK@B,#/%)["-."W#"M.RCPOTK+L)N .]:D#87-0-JQ+/( ".]<YJ
M]HLA+;5))R>.M;EQ)N%9]Q'YK'BK0FS(C@+R#BK<,81<,JXSGIW]:MQ6X0]*
M;<Q;.U, CEW#'4&I8TWG;C[W7_Z]0PJ6/M5Z"#9S05$=!;+#^.!_A4AB"4AS
M2T$CHES^-23P;HNE.MX\"IDC)&"*2=RDCU3]DS]J5O@F]_X7\467_"2?#/Q)
MF+5=(E'F?9]V 9X1GAAP2H(S@$$, :O_ +4'[*0^"OV+Q-X7O?\ A(OAOXBQ
M+I.J1G?Y&[I!,<<,.0&(&<$$!@17CC6^*]D_92_:G_X4T;SPOXGLO^$B^''B
M+,6JZ5*-_D;L S0C/##@E01G ((8 U*.>=*4)>TI;]5W_P"#^9Y">15=QM/-
M>X?M1?LKCX-BS\3>&;W_ (2+X<^(,2Z5JL9W^1NSB"8XX8<@$@9P00&!%>)W
M$);(I\QO3J1G'FB0K)\_TJ]:OEJRRGE-UJQ9W6V3;GFB)5R\\.]B>PK)U-_)
M?UW'M6T'5X<@J>*QM44L#@9HW&T16SEGZUHV]GNQWJAI=DTHK>M+5HXQGBI!
M#8;-2O2H=0MA'&2*T45<CTJOJB!T(':@J1S$LYCD;BM#2Y6D&,57GLR9.F:T
M-*3RQTYH(1<6W"1_-WK*ULF*V8KP*W0N]*Q?$R 6I5>]5?0J6ARK7VZ?/9>*
M]2\$_"Z^AT<:CK&FZ@MC*A,"H3&T[9  SM(& <D$@D# YQ1\ _ %GINE7/BO
M6M+N+M890FD)(,6SNN=\[#&76,[0 .,DDYQBO5/"G@Z3]H;QRDFM7FJZ9H^F
M0F>2;3X@+0*HPL:G[J,V0!@$DYR#U"LWHCPL=F#A+V5/?J_\B]X0T'_A8.M6
M&@^#;2V9[>V^T_ZQ +.;9M^8!P26.,DAB"N,$9%?4'[/GQ-TG]D'X=-HOC+4
MK^^DN;F2=+BUM9;B!'. 85"@X.1G/<DYP0,_.WA[2='_ &>_$ULND:?Y6%DF
ME66Y!O+E0"R"=^&56/!"X'ID\CB/%'QR\7>+;NX^U:A-%;B0R0P#/DVX)!*H
M !A3^///7K[>&R.M4]YK^NU^_D>-"E*H[K7_ (/GW/KV<67C'Q9<M<?#W3;K
M1-0>2?3XKZ%MD[.Q)F;:K!<JV"#DYST"@#.\%_LF>%[FZU2QL[*YTB:2".YN
M+>WE$D$$A8LJY7<QC<(5R&) XV@@D_+>K_''7-9C@N+B?4(;&WB$:.C>8L4:
M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
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MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
M XQVXJY^TE,NI>"?#,T[1R7\,DD44B2>8)+<HK9#=&7=@@^YS7Q)TY3-QQ*7
M>Z_4\2F@Z;11' 73G@U<:'CFG6UON;UJ;GU?*4Y[/=%TZ5EW%JX;BNL-EF.J
M%Q9A7Y6A2#EN8T$90<TMQ<;1MQ5^XL=HX%4+FWR?>F3J5)I /K4ELRRL,\U4
MOHV5J6QDPP]JM"L:IA&WIQ5:=UC.,5</^J %4KF(!LTP>Q#)/@U2O'660KUS
M5BYX6JH.6I(@;;Z2-^[%;5C9;(P,5!8#=ANM::NL2^]2BHH=:1>4.:U+&;RJ
MQI;CY">E6=,NMSX-/<RD==HY,P!KKM"AR@W=JY7PS^^5:['2TQ&,4C"2-%MH
M3BIO"VH?V7XHT^XS_J;A&/TR,_I54J0M0\I+GOU%(QD?'/\ P5B\'?\ "(?M
MKZU<(NV'7[&TU)2!@%BGEL??YHSFO ]+EV./?%?8G_!9[P[]NU3X8^+(UXU'
M3)K"5A_>0K(H)^CM7QMI9^:FG8[,.VZ2_K8[GPQ<L&45V%O<;4%</X:?E:ZZ
MV;*"GS'1T+LNI$# -,M;AGER35.67RY3Z4^S?=)]:HQD=/H[>?(/YUU%G;>8
ME<OX83I77:9"PZ]&I-7*B+';%3MJW:H5-.$:Y]#4UO\ +2V*";:.HJC,%>K\
M\>X52G79TJN@I;A#%FFZ@_E14U;DHO2JVIW!D@Z<TH[ U8JI=X>MS2%5P*YE
M06'O6]H3;8A2D);FO);?+P*KFRRU7(V^2IH+?S13Z&A8;QW9^#?AW>)J5_<:
M=IPN%#R0QAVD9P0%V\<G:<GT&.*\+T;QL;R"]G:2VLA&DES8Q-.6CD4]F.<[
MPN<@G!YP,\'NOVCXE7X4RVNQB\UW#(CY.$92>O'7YN/QKS'X&WWAR^TW5-'U
MRWO(M54;;&YBN1$D:CYB'5E.X@ @#H2P!P0#3IQYI)'RN912Q#7H9VFZUJVA
M>(WUNUGADNE5E9GC#1RHRD#:IR""-QR.1C/%>C>$?BU<:#<:=J5M9?:EMY0\
MEK<9\B7&=P+ ACG)YX[=ASG6^EZ+I^L0?8)6:&.V)>&=70;F*DQD\@ Y/)R,
M]\<UZ;X4^'.G_%'14M;>ZNIHYAYDDEO'ODX<* =O.021QGL37U7]F3DG"GLU
M^GZLSJ4&]+%WQU^T[K7QS\&6'A=='TO2]+LY&D6."$&:1B "3*Q+$D 9R?R%
M>J?#[0M,TK0A9PVUOYDEJ%$LTH6/) R$50,L"22<XSU'2N7\7_ "'X=6,4.G
MW,D;QW A:Z"@[^C%0>=Q*D@\=\G KTN/X&_\([8RE=0M]Y^73[1,$B,+DN58
MC )W#)QDCC@YKHPN&EAX)2BW*3_*P1Y(4M4_>E;31Z?I^9I^%/&5MX=TZRLY
M(/M"VD0AB>Z0NL>3D$C 4G' R",?B:W=%\+:EK4=K=7T5PMG?\02,I6':>?E
M& ,@<#N.E,^"7P]NO$BZ2M]8HUU;7#7$R2H7FDA5\% .@)&.N.N!P:ZSX9?L
MU>+_ (:?%OXG>*/%?Q(O/&7ASQB5FT'P^(G6'0H_-WHI7&Q#&H$8$9.XY)P.
M*\7/JTJ5:-*%/F4GJ[KW5_P6?04\KP=6C7JXBNJ<HQ4HQ:;<W=)QC;9ZWN^W
MS3M#\&V-G>"UMKQ[B[C8EIBJHH S\B$<D\@DGWQFNNT2!O%&NR:?K$<EU--&
MJK,Q/F (,!<XZX]3^M/3P4='*ZC-8W%C;R!GB1EV'=C&1[9Y]LXZUW7@GX6S
M>)?!=UK4]S-;W-KN:,%MO ')SZD#@\5YM:FDKQV/G:]'E5UT/BC]LR35O^$S
MT:UNHX8=$M+:0:9%&^XABX\YW[[BP7KD8"@'K7D^<1BO5/VW+J^N/C)!#<?\
M>]MIL(M0 !\A)+'ZE@>M>0F4I&<US\I]-@?]WAZ#;R]\GH:A6Y:?'.:S;N61
MKA5569G8* !DY/0 =ZWKKP'X@\*V\%QJNBZKIMO=8,,EU:O$DG?@L!D^U3S)
M.S.O5B"W\U%SS236<JPM)'#(T:?>=4)4?4XP*O6H'E9SS7HMIX:\5:E\5O /
MB'2/B%:Z'X#TGP^TVK>",#[;J/E^8)K@0\M<1RGC>0 N"03C%>?F&.EAHJ48
M.5VE9>9Z^3Y;2QM:5*K6C22C*5Y7:;BFU%63U=K(\B-X;=<DU3N=2:1B<_+@
MU0U[4-URX4[5W$@>@)R!^50V!:Z7 KT#Q;ZE#59FE<_B:M^&%\QB.^:+[2'#
M5;\.Z6T<@.UE*GGBJ3%8ZBTM<VWTJI>6'F'ID5=BF\I<"NBTWP']MO-'LKG6
M?#NG:OXB0RZ5I=Y?B*]U!1N *)@\,5(7)&<<5C6Q%.BN:K)16VNAW8?!UL1)
MPH0<FDW9)MV2NWIT2W?0ZK]F5V'@SQQIH.S>-/O5/;*3M$1_Y&!_"O1?V;OB
MBW@WP;XD\87IV0>'79+.,GBXG!,5O$/?<,G'4;B>E>;_  4W65IXYMV_<7!T
M-D9&&&0K=0;OH5&?I3O'.I_8/@=X3T^W3RK2_N)]2D /^L<*J@GUQO<C_>K\
MZSC QQ?$%/#S7NR49/SY5)V^=K'J86RRZM/JO=7_ &\XW_"YY?XDEGU.^N+F
MXE::ZNG:::5N3([$LS'W))->U?L7?M8S?"/2!X4U>_>QTQKE[BROBAD6Q:4J
M)D8#)V,%# @':XST)(\6O)EE8CUJ.QM5,FZOT#&X2&)HRH5+VEVT:\TSPHRY
M9J22T[JZ^X^H_C1^S'H_Q?\ $FN>)_ OB*.[:[E:Y-M<7,4\<I(!(21#N4>@
M=3@=2.M<%X/^$\WCWP!X8\/J_EG5+J;4KQI0?)MX8I<,&'1]P0 8/5P!G)(\
MKAME524^5L8)7@_B:]\^'_Q?A^'?A[P5<:PGG>'+C26TZ]E@\M9;/%V<N=Q!
M)50F2,X';%;Y#AL10J2C.ISJWN^ZDUY::/RT3\WT^,X\E#^SHQEI%RBGN^CW
MOY[LR?BGX3_L3P]XNA4VUE=NMOY:QY$NT>8REL?*BX/3J3CC&:\A\-7.FI+)
M<W NH;^ZLEN_.B"E3<KE=@YXC8'.3DY &,5O?M"?$9=;\7^*H](\6Z3>M.42
M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
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M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
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M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
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MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
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MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
M7EF S@ D@8/;/2O*?BQX_P!6U;7SK&EW%U]@8!KLQX^0_=5^AP#@#D\G![UE
M+"N4KL^:=6I0I24(NRW7YOU7_!/?=#^&GC;QY\&_&^K>"[NQT;QP;22UT$WR
M++!970=3(0T@*-B/<$)! W DCK2V'@.XD^'7A5?'FJ6VH^.+331#K]UISQI!
M<S[SM/[L!2X7 8J,$_2L'X4?"S3OB)XD\!_%#7)/%T?B#X8^'[RRM;>UO4.D
M7Z2>8S32KDLKJ'(8 ?/A03@"J'ADZAXJ@6;9-#:&/S4.0#CL0,\$CG![9K\Y
MS'*L76Q\IQ@[+1*-K6[Z+\S^D.&>(:.)R.CAX.-2I[LIR<&IQE9QY.9NS37O
M.RLY6?2QU.G^&;+149;'5[C?U*W"AN_ !&#7266M^(&TK=;127_EL(QY3C;@
M]"3V KS'59;B">-=\D8F ".ZX!)Z<Y(&?>MS2_B+/\.]42WD;,,T8\T9ZL>2
M?P[5Y.(P-:C/EK0=^S5CV:%2Z;>WD>LZ7%JS60;4+^.Q(SF*']XW3UX /YT^
M%=%N(W6:>^FE7)W^:%;';M7F?BOQP=$:SFNKJ06&H ^5<+R$88)5AZ@'(]1T
MK%;XB6CZBR1W=U?(8]Z2QH%49_O'/'X@$=P*G"Y7B,3=4(MOR7ZFSY7LTEY[
MGIWC#PCX8\3: T%YYVY?]7+(P:6/G) ;&<'TZ5DZ/\%O =] &LK*_N) Y+">
MX+'/7&%P"H['\Z\\U#QC;W-S#;37+VX8D%Y&P"23UY('0]:=H_Q D\.:LL*R
MA5B; .[M5RP^,PJ]E4YH^3NON)C3I_Q)I2/9[3X?Z58P".'0]!5,DX=,M_6B
MN?M/&T=_;K(MVT>X?=&#17'^]_F_%G1[:CTIQ_#_ ")/ _A_P]X.;=IVE(L@
M;FXDP7/T/^%=>NK1^);GR+>=K*=N!@ K@?C7FUSJ'B3Q!/%IBZ+:Z2"2)+TG
MS$VCJ<@XSZ #FNTT+2[#X=^#9-25KG5[F3,4EQ*,(A')"CM6^+PLJ;YL1)-O
M:S4OOM=(UA4Y?<HJWRM_PYT5MXTN/"$)MX)&N$\L^;/U8M[#L!V_6L#Q=XTL
M?+^T/?6Z[E+ RMDG'?'KFN>C^)T-]<,RPV9)_A>,8(]"*<VE^'_B3KC6=YI=
MO%*8MSW%O(81$B\Y&#C'MCDUSX>EAZE1?6;QCULDW;T;1S2K4T[[R\_ZN<[K
MOQ5_M'2BNFSO>S,2FU"?O9XP/0U>CTS7M,T$PQ6EQ/=W $ERQ(&/1 21D#OZ
MFMSP=X?\/^!;P6^F26T(G.UKFX4/*[=  ,8!R1TKFO$?C34!J\MN))'*.0K,
M",X.,FMJWL(2E#"WE"^C:LW]PZDERJ3WVLOS.<UGPMXJEMY(X=%FGADPS1"5
M,AP<@]1P<UQ]_P"$+X0&35$O-/!!VQM$5&>Q)].W6NPU;XC2PW?ERR-'.IY'
MK7=>!K";Q3:B:YD46P +&12R?3'.2>P'Z5Z66X^C0NZ]%33[MZ>G3]?,XIR5
M1<COZ'CUC->0W^E>%=.D2S_MR=5N;A@6WM@GH.2% .!GD_6L36-?L8O!UEXL
MT637/[-DOKBQ:WU2R%O=B2WP6D"J3F-L\9P0<@YKZBG^#?ANWT\ZHUO')<VS
MF:&6Y;'E,#QM' !!Z?SKCO%OQ=NH)=L]W]ID;*C('3T]*\F5:4ZRG3^'6ZMO
M?SZ6V.^M+"PP\H\KYWR\LKZ12OS+EM:7-H[W5K/>^GRO9_%%=7N6:X_<VKN7
M\A=V+=6)48Z D<9/&>.W%3:SXTDB$47V:1XG#@/+"=W)X('0G'?MQCO7T%=?
M$4Z@!%-';2AB&V.BD$]1VP<&I?"N@^'O$6IJPM;73KV-A)NA0;)#_M+TR?48
M-?82XLG&@L/AZ7LUM=._Z+[]7U\SRH4>;X97_#_,X_P1HVF_!O3+6X>VAF\0
MW"^;)/( W]GY&1'&<D!L'YG'.>!@ YK3_%F475Q<S7J11J<N6).!GMU)J?XA
M? GQ]\6O&M[%X1T6XO+:WG,<MS*ZP6T3$Y):5R%[\X)/?%=!X>_X)\:Y8Z;,
MGB/QEX;M)IUVM#9VLM]C)Y!9BBG(YR!U_.OF)2I1?-7EKU77Y;_D:5^:+5*B
MKJR_'77S]3E]%U%KS1-9\421>)M;L8KZ"RCTG0[5;B\DDF./-(8[5C4#DGG)
M XKGOBAHLG@_X@ZII]O(MXUC/Y:/M\MB" <$9(# G! .,@XXKM3^P]_PC%P_
M]C_$>ZLIYB$<6L3V8=3U!(=C[XQBN1\2_LI>+OAZEW)8RMXALU_>>=!<&2=.
MC%F3:K'!SR"2.>@)KW<'6R=UI3FW*#2M&UFGU?-=7O\ TCHK7EA8ITK33DW+
MFO=-*RY=ERV;NM[Z[(Y.U^(U]97K;[E(OLI(D#GD8[?45Z#\(?#/B?\ :BT2
MY=[B'1O!:3"%]0F@\U[QU.2(%; RI&?,)PIQC)&*\XO/@=?>.-?TGPY&\=G<
MZK*L<QSD01 %I9"<8 1%8G)SQWKW[Q-\4H_#^EV6@>'8O[.\->'[9;'3X^-S
MH@QYA' W-RQ)Y).:^5SK&1IOV6&5GY]%T^89/AY<_MJFJZ7_ ,BQ;?!WX9>%
M?!>L>#SX7AUS2]7\IM3FO[F1KN]>)BT9,JD%0I)X4 '/2JOC?Q#=ZCJ/VB.X
M_L^VABC@M[>#/E01H@154') "J!7+R^+O)CGN,R21VX#3R;"P3<< L<' )X&
M>,UP/BKXLW.H:VEG#<)EL-(X7.Q2<#CID^_2O#HY7B:U1-Q?O=6M[*^_E>_S
M]#WJF<<]Z#JN2B[\O-=)NR;Y;V3?*E>VO+;IIV%MKNJ:=KOVAKB&XM(U>>=I
M#M,2("Q<CT& #CNPYYKI--_:&O-*D@O_ +,T%C?1HUBX0A9UV@LV[/.=PQCL
M.^:\J\2?#:S\565GYLMS=>8DJSE+AHGC#@$2!NA(94.S&",@$=:SO%7BC0O"
MVCZ5H\=KJ$ESI%JD%[J$DSD7CDDB18S\J@98<<D!<@ #/Z#5X3R]Y-[?F<JU
MM4EK\7\M]NG-N_O1^://LX>?/#5:26'ONV[/W;_%;?KR6\^TCU;XK_M"W6L^
M#;U;B!KF\N,?V9' A<&52&43+D#:0""<D X.#C!K>'/'FH>(+JQUM[35/#D]
M\_F:?9M');3QA",NC9'F M@JX R", <UQ/@!Q+8),YAN/-.^T<D'([Y/3D$C
M'U!KT3P7&/ WA&RUC5+[[5?P$V>E12L2L; EFD56)PL88$#.-S+V&*\3^T<K
MIY)]05']]?XO75V>K6D4FMF:_P"K^:SS[Z_"O_LS7PZ[I:76B>K<DWJK>A[7
MXI^*MYJ^@GP[<C3Y/$+:9':7EVD0$LEPFYUB8]/DW;#CC.3CI7!_#[QE=6.Y
M9H7C95*N2PR,#GKQD>AXKC=5\;V&BK8LLX,CEG=@1R202<]>3^-4="_:4\-Z
M[JKV:W=O%JZF3-@)4>[N&1RN$4,=S,1P,YYY .<?+X+"UYSE.,7);ORZ7?EY
M_P"9]IB,11HTHTJC4;W2OI=V_/LNVVQVTWQE;4O$,%GI?DV>J1VSF:6^(CP%
ME"RMY;# *KY17!PX<M@ 8JC\1-5UJ]G9KZ\S&,XC0%0 /;->R?#?PM;ZH#<7
M,>V:6-<[AN8 # '4@8!P<=?>N%^,7@VZ\5^.8M'TV%TM8 );N<$#<QY"9] .
M3QC)'I7V6;5</F]>C' X>-%0C9V=[M;O9?(^-X9P.,RKVRQF(==SFY*ZM9=$
MM7TW/-_"VLJMY;1W5\++3[F22%YG&$C*PO*2QR,*0A&>Y('K5[PW\25U>TFM
M=]F5FLI9X'&-DJL"5V$<$X&/4UL>)/@"UEK6ES>4S"Q621_N;=SH4(7@E6"D
MG)!4\ C/3SOQ)IVK:IXIM9M9FL-/F,,-K+<Q6Z10HB802LJ*H!X!. .?89KZ
MZKP7E=?+*<<-+]\[)NVN\MUK=;:QUM;1GGTLXS_#YMB*V+@OJL8MQ=TD[*%[
M-M6>]E)\K=[-(TI;&\&I(Z(T6 N".". >*[3P)^QCH_[2GQ(TF^N+7^RM:L;
MRWO)[^*)3'>K'*K,DR<;F95(#CD=PPZ9^E?$'2_$_CF'1;?2)-0\8Z,;B'4[
M.SD$HL[;>!%<NW.#(JH0H!)#< 8K[4_9 \&0VEO=77V62$XD5#,@!DP,!Q@G
MY3VSS["OD\VX7Q>5U:<:Z5Y=4U;?[[6MTMJ>AEW&N!S?"5:F&;:AT:=]5HWT
MO>_7IJ>+^/?#[W/B?5)%LV:[NKR5@K*/E!8L">W0_C7 ZG;KX)U$PZLK6(NH
MIFMI?+)B=HTWE&?A%9A]U2020V!@5] ?M(:'XFU75=*M/"5CH\T=UJUO#K#W
M^_$>F8;SVC"%6\X[55.< G)&!7S1^US\+K'P?XB35?$$,>IZ5!?FXL-/BU'R
MIOM<\1BBB6&1E\\E5+D0DL#P%.0:Z^$<GRNO6DLSE:-K_.ZV=]/NMYW9P\99
MMG-/"4YY1#FJ2DE;?2SO=6V]'=;VLKEVPTJ/Q;X CU6QU.-FNH5VWEGN5)&9
M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
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M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
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MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
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MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
MCT %>C>&[GQWJ7B)]8A\/K*VH2>8D5K,@ 4#"A8MV0   !SP!UKV.+*F45L%
M3A@/CV;Y7LNEW;JT[JY\5PG1SYXZO5S)^YNES*UY=4E?9)JSLET[GTTF@R>*
M[K3X;7>;N2/RMB@-\W0 CKG->:^)/V,O$VD?M/Z'=W%C;Z/:^+!(;Q[F4)$)
MH0-V#_>=65@HY)#^E>]?\$K=)U+Q3\1M0\0>(=.DM=)\/6S&*6[C*B2X<@ +
MD<[ ')/..,\U5_:VD^*W[2GQ9TGQ5H=AI.A^!_#L\TV@KK#FVBU21)8U$Q8Y
M+&1MN !RN,9P<_G^6Y;6LZT9_#?2U]$M6^R_R/TC#YE&%3ZK72Y6EJW97?PI
M=W>QTWB.*/X2>!)M+T];6T6U(2ZE\])'C=A\IEVDE=W100..>IKP_5_CG8V5
MYMN);B1R2-X8$ \YXYXZ8Q7E7Q'O/^&<O$_Q(UZS\&>-H=2^)5UC5M3N[V*_
MTRW8R^:XA>(MU;A0Q!49& >*\@O_ (JI?W :*7=SDJ>"/4$=<UZ>5T_;P<ZB
M5[][NW3T/2XAE3P=:-+#3<J;C%W<>5.32<DM7>SNKIZGU%=^+7\5Z>US#>1L
MD7"H 0P(X ;G(! ST.!S6':>+;S[:L;/;P$. C-DAR?T&/?%>"Z)\3Y[&5)(
MW968\@]/RKM]#^(8NH-]Q"PW9!. 01WR<]3T-?9X?+\OK4.6;Y)+K?\ '71_
MUL>%#&4YGO?ASQQ=>%;B"\MY-TRD;F;E.HX ]ZV-:U;3/BGICMJ2!+Q"3%<@
M /&QYPQ_B4GJ#^&*\5T#QC):I$E](T4$@/DKRS.N< 8[8X&376>&9I+JZ=84
M9H9V *+RV2<#COGVKY.IAU3D^5[=>X_K#D[;>1R,7CW4- \42VOD/%+8RD2I
MO.)#R00>F",'/<=ZZNY^-MG-$D&HV=Q$9"0?W1='W9 .Y<].I&>A_"M?XP?L
M<_$+Q#XJTF;0-%6ZBE@*Z@WVF-%L&!#)YQW90LK< C/%:&C?L&>(M/E^T:KX
MJTFS++_J8(GE9#GH2< CW_2O=R_B)8.DHMKEWMU_ <_:\_+35^^W5?Y'G\7B
MQ; W46DW4,EO,@9H\X:+KSCU'3CJ/?-9:^*KNWU5;P2+GA2,Y'3!%>EZ_P#L
M5W2Z@L]MXHMS/GY]]NRJ1C!Y!)S7--^S!KVA%_,EM=23<0/(EP<9X^4@'/YU
MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
M(XR,TW0O%VM74^V/7+B2&2!YCTR@)(Y;).1C)YX&,<U<TNRFUG2)H[=6D.%2
M26(9D(9R"X&1N/S$9/ QG@U\C]6J1KRJRFW%I>[V_P"'_KI;HQF88:>74,%'
M#QC4@Y2E43?--2V36RY5HK?<G=R?\+[C2_$/AR_TNWT[[':ZE"8Y;:;]Y(LQ
M8!0QY!R 7XZ=3CBN$_;8LS\%OV*?'\>@QW-S-X@L6T73+.)2\SS3R&,D= -L
M9=B3@ (3G KV;P5X<;1KVY5_LND6T<4<2!)(VN'<<LS$9 &<C!X([8KXI_X*
M#?M$>&_VF=)\8>#?#^I7VI>&?!)&CZT-%E'V@7-RV&G R-\<>SR\@@-YTG)&
M">#.L9[#"SDE=M-)?+]$=O!>3SS+-Z4(Z1C*,I/LDU;3=MNR26K^1^9_C72-
M5^%FIPKKVE7VGS2Q>?$MP !(O0.&PRL 1SC.>G%=MXW^./A\^ M9\_5)KS5+
MO3XTL]'$<<L1#QEIQG.VU"/&CDC)<@@#!X\O^+>HW7C2W\/^#_"NC>(I=&\&
MI<VYU+5PL#7$LD@:3 W%45"H"H&)ZYK&\&?LC77B6[6Z\0Z[:VVDVY9I[?3P
M9;JX(&0BLP$<>?[QW$#)P>*\;AWB:ME>#JTI1BG5BKW2;2UO;1[I];I=C]3X
MZX,H<0YE0KJI.4<-.7))<T(SU7*Y)R]W5)V34NBEH4/A#\1]4U"\\BUTNXU"
M\E9F*V\86.-B<CH" /0 <5[5X=\$_$OQ&T:[_#NA0A0IDGE$DH7KT^<CZ8'T
MJGH&B0Z<BVNCVUOH]G;#:D,!^4]LNQY=CW8DD]L# '5:+XEU#P^AW-"Z+T,3
M#+GH,#J37#6XDJXA<D)*/R_X)]5_J[["%ZT[OLMOZ^XVO!?['R:U:W&O>(O'
M%AIEA8S""6^N[5A'+,49Q'&HRS,%1F.%X )->C:#\,H? VMC3+O4=,FN=6%O
M=:;J;R9TZ>%OFCN&?/*X.0, DK@C(KG_  +\=(TT.^T'Q5X7FU?29)OMT,L$
MZVMQ83&)H6=)&1UP\;LA!!/.000"-O4/BR_QC\:6\*V-OI%HEHNFV-H"9%MX
M5!49;'S-EB22!DGC%?/XZM6]IS3ES_/[_,]#*ZU.@G&C&2E)N^BM:RLUJVVW
M>]]/+J_'Y?@)X[O-<U74IM-OM0LM#O'&HW2 .2PR\LI&<G=R<C( (&>!7,_"
MR6WN_&EK>7]LMQ!;7,ER8C )"ZD' <,,,J\'!''XU]&_"_XJ_P!EZ??02-JB
MWUO XBCAD(>=5Y>+&0&. 2 >3C )SBH_&/@CP[\3/!#^*_#;JMW!;B2XB$8B
M9X0=I<J  0",-Z'!Z'CTLMS:IA<3#$QA\+6FZ=G>WS[]#S>(LJAF675<'S?&
MFM&U)77*VM]5=Z:I[,Y7X4_#N'X3:*(8?$$-]XBN8UN606:)83F5V<E2@#JJ
MG"X&!CC&<&OI=OBWH^B_#:'2;N^LX-7U5%BBB$H$LX) D*(3N( /7G&>3FOG
M3P-X0NO&EO-:PO-8RW%N\"WT( >VW# 9"0?F!P0.>0,UZY;_ +(V@>*;/PG#
MJNI)J'CRPLF_X1N/4+]X)-7GM@9%FF2,;6"R1LXW$ D.!D9%?0YGF\<VQ]+%
MXF*BERJVBVZ<VE[MZ7].A^9Y+PA#),LJ8.A.525YSO9OI>[BMK)>]9]'+R7K
MGAJ?3M#T^#2[A;>/5Y$$JV:D22&V)PL['. A49))ZJV,D8KD/CO\4;7X6> M
M2U"RTZ;Q-JT" VFD6T;-+>,6 X*JQP,Y( )XQCTYO]E_5M,^*GQEUKX;>)M8
MO[7XB:7HUO>:KI.F/&+/2C&0KVVY058YFCD( *@O@$$,*]H^-^I?"?\ 9V\)
MZSIVL>(-,\,ZY>:3<&WA@E,NK9DB95>(<NK$_=.0,C.0 37V><X[*\/5O@)>
MTT3OJE=Z]4G;RM?>[V/G^%<WSF>%?]M453J<S22:?NK3HY7;UN[V:LTMS@+C
MX!ZI\0/"%SJEQHU]INIWEN%M-.M&1);9I@$=I"PVG:KMN!&< C&<5A_MA?!/
MQ]\%_AGH3?"NSN;G5;B:"R_<V]I#86C0G?%/,9\PVZ%@H+  X#88'%?*W[%?
M_!6'XB?LP:)/H?BS3V^)6AP,!8R:A>M%?V8'!43;7,B'J X)!Z''%/\ ^"B?
M_!274_VZ?"OA_0]/\)OX/T71)WOI8WO3<RWLY38I8A%4*H+8&"26)R, 5\O4
MXLQ=3#2PTJON.]X[Z.VFJ=DK75NK;WL>Q1X)HU<WIYC'#+G5O?VLU?5V:;;N
MD[WT26US]4M*_:(^&>L>"]'T3_A87@%_%>GVXEO[&TUJ"0(^T&;9\W*JP;!/
M.!G%?GK^TI_P5Y^$GPR_:IB\8>'_  [XT\9:A9Z+/X7N=0MK\:?IZ6KSB1Y8
M(G!,LJD?*Y" C!!/!'QG\/? MIIUG<Z]J\MOI^GFV>+[1,P$@<8R(EQESCC(
M'&>N:V+OP?H_Q9T3[+I-_INIW$2 E5BQ*@QP6B8!L>ZYKPZM2I-1G".A]!3R
MJ&#G*G4FY*[N]DF]6KKSZ7N?<'_!,#X*^$;NZ\2?&SX=>)M4^+VL7)MO#26&
MN1?V#<Z-;2R1RW;W,TF\3W2IM=BOROVY.![O\96T?6?%>M6-Z+K^U(8)K?1[
M&#4(+8Z[.ZDP6ZR296&9]@*EUQR0":_.3]CW]N#Q5_P3'UG6[-?"2^)O!_B1
MH)KJW>>2$6EQ$I0R1-A@A=,!LJ0=BYQBOT"^!GQE\'_\%%?AMJ7C#X5PZ?I7
MC;1[VWM]4'B2V-Q-IT3[W**5)5EQN,; ' 60 (QS7J9;4P5-SGCH2DG!I*-K
MJ335TFTGYIW[I71X_$&#S7$SHSP<H02J0<IS<N24$X^Y/DO**36C@HRU:;=U
M;P:R^$<FB?$ZYL_#MG?7:100WEU;"_65K.;R@TB/.N(V,4A*>:, D<<'GUS5
M/C+>7GA>&SN?&T?PY\06_B*XF\0V5]-^_O(%DB,3*ZQN)%$*.@MR1S*,D@54
M^,GP1UWX<ZAXCL=)TK1/$'AG6TDMGL=14LLD!<.J."P+89$8$-G(^M?/OQ9^
M'WCWQ5KMYK.K1V/VF[)E<H^%3   "J,    #L!BO:EG5"OE\\NJ34:;LU*[Y
M[]4TDE9V6RW)PF4TZ6;8?B"/\6"E%Q<%*FXN/NOW^9N2;:U>BMJWHO/_ -HZ
M_P!(U?QMX@U'084L=)O]0EFLXBNQ0C,2!@<*#S@=L@'I56Z^ TG@+3K">UU&
M,:[-##J$4%N@E$Z."7$<F[&Z+:=X(!!/4C!JOJWA35((4^W#S#D&/"[4 !Z#
MKCTR<_TKM/A5X*\6?%?7(]%T_3;%KC4(IX!=/"/,MED):25GZKA206'48XSB
ML,'F65.-1XYM\J]RU[MK6]UL[I)>KO;0Y^(,-GN(J4HY1R\K=JG-;1;:I[QL
MVY+R374\'\+?$JX\0_$V'098WN;:ZF^R11H"Q1&&T;1D@#N>/TXJU=^#KV[^
M'_A-YF=KNTT(0%G^\52ZE1<GN0@&:^]/V?/V"/!O@#4SKS):WT_V>1)+U(94
M6W105D= QSE@" V 3GC&:\Y\=MX-T31+;0=*.I00::KVUI%(R^7M+;R%!R7&
M223TSP.@KX#&9A>?/&+=[=-;+1/OU2/U;)</A\/34:VG*G>W1RM*W3;EDWM8
M^.O$WBZW^&38AOI%U"SRZ&++>7QS@>_?Z=:I?\-0:K)HJW5U$YR5!D%P%Y)X
M^5B&Y[X&,>U;GQM^&7A/Q/J<T;/JVAWCN6F:TDS%<9QD,C=B.P*]3BO"/B;\
M(M4\+W=QJ5K/;W&DMA8I-/MV1+11T$B$D@D#[V2/<&O=RG%)*V[?22_+_*_R
M/!XB>+A+ZS1@O9+5.+3T?5K?Y[>9] ?##XDW7CWQEIVDR7+6USJ5TJ- 5\QG
MA(W-(IS@G . ?SKTV]^'_ACQMXE6'1;6235K&YFGBN)=0'D7MI"<G8IP"<8)
M  QGKC%?(?P9\3GP)K$&J26K75U"K-9R!]R>;C 9NY4 G(X.<=LU]&^$?C+X
MDOOAV-/T'PAIMO;WEHFFPW[6X+Q$_(YBDP#&2I7)YP2#W 'VN5YAE'U2LL?!
M*INDDW=1VWNKWOI=)JQ^3\01XCQF:8:64U'[+:3YHJSD_>T5FX\J5M)-.]CT
M7X#74GBO75M9;-(K&#),K#_5@GH3G."37I3_  :O[WPG?265LUU8PRNETLC!
M8XT;(.6Z =N?7CFOFS0;3Q_\-KV2231[RXA7RXC+:2I=(&)VJI\LGKG R,DX
MK])?@)X]TGP#^S+I_A74O"L?B3Q7JCR7M[IFQ]\ETS_N;4A2"^W"%^3@' !-
M?C-3+*WUZRJ)1EW6[Z:*^]^FQ^VO&8BA'ZPJ;E&-G*,7\*2;;N[;)/5VN[;7
M/#OV"?V;-0T+7-:GU*:WMX?#=SFWB^U""YD3 <2@MC;&5=2&) ()QTKZ)LM*
MO1XVAUKPMK/F7T<\6I#2Y+CSM-OX4(42+*K$%<E@2,XP 0217S?\5?!OCWPG
MXA\=6_Q#LH;R'QW9SZ=JFE6%RMAJ%M;.B-&L!SL7  P,@%>!]T ^.S_'Z3X-
MZ!X3\*^'=&\4>#--\%I(^GSWTNZ\,LDF]I"Z@  '  &1P3W-?<9?C,3@\8J%
M36+5G?2^VEN]K??YGYYQ1PS@,VR>684;QJ<Z<.6/,E&TN9N:>B4E:SCKO?2Q
M]K? +]E7P+\#M<\2ZMX(\*>(='UOQ+%<(EA<P0R6NG-)YFZ2*9%#S B1PK.Y
M.T@$$C(=H%B= <^%8_#>E277FB:9Q)+;W)E ! #Y.Q@" =OR\\]\?),'_!2[
MXD21OG6+"[EDR?MC6,7VD,>"P=0,GJ>1CGD&NG^&_P#P4:UVRN8(=<TG2=:"
M2K_I?D+'=6T18LPC&0H.23VR0 3WK[+*J^&P<72PR<$W?RO][/RGB2'$.<5X
MXK,*_MIQ2C=M?"NEFDK]WNV];W9[#H/Q,;0K[4Y+32KR[A1S%="]O5F6W4,0
ML:,V,C=D\YYZ 9R>]MO']KH_B"UUF:PO#/A8VCFTVY7RI"-Z@.1@ \ [3AE]
MN:Y3Q)^UW\+_ -E>ST?4-4;6/'7B3XEV8U"WTZUM579:O<B-68,C()BR'A\+
ME< Y()[+XA_M!>"/!7B&V634?%&N7&IV$-_;0M;"'[/%,NZ-F#$*&4'!C ."
MN,@<5W2XHPU:M*A[17COY^G?S//Q'!?$V'R^AF.(HN-.M=0=HK;R3NKK:ZL]
M;=3U;P?\9M5N;&W6UT1-.TRWC8(3<O90AF()811D  8.!GD'G)JG\3O%K26$
M&I>))M-T;P[&&:1[BY/VJ\4@@"(;BY+'!!Y(&<#.,>8Z9\:/^%EQ_P!E^'-*
MU":^N+9A+J%_<K'#%$#N8B)24  ZER!@=#7AFL?L<?%?XD?$W6-4U:>W_L^Y
MG/V+6;V\65;F# V-$L9;**O Q@<8KQ<1G6&A)JFU==7M_P $[,OX3QE6FI8M
MVC>UE9M^79+YLU?B7^UAH_CG1;CPYH^EOX9T/<=P$#^=<KNR!*Y_A! (0' '
M4D@&O-9O&MV=.A5;J.:VAW(DBL3D'(Z\'@=,]J]2T_\ 89NM%L6BO/&5M-*<
M[EAM#MP?=F!S7-ZO^Q;>:?'<?8?$MLZDAE6:$I\W?)!( QWKAQN?4<915%1C
M[KO?6_X]^NY^A8+ 2PU'V5&"@K;)J_SUU.1\%>,[CP[J05F\R-B"5^O<5P'Q
M/G?0OC)J.EV9O+RY>19XK>UB,CHKJ' VC)(&[DD8_"O:_"G[-6KP^([*WF6W
ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
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M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
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M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
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M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
M@1;\:B4GK-[ME8&E"5916R3?ST1Y5)HZ^&+."%2I2,'+#IGI_*O./'7Q ^VZ
MB8K=ODB;YF/<CCCV%>\GX?S>(Y8K2-%CL60N]RYY3/;'<U+X4_9V\%^%K_[1
M<6#ZS=Y+%KIOW8.>R9QU]<UA+DII3F]7T/<J*I77LZ>EGOY?YGBWPBUO5-=O
MEM;."2=@Y,11<X8G))XY-?4_P+_9\U'19XM:U%$ABM2)BC,-TC#D<="216IX
M6GTW3V46&E6-BR9P4A10,]<<#K7=>'O%?VBYBBO)%\OIB X ],CT]<48K-:V
M)C&E4TBK=OO^X/[/Y%=2NU\ON.;C\<1I>3R7,[%Y7^Z>@[D5A^+O&KV]O_H\
MC*"P,C(/F"^WK_A6I\:_AK)IG^GVJMY1!=57[O/((^M>,Z;K\GB*XDL3<+#(
MC[I9#G$:CKD]![#J>PKGHTI4*RFDGRM/R9./QGM$I0V?3L^J?H=KJ7Q8FN($
MDM(YF,>6RK84#H !R ,$\9QGK7F?C3XT7-\K0.D9"L6.9#YA(/3/( !Y&/4Y
M.,5U7B/6_#J6GV.#59)IU^4I$@8N<8SM&37 M\-]0\::@?[/TF]?8<M)<)]G
M3TR3(5&/SKW<9Q1[2#A4DH*VNNO]?(SAEF:8K3#TI-=[.WW['?\ [//CRWN[
MK4U748=&UN^T^2VT:^O;0W-O87C$;9&4!L@@$ X."<XKH/VD?C%>VVE>'?#:
MW]K?W<&BV4VIWUE9_9(=8N9$WF<+@%EPX R ,ACC.:H?!'X(>*+CPWX@N=)C
MTFZU#1;8RR6UO(SW(0 DNIV[656V[@#D Y&0"*H>/_#C^/?V?[+X@6=F]S)X
M7OQHFLR1'_CPBD!DA!7LHE,R@] -@[U\%FF&I8MK%T6Y*.ENFG5(^\X<]ME[
M66XY1B^936BYKM6Y7)*[5MHWM?7>QYO#XBGBU02;5=\Y.1G\Z]&\%W$WC?QG
MIMOXCF:QT4R1HJA&47#$$B,,H.W(!R3CG ') KD=!L;*&6WU"ZECCLGD0DD\
M@9!/&"6!'8<^F37O'C/6= UC0[V]T1;#2K0.TFDRV*RMY@5(TR9<8CD4DL5S
M@D$ 9)->_P 'Y+A\5+^T<3_#I7OIV5W>ZMMKV[O>WB>*?&U;!QCE67Q_?55[
MK[7=O=L[WOIIKKHMKXMUX;A;PO;:AI=IJD O'GBN6"F>QM&1MHB2;G+$%6 R
M>&.3\IKSO7?AG-JN>;@/(I7(8J3G^$^HS2^%/CK);?$!=)D^SVEI'(\EQ;Q8
MCCGF;"M*VT8W$<YXP.@ .#ZSXFU*WC*W%BZMD*%C*@C)SC)SP/7-?4YYCL-4
MQ,9Y53Y(26^J?:S5VM%VTMN[W(\.\/FU#+O8Y[5=6I=[V:771I*3NW=\VJ>B
M22U^>_"GA6\M[Z33+KS$4/NCR!D'NI./\\UZ9X*\%Q^"O$ME?6]S(JPY-PO\
M.T^O8X]_2F^*?AOK7B_6[:3356;47VO';PR*IEY !!) QNP/QYP*@\:O)8^$
M;'4(7AE.I^>C16;M*Z/"Y2577 *X92.>.XR,&OSO.N',SK2>,PL'*&G-9.T=
M'OV24=]D>]4XJP&78^E@ZM:,)RNXIM:NZNK;N3<E9;ROWW^K_@DJWWCO2=+O
MK^ZBT34;6ZA^S)+FWW7*(%FVYVEDECB8'L-PZFO'_C%?V^K76JV*1V>GZM;W
M4ENWVEAYJ =<#&!QTYJ3]ECXGQ^*/!S6\QQ=Z(2()3P\84DX/<8QT/I7FO[<
M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
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MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
M>H^G6IR_+WC*MKVTW_R1[TY*-HQ.RL]7DL)%*ONQZ]*[SX=:M'=7*R@MYAZC
M'RD^GI7EVIZ8J:A&+=%MX9E(VJQ.\\<D=OR%=O\ #2&?2KN+S%9(6X)[>U9Y
ME@7A*KI-WV?;0R=W*S/6/%7B"/2/!=Q+>!!!$NZ+?TYX*_U%?+GQ \(206HU
M._BV-J<R_P!GZ4JLGF*^2L\V"#M8#Y4R"<@G (!]K_:=\8)H/PNLVN&Q:I>1
MF\? _P!2 6<?4JI ]Z\8^-EI\3O$.D0ZE_9MGIGAZ6P75IM5O9T^TW*2IYJ%
M54LRQA75$7()&#C!S7S^88K%2Y:-'X>KV^5SZ/(L'1HU98IQYI6VM>UNMEU\
MQW@/XBZ;X"D&GPQ1W;Q FYDB588$ .-JA0-Q)X#$X/4#'-.E^).J>)KEO(3<
M6?:J06RG![ $#D^@R<UY;^QYX^M?B)JDJ7.CW%Y);,1Y"Q;CN!R=R]SCH#UZ
M=#7V=\.KAKOQ9I^LWUE'9+>6\%AIGE0/%>./L\J-*D; 1I(C $@ D]SG%&"X
M;5?!XC&3J*,J2ORO[3M=+Y]+7OY'3F7B?/+\PPV6TZ#G[9J\EM%-I-];VUO>
MUM]=CP30OCAXJ^"_C*WO;&[O]%U")PXD:(QD@\'<K 94]"#D$9&*^H_V-_AU
MH.IS^,_$BRV3^&_B1$EEXN\.6^2MH97$:7]NO0[)G0D8!49QG&:^1?%PUOXY
M_LRKJ6WQ:^I>!M?DTT7>M%6FU"&X!EP6(W9CV 8R<;O? K_LB?M.ZU\!/BOH
MEUJ5Q?6EK!<A)'4;3M)P01Z'_ X-<^3X+$_58YC!?N]5)+JMG='WG%V4TYXF
MME6):CB*3]RHK;JTHZ[I233[Q;VO<YSXM>'M:^$7Q%U#1;I)+>XT:\>!$8<Y
M1R 5'()XSFL5O'.J+_H\4DWFRDN\:$@%CU) X)/<XSZU^JO[4G[&?AW]M;P3
M'\2/#L/_ !.FM#O6 JHFD4\DKW\P>AR#@\@FOCGX2?LCZJWQ"U#3IO O]J6U
MD,2Q:AJ#6"HY&!YF!O8=P!Q@9Y)K.M"6&_=IW4MFMI+1I_EYGDX?'83'4O;N
M*4Z;M*+M>$M4T_+5I/9WZ7+WPT_9S\*7(\"Z=)X3N]?U+QE;V]U?>(_[4,'V
M9I1*7%NJMMS;^6-^]2">"02 66/[-NJ67AB.\U[QSI=N;K5;NQLGLV21=L2!
MHWE+NH*R8.&C!5"6W' %>\?#O]DJS\"Z%=:?>ZEJUOI5]N,^A:3J,\>G1@_>
M&"VYMW?D9[BL+5_ASX5^"^L:7J.DQV-O)IJBW@MI;19K>*!W'FQ1F4.Z!EP7
M !!*@_+G-?5<"YA@\)7JQS>;<&O=71/7R]WUNDFE=-7:^&\0_P"W<1@Z"X4@
MHUHM<[5VY)-MR]YM/?6"B[I/E::2>.O[-]S:?#R&)]<CCO;H^2M_/. D#8/*
M%=NW!')&2.PK@7_95?1AXCT71_$RMKFL/ TE\U[)/:/&Q#3$H%R;ACG+9.0W
M)&!7IVK?'+0]4U2XT?PSI_BJXO+1D8K92&*'>YR0 "<9'(!P0,X ZUZ!KJZY
MXJTI;S-MX<CLT/EGS(IKL9'),LI"*3CD*"3TR:SCQ;C:5&MAL/\ PJC>\5=7
MM?K;5:-:K\@Q7 ^"QF/PN9YJG[:BHZJ6CMJNG-I)W3T9Q'@S]G+2_#!M[CP[
M:ZKJ&L6S*FH3W%Y^[F7:0V8N3DC!&>>W>L_XLZ[I(^"N@WLO@/2O&=[JSRVS
M7&J2M#:VS6\\<$5MM#*YN&%PV" 7"K]TA21=TKXAVOPUNU:;6=4M)I\_-;6]
MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
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M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
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MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
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M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
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M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
M."1CO5[3/V/]+T=_AWJ7CK4M4L=0^&&HR:C +/5$CL;PM*) L@ZEE8 $J.5X
MS@T?'?\ :$T[X=:UJWC":22V6"&XU'2K4R")M0NY$\E'1,;BBE\ER,#N22!7
MA2Q524JWUB"C3CI%WOS*W;HSTZ.4X>G# /*J\JF+JZU(.'*Z<^;1*5WS*UI-
MZ);=SXNL/VPT^'W@S^R\0WVN6A$73S+6TD7@B1@1YC @Y1. >"1@YXGXA_M!
M>(_BG96TFL:A-?06ZE(HWB2*"+)R2L* +GMEMQ/&3Q7*Z7\(5O-3,_G)/:[Q
M+*03OB9SDAP<8!)^\,@^N:=XTUJ/2=52UA@@=81LCC$>!'_M8SSGMFOQ7'XA
M5:W+3]6?Z0\+8'!8+#TXQBI5+)\S6J].W]7N>M?"KX3:'KWPZNM6U:>[N[B9
MO(LK;3(B)1)(T:12&8@IM#DAHR-Q RO7(KQ>![?X<Z]>/J5YN73YVB9_LWV>
M:1U.&#(PRI!&.1[CKFN;^%?BJ-532],NFDN=0;]];X+K=L"K ,G*Y0J"" ""
M,YXKU3QUX58?":[NKYUEU"XE9O/D_?RM*03\QR6.><UT<5<0Y+7RC"9;A,/*
M.)<DI2OHUJNVJO=:I..B3E'4_+\#1XJRKBK'8[.<Q4\#4=J=-1U@WRMZ7M%M
M).\7)3NW*,)W2P6_:YAAL/L#6]K/90')C9 &?GN^,G\ZZ#P!\4;'XJ:W-:QV
M=AH>EFV,\E]= ^1&BD*Q&U2S?,<<9YZD5XIX+\!:-KK+<WUM=7=U&A8JV LC
M$X "G(.>@(&/Q%>H?#7P3'H.NRWWAZQN-!O_ "VBBN8\R!,D$AHVRK*V,$8&
M>O!Z=W#O .74L52J9C*T-&[;6WU?;O97UT/3XQQV)_L6O/AZG_M'*^6[W;ZK
M9*5]FW;OI=KS3]N/X!V_PR>TDMY;_4]/O[V[$5TD 3S!&$RP52V%7D$YXP0<
M8!/R[I'A%6U!I&FFMUW!D"$_./?TK[\_:=\*^(OBCX3N_M5K'I$>CRM/:V]K
M(YBG>9 DDI.3C>J*"@.T8X')S\L_#OX*W&H^+C!=7:(JHTMS)M)%I&@RQ(P"
M2>B@=20,C.:[,WGE=/,*U#+G:G"R7;X8N^K;[MW=[[]CA\/*N=8[)Z,L]ES8
ME.2GU:?/+31):*R7*K6VNK-^F?L5Z=J7A?4+KQI-JVH:1X=\+,# ;:Y>%M3U
M(KF&!55@7V@^8Y(("A03\P!^U?V&O VG^+M,U;X@:Y):W^H6&H)!;1S*&%O(
M0&DN"AY9EWC& <;<]3FOE?3_  I=^,M'TK3]-M)++1= B9+.V')D8G+22'HT
MKGYF/T X KW?]B_XOV_P5\<VGAC6+NVM[;Q%*P02G @N#M158XX#E0#GH<>M
M>/DF;89YA&,_AV6^C>EW;2SVU\MCV_$K+<8N'*ZP4W[9V<HJS;A%W<4][K=V
M>JO'56/H#Q;\:/#>J:A<6HBU4B6X=(K\0@VMVX(QDY$@R<\D''!/%=7\ _B1
M9Z7JNIV>GSR+->%GDC<A8XY-^$V9(+$JV"0"1UP:SOCKX8^'^G>&+[4)M92S
MN[5PS;HBW).!AHE8'!/7TZ@5X[X0O++Q%=C-]':PV,<ESYA@,JW+K\RJH!RI
M8]#V)_"OV+!QC*G*_P".Q_&=&*Y7<^H?B9XNL-?\%ZGHNF^.]1T'5-6\N.WU
M:VMV:;3VW@&-M^W;NQC*GV##OYI\>KFWTCQ5;PZ?K=O/+<M&TA@9"F0H5GE(
MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
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M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
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M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
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MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
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M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
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M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
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M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
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MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
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MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
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M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
M@ 8'()KX7_X*^_L]:+XD\(V]O:1V>FZU_:$ZVD,5\M^;I$EV0REU5=ADB9G:
M,@[-HR3TK[[_ &BO#WA/X)_#"X\<6^H:WX9U+1M7DU:35+/.IZM=+<S![BRA
M>=\I'(>1&K!%"G(*Y!_+S]KC]MBV_:&^.NH>)O!?AC5(]!LE9(K:90Z6XR2T
MKLH(7.?7 ]:RYZL97EI;:ST?KMM\MST<+@<-C;2I3<XR34W)<LHM-VLKN+4D
MU:[FTXO6*LG!8_!>V^'GP1L[>QW6-C##)'9B?'F2%SEG;_:/4GU-?.FEZ5)>
M?$5K>'8UOI\<MQ*TD;NI1%^=@%()*@Y SC(&>*]\\6_$34OBA\-(+RZM_(>+
M"?N6W(..",9 !KPM9SH_C&&:2>YB\P218CR #(A4G'8<@D@9XKORF4%C*=2L
M_=YE?[];G1Q!&K3P%2C@U[\8OE7HM$K(]R\5_$?1_A[\-M>F\/W[Z[:Z<UM'
M!/*@C:6:0  JF22 QR0.HYZ @\;\)_B-HJ_$30]4\7Q27,D4X+6\A<IO&<K,
MJ#>R,<!@I! Y )XK!\'^/X?B:=8^'>DZ)86>EPK9R:D\@#SW$Z$E-CK@JOR9
M*],''05B?%OP!)X-U"RBT\31ZA]H,:-$Q$F]N %/7))QU[U]MB<^R["XF+PM
M/F5E?L_6^O\ 7W? Y+D^;X[ UGFDW&;<DFG9IZ:IJZ5GLK>M^OU+^VU)IVM_
M#*RUJXC1+>]OX-/T/4;"QE*)IRVV]9(Y\*DR%BRL9&WD],E2*^;_ -GCX1^+
MOB7\-['Q[I7A2YU313=7L,2I=)"]XL&02J[@[%0<L%!!VD=S7TS^U'K*^%?@
MEXPCL-2FU&]:WTK2=7T 78-IX69=A4JF '.Y"@V@8W$FOGSX+?M(:E\+?!6F
MZ'8^&M$N6\-VU[_8VJ32R^=HS3N78B+=LDR78 D9&5R"!7PN=\78O/)K,*-*
M-.46DE>Z7+NV^KO;=7MH[Z'VW#/ =#AF@LFQ&)J5J4H.4N:#4KU(IQBHR:<8
M:V<HNUO?BG<=.WB+QQHUAJ5UJ-QK%G:VJ:?"L[F0V<2\A5!^[ZDCD]R:VM.T
M#;IX;';-4?V1;J\\8?&&P\(PV\<][>QM*B3/Y<4]LJL\SLQ^4&(*S-WV\XXK
MWKQS\$%@\5Z#8Z-J&EZSI_BZ>.'2K_3IO-@N \WDG!P""KY!!':L(8B=6I:O
M-RDU=7=WYO77??S/4Q%&E0H.6$IJ$(M)\L;).VBT5E=+1=EIHC[8_8LTSQ9\
M)_\ @E=H\?AOPN_B34/&VIW-S*AU*&P&GP/,09R9 2Y\N+(5023Z#FO/O''A
MSPW!I&N^'?$EC#KGAOQ"L2WEJS^6VZ&0212*2K*2K#)5@01D$8K[!^)D^F_"
M7P=X5\ Z?'?V4;(UEI,MM9236\#6MN6_?R+\L"%%(#,>6)&.I'RA\=O#\=_J
MTLUB4FMYXDN(U0CY-R!F0CJ-K%A^%>-FT[OD;^'1_G_7R#A)RC>M.\?:2<XM
M73T=D[[:.-E;JF>/>.="L?B%=>&=#TVSATGPQX9MGLK!))XYIY&8@O+*8E R
MQ51@*!QW))K/^*'[./@7Q)X1E;2=)2.ZTNS$KWJH\HGG:4HBLTC !<9+QA"5
M;G@#%=)X-@_LJZ>XFBMSL8@QR. 2!UXZ$5WGC#4_#=SX4GE4/9O=PB*.5\;X
MI791N.%Y /0GD#([UPY/Q-3RR=3#5</[1U5RP;TY6^M[-ZWOTLTFCS^.,DQ6
M,Q=#&4,1*FH2YIVN_::W:>J7>^_,FTU8^!-;^'6G^"-9BF^RIYULV=GE^:,C
M.,K@Y'U%9Y^"VN?$SP[/>6JZMJ>BZ3"$DEF#RP:8KOM7:&/#$CC8#UYYZ?;(
M^"</AEHHWFMIH[P9BD*AC(22""<YR<9SFJL'PKAM_%>EV<UU>+I>G7$DQ:"7
MR9;,M&2!%E&0N)4CDP_ &\XYP?TSA+)\%7FZ>-Q,H12;WLGM=:Z:K3\EL?+\
M>YYC<+AH8C*\)&M6E*,;6U2UL^[M*STT6K;M<_/_ $CX-:QI&L[;6-S!YAWQ
M2PDJ6^Z3MQE3CN,$?A7Z;?L!?\%&_%7[,7PZLO#OC0-XC\-VR[+1FG+3VB#D
MH&;)VCL#D#I@5Q5SX1T=UFO'BD+3 NF\*).>2S8 &XD\D  G.!S@>._%W3KJ
MSU)KA8O(TZ+'VB,Y4%3Z =^N/UXKYO,,KQ$:\G@)N\6]>Z7^?9W\SZ6BXXG#
M1^MTDXR2;BW>U^S5M5W5NMG8_4OPE\6OA/\ MX:#,WAK6;?3=84$3:9>A.?<
M)GD>Z$'U4]*^9_C7^RM;Z%J$DD;6K:<SO&TEK:Q74+LI(9 R@,&!&"K $'C%
M?+?@RSAC73]6L9)+/4(YEEM+F!B)$(.06&0""<'/!'?(XK]"OV9O"OAT?'7Q
M9XPUNXALYI/ 5EKM\'8QV]M,S2K/<L,[0^VW7+$;AEB.I->?@84LQYN9<M2.
MMUI?O=;7]+'KQJU\@PL,7!N="3M[-ZN+TM:6]GYIVM;6Y\-:_=:#\.-8BME9
MKO4XY=Y22T,0&/N@JW'X8(]J]&^'6NZAXYGTZVT.S\3^(1IN9;JUTZV9;>W)
M!P=Y9D&">2P '/3I7@4O_!1GX@WOBO5IH]:DUFRO[F1D77534X/++':1%,K!
M21@YXQZ9K4T3QW\7/VMM9308_$WB#4[.Z!1=,M9TL-.  'R")=D0&2H"D9)(
M R36&'PW-45*E&4I2Z)?Y7_(^BS7B1X:+KXF4(4XK5]DO51N_P#MY'TAX]\#
M0W/AZVL_$WQ2\%Z$T@+RV&IZM!?S6>>1F*V+,<="25 YX' .#!\5OAG\$-"M
MK>;]H+2]0U"R@EMK)M-\)2W-Q90R'+I#.RJT8<<'## X!Q7R;XI^ =K\-([L
MZC-;K>C=Y,EF@N+>X*DABL@(!PP() .""#7FMU>1B\6.."-9"1F0L=V/<_X5
ME5ING7EAZ]+EDMU*_,GYZJS^5SCP.=_VC"-?"5E.F[V<5!Q:\KQE=='[VOWG
MZ9?L7^)/@O;>,[C5M#UG6O$'V KJ,!U'2Q#-J%UN*J2C.Q_<Y)13P6?>>5&>
M?_;A^+GCKQ?XJNM0C\.:C%LG\R%[R9401 $@J=Q!(QG ''I7S7^R)=6,LU_H
M-XL;?:_](B=N3D+P >HY []:^O!XCOY?V?\ ['<:C;WT4]A(N8F!NK!-N&61
M<%@JJ25=<D<9&!QVT*BK5(X2KI!.^GZ[_P!;]UV8FE4PE.><8=<]9QY==UY1
M2LES=5W?NZV3^(KG3[Z^\0G4=42YTZ:_4W"1SQ,-Z[@-VYN6!+ AL '/'I7J
M_@^Z&F/:A;Z&2;AE9>8P!T))'&#U!&/6HUETNWN?%.K3ZOI]TEGI$.GVME>P
M2%9[8,-QB. RR$C"C.,@9'IE_ SPE;_$"!KO4$NDC7-O"B,4\MAC.X9YR3C'
M3V]/L\=D-*A[.KA)75E>ZV?HV[IZ6TMW9^6Y%Q%C,SEB,/CZ;A)/=/=.VBLD
MTT[WUO?96V]]\%>,M4\>^-A-?6UQ::++<N]M!ILQB^QS/@RS,P9O,C>0$A %
M"9)P1BO=]*GU+1]8T%-+T^UO()M0$&J3W=\8)=-M0 1+&O!D8_-USR%&/FR/
MFWX7:5;^'M<D:/4=0C@60&)85$L;XR""I[#@<?7.:]JT/XFZ5/X-?6)5O+>;
M39Q;W$;[<22$C8(LD9W!ACG)Y[@BN?B#Z]F&(C)Q6R24;]^J=]7U:T]#BR'+
M\#PW3E"4KQE=MS>GPVWCRZ+=+NM;K0\M_P""HNB^%]>N=&UFRU'2X_B%IU@U
MQ=:8LF+S4]*4E3,$[F%@3R<[/,."$./A::>Q\47LMO:Q+'/IT$8O"O1VE,CQ
ML1ZE5(S["OT;\=?LB>%_'G[2/A_XN^(_%7B*;PNMN;U8X&@AT734M;1]KW\[
MN&^SRK+*%1%^9I7#-M(%?G?IWPMM?A!\7/'UIIVJ+K?ASQ-?PZMH&IN^[[;I
M6QFM7!P,#]XZXP#B('&"*\6,HN,G+=:?/0^JP\GST84'S1EJWT2?,K?>M/O6
MEC.\!>,X_#/C:(7%@FIH4:&>.[N"J2Y(8 9! (*C!QG/<\"K/P1_:(7]H/XJ
M>(/!^JZK:RSZ+,X\.V4Y :5#)(MQ$KX"NX"QNH4 $9 &0:\SOM=OO^$RU6:U
M20#2D:[W&,L)2CC" ] 2"3GT!XKNOV%_^"73?M/>&XM8GB\01SW^LP00:AI=
MF]S]@EG,C+))(DB"&WB"9>7)(++@5ZU3/J]3!O#XB;<5;S>NBVU?X[^2/"Q?
M"M'!YI2S# T5[1WOT6FKO?177:VVF[O@_&OP)-\,_B/I.K6=E>2WWFG[/#"I
M$LD;</$1@DAAR!C.0"*](^(/[+FO_'B*UD6PN-);3[:6XU>^U2PNK:#P_:Q)
MO::[+1 @$'"K'O=SPH[U]!?L=_!SQIKO[64UQKVF/XMO_A!X2OKG31?+]FBU
M35X9YH;2UGE8* [L@?).2NTYP<U]$/J/QD^.NF_#?6/$T-]X$UTZU>2WVBVV
MG3KI&IZ*BQFYM[PNIC\\?=A<J/,!8+@Y)^=<HJI&E*]V[+YM+\V?;QK572J5
M\/R)))R3EK=QE+2-KM*,7=[+3=)V\S_9E^-/C+X3?LE^&_"?P#T'_A;$OA6^
MG3Q3_P )4'TVXLIS()4BM[>4@K&3N,1)8H%!(#$X^F+K3]1UGXH:1KVM-H;Z
M:EE'(MC?6*7-WH=^Q4N\%T!D1@9##')4,I&:M>+]+-MX!OEL_$TOP^L=+:/4
M;O5[2&..*VM(,M(CDX"QE<$D'JJ@@@D5R_Q4^(!CU)VM1";:]474#0N)(WBD
M =&5AU4JP((['M7L5L/.A-TY]EV\^F_WGPF8U%.BL332]Z4D])76D7K)I1;=
MW91U26NZO\_?%W]F/P[\+/A7XDL[C1_B+XB\)>)?$4]_J?A6&\M+R_D?SHXH
M+^*YA(:*$(CR%!ND=9&#D\&OI?Q;::?KUA9ZO]C^W)I,BK<0)]ZXB48 &2,D
M8'!/.,$C.:\@?Q+=W6IQ)&KM+*P4+&I+.2<  =22>,=37HO@"]O(=.U))HFB
M2"/$_GL(%A;H Q<@ D\ $Y)XK&BX0]V;^?Z]CGQ.)GB]HZW;23;6MM-6WTM=
MMMZ)MV1X]XN\?R:BL.R9+B\MH%2\N8]/2P^U3#.YQ;HS+&""HV@G.TD\GCQ+
MX@>/[S6;]XO-D7!X'^!KWCQEH-CXMUVZA4S:7J5NQCG CS[_ #+U!_,$<@UY
MWKGP BDO%_TUI"6R7V#&.Y'.171"FHI1Z+OK^)Y];VM2I*I)+WFWHDEJ^B5D
MDNB226R5CG?A3\+=<^)?GK:3[;:/ <NQ"%O0<'D]\5U^L_">^\$QK;W,2J"N
M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
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MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
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MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
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M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
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M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
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M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
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MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
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MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
MAQ\4OB%\(];CN([R^DCX5WMWV.5]#MVDC\:]4UK]KJ\\(_"F&'P?X8N!?6(D
M8O+(XD+.26(8DL!DDD@Y/ X ->@:'^Q;XIN-.L%FNO#UMJNJ0FXL]%N-01-1
MNXPH<[(\8)"D-MSNQSBL'7OA+_8>BF6ZBC81R RH#\I4$9!QR 0"#7ROL<%5
MGS*SMTO^9[^#XCS3"P5!II35TVG=K;1OIOT>I]%_L6>$--L_"&@>+-8T/1/[
M1U+3X-2BU/7#+_9T4L@SBVL4):\F0J6:9R A9%!4@DY/[9__  507X:^-8M/
MTGQ=X3^V:<FU[_5=-_M"\E8')\JTC#16R G"AR9&P"3C%?$'[4G[7GQ3\9^(
M[);[QM>>3J^EP)##:I'%%90L 4MU"JI 48!/;DX/.>3\?_L566EI#-:^(VUJ
MY@@5KTQ1E([B1\_O%9FR2LF8V4C)55<$@G'5EN48G,>=X7W:<=6]%;7KT_!N
MR>MCT<^S[+\!7H0S']YB*JY4FFXW:Z/?79J\8W:?+?4^KH?VO/&W[3OC/1O$
MB>)=/^PPVP%_J=Y>RVUN]VTH6*)+=6"PJ%Y.T#/()R.>]L?C=IOQ4\5S6NK7
M5G!KEN1#;ZJ)"\%_P<!V!.0#]U^WN*^1?@'\(]/G^(NCP^(M3O\ 0=.O;BWA
MG^S8MHKR,$*T8."J, ,@D'!YQD@UZ'^T-\/(/AZFE>)O MMJEOIEUJ4L9_M:
MWEA6_M8YF"3P[V+B11M60$9(8. %.#]5Q+PS/&Y4L7A::BJ5^9WNY62U5KV[
MM/5)IW:39^?\&<7T^'>)Y97F-:4GB.7D222A=O2[T:V2:T;BXM)N*/MCXA?'
M/Q5X _98U#[3;:+J5YHD;-I]I?6[7*)E2>><'.,C!ROL#BOAWQ!^U/\ $3Q#
M/!]NT#PFTRJ'(@BGMP<\[#LD!(]>?QKZU^(]\WC#_@G5'XHMW1FBN5L[S9(2
ML:L5 *GJ2&4 GJ<^U?,GAOP?_:]_$\:;@J9/&:_-^&9PQE"<JRYK/E5[-JUE
M8^VX@S:="M*67R=/WI<W*VDW?MYWOU>NK9AG]K3Q!!F&Z\&+*A 7RXKP20<=
M<"1-P!/;<3[]ZX?6='UKXO7T)U2"/3M)MF,D5C H4.S<EI&ZL23W)KZ,\-?!
MN/5]0/VF/9&F2Y"Y( ]!WXY/I7<:%^SQI^H>)]*T]5CBEU2>.$2$DK'O<*&(
MR!D @\\'G K[+#<+TX1>(II1?S?^9XU;/LTQ%'V52J^5_P!;_GW/#?AEX.LW
M\*:IX7U3PUIOB#PWK1@>ZM;LO&$DA8M%(CH0RLI)QBO<O$WAZU\1_LYZSI]M
MI]MI6G:+IL<&G65MG9;HC@@;F.YB2222<DFNB\*>%?"?CF3Q5:^'='\5:;+X
M-7<UYJ9C6'4]MP8' B #1-N0LN<A@#W!K4U+P^]A\)O$^Z+&+(Y7IQD8KYV-
M:C6J?6*2][:_70Z\1A\TP-LHQLI1BFI\G->*<HZ2LFUS<K]5L^J/C&Q\*+!+
M&K#+8W-726WA0368++R!Z=:Z"T\,K=7H=AM7:,#Z=:U;^PC@B"+MZ=NM>M[2
MZ/G*U'DJ.)YU_8GV*Z)"JV.WK7(OX9CM?',5DEDTUIKLKQR!9 G)1CWXR& (
MQW)('6O5I;!9)RKKMS6?XH^'G]O:<WDEHI4P\4J<-&_4,#UR#7/B*?M*;B]S
MLR?,'A,3&;VOJ>#_ !-^!>F>$M-AUN-;G5M.NKK[/<(%$<MLXR<@X(*NH(!(
MP2&'4&O<OAA\*]'^)/@GP_X<T;3M*.CJ\FZ6X9Y)I+N"(,J"9E)MRQ)#!?E)
M4<] .=\*^&+CQ)%]OO;&YU)=#O5AU/3DNO*6Z7!90<G Y+.IP<C(X.36I<^)
M=3\1Z<-,\3WEC\-? _AFXVVFE6:,^JZH48< GY@,KS(V%)Y ;&:UR;/GEJJ-
MP4W)6UZ>?9ZVT:U[KK]+QIPQ'-Y4'2K2IQC)3]WJK;>6EUS7T[/IJ?LG7 L?
MBWXI\77D$=VOA6VFO&\N%809U5EBB ^Z H5R/<9Y.#7F_A/3]3^(6LWNLWY:
M>ZOKA[N[=L_O)G)8@>PSC'H*] T?X^KXQ\+ZMX:\*^$[6RM-=FCM9KN!0(X+
M4/@[EP2S["P,A))+$DYXKVCP#^SBT2W<=K;XL[.0B=AC*$\CCK@BO.RV-2"G
M7J*SEMZ+_AR^+*\*L:5.D[J.K]7MY76OWG.^$O#^DZOXGM_'I\,H_CC2M 70
MX]1^WNUO'"L;1JY@QPZJQ'!P2<D'C%72?AM'+]D:XVI\A17*G8@P<,.,D$<C
MDD?C7M7PV\"::?'^E:3<Z>MS:RW!?!(59Y0A*1LV1A68*,9P<\US'[.'C_XN
M_&[XIZIHOQ$LM!L-%71&N;W0X%WMHCA)=DN=@^S3I,JJ8BV&5A@$\U[V'XHP
M66)4L/AGS3=W9Z-[7\_0K+\OQV>8&MB9UURX2FDE.3OR^\U&"L]+WMLKM*^I
MS'AG;H'F><B1J!M4*,!L>G?'I7/ZW:R:IJCR^6PB=MHP.YKWKPI^S%_PD-B;
MO5M2960;A'$@V@^A)Z\^U9NJ?#ZUT*^>)=TP0;5 7+.QZ8]3GI7FU\3*M6E6
MGNSXWFYVHKH1_#W2M-U?X4W$.I-"6M;F.)%D.UI5<$*JG^\"./RKB?&'PUU/
M2(S>Z)<MJ&G$G"\^9 >ZL.H(Z57^.M_'9Z7'I*RM;QQNMS?"!@I#+RBEN@(Z
MG'>LKP;^TOX<:58[B[O+.Z50C3HW^MQ_?!!#'WZU-DXZ/5'I8C+JU1>TEI>U
MKORMW\D<UK\^O7V8_)F!.%Q@GV%:&A?!36-5L+;SG2/)# #((XP./7_/%>B0
M?$72/$$16#5M*9W V/*/*;)ZY(R.*V=)GU81AK&Y\,W##HTM\0?RVUU8'%5J
M#O1>_P SSY8'$TNEOP_,PO"'P6;28@UT%N9% W&3Z 8 P!C\S797WA.QL/#R
M*+>W3;T( !P>E<I\0OB'X@\+6&;J?2XE;@FRC><H.YS@<5R5Q\=VL$L8UCDO
M)+O+QR3+MC&#C<5ZDGL"0/6M,5BL37]ZJ[V^X<<+4E\;7_ /6?#NE_9[+[1>
ME8;7:3%$.'N>>B^@SW/%<YXJOYO$VL",-\_$<<<6=D"]E4?S/4GDU3AUVZUZ
MS$UQ<2$S#!<GYG^G8#T &*[[X<>"HK007#+ELALGDDCI7'%]6;5L1"A'V>'W
M>[_R.5C^%MQ9JLC2212@9VEB/S/K43PZKX?EW0R287J-QYKWM_#D-[8C<JYQ
MS7$^(O"JM>>7"%.]@N/<\5<:R;LSR*DYK529\^?\%-/%UX/V9_ &@LS"?4-0
M;4)4/4A(SC/XR5\;:)=SRE56.16! 8KGL?2OK+_@J;XTTN+X[^&?",[K'+IF
MB+,BMPKF1R"![@(O'7D5XOX.^'MG=:A%(EWL#$%E88R/2NQRE3ES1TL=N"C.
M5-3W;+'@'X5W6H".=4D=6^8\YSTKZ1^"OP6GU-TDD=;< @#<O7W%9?P_L+/1
M+*-45E7'WF7"_FV!7:Z;^T=X4\"W=O9S:QIYO+A@D<,+>?*['@#"Y"Y/<G@5
MY5:-2M*^K_KN=TJDH1LM/4] O=0C\)W$?A^UE:.[N5+W,JMAHK<<G/N_ '<#
MGO3K?4(9;A&:55(X51P$ Z8%>1_#'QA=>-M=\0:M=;U>XG\M.A.T9)X[ <8K
MO]+OK73$CFF&\%@HR>2S'"C\2:X9J522IP]$EU9Z5&*IPO+XI;_Y>GYF[XKM
M[76+)H<(ZR*4E5AD2 ]<UX%\0/A]-X*U7[1II:6S;ENK&#Z^H]#V[U[)XODN
MM%MY)UB22% 0WEOO8XP#M'!..<CT&?:N0\*^((=9U.7YTF@9@"#V^H[9]#7=
M4RW&8-7KP:7WK[U=''BJ=U=FI\$9X=>%O!<,R2KD>;@LIR.C#Z]"*[[Q-X(D
M@MVD@XY&TH<CGW]*RM&\*6/AZ83:>4C5@2RYZ<<CT]_;M72Z#XVCTZY\N9FD
M7&YB!G'J0/7U'?J.>O#*TGJ1[&I4I<\=6MU^IYGX@\8WGA^3[',/+!.%W='!
MX^AJ/P_XKM=#FMK6-O/ARKAF^[&1G@]"<>N:]"^*?@RW\77$5U%!&Z*H=@O\
M8/0BLWP%\*;&YO4N%A=ER 5^AY^F*]3*\TJX"?/27JNC.2-:=-Z&YX6\-2>,
M-2BD41E5B55"KCDY8D]\Y//TKKI/AM)I+KYMK(LC8*LZG'OS["NV\ >%=)T9
M8I(X660$<Y/![5U'BO6[--(:&5U\RY!CC7(SD]\5QYA4K8NM/&XC2^OW:)?<
MB:>(=2NDE?N<MH=W9>#_  9J=])(OV?3X3B3IOD(. /<5\CV?PLOOC7]NU*S
MU*71]/-RWD*B9:[.3N=CD$Y/2O;_ -MGQO;^"/ASI7A7364W6J8\W9UR>"3^
M'\ZP=(@MO!FBV5G:#;%'"(P#U! Y)]R>M34J>SIJ%-ZO5_Y'11IJI4=1]]/U
M?S=_N/#?%'[+7BJ*+<+N._0?=!F*,>?0\?K7-W/[-'BK.V;2GDCQD;)$8?B<
M\5]*>(_'_P#9MK%$L:R3R?=W9"C'=CUQGTJ"WU#5M1MCYUS'%(1^[0!0F #G
MZG/;(-=67Y?C\9'FI))=WI?TM<TE1<GH?)WB7X0:UX6@9FTZZCC&2<+N ]>5
MSBJ'P^\6:G\/O$)FM;J:Q=N&4Y*28[,O3/OUKZ9\817N'\Y4F4_=E@!("D9!
M8=C]..#VK8UWX8_VQX@U>QU#PAX5A^&UCHBW.E>)(YM^I7M\8HVR6R"&\XNA
MB(.5&>.,Y8V.)P,E3Q<'[VS6J^\ZL%AZLN=<T4H1<FI-*Z5M(WWD[Z):O4Z;
M]G[XGW6NV5M=;;;[0P!?< ZN?4-C//H?SKZ*T+X@1W%N8)BMO<LFT>6P!!(X
M(&3@]QUKY$^#-O\ \(?=Q_95V(6&Y>H/_P!?'>M?]J6-;/QKX1N+6>2TEUH+
M%)L8J#@C!.#U[4\+)5*G(V>?BJ=&LN>,;'T'\-_"OA;]FGX6:396]W?:Y<:-
MY_V/4=9O#J6I&29V>9S/)E@SLQR%(4#    %>2_MC?L6>#_V^_"7AAO%U])I
MNM>$KJXO=,O#;"[@47"*LD<D.Y2P!2-E(8%67/()!YS7_&5QJNIK#$DAM;%A
M&$'3 /)/N:[D>/?)N8DN&\F.0#;NX&/K]*,9*-2'L8KW?S)R_'8G+\9''X>?
M+5B[J5D[?)IIIW::::=W=&==ZEX?^!GPRTOP7I,\VI'30[SW,=F(S=W#X#R&
M*,;8\[5&,D\9))))\O\ 'OB36(['5[*RN+:[DTR>.SU2SMY4DNM*DN8A*L3_
M "Y3S(T!(C<@@ -R,5U7Q"\?6&CRII\!COE<LWVE"?+D)R27SR,'UZGDGTQ+
M;Q%JGQ%FATVUN'O [@K&B'*!0 "1PS?+P"QR  !QQ7TV'X=P'LJ=6-12BOB^
M[1+71I][GH?7%B)5,1B).52=W>Z7O-W;:MJFFU9<J3:Z*SYKX5^%;OQE;7EJ
M_AN'7-.D,,EU:7EH9X2T4@EB?&1RKJ",'G!!!&14G[0GACPS\=O&NE>#_B+X
M2TO1_A!):7?B#6?%EI<C1AIFINX0*TB%5S/N".) Q?S5  P2/<?"W[+D^KZ5
MI\>K6=G-'I6JV^N6$9FFC:VO(0PBD)C90P&XY1@0>XKH!\'UT>&[AUBWM;ZT
MEB>22"X@6:&?!R R,"IYP1D<$ ]17SN+IT5BY^QLXZ6>[?EMLGMY=2J>/C3I
MQITJLG;F;C>RBW9<T;2=VTE=N*M9)W. O](M=%CL_"NDPV^G:)8VJZ;;00Q+
MNBM$'RPB3!?9CL6.<DG))K"\1?"SP_K?@[Q%X9UK3/M'ACQ18-I^HP6SB&3R
MPRNKHW0%613@Y!Q@Y!K/^/O[0G@7]F:VTGQ!XZU+4([GQ)//::)IEB +C4'B
M\L/AF!4$&1  < D\D#FNG\:7$.O^ ]'U726NKC2->MX+V$SP&*X2%R04E3.5
M8,"K#. 0>HKAC"&*Q"PD'K)I/YG1+ YAA84\T<91@Y6A/^]%WT>]TTWYM.U[
M.WRC^T_\*]!L_@KHO@CP7IFH2:)HU])?SW$\,4$L\A0HA58PJJD:D@$9)&,G
M@"OD7QA\-/$W@NX::&22XA? V3.QX/3)SC/OBOTR\1W.DOH863Y<1B%U8!I4
M.<$@\@@ C))SST%?-/Q-\#S:I?"SCVM;D!Q)R>"<J#QU'>OM,3P[@\!A;-VM
MM?J^QCF.:8FK7>,JU'*<M6WO?]/EH?.GP[^.&J?#'4 UYX:M[^T9#'-!<(9X
M74]2,$,I'4$$$'H>M>H>$?B)\+_'7BW3-3U?4K;PCI=B"=0LH3=SW5ZN"6B0
M$D#=T&,GG'/2NU^'_P"RA=>+=)U#5;_5-#\/:#I?R3ZCJ4I6+=M+%%5069@J
MDD < 9-9WQE_9&D\$:''>>?I=]'/;K?Z??Z?*)8+R,\I+$^.02/3((P17Q\J
M>%=1J+][=GMY7Q1F.'@JSI/EE[JFT[7MT>UUOJ?<_@3X5_#_ .'>GV6O?$:+
M3O"37%L+BQ\/27:)J-G!C</.5"WV=0FTB.,ELDEGR"*^0_\ @H[_ ,%;?AIX
MLL#X)\#Z'JFMZ1ILA4V\%X^FZ2[CK)*8SYERW;)(  ..237P[^USXY\3^-_C
M;KVJZQK5]J=WJ;>9-,\I.?, 8A3GA<$#%:WP!_9;\/\ Q9^&6H:E>ZW?17UQ
M<BSM;2WM#+/ %"EIB%R&'F%5*\'R_,;.1BO2R_!5,QG]5PJ6OI>R[M_\->QT
M\0YU1R6G'-<PK2E*-DF[N,6]/<@KV>^K;=KV70Z/X-_'^[^*VF>(?"OAA=/\
M+7>L11I;:=9WEQ;V]W,6"^;+*TFZ0J"Q"DXSQ@YKWB'XGM\#_#]EX=F\3Z;J
M[2&26&6V=X&T]D8(RN&Y)8@D8 R.HXR?G#0?@$=#,EG")&M;>=9IOLY1Y7*C
M8SHX )Q\Q4 8 (.,\U]-67[/?PT\:_ 6Q2UMM<UC5;/1[O4-5UZ8ADTXI*IB
ME8R2*JA%#>;  <I\Q8$#/W>%X;^MY9+ 8>$5..O._5OU5]D]NCM='Y/G'%^(
MX>X@HY]C*TY4ZON^S6J?NI+NM-W&U[:INS1ZYX'_ &I[;XV>'K/P5XFA35OM
M#I;Z?<";][&SD*H5N>3D=B".",@5]G>#_P!D3X/_ +..DV[67@_P]>ZY;JIN
MM<O[&*XO99.C,'8'9@]E  'J<FOR&_X)N_LJ_&JS_:5T#Q1>Z9)I_@'1]=CO
M+F^U,""TN4C?S"+-" TH8@;#&-G(Y %?KQXP\7V>E^%]8U#4/MAN;=-PM;M?
M*;)!P-O)QP3T]CFO"RO+Y*3=6.J=D[6?S]/P/9XGS2EB:J6 ;C3G[THJ5X\S
MW:L[6Z].CL97Q=_8]^&'Q^O&OO$7@OPSX@D:+:)+[3(F?;VPVT,,=N:^5_B7
M_P $RO@C\.;V:9OAGH<MI)O:,0RW#-; C^&/>4.3U../2OIK0?C-$^A6T-J)
M&5(U>9ILK' I. #UZ]AZ=JS?CAXNLV\'3M&/ME](Q5%"':% XP.203R>AZ5Z
MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
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MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%1W%S';+F21(U]6.*YW6_C)X1\+JYU/Q5X<T\1
M??\ M.I0Q;?KN88I2DEN7"G.;M!-^ATU%>*^+O\ @HS\!O JG^U/B]\/[7'4
M#6H9"/KM8UYGXK_X+F?LK^$BZR?%O1+YD_AL8)[G=]"J$'\ZPEC*$?BFE\T>
MKA^'LUK_ ,'#5)>D)/\ 0^MJ*^ ?%'_!R;^S/H:M]CU#QGK3+VM-!D /XR%:
M\X\3_P#!TW\)].:1=(^'/Q"U9>=C2BWM=WUW.<?K7++-\''>HOS_ "/:H>'W
M$=7X<'/YKE_]*L?J+17XY>*O^#K.=E(T/X*R ]FU#7EP?P2/C\Z\V\6_\'3'
MQBOV8:/\-_ .EJ1A?/N;FY8>^<J,_A7/+B#!+[5_DSUZ/A+Q-4WH*/K./Z-G
M[K45_.WXJ_X.0_VH=>1EM-0\$Z*K'@VVAB1A]#(S?RKSOQ-_P6\_:I\7%FE^
M+6I6&[J-/T^VM@/IA#BN>7$V%6R;^2_5GK4?!7/)?Q)TX_\ ;TG^43^FBH;B
M^ALEW331QKUR[!:_E/\ %O\ P42^/OC0.NJ?&/XC74;YR@UB2)>?9< 5YWKG
MQ:\8^,I2VK^+_%NI$]3=:Q<R_P#H3FL9<44_LP?WGITO!'$_\OL5%>D6_P W
M$_K,U_X\^!_"<+OJGC'PKIZQ_>-SJL$6/^^FKSGQ9_P4R_9]\#;EU3XQ?#^W
M9>H76(I<?]\$U_*O?67VZ0M(SS/_ 'I7+G\V.:;!91V2_P"JC'N%%<\N)JC^
M&"^\]&GX+X2/\7$R?I%+\VS^E[Q7_P %X_V5/":ON^*NFZ@\?\%C9W%P6^A6
M/!_.O-?%?_!S'^S1X?4_8I_'.M'_ *==!=1^!D9:_GUCG1T_A%5[NY+C:HS6
M7^L&)>R2^3_S.^GX39)#XY5)>LDORB?N-XF_X.M?A7:F1=%^&?C[5&'W&GDM
MK53]?F8C\C7G/BO_ (.P[^0'^PO@K&GH=0UX'/\ W[CK\>8?,@_AZU,)"_5:
MR>=8N7VK?)'=3\.\@I_\N.;UE+]&C],/%W_!U5\:=2D>/2? 'P\TD-G:TKW-
MRR?^/*#^5>:>,/\ @Y+_ &I-;0_9=;\&Z,K=/L>@H[#\9&;/Y5\)3Z=YS[JD
M&G*1\W-92S'$RWF_Z]#LI\*9-2^#"P^<;_\ I5SZAUS_ (+<?M4>-C(9OB]K
M=BLF<K86EO;#W VID?@:\R\:_M_?'CQO)LU3XQ?$>[1OX3K<T:\^@4C%>7A4
MM5]*"$EYZUE*O5EO)_>SLIY=A*7\*C"/I"*_)&EK_P 0/%7BUV?5/%OBC4F;
MEC=:M<2D_7<YS7.WUE&T<C.&FD*\M(2YZ=R2:OEE7O45ZI:W?;Z'^59^IU1E
M):)G]/G_  1;&W_@FK\,,<?\2X\ ?[9HI?\ @BZ,?\$UOAC_ -@\_P#H;45^
M@8/^!#T7Y'\J\0_\C3$?XY?^E,ROB4FL-^U3XP.BFS:Z6"W+0W3,(9E* $.5
M!/N,=P:Q=1^'%]KD[>9HOAM_L9+72B[N88[?(W$(D> PQD_,#D\8 K4^+&E0
M:Q^T[XRAN+C4K3-M#)&]G>26SNRQ [24P2,<X) X[FM"'X):/>:?9S74NH2R
M0()/,:]<G)&<LV<MSW;/'M7/S)-^OZGVV$DEAZ=_Y8_DC#O[+4-'L+4^=X;D
ML9@&MHY+=SYA(P?.?YLI@XP%!'K5>]\&_8;ZV75?!>EZL\:%H(-&5,VF#PZ>
M:R$ D\C/!P0#S6H/AW /#HU*VEN[E;@LK1R7+RQ;2Q&(5/"@GD@ 9ZXINO>#
M?#_A,R0ZCXDURQCCA%R_FZM<^=""P4%6SD*3QM!Y..,"CF6R.KVBZ;AH?BZW
MTB^>Z71?$4BI'Y(@CMA=W%HV26#&-BN#V^8XZ<<BD.O7>IZ+)80:3JOVB_G,
MZ7"VWDV\8)!4;F)^;(P0,G.<\4RV\/>']:FCMK'7+IXYH1)9M;ZH8&O7.249
M@P,A/4@\\G([U9T_P1I&O:!=:@NJZY&(E:*:&?491%9R(,%=F0J%2!@J 1U!
MYH]W<.:*U]"76=2\336"MJ6CZ+I]O%(LGF_VB]RI?. '00KA23R03CL*AN9?
M%WAR]@N)O^$?U"Z:-E%M!)+90&( $DEBXRIY!QR,]*HNEYX6M;6WN'FU*UMW
M%[";G54+R;EXC)E(<+G)#.2,G&>!4>I^*+S4-2>[DOM+T2:[41M$98KZ>*W7
MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
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M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
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M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
M@"M]VL>>1!*>.,USJO.H[R;/:CE^&PZY:4(Q](I?DC/MM'L[1\K96W_?H'^E
M32\#A$0#L% _I4S7(SP*C+^:W/%+K=FW2R&I*%&2:3SQ(-O2I/*CZ9J&2W7/
MRFD[-E1ND->W#@X:H)%:*IOLSH:D"Y3YJGFL/DOY%%'YYIYD#BEN2@-56FVM
M3Y>8?-R:!<1[34*R;<U)EI#BHY%VM5K:S,9;\R!P6-1E"*"Q%-9^*7*UL/F3
MW&/]ZHJDJ.J6QG=7T&OTJ-^E2$!C32.:7*/F1&3Q3<'.:<1S2/\ =JXWMJ9R
M\A<<5'*F::S-O]J<6Q3,Y1:(_)&?>@-B@-EJ":")>8$YJO-+MXJ<_,*81ZUH
M8-$"[5/7FI%;C[U(\"ELT&#(X--.QC*)6N]K'@\T^*/*T260<]:=#'Y?\6:L
MYY1T(Y8E3MNIICW+Z58DQ3<\UHI'/*)#LVI5:1V=]J\8JV[XYJ%;B,'IBJ3.
M6< $94=>:C>X93TJ8S*W>DX:M(G'4IC(W5Q[T]N.:0Q ?=J'$F_VK2+.2=,>
MZ[E]Z;"C1]33Z"<57,<DZ97NXUN/E--@M%MU_AITL#-(#G I)X6:$\XK12.6
M5,D#@]Z1^E4+>&5)NN:ND8 J[HYY0(Y)=H^;GVJO=JRQL8QC(/\ *II+8O*&
MS\M22@>2WT/\J9G[/4_IZ_X(N_\ *-;X8_\ 8//_ *&U%,_X(Q?\HV?AC_V#
MS_Z&U%?HF#_@0]%^1_)/$7_(TQ/^.?\ Z4RE\2Y53]I'QL&UJVT8-!;?/<6\
M4Z2G8,(!(0H8]CGKZ]*O6?AV$:3#=_\ "61P-L*RQ1PV9\]AR5(V[@^.JH1@
M]!W*^*+NVL/VH?&4EUI=UJL?E6N([>W,[QL$!#!._H2.GTI&/A]+^6]D\$WM
MY<7#F17%A&6B7L69BH# C.!E@*SCU]7V[GU6'E^YII?RQ[=D3:%IEUXBN$M[
M[Q/#<0[%:"V2UA@D#8) X)+%0,<8QZ5!>:79V6IBW;QM?37#29FG-W!YMD/3
M<%&Q2>,'CJ!@U!JUCH>OV4=FVC^9=QEI)IWMA&L1)R &P-SD8R4/;DYJU977
MA^*TCAL_#=^EG;D_:8FTLC[2",852?G/<]\<U7+_ %9&W-;7]$4[^VB\,:Q/
M<6&K6%Z]S"+;==:D57:V25B7#(S@\XQDY/KQ*=)UZ^MQ?+?PFQAC\C[+878^
MQ[,8&]6!;?SD@8Y  QUJ_;W>B:7.+A?"^JPV3*!#;0Z05=&)RSE!C&>Q[_A6
M='IWABTN][>'=4:^D)DBGATYRB@YVEPI"EESR2#CUZT![0B6RN3=[;CQ8]Q<
M>9L:(3Q%; = XBP !CC)R".N<U7M(]/L3(MQXS\.Z:%E^6[M[.UMGO,9R27!
M5FSP748[#%:4D^D0.)[BSDM((T6.:"73W G8 #9&N#N5N<<X]:FBU2WBN"\N
MBS6NB2*5-O-IQ^UVC <>5Y8<,I../X<\D#BJMV_)?Y#YG_27^10D\.S7;&X6
M_DN[Q'6%'C,9E@4 %#&R@DH<D@D9SD&KNJ?#R^L-+^VPZEJMO<.H239,HDME
MSG9&<<*3R1UR>M-A31;6/_2=%UJRNIE(BN+.Q=S9*?N@R*.QP2 " 333XEOM
M8*:?>:Y8SFVP'AM8'2>7T>=FPJ[?2/J<'..*5GT#VC>WY#E\"7]M%8K?ZQXF
MGDOI3%E[M5DM@>,HVT$$CKCG'3!H30H],U"XATW7A#':DV]PVKSFZ6\)'S19
M9PV5'OD'C!%-N;?1=+U"5]!O-6NM0B_U]Y 9=2<,,81=[%7YZA3P.#BH[;[#
M=ZA;V_B:\TVWCAS/ FH:2;9#N.7+-([*)&'49! Z BERO<7,[?\  (;>SGO+
M>+S+[39HX?\ 1T2,^4+15'1]Q)! Y+$X/4#%!NK.9HV7XA?;9(CAH[:XMA!8
M(,C?M49^7IN8GW]*T!+HJ7+S3:/)J4+ I*MKIOV@3 G]WD_Q*!TY('3K56VN
M+*>=O+M;Y(T^=XFTF>*<+G[B@@1MQV!)]*97-=V_0- \*:&NF2+9^*'TB1I2
MSSV=[#$]WGGS&)SNW9SGU]L4[4?"EFVF/=?VGXBU22*<6R+97K+)>$XVEVC8
M*P/.21C' ]YKJ\\+W>K"\UC0X[73I$"I)J&GE)(F&!M*D'Y2.^.N>>:BG3PR
M'GU&.^L/#TT:A;(;Q$TD0Z'RU(8@GD  ]<8%*SOU)YW>[O\ =_3+=[\/FT_2
M4OVN+EKHJL8BN'!\@$X"(V 57/(!SCKFG77@3^P[ZSMX=<UZ.:[8LC3W!NOL
MC8Y9&D# <X!4Y&.0!67!K$VOW#M<:OXHU)F&U!#I1L]/![$AAN!'8DYSZBIH
MDL)%N&U:W\7:['= Q^7=V;R\CJ3&H"HHXQ@<]31ROK_7WBYI6U9+I?A#^U5V
MZ;XDN9Y(W<?9)98BES@\RLFW))/.< >F!44FEZA;121_V['IT2RE7M+;RA/>
M29"DLS $(!C(3MGGM5>XTS2/.D37M-TGRC$$L/*M98;UW'"J74D@$=<  >XS
M3I=(M;B]A-O8VT<5M"(C+/9'[1*W.2'D^8(.@P!GDY(I\I7,[_\  0V\&FRS
MQI8^/;G8&*2SVNH0L+1NBJ_! C!R!G&#U)S5^2/Q3)/'-]MT&ZGM8B1+$Y$-
MW >IF&?ESZH3TSCM6K=RZ)_8^ER3OHOV&3(N[D")8/E'*-TP"3CD\=Q6'-IW
MA;4'E_LG19'LV/[MK2V>*)Y@>)#M(!CQQD@J3V-)*_0F,[DWASX?_P!L&:^A
MUJ^TGS2'E@TVZ"+*<<%@RG((& < D55BN+NW,<=GK5A/</&T2V?VE8+BTC;(
MR3ALD,,J2!SQG!K6_L/P?XUTV\O)M%LX[W34'F&]M"CAOX3G@LI/ (/Y57CU
MC0/[,>QFT]X[\E2SR:<RI>$$$A7Y!P..2"0.,T:O</:-O_@&##H,B%Y+JX\4
M:M)*G!AO':[('&(SN54YZD8]S3;RVOK*-)OMOC:SM3A6@M;M&EB..2P8-O8G
MKA\]^:Z?Q'HEOIMY</\ 9=8AL8"I:2SR;@LP& @4;@><9SG&>1Q5"2XL;4GS
MD\6V]FR#ROM,4]T48<9ECPSACT#9.1]*K<OVB8[3O R:MX7GOEO]:MW56S"U
M\RH^T9#';]V3GEU(.>N:FA\"R01Z:UQKGB66UU !!!->^:;=BN5VLH#9'3=G
M(ZDU7:>^=TLX+[4(K)OWKQ6^F,/,4]=\L@S@@<(@#>I%-&FC+^3I7CBVDW!D
MENKE94R#D"*-I&56/& 0!C@\<5/*R7)WW)+#X<V>H>(KO3H[SQ#)!9@&2ZEU
M69ID?'(C8DE< X)!&>G:J]QI]QI%Y*MG?6%_%%*K"2]N@;F21/NN6!&]><'(
MXZYR#3YH-'>-;?7-)\6:A,V9GA^R$I(S=Y%A(0L<G(Y'I4Y.E1Q,8/#DT+J=
MUL&TX(MO",!HF;!"EAGY1SSS@T[,%4=QMWXHNO$LRQMI&CZ;N;=)>R:O!-Y9
M'0CRR3R?[Q'L":A.F2:EKBQS^+KK4)KAQ']HT^:)5L)2,A44;M@(P,DDG.:L
MS77A26T"6_AQ]/\ WBR2PW6C-%%/&/O$G 0X'(R<Y' -+J%_X5O;8+H&_;;J
MWG#1X6CFC!Z8&!C)ZD=.324>R)C+I;\!FJ>!)H;Z:-O$VL6<EBB/]MEU(1;P
MV00X VE@ ,$@\>AIEAX4L]4CA?\ MK4CYLIM9#;W;*H)!VRX4@JS]F&"<]<5
M6L=&T.RL5AUS2[73XY#FWFGCDO%MG)ZO*P(!(ZN< G@'BI[ZQT%H(5(D.M.I
M"O:0M*\<.<JTA7A%R,@DCV!YI\KV+YGM^AH:I\-X?#EE#YNMZ]*MQ,(C-<WS
M/]G7!PRECA2/7.3W.:R;S0O#NFWBV\GB6_%LJAGNY==?<7/W8EDWDD'NF<'.
M<&G*NGW^HO?ZU=6TUU=(8%,EG<6R7)48$>R3(4G')& ?Y3V5WH_A9;FSNKOP
MOIXDCR@$2GRIFP1N53A% ]0#W)-+E:W)YFEJRWH'PXT_Q%8I?6VM>(XY V&2
M/59O+@=>J>7N"@>Q&,>U5KOP1"=!74KB_P!;99"(UM_M1%O$I8C=Y>0IP><D
M$@]*JJNEV]QYUO>^)&OKC^+0E?9*@X4R$J5P3P"1G'3BEAL='LM9COI_#VH-
MY*'SIC;M<S7+$ 8B ;Y8P/O' !_6CE=Q\S3;)M-@%YJLEK8^-I+!9GV@NEN\
M]^R\;D+Y! /!(3GJ,'DW-.\"37>H7EJWB3Q$C6;+ON/M*"28<DJQVX"YS@ "
ML^[_ +#UK=MTG5OL:'F!]/\ +DCX^4PCDDJ>0!C'K1=F_NK18)KKQ0;6Z&R8
MR:,B2S@#A)GSE%QU.!D<YY.3E8<W;\@MS>:0EY;V^I6%_I]ZS1-!>:B-]L <
M!X@P)92.HZ#J".E-MM.34M6>/6/%'EP[2EO%#<"*S3 P!%TRRC^(DDG)&,<6
MK>;P_8O;?:-&N(7LFQ->3:21&8@"-J,5)*C(X &1GH*V-1TSPMK.A0+IT>BW
MEF;B-62 H\2*2<Y520!U[#%!+J6_SL<]=^'[?2KF-=*\1K=2)'B1KB^2<R#=
ME49W8DD'D $'MG!Q2ZSXTU?Q):1IFQT*.'F>ZBOH+BX?'7:!DQ+P221D#@8/
M-;'ART\(V]S-9W1\*QW$EP6@LL0 (H)"L%/)8CG..>W&*DU'PU8Z=)K-U;V%
MB+@3QQK,8@I3=C)9EP2HZX)/3I1I>S0>T5[/H4M6\*P:?IJ72^)M4EAN(E:*
MR:ZC-O.#C+(I&X]<@@G'6J-MX;TR37)(6\7ZA#>2A4M[I]5C>XGXRPC'W549
M ( R3WS6CXA\&:%X8N+=+/3K5]2N1YTMR\9EDVC@D.QR,G@ <8R, 58\9Z%X
M?TL6]FFC6U[M4RS:=:QIO93T(4D $GD$D=#0OZV!5/76_8AT_P"'-K,]ZEWJ
MNMR2V4A\V>6Y9&D4J""Y "L!C([#&>#S638Z!;Q:/),?%6MSJH/D6<VI(\=R
MN>'"MF1E[C)SD>E+-!:);K'"GC2RAE78MN7)BV@8VSL^X8'( !Y' .,59DO=
M"\W=;^#]4-RXVKJ%U9Q1E&Q@$EW#X'L",=*.5CYG_5AUWI:Z(T-Q9Z]!J5Y&
MRL!>72>8">0&91PH'&2.!ZU3U6_F\17J3:KJ.EZ:H !M]/U,3+)$#\Q+X7=C
MJ1@8X)S4D$?AJRE3_B2C26A.;][C3SMDC[E67(96/4')P<D#!J]+?>%;>39I
M9T'[#)L.^W=$BC ),K;@-H(& 02.OX46L-2=S'TC0M,M+>^?3_%;I;LQE^SI
M?QW27XZA_F+/GL=I /0@UI/8:Q+I4TD/C"QUO30FZ>*6UB$R*>0 T1&T@XP"
M#WSFM'4O$GP]GN(RUYX=FN!GR7B"2%&/ (9<A3GH215"XTOPQ'IUK(FEZ)_P
MD$A.P0HC7"<D-(0HW=.>0,DXSS2U>NI'M'+5_DBQIWPXC\1Q31W&N>(II+=Q
MB2/4'AD*L 1DQD'9R=H)/YU!;_#2SU#6;ZUM-:U2W\H*L\"3@K>$#DR[@2^.
M 3U]35*ZM/"]Q)NNO#&M_90,HEO:3Q-&?XR\:,!M)Y!.<Y(Q4BV'A^66*3P_
M?6.D26H TXMB'>?^6D8$FT^Q7CUX.#3L_/[AJ3VN_NT(5TB:08D\4ZH(H+@1
MW%@LT0CB3.-Q.T,(SP ,D GKFKFM?#/3])OT:2_N;S4-2.U[FX9//\E><E\#
MY4&,'&!QGUI]GX%;5-0M]UE:S23%HC=.P9XU4'>!@[CG/<X[]ZCU[P]X?M+N
M:PM[ZXO)(<+=)?7,MU# OIOD)1<8Y4$$#!(HZV*]I[UD_P !D'@>%M16&Q\2
M:]%;K"97OX=4$QDP>0S,6X!/ [<]JAT[1]!U4K%=>*K^&\5F=(WU8VLERN>'
M=5*[MWJ1C'&*AL-3M?[/DM[6V\)&SD#692VU%#;RACDMC&"Y_P">><GKG%;5
MP_AW1-*AAUBVL=6NI_WEO;6]J+AR@X'3*G:<Y.1@468.31CZ<S>%[NWOK>;[
M>\>[S(?[23<8B2"A61AMP0"I)P!P,9JTEYK'B?4);V;4+'0T@(-J9UC9;0'I
MO.XK(Y'7:0H[>IDDDT"]M_LYTF&UU0[3,]U8A!=Q]PKL,.HXX!Z=L#-2ZT?"
MKWP$&CV?B"TMXS%%!86R7 CER=P!SL7 X))&.!3MY Y];:^G](J2ZI?:'/<F
M/Q=X7@#!9+B\O;8!9F(QNC"S!1C(!!SS6?<PIJFGG3YK;1-3L&E,T-V+U8)0
M^02Y1OO(QZ%#P#R.IJ\;.S:S6&ST.YTR19/.A:>QBE6V7!#*>&16)P>^1W/-
M6K>?0[73)H[Z319M:D!6U2=(VN3D<X4 ,%//0 4K6#FMJO+^M#/M;R_U&Z>W
M\SP[HMO&<I<69>=(F ^7<\@$;  ]@1G'IBG7OA:XN-"U"XCU[7+R:S8(]I;W
MXLH)V)!#[XU+ -G.0 #T Q6UH+>%=1>6TN(]#^Q.BM%&X2.$,!AXU5L=#SR.
M^<5GZPOA.XU:&YTF_AMS9(8))=,!8J#T3Y00RD\$#([\$9HUOL+VEW;]!='\
M%V<>@P7VK:EJ&GKSA7U9V2<8Z.6(,QZXW G'0"H(OAW$OA1M36]U5V/SB.XN
M?M:QD-@.@E! ..B].@/K6E8^&O#NM:=/JVJ:O]M-DPA\V_*1QZ6PQA%5@%4]
M.>IXY-4;J_\ -\FUO+RQDT^S)GBBM()I;J522 2!\I!.0 ,YR"<8HU>PU4;>
MC_ PM=^!T+2M;R1ZE>.P61[EHT$DJD9VY5<;1G!P <YP:H1_!CP_JVH6T3:>
MT,.\"62"\ELS H&68E1@A<=#@=\UT8BTZ'?_ &-I7C;2D4DNMI*(IY,XR0LK
MDA1W! [$ U/]F76=MG(?$T\EWD1P7(Q'=@#@71" #..!^>:.5=2O;2M9LYV/
MX;Z:BS7FD^*]6TNVA!6"%M0+_:5'_+1?GW8!YXX(].HW?#/@OQ6EY)#:_$KQ
M+)&L2R+<[D:-P>1M0D\'U)/2MB;4O"\.DVDM[IME!K.UHX;3RQ+=(XRIVG&X
M*#_$<#'H>*RFN%T15FT:WUC3KBT!1DGTMYHCN^\(E#*6R<MP0 ><'I4^S[:?
MUY&<I*>DDOFD_P!"SJ7B#XF>#)41?%E]J(?.P#3HIV..[#(8+ZD D9R :LV?
MQD^+4<BB'^Q=0+#A;FR>WW@ ;F7:3E03UXS[5CZ=:>';,--<Z=J&K)=%68I9
M32W5S*#GS9 V"N#PH/3L,5-'LLI9)-+7Q!9W7F&>!I+>2XMD7NC+N 4G)R@(
MR><@U2B_,REAL/+25-7_ ,-ORU.JU/\ :*^(7ABR#W>@^%M0F50[V]M?/'.%
M/0[6[>_3/%6[']K+Q 8T>7P'<74#IO66QU**56 Y(Y Y'<'!!XKB/.&N7G]H
M7TEO-=;?+>XCTJ6T>)!SM"29D/KP2#T%27;^%[F59%T-K.R602WD]Y8/:B4#
M[LH)&20><D9]>M'O+JS!Y;A'O3^Z_P#F>C1?M=PVNG?:M2\'^*M/@*AC(84=
M%4]"3NXJS:_ME>#9MGG?VU9A^ 9M.DP3C.!MSG\*\LN=0-[']A\S^VM#5_M4
M-O-:3*UP ?EC:5U,84'D D'MC&*D4Z"+!X;FWCTS6)P!;?8K=QL7((1' "G:
M<G!(]<8JOWG?\#"62X1]&O1_YIGLEE^U5X OR%_X22UAD;HDR/&WY,M;FF_&
M?PCK&!;>)=%D+= +R,'\LU\XS:7HMU;7!UFR\3:\MQ\NRYC83EQR2%W*L*^F
M" >IJB/ OAV]AC:?1_$VTOB))+6*ZQCH)3'NRJ\8.[/7.:?-,PED.'Z2DON?
M^1];67B*PU%<V]]9S^\<ZM_*KP.X5\9K\.] 2<VNHMI]M? $P)#;S6DLPZ@$
MJ=A;Z8]QFKD?AGP]8W?EZ;XRU+[0@!$-EJ4A8 8W G+*"!G(R2/2G[2?5?U]
MQC+A^/V:G_DO_!/L"BOF/Q'X?U[0FMDT?XA:]9^<I<M>WB2QA1C'WL<G)QDU
M1'Q)\;Z%JB6Y^(EI. .(3I?VVX)R>2L:DA?]HX!!SG%$:S:V9S_V#4:O&:_'
M_(^JJ*^:+;XZ?$ZUNO)5=/U(JNYY9=*D@@48SG?N&?P!JQ'^U=\0+*-OM'@F
MWO/+8*PM_-5W]2H.<J/7I5>U79F4LBQ2VL_G_G8^CZ*\$T[]L36W,:W'PXUW
M?("=L%PC,F.S*P!!]JT&_;7TO3/EU7POXNTQPI9@]EO"@=<D&CVL3"63XQ?8
M^YI_DSVNBO'](_;A^'VK XU"]A"_>\RS?Y/KM!(_&MZR_:C\ WW'_"36,;9P
M5F#Q$?7<HH]I#N82R_$Q^*G+[F>A45S>G?%WPKK&/L_B/19CZ+>1_P"-;%GK
M=G?KNM[RUG'K'*K#],U2DGL<\J<X_$F7****H@**** "BBB@ HHHH **** "
MBBB@ HHJI?:O9Z;&S7%U;VZJ,DR2A ![Y(H"S>Q;HKB_$/[17P_\)PF35/''
MA*P5>#Y^KP)_-J\_\2?\%+O@'X3D=;[XL>"U:/J(M06?\O+W9_"L9XBE#XI)
M?-'?A\KQM?2C1G+TBW^2/=**^3O$?_!;#]G/0E/E^-I]48'&VPTJYF)^AV ?
MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
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M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
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MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
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MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
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M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
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MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
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MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
MW4WAM];MEU:*(1><9&MM_F!1%^\)*X"?-TYH [ZBOGC4O^"JO[.K^#O%6K:;
M\<?A+>1^$R+>]D_X2FS$$-RZ2M#"TF_;ND,,@4 DG8V,X-? W_!$#_@Y!7]M
MO7OBWJ'[17C?X-_">QT632T\+:;-J,6D+,L@NS<D27<Y>X(V09(("Y' W4 ?
ML!15#P[XBL/%WA^QU;2;ZTU/2]4MTN[.\M95F@NX9%#)(CJ2&1E((()!!!'!
MJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
M>$GH$R30![O1110 4444 %%%% !1110 4444 ?ST_P#!RE_RL0?LG_\ 7MX7
M_P#4CN:Z[_@^!NI++PO^S;-"[1S0W^O.CKP5(33R"#[$5ZO_ ,%O/^"5OQW_
M &O/^"S'[/?Q6^'O@?\ M_P'X'@T%-:U/^U[*V^QFVUJ>ZF_=33)*VV%U;Y%
M.<X&2"*Z#_@ZH_X)D_&W_@I#X:^"EO\ !GP9_P )A+X2N=7DU5?[5L['[*LZ
MV8BYN)H]V[RI/NYQMYQD9 /"?^"K7_! CX&_L\_\$3/$/Q6M;/7M1^-.@Z;I
MOB+5/&-[J]S<W.O7MU<VR7?G1NYB\MS/(5 0,I"G<3N+)_P0:_X(I?!__@IC
M_P $V;;XG?'A?$_Q"\6:VMSX7T*[NM<NX_\ A$],L&-O;0VBJX4%&1W&\,@#
M!=H&[=^DG_!6_P#9:\=?M.?\$=O'OPK\$Z)_;7CO6M TVRL]-^UP6_FS0W5I
M)(OFRNL8PL;G)< XP"21G#_X-Z/V0_B%^PY_P2_\*_#OXH>'_P#A&O&&FZIJ
MEQ<6'VV"[\N.:[>2,^9 [QG*L#@,2.^#Q0!^<W_!EKXYUS0_&O[2/PYDU2YN
MO#>C'3]0MK5V/E0W7F74$LJ+GY3(B1!L=?+3/05\T_\ !M3_ ,$WO ?_  4@
M_:A^,6E_%0:KKG@'P.UOJQ\,0ZA-:66JZA+/<1033^4RLPBC6<  @YFZXRK?
MH+_P;1_\$M/CK_P3_P#VA/C]KGQ:\$_\(KI?C:"U31IO[6LKW[84N;EV&VWF
M=EPLB'YPN<XZ@X=_P;$?\$M?CI_P3U^-WQXUCXO>"?\ A$]/\:0V"Z/+_:UE
M>_:S%/=NXQ;S2%<+*A^<#.>,X. #\[OBU_P34\*_![_@Y'F_9>\ Z]XJ\&?"
MOXAS66G:M::?J<HN)=(N;"*_NM.,Q)9XG:,H/,+$ INW$$GM?^#G+_@F9\*_
M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
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M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
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M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
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MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
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M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>oncyf-20201231_g3.jpg
<TEXT>
begin 644 oncyf-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #C L,# 2(  A$! Q$!_\0
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M_@AX>\%V4D$5IHMENOK]OW:SSD;[BX<D\!G+-R?E7 Z**_'KQ%)=_P#!2/\
MX*&&WLFFE\(RWBV\<@+#[/HEJ?GD&>4,HW, >DEP!0!^B_\ P2T^#K_"?]DG
M0+N[@\G5/%<S^()PRD,(Y0JVXY[&&.-_^VA^I^NZ@L;&WTVRM[.TA2WM;>-8
MHH8QA410 J@=@  *GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XCXW_ !$B^$GP=\:^,Y=O_$CTBZOXT;I)*D;&-/JS[5_&OQ/_ ."6?@IO
MB1^VMX>U&_"WBZ+;WFO7'G_,7D"&-'_WA-/&^?5<U^BO_!73QR?"/['.IZ:D
MACE\2:M9:4-O4JKFY;\,6V#]<=Z_-K_@FO\ '+PU^SU\</$GBWQ5<>1I\7A+
M4$C0'#SS*\,J0IGC>_E%5SW(H ^\?^"MW[6'_"K_ (:Q_"GP]>>7XG\60%M2
M>(D-:Z82589[&9@T??Y%ESC*FM'_ ())?LQ?\*G^#<OQ%UJT\OQ-XT1);;S!
M\UOI@YA ]#*?WA]5\KN*_/KX ^$]:_X*%?MM"\\97"R0:E<OK6M*KE0EC"5
MMHN^W'E0KW"G<<X)K]]K>WBL[>*"")(((E"1Q1J%5% P  .  .U $E%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !11574M4L]%L)[[4+N"QLH%+S7-S(L<<:CJ69B ![F
M@"U17R/\5O\ @J7^S_\ #">>T@\2W'C34(>&M_"]M]I3/;$[%(6'NKFOFSQ5
M_P %Q+..:2/PW\)I[B+/R7&J:TL38]XDA;_T.@#]2Z*_(%/^"WOC8,N[X9Z
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M"WVB_#LRB&*QC4B\UER0%,X4GY=V-L0]<MN. H!U'_!4[]M#PC^T-J&@^!_
MLTNJ:+X=O)KFZUI6Q;7DY0(HA7&65!O_ 'AX;<=N1\Q^ *[#XF?"/Q9\'-4T
M[2_&6D2:#JU]8QZBFG7++]HBA<L$,J DQ,=C'RWPX&"5&1EWA_X+_$+Q9I=K
MJ6B>!/$VLZ==9^SWFGZ/<3PS88J=CHA#88%>#U!% &C^S_\ &KQ!^SY\6O#_
M (Y\--NU'39_GM6&4NX6^66!QZ.I*YZ@D$8(!K^F6OQ<_85_X)H_$#Q5\3M
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MVP/A_P#M9>';N_\ !]S<6VI:?L_M#1=201W5KNSM8@$JZ$@X921QS@\5[?0
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M4)L/'5C>_"'X9:DMYHA;9K^O6KYCN\'/V6!A]Z,$?.XX8C:/ER6 /D;]MO\
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MZSH,]VL3W%G/+#=0S7$EP'5XT< @RLI#;?NC&:L_MU?\%-_AIXI^!OB3P/\
M"S7KS7=>U^+^SYM0ALIK:WMK9CB?YI51F+IN0;5(PY.>.0#X8_;R_:GNOVJ/
MCE?ZK;3R?\(=HY?3_#]LV0! &^:<C^_*PWGC(78ISLKZV_X)!?LE>%O&6EZC
M\9/%5G#K-YIVIMI^AV%R@>&VEC1'>Z93D,^9%"9^X49L$E"OY=U]3_LY_P#!
M0SQW^S#\$M=\ >$M+TV2YU#47U"VUJ^#2/8F2)(W"1?=8_NT92Q(!W95@> #
M[ _X+6?&K0)O"?@_X4VLR7?B)=33Q!>K&V?L<2030Q(_HTGGLP'4"/)&&4GP
MC_@D+\!;SXA?M#'Q_=6Y_P"$>\&0O*)G'RRWTR-'%&/4JK22'T*)_>%?.?P9
M^#GQ$_;0^-3Z;837.L:YJ<YO=8UZ^+.EK&S?O+B9_3GA>K'"K7[_ /P ^!7A
MG]G'X6Z1X'\*P,EA9*7FNI0/.O+AL>9/(1U9B/H %48"@4 >BT444 %%%<=\
M8OB-#\(?A5XL\;7%E)J4/A_3)]1:SC<(TWEH6V!B#MSC&<''H: .1_:K_:,T
M7]EWX-:QXTU5HYKU%^S:5I[M@WMXP/EQ#G.W@LQ'1%8]<"OP@_9_\#S_ +5G
M[4V@:1XKUJ.)_$^L/>ZQJ%W.L3S@LTTZH21F23#*H'.YQQ@56_:>_:F\:?M6
M>/V\1^*[A8+6W#1:;HUJ6^RV$)/W4!/+-@%G/+$#H JCR".1X9%DC9D=2&5E
M."".A!H _J@L[.#3K."TM88[>U@C6**&)0J(BC"J .@  &*FK\K_ /@GO_P4
M\22*P^&WQGUC;*-L&D>+KUQM(QA8;QST/0+,>N<.?XC^IT<B31K)&RNC ,K*
M<@@]"#0 ZD9@JDDX Y)-+7R/_P %.OVB#\!_V:-3LM-NFM_$_BXMHNGF,X>.
M-ES<S#TVQ$J".0TJ'M0!^2W[>G[1'_#2?[2'B+Q!97+3^&M/8:3H@SE3:Q$C
MS%]I',DGKAP#TK]8?^":G[)4?[-_P6@UG6K/R_'OBN*.]U+S4Q)9P8S#:#(R
MI4'<X_OL0<A%K\H/^"??PEM?C-^UKX#T348EGTJTN6U:\C895X[9#*J,.ZLZ
MQJ1Z,:_H0US7M,\,Z7/J6L:C::3IT"[I;R^G6&&,>K.Q  ^IH OUB>,O&WA_
MX>>'[G7?$^M6'A_1K89EOM2N%@B7/0;F(&3T ZD\"OB#]IK_ (*Z?#SX80W6
MD?#2*/XB>)ER@O%+)I5NV#R9!AI\''$?RD9_> U^:UQJWQX_X*%?%2&S>;4O
M&6JELK;I^ZT[2XB?OD#$<*#^\?F;&/F;J ?K+H'_  4P^'7Q)^,F@_#?X::/
MK?CK5=4O! VI0P"UL8(AS+.6D_>%40,Q_=@$+P3D5\)?\%E_B=;>+/VC-$\)
MV<BRIX5TA4N2K9VW-PWFLOX1" _\"-?6W@?X0?#_ /X)2_LYZ_X_UB:+Q)\0
M;RW6T>[8[!>739,5E; \I%N&YF^\5C9R/E5%_(./_A*/VA_C+$L\[:GXN\9:
MTJ-,_ DN;F8#.!]U0S]!PH'H* /=/V7_ /@G'\2OVI_ -YXPT2]TCP_HJW#6
MUG-K;RI]N=<B0Q^7&YV*V%+$8SN R5./</#/_!$GXDW5U&OB'X@>%=+MR?GD
MTR.YO749[*Z0@]^XK]9OAC\/=)^$_P /?#O@[0H1#I.B6,5E ,8+!% +MZLQ
MRQ/<L373T ?&O[/?_!*_X/?!&^M=9U:&X^(7B*W*O'=:XJ_989!SNCME^7KS
M^\,A'8BOLE5"J !@#@ 4M% !1110!^='[4O_  2!\+_$*]O/$7PEU"W\%:S,
M3))H=V&;2Y6Y/[LJ"\&3V 9/15KY6\'^&?VUOV&9IM.\/Z!XBF\/&0NUG8V@
MUO2WR<EPL8?R=QQDCRV/ /I7[@44 ?CM#_P5<_:?M9(;*7X8^'9;QEW*LOAW
M4A+(!U;:+D?H.U-N?VEOV\_V@%-IX:\)ZSX<L[@X\W1_#WV"+! ( NKK.W@@
MY$@//7!K]BJ6@#\B_AS_ ,$B/BE\5O$!\2?&_P ??V?+<-ON8XKIM4U2;KD/
M,Y\M#Z$&3Z5^BOP!_9.^&'[-.F_9_ WAJ"SOY(_+N-9NOW]_<C@D/,W(!(!V
M+M7(X45Z_10 4444 %8GB_P/X<^(.CG2?%.@:7XETIG64V.KV<=U 7&<-LD4
MKD9.#CO6W10!R/@GX0^!/AI)/)X0\%>'?"LDXQ*^B:5!9F0>C&-%ST'7TKP[
M_@HE^S?XK_:@^ 5OX5\&W-K#K-GK5OJ8@O)C#%<QI'+&T9;! QYP?GC,?KBO
MI^B@#\T/V3_^"0-OX!\56'BKXOZMIOB2>Q=9[;PYIBO)9F4'*FXD=5,@!Q^[
M"A21R67(/Z7T44 %%%% !6?KWA_2_%6C7>D:UIUKJ^E7D9BN+&^A6:&9#U5T
M8$,/8BM"B@#XV\:?\$F?V>O%VI27MMHFK>&6D;>\.BZFZQ$]\)*) H]EP!V
MK2\"?\$L?V=O ]S'<R>$KGQ+<QG*OKVH2S)^,2E(V^C*17UO10!F>'/#&C^#
MM'@TG0-)L=$TNW&(;'3;9+>",>BH@"C\!6G110 4444 %%%% !1110 4444
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MY6&%!+*5]F>5!]8J /TPAA2WA2*)%CB10JH@PJ@<  =A3Z** "BBB@ HHHH
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MZ:_H7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3Z79:YK5OX L]1@O=0MTGE@NS:1AIXV8$I(<GYEP>3S0!O?\$V?VAO"7Q1^
MOAKPA9^)9M;\<Z!IOG:[!<07'F1M)/(0S32(%D))ZJS'GFNY^('_  4"_9\^
M&/B"?1-?^)NFIJ=N[1S0Z=;7.H")UX9'>VBD56!X*DY!!'4&O._V(OA/X,;]
MA70;U+6Q\%W_ (B\-7%OK/BS2(+>SU#R2TH:5[ED/*+DAGR%QGM7S'X?^.O[
M#7P#TQ/!?AKX;7OQGU199(DU>_\ #UIJ,U[<%L(OFW C.TE@@\F+&%SAB06
M/TK^$OQP\!_';0'UGP%XHL/$UA&569K1R)(&9=RK+&P#QL1V=0>#Z&N)NOVV
M/@CI[>.%O?B!8V#^"[\:7K:WMO/ 8+HO,@AC#QC[0^;>;B'?PA/3!KX9_P""
M;^OZ=??M]?%%?#7@C4/AEX8U'PF;V'PG?%PT!6>Q"2%6 P&\V211@@"7"G&*
M3]CW]FWP5\<OVXOVG-=\;:-;^([/POXLO/LNEWZ^9:O/<:A>8DDC/RR;5@8!
M6!7YSD' P ?>?P9_;!^#O[06K3:5X"\<V6MZK$C2&PD@GM+AE4 LR1SHC.HR
M,E00*^3?^"JG[3EEX+G\$> =&\8WNCZRFKVVH>(-.LTGCWZ:<E=\BKM="RG,
M:L2<<K7/_ME?!OP?^SY^V!^R_P"+_AYH%CX0N=;\2I8:C::-"MK;RQI<6D?R
MQ( B%H[B5&( W C.36Y_P5T\%>'GC^$.M-H.F-K-_P"*8;&[U$V<?VBXMPI(
MADDV[GC&3\I)'/2@#[+\)_M,?#'QM\*+GXEZ7XNL_P#A!;=Y(Y=:OHY;*)&0
M[64B=$;.2 !CYB0!G-<!X8_X*)?LZ>+_ !&FAZ=\4--&H._EJ;ZUNK.!FW!<
M">:)(SDD8^;GJ.*\1_X*:?L_7Z_L]>%+7X8^![9_"?AW7QJNL>$_#=F+:.>$
MQL#+Y,"C(!W!BHW 2;N@)'@UO^T)^Q'\=/"+>"/&/PL;X+7IV1#6M*T>!9K6
M1  ,74,;2L<@J?-B*G.6[D 'ZZ45QOP;TS1=%^%/A+3_  WXAF\5^'[33((-
M/UJXN8[F2[MU0+'(TL:JKDJ!\P SBNRH **** "BBB@ HHHH **** "BBB@
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MO2-#\9WMO:3SZ7HT4B16D9U"V\N-]\DA\S;@MAL G';)^AOV.O\ DT_X/?\
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M#?\ PV_:]^&>L^)M?M;JXB75(M&LIK358\D9$,GDPLH23:'CR&5AD DYT/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>oncyf-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_770d05ea-c2a8-4b79-b171-fceea4e0638e_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of increase in value of currency, amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a2a33f0e-7a0a-4ab6-85a1-7426b407c835_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4c1078cf-a88c-422e-a4b1-96927a38b0c4_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_b7918deb-dda7-4e72-b1b1-cbcfbd2771fe_terseLabel_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_label_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement [Member]</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_documentation_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:to="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_12bf83b9-e7e5-4e29-b730-7332adb4c41a_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_98536d0b-6cfc-4a70-814a-c147a6f2a981_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:href="oncyf-20201231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_031ca05d-fbb2-4795-ad20-6e19d6c215a9_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to incentive share award plan</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_e97bb5c6-a24b-4634-a13b-35762768a2d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_95951c8d-cab2-441a-a8bb-5290299bccad_periodStartLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, beginning balance</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_a67edcf0-a3ea-4eda-8541-95f3ad0481d7_periodEndLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, ending balance</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_label_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_documentation_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:to="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_62311055-a234-43a5-bc7a-ad688d3d7b5d_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_f3c1ef6b-b9e6-4628-befb-bb9a0999b489_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_c0a0f33b-bece-4564-a7b8-2bc05081f91d_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_1a246340-6985-4eac-a9ad-923a75c978d5_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_98b252a3-ba46-4826-acbd-cc1c52548af2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_2f8e63e4-0c4e-4a7e-9a68-231afcbf5314_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_9b96a67c-3f60-4219-b087-9033e20f85ed_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_7d71cd3c-4d67-4099-8b69-4d936fd4c415_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_92e03cd6-f66c-44ee-b639-b26b7aebcdfa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_ea8b8445-8ca5-48cd-be6e-75d96fe8b3d1_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1" xlink:to="lab_oncyf_SharesIssuedPricePerShare1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_820915f4-70c3-409b-98e3-45b74651888b_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_76a74428-ccce-4de5-813b-8eb20f452436_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember" xlink:href="oncyf-20201231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember" xlink:to="lab_oncyf_InvestmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cb2ec588-40cc-4b2d-85ca-fc52eb2b6fdc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_026152e1-678e-4bc0-b1e5-2a1e0ae9b53b_periodStartLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, beginning balance (shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_69b99461-a82b-4f97-8665-e2d58fb0391b_periodEndLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued, ending balance (shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:to="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_7c95c0d1-0ba5-4983-9da5-764c2b6198d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_a04170ea-cbbe-459b-be68-093c5d69e677_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_ee07edcc-ccf8-4aed-b287-0334c500c4fc_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_97714433-1c04-4866-ab81-c12ff4f1792f_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember" xlink:to="lab_oncyf_SharesPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_35bb7f36-8d2c-422b-b21a-5a74183a768d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_bb298175-4d62-40d4-b00a-f577ae5b7418_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_2f838973-f6cd-41e8-a8fa-2f371956f4bf_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_90f75727-c539-4247-8c2b-b10cbe2d5818_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_e402c9ec-f67c-4b4d-a821-bf2fa4b038e8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_45e09686-1e22-445e-8599-46d0cd5a83c5_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding at the end of period (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_a52a08a4-92ee-4ed8-8c2a-07fd33ed103c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingExpensesMember_bca72bb0-2c2a-485a-a22f-b07330b717d2_terseLabel_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in operating expenses</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_label_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:label id="lab_oncyf_OperatingExpensesMember_documentation_en-US" xlink:label="lab_oncyf_OperatingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember" xlink:href="oncyf-20201231.xsd#oncyf_OperatingExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingExpensesMember" xlink:to="lab_oncyf_OperatingExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_8ca0fa3f-23a0-4141-b00a-1d91014cfe95_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_2c16a490-49dd-4e06-a2c4-905f52cd9fa3_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_94d8223a-27d3-4e39-9783-3c6fe2322c6c_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_label_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:to="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_1c6f0e29-e194-46f5-9f4c-7adc2bf3141c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_40c98f12-0335-486e-ac63-aca198c3ef92_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_860a75a9-97fc-466f-9feb-78935626d377_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_15066e6a-23ed-4fd6-a28a-c6ddf3cd4181_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_d5e5b66f-fee5-4477-a1d8-8f3985ee0958_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_52be4cec-dd61-4306-b015-999780e00ee6_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_10d87bae-0405-4c29-80d1-892b0e08845c_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Surplus $</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_ba4d347a-d3dd-4519-b20b-0809c63bade3_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_463e2214-b2b5-4478-8b59-7079528f24da_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_8333be5f-7415-4382-a247-444eabda53da_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_35c0b7d6-d1ec-4d91-abd5-486cc3f9b7da_terseLabel_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 United States ATM</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20201231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_c2c3d9df-2f04-4b9a-a1fe-af59ff84aa2f_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_label_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_documentation_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsandRightsOutstanding" xlink:to="lab_oncyf_WarrantsandRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_85b06888-cf98-4717-9b60-4fff77db0749_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_532a3711-4c3e-4fd7-81ea-00a27cb07e5b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_b110f526-200b-4d3a-870a-2d36da7c7f36_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_db5189ac-794c-47fe-aa09-2b500c1a4586_terseLabel_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_documentation_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="oncyf-20201231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_c93ad55b-1487-4f13-88b5-ab454ca6d141_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyOneMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyOneMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyOneMember" xlink:to="lab_oncyf_TwentyTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_26774541-c572-4adb-b978-3764610a3805_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_c45fbc50-fec8-452a-b790-168bb1bab282_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_dd63c0e3-a95e-43cc-9be2-63cfa7b21a66_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_ae103db6-837a-4602-83b7-d39767f97b13_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_eebab4e4-e103-4202-928a-5b3e53914116_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_18d758cc-64ab-4c4a-89fd-76c3e9363143_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_label_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) from Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesfromForeignExchangeImpact_documentation_en-US" xlink:label="lab_oncyf_GainsLossesfromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) from Foreign Exchange Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact" xlink:href="oncyf-20201231.xsd#oncyf_GainsLossesfromForeignExchangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesfromForeignExchangeImpact" xlink:to="lab_oncyf_GainsLossesfromForeignExchangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_bf3d99ea-fa91-4cfb-ac84-ea9f128395cf_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_809466e0-4af4-45b5-9394-f2c90b0cf872_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_acfa77f8-45a9-4b9f-bd9a-af2f41e115bc_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_0e13d7cc-bdea-483c-bfb9-136693af8d54_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_528318f6-0012-43d3-8617-44b168585c25_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySevenMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySevenMember" xlink:to="lab_oncyf_TwentyTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_65848afb-d53a-427e-8ac4-4d433b8b0065_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_d14ef77a-7f2e-4b0f-b229-c8bcbedd4547_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_b7faf3bf-54ae-44e8-9f01-305667a1d6cd_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, Canadian [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, Canadian [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementCanadianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_3f9afa5b-5aff-4b79-9f72-e1b64684a3f0_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:to="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_63cffeef-4f7a-463e-a9dd-dd7082880fe7_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_8a669dd2-6428-4976-8691-d4fd60aae698_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability - non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_8b4f4e09-981b-4fbc-9ad6-3fa72dda5294_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockAxis_d4265cfd-2002-43f8-a8ef-e0a1c0b7adf7_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis" xlink:to="lab_oncyf_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_399ccb32-69cc-48ee-8b86-7cc83b2d0579_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseinPrepaidExpense1_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:to="lab_oncyf_IncreaseDecreaseinPrepaidExpense1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1Table_a4e92f36-00ce-4cd3-b14b-f9e706fbf8f9_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_label_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_documentation_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table" xlink:href="oncyf-20201231.xsd#oncyf_Currency1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table" xlink:to="lab_oncyf_Currency1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights_387801e6-6795-4f8f-813b-a8525889f06a_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pre-consolidation shares called by post-consolidation shares (in shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Pre-Consolidation Securities Called by Post-Consolidation Warrants or Rights</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Pre-Consolidation Securities Called by Post-Consolidation Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:to="lab_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d887f184-06c7-4fd5-87d6-28ff14706406_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_4547f169-0d02-42e8-8064-126e87cc1eab_terseLabel_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying share price (usd per share)</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_label_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:label id="lab_oncyf_WarrantIssuedUnderlyingSharePrice_documentation_en-US" xlink:label="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued, Underlying Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:href="oncyf-20201231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:to="lab_oncyf_WarrantIssuedUnderlyingSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ea8f6bc2-9022-4871-915a-cfa67f84371e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_34d909bf-1516-4298-ab3d-684094049e21_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_d86a4f31-1de7-42f4-99e4-a645d033d67b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_7fc8ab38-54ca-4a59-961d-1a24b9d2fc62_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:href="oncyf-20201231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_cb92dbb1-cbd4-48b1-8a35-591a95354b4d_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_3ad96629-9de4-48b1-b2d3-c34ee5b8007f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_bfb877ec-4801-453f-8198-f9f2b249bb56_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_7904e05f-955d-4878-ab7b-81cacd50ea1e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7ae6829d-06ad-4979-858e-478b66c2dcfb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_8759d46e-51c0-4e6f-ab1e-2cd79b9b1349_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_6ae7d9ef-6df5-411b-931f-4335c4bde84d_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_b8c3faed-1e4e-4fab-b377-93467d896259_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_7ea6aec7-eb56-4cd7-b595-c8d4b0c91547_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_39485308-4518-46c4-b051-dfb93ca110d1_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to equity warrant exercised (shares)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lab_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_d23af7a7-0c11-4bbb-b6ec-26e1dcce61c6_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_283b1e1b-7189-46de-b10d-a84a02cb181b_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_67f62c69-40b3-4bb7-9e80-a40091c9e4d5_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_8b413da2-c41b-4919-b63d-bd302dc48b25_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_baa0a344-a20a-4b90-b2cf-793ba328541c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_5e9caa46-4aa2-43a2-86fd-5db98a638164_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Onerous lease contract</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_119a65aa-a310-489d-9cbe-dc8d2f5a1c36_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_b8f2f1d2-364b-4b4f-9f07-572545a9692b_terseLabel_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:label id="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_label_en-US" xlink:label="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lab_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_e547615b-a3f1-4b6f-8f88-3fb9556ab71b_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_6b5c58fd-faf1-4c2f-86cd-38c02b342297_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAbstract_906e66a3-0e56-49e5-99f9-c5c69093b887_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_label_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_oncyf_CommitmentsAbstract_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAbstract" xlink:to="lab_oncyf_CommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_224f3100-10d3-4bc9-80fc-9851f6251b46_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_554b1b1d-618d-43c3-8ab4-db81f2d94605_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_594bcfff-5687-45ef-b24f-983518416b36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_6752b6c7-9e09-4765-9c13-eb25c7317a4c_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2032</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyTwoMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyTwoMember" xlink:to="lab_oncyf_TwentyThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_90a3826b-2e8f-4722-ad62-dd4dfde3d0b2_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFourMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFourMember" xlink:to="lab_oncyf_TwentyTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_7d196424-837d-4434-8840-de48914bcdff_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyMember_43b5ae2a-0664-4676-88fd-950fa57eb217_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyMember" xlink:to="lab_oncyf_TwentyThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_aa5d1323-a130-4220-a7cf-3cf1a725fbd5_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_b626c2dc-f48b-4568-bc64-6dcd64884730_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable into common shares (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DividendYieldPercent_cdd22a0d-7d16-4630-8908-3807739c6ba0_verboseLabel_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_ba1c6554-f013-49da-93b4-6a595c1dc84a_terseLabel_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_label_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:label id="lab_oncyf_DividendYieldPercent_documentation_en-US" xlink:label="lab_oncyf_DividendYieldPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent" xlink:href="oncyf-20201231.xsd#oncyf_DividendYieldPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DividendYieldPercent" xlink:to="lab_oncyf_DividendYieldPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_d217e95b-9fa8-45c7-90cb-524dc606b4df_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CollaborationAgreementMember_61e5be88-24d1-45f8-b8b1-66882ae018c5_terseLabel_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRACELET-1 collaboration agreement</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_label_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CollaborationAgreementMember" xlink:to="lab_oncyf_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockDomain_832ff5e9-af65-4c4f-b069-dd2e1f595a2a_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain" xlink:to="lab_oncyf_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_d02c1f44-95ee-4a1b-ac75-39e781cd03c6_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign jurisdiction tax rate difference</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_e113bad3-017a-49c4-9c68-a373fe78c926_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity (deficit)</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfRenewals_23f165da-3702-4ad5-96f3-66e713754856_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfRenewals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension options</link:label>
    <link:label id="lab_oncyf_NumberOfRenewals_label_en-US" xlink:label="lab_oncyf_NumberOfRenewals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewals</link:label>
    <link:label id="lab_oncyf_NumberOfRenewals_documentation_en-US" xlink:label="lab_oncyf_NumberOfRenewals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfRenewals" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfRenewals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfRenewals" xlink:to="lab_oncyf_NumberOfRenewals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_28a87358-e24c-4e02-8369-2f223ed5eba1_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability - current</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_86303f39-b3c9-42c6-ae14-3518327e1444_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.02 - $3.90</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b353b832-877a-4820-b6da-1841be7be618_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_66d978c2-0e1f-4f4c-a554-69f1b32df70d_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_59bcb4f5-1e27-44c3-be38-29b33bd46c30_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_42f513fd-8051-4995-b128-3b224f51bd03_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_afab9b01-28d4-4f8f-ba67-72a8c04dde48_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_84fa7dea-41c9-4e0b-86eb-e78f2e97dffe_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_a3c05881-b218-4dca-bbb0-b71327c54c56_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_a8dbf656-2cbb-4b20-9a95-5cb528926c8f_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_4222f9f9-2f02-42d9-b9ec-4d7cf77610b5_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_3566bacc-c980-4706-bc7b-05f9dc844790_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_22de8676-68e2-40d1-9a27-daf19f20c734_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsMember_2cf90e10-600c-42fb-b088-2e03ec7e525e_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants $</link:label>
    <link:label id="lab_oncyf_WarrantsMember_e0c5e12c-a19b-4798-8800-014f946ae4aa_verboseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_label_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_oncyf_WarrantsMember_documentation_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember" xlink:to="lab_oncyf_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_135b8576-5dd7-4bb8-8578-00c495606f71_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_f1b17e9d-ed4f-495b-adfd-9ba18d9f3b05_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_2732df2d-ea5d-458d-bcab-2aa136da52c0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_4e0fa1e0-f945-4d4a-aa52-cf2aad2f7d6d_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_27bea8eb-29c2-4dc1-b6e4-7331659fe44f_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment due period</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Period Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_1be31f78-7cda-4612-9ee8-6aca03c8ea3d_terseLabel_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_8982538b-dd0d-47da-b064-64b77b9503cd_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain" xlink:to="lab_oncyf_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_cd2ce076-fa86-4296-bf35-9b74f236b6b1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_0938eb17-5c2f-4397-ac35-b9ce1c1e577e_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_fc84bf1f-8450-4346-9a57-2093edd1ec80_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_e76fbc14-f68a-4e24-b50c-23502d809a98_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_cf5765cd-daaf-4163-a0f0-7cdbd7a7bf40_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2033</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyThreeMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyThreeMember" xlink:to="lab_oncyf_TwentyThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_12e83b8d-d740-4717-83e7-56a81f635233_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:href="oncyf-20201231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_08881481-fcc6-4ed7-84bf-e5070b5837d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_bfddeebd-6704-4b3c-b1b5-86b6aa159bae_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_label_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Increase (Decrease) in Contract Liabilities</link:label>
    <link:label id="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Increase (Decrease) in Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:to="lab_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquityShares_8ba57a88-9267-4d4c-b274-b50f6d3da21d_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares" xlink:to="lab_oncyf_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_d9a52cfd-03f8-48c6-8cef-f172bf8ff0de_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1a9c6f38-3760-4c82-8442-52cad4a66909_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_1109d922-ba7a-4b69-8091-298b3d9db0cb_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain" xlink:to="lab_oncyf_ConcentrationRiskType1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_caa99c39-5b1b-48df-8f47-96702d153c45_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_20594285-29b6-4444-b921-43c6a667955c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incorporation and Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_0950731d-293b-4b86-a753-3812df9960d1_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to opening tax pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools" xlink:to="lab_oncyf_TaxEffectOfTaxPools" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_59ce3399-4f8a-440b-9e93-ce3e903fa742_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_aa207955-caca-4fda-94ff-ef92eea3c51d_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:label id="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_549f65e0-8bff-4018-8627-b8e1020b432a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_edb94438-d607-40ea-b6c8-568683fc5d37_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_440d3730-0708-4f69-97ce-fd28f399a358_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_c2eacf51-a75a-4224-939d-9f3998fb36e4_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit $</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_e705bcdf-8ea0-47ea-ad42-13c6fac262d1_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber" xlink:to="lab_oncyf_ConcentrationRiskNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_96657840-88f3-4af1-bb93-aab8e6f3c493_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_7a481fb9-9e5c-4a1b-8270-265e04f35aff_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected forfeiture rate</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_label_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:label id="lab_oncyf_ExpectedForfeitureShareOptionsGranted_documentation_en-US" xlink:label="lab_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Forfeiture, Share Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:href="oncyf-20201231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:to="lab_oncyf_ExpectedForfeitureShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_08a947b3-85f4-4957-9399-a9761fded8d3_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8497cc6d-9f32-4a7f-b9c8-227cb0536fa5_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_8fb3ef94-1574-4ff2-b06e-fb53df66ff57_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share purchase warrant per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:to="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_32ce9cef-3b97-4f61-a73e-5322a9a139f2_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_aeb99d9b-9494-4c0a-a94c-af681410330d_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_841eed64-b00f-4078-b0c8-72aceaa1901e_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_fde18d3f-e9b6-4cf4-9ddd-78a0ff0d9fe0_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_d9f75e9d-c25f-4325-9ef5-d9668dcaf89c_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost, commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_label_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_documentation_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:to="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_5fcd4e1a-0e80-423d-8809-fce987f53f94_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_427cbd82-9430-42e5-ad50-c5b5252d5cd6_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_21c91d24-a898-47ca-8b49-e2b4c042fd78_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_3d05a426-aa1a-4bc2-a16c-58ef461477a1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_339c50da-6f8f-420b-92c1-9b46e9b8687d_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital $</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_7e88973c-1fc8-4dc0-b1d9-fc8d66e9b775_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_8abb53ea-bbdd-4c25-89b5-bdaedea460b9_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2034</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFourMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFourMember" xlink:to="lab_oncyf_TwentyThirtyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_f2f72863-b31b-44c7-9880-db948778f1fa_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.54 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember" xlink:to="lab_oncyf_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_b9811fd2-9da2-4ce6-befe-62a5b358873e_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyNineMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyNineMember" xlink:to="lab_oncyf_TwentyTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_6eb1f021-a300-45b7-83b9-3c76fd6b118a_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_ddecd3b0-14c9-464a-9bcf-b90235586da2_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory_6bed0c40-e9b3-43e9-acb1-b42dd5e26802_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparative Figures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of comparative information prepared under previous GAAP [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" xlink:to="lab_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_b5c194e2-6bd3-48b2-9dd9-40b27f15490f_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$7.42 - $52.63</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_68eb0edf-9929-4181-af77-261d26ef53cd_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_a2f2d810-7f5b-45be-8b15-fccecd45c7a9_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyThreeMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyThreeMember" xlink:to="lab_oncyf_TwentyTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_8493d0ae-cba4-47ea-b20f-8c9cf5b311db_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_f5f7f02e-ad57-49d2-9638-5a8f0d4bebfa_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_512702db-dcaa-48db-9ca2-d5d8c148c6de_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (amortization), beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_b4854fbc-2808-43d0-bf09-dfa2ec9f587f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (amortization), ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_c71f4e50-84ff-4ca4-8526-0aa8f3dff35f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_20302d94-391f-49e7-9f13-a14f76a58dda_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_2a2837fd-45b3-4fc7-8f6c-ee8ae698c89e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability and Receivable</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_6330eabe-6674-4400-80a5-cfb6b983c092_terseLabel_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per warrant (usd per share)</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_label_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:label id="lab_oncyf_FairValueofWarrantIssuedPerWarrant_documentation_en-US" xlink:label="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Issued, Per Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:href="oncyf-20201231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:to="lab_oncyf_FairValueofWarrantIssuedPerWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_471de643-b666-47c3-8378-247e6dcca7d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_e60da8d8-3b4a-4acd-bdb2-0446b7be9ce3_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for derecognition of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_712aaf5b-2871-4d76-ac9d-47f2f05b2e42_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_391793fa-3504-4155-b6ed-d4876c451309_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_3b2c14a8-d03e-4e74-b8c4-c5a41b0d234d_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization - lease incentive liability</link:label>
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_label_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Lease Amortization</link:label>
    <link:label id="lab_oncyf_AdjustmentsforLeaseAmortization_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforLeaseAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Lease Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforLeaseAmortization" xlink:to="lab_oncyf_AdjustmentsforLeaseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_46fe74dd-6fb9-4a08-b5bb-545b05522da8_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_4a60978f-0d34-4e2d-9ca7-43eeb949b2c3_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_ee3f976d-964d-40e5-ba0c-00580ac2a718_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans" xlink:to="lab_oncyf_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9d355df5-19e7-4186-9cfd-2cc470695360_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_98508089-5a45-49e5-9f3c-093176318964_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_a96bfffd-c2f7-4894-bb06-7f2965597a98_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to warrant agreement</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_7da219c8-c635-4be3-b241-ce8694ae0358_terseLabel_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares</link:label>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_label_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares [Member]</link:label>
    <link:label id="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember_documentation_en-US" xlink:label="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital, Excluding Commitment Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:href="oncyf-20201231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:to="lab_oncyf_IssuedCapitalExcludingCommitmentSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_240689cf-ef68-4dff-937a-42d164ad8276_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_cd7c2085-9cd1-495a-b979-9728ffcc87ab_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_ac6c6b56-e5c7-4962-827c-875ea2b545dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_cc5822d5-8f4a-457d-883e-d46f3c5479c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_a5548c80-6afd-4211-b64e-08bcb191d8c1_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.80 - $3.01</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_4db94e1d-63ac-42ad-97f4-7002f437b431_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_b8b8a779-0e2a-49f8-8f9a-e0f948d1f652_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_28443ad9-2042-4a4b-ad6c-edc5b78268ec_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_a2a0df8e-1e2a-46ae-a6db-910a92ae03a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_2fa645a8-cd80-4ff0-aa2b-3d9806e5b04f_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_d708cdf2-9fdd-4c07-b535-8410cfc096aa_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_e3dda3d1-11b8-4213-9ffa-cda022227076_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_596a5098-9a30-4699-bbbb-b50a1eadf255_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_8d7863d6-6c05-4e3d-bdd2-ab4a5dc90faf_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table" xlink:to="lab_oncyf_ConcentrationRisk1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_37fbad7e-ebae-47fe-9033-77fdc5eb8818_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ab9ca1e9-1846-4b6b-8d71-b48fa8a2e4d7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_793ea952-db70-47e6-9256-f4e3d52b589e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_a0cd32ec-500f-42bd-8eb9-a227e2b8b496_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_4418fe4a-1cc7-482c-9be9-5113c8d80bff_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_c00b9a3d-6fdc-4073-b57f-4d6f141c4ff3_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_815f39bb-a2b7-4dab-87f6-9e2880f3b236_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_ab5776f8-41c4-46ee-9a4a-c8ba51507c50_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_d2f37e77-7577-440e-96fa-0308a4a8f665_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_36db8008-a968-4004-ba5c-0c06a0e2fc97_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderSharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Share Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:to="lab_oncyf_SharesUnderSharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_6ce6e71b-03f9-42b1-bcf0-8d5e9e23fcf5_terseLabel_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current annual interest rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_label_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:label id="lab_oncyf_CashEquivalentsInterestRate_documentation_en-US" xlink:label="lab_oncyf_CashEquivalentsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsInterestRate" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashEquivalentsInterestRate" xlink:to="lab_oncyf_CashEquivalentsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_86ba1353-dfba-44e8-b0e6-6e433534d6dc_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Annual Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:to="lab_oncyf_ContingentRoyaltyPaymentAnnualMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_d419e858-7f55-454e-9f3b-ccd6b6736c4e_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Alberta rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_609dc9d0-6426-4b3b-b5a5-b22ee2a2d86d_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for issuance (shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_4d7f7188-4135-432e-b5c4-750b37c6e63e_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_da185a7d-1a63-4aa6-9ec4-2db5db871402_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b086386-a010-4fbf-bd0e-c6cc8490659c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_408eb6cb-afd8-464f-bde6-d548116ff981_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_0396d670-1ea2-4f68-8c0e-190fb8837760_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regional licensing agreement</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_e7417251-6c91-43ca-9dc1-82c153302e62_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_22b4cc44-cc97-4ada-960c-64ddbb9f1aeb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_57964bca-ca2b-4e9f-aa3b-8e7b768c4551_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_ad6cb52c-f28f-46ef-92a2-2385d69a4d8b_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_e4e343ae-e1f2-4d86-b358-ba0e4f4de728_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment in respect to prior periods</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_fee8ea52-a647-4a15-a3cd-faf026320f1a_terseLabel_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_label_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_documentation_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:href="oncyf-20201231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:to="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_1ef80eca-564c-4df8-936c-4fd54824b704_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_f4fc6932-6c91-4c18-ab53-61b2071f7e7d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_e88c3319-a57f-4ef0-9ac9-fa653c91bf6b_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:href="oncyf-20201231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_1bf81a9b-ec7c-4ada-b112-2801f411a2fc_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_f763c308-a1e2-457e-a9ab-1f0fa03ee936_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_ee3b56ed-09c1-40e9-8ed7-a8b54fdf816f_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_d7eed61d-c33c-4496-8a5e-ff0ce15bf7ac_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current tax expense</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_18562c7a-a5f8-41f6-b1dd-3a242a2f1b67_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_f3e77e37-290c-4e4a-b9cb-22e2a3631486_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1LineItems_2464d18c-fed0-4036-a4c3-a28fd1678e76_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_label_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems" xlink:href="oncyf-20201231.xsd#oncyf_Statement1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems" xlink:to="lab_oncyf_Statement1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_aa7d4425-f53e-44d5-be94-401ef28d4721_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_029f10ed-8995-47c5-8e31-a8e59365f1d1_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyTwoMember" xlink:to="lab_oncyf_TwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0350fc9f-f531-4ffd-be0a-a732cae202ae_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3270e431-42ae-4ad9-b57e-1c242da6fb19_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_6112546b-79c7-4ea4-998c-70a28d89421b_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_f3c3e6af-b80f-4e7e-a435-0c83fa748989_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_38700cae-e30c-4ba2-bfd6-ae70bdfccae3_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_74deccaf-d299-4e46-b082-81e5c7aad834_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment on net sales due to founding shareholders, percent</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_label_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:label id="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_documentation_en-US" xlink:label="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:to="lab_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_e71ee184-2235-42fd-99b6-ef75ba24185b_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9e1fddcc-7efb-42c0-9387-05c3f5844a57_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_60598095-03d5-46b3-9e28-2bc98d740c63_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_0359b5f6-9a87-4664-a0b2-f1604d1f1b9d_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_b55e3a7b-53d4-423f-8d12-ca8a2b7020d9_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_f0d285da-93f5-4ea2-bad5-54e5e02258b9_verboseLabel_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Warrant Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderWarrantAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Warrant Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderWarrantAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderWarrantAgreementMember" xlink:to="lab_oncyf_SharesUnderWarrantAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_449fc0cc-ffc7-44f4-b2ca-fee7380490e4_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_e47b55b5-da3b-438a-81dd-c4ef856e766e_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_75067c69-51c5-4000-aa40-d7e68a3760af_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_4dfb6498-fa37-40a5-9f2d-bfc712f7fbee_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_3e079206-5998-46a7-baab-fdd43a3c5842_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued shares</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_6111dcd0-289a-477f-8c8b-57c6402e9c8f_negatedLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_9e7640a9-c95c-453c-acca-0bef95b6b5c4_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingenciesAbstract_cbf7a48f-9b14-4a1c-8f29-8e5c18e32100_terseLabel_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract" xlink:href="oncyf-20201231.xsd#oncyf_ContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract" xlink:to="lab_oncyf_ContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_87c6c162-d30e-4c2e-90b0-21adb923dfc6_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_beacc099-61c0-4d87-afb5-b4e3c7d55cd7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_a2621661-5501-4619-8c23-453850464959_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentSharesMember_8e04b780-b611-48f3-bddf-ee1e97715c5b_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:label id="lab_oncyf_CommitmentSharesMember_label_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares [Member]</link:label>
    <link:label id="lab_oncyf_CommitmentSharesMember_documentation_en-US" xlink:label="lab_oncyf_CommitmentSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentSharesMember" xlink:to="lab_oncyf_CommitmentSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_d812f41d-1ee5-428d-9feb-742b034faaaa_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyEightMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyEightMember" xlink:to="lab_oncyf_TwentyTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_25d7d705-7e8b-4bdd-8934-27d6b10718ea_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2039</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyNineMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyNineMember" xlink:to="lab_oncyf_TwentyThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_a7c6b88f-682f-4147-bcda-5f6b7ad047e6_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_4307f099-8899-457a-bfc4-bb51f1358477_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_4547df1e-d39f-4c2f-84bb-3ed443e4b07b_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm" xlink:to="lab_oncyf_SharePurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_4bca14ea-28e4-4b89-a172-c46e6f37761d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestatedMember_84661c92-9fb6-4ed5-b3f6-3b3985bf584f_terseLabel_en-US" xlink:label="lab_ifrs-full_RestatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently stated [member]</link:label>
    <link:label id="lab_ifrs-full_RestatedMember_label_en-US" xlink:label="lab_ifrs-full_RestatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently stated [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestatedMember" xlink:to="lab_ifrs-full_RestatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_35cd837c-34a7-43a1-872b-970db89edcc3_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_958d11f6-82d6-4c62-9199-9b0f2b04b16f_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pounds</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_61b2e30e-488d-4153-b00a-f1aa8aca1c23_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses and Adjustments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_25b8a611-eb6b-4337-999f-8e1849841607_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_05402de2-3059-4041-b80e-91930caf8088_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_489eaef1-cfc0-4716-b889-732a9fb641f6_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="oncyf-20201231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_1e28850d-b73d-4ade-806f-984bce629daa_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income $</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_ee620634-704a-4aac-afdb-babeec20bda0_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Outstanding [Roll Forward]</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:to="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e6bdf0a1-2f0e-4773-8983-5ec91bc21dad_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EquityAuthorized_e3d718df-7613-4fd3-a637-b921097ba402_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_label_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized" xlink:href="oncyf-20201231.xsd#oncyf_EquityAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized" xlink:to="lab_oncyf_EquityAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_96958cdc-0a82-4d44-a87b-952ac34423f1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_33ab466b-2184-4b16-8884-5d7fe5f5621e_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_d311c555-37b1-4d19-9a53-4846562314aa_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis" xlink:to="lab_oncyf_ConcentrationRiskType1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_c4312388-0537-48e3-9c3c-a8b2ca531516_terseLabel_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember" xlink:href="oncyf-20201231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestrictedShareUnitsMember" xlink:to="lab_oncyf_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_fa0efc63-b418-4c7b-84b0-b64a815d97fe_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3635b078-82d8-4f3e-9d34-89e814660514_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_d7335310-d8bc-4afe-a7b4-d0f585ab5dbf_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_fa0aba84-d616-4f76-815a-b0e5964ce753_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2031</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyOneMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyOneMember" xlink:to="lab_oncyf_TwentyThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_7a092aac-5fed-48f6-9996-c5ebf4de9a1c_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:to="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_615f518c-3961-43c0-8902-e97a3d93387c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_f61ed981-2383-4b44-82c8-3f3e5c9d3d68_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_ebf9240b-cbaf-4b9d-ac0a-804ddd87c65b_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_a23bdf71-b0bd-4d5f-ab47-1e67e1cf46ea_verboseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost, warrant derivative</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_925644d6-40fe-46b8-aa9f-b521375b5f9e_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_efe8a537-7e14-4e78-9328-bf6d4a417f45_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of outstanding warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_bcad523f-7e71-42eb-bd94-3c92c8d668e0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_7aebb0c9-0c18-41aa-af1e-4bef6c562041_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_d37e20f4-226c-411f-9c66-17c67974243c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_480da5cf-c626-40eb-a094-e31c53f959c2_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2038</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyEightMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyEightMember" xlink:to="lab_oncyf_TwentyThirtyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_9aafc92f-f7f0-477a-adb3-8367ec3afc98_terseLabel_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment, maximum</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_label_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:label id="lab_oncyf_FundedandRoyaltyRepayment_documentation_en-US" xlink:label="lab_oncyf_FundedandRoyaltyRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded and Royalty Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment" xlink:href="oncyf-20201231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FundedandRoyaltyRepayment" xlink:to="lab_oncyf_FundedandRoyaltyRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_06784ff2-a84f-41ac-8cf9-5d82e81772a8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_1cc3236d-396d-4a30-9714-566f9c38cf89_terseLabel_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance share units</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_label_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:label id="lab_oncyf_PerformanceShareUnitsMember_documentation_en-US" xlink:label="lab_oncyf_PerformanceShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember" xlink:href="oncyf-20201231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PerformanceShareUnitsMember" xlink:to="lab_oncyf_PerformanceShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_cabfa5ca-1548-4035-a830-31b5b8241df2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_feeb0246-dcdd-456c-b828-b4e4ba0df0f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1LineItems_4c1406b3-b1e7-40b1-92ac-0d83093cadc4_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_label_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems" xlink:href="oncyf-20201231.xsd#oncyf_Currency1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems" xlink:to="lab_oncyf_Currency1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_77a88d08-a5ec-440b-a7c6-b3890119a884_terseLabel_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from common shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_documentation_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:to="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_c55f087b-7a1b-4494-bd9e-e88d4e1d4a32_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract receivable</link:label>
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_label_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Decrease (Increase) in Contract Receivable</link:label>
    <link:label id="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for Decrease (Increase) in Contract Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:to="lab_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_143700f4-bf4c-4123-916a-abc68372cd38_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_ba1169e3-eee5-4ed6-af0f-cf1d87bd0a09_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_ff86d816-4101-48b4-bf6c-8edf21a3e0dd_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual installment of gross sales of product, percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_label_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:label id="lab_oncyf_AnnualContingentPaymentGrossSalesPercent_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment, Gross Sales, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:to="lab_oncyf_AnnualContingentPaymentGrossSalesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_85989f56-0604-46cd-afa3-5cd858423fe5_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a9d0bdf9-40f5-4442-8544-69c0509ad7c5_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_d9ca2c82-bd88-4d5f-8b37-40ffa4fe81e9_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_d96c4e6f-4d26-4b84-8da4-58aa55742a8d_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_76069f5f-e687-471f-b2cf-8578dd1b48eb_terseLabel_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Consolidation</link:label>
    <link:label id="lab_ifrs-full_PreviouslyStatedMember_label_en-US" xlink:label="lab_ifrs-full_PreviouslyStatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously stated [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreviouslyStatedMember" xlink:to="lab_ifrs-full_PreviouslyStatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_3cf3b20a-fc6f-4413-ac4a-c88ed32a3c87_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_9d67fd3c-4b50-4cf1-a138-03036f35742a_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharesPerUnit_492c4a06-37a3-41a8-9469-13b6346e7379_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit" xlink:to="lab_oncyf_CommonSharesPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_d856018f-badc-41ab-9f6c-4b4b1b8031b2_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_261380b5-992a-484c-8f7f-37ce46ecae9e_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentySixMember_ab4b264c-3211-4b31-92d9-68fdcd9e03df_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentySixMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentySixMember" xlink:to="lab_oncyf_TwentyTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_485e8b03-add2-444a-879a-85d9fd6cd59c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_879d6645-78c6-46e0-82a2-3027e18c6be5_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_b14b0ef8-a66f-43d8-b389-ffedccbee8ef_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Exercisable (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_7f7f1db4-b557-4ed1-ba8c-61658a6797fc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight_e5223f83-1a25-4a74-9083-95c00b186f68_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of post-consolidation shares for each pre-consolidation share (in shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Post-Consolidation Securities Called by Each Pre-Consolidation Warrant or Right</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Post-Consolidation Securities Called by Each Pre-Consolidation Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:to="lab_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_4221023d-3540-4746-90c0-0af4470bfb43_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_313901b8-e4ff-46eb-a1df-ccadde3b7908_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_d2f68fb1-ee84-4bb0-8952-27eb9082f1b5_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2f083ac0-5080-4d05-afec-95b1b4d698e1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_bb195b73-b100-4deb-80ee-739404151d4b_terseLabel_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment on sales revenue, percent</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_label_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:label id="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_documentation_en-US" xlink:label="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Royalty Payment, Percent Of Sales Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:to="lab_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_8d90d850-a9ed-435e-809b-b9f692c000a0_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_d5a00939-b69f-4d2d-8cec-99255d988634_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_edd81204-7c89-4a75-867f-29b20fc28601_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_fee8c2cc-db8f-44bc-9e12-23af3383e655_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_7fc4a3f9-6dca-4425-bd5d-f7dc1545ac3d_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issuable per warrant (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_d84b5e03-a278-4862-97b5-11e1257b2879_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MedicalEquipmentMember_00295838-d08a-42ef-b84d-226e962c588e_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember" xlink:href="oncyf-20201231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember" xlink:to="lab_oncyf_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_bf07b77b-e7db-4b68-90a3-06a7a05cec1b_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_248899b3-be09-4b14-9e10-8e5a9b18ce07_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_3a3696e8-bc30-4512-8558-d45676991670_terseLabel_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding, percent</link:label>
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_label_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Outstanding, Percent</link:label>
    <link:label id="lab_oncyf_NumberofSharesOutstandingPercent_documentation_en-US" xlink:label="lab_oncyf_NumberofSharesOutstandingPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Outstanding, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent" xlink:href="oncyf-20201231.xsd#oncyf_NumberofSharesOutstandingPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberofSharesOutstandingPercent" xlink:to="lab_oncyf_NumberofSharesOutstandingPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_981d30bb-57d8-4981-a6d8-7df3f7dbd226_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ComparativeFiguresAbstract_label_en-US" xlink:label="lab_oncyf_ComparativeFiguresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparative figures [Abstract]</link:label>
    <link:label id="lab_oncyf_ComparativeFiguresAbstract_documentation_en-US" xlink:label="lab_oncyf_ComparativeFiguresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparative figures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ComparativeFiguresAbstract" xlink:href="oncyf-20201231.xsd#oncyf_ComparativeFiguresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ComparativeFiguresAbstract" xlink:to="lab_oncyf_ComparativeFiguresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_43a6df29-82c3-42c5-8f46-d78d532312cb_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_3e885104-e0b9-4868-81af-70879dd46644_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_acdf3c27-3393-4d39-93fd-1c3d1961ded9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_7ca21131-9bf7-46fa-9ae0-ee12a0f302e4_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_c440b075-6507-4f53-8d2c-15ad84bfada0_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_1a59fa0f-8141-4cdb-b826-362a522f4197_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_946d062d-4909-4258-9c95-aa06d0d48eb2_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_b7ad5109-d3a2-44df-8740-f9513c4c2531_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_80300df6-8e36-4ffd-b513-9477beb7798c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f35ffc72-391f-468a-a421-cc2264165c20_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_61afa5f4-fae7-4a3c-bc4a-cb70d6907480_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1Table_be752641-cac8-4d36-ab7a-829c17e3aece_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_label_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_documentation_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table" xlink:href="oncyf-20201231.xsd#oncyf_Statement1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table" xlink:to="lab_oncyf_Statement1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_0047db0e-23d5-4295-b0f8-67450f7746de_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_d375d1d5-805f-42f9-aab3-e7feaf6a549f_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:href="oncyf-20201231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_18004909-f38a-4d7c-8574-08fccaf5a102_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_8ddfd5ac-8d31-4077-bb43-abbc1df76497_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SYNSORBMember_7e40f73d-8adb-417d-a5c5-5e0dfe6b8fd2_terseLabel_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_label_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:label id="lab_oncyf_SYNSORBMember_documentation_en-US" xlink:label="lab_oncyf_SYNSORBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SYNSORB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember" xlink:href="oncyf-20201231.xsd#oncyf_SYNSORBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SYNSORBMember" xlink:to="lab_oncyf_SYNSORBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_90cef526-98e1-420c-bac7-aae5715cc112_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:href="oncyf-20201231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_e17ec3a6-a87b-450b-ac71-53bb0927ae29_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_35023d2d-0208-4666-91ad-dc5a20d3d4d8_terseLabel_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:href="oncyf-20201231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_ba5141e5-9954-4d47-beb6-ffea52f1b5d0_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_9d08bb9d-841b-4e92-9a88-5800d73e5367_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_fb83c196-0fc5-43b0-aeeb-5179d0d9d2b8_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_f5c1980d-f0e4-4e53-aea3-92386ce91448_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_bd4a3380-081a-4f4c-85c0-20286b6c3fb6_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtySixMember_9d2e49e6-c399-432a-a7e4-54c6a3fcb1d6_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2036</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySixMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySixMember" xlink:to="lab_oncyf_TwentyThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_bc4c2796-b005-425c-892a-d53265710679_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_8af9d4a0-e182-47d6-bafa-316c5221d02f_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:href="oncyf-20201231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_5e65a863-f57c-4b25-88a7-c225d48f7b1d_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount" xlink:to="lab_oncyf_SharePurchaseAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_698c7614-67d5-493d-91ff-ac07cc46d103_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0a548449-604c-4861-bdbf-b9ac507f7fec_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_acd95ee6-8f89-481f-8ea6-f8b27d614fb0_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_f6b29c94-549d-43d7-8f03-2751bce1becc_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_82020422-ee45-4dba-8fbb-c98fd1bbf552_terseLabel_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Derivative $</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_label_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Warrant Derivative [Roll Forward]</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_documentation_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:href="oncyf-20201231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:to="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_cd988598-7525-4897-930e-9de110c3a290_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_3249f7e7-22bb-4a5e-b798-9e0b05a9fac1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_c7391275-622a-4554-b12a-ab585719ca93_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2e1c3625-2271-4997-bf9a-6822ebb0987a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_96b20160-5ba2-4196-82c8-38f3bae7f735_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_cb0beed3-d0de-425d-b0cf-3bb3a2717fca_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_ea6ed222-cdd0-4ec4-8e42-5f0d24cd470d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_d3d16d0b-9347-4141-8b2b-644ac658c08e_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_d8332a46-fddc-49f0-bb0f-81c88dcb4b49_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_081557e6-4d8e-44c7-9321-612a1c1aaf17_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_0c808e85-63c2-499b-91b8-35369c419c3c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_85868617-b8a6-4c10-a846-7a65bcf872c1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9de3d9a8-510c-461a-92ff-655f3179d5e9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyFortyMember_2b61db2e-78b6-4a17-af94-1462a0f1e8a8_terseLabel_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2040</link:label>
    <link:label id="lab_oncyf_TwentyFortyMember_label_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty [Member]</link:label>
    <link:label id="lab_oncyf_TwentyFortyMember_documentation_en-US" xlink:label="lab_oncyf_TwentyFortyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Forty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyFortyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyFortyMember" xlink:to="lab_oncyf_TwentyFortyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligation1_03f70375-7bea-4bda-ae16-7ae32c2da774_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1" xlink:to="lab_oncyf_PurchaseObligation1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_a1c6f1ed-c7bb-4d6e-b3ee-fc84d4fc86ae_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:to="lab_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_058b8729-06f5-42cb-a79a-8f1b13213872_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_52f5d193-d454-4f35-8ac1-b3bb80b951a7_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_9be472c5-ecdf-4f6f-bf82-909989b11ab1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_6f190bd9-252f-41b6-9925-8cfb7c93cfbd_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_3edb851b-1891-4f9e-9631-54215eddbc0d_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:to="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_0eb2c892-ce2a-4ec1-b5b8-925a3e713422_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee share-based compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_a662849c-c163-42f2-a10f-1341a01db5b7_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:to="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e2f28fb0-6aa3-412b-88f4-c4c1cf1352a2_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to stock option plan</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_fc09385e-3306-4f93-9eef-207fdbb778f9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed surplus</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_04fe339d-6bf7-4384-a42f-9124a92568c3_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_b941f8bc-ef32-4a23-839c-c973712105e8_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4f7eec0a-d4e4-491b-a241-288e6bbb6ae9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_49a3d4ea-ad33-4b1a-9720-5400a8e00de0_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_689ba5b2-1b4f-4b6b-ac04-64a94de0a8bf_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1" xlink:to="lab_oncyf_CommitmentsAndContingencies1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_eefe9160-92b9-4fff-8cb8-97ff6755c6dc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_843ada0e-2191-4165-a0d6-74c31bf62c08_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_2f0cc087-bcf4-4378-ba1a-4996797f89ef_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2020 &#8211; 46,166,980 December&#160;31, 2019 &#8211; 32,198,453</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e0503838-8b06-47b7-82a9-2922bf1e2a5a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays_505b0e47-a9f5-4e1f-82f8-5d5db8a349ce_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediately preceding trading days</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Consecutive Trading Days</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:to="lab_oncyf_SharePurchaseAgreementConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_a353c41a-792b-45e0-acd9-e781b0b15a57_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.91 - $7.41</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember" xlink:to="lab_oncyf_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_c43e4825-0e2f-4da8-8074-24649add67b9_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member" xlink:href="oncyf-20201231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_5a388aa8-d730-4d3a-9dff-942c011a10c7_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_c681e4ec-f1e1-4ba2-bf5e-ecc2ca093fa8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_a6356aa5-9425-4fff-8407-4e4f8feb25f0_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2035</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtyFiveMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtyFiveMember" xlink:to="lab_oncyf_TwentyThirtyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_d9fed52d-e9d1-406c-a89b-62e9f2d3d1f8_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_a959c617-dace-4d65-a181-6a6cbf13e4e1_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_6b457f4c-36f3-40df-be0c-70f22fa9825b_verboseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_412cacaf-c7d7-4463-bf14-aae9e2c6db3f_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_a2a23563-c1ea-4dcb-9ba7-7b7cd660b4c6_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_e07fa854-0238-4506-8699-4faa4b396188_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_79e0d762-3084-49b6-b419-8cb03774d734_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract" xlink:to="lab_oncyf_DisclosureofincometaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_6013316d-beb6-4cb4-9731-3af9479f2d51_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:to="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_508a3c14-91b7-4e1c-a635-088c86189423_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability balances</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_df49320f-442d-4364-b070-1ec16646b443_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_d6c73638-af96-4d25-bf49-5585e7fe05bf_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_8e3a416f-b4b7-4a92-804e-7aaa845eba57_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange loss (gain)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_68beca8b-ad53-4de3-9d77-88818ff983da_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_389fd1bd-af78-473f-b7d2-a306565d9361_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_4c7689c1-13bb-4de2-9b42-0d6f9e152816_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_e6c098be-e726-408c-8653-4997bb96217f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected hold period to exercise</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_57c524e3-ae2d-41fe-8a73-240a9576ccdd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_037ee779-22d3-4a2e-9d53-d49b090738c0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_c72d30be-b997-436b-ac53-145387f810d3_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_ifrs-full_Equity_e6c353ca-edf4-4d48-9c44-6c1f9be6e762_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_d227cc13-90b2-4302-af1c-fd446649e371_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_b786eeb8-bc2d-4c0f-803d-aaeae24e328f_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_ef194e60-2aab-42b7-bc80-0af1d8e1ad48_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:href="oncyf-20201231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_e3fec7d5-1940-4602-82e9-1e022750a878_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_6d7ec6b9-8da9-4fec-8e86-b64112f41564_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_c6f91253-81b3-4268-b6b4-3f3693fb9550_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_9c8cba28-63fb-48f2-88e8-dd15770af554_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_77612632-a2fc-4536-a941-f8c501d4ea6f_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_4f9cd8ce-6b29-4a92-a25e-9117a7e04eef_terseLabel_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_label_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:label id="lab_oncyf_TwentyThirtySevenMember_documentation_en-US" xlink:label="lab_oncyf_TwentyThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Thirty Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyThirtySevenMember" xlink:to="lab_oncyf_TwentyThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_ff7af78b-d8f6-446e-b390-8cb1d3acc2eb_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_d7dfa47d-b6ae-4e8d-9977-72fc777e1b8c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_89585a18-87fd-4299-a456-6da2bff25610_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived" xlink:to="lab_oncyf_ProceedsfromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_99486105-e605-4d5c-8b91-8b842075c4f3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_c4cb0a05-f711-42fd-9a10-b801612b7d32_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Included in research and development expenses:</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember" xlink:href="oncyf-20201231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentMember" xlink:to="lab_oncyf_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OverheadRepayment_d219c857-5abc-439b-952f-4b205ecfe742_terseLabel_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_label_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead Repayment</link:label>
    <link:label id="lab_oncyf_OverheadRepayment_documentation_en-US" xlink:label="lab_oncyf_OverheadRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overhead Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment" xlink:href="oncyf-20201231.xsd#oncyf_OverheadRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OverheadRepayment" xlink:to="lab_oncyf_OverheadRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_48120179-56b2-48c2-bd28-dec6f693196a_terseLabel_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment in connection with Share Purchase Agreement</link:label>
    <link:label id="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments made by entity, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="lab_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_198526d9-03df-49ec-a892-f4ce65f20d29_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_3afcdd78-7b3f-4c38-a8db-bc000d5e12aa_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_c63576dc-6a19-4e02-a906-e8910f318c22_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:to="lab_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_15d861d3-6a18-4fb8-8f5f-f61a817b87b2_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Warrants</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_5fcb2300-0f42-4302-9f02-54778411a400_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:to="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_1808a679-43b6-4274-aeb8-a17f2c4add9b_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_f3ede6e5-abc0-413c-abaf-c49d7821fd97_terseLabel_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_label_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_oncyf_TwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_oncyf_TwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TwentyTwentyFiveMember" xlink:to="lab_oncyf_TwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f3c8ef9e-5869-4e45-8d8c-0d353165db1f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_a09d50a3-ff22-42ec-9d47-695928eeb9b1_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_616c14ed-28f9-4235-bf31-7b6d03b868e8_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_934d2fda-9771-45e7-a45e-f096af6b3eb7_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_40d132c4-9831-4215-8bc3-c7180259626e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ef98b3be-c034-4288-9003-acd963cc4cfe_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_970465b8-b4e2-44fa-80ae-ab7bcd93d663_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_a5397180-1efe-4fcc-b5c3-6d242f04fd92_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_7be7ec93-815c-4050-863e-2b6149eed493_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:href="oncyf-20201231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_3345c4c3-2616-4c24-8add-797213b5307a_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in the year</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_1e2d5d15-9121-470f-96ac-ba6c537b56e7_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_37fb241d-cf70-4906-9ab4-160ae6eefd60_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_c52d7267-b9c8-42e7-896a-7895da9f5509_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_784d0d25-98c3-4386-bebf-c60db181f945_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_2d9460b4-9397-4c3e-9269-0b31397e10ae_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_2508a3e8-0b90-420d-90af-810cb96e31ac_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_7f3df41e-ddc1-4147-9990-bc731d7ba205_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Furniture</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_ca9a2354-4308-44bb-9392-6ca4d8ae26c1_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Warrant Derivative Agreement</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_11899a64-7518-4886-85c1-904778dd026c_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivatives</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:to="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_f4bdb81b-a19a-494b-9d00-59de570c374f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_e32a9742-1113-4477-b457-1188e4b0cec5_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueCostsMember_809ab931-afa3-47d9-8ad5-10b9de120bc6_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember" xlink:to="lab_oncyf_ShareIssueCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_570062af-081c-4d83-9b2a-414da5335b20_verboseLabel_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Common Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:to="lab_oncyf_SharesUnderCommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_7c598b08-66b7-46e4-8692-3e6fd9e726d9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_3d19235a-9262-4b46-872e-ecbe82b48f06_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AnnualContingentPayment_300a07d7-f0e2-4ecd-8924-3785f36a73d1_terseLabel_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual installment of annual product sales</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_label_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:label id="lab_oncyf_AnnualContingentPayment_documentation_en-US" xlink:label="lab_oncyf_AnnualContingentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Contingent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AnnualContingentPayment" xlink:to="lab_oncyf_AnnualContingentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e2e1c730-814b-4d64-9112-0e26e88fb139_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_c7e0d1c6-2a0d-490b-b0e5-040e7aeff168_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_fbd51256-6977-4ca6-82fd-d3d53a29b5ca_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_20b77dcd-249f-4747-bbfa-a568943606ec_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_fb1c7511-36f4-44ce-a2f7-af811a6a5006_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis" xlink:to="lab_oncyf_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_933e02c1-1fcb-4a41-bcbe-54d3e30d8464_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_fc5c2637-b48e-4156-808f-a4c7f5e6244a_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax benefits deemed not probable to be recovered</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:href="oncyf-20201231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_27a8f19e-356f-44af-86a2-1bc0c9d4c546_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>oncyf-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:dd8f7bbc-77a5-4d04-bd80-5a3f1ebe86f2,g:d1cc291f-92d4-438f-a18f-855d5e8b9edb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_46cdfb30-6797-4b82-a34b-574353986335" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityRegistrantName_46cdfb30-6797-4b82-a34b-574353986335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1bdf63e6-7c68-4010-a552-074a28f535f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityCentralIndexKey_1bdf63e6-7c68-4010-a552-074a28f535f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_70115964-d027-472d-aac6-fd7495b234d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_CurrentFiscalYearEndDate_70115964-d027-472d-aac6-fd7495b234d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ad60804a-907b-4bf1-9834-21e511372c85" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityFilerCategory_ad60804a-907b-4bf1-9834-21e511372c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_894db4e9-d30a-41ce-9d7c-0bbfc322035e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_DocumentType_894db4e9-d30a-41ce-9d7c-0bbfc322035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6e74d312-c60d-4692-961c-27b69b634add" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_DocumentPeriodEndDate_6e74d312-c60d-4692-961c-27b69b634add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_03ac9cb2-5458-4de6-8622-a49d907a786a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_DocumentFiscalYearFocus_03ac9cb2-5458-4de6-8622-a49d907a786a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_73a917b0-0742-4bea-abff-2dbade42a6f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_73a917b0-0742-4bea-abff-2dbade42a6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a3a1fce2-f3a1-455f-bdd4-839148ce187e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_AmendmentFlag_a3a1fce2-f3a1-455f-bdd4-839148ce187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2af46394-136f-4f13-80a8-e1d6c4a08532" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2af46394-136f-4f13-80a8-e1d6c4a08532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bab86084-ec65-4ec0-ba62-797b87743d24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bab86084-ec65-4ec0-ba62-797b87743d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6dc872b9-679a-46c3-b82c-e66a2db13076" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityShellCompany_6dc872b9-679a-46c3-b82c-e66a2db13076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_22c8a358-d891-497e-b863-1c82bfe0d64f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityEmergingGrowthCompany_22c8a358-d891-497e-b863-1c82bfe0d64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_eab25cc1-de0a-4ee3-a675-50bf16a2f0a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_eab25cc1-de0a-4ee3-a675-50bf16a2f0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_cf917754-5ffa-44d6-b559-57dc632009a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityVoluntaryFilers_cf917754-5ffa-44d6-b559-57dc632009a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c2da952a-9d5a-4070-8e3f-91d99c340b2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityCurrentReportingStatus_c2da952a-9d5a-4070-8e3f-91d99c340b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_397ee877-8f26-4cb7-8fef-3367c57134d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d59850a-dad5-4d0f-8523-45062a32dec6" xlink:to="loc_dei_EntityPublicFloat_397ee877-8f26-4cb7-8fef-3367c57134d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_005fc856-97d2-4481-9019-20275904451a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_ae23c0d6-cc05-4dac-a583-8d3e21f184c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_005fc856-97d2-4481-9019-20275904451a" xlink:to="loc_ifrs-full_AssetsAbstract_ae23c0d6-cc05-4dac-a583-8d3e21f184c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ae23c0d6-cc05-4dac-a583-8d3e21f184c4" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a61bcc0b-14e4-4323-856c-ac9662a9aee8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a61bcc0b-14e4-4323-856c-ac9662a9aee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_5742c1d5-691e-41f0-8899-00f461ce8838" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:to="loc_ifrs-full_OtherCurrentReceivables_5742c1d5-691e-41f0-8899-00f461ce8838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_02c67d4e-629f-4641-8892-8d8bb5660bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_02c67d4e-629f-4641-8892-8d8bb5660bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_2995b6b5-cfe6-4ab5-825b-ea7759f28bab" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_2fa25320-9599-4df4-9622-6c4249d09022" xlink:to="loc_ifrs-full_CurrentAssets_2995b6b5-cfe6-4ab5-825b-ea7759f28bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_f85b617d-013d-489c-82fe-bdf5c836e527" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ae23c0d6-cc05-4dac-a583-8d3e21f184c4" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_f85b617d-013d-489c-82fe-bdf5c836e527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_19668a11-e8fa-459d-ba8f-4f3c20a649a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_f85b617d-013d-489c-82fe-bdf5c836e527" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_19668a11-e8fa-459d-ba8f-4f3c20a649a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_576b34bf-2d88-4ea3-9c7a-befa9b239598" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_f85b617d-013d-489c-82fe-bdf5c836e527" xlink:to="loc_ifrs-full_RightofuseAssets_576b34bf-2d88-4ea3-9c7a-befa9b239598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_0641b177-159d-4e84-8706-84f1091ca1d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_f85b617d-013d-489c-82fe-bdf5c836e527" xlink:to="loc_ifrs-full_NoncurrentAssets_0641b177-159d-4e84-8706-84f1091ca1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_4a19c9c3-7606-40b5-8428-f073772df9bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ae23c0d6-cc05-4dac-a583-8d3e21f184c4" xlink:to="loc_ifrs-full_Assets_4a19c9c3-7606-40b5-8428-f073772df9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_005fc856-97d2-4481-9019-20275904451a" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_3485a1f5-36b4-4b40-a40c-244f217eb1ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_3485a1f5-36b4-4b40-a40c-244f217eb1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_1e8c8149-951b-4c07-b0a8-e0180794f69c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_1e8c8149-951b-4c07-b0a8-e0180794f69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_eca79dbb-40d7-4b48-a14b-5ca9ab0a16b3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_eca79dbb-40d7-4b48-a14b-5ca9ab0a16b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8bcc5dd1-3bef-4b09-95c5-ce7d072bd838" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8bcc5dd1-3bef-4b09-95c5-ce7d072bd838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_7144d249-a0ca-40e1-bac9-dfb8ada07525" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1c40d604-1b6b-4ffe-85c3-d1b6c51323bb" xlink:to="loc_ifrs-full_CurrentLiabilities_7144d249-a0ca-40e1-bac9-dfb8ada07525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_956cffa9-f221-41fc-8608-cb9785c06161" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_956cffa9-f221-41fc-8608-cb9785c06161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_5475cd86-56f1-4257-b2ee-2123245ac166" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_956cffa9-f221-41fc-8608-cb9785c06161" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_5475cd86-56f1-4257-b2ee-2123245ac166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_5bd1e061-1052-4d64-a52c-dad0f221cd99" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_956cffa9-f221-41fc-8608-cb9785c06161" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_5bd1e061-1052-4d64-a52c-dad0f221cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4e9b1333-fc99-47c7-a07a-ead96f1506a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_956cffa9-f221-41fc-8608-cb9785c06161" xlink:to="loc_ifrs-full_NoncurrentLiabilities_4e9b1333-fc99-47c7-a07a-ead96f1506a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_7ce68e9f-cfab-4c10-97b6-59d863411838" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_ifrs-full_Liabilities_7ce68e9f-cfab-4c10-97b6-59d863411838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_1a219e57-cb1b-4b4f-b7c1-0c9b00afc0ed" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_oncyf_CommitmentsAndContingencies1_1a219e57-cb1b-4b4f-b7c1-0c9b00afc0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_bee333b0-3467-4d5d-bdc2-1edb4e7a4286" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_ifrs-full_IssuedCapital_bee333b0-3467-4d5d-bdc2-1edb4e7a4286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_8daec564-fef6-4a9f-8c86-d932f35e1b18" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_8daec564-fef6-4a9f-8c86-d932f35e1b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_4c6e8dad-e7b5-4efa-96d5-a64344bc80e1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_4c6e8dad-e7b5-4efa-96d5-a64344bc80e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6a1cb423-15cd-4cf4-b768-bc4fb5dd8646" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6a1cb423-15cd-4cf4-b768-bc4fb5dd8646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_29179227-4604-4095-af73-4fbbd6e726c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_ifrs-full_RetainedEarnings_29179227-4604-4095-af73-4fbbd6e726c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_fd6a5afd-e99f-4c5d-9e65-f4c69c645268" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d0be7ceb-5988-4bcd-9871-f2f023f5db70" xlink:to="loc_ifrs-full_Equity_fd6a5afd-e99f-4c5d-9e65-f4c69c645268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_6e7742d5-8c24-497f-b02c-4833fc180f3a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_46caf9d5-6406-416f-bd17-45804bb879bc" xlink:to="loc_ifrs-full_EquityAndLiabilities_6e7742d5-8c24-497f-b02c-4833fc180f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_898cbdd2-d492-4a96-bf93-6b9f07e27e7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_93e7f840-2cfe-493c-87a2-3caac38cdc40" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_898cbdd2-d492-4a96-bf93-6b9f07e27e7c" xlink:to="loc_ifrs-full_EquityAbstract_93e7f840-2cfe-493c-87a2-3caac38cdc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_1d48049f-1a4c-4d8a-8e8c-65a90287c7b0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_93e7f840-2cfe-493c-87a2-3caac38cdc40" xlink:to="loc_ifrs-full_NumberOfSharesIssued_1d48049f-1a4c-4d8a-8e8c-65a90287c7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_0339278d-f551-432b-9520-305ee81f332b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_0339278d-f551-432b-9520-305ee81f332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a2ce6e79-3a6d-4c8c-996d-79bc1a527012" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0339278d-f551-432b-9520-305ee81f332b" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a2ce6e79-3a6d-4c8c-996d-79bc1a527012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_24d0201d-f05e-4c75-aacd-f9aa6de9cd84" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_0339278d-f551-432b-9520-305ee81f332b" xlink:to="loc_ifrs-full_OperatingExpense_24d0201d-f05e-4c75-aacd-f9aa6de9cd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_78603083-f6f6-4dc6-861a-bfb792db7e47" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_78603083-f6f6-4dc6-861a-bfb792db7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d823f806-66d8-4185-85f8-e04581bed297" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d823f806-66d8-4185-85f8-e04581bed297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_fcc47bab-7613-4b02-a8d8-69bd4fc7db8c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_fcc47bab-7613-4b02-a8d8-69bd4fc7db8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_8be004f5-6be2-4f85-b71b-75fcc5f4269b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_8be004f5-6be2-4f85-b71b-75fcc5f4269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_96b0d279-fbc3-4ec4-a632-15e150a0b356" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_96b0d279-fbc3-4ec4-a632-15e150a0b356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3f450022-3e50-4bd5-a653-1203c231b9e7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3f450022-3e50-4bd5-a653-1203c231b9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_6421389c-c175-49d4-a28a-f4e84963ec3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_ProfitLoss_6421389c-c175-49d4-a28a-f4e84963ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_f53b01c6-d558-4386-9120-3816320b2196" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_f53b01c6-d558-4386-9120-3816320b2196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_13fbc3cd-c443-4827-942f-31641f509804" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_f53b01c6-d558-4386-9120-3816320b2196" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_13fbc3cd-c443-4827-942f-31641f509804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_370158e7-4d44-45e4-a1eb-45de099dc6e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_ComprehensiveIncome_370158e7-4d44-45e4-a1eb-45de099dc6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_22eaf7fd-51b1-453d-9ff2-025e9364deee" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_BasicAndDilutedEarningsLossPerShare_22eaf7fd-51b1-453d-9ff2-025e9364deee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_1cd36ed9-6207-4649-b6c5-45945c04539e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_WeightedAverageShares_1cd36ed9-6207-4649-b6c5-45945c04539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_638ef341-c6e2-4a38-a6c5-eb8ae1803b06" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b95a5084-ffd3-431f-a422-0a017ab90d46" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_638ef341-c6e2-4a38-a6c5-eb8ae1803b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_525cac81-7453-4c10-8586-dc1673a2d68a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_525cac81-7453-4c10-8586-dc1673a2d68a" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_5b55c3fa-1b44-4678-a2ba-417612ed1572" xlink:to="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_fe8e09b0-4e2b-4ff9-9a8a-bd5ff3401bf8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_IssuedCapitalMember_fe8e09b0-4e2b-4ff9-9a8a-bd5ff3401bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_88f38712-0fe7-4f4c-8123-a3264b42c39d" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_oncyf_WarrantsMember_88f38712-0fe7-4f4c-8123-a3264b42c39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_46bdc37e-f65f-4b96-9d45-bdd1cb96f01e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_SharePremiumMember_46bdc37e-f65f-4b96-9d45-bdd1cb96f01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_ccc7c1d7-156b-48cd-ba4a-72d44ca41e01" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_ccc7c1d7-156b-48cd-ba4a-72d44ca41e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_e30221a0-7c75-4ecf-bd3b-33abe81ecd2e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b4d78f3a-42ac-42d5-ae64-4a8a859b5b01" xlink:to="loc_ifrs-full_RetainedEarningsMember_e30221a0-7c75-4ecf-bd3b-33abe81ecd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:to="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_57090ecb-de48-45f1-b2c5-bf5147022f65" xlink:to="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_27220ed4-0bfd-41e8-a2c5-6ad79ef441c3" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_27220ed4-0bfd-41e8-a2c5-6ad79ef441c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_9d63f8bf-e46e-4821-ad1f-42f52a232d01" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesPublicOfferingMember_9d63f8bf-e46e-4821-ad1f-42f52a232d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderSharePurchaseAgreementMember_e425ee8d-00b8-49f7-86f0-dc733a0ff7e0" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderSharePurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_703c2878-b7ce-4475-8ec9-6b928f4d7971" xlink:to="loc_oncyf_SharesUnderSharePurchaseAgreementMember_e425ee8d-00b8-49f7-86f0-dc733a0ff7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_24197444-cedd-4c1a-8ff9-fc121bf86804" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_165e26d5-b064-4676-b7f3-8319ecf353f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_Equity_165e26d5-b064-4676-b7f3-8319ecf353f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_aa566561-d2fa-4008-9f74-c23795009acc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_ComprehensiveIncome_aa566561-d2fa-4008-9f74-c23795009acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5a92da45-42f0-4404-95aa-1168d8be9629" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5a92da45-42f0-4404-95aa-1168d8be9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a2839384-61d0-4d14-a936-c7d3a78eadbc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_a2839384-61d0-4d14-a936-c7d3a78eadbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a55e30f1-ba55-44a6-9ef7-8ffe837d14c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IssueOfEquity_a55e30f1-ba55-44a6-9ef7-8ffe837d14c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_c4a6308c-6823-4bc6-8f87-ddceec7798b7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_c4a6308c-6823-4bc6-8f87-ddceec7798b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_d15ffb1b-f16a-4a88-8168-ecd41a8e95c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_d15ffb1b-f16a-4a88-8168-ecd41a8e95c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_d75cb7f5-927e-4de0-9ec1-6eaaa3e859b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_d75cb7f5-927e-4de0-9ec1-6eaaa3e859b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5e52051d-e38f-4f41-810b-b2ae4ecc9c37" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_96007dc3-d130-44a1-b04b-6e9db22bf481" xlink:to="loc_ifrs-full_Equity_5e52051d-e38f-4f41-810b-b2ae4ecc9c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_ea8a3abb-a309-4f0d-9b86-9c243df64355" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:href="oncyf-20201231.xsd#oncyf_Statement1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_ea8a3abb-a309-4f0d-9b86-9c243df64355" xlink:to="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:to="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_7e5f1528-78ba-4517-833a-3795bf543112" xlink:to="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_1e95e4d2-52d6-49eb-9d45-eaa15563f84e" xlink:href="oncyf-20201231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_1e95e4d2-52d6-49eb-9d45-eaa15563f84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_a3c1f24d-fec0-46cf-a6c2-23eb376a226e" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_a3c1f24d-fec0-46cf-a6c2-23eb376a226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_43bb5b44-ccc5-46d1-ab23-884f3366e829" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_43bb5b44-ccc5-46d1-ab23-884f3366e829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_da2c218c-5772-4498-b8e8-4b57d617cf34" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_93a05c78-4a38-4ff0-843b-fa3e49798476" xlink:to="loc_oncyf_SharesPublicOfferingMember_da2c218c-5772-4498-b8e8-4b57d617cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:href="oncyf-20201231.xsd#oncyf_Statement1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_b12f9b27-2d0a-4ff8-91ec-19f13de2dda3" xlink:to="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9aad710e-252b-4671-a43b-be0a5dfba5fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_ProfitLoss_9aad710e-252b-4671-a43b-be0a5dfba5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_29133675-2d99-424a-9fea-d5f491dc43fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_29133675-2d99-424a-9fea-d5f491dc43fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_610ca9ec-16a3-43b7-9870-82d931b5ee5a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_610ca9ec-16a3-43b7-9870-82d931b5ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_24d9ea8d-7381-4cd7-b362-55681ea93bea" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_24d9ea8d-7381-4cd7-b362-55681ea93bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_aafd3988-b83e-4621-a5c3-31fbe1a2cb0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_aafd3988-b83e-4621-a5c3-31fbe1a2cb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2cfc2cea-8c8d-443c-bf5e-8e0eff1ad8d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_2cfc2cea-8c8d-443c-bf5e-8e0eff1ad8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_5c4c9b91-54c1-4ef2-a3f6-87e1cf5189d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_5c4c9b91-54c1-4ef2-a3f6-87e1cf5189d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_1801ad11-e3f2-455b-a35d-b2c9ec369589" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_1801ad11-e3f2-455b-a35d-b2c9ec369589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d0bab866-aaf4-4200-af61-6c1c5fcd50aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d0bab866-aaf4-4200-af61-6c1c5fcd50aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2736337c-db67-41c6-9b96-6bcc685373c5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_2736337c-db67-41c6-9b96-6bcc685373c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_03a94fad-2350-46b3-8df0-09c4e40284cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9eea9d6b-6428-47b9-9415-f9d01a95b846" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_03a94fad-2350-46b3-8df0-09c4e40284cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_abff5c9b-e055-4333-b8f1-ccfa9bf6dc50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_abff5c9b-e055-4333-b8f1-ccfa9bf6dc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_76f0fec8-22d8-4fd7-9c04-9880f0ee220d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_98464902-887e-4798-9be3-1fd2f272841c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_76f0fec8-22d8-4fd7-9c04-9880f0ee220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_d022d4ce-4985-4e92-a093-1235e34387d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_d022d4ce-4985-4e92-a093-1235e34387d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_5c2573c0-ba72-4418-8cb6-8189f3f303af" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_5c2573c0-ba72-4418-8cb6-8189f3f303af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_6833fb3f-2cea-4798-ad16-6c404fef2d72" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_CashOutflowForLeases_6833fb3f-2cea-4798-ad16-6c404fef2d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_51719c41-2876-4e17-9e0b-83a3795d9b06" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_da0843d0-1ff7-4ea0-ade9-fb02ec566b0a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_51719c41-2876-4e17-9e0b-83a3795d9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2c4ec236-bf2d-41fd-abb3-d3175f16046d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2c4ec236-bf2d-41fd-abb3-d3175f16046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3a54d39a-f301-4f5e-9e52-768838c6bb54" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3a54d39a-f301-4f5e-9e52-768838c6bb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_556cbc91-f1cb-4746-ac3b-2cfe92e8bc7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_556cbc91-f1cb-4746-ac3b-2cfe92e8bc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2dbb39fa-bb65-4203-9a40-bafeeac83537" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_022324ff-5c46-4e2a-8e1e-abd6a4995ae0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2dbb39fa-bb65-4203-9a40-bafeeac83537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncorporationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_87b77153-1e19-4402-aec7-33b2a839b5b3" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_44e4926e-639c-4119-a0bd-3c075d942206" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_87b77153-1e19-4402-aec7-33b2a839b5b3" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_44e4926e-639c-4119-a0bd-3c075d942206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="simple" xlink:href="oncyf-20201231.xsd#BasisofFinancialStatementPresentation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_85e9ce3a-d62b-4193-b82b-f32d82715cf7" xlink:href="oncyf-20201231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_a89a5f15-d6b1-4fc8-a906-9a4aa90a9ae5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_85e9ce3a-d62b-4193-b82b-f32d82715cf7" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_a89a5f15-d6b1-4fc8-a906-9a4aa90a9ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b9c2ccc8-b864-4560-b86a-7eb974dd62d8" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_46c0bca7-b1fa-4660-868b-e56002cc5c07" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b9c2ccc8-b864-4560-b86a-7eb974dd62d8" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_46c0bca7-b1fa-4660-868b-e56002cc5c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_7a339b1c-d77e-4dec-91c9-622c6fbfde08" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_7a339b1c-d77e-4dec-91c9-622c6fbfde08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_e25b468a-d9eb-40a2-995e-6484d43c9725" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_e25b468a-d9eb-40a2-995e-6484d43c9725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_1b77d9e1-bbf8-4d6c-b600-d5a2fed6c1c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_1b77d9e1-bbf8-4d6c-b600-d5a2fed6c1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_ec789ba4-df14-4672-9c63-4d97bf64e0d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_ec789ba4-df14-4672-9c63-4d97bf64e0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_e2e5702e-6bfd-4fbb-8389-73f421571213" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_e2e5702e-6bfd-4fbb-8389-73f421571213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_9b0e27a4-b91f-4a16-ade5-08f67b7bee3a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_9b0e27a4-b91f-4a16-ade5-08f67b7bee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_dcb549d3-22af-4882-a569-f59a8537bfb3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_dcb549d3-22af-4882-a569-f59a8537bfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_dbbf1dc9-ffbd-4223-be24-c0da750d851c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_dbbf1dc9-ffbd-4223-be24-c0da750d851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_f495b486-18c4-4fdb-9f15-5581359b0cac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_f495b486-18c4-4fdb-9f15-5581359b0cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_f4edb4f5-807c-470e-b46e-ba3b647e729a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_f4edb4f5-807c-470e-b46e-ba3b647e729a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3eadd86a-4935-46ad-a282-e7bd60e393b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_3eadd86a-4935-46ad-a282-e7bd60e393b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0754bfe3-eb3e-40db-95c1-aa1553982320" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0754bfe3-eb3e-40db-95c1-aa1553982320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_b3eb21a9-228b-40c9-bf2f-0f3d21568042" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_b7d172f9-1843-4b5e-a7ec-c7f7d2166a4f" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_b3eb21a9-228b-40c9-bf2f-0f3d21568042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_1ef08b54-70eb-45be-8fec-589594f6766c" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_b376f22e-bb29-4ee1-a084-e3a1a1222a93" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_1ef08b54-70eb-45be-8fec-589594f6766c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_b376f22e-bb29-4ee1-a084-e3a1a1222a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_816ce1d7-d658-432a-9063-f550b5bd969a" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_816ce1d7-d658-432a-9063-f550b5bd969a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_f2bfa472-131d-4f97-ac8f-07d8b12368a2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_3f01a52f-cc29-40af-8c31-123ffc96ebeb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_ifrs-full_OfficeEquipmentMember_3f01a52f-cc29-40af-8c31-123ffc96ebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_884622f7-51f5-455e-8e9b-2003084a2494" xlink:href="oncyf-20201231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_oncyf_MedicalEquipmentMember_884622f7-51f5-455e-8e9b-2003084a2494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_993d8e52-d437-46e4-b010-8bd153296f7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_a185a9a7-6368-4634-b67f-8b2a257b1f6c" xlink:to="loc_ifrs-full_ComputerEquipmentMember_993d8e52-d437-46e4-b010-8bd153296f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_7602ae6b-fcb7-4147-8fd4-9015361e19e6" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8e298fc0-3a0f-4cdb-a59b-02a8e9ffb730" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_e0c990d4-c4ab-4b38-8a2d-51dd713ca487" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_8e298fc0-3a0f-4cdb-a59b-02a8e9ffb730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_5600d58e-c4d0-4c31-836f-d1feb9b5ea5f" xlink:href="oncyf-20201231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans_3acd347d-65b7-44c3-9d33-d3f16146b40e" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_5600d58e-c4d0-4c31-836f-d1feb9b5ea5f" xlink:to="loc_oncyf_NumberOfStockOptionPlans_3acd347d-65b7-44c3-9d33-d3f16146b40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_c03c5f52-9fdb-4ceb-bdd6-a4498074c9cf" xlink:href="oncyf-20201231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_5600d58e-c4d0-4c31-836f-d1feb9b5ea5f" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_c03c5f52-9fdb-4ceb-bdd6-a4498074c9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_ce16759f-438c-4ec0-8b75-f09ed52cf3d5" xlink:href="oncyf-20201231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_a6f44565-71a5-4d7b-b71a-3472912f5072" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_ce16759f-438c-4ec0-8b75-f09ed52cf3d5" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_a6f44565-71a5-4d7b-b71a-3472912f5072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_61902ae7-62d4-4f9f-86a6-eb07433ed964" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3abecb09-5481-40a5-ad66-82fd17955b9a" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_61902ae7-62d4-4f9f-86a6-eb07433ed964" xlink:to="loc_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock_3abecb09-5481-40a5-ad66-82fd17955b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CashEquivalentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_76234ecc-d432-471d-9b75-1c2d8c7e4b15" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_9cbbc0d8-ee98-4cd6-9666-ffc4f5e56e2b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_76234ecc-d432-471d-9b75-1c2d8c7e4b15" xlink:to="loc_ifrs-full_CashEquivalents_9cbbc0d8-ee98-4cd6-9666-ffc4f5e56e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashEquivalentsInterestRate_ac70f751-b022-440d-858b-23792498d29b" xlink:href="oncyf-20201231.xsd#oncyf_CashEquivalentsInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract_76234ecc-d432-471d-9b75-1c2d8c7e4b15" xlink:to="loc_oncyf_CashEquivalentsInterestRate_ac70f751-b022-440d-858b-23792498d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_fe06ca83-56c6-493e-a3d9-7de64541cf21" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c8f93a61-9e9d-4ccf-ae4a-62efa867fd40" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_fe06ca83-56c6-493e-a3d9-7de64541cf21" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c8f93a61-9e9d-4ccf-ae4a-62efa867fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3c7ee3d5-f7c5-4a51-a4f1-6c61b8a23b49" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_b07358df-ab2e-4418-957a-a1e9151a3fd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3c7ee3d5-f7c5-4a51-a4f1-6c61b8a23b49" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_b07358df-ab2e-4418-957a-a1e9151a3fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1ecf45c8-d1e1-4871-8c00-547ae8f42f91" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1ecf45c8-d1e1-4871-8c00-547ae8f42f91" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b4b5fba7-724d-4282-bc74-e3df53d7eb0a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_54e65a46-c084-47b0-b2ab-6fd1ef02c7a5" xlink:href="oncyf-20201231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_oncyf_MedicalEquipmentMember_54e65a46-c084-47b0-b2ab-6fd1ef02c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_025ccb32-f76c-4236-b2cc-22cdeffa933a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_ComputerEquipmentMember_025ccb32-f76c-4236-b2cc-22cdeffa933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_6a0e1634-ca3f-405d-ae05-b720b43552ff" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_6a0e1634-ca3f-405d-ae05-b720b43552ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_16ce2c5f-2a99-49e7-8b3b-d3d299ce876d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_OfficeEquipmentMember_16ce2c5f-2a99-49e7-8b3b-d3d299ce876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_28534278-2146-42b6-a153-6e875aa23a41" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_bf2cec50-34e7-4050-ab20-146b2d5c09e3" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_28534278-2146-42b6-a153-6e875aa23a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_d1877001-1d44-4996-a88e-38286738ec98" xlink:to="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_276e3ba7-b6a2-4088-a6ad-969b364c0f9e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_276e3ba7-b6a2-4088-a6ad-969b364c0f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_f273d3fd-9d4f-4cec-927f-3e651751c62f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_cfc2b718-0547-440b-aff1-a6e9a83e1d53" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_f273d3fd-9d4f-4cec-927f-3e651751c62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_5e7901da-536f-4084-aa26-3e573e3aa42d" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9a71a0e-7721-487f-b86c-110590dd728f" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_8d304126-889a-4656-ab9d-577a5cdb8f27" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_8d304126-889a-4656-ab9d-577a5cdb8f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_05fc3509-b79d-444e-b6f8-ad9b8e257321" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_05fc3509-b79d-444e-b6f8-ad9b8e257321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_f05ee5c0-75bc-49b8-93f2-f06b225693d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_f05ee5c0-75bc-49b8-93f2-f06b225693d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_b19e106b-f5a1-4d70-9d59-1a924ffe7aa2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_b19e106b-f5a1-4d70-9d59-1a924ffe7aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9308c15b-c421-4110-ba20-45e55ffba603" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_52500d47-3b5c-49e8-b316-261509fe4da5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9308c15b-c421-4110-ba20-45e55ffba603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_86b72311-0337-4d18-9847-32a11b810fd4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_ec71a51e-8180-4213-b446-6445c88f56ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_86b72311-0337-4d18-9847-32a11b810fd4" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_ec71a51e-8180-4213-b446-6445c88f56ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2ec76610-7e9f-4982-aee1-6ca166c2db39" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_fb045bea-854b-40c2-b9b7-f0ca6062ed4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2ec76610-7e9f-4982-aee1-6ca166c2db39" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_fb045bea-854b-40c2-b9b7-f0ca6062ed4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_2e0b4d5d-8f58-40de-8aeb-07c1d6a29926" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2ec76610-7e9f-4982-aee1-6ca166c2db39" xlink:to="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_2e0b4d5d-8f58-40de-8aeb-07c1d6a29926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_63db340e-7c75-400b-bf12-52b85bbbabe5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_2ec76610-7e9f-4982-aee1-6ca166c2db39" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_63db340e-7c75-400b-bf12-52b85bbbabe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0d4a758a-c29d-460a-9234-4a93ac3f9693" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_0d4a758a-c29d-460a-9234-4a93ac3f9693" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:to="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_533a0ddb-a18a-4239-beec-1136af7acb61" xlink:to="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_20e075f5-1474-4af1-820a-0704bb5f9e04" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:to="loc_srt_MinimumMember_20e075f5-1474-4af1-820a-0704bb5f9e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c15f783f-98eb-4576-950f-f85a2da04fc7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3646cc7-b8a9-487a-a403-4955fcf1f622" xlink:to="loc_srt_MaximumMember_c15f783f-98eb-4576-950f-f85a2da04fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d0c0cd5-3b88-4209-8090-5fd6c6991e12" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_338690ba-d63b-4977-a68f-2c749348e2e2" xlink:href="oncyf-20201231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_338690ba-d63b-4977-a68f-2c749348e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_efd12763-a8ca-45c0-9677-8b926586c150" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_efd12763-a8ca-45c0-9677-8b926586c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_49e48b3b-e4c7-4532-a95c-b5c3a2f2e97e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_ifrs-full_RightofuseAssets_49e48b3b-e4c7-4532-a95c-b5c3a2f2e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfRenewals_9fc9a535-7ecb-45c8-a198-b97e646e4a6c" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfRenewals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_ee1b7bee-2eef-46b5-a0bd-18b3549bee99" xlink:to="loc_oncyf_NumberOfRenewals_9fc9a535-7ecb-45c8-a198-b97e646e4a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_f3ef4447-8172-40ea-aba4-b1b7807ac366" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_RightofuseAssets_f3ef4447-8172-40ea-aba4-b1b7807ac366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_68940d46-9be3-4701-9bbc-4eeb7a72b1b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_68940d46-9be3-4701-9bbc-4eeb7a72b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_42da4b60-e339-47e3-852a-2cfce551403f" xlink:href="oncyf-20201231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_42da4b60-e339-47e3-852a-2cfce551403f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b8f2414d-a0d7-4445-8ed2-ee5306db90a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_RightofuseAssets_b8f2414d-a0d7-4445-8ed2-ee5306db90a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_1ab379d8-2a05-4e64-9114-1d83fedac7b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_1ab379d8-2a05-4e64-9114-1d83fedac7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_c1b14052-c6d0-4778-b3ae-011aea9d20e2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_LeaseLiabilities_c1b14052-c6d0-4778-b3ae-011aea9d20e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5047e638-a9ed-4287-b928-de67354c83c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5047e638-a9ed-4287-b928-de67354c83c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_6fd512e6-5a01-4342-b2b1-05925f8a46b4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_CashOutflowForLeases_6fd512e6-5a01-4342-b2b1-05925f8a46b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_a7de54e0-b998-4f37-87ab-b2472a1b4bb9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_a7de54e0-b998-4f37-87ab-b2472a1b4bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_8a69a21f-cbca-4104-80c6-da85bd6b3391" xlink:href="oncyf-20201231.xsd#oncyf_GainsLossesfromForeignExchangeImpact"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_8a69a21f-cbca-4104-80c6-da85bd6b3391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_dca9de8a-3864-42a3-b51f-db44e05bd531" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d0d0e7ff-134c-4992-9543-a43ad16608f6" xlink:to="loc_ifrs-full_LeaseLiabilities_dca9de8a-3864-42a3-b51f-db44e05bd531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_be1f6064-7038-4df6-b2e8-483636e94959" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_be1f6064-7038-4df6-b2e8-483636e94959" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:to="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_5c912107-0c03-48c9-8d20-a5486f7d866f" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_c1cf829b-db28-4c7f-a8f1-21ff652139e7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_c1cf829b-db28-4c7f-a8f1-21ff652139e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_965b8dce-84c4-49ef-a33a-3256b798afbb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_965b8dce-84c4-49ef-a33a-3256b798afbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_138ad655-f7db-4cf8-9480-61a92ce5d9a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c39dc72f-d4dc-46e1-932f-9c768b9b204f" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_138ad655-f7db-4cf8-9480-61a92ce5d9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_58fbc700-0633-4a94-829a-6ab5aff1db56" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_a4bc9b8e-83f9-4159-bfee-393d86f1faa7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dfed141a-7271-43b9-a846-b3a4abe9f25c" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_a4bc9b8e-83f9-4159-bfee-393d86f1faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivative"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ceeae45a-b582-46d8-bbbc-ca19dea64d45" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_48c2e858-3255-4219-b48d-356542ec5140" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ceeae45a-b582-46d8-bbbc-ca19dea64d45" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_48c2e858-3255-4219-b48d-356542ec5140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4b5c28cd-017b-40ea-ac57-05982b76df0b" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_be942041-8d7b-449d-856d-e99f85fb79d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4b5c28cd-017b-40ea-ac57-05982b76df0b" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_be942041-8d7b-449d-856d-e99f85fb79d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_fc0daf5d-2576-4f1b-b1d1-de2ae83c2c55" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_fc0daf5d-2576-4f1b-b1d1-de2ae83c2c55" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_a85e5218-796b-4086-ac08-1b03501732f5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_403ffb8d-0909-40fc-8283-4a9abc575bc0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_8a1c8209-b34f-46e4-a24e-40ed253ea742" xlink:to="loc_ifrs-full_IssuedCapitalMember_403ffb8d-0909-40fc-8283-4a9abc575bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_19a75d0f-d888-4ae1-bfb0-cf4226ce83d4" xlink:to="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_3f5bd074-cabb-4411-9734-33a2483d6839" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_73608412-a049-447b-9298-ecbc93dd038f" xlink:to="loc_oncyf_WarrantsMember_3f5bd074-cabb-4411-9734-33a2483d6839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_f2d7339c-e541-4fb7-9109-4e56f906d2d3" xlink:to="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_064d6353-b0a2-4f25-ba42-7c914dc1624d" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_198d32ac-5a1e-483d-b585-e7717fefed00" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_064d6353-b0a2-4f25-ba42-7c914dc1624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_05be264e-532e-45d3-a620-4cf3ad975eba" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_IssueOfEquityShares_05be264e-532e-45d3-a620-4cf3ad975eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_84a56427-125b-4f86-8cd3-de4fd890713a" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_84a56427-125b-4f86-8cd3-de4fd890713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_98c9b971-6922-410a-b482-8e9d97824cbd" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_98c9b971-6922-410a-b482-8e9d97824cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_882d4c1c-6616-401a-939b-1caa484530d3" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_CommonSharesPerUnit_882d4c1c-6616-401a-939b-1caa484530d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3c7d3155-ca82-483a-bc34-987e8c4c201b" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_3c7d3155-ca82-483a-bc34-987e8c4c201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_e0fbea44-d9a7-4871-850d-28bb081903ae" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_e0fbea44-d9a7-4871-850d-28bb081903ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_b8dac380-e909-4fdd-b631-8fcf6b8e9a96" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_96f785a1-d450-4d2d-95f2-03ce9e6909b0" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_b8dac380-e909-4fdd-b631-8fcf6b8e9a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_5108b35f-bac4-4fa9-b815-bfbb751bc5bd" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_56173fea-0c52-42c1-b154-a019ecf1663a" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_5108b35f-bac4-4fa9-b815-bfbb751bc5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_af2e1d33-ee0d-41db-a377-e4d0ef62b0cc" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_af2e1d33-ee0d-41db-a377-e4d0ef62b0cc" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_a6489098-706c-4abb-afd7-39d8d89e67a0" xlink:to="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_cf48927f-9f45-4769-b431-fc077821decd" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_48618cb2-44b4-4200-9020-2a9344f37615" xlink:to="loc_oncyf_WarrantsMember_cf48927f-9f45-4769-b431-fc077821decd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_731d1b66-2118-4f32-b239-6ae76ee3fe1f" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:href="oncyf-20201231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_7c0dc729-7158-4a4c-b70e-1a57c0d0de9c" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_7c0dc729-7158-4a4c-b70e-1a57c0d0de9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_8d47be35-b565-49bc-9414-7ee4badd67de" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_8d47be35-b565-49bc-9414-7ee4badd67de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_d4d5ca92-c5b3-4cbd-9070-0636f763f796" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_8d871c99-b4d9-41f2-9ed4-d8af23649fd2" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_d4d5ca92-c5b3-4cbd-9070-0636f763f796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:href="oncyf-20201231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_986e4bcc-a676-4303-9846-41bed1cf661b" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_bb03f61a-020d-4f04-a442-414bc869beb0" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_bb03f61a-020d-4f04-a442-414bc869beb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_4f9f5fa0-1c05-4974-a3bd-eb7f23dbeba8" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_4f9f5fa0-1c05-4974-a3bd-eb7f23dbeba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_ca0fc4c4-a698-4b07-95c4-30783af4aca1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_ca0fc4c4-a698-4b07-95c4-30783af4aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesfromForeignExchangeImpact_c1576e38-da00-447c-9998-97922ecf42cb" xlink:href="oncyf-20201231.xsd#oncyf_GainsLossesfromForeignExchangeImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_GainsLossesfromForeignExchangeImpact_c1576e38-da00-447c-9998-97922ecf42cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_23d6f000-406f-456c-9382-e6a60d6326bb" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_615d81ba-b32b-42bc-9bfc-93744c2c2152" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_23d6f000-406f-456c-9382-e6a60d6326bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_61a2bf55-3a49-4bd6-8f6b-91891765b121" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_61a2bf55-3a49-4bd6-8f6b-91891765b121" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_ee77d422-4112-400d-8ea7-8e4633bf8fc7" xlink:to="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_566cbf07-1db1-4666-b950-62d0edb1ac1a" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_ef558c49-2abc-43b3-a01a-39e5ca19ed78" xlink:to="loc_oncyf_WarrantsMember_566cbf07-1db1-4666-b950-62d0edb1ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueofWarrantIssuedPerWarrant_a6abd04c-7b29-40d3-907e-cd661d5d59a0" xlink:href="oncyf-20201231.xsd#oncyf_FairValueofWarrantIssuedPerWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_FairValueofWarrantIssuedPerWarrant_a6abd04c-7b29-40d3-907e-cd661d5d59a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantIssuedUnderlyingSharePrice_38a7858e-41c0-47a5-a9e6-3c0b53892dbe" xlink:href="oncyf-20201231.xsd#oncyf_WarrantIssuedUnderlyingSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_WarrantIssuedUnderlyingSharePrice_38a7858e-41c0-47a5-a9e6-3c0b53892dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_a59bf299-d95a-488d-a761-46aa92adffe1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_a59bf299-d95a-488d-a761-46aa92adffe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_621fc395-8129-4903-98ac-d358c84f326f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_621fc395-8129-4903-98ac-d358c84f326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_5942e05a-8085-4e5e-84cb-293c2458e17f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_5942e05a-8085-4e5e-84cb-293c2458e17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent_6275fcab-e63a-48af-bdc8-b661b99aa957" xlink:href="oncyf-20201231.xsd#oncyf_DividendYieldPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b62d46e2-5eec-47b5-afb3-f9ab2275151c" xlink:to="loc_oncyf_DividendYieldPercent_6275fcab-e63a-48af-bdc8-b661b99aa957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DividendYieldPercent_2696b728-7430-474c-9ada-846a9a0ba9d2" xlink:href="oncyf-20201231.xsd#oncyf_DividendYieldPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_3a127e3a-91a6-4c1c-8a80-ff770aeb68fb" xlink:to="loc_oncyf_DividendYieldPercent_2696b728-7430-474c-9ada-846a9a0ba9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5da65615-b77d-42e4-820b-0956e308980c" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_c8f16e43-6e86-4bdb-a505-ca5e7c022371" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_5da65615-b77d-42e4-820b-0956e308980c" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_c8f16e43-6e86-4bdb-a505-ca5e7c022371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4dd52a2c-e31d-4d69-88d0-579dd5133d74" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_03aaac48-3b3a-4a24-b42b-c2937c39eb55" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4dd52a2c-e31d-4d69-88d0-579dd5133d74" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_03aaac48-3b3a-4a24-b42b-c2937c39eb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_9ded0661-9eb3-4d53-82ad-cce52ece7351" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4dd52a2c-e31d-4d69-88d0-579dd5133d74" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_9ded0661-9eb3-4d53-82ad-cce52ece7351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalShareConsolidationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_43312552-08fb-490a-9b36-beff13344bdb" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights_0b8fc42b-0e7c-4d50-9f01-1bf862676e90" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_43312552-08fb-490a-9b36-beff13344bdb" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights_0b8fc42b-0e7c-4d50-9f01-1bf862676e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight_81bf8c20-aac3-4e1f-a804-831e2d67a4ea" xlink:href="oncyf-20201231.xsd#oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_43312552-08fb-490a-9b36-beff13344bdb" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight_81bf8c20-aac3-4e1f-a804-831e2d67a4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_dce6af0b-1a34-4346-8993-f6aea624b375" xlink:href="oncyf-20201231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_43312552-08fb-490a-9b36-beff13344bdb" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_dce6af0b-1a34-4346-8993-f6aea624b375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_df660d87-a88b-47d1-ac4c-517904c7a55d" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_df660d87-a88b-47d1-ac4c-517904c7a55d" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_c3268b85-3e6d-4d97-953b-cc1ee6daf769" xlink:to="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_311083bf-3698-4525-89c4-74833c73906f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_82b2c9ae-0e2f-4666-9ffd-d3a69dbfcd88" xlink:to="loc_ifrs-full_PreviouslyStatedMember_311083bf-3698-4525-89c4-74833c73906f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cb180269-03b1-4ccf-bc71-ef8762e4faad" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f946280a-ff2f-43d8-b018-65928a425cc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_6ef54be7-84c9-47a5-bd27-b53d90f97f7c" xlink:to="loc_ifrs-full_IssuedCapitalMember_f946280a-ff2f-43d8-b018-65928a425cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_73313b2d-1a5b-4681-a72f-c05249868dc2" xlink:to="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_4be32f07-5904-43b3-8615-c89b014a95f9" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_4be32f07-5904-43b3-8615-c89b014a95f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_6c1be2d6-809e-4db5-b2dd-c8f53de15d9a" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_6c1be2d6-809e-4db5-b2dd-c8f53de15d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_cb42d4d0-9b13-41d4-ade5-705267277dd5" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_cb42d4d0-9b13-41d4-ade5-705267277dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_580817ed-e04f-4dbd-aae8-b5d24ae9e7d5" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_580817ed-e04f-4dbd-aae8-b5d24ae9e7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_b024fb9b-732d-470f-9112-426bf9b07000" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_b024fb9b-732d-470f-9112-426bf9b07000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_b2ae3943-c8ad-40f8-b7e5-fc1f09f643d1" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SharesPublicOfferingMember_488c8cf3-aed5-4a6f-bb5f-06a1c8ef2ff5" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_b2ae3943-c8ad-40f8-b7e5-fc1f09f643d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderWarrantAgreementMember_372a5b51-388f-48b4-ac41-8fab869dd6d2" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderWarrantAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4aee3f9f-4bda-4de6-b0b3-c57d86743181" xlink:to="loc_oncyf_SharesUnderWarrantAgreementMember_372a5b51-388f-48b4-ac41-8fab869dd6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_559cef4a-0d0e-4a82-82c1-68a44ccbbb92" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_87fc0239-5681-44af-a203-9bb472c3151a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_NumberOfSharesIssued_87fc0239-5681-44af-a203-9bb472c3151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_eb69d0f3-056b-42b6-83fc-b7c5efebbc39" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_oncyf_IssueOfEquityShares_eb69d0f3-056b-42b6-83fc-b7c5efebbc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_bc5f5b74-e9dc-47f9-8606-94476546e525" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_NumberOfSharesIssued_bc5f5b74-e9dc-47f9-8606-94476546e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_faa77c3d-9010-4794-b5de-8f240ae48bba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_Equity_faa77c3d-9010-4794-b5de-8f240ae48bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_23c5bfe0-761a-4cad-8fee-63c173010396" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_IssueOfEquity_23c5bfe0-761a-4cad-8fee-63c173010396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_29a377ae-3fe2-49d5-9cb1-f17845bbe216" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_29a377ae-3fe2-49d5-9cb1-f17845bbe216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b2687f57-d8f2-4481-962c-ec24527cdfff" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2c114fe9-a5b2-43d6-a1bf-0eeebb13adae" xlink:to="loc_ifrs-full_Equity_b2687f57-d8f2-4481-962c-ec24527cdfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_b8bec95a-a4e0-499c-965d-7e72121fa0cb" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_b8bec95a-a4e0-499c-965d-7e72121fa0cb" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2812ed54-a406-45ea-afb7-8d3bc5f62c8a" xlink:to="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_3b8f21b9-55d2-4b0e-a84f-53daa8ceb773" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_44521999-2f92-44ad-bcc0-f1c636a9a864" xlink:to="loc_oncyf_WarrantsMember_3b8f21b9-55d2-4b0e-a84f-53daa8ceb773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14f730c0-fb40-46d0-95de-6b5b9bc8b63c" xlink:to="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59d40f0d-698c-4bd7-b628-244c03d9e494" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:to="loc_srt_MinimumMember_59d40f0d-698c-4bd7-b628-244c03d9e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c55e486d-693a-4747-8d92-c70a1fc0caf8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53f27e48-412a-4fa5-a36b-19199af18915" xlink:to="loc_srt_MaximumMember_c55e486d-693a-4747-8d92-c70a1fc0caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_14119d35-8c6f-4f53-aa29-dbdd9fbe0553" xlink:to="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_afc0d0e0-27d4-43b8-948d-c2903a5db9cb" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementCanadianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementCanadianMember_afc0d0e0-27d4-43b8-948d-c2903a5db9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_597b6a97-807f-4fb4-b676-4cf2e7340741" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesPublicOfferingMember_597b6a97-807f-4fb4-b676-4cf2e7340741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fa888703-0f22-47a9-8049-b0ee9f3a5d80" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_fa888703-0f22-47a9-8049-b0ee9f3a5d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_e9b7130c-9ae5-4741-995e-80a404e6ba00" xlink:href="oncyf-20201231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_e9b7130c-9ae5-4741-995e-80a404e6ba00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_fa52a9e1-7373-41d4-8370-f9b9ff9427e4" xlink:href="oncyf-20201231.xsd#oncyf_SharesUnderCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesUnderCommonStockPurchaseAgreementMember_fa52a9e1-7373-41d4-8370-f9b9ff9427e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_3a423b8b-e3bf-45bc-ab6a-5e3bffb7c42c" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_4daf4387-0011-4eba-8a2c-d8c78a882b0f" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_3a423b8b-e3bf-45bc-ab6a-5e3bffb7c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RestatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_26405459-47f8-4603-b830-6f344fa08b10" xlink:to="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreviouslyStatedMember_f61b1c4e-47a6-480f-aa67-96591948f952" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PreviouslyStatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RestatedMember_aea612b7-f19b-4d77-96ab-052cfd75bda1" xlink:to="loc_ifrs-full_PreviouslyStatedMember_f61b1c4e-47a6-480f-aa67-96591948f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e70d28a5-e4d1-4697-8b78-25b7505531d0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_efbcb054-88f8-4a54-a1a9-e5e7bc1e1453" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:to="loc_oncyf_WarrantsMember_efbcb054-88f8-4a54-a1a9-e5e7bc1e1453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_3638dcdd-e249-4873-90eb-6320217dce0b" xlink:to="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentSharesMember_f8600888-d76f-4446-bb4e-fbf739326c0a" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:to="loc_oncyf_CommitmentSharesMember_f8600888-d76f-4446-bb4e-fbf739326c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_fa857e28-368b-443a-ade6-a3f90aa6a25a" xlink:href="oncyf-20201231.xsd#oncyf_IssuedCapitalExcludingCommitmentSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IssuedCapitalMember_2d0773b8-de29-4314-b534-6a4343883d1f" xlink:to="loc_oncyf_IssuedCapitalExcludingCommitmentSharesMember_fa857e28-368b-443a-ade6-a3f90aa6a25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_35ad4b4d-df1f-4fac-b476-0133fe9925bd" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_9eb4c08d-9224-4a4b-bb69-0827ad162fd9" xlink:href="oncyf-20201231.xsd#oncyf_OperatingExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_f8b3f6e9-56db-48ef-886f-f39f23dbf6a2" xlink:to="loc_oncyf_OperatingExpensesMember_9eb4c08d-9224-4a4b-bb69-0827ad162fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c0c08278-4acd-440c-bf47-956112054fe1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_e1a3e478-4e09-4cf7-b923-ac5bcee93255" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_e1a3e478-4e09-4cf7-b923-ac5bcee93255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_f3fdff62-1764-4282-bce2-d91fe0cea8b2" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_IssueOfEquityShares_f3fdff62-1764-4282-bce2-d91fe0cea8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a967c841-c5fc-45ea-95e5-c3080d5fa34f" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a967c841-c5fc-45ea-95e5-c3080d5fa34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_32f69e41-3270-4aa7-a1d5-2a21cff2aea4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_32f69e41-3270-4aa7-a1d5-2a21cff2aea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_55c46cb7-3fe2-417a-9951-415881b403b9" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_55c46cb7-3fe2-417a-9951-415881b403b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_f8ed1296-191f-4ed4-8e0c-cd7228caf806" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_f8ed1296-191f-4ed4-8e0c-cd7228caf806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays_ef6ef922-ca36-4e57-b2c0-421c42d3f65d" xlink:href="oncyf-20201231.xsd#oncyf_SharePurchaseAgreementConsecutiveTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_SharePurchaseAgreementConsecutiveTradingDays_ef6ef922-ca36-4e57-b2c0-421c42d3f65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberofSharesOutstandingPercent_33b5a991-cb0a-499b-9b0a-ee4faa4c7040" xlink:href="oncyf-20201231.xsd#oncyf_NumberofSharesOutstandingPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_NumberofSharesOutstandingPercent_33b5a991-cb0a-499b-9b0a-ee4faa4c7040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_d77d0211-00b2-4b29-b765-91899183a4eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_d77d0211-00b2-4b29-b765-91899183a4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_feb30cdc-e53e-4bac-a8c0-4a6c343388a9" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_feb30cdc-e53e-4bac-a8c0-4a6c343388a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_371b02c1-60b4-4ada-a74e-a7c2eb81902f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_371b02c1-60b4-4ada-a74e-a7c2eb81902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_84a6eb4f-9aeb-4202-8605-26d77acac47c" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_CommonSharesPerUnit_84a6eb4f-9aeb-4202-8605-26d77acac47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_033e1c36-1372-41ec-8d48-f26d7eaf77e6" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_033e1c36-1372-41ec-8d48-f26d7eaf77e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_1ff520a9-b88a-455b-9a89-640c9d9b7f52" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_1ff520a9-b88a-455b-9a89-640c9d9b7f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_82ac26de-b87c-498e-83ac-18d181aec822" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_82ac26de-b87c-498e-83ac-18d181aec822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_de468305-fad8-4c28-90f3-686991a6d7ca" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_de468305-fad8-4c28-90f3-686991a6d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_091bd862-7b31-4cff-8382-2a77835646e0" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_3e220d12-4615-451b-b187-20870baa5bac" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_091bd862-7b31-4cff-8382-2a77835646e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9987a1d5-d3db-4020-ba3a-558fe8885fbb" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_9987a1d5-d3db-4020-ba3a-558fe8885fbb" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e5cb4430-a25f-4f12-9a66-749844aa4b19" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_b6222d30-1de6-407e-84a2-cce5ab3ea5c9" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_b3ff3cc8-fe97-40bc-8b52-8f174f078e42" xlink:to="loc_oncyf_WarrantsMember_b6222d30-1de6-407e-84a2-cce5ab3ea5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_446e9020-e418-4e72-a344-6beae38cbe32" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_4bbc3635-5db0-4559-ad41-f8161b2a5720" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_4bbc3635-5db0-4559-ad41-f8161b2a5720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_9edd6e3f-f39b-4418-bb80-034f61946d6d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_9edd6e3f-f39b-4418-bb80-034f61946d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_c37225ad-2727-4f32-b6f6-1c7edb321acf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_c37225ad-2727-4f32-b6f6-1c7edb321acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_028e410e-3ae8-4f15-9fb9-d35095a040a8" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_028e410e-3ae8-4f15-9fb9-d35095a040a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_44dd5904-dfea-4903-b68e-9c578e1d638e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_44dd5904-dfea-4903-b68e-9c578e1d638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_045d9074-8feb-482f-a0b6-eef42beac98b" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_045d9074-8feb-482f-a0b6-eef42beac98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_c57b2720-3262-411d-969a-2f105253cbeb" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_07558460-f4a9-4b4e-a48d-a53cc8182641" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_c57b2720-3262-411d-969a-2f105253cbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:to="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_c1e3976c-db9e-4f4e-a5b4-4bbf53510117" xlink:to="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_0ac40f1e-fe44-4c3c-a7c9-af35b7dd0920" xlink:href="oncyf-20201231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_74552367-50c4-42a0-a831-64acd30ca612" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_0ac40f1e-fe44-4c3c-a7c9-af35b7dd0920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c7224f3a-7ac1-45e7-8f5c-b13bb2f92fb0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b6b48405-44cb-4b05-bad0-bac4e18088a1" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_IssueOfEquityShares_b6b48405-44cb-4b05-bad0-bac4e18088a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_70fad9f1-7a50-49ba-987d-2c2135f55a64" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_70fad9f1-7a50-49ba-987d-2c2135f55a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_74701069-8d3c-41de-8514-445a3407a222" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_CommonSharesPerUnit_74701069-8d3c-41de-8514-445a3407a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_cb5a86d8-e9ed-475f-8f8a-b24c4b311945" xlink:href="oncyf-20201231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_cb5a86d8-e9ed-475f-8f8a-b24c4b311945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_569ee3b6-bf7d-4099-9dd8-e7930bb7b993" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_569ee3b6-bf7d-4099-9dd8-e7930bb7b993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_688b7075-6f48-4017-a89f-723754bbdfcd" xlink:href="oncyf-20201231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_688b7075-6f48-4017-a89f-723754bbdfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_3cb21c21-dcea-4bb7-b28b-ff484c57fba3" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_8c3d84a3-6be4-45e5-b628-0b8a0d0285b2" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_3cb21c21-dcea-4bb7-b28b-ff484c57fba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_f5f6c88e-7ceb-47d6-b06f-c4a49f25ba1c" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_d2efa0dd-e6d2-40ec-8140-cf22b2666df7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_f5f6c88e-7ceb-47d6-b06f-c4a49f25ba1c" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_d2efa0dd-e6d2-40ec-8140-cf22b2666df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_2e7c4e30-3a71-47f5-b597-df1d65bdbea9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_2e7c4e30-3a71-47f5-b597-df1d65bdbea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_f2f7a287-85e6-4640-9295-c0af5be82076" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_f2f7a287-85e6-4640-9295-c0af5be82076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_117a891a-4d21-4fb6-8363-e350ba86dc27" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_117a891a-4d21-4fb6-8363-e350ba86dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_adaa86b8-3644-4534-b852-524aace52820" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_adaa86b8-3644-4534-b852-524aace52820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_845543db-1a4f-47ae-8581-0420d0199ed1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_76e535c6-1540-44d1-949e-048a65cc1f2e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_845543db-1a4f-47ae-8581-0420d0199ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_d99fcce7-1ae8-4f38-8699-21a9b24b8294" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_d99fcce7-1ae8-4f38-8699-21a9b24b8294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_aaae771c-f222-42a7-8d86-7c917cf928da" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_aaae771c-f222-42a7-8d86-7c917cf928da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_fac297e8-78d4-42e7-9211-dbd4e7ad26b4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_fac297e8-78d4-42e7-9211-dbd4e7ad26b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_e28ee166-a220-4539-8d98-b793a594da4c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_e28ee166-a220-4539-8d98-b793a594da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_ae8b740d-e2c7-4802-be97-38cc8e16200d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_ae8b740d-e2c7-4802-be97-38cc8e16200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_a68e3158-0d36-41de-8cac-2ab7b54cf823" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_a68e3158-0d36-41de-8cac-2ab7b54cf823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_9d54d5b2-b733-4eba-b18c-b64d91d5d8e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_9d54d5b2-b733-4eba-b18c-b64d91d5d8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3d265f45-b0c4-45f7-a2a1-8340196e4bc5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3d265f45-b0c4-45f7-a2a1-8340196e4bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_aa86feab-3546-4185-aaa3-aafc2e12696e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_aa86feab-3546-4185-aaa3-aafc2e12696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_dd4edde8-1773-4674-9c5d-1258a56be854" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_dd4edde8-1773-4674-9c5d-1258a56be854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_72cea531-e0eb-46d7-9a6b-fce86e13531f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_72cea531-e0eb-46d7-9a6b-fce86e13531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_71bc5a34-6865-4a55-a188-a482ff296c5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_71bc5a34-6865-4a55-a188-a482ff296c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_21ba6d0c-829e-41f4-93b4-2ce4a43f0711" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_21ba6d0c-829e-41f4-93b4-2ce4a43f0711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_f287e61e-25e4-445a-a7a8-7193e3d62f8e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_ae9e5572-281e-4abe-b0cf-7ab7ad9b426f" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_f287e61e-25e4-445a-a7a8-7193e3d62f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_a912f1b1-28bd-4a50-8cd3-15c01fe480b6" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_a912f1b1-28bd-4a50-8cd3-15c01fe480b6" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:to="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_25687628-b264-4055-8e89-d3be092e1729" xlink:to="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_44e6b74f-1efd-4c83-b2a8-b1aa5254b4cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:to="loc_ifrs-full_BottomOfRangeMember_44e6b74f-1efd-4c83-b2a8-b1aa5254b4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2a71710b-9b21-44df-9f92-bb7a3c1b4da6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b1d1b315-deb2-46fb-bc36-18854d0654ed" xlink:to="loc_ifrs-full_TopOfRangeMember_2a71710b-9b21-44df-9f92-bb7a3c1b4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ae08b2a4-c271-4ba5-b2c7-ed5554aec426" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_5fc5b65b-5de2-4bef-bbf3-78195134f600" xlink:href="oncyf-20201231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_oncyf_RestrictedShareUnitsMember_5fc5b65b-5de2-4bef-bbf3-78195134f600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_567c6f12-2c13-4043-9429-31cc668280d3" xlink:href="oncyf-20201231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_oncyf_PerformanceShareUnitsMember_567c6f12-2c13-4043-9429-31cc668280d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_55eacfac-f3dc-432d-a016-410cc12df0fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_388d245d-ce1e-4e38-9368-67c5b9565a0b" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_55eacfac-f3dc-432d-a016-410cc12df0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_264a1538-709e-478a-a6e3-7fb748175118" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_a1088ef9-f443-413d-9844-d0adf3499559" xlink:href="oncyf-20201231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_a1088ef9-f443-413d-9844-d0adf3499559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9a665cf0-49bb-4c9c-bb61-4d42758771be" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9a665cf0-49bb-4c9c-bb61-4d42758771be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_f4c2ab8f-0738-4a7a-9752-6e6e4a2ed026" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_fed5b85c-4549-4a0b-9d0f-d54ff6e129f5" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_f4c2ab8f-0738-4a7a-9752-6e6e4a2ed026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_0ba15efd-e91a-48ab-90b2-45543ce89987" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_0ba15efd-e91a-48ab-90b2-45543ce89987" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_a8fe3579-7e5f-4c1e-a147-0dbd336138d1" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_3e701bd1-c362-4d9a-8b7a-0efd811c60a7" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_3e701bd1-c362-4d9a-8b7a-0efd811c60a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_538d9ca3-2ae9-494e-88b1-e21082ad8073" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_538d9ca3-2ae9-494e-88b1-e21082ad8073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_2a579206-ef72-408d-ad40-5d92d3db299d" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_2a579206-ef72-408d-ad40-5d92d3db299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_3926ec7a-0226-4029-a1c0-6440b9a152a7" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_3926ec7a-0226-4029-a1c0-6440b9a152a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_880c615e-fc3f-478a-bbe6-1f49c3224040" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_4622049e-1b71-4790-a193-f05f8359bcdb" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_880c615e-fc3f-478a-bbe6-1f49c3224040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1dec3ee0-b060-4b04-8845-595b12bc0739" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_7fd6476b-8259-4898-b064-697e8f2a23bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_7fd6476b-8259-4898-b064-697e8f2a23bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_d8f649ed-e560-4475-8dda-9a964a076d2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_d8f649ed-e560-4475-8dda-9a964a076d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a6ec4601-4814-4e5a-bb86-7b5ed06b5534" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a6ec4601-4814-4e5a-bb86-7b5ed06b5534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8fb2190e-0d20-474f-bd22-ad31840a13d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_8fb2190e-0d20-474f-bd22-ad31840a13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_88e55d28-3d2d-4651-9129-3b37246770ce" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_27bd446c-fa2c-41c3-9206-66d6bd8d14e6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_88e55d28-3d2d-4651-9129-3b37246770ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_0ba15efd-e91a-48ab-90b2-45543ce89987" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f9d64ccf-932b-4399-90b1-236c0a558446" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f9d64ccf-932b-4399-90b1-236c0a558446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_fb0dda0f-17dc-4bc6-a487-33518d0aaa31" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_230aa51a-9263-4fcf-9da9-fc18de4ac437" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_e55c2211-4930-4b0a-a20d-3dec99591110" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_50c0744b-8ad7-4379-8c74-3ca37d419598" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_998eae77-aa05-418f-9d98-3ec0856e7aff" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_9ed2ac17-5f8d-426d-88d0-153382c3edf1" xlink:href="oncyf-20201231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:to="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_57e3c2aa-40a7-489e-8222-ff806fb995a7" xlink:to="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c289b053-a989-481d-89f0-23a518f31928" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:to="loc_ifrs-full_BottomOfRangeMember_c289b053-a989-481d-89f0-23a518f31928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e001809e-4377-4b5b-ba55-11daf2cc4c4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_bb694d6a-84cb-4c08-ad18-b50f4e2a09ca" xlink:to="loc_ifrs-full_TopOfRangeMember_e001809e-4377-4b5b-ba55-11daf2cc4c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable_8c8e06f5-7f6a-4c9a-8db0-51172dc5ec35" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_06255b07-265d-4f9d-85f3-436bb01877a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems_040b58b9-256f-4bfd-8f90-e372394f16ed" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_06255b07-265d-4f9d-85f3-436bb01877a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_66158a02-1621-4b9a-8a33-74f0b4703586" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_66158a02-1621-4b9a-8a33-74f0b4703586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_3167872b-aeaa-46f8-a7a8-953592887de6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_3167872b-aeaa-46f8-a7a8-953592887de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_8c3c0873-5c86-45a6-81e0-3972762b9ec5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_8c3c0873-5c86-45a6-81e0-3972762b9ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedForfeitureShareOptionsGranted_ed3b9270-59cc-4a69-975a-6ec4323cce10" xlink:href="oncyf-20201231.xsd#oncyf_ExpectedForfeitureShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_oncyf_ExpectedForfeitureShareOptionsGranted_ed3b9270-59cc-4a69-975a-6ec4323cce10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_643c16bb-174f-4f3a-ac7f-02f147f4b144" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_643c16bb-174f-4f3a-ac7f-02f147f4b144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9f1ff082-afa7-4897-a494-5412e8765729" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_4e71cc86-1daa-4ad6-b71f-6c522dcc6907" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9f1ff082-afa7-4897-a494-5412e8765729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_21137a66-0c54-443e-b4c1-00c0a9b95002" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract_21137a66-0c54-443e-b4c1-00c0a9b95002" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_68a90b68-b826-46fd-8474-7ec20c3654b9" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_270985d3-22d8-4013-88a7-5ce874284fc3" xlink:href="oncyf-20201231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:to="loc_oncyf_RestrictedShareUnitsMember_270985d3-22d8-4013-88a7-5ce874284fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PerformanceShareUnitsMember_eba9aa2f-4264-47ba-ad16-1ba44f48d5c3" xlink:href="oncyf-20201231.xsd#oncyf_PerformanceShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_fa74cc6a-d2aa-40c8-a9c9-f9e17d4f9dba" xlink:to="loc_oncyf_PerformanceShareUnitsMember_eba9aa2f-4264-47ba-ad16-1ba44f48d5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_944be672-266c-465a-bcb1-69a88c956e71" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0d571e31-762a-459f-a2fb-a400610e092a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_0d571e31-762a-459f-a2fb-a400610e092a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_8f1f7d33-2891-4b02-9a10-c32ae9fc44f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_8f1f7d33-2891-4b02-9a10-c32ae9fc44f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_9239e601-3877-4d3a-b760-a139441f2931" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_9239e601-3877-4d3a-b760-a139441f2931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_fb9cc2c8-468b-4104-8bdb-8a7740c7ec05" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_fb9cc2c8-468b-4104-8bdb-8a7740c7ec05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_db8aab07-b006-4f1d-8c17-7ea9a25faf4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_db8aab07-b006-4f1d-8c17-7ea9a25faf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_cd707a89-096b-4f9b-829a-0720c888fe50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1fc8dbab-c132-4a71-9a4a-6e71460da068" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_cd707a89-096b-4f9b-829a-0720c888fe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_c8f7b90f-459e-4625-bdd2-fd7365b6035c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1cd0265a-ad7a-4585-a0df-be76fc8cde37" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c8f7b90f-459e-4625-bdd2-fd7365b6035c" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1cd0265a-ad7a-4585-a0df-be76fc8cde37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#LossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_8bc47c06-4abf-4d63-a270-1cd79b548e4b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_956d14aa-df8d-4f53-82e1-266476a6335d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_8bc47c06-4abf-4d63-a270-1cd79b548e4b" xlink:to="loc_ifrs-full_WeightedAverageShares_956d14aa-df8d-4f53-82e1-266476a6335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivable"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_e197c430-bd63-47fa-96fd-1989e3776b09" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_9c3b48ff-5e78-4f76-8030-93ce8e7472e2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_e197c430-bd63-47fa-96fd-1989e3776b09" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_9c3b48ff-5e78-4f76-8030-93ce8e7472e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_74f8ef73-cd2e-4f53-9f53-990f60c81c76" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_5de4eb51-5d4c-4ef0-9e70-85ae482d09d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_74f8ef73-cd2e-4f53-9f53-990f60c81c76" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_5de4eb51-5d4c-4ef0-9e70-85ae482d09d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_fe1bfe01-9b88-4f40-bfac-93f17d703b1a" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_2fc3eaca-0314-4dbb-beaa-047ac2261abb" xlink:href="oncyf-20201231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_fe1bfe01-9b88-4f40-bfac-93f17d703b1a" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_2fc3eaca-0314-4dbb-beaa-047ac2261abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_77d9e0b4-0e5d-4b87-a69e-b3222d950dd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_ContractLiabilities_77d9e0b4-0e5d-4b87-a69e-b3222d950dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_e09b69c2-3a79-4a25-a6b9-9b3108def9a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_e09b69c2-3a79-4a25-a6b9-9b3108def9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_b48dcb8f-4db6-41d0-9e7a-296092d3de77" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_b48dcb8f-4db6-41d0-9e7a-296092d3de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_aa2bebad-71a8-4ebe-baa6-332ae3b79d84" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_ContractLiabilities_aa2bebad-71a8-4ebe-baa6-332ae3b79d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_36864336-8104-4895-83a4-79f670ad8fba" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_CurrentContractLiabilities_36864336-8104-4895-83a4-79f670ad8fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_5ab95f0c-7951-418d-8602-417f4083a869" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_5ab95f0c-7951-418d-8602-417f4083a869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_573f1824-4c19-443a-b1a8-72441b0d5635" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_7a7fcd84-9142-4078-88e1-0b918e781e99" xlink:to="loc_ifrs-full_ContractLiabilities_573f1824-4c19-443a-b1a8-72441b0d5635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract_a01f9569-fdfd-4f34-8bab-fcddbdd1ba43" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_61381f8f-8371-4d61-9231-96f79e94f2b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_a01f9569-fdfd-4f34-8bab-fcddbdd1ba43" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_61381f8f-8371-4d61-9231-96f79e94f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAbstract_91310bda-4ba4-443a-8954-077505a5e409" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_144ec874-1895-4671-b41a-bab5ba6e617a" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_91310bda-4ba4-443a-8954-077505a5e409" xlink:to="loc_oncyf_PurchaseObligation1_144ec874-1895-4671-b41a-bab5ba6e617a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CommitmentsAbstract_91310bda-4ba4-443a-8954-077505a5e409" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e0bf7f9b-c249-4d02-8001-1f40549d54bd" xlink:to="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_78026b2e-183f-4972-8302-4093362591b9" xlink:href="oncyf-20201231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_cfe178e1-9326-4434-979d-71a0e41643a5" xlink:to="loc_oncyf_CollaborationAgreementMember_78026b2e-183f-4972-8302-4093362591b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_c203258d-1686-4258-9ae2-39198e6df56b" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_ef5118e9-f9e2-46fe-a931-ee3c58521d9f" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_PurchaseObligation1_ef5118e9-f9e2-46fe-a931-ee3c58521d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_8fe07a6c-7875-4d71-aa82-92d772cb4502" xlink:href="oncyf-20201231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_8fe07a6c-7875-4d71-aa82-92d772cb4502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_bef765a2-4f05-46a0-bf3c-6ad566b55c39" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_ifrs-full_OtherReceivables_bef765a2-4f05-46a0-bf3c-6ad566b55c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_4d0193fa-73bc-43bb-95b3-5dc675cf2f5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_4d0193fa-73bc-43bb-95b3-5dc675cf2f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FundedandRoyaltyRepayment_420c349b-9aed-46d9-9819-c218bc9bba6b" xlink:href="oncyf-20201231.xsd#oncyf_FundedandRoyaltyRepayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_FundedandRoyaltyRepayment_420c349b-9aed-46d9-9819-c218bc9bba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OverheadRepayment_7548651d-ca98-424b-b74c-450e13954d9c" xlink:href="oncyf-20201231.xsd#oncyf_OverheadRepayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_OverheadRepayment_7548651d-ca98-424b-b74c-450e13954d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_73ee628b-bbe1-46ad-b785-f6a6527e7a92" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPaymentGrossSalesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_AnnualContingentPaymentGrossSalesPercent_73ee628b-bbe1-46ad-b785-f6a6527e7a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AnnualContingentPayment_33a70db4-07d4-479e-b79a-a1d948fe87da" xlink:href="oncyf-20201231.xsd#oncyf_AnnualContingentPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_1fcc162c-ee78-4fff-a5dc-b6e3d940dae1" xlink:to="loc_oncyf_AnnualContingentPayment_33a70db4-07d4-479e-b79a-a1d948fe87da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="simple" xlink:href="oncyf-20201231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_00c7d419-c606-4c89-9f06-ec3219c4636d" xlink:href="oncyf-20201231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_9947b885-1581-4369-823d-6d0e7cec8a97" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_00c7d419-c606-4c89-9f06-ec3219c4636d" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_9947b885-1581-4369-823d-6d0e7cec8a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_ea6e2dcc-3d54-4936-b239-43d318af8f1a" xlink:href="oncyf-20201231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_ea6e2dcc-3d54-4936-b239-43d318af8f1a" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:to="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_c252d364-9bd9-41a3-84e5-94e79161a85b" xlink:to="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SYNSORBMember_2691d3ef-7d4a-474c-9b77-70a4e1381390" xlink:href="oncyf-20201231.xsd#oncyf_SYNSORBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_33f30e06-1402-460b-897b-392724a358f8" xlink:to="loc_oncyf_SYNSORBMember_2691d3ef-7d4a-474c-9b77-70a4e1381390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_f6220e44-e709-4ba0-adac-f6c3b8410543" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_67960efe-3318-4ac2-9120-3d0d9aae05d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_67960efe-3318-4ac2-9120-3d0d9aae05d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b37e1cf6-fc6a-4d8e-aa83-2fd3a01b5f97" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue_b37e1cf6-fc6a-4d8e-aa83-2fd3a01b5f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_78a81c81-ab0f-461d-8bd9-8125e6ee3b79" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage_78a81c81-ab0f-461d-8bd9-8125e6ee3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_6a0f6630-5ec0-4f3d-bd0e-d06fc079031c" xlink:href="oncyf-20201231.xsd#oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage_6a0f6630-5ec0-4f3d-bd0e-d06fc079031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_a805cdb5-0281-42ee-ad25-9b7f339d2e9c" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue_a805cdb5-0281-42ee-ad25-9b7f339d2e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_925eb3c1-d333-453f-a287-60c855496114" xlink:href="oncyf-20201231.xsd#oncyf_ContingentRoyaltyPaymentAnnualMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_b9af225e-8a12-4f9e-a94a-b18b2f283370" xlink:to="loc_oncyf_ContingentRoyaltyPaymentAnnualMaximum_925eb3c1-d333-453f-a287-60c855496114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_fd6779b3-ba17-4a9a-906c-6992054293e8" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_c6672056-afde-4a6e-b2f8-ee59e622132e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_fd6779b3-ba17-4a9a-906c-6992054293e8" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_c6672056-afde-4a6e-b2f8-ee59e622132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_b62bfd13-faf3-4942-a6c4-d0035307ca58" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_399a1aab-e905-43da-a076-c04f1d363b61" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_b62bfd13-faf3-4942-a6c4-d0035307ca58" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_399a1aab-e905-43da-a076-c04f1d363b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_a7db86d2-b9b4-4f1d-84c5-67a1bfb939b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_b62bfd13-faf3-4942-a6c4-d0035307ca58" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_a7db86d2-b9b4-4f1d-84c5-67a1bfb939b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_747c27b0-36b6-4ec1-b95b-5c50457f8264" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_AccountingProfit_747c27b0-36b6-4ec1-b95b-5c50457f8264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_40660aa1-f21e-4afe-9963-26d363056228" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_ApplicableTaxRate_40660aa1-f21e-4afe-9963-26d363056228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_dc4ba602-a243-4fbf-8e40-987ee1189ba2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_dc4ba602-a243-4fbf-8e40-987ee1189ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_4b5465a2-36c4-453a-906f-6b137ed8ca7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_4b5465a2-36c4-453a-906f-6b137ed8ca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_d923469f-f5f5-471a-86c7-5c35223909a8" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_d923469f-f5f5-471a-86c7-5c35223909a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5be69873-7eeb-433d-9321-182cd32ffbb2" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_5be69873-7eeb-433d-9321-182cd32ffbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_785e0301-71c7-4592-abba-3f9cad41797d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_785e0301-71c7-4592-abba-3f9cad41797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_58b6a9e9-5689-4d2f-b973-ad7aa232b82d" xlink:href="oncyf-20201231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_oncyf_TaxEffectOfTaxPools_58b6a9e9-5689-4d2f-b973-ad7aa232b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_7dc11aa0-a6b6-4cc1-b721-f418438044ac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_7dc11aa0-a6b6-4cc1-b721-f418438044ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_37109522-4321-45ca-9736-b3da9a01fd6f" xlink:href="oncyf-20201231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_37109522-4321-45ca-9736-b3da9a01fd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_65f2248e-d67d-44d4-89e2-a0f228c35855" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_65f2248e-d67d-44d4-89e2-a0f228c35855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_66263723-1249-4b84-b8b6-be0fb5532f8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_66263723-1249-4b84-b8b6-be0fb5532f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_69bd7391-342b-4d63-a428-462849bff880" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_498a3429-d05e-4d72-93bd-fd3d9551330b" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_69bd7391-342b-4d63-a428-462849bff880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNoncapitalLossesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_b27a7483-31df-4c07-a1be-fdea2c7e4755" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_b27a7483-31df-4c07-a1be-fdea2c7e4755" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:to="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_77a23f06-3a94-46e4-8a26-32977da838bc" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_c4e45621-face-4c7f-bba7-7ebb9e656be9" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentySixMember_c4e45621-face-4c7f-bba7-7ebb9e656be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_efe15a38-96dc-4a2d-885f-c27891b929f6" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentySevenMember_efe15a38-96dc-4a2d-885f-c27891b929f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_93f9040c-4458-44c5-8d6c-bc9e1d7749f3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyTwentyNineMember_93f9040c-4458-44c5-8d6c-bc9e1d7749f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_65a0e18c-dd44-4025-ba28-f7690b94d6e5" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyMember_65a0e18c-dd44-4025-ba28-f7690b94d6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_990dcff1-1e30-4f8f-b9df-7af74e5d84ee" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyOneMember_990dcff1-1e30-4f8f-b9df-7af74e5d84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_790a1be9-187d-4a25-9175-45c15263c957" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyTwoMember_790a1be9-187d-4a25-9175-45c15263c957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_d2f239b5-9870-477b-a0f0-b123853c3ef1" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyThreeMember_d2f239b5-9870-477b-a0f0-b123853c3ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_ece7433f-c06f-4da1-887e-a94db91783e5" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyFourMember_ece7433f-c06f-4da1-887e-a94db91783e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_5516d876-8217-4222-bb5c-bcdaacee592f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyFiveMember_5516d876-8217-4222-bb5c-bcdaacee592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_a7514373-1722-48f6-be79-9b2e07330a01" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtySixMember_a7514373-1722-48f6-be79-9b2e07330a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_97b07a0f-4ba8-4bc0-b624-1cc537dda94f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtySevenMember_97b07a0f-4ba8-4bc0-b624-1cc537dda94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_e5e5975a-7e28-48d2-befa-84de91759289" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyEightMember_e5e5975a-7e28-48d2-befa-84de91759289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_83ba498e-d8ef-427e-9257-474da09e2721" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyThirtyNineMember_83ba498e-d8ef-427e-9257-474da09e2721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyFortyMember_def0ec65-588b-40f4-ba98-07c9b13ee3d7" xlink:href="oncyf-20201231.xsd#oncyf_TwentyFortyMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_5152a35a-470d-4225-919c-44e053955466" xlink:to="loc_oncyf_TwentyFortyMember_def0ec65-588b-40f4-ba98-07c9b13ee3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_94194433-b1d9-442c-bcaa-96a814a00e3b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_f67f5ea6-15f5-46b3-b08d-d2138f9a2a7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_34ddeb6a-c643-40ca-b21c-ddf88d2699c9" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_f67f5ea6-15f5-46b3-b08d-d2138f9a2a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_78fc4898-4ec0-4622-9aef-94834a562fdb" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_124521e2-aff5-44b1-93ce-466f9f06ba3e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_1502eeec-8e3c-407d-9ee0-86376380b21c" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_124521e2-aff5-44b1-93ce-466f9f06ba3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_1a81c5ed-f3e4-48d5-9751-76f33cad579b" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_1a81c5ed-f3e4-48d5-9751-76f33cad579b" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:to="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_33402a0a-d941-4ca9-abbd-ff15c0848c50" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyOneMember_40439d50-91be-461a-8070-80558cbb3571" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyOneMember_40439d50-91be-461a-8070-80558cbb3571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyTwoMember_de551bb3-a136-4624-a09a-7adf4c6f5c08" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyTwoMember_de551bb3-a136-4624-a09a-7adf4c6f5c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyThreeMember_90aafb3c-d5d4-40ca-bdee-482fac98eb2a" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyThreeMember_90aafb3c-d5d4-40ca-bdee-482fac98eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFourMember_acbe2116-6ed2-4d52-8f88-da7048d1ca15" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyFourMember_acbe2116-6ed2-4d52-8f88-da7048d1ca15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyFiveMember_8de9a0a7-f8a6-45dc-afd0-3e6ffba37999" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyFiveMember_8de9a0a7-f8a6-45dc-afd0-3e6ffba37999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySixMember_963b153e-c62c-4e74-8fe3-d5a397d618c7" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentySixMember_963b153e-c62c-4e74-8fe3-d5a397d618c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentySevenMember_5d010a17-4b88-438a-9ce5-28097de86e1e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentySevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentySevenMember_5d010a17-4b88-438a-9ce5-28097de86e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyEightMember_3b4ca50e-b83d-46be-b0c5-88466fe899c0" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyEightMember_3b4ca50e-b83d-46be-b0c5-88466fe899c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyTwentyNineMember_75184abf-0025-44df-9f77-55995548561e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyTwentyNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyTwentyNineMember_75184abf-0025-44df-9f77-55995548561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyMember_630f3dcc-77dc-4462-8361-206ca425f55e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyMember_630f3dcc-77dc-4462-8361-206ca425f55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyOneMember_a0eec5c3-d607-4780-9a95-671f648f661e" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyOneMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyOneMember_a0eec5c3-d607-4780-9a95-671f648f661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyTwoMember_8b5df3c3-1a02-4150-ac87-510b4a8eecd3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyTwoMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyTwoMember_8b5df3c3-1a02-4150-ac87-510b4a8eecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyThreeMember_a9fb5f85-e558-42b7-a86a-8be920d0e1e3" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyThreeMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyThreeMember_a9fb5f85-e558-42b7-a86a-8be920d0e1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFourMember_5473d11d-3d43-42a2-a28b-6ca45ea04b38" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFourMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyFourMember_5473d11d-3d43-42a2-a28b-6ca45ea04b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyFiveMember_3497ff37-8ed0-42dd-a9a7-097f3d23738f" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyFiveMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyFiveMember_3497ff37-8ed0-42dd-a9a7-097f3d23738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySixMember_607b046b-08ef-430e-b9ee-375b2f492a68" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySixMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtySixMember_607b046b-08ef-430e-b9ee-375b2f492a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtySevenMember_a8dbac40-9db3-4d9c-a850-35caee17c935" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtySevenMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtySevenMember_a8dbac40-9db3-4d9c-a850-35caee17c935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyEightMember_66bf1f32-5af3-47b1-badb-d0b904b1177d" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyEightMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyEightMember_66bf1f32-5af3-47b1-badb-d0b904b1177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TwentyThirtyNineMember_4f0891c2-ab72-438a-808b-023dea3cf022" xlink:href="oncyf-20201231.xsd#oncyf_TwentyThirtyNineMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_ee4d6ebc-0f5c-4f2d-90d6-20fb8b8f320a" xlink:to="loc_oncyf_TwentyThirtyNineMember_4f0891c2-ab72-438a-808b-023dea3cf022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72644335-c779-4367-bdeb-c62a83d0d219" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_a1e65e5e-c16b-4856-a82a-4bac54bd0850" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_a1e65e5e-c16b-4856-a82a-4bac54bd0850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_a6e051f6-77a9-4e59-8652-02b431101bf2" xlink:href="oncyf-20201231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_f3768a49-629d-462d-addd-5774269ea972" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_a6e051f6-77a9-4e59-8652-02b431101bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_bce9953f-128a-4481-9f73-6ea1ac637e06" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_279a8208-5cac-4db8-ae6c-dcc2e490945b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_b741b1fd-b65d-44a2-b5a5-eec62c0153c1" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_279a8208-5cac-4db8-ae6c-dcc2e490945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_bf87f720-3f1d-47fb-81a9-d09b61ab0925" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_bf87f720-3f1d-47fb-81a9-d09b61ab0925" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_83c77754-4d1a-49e1-b411-9a133b895861" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_64b4342c-a075-490f-9eea-f23aca32dc27" xlink:href="oncyf-20201231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_64b4342c-a075-490f-9eea-f23aca32dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_c3c86c9a-64b9-4d68-babf-3a774ca69ae3" xlink:href="oncyf-20201231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_c3c86c9a-64b9-4d68-babf-3a774ca69ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_1f14e61c-cefd-4e2b-b366-d23b17fa70f4" xlink:href="oncyf-20201231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_1f14e61c-cefd-4e2b-b366-d23b17fa70f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_b80516d2-e8ec-4e94-8f08-dd38528fd941" xlink:href="oncyf-20201231.xsd#oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember_b80516d2-e8ec-4e94-8f08-dd38528fd941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_7305f29a-de4a-4b17-b987-c8143c46f03f" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_ShareIssueCostsMember_7305f29a-de4a-4b17-b987-c8143c46f03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_3e9ca0ff-9249-45c6-a568-8abc21686e92" xlink:href="oncyf-20201231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_fedf5ca5-d9af-4c6e-b0b5-5d3c7bb25fb8" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_3e9ca0ff-9249-45c6-a568-8abc21686e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_4bc57fa2-ed94-450a-a7e5-77d43f5c7ace" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_2652c17a-a682-4da8-8e7a-fd306dfc360e" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_561c1baf-e509-4369-b8a1-cad1b0517170" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_2652c17a-a682-4da8-8e7a-fd306dfc360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_acfc0b0e-4311-4a43-8070-c48d185de3f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_c368444d-3008-449e-b797-ca74fe291588" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_acfc0b0e-4311-4a43-8070-c48d185de3f3" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_c368444d-3008-449e-b797-ca74fe291588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_35b61500-af61-41c2-a2bc-35f2a99141e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_dcc86e4c-1e98-46c3-a8ba-d398133b177b" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_35b61500-af61-41c2-a2bc-35f2a99141e3" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_dcc86e4c-1e98-46c3-a8ba-d398133b177b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#CapitalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_fa8b2bbe-7c79-45a2-bc14-a00bcbb105cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_50ee9152-21f5-41e6-88f0-c4ef3ed681af" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fa8b2bbe-7c79-45a2-bc14-a00bcbb105cf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_50ee9152-21f5-41e6-88f0-c4ef3ed681af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_2ddfd19e-df67-47c6-9401-848eb8d8359b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fa8b2bbe-7c79-45a2-bc14-a00bcbb105cf" xlink:to="loc_ifrs-full_Equity_2ddfd19e-df67-47c6-9401-848eb8d8359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized_7c566b46-7de0-4bc7-9349-9ed67cd51c34" xlink:href="oncyf-20201231.xsd#oncyf_EquityAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fa8b2bbe-7c79-45a2-bc14-a00bcbb105cf" xlink:to="loc_oncyf_EquityAuthorized_7c566b46-7de0-4bc7-9349-9ed67cd51c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0cae957d-52ba-4892-a647-fa78d8ab3108" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_b4f123bb-73f1-415a-87a5-810ec8bb1eea" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0cae957d-52ba-4892-a647-fa78d8ab3108" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_b4f123bb-73f1-415a-87a5-810ec8bb1eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_be4957fc-234b-467e-bdd6-89fa61e918fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_a627f4d2-e07e-461e-8eac-e186f9c1538c" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_be4957fc-234b-467e-bdd6-89fa61e918fe" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_a627f4d2-e07e-461e-8eac-e186f9c1538c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6f26ce69-d666-4754-8e65-d688774d55aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_6f26ce69-d666-4754-8e65-d688774d55aa" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_44d8110b-ad6a-4dcc-91ae-a63d3ae29904" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_6e7ec6ce-d800-4a2b-8b9f-bc0d2ff8ace1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c450b334-7759-4fc2-b4d9-3722b3361878" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_6e7ec6ce-d800-4a2b-8b9f-bc0d2ff8ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_3cd126c1-2a9f-46a6-afcf-d67936e5e63d" xlink:to="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_01719fa3-bd1e-4a66-8b2c-52e23f6263e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_766c6aae-d74a-498c-8b5a-726a3d7b404d" xlink:to="loc_ifrs-full_CurrencyRiskMember_01719fa3-bd1e-4a66-8b2c-52e23f6263e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_968c2172-460f-46b8-a2b3-54123a3a908c" xlink:to="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_7717dda7-0232-4d9d-a69e-ca1950163b96" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_USD_7717dda7-0232-4d9d-a69e-ca1950163b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_8cb03e27-9ac0-4b0f-b7d3-ff600ecec891" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_GBP_8cb03e27-9ac0-4b0f-b7d3-ff600ecec891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_387676b0-f9e5-4460-aa2b-b4dfca7a7fa8" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_86533567-7151-48aa-b9af-4bca80072ba3" xlink:to="loc_currency_EUR_387676b0-f9e5-4460-aa2b-b4dfca7a7fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_49a0f9a2-70a2-4a3b-a52e-7583280cfbd6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_49a0f9a2-70a2-4a3b-a52e-7583280cfbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_24cff1aa-f139-4d35-9876-be379b99e37d" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_24cff1aa-f139-4d35-9876-be379b99e37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_c65c35eb-0338-4e4a-9408-dccc66ef91bf" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_a68ff5ef-e81d-464a-86b8-cb8e7e866184" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_c65c35eb-0338-4e4a-9408-dccc66ef91bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_baae202f-3e83-4ead-bf47-b577eb92ce9b" xlink:href="oncyf-20201231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a43e1261-89b7-4442-90e4-0515f682eb7b" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_baae202f-3e83-4ead-bf47-b577eb92ce9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_4417c5f5-dadf-4795-bc07-8bc6c2d4856d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:href="oncyf-20201231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_4417c5f5-dadf-4795-bc07-8bc6c2d4856d" xlink:to="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:to="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_0d1c5e67-a55e-4aec-952f-93d41127173b" xlink:to="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_b314c5ee-2755-4b8d-975c-d4a4f0231f1f" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_USD_b314c5ee-2755-4b8d-975c-d4a4f0231f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_b0ba9927-8c2e-480b-b5a8-8d8eaf812a7e" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_GBP_b0ba9927-8c2e-480b-b5a8-8d8eaf812a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_95de4f61-bb43-4e0c-bcee-bf86759191f8" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f3c73bb5-593d-4ebf-a7c4-b2b31286650f" xlink:to="loc_currency_EUR_95de4f61-bb43-4e0c-bcee-bf86759191f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:href="oncyf-20201231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_38e6120e-cf1d-425a-841a-0b349fdd95e9" xlink:to="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_71e0505d-0dc0-426f-b227-01b18f5a0b20" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_71e0505d-0dc0-426f-b227-01b18f5a0b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_c7cc7871-e87c-4350-9b2a-69d3231d446f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_c7cc7871-e87c-4350-9b2a-69d3231d446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_958a6393-f442-474a-a22c-d6c829c53c73" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_958a6393-f442-474a-a22c-d6c829c53c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_e75178b4-2321-4e40-8ea1-99c2ba34b4e0" xlink:href="oncyf-20201231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_d0217f95-2956-409c-8433-fb5e5d0cdeb7" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_e75178b4-2321-4e40-8ea1-99c2ba34b4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_13cff922-f726-41f3-bc1c-60f52907084f" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_394444bf-36cf-40c9-abfe-f4c5d002b2e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_13cff922-f726-41f3-bc1c-60f52907084f" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_394444bf-36cf-40c9-abfe-f4c5d002b2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_9237955a-cc53-423e-8b52-101ad8b76736" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_c14e811d-4078-4c1c-9018-58e1ce633c81" xlink:href="oncyf-20201231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_9237955a-cc53-423e-8b52-101ad8b76736" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_c14e811d-4078-4c1c-9018-58e1ce633c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_3bf70f3f-c794-47f8-8b63-d75ae4d3a6a8" xlink:href="oncyf-20201231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_9237955a-cc53-423e-8b52-101ad8b76736" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_3bf70f3f-c794-47f8-8b63-d75ae4d3a6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_3f37e7e3-d5e7-4acc-b346-7b392274a05b" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable_3f37e7e3-d5e7-4acc-b346-7b392274a05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_e0cca1d2-8262-4d08-9d89-9b9bcfc8f0ce" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_e0cca1d2-8262-4d08-9d89-9b9bcfc8f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_9d00f203-ee77-46c2-a466-c697371aa428" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseinPrepaidExpense1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_oncyf_IncreaseDecreaseinPrepaidExpense1_9d00f203-ee77-46c2-a466-c697371aa428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0adace71-8c29-41f1-b6e5-e3902dac8d4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0adace71-8c29-41f1-b6e5-e3902dac8d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_0c988522-5401-43ac-bb04-8c472d1b6965" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities_0c988522-5401-43ac-bb04-8c472d1b6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_0c1ef976-b81c-4603-becf-4e23b3e8a6e1" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_0c1ef976-b81c-4603-becf-4e23b3e8a6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_61dbba9d-e999-43e2-985e-4371537b98fb" xlink:href="oncyf-20201231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_61dbba9d-e999-43e2-985e-4371537b98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_4d1993c3-8249-4668-9424-f751c7420932" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_2ac4617f-570b-4f54-a6f5-fa458ebd61ac" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_4d1993c3-8249-4668-9424-f751c7420932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_5279a129-37c7-4690-b02a-13ae32fb84ac" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived_6b430d38-063a-4403-af3f-c6dc0ad63991" xlink:href="oncyf-20201231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5279a129-37c7-4690-b02a-13ae32fb84ac" xlink:to="loc_oncyf_ProceedsfromInterestReceived_6b430d38-063a-4403-af3f-c6dc0ad63991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_400df027-4d9a-45d4-be0d-7f0a6b2ff95d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5279a129-37c7-4690-b02a-13ae32fb84ac" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_400df027-4d9a-45d4-be0d-7f0a6b2ff95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20201231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_c7397a03-2e99-4971-9aa2-76c11a305a52" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_1a59b62e-c33f-4411-a8e9-166ec557566c" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_c7397a03-2e99-4971-9aa2-76c11a305a52" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_1a59b62e-c33f-4411-a8e9-166ec557566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependence"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_1e18b55b-da1b-4991-b292-ce09969b7202" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_c800fd72-d7ae-4acd-9e66-72404881ecf5" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_1e18b55b-da1b-4991-b292-ce09969b7202" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_c800fd72-d7ae-4acd-9e66-72404881ecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#EconomicDependenceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_31d057da-2ad2-40fc-a453-b68cf665db07" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_31d057da-2ad2-40fc-a453-b68cf665db07" xlink:to="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_29d0cf7a-95a4-47a8-8f70-ce02ce456709" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_d86c5b6f-b40d-4913-96ef-9ca75e0dc811" xlink:href="oncyf-20201231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_67fc5082-e76c-473a-b4e5-5d42a0cc4817" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_d86c5b6f-b40d-4913-96ef-9ca75e0dc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_7aa6d7e6-d370-4a40-9502-a33810361a8b" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_ec88068f-22aa-45bd-b540-375cb2dd69bc" xlink:href="oncyf-20201231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_cc382621-e451-418c-b4af-20b0f3126e27" xlink:to="loc_oncyf_ConcentrationRiskNumber_ec88068f-22aa-45bd-b540-375cb2dd69bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5b5375dd-0075-4793-bccb-137e79f64bfd" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_52fcc1bb-d64c-4c00-aad6-0a334192b7bc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5b5375dd-0075-4793-bccb-137e79f64bfd" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_52fcc1bb-d64c-4c00-aad6-0a334192b7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_536f24c8-f5b6-44f9-8285-f15a9a3fc28a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_ec8b77b3-37f3-432b-814c-35b31e92f38c" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_536f24c8-f5b6-44f9-8285-f15a9a3fc28a" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_ec8b77b3-37f3-432b-814c-35b31e92f38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#OtherExpensesandAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d2064755-1a7b-4ac2-b977-6ec8dd4231f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_d2064755-1a7b-4ac2-b977-6ec8dd4231f6" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:href="oncyf-20201231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_f508518b-ae36-4d0f-9c93-2ce6bf8e1305" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentMember_3930f3f7-6911-456e-a0be-f104d78022e2" xlink:href="oncyf-20201231.xsd#oncyf_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:to="loc_oncyf_ResearchAndDevelopmentMember_3930f3f7-6911-456e-a0be-f104d78022e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingExpensesMember_08c0e53c-9055-4fa0-b7b1-11f209c4b327" xlink:href="oncyf-20201231.xsd#oncyf_OperatingExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_90a107f8-49d9-4903-8086-f75557da9917" xlink:to="loc_oncyf_OperatingExpensesMember_08c0e53c-9055-4fa0-b7b1-11f209c4b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:to="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_5d569d95-f082-4cfc-a375-372849acb51d" xlink:to="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_8e2d121a-91ee-40b1-b7a0-4ce06854127c" xlink:href="oncyf-20201231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_34d85d58-009d-4c13-9a75-54ca14439648" xlink:to="loc_oncyf_WarrantsMember_8e2d121a-91ee-40b1-b7a0-4ce06854127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:href="oncyf-20201231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_12b0ecf3-ef5e-427c-9608-bdf9e33483db" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_bd681254-ed2a-4c90-b851-eb5b08104e69" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_bd681254-ed2a-4c90-b851-eb5b08104e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_68fb6404-84a1-4d8a-ac8e-6d1aa541bb15" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_AmortisationExpense_68fb6404-84a1-4d8a-ac8e-6d1aa541bb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_25dfb64f-85bd-4ee0-ae47-458823757dfc" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_25dfb64f-85bd-4ee0-ae47-458823757dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_cd12c992-a13d-45a8-9816-6ea329a35760" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_cd12c992-a13d-45a8-9816-6ea329a35760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_51f9224f-b713-4ada-bf25-b49eb1f5be83" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_51f9224f-b713-4ada-bf25-b49eb1f5be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsforLeaseAmortization_f24541b2-965e-4eb8-b176-1133082afb56" xlink:href="oncyf-20201231.xsd#oncyf_AdjustmentsforLeaseAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_523f9a86-70e4-4f7b-ae33-4db5778922c9" xlink:to="loc_oncyf_AdjustmentsforLeaseAmortization_f24541b2-965e-4eb8-b176-1133082afb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_e8c4b157-52da-4a22-8896-ed371c65aea6" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_86937316-65f0-4d1a-9212-d151df8d16a6" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_e8c4b157-52da-4a22-8896-ed371c65aea6" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_86937316-65f0-4d1a-9212-d151df8d16a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_1d46863e-9007-43c8-bf9c-2e9cd194c87c" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_64586be7-797e-48fe-b70e-3c1906795636" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_1d46863e-9007-43c8-bf9c-2e9cd194c87c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_64586be7-797e-48fe-b70e-3c1906795636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_f15014bd-f7cd-4c1e-bf88-7806d44c2539" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_c94bfc0b-88c9-422c-a954-f6f097c9daaa" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_f15014bd-f7cd-4c1e-bf88-7806d44c2539" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_c94bfc0b-88c9-422c-a954-f6f097c9daaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_800c6b94-f494-4c0c-89c5-ede4c7042d8a" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_f15014bd-f7cd-4c1e-bf88-7806d44c2539" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_800c6b94-f494-4c0c-89c5-ede4c7042d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_124b7412-c42e-4be3-96ee-a338464fd5c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_f15014bd-f7cd-4c1e-bf88-7806d44c2539" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_124b7412-c42e-4be3-96ee-a338464fd5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_b6a33fff-af38-4ebf-8ab4-7ae6e980eeb0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_f15014bd-f7cd-4c1e-bf88-7806d44c2539" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_b6a33fff-af38-4ebf-8ab4-7ae6e980eeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_6d1c47a8-9a99-4f62-a8fd-19eaed24f082" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_3077bb02-2006-4ef6-a5bd-15bed24751b0" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_6d1c47a8-9a99-4f62-a8fd-19eaed24f082" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_3077bb02-2006-4ef6-a5bd-15bed24751b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_90c4b66c-3b65-463a-9b36-17997863dfa8" xlink:href="oncyf-20201231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_90c4b66c-3b65-463a-9b36-17997863dfa8" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34ece79d-5e97-4247-97ef-1691410636ee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8f340376-b123-4a99-8f85-511248d6b750" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_8fd40dc7-9887-46a9-8fea-8089f662ed39" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8f340376-b123-4a99-8f85-511248d6b750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:to="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:href="oncyf-20201231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_c930fce6-55a8-49ff-abf8-fe3f7d3bde9d" xlink:to="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_d7f63653-ad2c-41ac-adb4-00f9dcc6e80e" xlink:href="oncyf-20201231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_7a94ffc6-d92a-42c8-96d8-f4f151e6952e" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_d7f63653-ad2c-41ac-adb4-00f9dcc6e80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_4575a1ac-c05e-483d-ae0e-362fe9aa1a4c" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_de4046cf-2e30-4cb9-9fa2-a236b885bf8f" xlink:href="oncyf-20201231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_IssueOfEquityShares_de4046cf-2e30-4cb9-9fa2-a236b885bf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9d394e24-85b2-469f-b321-fb393e40d9f3" xlink:href="oncyf-20201231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_9d394e24-85b2-469f-b321-fb393e40d9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_db84d54c-7bcc-43a6-ae2f-4b49a53ed945" xlink:href="oncyf-20201231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_db84d54c-7bcc-43a6-ae2f-4b49a53ed945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_64737c69-6769-4bf3-a8a5-40c4a021db35" xlink:href="oncyf-20201231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_64737c69-6769-4bf3-a8a5-40c4a021db35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_95ec954f-7f7b-4020-b34a-71b65555fff2" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_6c45c54f-6606-467c-a8bf-5f2ca14c60c5" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_95ec954f-7f7b-4020-b34a-71b65555fff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="simple" xlink:href="oncyf-20201231.xsd#ComparativeFigures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComparativeFigures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ComparativeFiguresAbstract_38c21319-17b7-4534-8f26-850ea40907fd" xlink:href="oncyf-20201231.xsd#oncyf_ComparativeFiguresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory_aa2c7f7d-f948-4b66-a136-6065700d5c3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd#ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ComparativeFiguresAbstract_38c21319-17b7-4534-8f26-850ea40907fd" xlink:to="loc_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory_aa2c7f7d-f948-4b66-a136-6065700d5c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>oncyf-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oncyf="http://www.oncolyticsbiotech.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oncyf-20201231.xsd" xlink:type="simple"/>
    <context id="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15a34dc52087401598ad74c4d7ac44b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32c78d9692194534851ffc8c75765b43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6d2dc50163e54e6db20f3ccf3ba816f0_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id935cd2438124cedb738b9f24443737b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6435e19e015d4b808b125677fa352829_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i60063ff60dff4605b4e8b5483faadde5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i906da6928e2f4d77ba1644f365f7df40_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i69e26aa497764738a8d24ee240e72834_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i094c62fa747f4899aeca008f52c1fa6b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idaa6d8dd8f6146b78474b69d14555dcc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i709c9ca13b8045cd8feecfcbfced3580_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idb8127fce9e04a639cbec7243495cd9f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id770e57addee4de3aced4720a0bad691_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i17b8081505894c88a322be3d879c0edb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i150aa4258e9c4a31b2082f36f70929ac_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i99d71b0468ef40768a5f915151140251_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21916c58eb054ab08a45ae978142cd8f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i962cc14c35434620bd55808cd2ba8d73_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51f0a2ff107346a1969c67caf312a512_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icf7a8f3213d645b8a8fa1b6364129806_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i25846079a5ed4549a9e8ad780e2b2d07_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i486bc14f55c74a9d826bd06a228146ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab548591894744e4b55cfc4ab2de9220_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iedf74771c263472a9fbac91516305b93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e1683597bdf444baa0a2c591f2efc8c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderSharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaae50a49b8984e75aee582dcff0d7703_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a319f8e847b4b4bb642fd9d86aa5225_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29a43f0a866349d8bc5f0b63f8d0e784_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i562af6df16fd49e5b90954aeea2d4aea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96b9cc93c17f4804b0117d1b5087e203_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a3a4fc591144d32b93f7d833c2d6c8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibdf2ec1b8b034942a3533ec514919b05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76695d2971ca43c4829d183db3ebe53d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i914f2dfba8874652a9bc67c5190a974e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie624bde674254422be5db7d03183d08e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i146d8b2a85a9470192da0785eb8a6240_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60c164267fc04f55a74c61c77cf6e840_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6090088661d04f81ad4934969e730d18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacc3c9e5c988498783bbc9fa6d366285_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99c0248efb984ca8b2400ce4a3fa18cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c4f5982efe94fd9bfde6746d570342d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7eb63a1dc564425a34c178e971918c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53aacee4c85d4d55b6cf4d4273d55c08_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie23b49ebdb2744409fa1b9c0240e0941_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e0091234801409c93750ab9a547e561_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i591759eeeca54189b9eeaf5b33f1ebf0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7aec3edd676f499ab586efe1570a2ae3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacdf4b3e43034c8187484f366189cec0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4fe19e601e24c888cb45375f76fb410_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02d52a25ccdf40d1a3e77fa4d8cedd50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib06e365abc0d41b58a7b3cdfa48a3679_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5b6986d4b1f04f6a904bdd51c5d79c18_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2c148463e6434c3aaafd2ff899545a17_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaaa4f6a1ffb546c5a334dd8511ac2d42_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4655f1fa7ede498fae573a51a97ed506_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i56533e258a8349e2b1036c892d892ccf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2cea8db44544431e891019dff150dd98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee202aacf30f4366b9853640242782a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i257b3f18166343278211f238c2dd1391_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8a7de3dc38546928f9df260409a9610_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i975b34c09afa4efca073be66a065bf73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c222353eac842659f464fd34266ded9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i268d98dd221747dd8a4a11bc620dd8f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie83afaabad954ec4895f2c369a9d6f75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia99ca2509feb4a0ea2f8357c20cae1ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc3cd77a1b7d43c5a6cd445b718cdf8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71bcd083c6824318a0e66fc53b430792_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89b6f7f3189d49abb49de0e01b7e44ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f6d1b20ef4741adb4cf59f9baae80d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06f34c507c5a459a8a88148e94bf32e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd0cebabc5f343b080b31d7829dc92c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1af37e2b626f4990a2de0594206009fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i95589ae338604bb095806c15a829cbe2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5608138db81c4378b9e3057d7fe8a191_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9f507765d834457c84f195dc7edc1f22_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icdd208fddb4e4c54a4009d5ed906ab60_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib110db811cd046fbac2029260a02467b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1656f7c240ef4a678ed77b1775d078d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd46cf77bd84410f9d1ab54ec16f5575_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17b47ea4e17640a387dc2928c713393c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53a02a4f770f476189f841381bc8b9d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c686540959c4e5c86fbde52e38211d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f643d6a99d44ee996c4b204e5c8cef1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4736152495f44911a78b2700c5477e6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93ba725d95a6450888552f6a4b9c7cda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ca8fc2742454766b4a9bee74b6996c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80e12d3e53584943aba148ce1dd9619c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89fe6774bf5c4a27849fb882fbafeedf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2870641ce4c84e3b8447a0c27f0e300d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic591edc2e85b4d218e8613fe7eab62f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d577f40a6943b58f48867c0d5abfc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14cbb33f0a794897ae108913ed8cf4f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27cde419036d4d169847c09cbecf4717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie74dd4d434d245e2a524758edc8a73b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa2fdee1c89e4724bc66d086bb390c86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if32873cbf8ad4247a3aa058d3a8c0f0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e06eabd4bba416db2a6ea0aae6fdcf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9345d7396c654329be1b09069b9f5e75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i125186a4e4e54e67bb5d103d16aec302_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic411ea96f38e4c2a8f99ab7b026cebf3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6977c19ac3804e89bd0cdabd80283dd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ee20efa67c54f03b5de8025f70b242c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide6d8e3c655c4d70ab1c6f8d0cc12aed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0538bd9470324b8389be50058e5cf219_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1546a2edd29843b68c4ba7b149c00e10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="ibd2a68a929fc4eb59d764ac865a75d38_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="iab43b4228a174ca4b41758b41e9e7bdb_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-17</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic47b4b76e637454fa2794190496a94ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7073102f39754418a48b29815277781f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idded585e6408411a94c46d5d947389d3_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="i7f79d8de4290471c8bd4630bf062b395_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-05-21</endDate>
        </period>
    </context>
    <context id="ife2ce693bb1e4e538d5f9509be7279ff_D20180101-20180521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-05-21</endDate>
        </period>
    </context>
    <context id="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-05-21</endDate>
        </period>
    </context>
    <context id="ic3cc312234b04ffe88d045cec709e645_I20180521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-21</instant>
        </period>
    </context>
    <context id="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-22</instant>
        </period>
    </context>
    <context id="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id9699ac58b344404a871327fc97617f6_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9c1b8fc753754267b5ee38bbe8188c69_D20180523-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-23</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia523aae440294924869d91f14d20ba80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42ce7a75633844d5a5c8538827785c0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3e853028eaf4f4687a1425b818892a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20080a94d52341bf8043af636627ec2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50194a1104f0447dbe8bdab6b84fb381_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86af6651ee84454ba8d1a822e9eb52bf_I20160225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-25</instant>
        </period>
    </context>
    <context id="i971a344a7f6e456094ca126adf0186ff_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if769c8e2f8534ccc947473705accee72_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementCanadianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-05</startDate>
            <endDate>2018-06-05</endDate>
        </period>
    </context>
    <context id="i15bfe04f75e74d34a9bcbec045406bbb_I20180605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-05</instant>
        </period>
    </context>
    <context id="ic7797595a0e345bd82875cde18a102f6_I20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-27</instant>
        </period>
    </context>
    <context id="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-27</startDate>
            <endDate>2018-09-27</endDate>
        </period>
    </context>
    <context id="i2cec20e510e74bd3b6a829215e7e1186_I20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-27</instant>
        </period>
    </context>
    <context id="ida04d93b266c4c888708cd83f197cba6_D20180927-20180927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-27</startDate>
            <endDate>2018-09-27</endDate>
        </period>
    </context>
    <context id="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:IssuedCapitalExcludingCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:CommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i694e083ddd244a1590868a988368affb_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i4c90e3a44c2a4d788944653b7f87451b_D20181024-20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-24</startDate>
            <endDate>2018-10-24</endDate>
        </period>
    </context>
    <context id="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i562f369a1b84407798feac1b05faee8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05d73158ebeb4204a27888336398e6ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2b7d32d88cd49f39016f010737d5836_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id181bdb06f844a62bdf467f41ba1dd43_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i170cc49c63b04227a02de91e6163db24_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i862c5b4961c74a48a39f058918e7d03e_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="idc96efef1fbb4efcb5325460bb72a700_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47812f018f2f4cef9ae9380e51b482b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-01</endDate>
        </period>
    </context>
    <context id="i15e7713f103e4177900f7c2683516777_I20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-01</instant>
        </period>
    </context>
    <context id="iba9fe4ea63e045e096465e2bfb11ba95_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib7326a67f5024a94b5c25675622288c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i363f02f84b6946e8a01f345e20f5224d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0ef329fa905d4c3185e2177c3e6dee42_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65287d01f32c419ba89f7f594cd47caf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24bbb67471bf4b8a92598ca24be99b9c_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="ia5ef05068a8440d6a4ba5000646081ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib21db9d5af5b44628e536172b106e636_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93af58043e324a92a840919953931d39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2d6c1efdf1b45f6902ca44f7d279adc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48739a7cd7d84144a5f4e605f94af42e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f4c186a1a8848be9fc5a892d41b0be2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1865037223514d83939793fbf4bc69ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib597056817fd4c54bf70bc918648c2e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34d5b6c5f2e84005a152b1904fe0c190_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8643920cc194ebb907287f7a4b18747_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58518506fee64ab482067aea42680848_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36557f93937d4dfb8b9c2f7b122eec39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0895434d6a7f4a60aa00d05659a746fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31f893a9adab4729a2352e2afd1e63c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e98e8622faf479ca1780f0865b894c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88f71c7cf6714950bc9da0b9936fb3bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43b192cb3fe24ee0bb059e2280534d09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fc681ffda9640f2a837978353fda2e8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a6ff11f5e994a3ba6d29746ff0a9970_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc04adeb60ac4cd197686969029179ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26c471998cb54e5198f60c7e8a879104_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a75edaede244932b30bf68f09001b73_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibda3a9497dd94381bf80f0a2b9616cad_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic5661766048540b6a4217ef7021adea7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9be04968d7ac45418925f2727fd67f7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff34051430c94f87baaf766281ba7412_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2899ca476be7407391ff311c63456837_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67bdbb4f6a5e46ceb26e20c137bccd91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:PerformanceShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5fe69759d8547afa04be2fd7beb55b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0330059b7334744a4426087fd12ceff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fd64c7e97d84e4588d426a71091008b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedf7891a1e984661bf760a99c195c570_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">oncyf:SYNSORBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36ad307898ce427b8790187e5e3b200c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54d89438e9834962b588ec713f9cd690_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd3f0138f46c4695ad37fbc8f2fdd536_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf141931e3d34eaa866f4acef645b42c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifed0ad348c7d44b8a47c4217a6d28e36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38a469cc0b8945629f3b38ad881e0e5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia09469d6bdcf47b6bcfcf25aee7cb4b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39ac27a554b240599f9bd777a1fc6041_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ca105778fa3488ab4fcac5815684208_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eca0e1194124e76a337dbb158229685_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6b678dac805480d81678cec8ff97f34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2a1e703d63441b4bd16a9d814bd0759_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60114d1ecfaa437a904d6c5f10744623_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i060c05e904e543c0b502d08304c1d52c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyFortyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd0824dc040346089bbc41d9b1bc5c4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12e526825a3a4c41ad8c2653148296cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7656abe4911c4cfdb005eaabc3cad80c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0965b8657ffb499a9cb5db812656c63f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id63c5c00c60c4df1a2140b12e0626f97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23653b0174744934a761bcc2fb2c6c28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i157e9a3c5d344966b0455389eb83448b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa85527afb2a4cf99bce5e48d4143c65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10628d338fe649f8be7f5a4c729aff30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94e7b2e1b5084522b265069419c11268_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a4b9c9d6c38474ebcd1343720d274a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6adeb07951ec41eb8fba6df6d47342b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0637845ec63458e85e2cbae28f8f5d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c77b28bdcf1403cb5d35cd988bdcfe7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9ad5f87e7304d85bd63633afc56fe8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i871337f4238f4abd9e90092d1f02384e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iababe61944e54b2c9ceccc57bf2faecf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie482d3a1b82148c1bd56712a715af083_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7801864cfd79494a9a797845cc05d6ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab3c42e6c6fd41feb4b54f0b9082e910_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">oncyf:TwentyThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79faad7289cd45f58106ae2fdd652ec1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56e6aac06972419c9ec828611697e6f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8378abfb369e439497cb8d7d53a35bf7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if898df29e89b4ec3a60df1b042af3863_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5cacf4383b8479f8cf65a36c967cae1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9020465658f74f4fbde6469e191a8c40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a02e778e8c84e928734637cf208bd4f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibf277f3b07e54dbb8e328eacdafdddbd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4063dfdc87384c3e85d8174c150d31b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i931661a623914b388fdfa5f4e409ccaf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b0bf7d64d344c48bd924d075e96c40f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i658b28d872bd41568deaa26495694e07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i878f5c4c5d6f4d41947cf6fb9d21cfdf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b1ca5e55ba34078871b684db87e823e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i15589c7e1a2b491aa913407d6863f338_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia16bc392d6f74d4dbbf71003e9881f32_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17a004d3e9c7446896d6d5d1956caf96_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8dcb30c64a054057ae8268e11a956cf5_I20200612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-06-12</instant>
        </period>
    </context>
    <context id="i84b52d8638644519af44304507a14d80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i269daa67eeae4597bc0a7db7539e1081_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5c5734d8c674bc1ad227ce90090ae8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic994dbffe9564855820d86ebe9bc1885_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieacddbbb17314a6bbe19b73efcd83368_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b307c503b264545a9529c655c522919_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61dbf81b2c67488eabed83aa307e45c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia846c8c806434b23ad5a6d843024e310_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i640ad69a2bed48779ac6bb4eb9764cd1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i137e70b443b146e3bd028f654a8470d4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:OperatingExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="id1dda167e3394214b8a7f2f4ef0d20bb_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="manufacturer">
        <measure>oncyf:manufacturer</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>oncyf:plan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="renewal">
        <measure>oncyf:renewal</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="year">
        <measure>oncyf:year</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityRegistrantName
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xLTEtMS0xLTA_7b90dd63-d16a-40ef-8795-aa204f246f41">ONCOLYTICS BIOTECH INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8yLTEtMS0xLTA_c72cc472-8e1d-4e8d-8431-b32f29881b2d">0001129928</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8zLTEtMS0xLTA_16dde344-46df-4871-a923-8a9d9a835622">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF80LTEtMS0xLTA_138b1a64-f61e-41db-8210-6debb132b2a6">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentType
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF81LTEtMS0xLTA_0aa9acd9-dcc3-429f-86ef-e872f142fff5">20-F</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF82LTEtMS0xLTA_f2dbb72e-9c3f-4b45-ba05-118b4957396b">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF83LTEtMS0xLTA_dca360cf-e793-42a5-b9ae-66ff06e4a521">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF84LTEtMS0xLTA_83e799bc-9302-4bc6-acd8-a0f93705b6d6">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF85LTEtMS0xLTA_61e28688-3889-4e4a-abff-6ff810a06569">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMS0yLTEtMS0w_1b4fa9be-edc7-431c-a1a2-6de0af6b0c75"
      unitRef="shares">46166980</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityShellCompany
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMi0xLTEtMS0w_903e5243-605a-4749-8c53-5273877baf01">false</dei:EntityShellCompany>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xMy0xLTEtMS0w_08550afd-28ba-439c-8ed0-7d8f3015639c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNS0xLTEtMS0w_a65158a2-4336-4a96-8ee5-6a6349a629d7">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNi0xLTEtMS0w_40179f7f-8fea-48c1-b89c-5002d04436e3">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xNy0xLTEtMS0w_556f2a03-0068-41cf-8b12-ca33263e138b">Yes</dei:EntityCurrentReportingStatus>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N180L2ZyYWc6ODhlMWNhN2M1YWEwNDgwY2FkNjFhNjI4MTQ2NWUwODMvdGFibGU6MDVlZWExOWU3MGIzNGU3MmE4NzQ5MDE5MGU0Y2MyNjAvdGFibGVyYW5nZTowNWVlYTE5ZTcwYjM0ZTcyYTg3NDkwMTkwZTRjYzI2MF8xOC0xLTEtMS00MDI1_8f4b2ad4-c40d-483f-9006-891dc89773c0">true</dei:IcfrAuditorAttestationFlag>
    <oncyf:CommitmentsAndContingencies1
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjEvZnJhZzozYmEyNzNmN2Q0NDA0MWQ3YWQ1NWEzYjk1OTBmMGRhMS90YWJsZTpkNDhlMTU0ZGQ0OTc0OWYwOTc2MDFlZWVjYTJjZmE2Ny90YWJsZXJhbmdlOmQ0OGUxNTRkZDQ5NzQ5ZjA5NzYwMWVlZWNhMmNmYTY3XzItMS0xLTEtMA_f7e1050e-d5da-4b3b-90be-566665b866f9"
      unitRef="cad"
      xsi:nil="true"/>
    <oncyf:CommitmentsAndContingencies1
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjEvZnJhZzozYmEyNzNmN2Q0NDA0MWQ3YWQ1NWEzYjk1OTBmMGRhMS90YWJsZTpkNDhlMTU0ZGQ0OTc0OWYwOTc2MDFlZWVjYTJjZmE2Ny90YWJsZXJhbmdlOmQ0OGUxNTRkZDQ5NzQ5ZjA5NzYwMWVlZWNhMmNmYTY3XzItMi0xLTEtMA_c97862c6-4e03-4c8f-8275-baf511609e5b"
      unitRef="cad"
      xsi:nil="true"/>
    <oncyf:SharePurchaseAgreementConsecutiveTradingDays
      contextRef="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362">P5D</oncyf:SharePurchaseAgreementConsecutiveTradingDays>
    <oncyf:StockholdersEquityNoteStockSplitConversionRatio
      contextRef="i24bbb67471bf4b8a92598ca24be99b9c_D20180522-20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjkvZnJhZzplNTIzMTI1ODkwMDE0ODRjYTAzMTgzNDYzMTEzOGRjMi90YWJsZToyNzZmMGY2ODY1ZDc0M2RkYjA1MGU4OWEyODNlOTcxNy90YWJsZXJhbmdlOjI3NmYwZjY4NjVkNzQzZGRiMDUwZTg5YTI4M2U5NzE3XzEtMS0xLTEtMA_1b11f56f-d74c-481d-89ab-a97c4b003f9b"
      unitRef="number">0.105263157894737</oncyf:StockholdersEquityNoteStockSplitConversionRatio>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i1a6ff11f5e994a3ba6d29746ff0a9970_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1Mg_cd3e7b72-8b81-4fad-847f-5db8340cf26d">P1Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE0NTA_028b8dc4-7e4a-4f5f-b344-5ed3a29ae30d">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4Mjk_c9939d36-c1bf-4c0e-9451-a1e30a1ffc57">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:ConcentrationRiskNumber
      contextRef="i32c78d9692194534851ffc8c75765b43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yNS9mcmFnOjVjODBlODlhZGFiMTRkNzQ5ZWUyMGY2NGFkZTQxYjI1L3RleHRyZWdpb246NWM4MGU4OWFkYWIxNGQ3NDllZTIwZjY0YWRlNDFiMjVfNzY5NjU4MTQ1NzYxOA_f172b17d-cb70-464f-aba0-f921ca15a36c"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMtMi0xLTEtMA_64405755-bebe-4d22-9660-2f3ad1fcdd8f"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMtMy0xLTEtMA_5e18efc1-06f3-4f34-b228-63e0e472463a"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzQtMi0xLTEtMA_3be87b92-16ed-4608-929e-702a28680d3b"
      unitRef="cad">89661</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzQtMy0xLTEtMA_0fb2c4e2-981f-4aa0-85e9-d2128fa53d20"
      unitRef="cad">2068772</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzUtMi0xLTEtMA_08f871eb-a20b-4bb7-a9b8-1503d79a9e97"
      unitRef="cad">2427200</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzUtMy0xLTEtMA_7346ca66-0ceb-4205-a824-62b81410e88e"
      unitRef="cad">2713591</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAssets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzYtMi0xLTEtMA_ef6581ef-73ca-44cb-8595-f7bdc81387a1"
      unitRef="cad">33736435</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzYtMy0xLTEtMA_b1b43a25-58ba-40b4-9ecc-810adab65bfa"
      unitRef="cad">18930384</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzgtMi0xLTEtMA_7233f138-1f45-4d02-9d5a-8f9c93fb4721"
      unitRef="cad">236664</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzgtMy0xLTEtMA_8ca6ee37-86fa-4be7-bd79-53eb9e3cf6b6"
      unitRef="cad">296768</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzktMi0xLTEtMA_e9a20665-a749-4393-a485-8fc3f4371ae3"
      unitRef="cad">372468</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzktMy0xLTEtMA_4a46aed4-c635-40c6-9ac7-669ace0a78dc"
      unitRef="cad">430713</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEwLTItMS0xLTA_69d50322-4db1-40f5-bbdf-f02b9c79503d"
      unitRef="cad">609132</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEwLTMtMS0xLTA_b49c7296-c3e1-4972-b195-5bd9b06eb2fe"
      unitRef="cad">727481</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEyLTItMS0xLTA_84dc94dc-ee82-4a0b-beea-b241dd8e0e53"
      unitRef="cad">34345567</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzEyLTMtMS0xLTA_9c164841-2fa2-42b6-a142-77532dac7f08"
      unitRef="cad">19657865</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE1LTItMS0xLTA_2a481be5-5d82-4da3-b8c4-20655825becc"
      unitRef="cad">1805015</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE1LTMtMS0xLTA_a4311029-0d25-472e-937a-db3cbff8800e"
      unitRef="cad">3173218</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE3LTItMS0xLTA_69e51115-8ac2-4aee-b8c0-50ed67bf1112"
      unitRef="cad">123985</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE3LTMtMS0xLTA_eba9dbca-865b-4082-87c6-dff353f610b9"
      unitRef="cad">847215</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE4LTItMS0xLTA_bf250e40-61bb-4a00-aa5d-5efd1899734d"
      unitRef="cad">248885</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE4LTMtMS0xLTA_2b997d94-c432-4bcd-8a1c-d3040c0c8105"
      unitRef="cad">339846</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE5LTItMS0xLTA_b9a189bf-6381-43a7-90a6-dd740c8123ed"
      unitRef="cad">531228</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzE5LTMtMS0xLTA_d621617f-4ee8-48e7-b088-6bf042d83b8c"
      unitRef="cad">8508764</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIwLTItMS0xLTA_775e9670-fcbf-436c-bc9d-024cf2ff9e81"
      unitRef="cad">2709113</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIwLTMtMS0xLTA_1b9e66e7-2a28-46c1-887b-db7ab04ff882"
      unitRef="cad">12869043</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIyLTItMS0xLTA_94ea7d5a-95a7-4d27-b8b9-b6d453aa8061"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzIyLTMtMS0xLTA_897bf93f-2ee0-46fc-8648-43cdb90fe280"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI0LTItMS0xLTA_97d15e02-a5ef-44ed-9984-2cce73db9a09"
      unitRef="cad">153174</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI0LTMtMS0xLTA_d7632190-de4d-471f-93d5-97eaa4a954fe"
      unitRef="cad">166429</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI1LTItMS0xLTA_f2f00026-1ac8-4f00-baed-0f18081facce"
      unitRef="cad">6883461</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI1LTMtMS0xLTA_ebb10218-1354-406d-9202-df20d4092ba6"
      unitRef="cad">6896716</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI3LTItMS0xLTA_55abe7b6-4286-4fba-9882-90975d9cccd5"
      unitRef="cad">9592574</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzI3LTMtMS0xLTA_7624de08-e0ae-4ec5-a55a-9bd6fefe0ecb"
      unitRef="cad">19765759</ifrs-full:Liabilities>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDlhMGQxNjEyZTg0NmMwYTZhOGE4YzM2YzlmMzA3ZV83Njk2NTgxMzk0NjEw_8c46a6cd-8463-4c60-ac1a-c46c05aab9a7"
      unitRef="shares">46166980</dei:EntityCommonStockSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTAtMS0xLTAvdGV4dHJlZ2lvbjo0MDlhMGQxNjEyZTg0NmMwYTZhOGE4YzM2YzlmMzA3ZV83Njk2NTgxMzk0NjA2_52b9b535-dd71-4682-a1d3-11277c711716"
      unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTItMS0xLTA_ae0ee2ca-6a6a-4bf2-8960-c06b66cfdc76"
      unitRef="cad">356824172</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMwLTMtMS0xLTA_395f91ca-cec4-4964-8c84-80e5bd94c369"
      unitRef="cad">311077859</ifrs-full:IssuedCapital>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMxLTItMS0xLTA_f0e6f903-93b6-48e2-a861-c8902869f316"
      unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMxLTMtMS0xLTA_cad801bb-1ec7-4b3f-a4e7-445c93b2584e"
      unitRef="cad">3617570</oncyf:WarrantsandRightsOutstanding>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMyLTItMS0xLTA_9f881a94-850b-4a83-ad86-0472c5f7570c"
      unitRef="cad">31022356</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMyLTMtMS0xLTA_2f37e57c-d655-44da-af17-264609ec4bd4"
      unitRef="cad">29338849</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMzLTItMS0xLTA_f37bd02a-4c06-4846-9072-98fe4d397d92"
      unitRef="cad">400225</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzMzLTMtMS0xLTA_51318a64-ba6c-4021-bb6c-36b23dadb352"
      unitRef="cad">464101</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM0LTItMS0xLTA_0de66544-4f0c-4e5c-8b70-4a9590e33bb6"
      unitRef="cad">-367111330</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM0LTMtMS0xLTA_3eb3b3e1-1e7c-4ca7-88e7-920459713c6e"
      unitRef="cad">-344606273</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM1LTItMS0xLTA_01e77329-bb5c-44f7-b663-a35b69f809b3"
      unitRef="cad">24752993</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM1LTMtMS0xLTA_46bfcb2d-5fe8-4ae5-991b-2a84cd66e9d7"
      unitRef="cad">-107894</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM2LTItMS0xLTA_50c2b4a7-0912-4bce-aee0-8595e95173e3"
      unitRef="cad">34345567</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMTgvZnJhZzpjNTI5ZTFiYTBkYWU0ODYwYTI4ZDNiZWI0Y2JhNWEyOC90YWJsZToxYzk3ZDdkMzc4MDc0YTJlODI3MGFhNmQyMDA1OTIyNy90YWJsZXJhbmdlOjFjOTdkN2QzNzgwNzRhMmU4MjcwYWE2ZDIwMDU5MjI3XzM2LTMtMS0xLTA_b4695163-2ffe-4a6a-9b9f-541cc9b9d9f0"
      unitRef="cad">19657865</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtMi0xLTEtMA_57bc22e2-a3ca-483e-84c3-44f01f23966d"
      unitRef="cad">12944510</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtMy0xLTEtMA_94792b5b-b78c-439c-ad69-a5e2d80c63b2"
      unitRef="cad">10817997</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzMtNC0xLTEtMA_3a564d04-a807-4c1c-ab47-996b264cd6b1"
      unitRef="cad">10027994</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OperatingExpense
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtMi0xLTEtMA_38650c75-4de3-487a-ad68-3d1c8727da8c"
      unitRef="cad">12514496</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtMy0xLTEtMA_add6e8de-7f9b-4a13-93a6-df7581abc54d"
      unitRef="cad">9558641</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzQtNC0xLTEtMA_7d14e9b6-8f38-4db0-82a2-7c5805c7071e"
      unitRef="cad">7244791</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtMi0xLTEtMA_55a7bf01-0780-4ec1-9301-6e6865c2e453"
      unitRef="cad">-25459006</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtMy0xLTEtMA_2dd2f8b4-b95d-4e88-9c8a-593260f4d6af"
      unitRef="cad">-20376638</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzUtNC0xLTEtMA_61af5e48-0615-4ef0-b922-b49bbcbeb8a3"
      unitRef="cad">-17272785</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtMi0xLTEtMA_afdd6306-55c6-4f57-8a8f-7427cc49555f"
      unitRef="cad">3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtMy0xLTEtMA_dc65d2fa-23da-4c9f-bdb8-e5ad7c508dcc"
      unitRef="cad">-12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzYtNC0xLTEtMA_ca7fd50c-beac-40c7-8357-e5db53718a3e"
      unitRef="cad">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMi0xLTEtMTU1_b7eb8744-6c7a-453b-a977-526ef739f3e7"
      unitRef="cad">-659173</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMy0xLTEtMTU1_2db2332d-f0a3-4cc6-b24d-184a5345cdb4"
      unitRef="cad">-316719</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctNC0xLTEtMTU1_0e733e35-e57d-405a-b067-8d56fb5f176f"
      unitRef="cad">610106</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMi0xLTEtMA_7b03ccbd-09b8-48ef-ab69-4faf0cdf6374"
      unitRef="cad">121194</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctMy0xLTEtMA_853cba08-b10b-41c8-8c3d-c446109b2a8a"
      unitRef="cad">179277</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzctNC0xLTEtMA_d53cd991-e38f-4e6b-aded-c2f022701ac8"
      unitRef="cad">173496</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtMi0xLTEtMA_95f666c6-359b-47fa-830d-01984cc85fdd"
      unitRef="cad">-22505057</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtMy0xLTEtMA_0ebc737b-c8ea-47f8-87b2-5f771cd18d4b"
      unitRef="cad">-33122888</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzgtNC0xLTEtMA_28a2ee46-9df6-4a1f-b665-4bf368a6b1d1"
      unitRef="cad">-16489183</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktMi0xLTEtMA_5f5419e9-0eea-4e12-85ef-7c595909afc9"
      unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktMy0xLTEtMA_2f0d664e-daf9-436b-b11e-681da5d80c93"
      unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzktNC0xLTEtMA_b7013568-2414-4b7f-89a8-99d403dc7078"
      unitRef="cad">548042</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTItMS0xLTA_760e7445-aabb-43fb-85be-ec8ad61708c4"
      unitRef="cad">-22505057</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTMtMS0xLTA_3228fa69-dfd6-442f-b978-12d821e8a745"
      unitRef="cad">-33122888</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEwLTQtMS0xLTA_5c265eab-173e-4178-817a-df912223f07a"
      unitRef="cad">-17037225</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTItMS0xLTA_1f4a4e87-bb09-49fc-a875-6896be8e185b"
      unitRef="cad">-63876</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTMtMS0xLTA_f4a65354-036e-49cf-aca4-b30e94f13021"
      unitRef="cad">-143403</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEyLTQtMS0xLTA_9a7e1ab5-9cd8-4f77-8e7c-75adae9e0ab5"
      unitRef="cad">233774</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTItMS0xLTA_b18228df-9e27-47f1-8fbc-b186ff2ef07f"
      unitRef="cad">-22568933</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTMtMS0xLTA_658d24ed-8e5b-4e04-a5e8-b18ee1cb4d38"
      unitRef="cad">-33266291</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzEzLTQtMS0xLTA_b49afd0c-6e15-456c-9f5d-aa64a7a30803"
      unitRef="cad">-16803451</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTItMS0xLTA_1fb4d9bf-c357-4fb3-b824-24cd37027f77"
      unitRef="cadPerShare">-0.56</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTMtMS0xLTA_989861e2-0f53-4cd7-ab47-936dff26ae11"
      unitRef="cadPerShare">-1.50</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE0LTQtMS0xLTA_6e182e74-6c30-486f-a91e-a17412d32b3f"
      unitRef="cadPerShare">-1.06</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTItMS0xLTA_b699c798-4092-4168-8a8c-be31ebbce2c5"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTItMS0xLTA_cbd5b67f-10ad-4a47-8d21-fd68013d5cc5"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTMtMS0xLTA_52da9c68-ff2c-439a-a459-0d9c2e4f6434"
      unitRef="shares">22137990</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTMtMS0xLTA_a5a1ce02-c5f5-4447-8d8d-fb50605bba93"
      unitRef="shares">22137990</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTQtMS0xLTA_817edb81-9af4-49ec-aa91-752a02aeaf95"
      unitRef="shares">16016366</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMjQvZnJhZzpmNDcwM2JmNzIwNGI0NzhmOGFkOGVlYmE5NmZhNmVhOC90YWJsZTo2Mjg4YmMyYTlmYzk0OTkyOTY4YmJmYWQxZWQ1NmNmZS90YWJsZXJhbmdlOjYyODhiYzJhOWZjOTQ5OTI5NjhiYmZhZDFlZDU2Y2ZlXzE1LTQtMS0xLTA_cc4b8b70-3a1c-4afa-b993-6aa5a2e73f3b"
      unitRef="shares">16016366</ifrs-full:WeightedAverageShares>
    <ifrs-full:Equity
      contextRef="i6d2dc50163e54e6db20f3ccf3ba816f0_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtMi0xLTEtMA_4920b968-f97d-41c4-a035-0888534b4e6a"
      unitRef="cad">271710138</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="id935cd2438124cedb738b9f24443737b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtMy0xLTEtMA_a7992a82-049d-476d-baae-33b2720f3d93"
      unitRef="cad">3617900</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6435e19e015d4b808b125677fa352829_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNC0xLTEtMA_459b4cb2-f5c9-4699-96e1-74d6bf7b4819"
      unitRef="cad">27028238</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i60063ff60dff4605b4e8b5483faadde5_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNS0xLTEtMA_f328674e-96c6-40a2-bd99-2a4233920cfd"
      unitRef="cad">373730</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i906da6928e2f4d77ba1644f365f7df40_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNi0xLTEtMA_6c9a6934-e67f-4a1a-95db-2740f1fe63a0"
      unitRef="cad">-294446160</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i69e26aa497764738a8d24ee240e72834_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzgtNy0xLTEtMA_d6a5f119-a707-42af-b947-d8b84b66e7f4"
      unitRef="cad">8283846</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i094c62fa747f4899aeca008f52c1fa6b_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNS0xLTEtMA_c8b36b52-d20a-40d3-8818-525765a9d3cb"
      unitRef="cad">233774</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="idaa6d8dd8f6146b78474b69d14555dcc_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNi0xLTEtMA_ea0ab1c5-62ea-487a-bbaa-1b4d83033efb"
      unitRef="cad">-17037225</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzktNy0xLTEtMA_5e0de05b-a51a-411e-9266-99a92f0ceb35"
      unitRef="cad">-16803451</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity
      contextRef="i709c9ca13b8045cd8feecfcbfced3580_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEwLTItMS0xLTA_446a8805-1124-4798-afac-08662d029b7a"
      unitRef="cad">620010</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEwLTctMS0xLTA_9015addd-477a-4874-bc8e-bdb2eef560c7"
      unitRef="cad">620010</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="idb8127fce9e04a639cbec7243495cd9f_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzExLTItMS0xLTA_4cda03e3-c31f-4aaa-a96f-ed878499b05c"
      unitRef="cad">11606882</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="id770e57addee4de3aced4720a0bad691_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzExLTctMS0xLTA_21c3a690-905a-44d0-bf63-9e0d464cf4cc"
      unitRef="cad">11606882</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i17b8081505894c88a322be3d879c0edb_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEyLTItMS0xLTA_cdb049cb-4821-4aab-8244-3209d83b08e5"
      unitRef="cad">3314097</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i150aa4258e9c4a31b2082f36f70929ac_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEyLTctMS0xLTA_229499ee-5e18-4adf-a386-dc01499414c0"
      unitRef="cad">3314097</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTItMS0xLTA_9d34b997-46b2-4e55-8274-e1ee62ecf3ef"
      unitRef="cad">197245</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTQtMS0xLTA_4adcf98c-5648-46ea-9dd5-47952ae6536e"
      unitRef="cad">-73707</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzEzLTctMS0xLTA_6213643c-8942-4412-b98d-51771d2b2017"
      unitRef="cad">123538</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTItMS0xLTA_76d59992-5723-432b-8d15-e59649fe3e77"
      unitRef="cad">109751</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTQtMS0xLTA_ab99acb7-9046-4452-80d6-3edfbf61f36d"
      unitRef="cad">-109751</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE0LTctMS0xLTA_347954c1-fea8-407e-9bbd-b2aaaed27aed"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTItMS0xLTA_259e2422-573c-416f-850d-c971f96d228e"
      unitRef="cad">1747</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i99d71b0468ef40768a5f915151140251_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTMtMS0xLTA_25f40e75-72ab-45ef-a00a-158df871098b"
      unitRef="cad">-330</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE1LTctMS0xLTA_cf50ba4f-1f28-414b-b20c-b681025377c3"
      unitRef="cad">1417</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="if4c8b27b07c44cf9a1ddf633ca6798a5_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE2LTQtMS0xLTA_2dbf7b0d-2291-4994-9558-954c9a594394"
      unitRef="cad">1415833</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE2LTctMS0xLTA_57897687-cfab-404e-89a8-e59576bf6b22"
      unitRef="cad">1415833</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="if4608fcf452449c4884786f51eb86c2a_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE3LTItMS0xLTA_a34c4abc-f54e-4256-81e0-20cf3ad94067"
      unitRef="cad">2366809</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE3LTctMS0xLTA_a6373285-3d98-4c7d-9b4d-429e7774e7cf"
      unitRef="cad">2366809</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i21916c58eb054ab08a45ae978142cd8f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTItMS0xLTA_b9adea68-7e5b-4974-8bfc-4a509e84a41a"
      unitRef="cad">285193061</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i962cc14c35434620bd55808cd2ba8d73_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTMtMS0xLTA_8ea3ca9c-3ebf-4e72-ae5c-b4ad540faae6"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i51f0a2ff107346a1969c67caf312a512_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTQtMS0xLTA_b5bc5bfb-beee-45e8-9bc7-02cd639ecb64"
      unitRef="cad">28260613</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="icf7a8f3213d645b8a8fa1b6364129806_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTUtMS0xLTA_f3c19ccf-93f2-4229-ae36-56430219e273"
      unitRef="cad">607504</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i25846079a5ed4549a9e8ad780e2b2d07_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTYtMS0xLTA_c6b2d2f6-cf09-4ddb-a1f4-7ef4ffcde2a1"
      unitRef="cad">-311483385</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE4LTctMS0xLTA_449fd1a3-71b8-41d6-b343-c600f9ca99f1"
      unitRef="cad">6195363</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i486bc14f55c74a9d826bd06a228146ed_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTUtMS0xLTA_02069ba5-ef45-4295-a6d7-8e963d51d0c6"
      unitRef="cad">-143403</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="iab548591894744e4b55cfc4ab2de9220_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTYtMS0xLTA_2f172b05-e7f6-4be3-b5ba-363c4f0d5b99"
      unitRef="cad">-33122888</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzE5LTctMS0xLTA_2b5acd32-585c-4e2c-ac55-5ef9c90dcea1"
      unitRef="cad">-33266291</ifrs-full:ComprehensiveIncome>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTItMS0xLTA_4b2122e3-07fc-4ade-bbf0-945707cb42fc"
      unitRef="cad">391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTQtMS0xLTA_908995c9-a670-4769-8335-dbb5599ab2b7"
      unitRef="cad">-391917</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIwLTctMS0xLTA_aace9646-2ed8-49fc-9adf-9ada5896362f"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iedf74771c263472a9fbac91516305b93_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIxLTItMS0xLTA_81275335-f618-4fa5-a0ec-028922c73193"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i3e1683597bdf444baa0a2c591f2efc8c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIxLTctMS0xLTA_262094cd-86b4-4d4e-95d9-003c988cd5eb"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iaae50a49b8984e75aee582dcff0d7703_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIyLTItMS0xLTA_328a8279-6132-431a-9129-54f24eff1338"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIyLTctMS0xLTA_9fe828fc-7ab1-496e-9215-993e5f84384e"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i0a319f8e847b4b4bb642fd9d86aa5225_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIzLTItMS0xLTA_d872c0d5-896d-4bb6-9e3a-7609fcaf757c"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzIzLTctMS0xLTA_8e1e8b4f-b0cb-4d3a-a9c6-66ab4a1fe0ad"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI0LTItMS0xLTA_2789dd8b-b92c-4534-93fe-816053ea2660"
      unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI0LTctMS0xLTA_a2b757f5-1c9f-48e3-bc3b-263b77464556"
      unitRef="cad">9152869</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i922ef8fd8751412f922750015e9bc65e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI1LTQtMS0xLTA_7afb1ce4-7481-4001-ab57-c0bfdc095c09"
      unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI1LTctMS0xLTA_7e5671fc-43c9-475c-9a4e-9ac207cac04b"
      unitRef="cad">1470153</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i136ba1c3bd6c43458333cb0aaa0b43b5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI2LTItMS0xLTA_a7ae45bf-327c-4945-b96e-b3b74761aed3"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI2LTctMS0xLTA_fcc7efba-61d3-400e-bd24-76eff25f01c8"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i29a43f0a866349d8bc5f0b63f8d0e784_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTItMS0xLTA_ce42aee8-5904-4638-9b62-878df76bd13b"
      unitRef="cad">311077859</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i562af6df16fd49e5b90954aeea2d4aea_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTMtMS0xLTA_3b7ebe78-a829-4677-b4ae-60e09be4ec50"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i96b9cc93c17f4804b0117d1b5087e203_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTQtMS0xLTA_f78814d2-6d48-44a7-8a27-202b2f09d267"
      unitRef="cad">29338849</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1a3a4fc591144d32b93f7d833c2d6c8b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTUtMS0xLTA_ee7a0165-b4b0-4feb-86eb-c7cb94037733"
      unitRef="cad">464101</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ibdf2ec1b8b034942a3533ec514919b05_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTYtMS0xLTA_f54ed513-8ec1-4dfe-a12b-88f40ef4cf8a"
      unitRef="cad">-344606273</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI3LTctMS0xLTA_d8ea68ad-ec6d-4623-87d7-f58449621f1b"
      unitRef="cad">-107894</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i76695d2971ca43c4829d183db3ebe53d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTUtMS0xLTE4OA_021ee140-e40a-43ec-8cdc-cfd377e8f819"
      unitRef="cad">-63876</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i914f2dfba8874652a9bc67c5190a974e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTYtMS0xLTE4OA_46212bda-9d30-48d5-9f7e-28baec540e70"
      unitRef="cad">-22505057</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI4LTctMS0xLTE4OA_cea47115-727b-4ea4-bc76-7a5f4cdbab19"
      unitRef="cad">-22568933</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTItMS0xLTE4OA_e785f5a1-4291-483b-a8b0-188af22d5ac1"
      unitRef="cad">385022</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTQtMS0xLTE4OA_ca6c9a3f-29d0-40b3-9c73-195e70173dae"
      unitRef="cad">-143100</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzI5LTctMS0xLTE4OA_2024aaf2-533c-4a83-9bb6-acbc660096b8"
      unitRef="cad">241922</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTItMS0xLTE4OA_1d01b14e-0096-4525-b88d-e9b8891bd5aa"
      unitRef="cad">732367</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTQtMS0xLTE4OA_3cae49d0-942b-4db6-af9d-620c9119503d"
      unitRef="cad">-732367</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMwLTctMS0xLTE4OA_5095c31f-ef09-45b0-a3ab-627204252b40"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ie624bde674254422be5db7d03183d08e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMxLTItMS0xLTE4OA_1b313b21-e1fb-4431-b6b0-0de7043f317c"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMxLTctMS0xLTE4OA_49051eba-5724-49fb-9b96-c9448e29006e"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMyLTItMS0xLTE4OA_1affbf32-698d-4a47-afed-ce5375c7ba7d"
      unitRef="cad">6332778</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMyLTctMS0xLTE4OA_7a34e01a-49a0-4a82-9f54-fc9d78ba40ca"
      unitRef="cad">6332778</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i0265aa91f8bc456e9b613a8c6e13c4e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMzLTQtMS0xLTE4OA_2520a124-65a8-4549-a900-04483d03c6d0"
      unitRef="cad">2558974</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzMzLTctMS0xLTE4OA_9c5872d2-e1a8-44bd-bcad-d3ac518a228d"
      unitRef="cad">2558974</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="id4024d06f67d4846b56090a3f0fc0f77_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM0LTItMS0xLTE4OA_787626ab-f6b6-4842-9342-f191152b8dfd"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM0LTctMS0xLTE4OA_6f5df0b5-1484-43dc-9fa9-5c862a1647c4"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i146d8b2a85a9470192da0785eb8a6240_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTItMS0xLTE4OA_11f69422-8a1c-4522-9ebb-7bb7249aab71"
      unitRef="cad">356824172</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i60c164267fc04f55a74c61c77cf6e840_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTMtMS0xLTE4OA_ea4c9a81-349f-4cf3-9d7b-7233194b4249"
      unitRef="cad">3617570</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6090088661d04f81ad4934969e730d18_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTQtMS0xLTE4OA_4c7c31d6-4c01-4e35-b639-e38015474d8c"
      unitRef="cad">31022356</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="iacc3c9e5c988498783bbc9fa6d366285_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTUtMS0xLTE4OA_aeea22da-7055-49b2-a286-8d5a8ed3174a"
      unitRef="cad">400225</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i99c0248efb984ca8b2400ce4a3fa18cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTYtMS0xLTE4OA_355711a2-7770-4d31-becb-ced1cb64ebb9"
      unitRef="cad">-367111330</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzAvZnJhZzpmZTgwMzQ3MTM3MWY0NDkxYjk5YzliMTVlMjVmYTVkYy90YWJsZTo2MjkxZjZjYjhjMGU0NzE0YTRlYjIxYTU2YzI1MjgwMC90YWJsZXJhbmdlOjYyOTFmNmNiOGMwZTQ3MTRhNGViMjFhNTZjMjUyODAwXzM1LTctMS0xLTE4OA_41faab44-fec1-454d-8b0c-a12a5f881aca"
      unitRef="cad">24752993</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtMi0xLTEtMA_6e40f2ff-d25f-40de-9ae7-98fdd0101132"
      unitRef="cad">-22505057</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtMy0xLTEtMA_df5759a4-37fc-4043-9847-e2b67bcefa1f"
      unitRef="cad">-33122888</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzMtNC0xLTEtMA_9075bc31-c570-47fa-a5f2-06ab8e6b0823"
      unitRef="cad">-17037225</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtMi0xLTEtMA_92c63fc9-85f2-4144-8cfb-125f5b59aa9c"
      unitRef="cad">88957</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtMy0xLTEtMA_718abb14-157f-4497-8fd0-496e37fed1d7"
      unitRef="cad">122982</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzQtNC0xLTEtMA_535e4ba9-33e6-40f4-b44a-11ee082485ef"
      unitRef="cad">95375</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtMi0xLTEtMA_28f736e2-3457-474b-aea4-fcd0a96c881e"
      unitRef="cad">357230</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtMy0xLTEtMA_9fe9f2f6-d664-4af1-a6e0-7abf2c6306a0"
      unitRef="cad">362592</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzUtNC0xLTEtMA_7f91e387-8e22-4118-8b34-89aa286b1bc2"
      unitRef="cad">0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtMi0xLTEtMA_56ed7286-cace-4b1b-964d-7f2443fd11b7"
      unitRef="cad">2558974</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtMy0xLTEtMA_f3553364-790c-4f55-b145-accd127e5806"
      unitRef="cad">1470153</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzYtNC0xLTEtMA_b5e858e6-c746-498c-978c-b92dc8abd97f"
      unitRef="cad">1415833</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctMi0xLTEtMA_43a7060f-67b4-44ae-b467-eeec27b9ebc9"
      unitRef="cad">68526</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctMy0xLTEtMA_f7feef5e-3ca8-4ae6-a9b5-a9ceeaab9218"
      unitRef="cad">94817</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzctNC0xLTEtMA_671758f2-a3d2-414b-be3d-10d951f14454"
      unitRef="cad">0</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtMi0xLTEtMA_e62d5638-3c02-4baa-ad9a-4d308e2f3c1f"
      unitRef="cad">645078</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtMy0xLTEtMA_03810734-5ca5-47d9-8a4c-3f302a2120dd"
      unitRef="cad">353189</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzgtNC0xLTEtMA_e241ceee-b3f9-410a-afc9-9ddc915db3ce"
      unitRef="cad">-374337</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktMi0xLTEtMA_3416480d-23f5-432f-b277-69e00cac855c"
      unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktMy0xLTEtMA_988f847d-71e7-4265-96c0-49b2b151ea0a"
      unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzktNC0xLTEtMA_b318fdee-cf42-46aa-bd73-af97f2ec1a6b"
      unitRef="cad">67588</ifrs-full:AdjustmentsForProvisions>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTItMS0xLTA_0b25e2f0-971e-4f03-8126-aaa2abfe7ba0"
      unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTMtMS0xLTA_67d5f1e8-add3-4ece-9d96-d89e18918266"
      unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEwLTQtMS0xLTA_649a70ba-5820-4648-957d-91a3c890641d"
      unitRef="cad">8189</oncyf:AdjustmentsforLeaseAmortization>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTItMS0xLTA_ec3dd849-aa53-4914-85bc-1903502f3e10"
      unitRef="cad">3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTMtMS0xLTA_63a2d649-0806-4e94-a90e-0d1320b8b3f3"
      unitRef="cad">-12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzExLTQtMS0xLTA_d8b1c07d-62e9-4603-ad5e-c26c7ece7e4a"
      unitRef="cad">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTItMS0xLTA_908f88de-10b2-4005-868a-4f210c102bdc"
      unitRef="cad">-209779</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTMtMS0xLTA_aa3740f9-c337-4897-9b11-c3a4e87db88f"
      unitRef="cad">1795777</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEyLTQtMS0xLTA_5780bff5-f7df-4a5c-a3aa-2a5c49f4d20b"
      unitRef="cad">-3904339</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTItMS0xLTA_19967308-7729-4b69-af87-5d09b6167d41"
      unitRef="cad">-22068441</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTMtMS0xLTA_85b559f2-4517-4a6a-930a-ed15dae4fd2e"
      unitRef="cad">-19906124</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzEzLTQtMS0xLTA_ccf81870-9263-4562-807b-391f427f6e10"
      unitRef="cad">-11920238</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTItMS0xLTA_81bb4d40-3a9f-4f30-8744-2e83b71c7a54"
      unitRef="cad">29305</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTMtMS0xLTA_1d99bd7c-8437-4b77-a575-00b57fa2ca4d"
      unitRef="cad">10905</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE1LTQtMS0xLTA_9709ebd8-a0a9-482a-a4c0-eb95e7868c6d"
      unitRef="cad">107466</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTItMS0xLTA_25b26a82-e385-4da4-9890-1e64912407c3"
      unitRef="cad">-29305</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTMtMS0xLTA_c81d9e62-fcd6-4d6e-b522-8af1a451d3de"
      unitRef="cad">-10905</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE3LTQtMS0xLTA_ea1ea46a-5903-4416-ae1b-313c63a40ee0"
      unitRef="cad">-107466</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTItMS0xLTA_cdb6081b-5e35-4e0e-befc-c2ef687dde07"
      unitRef="cad">241922</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTMtMS0xLTA_18b29d89-c7d0-489e-abd2-234161a3003f"
      unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzE5LTQtMS0xLTA_d546a8a4-33fe-465f-bebc-4257654bedbf"
      unitRef="cad">123538</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i0c4f5982efe94fd9bfde6746d570342d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTItMS0xLTA_7aaadf36-2b35-42da-a2fd-e0a5940a91fc"
      unitRef="cad">1696460</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ie7eb63a1dc564425a34c178e971918c4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTMtMS0xLTA_51d9ca67-9e94-47d7-9dd3-ce8192412797"
      unitRef="cad">3465867</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i53aacee4c85d4d55b6cf4d4273d55c08_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIwLTQtMS0xLTA_8fbd20a0-4060-41db-ad62-82e9add0e339"
      unitRef="cad">1417</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ie23b49ebdb2744409fa1b9c0240e0941_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTItMS0xLTA_600bb8c4-b3e0-4a0d-8601-f78ca990b28a"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i1e0091234801409c93750ab9a547e561_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTMtMS0xLTA_79e56023-807f-4345-8682-e96289fd4616"
      unitRef="cad">5360247</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i591759eeeca54189b9eeaf5b33f1ebf0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIxLTQtMS0xLTA_c0d2256d-4cc7-4c1f-8aab-4117b461a393"
      unitRef="cad">2533980</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i8959fc5ad053440094bd6d27d10d901c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTItMS0xLTA_621dae4c-3365-4484-a79d-168ac5cf5685"
      unitRef="cad">38296146</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i41752f9dd8d44e9eb56e06558e839e63_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTMtMS0xLTA_ecbf6489-fdd8-4b7f-a9f5-6ae2bf614c82"
      unitRef="cad">8131620</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i6103f68feeae4dc0a9ff3bdb25e56e73_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIyLTQtMS0xLTA_007a3cbd-b583-4f8f-bb1b-ce5bca406278"
      unitRef="cad">451675</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i7aec3edd676f499ab586efe1570a2ae3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTItMS0xLTA_c42e85a0-8854-477e-95f3-1afba42c73e1"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i3b01939b25f24f508f30c9aa05a73cee_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTMtMS0xLTA_18acac83-15f7-4676-a4d1-d46c7e744a35"
      unitRef="cad">4505359</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="id770e57addee4de3aced4720a0bad691_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzIzLTQtMS0xLTA_d4acfaff-7be8-4f58-9389-bd8f21040d6a"
      unitRef="cad">10188526</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashOutflowForLeases
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTItMS0xLTA_332cf8ab-feaf-478e-b2d8-c8d358beec0d"
      unitRef="cad">460724</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTMtMS0xLTA_2d6ff412-f88b-41cb-9535-28b72d0bb851"
      unitRef="cad">447497</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI0LTQtMS0xLTA_7b8f09ed-565d-4723-856c-ea3c2ebc6c7b"
      unitRef="cad">0</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTItMS0xLTA_d3322e3f-5509-415f-8ec9-b5a93f2915dc"
      unitRef="cad">39773804</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTMtMS0xLTA_cde6cf54-fab7-42ac-be5c-97c3a118702c"
      unitRef="cad">21015596</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI1LTQtMS0xLTA_1659b0ae-9219-47ba-857a-adcdbec9a18d"
      unitRef="cad">13299136</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTItMS0xLTA_5db094c9-19a7-4bb7-bd97-e5100b7f0ea4"
      unitRef="cad">17676058</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTMtMS0xLTA_42d34b24-3162-463f-af67-6f99a7bab65b"
      unitRef="cad">1098567</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI2LTQtMS0xLTA_fad8860b-4b67-4d3b-b169-3c72a535d27c"
      unitRef="cad">1271432</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTItMS0xLTA_f2179b6f-8eaa-4a16-9350-e0f101386acf"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTMtMS0xLTA_0c4eb03c-4080-4956-b61d-2206e80d59e6"
      unitRef="cad">13699881</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i69e26aa497764738a8d24ee240e72834_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI3LTQtMS0xLTA_98ec0741-2a19-48db-8695-ba2c0919327e"
      unitRef="cad">11836119</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTItMS0xLTA_a8b880f8-1c5b-4cc1-8693-b58b3c6d66c4"
      unitRef="cad">-604505</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTMtMS0xLTA_e7822abe-6741-4328-8154-653a589f87b7"
      unitRef="cad">-650427</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI4LTQtMS0xLTA_dfcecdfd-7a7a-4ce7-bc43-979ee243cac3"
      unitRef="cad">592330</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTItMS0xLTA_592d0919-b4e5-4f5d-a4a4-2dca95820426"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTMtMS0xLTA_ae2ca62a-8763-4924-b9a1-2e05d9efc74c"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzMvZnJhZzo4MjI4OTkxNTRhYzM0YjJjOTNhNGExYzlhNmQ4ZTNjYS90YWJsZTphMWYzZmIzOTYwYWI0NjlhYWJhMmNhZTNlNzhhMTk5Zi90YWJsZXJhbmdlOmExZjNmYjM5NjBhYjQ2OWFhYmEyY2FlM2U3OGExOTlmXzI5LTQtMS0xLTA_4118a5af-7be1-48e6-8d00-8a01efb31c7e"
      unitRef="cad">13699881</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xMzkvZnJhZzplNDUwY2JhY2E3NTg0MTcxOTc2NmU4MjIyMGZkMDI2NS90ZXh0cmVnaW9uOmU0NTBjYmFjYTc1ODQxNzE5NzY2ZTgyMjIwZmQwMjY1XzE1NjY_11010276-28dd-4d40-95b9-4cc24a8de942">Incorporation and Nature of Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;4, 2021. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDIvZnJhZzo4OGVjNjU1MGU1MGM0NTEyYTg1YjZiNzIyNWI2ZDZkYS90ZXh0cmVnaW9uOjg4ZWM2NTUwZTUwYzQ1MTJhODViNmI3MjI1YjZkNmRhXzEzODE_0bdf0446-d493-4209-ab78-36b8299b1e77">Basis of Financial Statement Presentation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (U.S.) Inc., and Oncolytics Biotech (U.K.) Ltd. and are presented in Canadian dollars, our functional currency.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDMz_55c41236-093b-4778-b83b-1c499f45dc30">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification and measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments ("IFRS 9")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent &#x2018;solely payments of principal and interest&#x2019; on the principal amount outstanding (the &#x2018;SPPI criterion&#x2019;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contractual rights to the cash flows from the financial asset expire, or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Loss per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#x201c;in the money&#x201d; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#x2019;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the &#x201c;Option Plan&#x201d;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#x201c;Board&#x201d;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDI4_aa5e59e4-3f77-48c8-ac36-f71cf4eca122">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDIx_429a699e-ceb0-488f-b8d4-8b7644dcf32a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments ("IFRS 9")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent &#x2018;solely payments of principal and interest&#x2019; on the principal amount outstanding (the &#x2018;SPPI criterion&#x2019;). &lt;/span&gt;&lt;/div&gt;Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDIw_3b2bccfc-88f4-461d-af7a-4b7e5f5ad699">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDE2_1ab72101-793f-4f91-b950-b50c48b43e1f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzcxNDY4MjU2MDcxMTI_cff13d3b-1dc0-40e6-9389-804ba5d24783">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contractual rights to the cash flows from the financial asset expire, or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.</ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDA4_b95cc2fa-3bd3-4633-94d7-223281a41b39">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDE3_36328cd6-97f4-4d1c-8085-19ceaa962669">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDAz_79de8b3c-cdd5-429f-979b-6bf3fe7c5210">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#x201c;in the money&#x201d; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDM3_dd48ee65-952f-4c46-8462-71f3983e2f7f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDA0_7d3fd11d-05f3-486e-81a5-db293ada21f8">Depreciation is recorded using the declining balance method at the following annual rates:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:121.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:69.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="iacdf4b3e43034c8187484f366189cec0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzAtMS0xLTEtMA_40228936-6d34-41db-bee3-78cf6a5e10c8"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="ic4fe19e601e24c888cb45375f76fb410_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzEtMS0xLTEtMA_fcc05c5b-a405-4e7a-bebf-1b5b93a4ff80"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="i02d52a25ccdf40d1a3e77fa4d8cedd50_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90YWJsZTpmMDI2MjkzOTdkNTI0ZGQ2YWEzYTEyMDMyMjY1ZmQ4ZS90YWJsZXJhbmdlOmYwMjYyOTM5N2Q1MjRkZDZhYTNhMTIwMzIyNjVmZDhlXzItMS0xLTEtMA_fef5808d-2de5-4ace-a51c-8cb711796da3"
      unitRef="number">0.30</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDM5_85b0f2cd-2448-4c9f-ab4e-08e329d609a7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDMx_f7521531-b04b-43b8-94d4-1b42d366c6d0">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDEy_e5abccf7-b2ab-4788-a9f6-941916c4768b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#x2019;s credit risk and payment histories, including payments made subsequent to year-end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzIwNDQ2_372ae9c1-9c44-4de1-a2c7-ed7550bec51c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the &#x201c;Option Plan&#x201d;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#x201c;Board&#x201d;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <oncyf:NumberOfStockOptionPlans
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzE1NzA3_188ae0a5-e06f-4448-8fb7-33bafd030d4f"
      unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
    <oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDUvZnJhZzo4ZGIwNjZjY2VhNmE0ZDUwYjcwZjMzYWMzOWE0ZWY0Ni90ZXh0cmVnaW9uOjhkYjA2NmNjZWE2YTRkNTBiNzBmMzNhYzM5YTRlZjQ2XzE2MjE3_eb4e5601-98a1-4817-abfd-79abb915623c">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNDgvZnJhZzo3ZTVlNGI5NGMwNzA0NmRmOTIwMzcxZjgwNGRiNmExNi90ZXh0cmVnaW9uOjdlNWU0Yjk0YzA3MDQ2ZGY5MjAzNzFmODA0ZGI2YTE2XzUyNzE_16e7937a-77e9-4860-b022-9947c2ce5b81">Significant Judgments, Estimates and Assumptions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2020, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of warrant derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIyMA_bf458bca-01c2-4e93-9b6c-9a3683588c00">Cash Equivalents &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of interest bearing deposits with our bank totaling $30,361,591 (December&#160;31, 2019 &#x2013; $13,058,092).&#160;&#160;The current annual interest rate earned on these deposits is 0.36% (December&#160;31, 2019 &#x2013; 1.17%).&lt;/span&gt;&lt;/div&gt;</oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock>
    <ifrs-full:CashEquivalents
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzEyOA_4f5bf3df-c367-4bde-a86a-e9736b60ca41"
      unitRef="cad">30361591</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzEzNw_78f4b94e-cda5-4cbd-8d2c-109e10c48a67"
      unitRef="cad">13058092</ifrs-full:CashEquivalents>
    <oncyf:CashEquivalentsInterestRate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIwNA_26253451-c818-4029-a6f2-80dfaa8c91a0"
      unitRef="number">0.0036</oncyf:CashEquivalentsInterestRate>
    <oncyf:CashEquivalentsInterestRate
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTEvZnJhZzpkYzhlNTZkNjJlYzI0ZmNlOWI2ZDVkNzgyMWM3MDQxNC90ZXh0cmVnaW9uOmRjOGU1NmQ2MmVjMjRmY2U5YjZkNWQ3ODIxYzcwNDE0XzIxMw_ff9afb26-10d9-40bb-ab4e-f7022934fbf7"
      unitRef="number">0.0117</oncyf:CashEquivalentsInterestRate>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90ZXh0cmVnaW9uOjk0M2VhMTI5NTQxNzQ4YTZhZDJkYmI1MDU2MDE1MWQzXzQ2_8a3684b5-f895-4945-b42c-7b31eadc828c">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:121.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:69.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;116,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,739&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib06e365abc0d41b58a7b3cdfa48a3679_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMS0xLTEtMA_f63468e7-48fa-4db6-ab9b-62d1e172fe90"
      unitRef="cad">60378</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i5b6986d4b1f04f6a904bdd51c5d79c18_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMi0xLTEtMA_f4b4f796-74a0-440d-ae55-33ed3f52e6d7"
      unitRef="cad">345941</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2c148463e6434c3aaafd2ff899545a17_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtMy0xLTEtMA_dc77e472-a9e3-45f5-8f33-8fb773eb7bcc"
      unitRef="cad">247438</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iaaa4f6a1ffb546c5a334dd8511ac2d42_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNC0xLTEtMA_a8694212-6ee9-4341-ba76-6ee23018c2e6"
      unitRef="cad">105229</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i4655f1fa7ede498fae573a51a97ed506_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNS0xLTEtMA_8c0abf7a-7930-48b9-a8f1-1af4843f68a7"
      unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i56533e258a8349e2b1036c892d892ccf_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzUtNi0xLTEtMA_281fcd68-9f5c-4182-9966-9aa7b3753444"
      unitRef="cad">1257353</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i2cea8db44544431e891019dff150dd98_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMS0xLTEtMA_129c2db3-8d90-42da-9a25-8814b09e3387"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iee202aacf30f4366b9853640242782a2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMi0xLTEtMA_6f68b397-3cb0-4b38-b16c-1a95eaf0bed2"
      unitRef="cad">7014</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i257b3f18166343278211f238c2dd1391_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtMy0xLTEtMA_3370db88-a223-4087-93a5-5efae639194b"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNC0xLTEtMA_96206589-5235-4b42-9195-cb53128828ce"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNS0xLTEtMA_f6b00fee-a954-4b5d-b5bc-8de7b632cfd7"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzYtNi0xLTEtMA_2ef946c4-c4d3-49ad-9fd5-80c72c896e03"
      unitRef="cad">7014</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i2cea8db44544431e891019dff150dd98_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMS0xLTEtMA_2eb18046-cd33-40a2-aac1-2c5c26de65e3"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iee202aacf30f4366b9853640242782a2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMi0xLTEtMA_7288948d-d2ca-4fa1-bae6-8710e4f7c273"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i257b3f18166343278211f238c2dd1391_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctMy0xLTEtMA_6fdf1b96-2190-4b85-bc57-5a94c86fb9dd"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i1a070ac8303a4cabb030e7aad35c62cd_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNC0xLTEtMA_e380d782-8992-46cd-b55b-3312eb7b9965"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="id2a45bf1e3aa425a9993670a8dea2d10_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNS0xLTEtMA_a3a067a6-55d7-4ecc-a900-80f426e03b80"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i8ff7168ea8744ed990884a4893c82e29_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzctNi0xLTEtMA_dc1d6b59-6226-41c3-9d6d-b4b0ccd10a61"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia8a7de3dc38546928f9df260409a9610_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMS0xLTEtMzEx_6879b832-c19f-45fd-8e98-4df96af7887a"
      unitRef="cad">60378</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i975b34c09afa4efca073be66a065bf73_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMi0xLTEtMzEx_254d16cc-935e-44d7-8c69-7d275d6442ab"
      unitRef="cad">352955</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8c222353eac842659f464fd34266ded9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMy0xLTEtMzEx_a13d6f45-3d2e-4f3e-adc6-0e11543aaf5e"
      unitRef="cad">247438</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i268d98dd221747dd8a4a11bc620dd8f8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNC0xLTEtMzEx_5c39b590-9e8c-43f2-b633-f7dcee8ada31"
      unitRef="cad">105229</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie83afaabad954ec4895f2c369a9d6f75_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNS0xLTEtMzEx_8c1d9135-5140-493a-80c5-e511fda1696e"
      unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia99ca2509feb4a0ea2f8357c20cae1ae_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNi0xLTEtMzEx_11e2dfc0-4c9c-4c9a-8cb4-29f46352b960"
      unitRef="cad">1264367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMS0xLTEtMzE1_6e2dad10-a558-4b24-8d7c-03ee44d7c44b"
      unitRef="cad">1134</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMi0xLTEtMzE1_7cc8d8e8-3135-49f2-a836-4c1154b5b7f1"
      unitRef="cad">27719</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktMy0xLTEtMzE1_b8e7cb88-6b1f-40d0-bd0a-3462bc8f1a72"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNC0xLTEtMzE1_45184add-b0e7-4677-9d66-1fa48601d855"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNS0xLTEtMzE1_2dc17a07-f500-4481-be96-b6b657e9e60b"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzktNi0xLTEtMzE1_bdebcd19-8c25-4ba5-85d8-350e0d037b2a"
      unitRef="cad">28853</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i323c1c1d55f7467a8a1aa528805974d1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTEtMS0xLTMxNQ_7e2177a7-ad9e-416b-9799-84ecb4596c13"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i4e2f9be64fa74d94b4fd4c82f96c2e41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTItMS0xLTMxNQ_4eef2496-9e43-4d33-a898-3afc6bc913c4"
      unitRef="cad">15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i5333292c8cdf4f1a9bcd0850a2d951bd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTMtMS0xLTMxNQ_61a6c87c-b3a9-4056-aabf-f589cc60d5f1"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i2fd6c21637334a12a8ebc1a8108b99bd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTQtMS0xLTMxNQ_37c8352f-3527-497f-ab09-d9fdda6f428b"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="id838d604391644a8af2eb5d9c1a2d311_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTUtMS0xLTMxNQ_cdc991d4-8a03-4e43-a41f-6aea331f2f7f"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i36bebed09da64856b2cf08d5de2b5588_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzEwLTYtMS0xLTMxNQ_c7d185ab-f15c-469d-a772-49d1ad3516dc"
      unitRef="cad">15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="idc3cd77a1b7d43c5a6cd445b718cdf8d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMS0xLTEtMA_fc07482d-8b1d-41c5-a5a9-623fda740326"
      unitRef="cad">61512</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i71bcd083c6824318a0e66fc53b430792_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMi0xLTEtMA_ec8e5cf1-00bc-4e7a-8897-488e17c599ea"
      unitRef="cad">365537</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i89b6f7f3189d49abb49de0e01b7e44ce_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtMy0xLTEtMA_84b902ba-37ba-4b98-8102-f6c90a6072b6"
      unitRef="cad">247438</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8f6d1b20ef4741adb4cf59f9baae80d7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNC0xLTEtMA_cf321c03-2c18-4164-b988-ffcaad5d5664"
      unitRef="cad">105229</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i06f34c507c5a459a8a88148e94bf32e9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNS0xLTEtMA_c5e49906-427c-48e1-ab0d-06edd3fa2b11"
      unitRef="cad">498367</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifd0cebabc5f343b080b31d7829dc92c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzgtNi0xLTEtMA_9d4ed25e-67bf-44dd-a6b1-f51f04bfd1ec"
      unitRef="cad">1278083</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1af37e2b626f4990a2de0594206009fc_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTEtMS0xLTA_babaa8ac-30f9-4f31-bc13-7362047ebcec"
      unitRef="cad">-24464</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i95589ae338604bb095806c15a829cbe2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTItMS0xLTA_19531485-5178-4d9a-b7c3-f0ea2b59d976"
      unitRef="cad">-174953</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i5608138db81c4378b9e3057d7fe8a191_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTMtMS0xLTA_f89c8a1f-25c4-4bdc-9c31-c4cdfe8daeaa"
      unitRef="cad">-157749</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i9f507765d834457c84f195dc7edc1f22_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTQtMS0xLTA_4f751a93-b8bd-422f-9639-ce6c47dc3656"
      unitRef="cad">-72828</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icdd208fddb4e4c54a4009d5ed906ab60_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTUtMS0xLTA_0ac22abe-3093-4734-89ea-5210748e1e5c"
      unitRef="cad">-414623</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ib110db811cd046fbac2029260a02467b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE0LTYtMS0xLTA_dde44c5b-b460-4012-af38-d243843dbb3e"
      unitRef="cad">-844617</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTEtMS0xLTA_4e3f4301-7b37-402d-91fb-2f0529b5ea9a"
      unitRef="cad">20244</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTItMS0xLTA_ee79c064-59ce-4d45-884a-ad3dc7b0156d"
      unitRef="cad">49093</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTMtMS0xLTA_b2e7a056-b26f-4f5a-b284-8acb5b82fabe"
      unitRef="cad">14668</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTQtMS0xLTA_96e50a15-8eb8-4514-9a02-f7f5c43c2100"
      unitRef="cad">5342</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTUtMS0xLTA_6646064d-2549-4b45-8f71-7b63d2aecb1a"
      unitRef="cad">33635</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE1LTYtMS0xLTA_4ef43370-543d-421a-a2f1-ad46e4bd64d1"
      unitRef="cad">122982</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ice3837e3ac0f4c169c8a89546e1e672c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTEtMS0xLTA_e75fc082-59d7-4d25-876e-42faa0376cc9"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ieffb13b1986543769e0800e23a0d9b03_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTItMS0xLTA_21d4c5ba-7fc6-4d91-a1e8-593d3fab02d4"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i31f7a0f4359943ae967634151ff47edf_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTMtMS0xLTA_4b46b4e8-0de4-4b45-8424-3f9c00803eae"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="if51cd2c7dbcd4afd9667f7dc577b76ae_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTQtMS0xLTA_bfb8c13a-12b1-4949-a395-6474ac50b5f6"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i27d4690a967c4648a45f1ec2259449d5_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTUtMS0xLTA_cb06b8c8-c00e-458c-b01a-cad3be6a869d"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i72c7a16f70f741d5a2192484e09f3481_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE2LTYtMS0xLTA_b4d3bbcc-acee-4497-924e-c698c5d9597b"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1656f7c240ef4a678ed77b1775d078d4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTEtMS0xLTMyMw_64f1666a-da46-4bfa-a4ca-33380735965e"
      unitRef="cad">-44708</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="idd46cf77bd84410f9d1ab54ec16f5575_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTItMS0xLTMyMw_f93f222d-e53f-4f17-9ef8-9926415a84bf"
      unitRef="cad">-224046</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i17b47ea4e17640a387dc2928c713393c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTMtMS0xLTMyMw_cf9a30bf-841e-4ff0-87b2-d366df6ab2a7"
      unitRef="cad">-172417</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i53a02a4f770f476189f841381bc8b9d0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTQtMS0xLTMyMw_1e6c42f7-f760-48aa-842d-c20105b89427"
      unitRef="cad">-78170</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1c686540959c4e5c86fbde52e38211d9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTUtMS0xLTMyMw_4646e971-781e-4b00-adef-0026da456a92"
      unitRef="cad">-448258</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i7f643d6a99d44ee996c4b204e5c8cef1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTYtMS0xLTMyMw_fbdef112-9eca-4281-b346-ee015027930d"
      unitRef="cad">-967599</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTEtMS0xLTMyMw_9e112183-63ea-4516-8b83-9e1e7afa831c"
      unitRef="cad">2942</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTItMS0xLTMyMw_9e6e358b-71dd-4dd0-9b02-74134f2c5972"
      unitRef="cad">40024</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i4736152495f44911a78b2700c5477e6f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTMtMS0xLTMyMw_81d9ed97-e556-445f-bdfa-03072d13e8a1"
      unitRef="cad">7988</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTQtMS0xLTMyMw_a794a8d9-72dd-4224-8c7e-a8b70c3ad5c3"
      unitRef="cad">4320</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTUtMS0xLTMyMw_707e7ad8-f0e3-4c4e-bf60-ccdb97d7f207"
      unitRef="cad">33683</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTYtMS0xLTMyMw_a6604176-14d9-462f-b79d-5e88de9d2a21"
      unitRef="cad">88957</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i41de7c727f6d4fbe8a87a4e9516a88d4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTEtMS0xLTMyMw_61e78301-dbe4-42e9-a98c-b61a6ac8ec4b"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i72bb5ba41cfe428998df7689379e049c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTItMS0xLTMyMw_58d5aa86-006f-4845-b915-e8321d076ab0"
      unitRef="cad">-15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i4736152495f44911a78b2700c5477e6f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTMtMS0xLTMyMw_5a8d6019-1f1b-4aa6-9dd1-8a0531a0e33d"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i448b89e0a2c54595b17778b6be580f1b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTQtMS0xLTMyMw_6bb1a64a-43f4-41f5-8dee-fdb224151b51"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ie803da30e56641ae9ff407ac934a0789_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTUtMS0xLTMyMw_0d59f5c5-bbe0-462f-be34-7d26c525925d"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i59a78ce11ad54efa9c45f0911a68c07a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIyLTYtMS0xLTMyMw_e14b5ace-9b1a-4be3-95a4-08d9a0e3ff67"
      unitRef="cad">-15137</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i93ba725d95a6450888552f6a4b9c7cda_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTEtMS0xLTA_3b640467-e7b1-4a4e-b781-a6132e7ee73c"
      unitRef="cad">-47650</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2ca8fc2742454766b4a9bee74b6996c3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTItMS0xLTA_59f1f9c2-a3e1-40f9-b77d-d8c2504fb925"
      unitRef="cad">-248933</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i80e12d3e53584943aba148ce1dd9619c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTMtMS0xLTA_57bc8d05-cc30-487e-bf35-e92002a017ab"
      unitRef="cad">-180405</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i89fe6774bf5c4a27849fb882fbafeedf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTQtMS0xLTA_0a4ebedd-7c88-45ad-9f32-55e0ed4961ff"
      unitRef="cad">-82490</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2870641ce4c84e3b8447a0c27f0e300d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTUtMS0xLTA_b317f0f8-5409-4144-8ec1-3332de36abb7"
      unitRef="cad">-481941</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic591edc2e85b4d218e8613fe7eab62f3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzE3LTYtMS0xLTA_99ecd810-5e74-4e36-a8e6-f3174f089a81"
      unitRef="cad">-1041419</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i85d577f40a6943b58f48867c0d5abfc3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTEtMS0xLTA_4cf2c249-60a4-43c3-88c1-ad041a5f98b9"
      unitRef="cad">13862</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i14cbb33f0a794897ae108913ed8cf4f6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTItMS0xLTA_6f7bddf3-c34f-4b05-b9b0-ba28a42a484e"
      unitRef="cad">116604</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i27cde419036d4d169847c09cbecf4717_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTMtMS0xLTA_5b87f7cd-adad-491e-8ba4-a4c565f73d1e"
      unitRef="cad">67033</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie74dd4d434d245e2a524758edc8a73b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTQtMS0xLTA_2d4187ee-9ffc-4195-84e7-9cf1f6faf5ba"
      unitRef="cad">22739</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iaa2fdee1c89e4724bc66d086bb390c86_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTUtMS0xLTA_56406d8e-111d-455e-b6eb-208547c5ae4c"
      unitRef="cad">16426</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIwLTYtMS0xLTA_3d2a7f57-259d-45cc-bde0-af8a6c4b3e03"
      unitRef="cad">236664</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if32873cbf8ad4247a3aa058d3a8c0f0f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTEtMS0xLTA_6d64fe8e-c800-4db0-8fbf-ea0df3618f4c"
      unitRef="cad">15670</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1e06eabd4bba416db2a6ea0aae6fdcf7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTItMS0xLTA_5187595e-0db4-43a6-8456-10e865d14ce6"
      unitRef="cad">128909</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i9345d7396c654329be1b09069b9f5e75_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTMtMS0xLTA_186c53d4-32cc-4f05-9182-72a339f2a56c"
      unitRef="cad">75021</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i125186a4e4e54e67bb5d103d16aec302_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTQtMS0xLTA_9fcf9311-bdaa-4586-b328-d182d97aacfe"
      unitRef="cad">27059</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic411ea96f38e4c2a8f99ab7b026cebf3_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTUtMS0xLTA_8f18a7ce-87ed-4f3b-82d1-78e14ad73886"
      unitRef="cad">50109</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTQvZnJhZzo5NDNlYTEyOTU0MTc0OGE2YWQyZGJiNTA1NjAxNTFkMy90YWJsZTpmOWVlMDgxOWNhNGI0MTkyOGRhMDY1NjhlZGE2ZGQ5Ny90YWJsZXJhbmdlOmY5ZWUwODE5Y2E0YjQxOTI4ZGEwNjU2OGVkYTZkZDk3XzIxLTYtMS0xLTA_3249ca9b-f784-492c-bcbf-78290a8d9a0a"
      unitRef="cad">296768</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3NQ_a70988b6-2392-45b3-83bd-dc20268e7938">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of leases consists of office spaces with lease terms generally between 3 to 5 years. We currently do not have leases with variable lease payments, residual value guarantees, or leases not yet commenced to which we are committed. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we entered into an office space lease for one of our subsidiaries. We recognized a $297,373 right-of-use asset and a lease liability of the same amount. The lease provided for one extension option that we were not reasonably certain to exercise at lease commencement date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right-of-use assets               &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:280.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:223.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Spaces&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease liabilities                  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:279.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:222.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Spaces&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;402,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity analysis - contractual undiscounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i6977c19ac3804e89bd0cdabd80283dd4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzEwNg_3fc25119-1030-4c26-aebe-423d93d0e3cd">P3Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i7ee20efa67c54f03b5de8025f70b242c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzExMg_a82e4e9c-9cbf-4985-a271-6452cf298f91">P5Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzUxMw_75c71c87-377a-4926-8683-7b65113bd27f"
      unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <ifrs-full:RightofuseAssets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0Xzc2OTY1ODEzOTU5Mjc_ba0ef9f4-7ae2-4efc-a700-28ed0fa0dcc0"
      unitRef="usd">297373</ifrs-full:RightofuseAssets>
    <oncyf:NumberOfRenewals
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0Xzc2OTY1ODEzOTU5OTY_f4ab2fc6-4374-4d1d-b219-769773456b65"
      unitRef="renewal">1</oncyf:NumberOfRenewals>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3Nw_3ed818f4-1a18-4a1e-84b4-ae0aa3322247">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right-of-use assets               &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:280.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:223.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Spaces&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;372,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzEtMS0xLTEtMA_c3ec2b07-dd29-4984-b7a2-4c12193f936f"
      unitRef="cad">808025</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMzc2_f1b69f8b-b80a-41f1-b5ec-458738b283ee"
      unitRef="cad">362592</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzMtMS0xLTEtMzc2_b421cf52-91f6-4b26-a2f1-bb973ccd5112"
      unitRef="cad">-14720</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzQtMS0xLTEtMzc2_076d6d89-eebd-497c-bb97-cc40e74069de"
      unitRef="cad">430713</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMzQw_d66a73eb-119a-4287-8c51-8b7a65f4dfc0"
      unitRef="usd">297373</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzItMS0xLTEtMA_7cce76ca-ecec-43db-8d03-c7765b1c3b09"
      unitRef="cad">357230</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzMtMS0xLTEtMA_f8a841e8-0525-4e9f-8414-a7a4bd1cf44c"
      unitRef="cad">1612</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTo5NzYyN2Q5ZmYwYzI0MTA4ODNjZGVlMDkxZTQ5OTJkMC90YWJsZXJhbmdlOjk3NjI3ZDlmZjBjMjQxMDg4M2NkZWUwOTFlNDk5MmQwXzQtMS0xLTEtMA_a164fcc0-4a93-4020-9273-c3942a89d594"
      unitRef="cad">372468</ifrs-full:RightofuseAssets>
    <oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzcxNDY4MjU1ODIxMTY_dae1dd70-6ec0-4417-921e-d2069d351e55">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease liabilities                  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:279.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:222.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Spaces&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;402,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzEtMS0xLTEtMA_2df6585f-b6f2-44a5-83a1-0983c9b2a786"
      unitRef="cad">882437</ifrs-full:LeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtNDEw_ea35e61b-92db-46e2-baea-cf9e46e18413"
      unitRef="cad">447497</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzMtMS0xLTEtNDEw_86b9b932-a15c-4df5-9ff1-488f6d39b468"
      unitRef="cad">94817</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesfromForeignExchangeImpact
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzQtMS0xLTEtNDEw_8b204ba4-e1fb-4fe3-8298-eb83200c3fce"
      unitRef="cad">-23482</oncyf:GainsLossesfromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzUtMS0xLTEtNDEw_cde8c58a-658e-4ffa-9612-5463a0301a31"
      unitRef="cad">506275</ifrs-full:LeaseLiabilities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtMzUx_ad1a24f2-cf64-448e-9f49-b6884f20e60c"
      unitRef="usd">297373</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CashOutflowForLeases
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzItMS0xLTEtMA_66c70e17-1176-4566-b2bc-88ade648effb"
      unitRef="cad">460724</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzMtMS0xLTEtMA_4c0086ac-00d7-4c8c-9d5e-a7f12ea3a2f8"
      unitRef="cad">68526</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesfromForeignExchangeImpact
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzQtMS0xLTEtMA_3cbc9064-d181-490b-b015-248b9169077d"
      unitRef="cad">-9391</oncyf:GainsLossesfromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTpiNzgyZjEzZDYzYjM0ZDQwYjhlMTRmNzMyYmI3ZDU2Mi90YWJsZXJhbmdlOmI3ODJmMTNkNjNiMzRkNDBiOGUxNGY3MzJiYjdkNTYyXzUtMS0xLTEtMA_3a7a8ebd-a91e-4e1f-9211-2b67bfb7c54f"
      unitRef="cad">402059</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90ZXh0cmVnaW9uOmY3OWU0YWFhMGJlNjQ1YTVhZDIxZTQ3ZTFhNjU5NjU0XzY3Mw_565ca4a6-c7b5-4767-b2d6-5bf896133503">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity analysis - contractual undiscounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ide6d8e3c655c4d70ab1c6f8d0cc12aed_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzItMS0xLTEtMA_7cf3be35-4711-41dd-a675-7ec8fe57e71e"
      unitRef="cad">286509</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i0538bd9470324b8389be50058e5cf219_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzMtMS0xLTEtMA_bfc0e287-06ac-42c4-8c1b-6134685d1cb4"
      unitRef="cad">172003</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i1546a2edd29843b68c4ba7b149c00e10_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzQtMS0xLTEtMA_e85ebeaa-9dfe-4b0e-b535-f6e636de7e2b"
      unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNTcvZnJhZzpmNzllNGFhYTBiZTY0NWE1YWQyMWU0N2UxYTY1OTY1NC90YWJsZTplMmM1ZjYyY2RmMjM0MGNiOTFjZGExYTJiMDEzMGZhMC90YWJsZXJhbmdlOmUyYzVmNjJjZGYyMzQwY2I5MWNkYTFhMmIwMTMwZmEwXzUtMS0xLTEtMA_3fc86354-030b-4b86-a890-53636ed55b46"
      unitRef="cad">458512</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIzMjM_6283e4dc-c186-4e2f-9156-9b44c2fa420e">Warrant Derivative&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under IFRS 9 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IAS 32 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments: Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:385.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:192.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:93.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued, August 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,935,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,687,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,608,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,508,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,418,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,636,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;265,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;531,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we received cash proceeds of US$1,276,532 (2019 - US$2,642,082) with respect to the warrants exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:202.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$3.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$2.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$4.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5Xzk4_77d77e39-ce22-40b8-b412-31bb8f27ec1f"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE0MA_bc8b5662-b292-44f2-b966-177cbc7c8e87"
      unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE3NA_5ce8db8d-d8c8-4e32-af6b-db4124afc9db"
      unitRef="usd">3742016</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE5Nw_7f3743bb-a69a-474c-be78-ac17d86cfec8"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIxNw_b3eeab08-3215-4da7-ab94-e3df8b4d28f7"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzMzMQ_ae41af16-8b4e-4147-80fc-245074457514"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzM3MQ_bcb00696-df73-46d6-901b-902fbddeff9e"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzkyNQ_0be3c5a3-717a-43ff-bbd3-11b04ef691cf"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzIzMjU_a93ecc2d-675b-483e-a24a-0bf9e2098660">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in fair value of the warrant derivative is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:385.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:192.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:93.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued, August 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,935,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,687,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,608,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,508,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,418,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,636,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,491,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;265,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;531,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:202.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$3.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$2.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$4.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzEtMS0xLTEtMA_3f21d302-ccce-4d5e-b127-52acf5b9a2a5"
      unitRef="shares">4619773</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzEtMi0xLTEtMA_23104e2c-9692-4eed-a879-0a2e214035ae"
      unitRef="cad">1657214</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMS0xLTEtNDI3_77d7f15e-7c24-4fc9-9b09-831a58628619"
      unitRef="shares">2935647</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMi0xLTEtNDI3_1d2c2ab5-1795-4e95-9a57-9fe6ff9e9ce7"
      unitRef="cad">5687003</oncyf:ClassofWarrantorRightWarrantsExercised>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzMtMi0xLTEtNDI3_c804f5a0-fc65-412b-b094-8c964ddbb549"
      unitRef="cad">12608808</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesfromForeignExchangeImpact
      contextRef="i0db4b98e740e4692b0ffbe00e29b11c6_D20190817-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzQtMi0xLTEtNDI3_261ba3b7-ad6c-4d84-bb0a-0f7d3f13bafb"
      unitRef="cad">-70255</oncyf:GainsLossesfromForeignExchangeImpact>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMS0xLTEtNDI3_f7a7d97e-fb60-4e64-a3d1-1fe08fdd080e"
      unitRef="shares">1684126</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMi0xLTEtNDI3_9fb6642b-c649-451a-bd1a-74c2ac19f0b7"
      unitRef="cad">8508764</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMS0xLTEtMA_c6a16b71-31c8-4a09-8af8-010869a928c4"
      unitRef="shares">1418369</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzItMi0xLTEtMA_f7310157-d325-4619-8b80-55a449de2762"
      unitRef="cad">4636317</oncyf:ClassofWarrantorRightWarrantsExercised>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzMtMi0xLTEtMA_6b761612-8de4-497b-bede-ff8f322669f2"
      unitRef="cad">-3491928</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesfromForeignExchangeImpact
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzQtMi0xLTEtMA_b5a3de63-e8c2-4151-98cc-773a2a29ee94"
      unitRef="cad">150709</oncyf:GainsLossesfromForeignExchangeImpact>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="i7073102f39754418a48b29815277781f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMS0xLTEtMA_0f83c0b4-e6a1-49b9-b6e4-9417e973a924"
      unitRef="shares">265757</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i7073102f39754418a48b29815277781f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTplYzU4NzJmZWEyYzE0Mjg5ODA1ZTRiMWE1MDg5YzJkNi90YWJsZXJhbmdlOmVjNTg3MmZlYTJjMTQyODk4MDVlNGIxYTUwODljMmQ2XzUtMi0xLTEtMA_a740cf09-f96f-4915-8f53-f6f323c8460f"
      unitRef="cad">531228</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5XzE2Nzc_84d1915b-9527-4940-855d-4773e4f628a6"
      unitRef="usd">1276532</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90ZXh0cmVnaW9uOmZmNDRmMGYzNGJjZTQ5MmZiZTg2YzE4NTc4ZWI4YjU5Xzc2OTY1ODEzOTcwMjg_400147b8-90fc-45a7-83e0-d3a08c53e4cf"
      unitRef="usd">2642082</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:FairValueofWarrantIssuedPerWarrant
      contextRef="i7073102f39754418a48b29815277781f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzEtMS0xLTEtMA_79ed952d-03e4-4d2a-82cc-f4fdc71718ad"
      unitRef="usdPerShare">1.57</oncyf:FairValueofWarrantIssuedPerWarrant>
    <oncyf:FairValueofWarrantIssuedPerWarrant
      contextRef="ic47b4b76e637454fa2794190496a94ae_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzEtMi0xLTEtMA_11d674d3-a399-4e0a-8262-48d2ca2daf63"
      unitRef="usdPerShare">3.89</oncyf:FairValueofWarrantIssuedPerWarrant>
    <oncyf:WarrantIssuedUnderlyingSharePrice
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzItMS0xLTEtMA_82dac367-e5f6-430d-acc0-d9f84a78d5e7"
      unitRef="usdPerShare">2.38</oncyf:WarrantIssuedUnderlyingSharePrice>
    <oncyf:WarrantIssuedUnderlyingSharePrice
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzItMi0xLTEtMA_78110400-3aa1-4e88-8918-42060b19b9e6"
      unitRef="usdPerShare">4.76</oncyf:WarrantIssuedUnderlyingSharePrice>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzMtMS0xLTEtMA_21567185-acd1-4bf8-8e46-c95b51945df2"
      unitRef="number">0.0010</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzMtMi0xLTEtMA_020ccb48-ddd1-4185-b12f-518ff9305751"
      unitRef="number">0.0159</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzQtMS0xLTEtMA_bb3aa4eb-b89a-4177-8271-ce462975083f"
      unitRef="year">1.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzQtMi0xLTEtMA_80c288ca-1850-41cb-b4cd-75c3f2d8b2f1"
      unitRef="year">1.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzUtMS0xLTEtMA_dbc918ff-4bed-4948-acef-f9f52e7a60eb"
      unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzUtMi0xLTEtMA_e4fc69dd-695f-4cc8-99da-050da6857fe0"
      unitRef="number">0.9000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <oncyf:DividendYieldPercent
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzYtMS0xLTEtMA_84219dfd-a300-4d04-99c2-5269f35dd690"
      unitRef="number">0</oncyf:DividendYieldPercent>
    <oncyf:DividendYieldPercent
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjAvZnJhZzpmZjQ0ZjBmMzRiY2U0OTJmYmU4NmMxODU3OGViOGI1OS90YWJsZTpjNzliZGY2ZDY5YWM0NTYwOWU3OTAxOGEzYmQ5MDUxMy90YWJsZXJhbmdlOmM3OWJkZjZkNjlhYzQ1NjA5ZTc5MDE4YTNiZDkwNTEzXzYtMi0xLTEtMA_9f7e583b-deaf-4813-aef8-45ae2d80c44a"
      unitRef="number">0</oncyf:DividendYieldPercent>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDU_c1ffda84-76bf-412c-8064-49e0c3dd8661">Share Capital&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Consolidation:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:309.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,805,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,710,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, May 22, 2018 - pre-consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,396,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,268,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, May 22, 2018 - post-consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,988,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,268,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,606,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to equity warrants exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(see "&#x2014; Equity Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,333,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,399,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,193,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,425,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,152,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,077,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,037,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,166,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356,824,172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#x201d; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362"&gt;five&lt;/span&gt; immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725;  2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726).  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to equity warrant exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,443,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,617,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <oncyf:ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights
      contextRef="idded585e6408411a94c46d5d947389d3_I20180522"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzIwOA_2b4a321c-6d0f-44c7-a26a-d8dd28dae5a0"
      unitRef="shares">9.5</oncyf:ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights>
    <oncyf:ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight
      contextRef="idded585e6408411a94c46d5d947389d3_I20180522"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDI_c063c697-f919-442e-ac5a-ffd16ed43c3a"
      unitRef="shares">1</oncyf:ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MDY_8f74f050-e733-44e7-beef-45a4ca9794f7">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:309.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:90.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,805,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,710,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, May 22, 2018 - pre-consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,396,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,268,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, May 22, 2018 - post-consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,988,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,268,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,606,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to equity warrants exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(see "&#x2014; Equity Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,333,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,399,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,193,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to Common Stock Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,494,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,425,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,619,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,152,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,077,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,037,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,741,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,166,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356,824,172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#x201d; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362"&gt;five&lt;/span&gt; immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725;  2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726).  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i7f79d8de4290471c8bd4630bf062b395_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzctMS0xLTEtMA_2d125eb1-2d5b-48db-abd7-5692d4b04512"
      unitRef="shares">141805722</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="i7f79d8de4290471c8bd4630bf062b395_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzctMi0xLTEtMA_9df22bd0-9551-41ce-bd9f-83756432ab42"
      unitRef="cad">271710138</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzgtMS0xLTEtMA_e189d131-4f0c-4af3-afaf-d340f6f61ae2"
      unitRef="shares">519500</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="iea0fb62fe9b0434599ce1ded56b05bd4_D20180101-20180521"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzgtMi0xLTEtMA_4227786b-bde4-46ea-865e-d9267a3dfe00"
      unitRef="cad">553650</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ife2ce693bb1e4e538d5f9509be7279ff_D20180101-20180521"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzktMi0xLTEtMA_3b4d4fda-4fe2-4474-b1a5-f3549c10c33d"
      unitRef="cad">33335</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEwLTEtMS0xLTA_d0c21f72-daba-4f68-a976-a5bdb287772f"
      unitRef="shares">71000</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i9afd5c9db18843408e1e0c1e3879d89d_D20180101-20180521"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEwLTItMS0xLTA_30f45a6c-cfb4-47c7-9e25-2894cbd8769a"
      unitRef="cad">38269</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ic3cc312234b04ffe88d045cec709e645_I20180521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzExLTEtMS0xLTA_d6a087a8-7717-465b-a663-4cba01176b1d"
      unitRef="shares">142396222</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ic3cc312234b04ffe88d045cec709e645_I20180521"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzExLTItMS0xLTA_c42ecf40-2c31-4b3e-8051-03cf2632d5e4"
      unitRef="cad">272268722</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEyLTEtMS0xLTA_b284cd4b-5c72-47b9-9731-3ce7bd45e147"
      unitRef="shares">14988995</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="id116bfc88a7a4ec58b8bfbf759879dbb_I20180522"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEyLTItMS0xLTA_97cf8a98-b9a3-4c80-88af-a98483d62d19"
      unitRef="cad">272268722</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEzLTEtMS0xLTA_959300ab-0ce8-467e-83e6-25c77e7c44db"
      unitRef="shares">1532278</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i5c1bfdf32e5f4589bd79d8b1b3318195_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzEzLTItMS0xLTA_1c778c6c-5d8e-42e9-a8de-d32eecbdaf9d"
      unitRef="cad">11606882</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE0LTEtMS0xLTA_396d28e9-0d81-454e-90e6-6d850407ec27"
      unitRef="shares">157</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i415dcb703b674f4a8f357e3d2824fa8b_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE0LTItMS0xLTA_8499d33f-75c7-4803-a4cc-50315b22ee83"
      unitRef="cad">1747</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="id9699ac58b344404a871327fc97617f6_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE1LTEtMS0xLTA_8da4fe48-e2b6-4f12-98aa-c6dbcb13d276"
      unitRef="shares">34329</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="id9699ac58b344404a871327fc97617f6_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE1LTItMS0xLTA_0d0f4aa6-081d-44d7-8f03-44bd1bd78f69"
      unitRef="cad">158976</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE2LTEtMS0xLTA_961004fc-a158-4b05-9a6b-e8ef1a85c0eb"
      unitRef="shares">28297</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i251bc6d695874c2dbb096fae835294c9_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE2LTItMS0xLTA_e6335eb8-29e3-4f29-b5a5-2b9045f8afd0"
      unitRef="cad">109751</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE3LTEtMS0xLTA_75d8158e-abc5-4844-bd09-7b8fa3c27c76"
      unitRef="shares">797691</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ib87b7405fed84d80860e9f0d07539a9c_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE3LTItMS0xLTA_3ec32ca7-2392-43b7-9569-fe36238c7213"
      unitRef="cad">3314097</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE4LTEtMS0xLTA_16ff9a5b-c21f-4d71-9d45-e4a33df8a3b4"
      unitRef="shares">18002</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i97463f4fd1bc4d5e906c80275f112198_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE4LTItMS0xLTA_e0c5e576-4cc5-4b93-91c6-b0742e5c8cb4"
      unitRef="cad">66360</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i9c1b8fc753754267b5ee38bbe8188c69_D20180523-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzE5LTItMS0xLTA_e1e4ac64-056f-4a49-a7ce-726149035eaf"
      unitRef="cad">2333474</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIwLTEtMS0xLTA_6c59dfb7-ead2-4076-b5f5-f52473a04e65"
      unitRef="shares">17399749</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="i261e9f0b056c4c50ae42d68e5ce5fcd9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIwLTItMS0xLTA_c9a2084a-1f4f-4d99-bda9-5552053e292a"
      unitRef="cad">285193061</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="ia523aae440294924869d91f14d20ba80_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIxLTEtMS0xLTA_8cd0f0c6-9b93-4c1a-972b-a1338379adcd"
      unitRef="shares">323301</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ia523aae440294924869d91f14d20ba80_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIxLTItMS0xLTA_108589a0-588f-4379-8562-0985df6d6dd9"
      unitRef="cad">391917</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIyLTEtMS0xLTA_5cbec77f-743d-4e81-adb6-95e6c9f2157a"
      unitRef="shares">2494943</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i39e49d72d6e6472483cb9abe4c60248f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIyLTItMS0xLTA_508a9715-db53-458c-822a-5b7d81aac777"
      unitRef="cad">5403385</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTEtMS0xLTA_99cc10f6-e74c-4718-8476-c826dcc571e7"
      unitRef="shares">4425040</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i603dc503ee8744ef89d7b6d9f6fd3d3a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTItMS0xLTA_d268cf0f-b025-4000-aae8-f85df41cabc5"
      unitRef="cad">8476454</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTEtMS0xLTA_989b201a-7bad-4045-a5e1-3b90b5a3a51b"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i4be93f0a2b564a7d9fe9844505c9816d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTItMS0xLTA_3ccc8189-4dd6-44a9-b261-1f4e80e22ae4"
      unitRef="cad">3314429</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTEtMS0xLTA_6a0ccb12-af04-40d9-87ef-1439125611c8"
      unitRef="shares">2935647</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i566a972b6eb34047a8293dbba64c1a31_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTItMS0xLTA_4d0f4e61-4cee-490d-b3de-56ed933a4326"
      unitRef="cad">9152869</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i42ce7a75633844d5a5c8538827785c0d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTItMS0xLTA_f9f0645a-373f-46d1-a320-180c813190a6"
      unitRef="cad">854256</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ia3e853028eaf4f4687a1425b818892a2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTEtMS0xLTA_21e3a452-6ded-4e14-9290-620ef1dc7d5c"
      unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ia3e853028eaf4f4687a1425b818892a2_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTItMS0xLTA_1f761d83-dc3e-4758-8922-d2fbf404a3b4"
      unitRef="cad">311077859</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i20080a94d52341bf8043af636627ec2f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTEtMS0xLTQ3Ng_a0e73f64-4e72-426f-9748-7b89da2b89be"
      unitRef="shares">133454</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i20080a94d52341bf8043af636627ec2f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzIzLTItMS0xLTQ3Ng_2c2d3421-62b1-4696-bfd2-7e7da235aa4b"
      unitRef="cad">385022</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTEtMS0xLTQ3Ng_b0bcb7e7-021b-49cd-999c-e4cac4bcae54"
      unitRef="shares">234172</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i0935214b543d4f208584c42c024ba0c2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI0LTItMS0xLTQ3Ng_608375a8-c1a7-4e4d-9a8c-d277cb4063e7"
      unitRef="cad">732367</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTEtMS0xLTQ3Ng_8e70e3f4-1790-4ea6-baf2-b425eb6d8a6b"
      unitRef="shares">12182532</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i42500999aef64afa8c18db76e97e7f37_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI1LTItMS0xLTQ3Ng_793db5ba-0988-4894-966e-72d49947e469"
      unitRef="cad">40037786</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTEtMS0xLTQ3Ng_8b54a26c-14ee-40c8-b57c-2bbe2abad22b"
      unitRef="shares">1418369</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="icd1c8470809f4a2fab282160a49735ff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI2LTItMS0xLTQ3Ng_ac70a0cc-015e-4a59-8cf6-6da7786dca4b"
      unitRef="cad">6332778</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i50194a1104f0447dbe8bdab6b84fb381_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI3LTItMS0xLTQ3Ng_e586e5ca-8113-41cd-bc9b-c10bcaa687f2"
      unitRef="cad">1741640</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI4LTEtMS0xLTQ3Mg_d149ca27-1a55-418c-844b-a13924eaa685"
      unitRef="shares">46166980</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ie79138f5f32b47bfad9ebc7eb3348d8e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTo0MWZlN2U5Yjc5YTM0N2M2OWI5MDk0NjIzMjljNTIwMy90YWJsZXJhbmdlOjQxZmU3ZTliNzlhMzQ3YzY5YjkwOTQ2MjMyOWM1MjAzXzI4LTItMS0xLTQ3Mg_2280c07b-0e98-4200-9f2f-c026f79e45de"
      unitRef="cad">356824172</ifrs-full:Equity>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i86af6651ee84454ba8d1a822e9eb52bf_I20160225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzkxNw_d5909ca6-f373-4d8e-a3f5-44450a07376f"
      unitRef="usd">4600000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:IssueOfEquityShares
      contextRef="i971a344a7f6e456094ca126adf0186ff_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzEzMTY_7b6f0819-170a-498b-a2d9-d6927bcfb49c"
      unitRef="shares">519500</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="if769c8e2f8534ccc947473705accee72_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzEzNTk_fb61bbce-d4eb-4114-84c2-5fa2eb3efb0e"
      unitRef="shares">54684</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzE1MDc_6340fbf4-1a24-4e37-98df-597d5501c39a"
      unitRef="cad">553650</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i7b7b6d3d4ce04558976e24552ec0acec_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzE1NTg_5e0cb2e5-23ad-4dfe-8963-a12d56db35d7"
      unitRef="cad">33335</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzI5NjU_e0791905-038c-41cf-ae73-8a0f893c4559"
      unitRef="shares">1532278</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i15bfe04f75e74d34a9bcbec045406bbb_I20180605"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwMTc_9ae93348-59e4-43ef-8249-decbba2faa2b"
      unitRef="usdPerShare">5.83</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwNTQ_c101232c-99ea-49f7-a1c0-16ffe52cf15f"
      unitRef="usd">8933181</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie26234bb498f4a5e92442766a8d6e81a_D20180605-20180605"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMwOTE_3f33d9cd-9647-400a-9081-0dab5b4d0114"
      unitRef="cad">1418356</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="ic7797595a0e345bd82875cde18a102f6_I20180927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMzMzY_df684ccf-0707-4cfb-8f25-c5963659b661"
      unitRef="usd">26000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="ic473318c6b55499784bd35d537a7f3ff_D20180927-20180927"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzMzNzg_6067afa8-3315-4aa5-9bbb-c7e258884028">P30M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i2cec20e510e74bd3b6a829215e7e1186_I20180927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzM5ODU_823adc1b-a921-4862-9a44-eb6a7ebfd759"
      unitRef="usdPerShare">1.00</oncyf:SharesIssuedPricePerShare1>
    <oncyf:NumberofSharesOutstandingPercent
      contextRef="ida04d93b266c4c888708cd83f197cba6_D20180927-20180927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQyODA_e3099c09-d8b9-405d-b835-c5ab07e763d7"
      unitRef="number">0.1999</oncyf:NumberofSharesOutstandingPercent>
    <oncyf:IssueOfEquityShares
      contextRef="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4MTI_8bc084f7-3e8e-470d-a1bf-f883d276c504"
      unitRef="shares">0</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI1Nzg_e19dc257-b465-454e-8da6-115af0bd956e"
      unitRef="shares">2477665</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ2NDQ_6cf58c12-0b98-46fd-af8a-05fc12c571ee"
      unitRef="shares">678182</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i13c1d13c98eb404293e9238b3f986b98_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NDA_1ea18ece-7056-4bf7-b3c9-19e122e83895"
      unitRef="usd">0</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ic20973e4b1e0456c80118e24c7fc4867_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4MjU_5bb20e2d-5774-4705-8d06-7d4d6eb80e68"
      unitRef="usd">4055725</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i414b5cb1f8754e9bb4c2cfc1a51ec868_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ2OTc_199c3923-d7d6-417a-bbe4-e688b0d10124"
      unitRef="usd">2055207</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:IssueOfEquityShares
      contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NTc_40313e61-32e0-4382-82f7-9e068cdeb8ea"
      unitRef="shares">0</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4NDc_8ef39272-cda2-43bc-b4b0-3aab05914e20"
      unitRef="shares">17278</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ3MjE_b5b3a477-726b-4b0c-ade8-eb5287208729"
      unitRef="shares">119509</oncyf:IssueOfEquityShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4ODA_17dd70be-3aa8-496b-b4a1-7a236cb7a876"
      unitRef="usd">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4Njc_8a882312-86cc-4265-8da9-337415a53abe"
      unitRef="usd">29758</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ3OTk_6658c8a1-9851-4117-8e82-495aa7997ba9"
      unitRef="usd">483690</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="i21d75fcc9d3b4238b4eb94a00aee2240_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4OTc_fe048b7e-a763-428f-a754-f6069c999f3a"
      unitRef="cad">0</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="i6c3906097c7c4fd39d1a754f91711192_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDI4ODc_bba1cf95-b3bf-4f72-952e-6b85986de2ea"
      unitRef="cad">3757</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="idf66db17dd304132b6d4bf4726ef95a6_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzQ4OTI_56d78fab-fc76-403e-9102-14586c74572c"
      unitRef="cad">208726</ifrs-full:PaymentsForShareIssueCosts>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i694e083ddd244a1590868a988368affb_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc2Mzk_81fd26bb-0d3d-4cdf-b2a7-0b129dcd1cc5"
      unitRef="usd">30000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="i4c90e3a44c2a4d788944653b7f87451b_D20181024-20181024"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTU0MTk_5c7fc285-9608-46a1-8a66-386a9e6957eb">P19M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NTE_2b2393af-9972-4363-bd70-51dc8d5f84fb"
      unitRef="shares">6741518</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NjI_67ac93ad-290c-48cd-9c30-5e08e43e52e2"
      unitRef="shares">4425040</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc3NzM_c93f0a82-2836-4ca6-9a66-5cb920f074be"
      unitRef="shares">18002</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MTQ_dafff168-7881-4d5d-992b-9806cecec0f9"
      unitRef="usd">17538342</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MjU_e5b11c5b-6228-438c-a7e1-48375e3e8bcf"
      unitRef="usd">6390691</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4MzY_9a3bb6c2-d267-4840-9441-85c32a2751f9"
      unitRef="usd">50046</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i562f369a1b84407798feac1b05faee8a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDgyMzg_2838dcf9-e222-4cf6-a064-67588a75abe0"
      unitRef="usdPerShare">2.42</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i05d73158ebeb4204a27888336398e6ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxMzI_02ab7a42-db1b-47d0-a40b-6bf99fb167e1"
      unitRef="usdPerShare">1.70</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="ib2b7d32d88cd49f39016f010737d5836_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyMDI_4ab06a76-72fb-431b-ba83-65fb1ae7f64a"
      unitRef="usdPerShare">2.85</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwNzY_76d51f91-b44e-4bec-b058-49c046867067"
      unitRef="usd">526150</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxNTQ_b8de1e08-ecc1-4c8e-a765-a74da7b34cf7"
      unitRef="usd">191721</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyMjI_dc79bfae-726a-4eec-ae52-fafc12ab2898"
      unitRef="usd">1501</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxMTI_ec283241-8688-4e5e-a42e-3e864758f157"
      unitRef="usd">17012192</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkxODM_6edf8015-3e88-42fe-93f3-0d156e04bbda"
      unitRef="usd">6198970</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkyNDY_e41d43c1-c7c4-476f-ae5f-58a3e54eb466"
      unitRef="usd">48545</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i7ea9135a9171439685c413a4fdf44804_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4NzU_189030f8-e633-451f-a683-e8d6a123a182"
      unitRef="cad">856754</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i945c6f94205c4859b2bd7d2062d6a85e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4ODY_0e792f39-13fa-4f4f-9a96-15215f1c9f0b"
      unitRef="cad">344834</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i5a95b53df55443b3a2a272d5bc00a211_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDc4OTc_6f7f19d8-d194-47de-80a5-a0649bcc15cf"
      unitRef="cad">135000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM3Njg_abff922c-fdde-4fb8-8df1-cdfbf9cecd70"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4MTM_3450663c-a130-4950-be86-40af49ff18b3"
      unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4NTA_05a43499-4728-4409-b6f7-fceca15f77d1"
      unitRef="usd">3742016</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM4NzQ_0e04033b-140e-4477-94ef-54dbc3ef13b4"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="ibd2a68a929fc4eb59d764ac865a75d38_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5MTQ_da8bb534-98a7-4282-8c63-b43db6c27d81"
      unitRef="usdPerShare">0.54</oncyf:SharesIssuedPricePerShare1>
    <oncyf:CommonSharesPerUnit
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5MjI_8456757e-62dd-4f82-86e5-14a0212abd76"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDM5Nzk_dd673414-79cc-4ed6-af85-753e1e794866"
      unitRef="usdPerShare">0.27</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i7d518a199ae3412d9dd2a2c7b2a7cd63_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQxMjE_1fb0497e-38c1-4fd0-a966-eb5295bda0e8"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="iab43b4228a174ca4b41758b41e9e7bdb_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQxNjQ_958cf725-693a-4757-8b04-32d161de8c21"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ic6b9773ebe9544849ee6caa1625d1ecc_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyMjQ_c53e29fb-b624-480a-a671-30f93f8c726a"
      unitRef="cad">699427</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="id181bdb06f844a62bdf467f41ba1dd43_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyMzc_8828c980-ddd7-4b60-a9f7-774ae893b781"
      unitRef="cad">466284</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i170cc49c63b04227a02de91e6163db24_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQyODE_6f8a3cc8-b932-4251-b2d4-0fda76fc0a37"
      unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0MzM_db971cd9-1b1a-4323-91f3-6daf6d4c0b99"
      unitRef="cad">4636317</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ1OTE_1d2c2ab5-1795-4e95-9a57-9fe6ff9e9ce7"
      unitRef="cad">5687003</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0NzI_84d1915b-9527-4940-855d-4773e4f628a6"
      unitRef="usd">1276532</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ2MDQ_400147b8-90fc-45a7-83e0-d3a08c53e4cf"
      unitRef="usd">2642082</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i4b730da7dedc49d7bd2f946d5e16448f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ0ODQ_dc40ab8e-efaf-4790-b4ac-a05722472752"
      unitRef="shares">1418369</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="icbebe8557ba049bbb0aac94a9799de91_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDQ2MTg_77d7f15e-7c24-4fc9-9b09-831a58628619"
      unitRef="shares">2935647</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i862c5b4961c74a48a39f058918e7d03e_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUwMjk_c3d67c73-8b8f-4619-8c13-06d520300d17"
      unitRef="usd">40000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="idc96efef1fbb4efcb5325460bb72a700_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTUzOTc_bab7d943-2479-4acc-98c9-ffcef39862df">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUyNTM_aeb9e9a2-7424-43a0-be49-0ae946b18733"
      unitRef="shares">5441014</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUyOTM_3565178c-25b8-4c5c-87b9-634f9df85e4c"
      unitRef="usd">12628775</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i47812f018f2f4cef9ae9380e51b482b5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDgyNzM_525d9866-5728-42c8-9797-af23b8dcf48a"
      unitRef="usdPerShare">2.11</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwMjk_1962b80d-b8b5-4ae8-9865-1103ef5b0b9c"
      unitRef="usd">378863</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkwNTU_aa9f7e06-487c-4e6e-922b-c89175f78bcf"
      unitRef="usd">12249911</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ic92e8cd8b48d410986b04766aff14f76_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDUzMzI_2fbd4440-fdcf-4a45-8acb-164454f7558b"
      unitRef="cad">884886</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYyNzU_f21d2f2b-0800-46ef-9843-c3805a499412"
      unitRef="shares">16445000</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYyODc_c7f1b4a9-3abc-4176-aa58-90e696e42a37"
      unitRef="cad">11511500</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i15e7713f103e4177900f7c2683516777_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MjQ_497767e6-bbac-4dea-ae52-49eccc979e90"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharePurchaseWarrantPerUnit
      contextRef="i15e7713f103e4177900f7c2683516777_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0MzI_3c213f56-ea3a-488f-b34f-37fe0e66f919"
      unitRef="shares">1</oncyf:CommonSharePurchaseWarrantPerUnit>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1
      contextRef="i15e7713f103e4177900f7c2683516777_I20170601"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYzMTM_b16d046e-5440-4fe5-86ce-99be3a2a01fa"
      unitRef="shares">9.5</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i15e7713f103e4177900f7c2683516777_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzcxNDY4MjU1OTQ0NDA_2eeff204-58f5-4c2d-801a-7ab6b0c20d56"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:SharesIssuedWarrantPricePerShare
      contextRef="i15e7713f103e4177900f7c2683516777_I20170601"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDYzMjA_2699e90e-71ee-4301-89f1-ef9845c1a9fe"
      unitRef="cadPerShare">9.025</oncyf:SharesIssuedWarrantPricePerShare>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzYzMTY_0624b97e-906c-47d1-8219-b4cf686bc128">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to equity warrant exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,617,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,443,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,617,570&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Exercisable into 1,730,894 common shares.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:135.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,834,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;769,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$7.42 - $52.63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="iba9fe4ea63e045e096465e2bfb11ba95_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMS0xLTEtMjA5NA_e22c9341-7438-4575-b171-b12591f9b189"
      unitRef="shares">16445000</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i69e26aa497764738a8d24ee240e72834_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMi0xLTEtMjA5NA_d909afd7-60e6-4edc-a840-f5a9b8177833"
      unitRef="cad">3617900</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="ib7326a67f5024a94b5c25675622288c0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMS0xLTEtMjA5NA_2dd218ad-c139-4715-8393-15ffe1023820"
      unitRef="shares">-1500</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMi0xLTEtMjA5NA_56c21122-2f69-45bb-8068-df4485473a67"
      unitRef="usd">-330</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i363f02f84b6946e8a01f345e20f5224d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzMtMS0xLTEtMjA5NA_de0962b0-d46d-4b62-9767-e3c214ed5f73"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzMtMi0xLTEtMjA5NA_cfe4492a-c58e-4c9b-909d-421f5625477e"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i0ef329fa905d4c3185e2177c3e6dee42_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMS0xLTEtMTA3Mw_55474f9c-a783-4b36-b700-954b2965e8e6"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzEtMi0xLTEtMTA3Mw_c2362081-fa17-4392-8a3c-e05182261ac0"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i65287d01f32c419ba89f7f594cd47caf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMS0xLTEtMTA3Mw_6b8a55bc-a821-470b-af9d-494cda57f893"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90YWJsZTpjMTBhZDA5Y2YxNjU0NzU3OWFlMjM3OTgxNmZmMzRhNS90YWJsZXJhbmdlOmMxMGFkMDljZjE2NTQ3NTc5YWUyMzc5ODE2ZmYzNGE1XzItMi0xLTEtMTA3Mw_d2dc79ac-7e9a-4f4b-92d0-f1788a519b6f"
      unitRef="cad">3617570</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzYyOTE_668ffa31-0207-4dc3-b5e7-7ad530f53976"
      unitRef="shares">1730894</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0ODI_26957c8d-7de3-4ca1-8990-ac4bb4c87258">Share-Based Payments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:488.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:117.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,246,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,817,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the&lt;br/&gt;  year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,764,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable, end of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,164,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:135.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,834,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;769,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$7.42 - $52.63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-exercisable options vest annually over periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1Mg_cd3e7b72-8b81-4fad-847f-5db8340cf26d"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:348.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:181.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Incentive Share Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have issued RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE0NTA_028b8dc4-7e4a-4f5f-b344-5ed3a29ae30d"&gt;three&lt;/span&gt; year period. The following RSUs are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:199.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154,923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;         (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also issued PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4Mjk_c9939d36-c1bf-4c0e-9451-a1e30a1ffc57"&gt;three&lt;/span&gt; year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:204.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We have reserved 4,616,698 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2020 was $2,558,974 (2019 - $1,470,153; 2018 - $1,415,833).</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI1MDM_532b27fa-244f-4652-b005-70b1084193b9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:488.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:117.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,246,947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,817,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the&lt;br/&gt;  year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,764,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable, end of the year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,164,551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMS0xLTEtMA_5f946737-41bc-4074-83dd-226052d2ba23"
      unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMi0xLTEtMA_12575a4c-cf62-4d55-a095-869dbd57ce90"
      unitRef="cadPerShare">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItMy0xLTEtMA_2b824a30-ee8f-4805-8c3b-9a143a0c724d"
      unitRef="shares">1249361</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNC0xLTEtMA_6bb0d3fb-1e3b-4365-8f2b-4fa86c156a58"
      unitRef="cadPerShare">8.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i69e26aa497764738a8d24ee240e72834_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNS0xLTEtMA_f45de674-2f9b-44a6-9610-39fc6039b34d"
      unitRef="shares">647156</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i69e26aa497764738a8d24ee240e72834_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzItNi0xLTEtMA_12ad862c-cb7d-4fd6-841b-e4ae114dc834"
      unitRef="cadPerShare">13.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMS0xLTEtMA_2e8db598-4083-401e-b5bc-931772b71cdd"
      unitRef="shares">1817500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMi0xLTEtMA_34ab3409-cec2-469b-97a4-5bd76ce377b1"
      unitRef="cadPerShare">3.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtMy0xLTEtMA_0f3fb612-59af-4998-880d-cf0501d5455f"
      unitRef="shares">1020000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNC0xLTEtMA_e929b930-3617-4b87-85a4-84883fad0cc4"
      unitRef="cadPerShare">1.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNS0xLTEtMA_6964455f-f138-4b29-9f4e-0843b84309b1"
      unitRef="shares">750467</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzMtNi0xLTEtMA_4665f626-8f3e-43b3-b3af-4ad9dae77278"
      unitRef="cadPerShare">4.97</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMS0xLTEtMA_7e09dbec-ca7e-4cf7-9256-2d93d4eb31e3"
      unitRef="shares">141418</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMi0xLTEtMA_a7e5af57-2923-42f8-9e9c-a8e755e26658"
      unitRef="cadPerShare">3.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtMy0xLTEtMA_416ffc55-df0f-4b1d-920d-f7880664b649"
      unitRef="shares">12839</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNC0xLTEtMA_308895ae-4b49-42bc-99da-d03760281727"
      unitRef="cadPerShare">11.35</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNS0xLTEtMA_ac276d4e-7cd7-4043-9b5d-22d0b376f771"
      unitRef="shares">105338</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzQtNi0xLTEtMA_3e009ba0-4c34-4e82-aa9d-8676753a0760"
      unitRef="cadPerShare">11.67</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMS0xLTEtMA_51bd4913-3e39-4cf2-88a4-f90d43fe4c9d"
      unitRef="shares">25520</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMi0xLTEtMA_f110f78b-815a-4969-9e5a-96abd92530ce"
      unitRef="cadPerShare">62.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtMy0xLTEtMA_a64283b1-4f9e-4fed-8cde-b06ac6d30b75"
      unitRef="shares">9575</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNC0xLTEtMA_c70f7fda-1b9a-41aa-9354-c6e8c89fcf78"
      unitRef="cadPerShare">29.07</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNS0xLTEtMA_640b66ca-ccaf-4eb2-8e62-620ab340c5f3"
      unitRef="shares">1122</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzUtNi0xLTEtMA_4e53478f-d57c-4967-9d17-0960c79d1c21"
      unitRef="cadPerShare">13.78</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMS0xLTEtMA_e434de26-49b0-4368-95a5-ae0a0def1cd7"
      unitRef="shares">133454</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMi0xLTEtMA_76d2bdde-427b-4487-b248-5f65bc1b0ee2"
      unitRef="cadPerShare">1.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtMy0xLTEtMA_d9e5232b-dc8f-434d-bee7-b8b851f9b323"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNC0xLTEtMA_7b2f1e2d-5e14-4deb-b337-8516491d88e0"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNS0xLTEtMA_961fd5f5-fa96-402a-8bd5-6bbeb215ab33"
      unitRef="shares">41802</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzYtNi0xLTEtMA_c7efa9a2-89cf-4693-9c98-210e672476d1"
      unitRef="cadPerShare">2.96</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMS0xLTEtMA_9da81ba6-152d-4ff9-b40b-ba73b8b808ec"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMi0xLTEtMA_f6ec9ab7-f5d4-4a5c-ae3b-07b177eb0506"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctMy0xLTEtMA_3e22da26-4a15-42e7-9346-8241ba986a63"
      unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNC0xLTEtMA_7cfe5e20-6338-4231-8535-e08ae1f33898"
      unitRef="cadPerShare">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNS0xLTEtMA_9e5ac20d-1da5-4991-a1af-61460ef33678"
      unitRef="shares">1249361</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzctNi0xLTEtMA_7bb7a6e2-456b-43d8-9960-be759076a8c9"
      unitRef="cadPerShare">8.73</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMS0xLTEtMA_12b8d786-c293-4adf-b001-2309aed88105"
      unitRef="shares">2164551</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMi0xLTEtMA_1871ea8c-f11c-42f2-b8a4-36d0337a4d68"
      unitRef="cadPerShare">4.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtMy0xLTEtMA_8f8d2159-cbc0-4833-a885-b5848cdbbe00"
      unitRef="shares">1327845</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNC0xLTEtMA_4fdc7868-6f0c-4e81-b6c1-78df9b04dad0"
      unitRef="cadPerShare">7.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNS0xLTEtMA_c9930baf-1756-4593-a219-b3f26e7bfadd"
      unitRef="shares">777245</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo0NTdjZTkyZjdjODI0NWMwODZkYjVlODQ1MDJhYjY3Yy90YWJsZXJhbmdlOjQ1N2NlOTJmN2M4MjQ1YzA4NmRiNWU4NDUwMmFiNjdjXzgtNi0xLTEtMA_1f2de527-0190-48bd-a8c3-0188bce1a9cf"
      unitRef="cadPerShare">11.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0ODQ_bf7ea6dc-a3ac-4bf5-8c11-6f52f0a243c5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:135.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;808,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.80 - $3.01&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.02 - $3.90&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,834,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;769,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.91 - $7.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$7.42 - $52.63&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ia5ef05068a8440d6a4ba5000646081ad_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYTkyNzMxMzE2MjQ1NDE5MjA5YTg1OGJkZTEzOTgxXzc2OTY1ODEzOTQ0NTQ_0494590e-acb6-403f-b95a-e8ab48c1639c"
      unitRef="cadPerShare">0.54</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ib21db9d5af5b44628e536172b106e636_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmIxYTkyNzMxMzE2MjQ1NDE5MjA5YTg1OGJkZTEzOTgxXzc2OTY1ODEzOTQ0NjI_7a9783bc-5ffd-446b-aa0f-cc08ea748a1e"
      unitRef="cadPerShare">1.79</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i93af58043e324a92a840919953931d39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMS0xLTEtMA_d6fad68b-e32c-4eda-9399-b0baeaa06c54"
      unitRef="shares">808333</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ie2d6c1efdf1b45f6902ca44f7d279adc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMi0xLTEtMA_c5e6d6db-18d6-47e7-98cd-33c44fd27319">P3Y10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i93af58043e324a92a840919953931d39_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtMy0xLTEtMA_8e043ea8-8cf3-4a41-afb7-b998eb5284ee"
      unitRef="cadPerShare">1.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i93af58043e324a92a840919953931d39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtNC0xLTEtMA_ea84ea8a-cc0a-48b2-be1d-12c8c9c6f537"
      unitRef="shares">545009</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i93af58043e324a92a840919953931d39_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzEtNS0xLTEtMA_19f26616-6759-4ee4-a0af-9b02d79fc097"
      unitRef="cadPerShare">1.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i48739a7cd7d84144a5f4e605f94af42e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTA1OWZmZDRhOTQ5OWViMjc2MTU1Y2FlYjhkNzA3Xzc2OTY1ODEzOTQ0NTQ_448df9ae-a088-44c0-a3a2-e882aedfda22"
      unitRef="cadPerShare">1.80</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i7f4c186a1a8848be9fc5a892d41b0be2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMC0xLTEtMC90ZXh0cmVnaW9uOmM2MTA1OWZmZDRhOTQ5OWViMjc2MTU1Y2FlYjhkNzA3Xzc2OTY1ODEzOTQ0NjI_4b3d006c-def6-4709-b86d-4fe63cf42e55"
      unitRef="cadPerShare">3.01</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMS0xLTEtMA_eabbab86-727c-4ce6-8d13-5ae8589694e7"
      unitRef="shares">459730</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i1865037223514d83939793fbf4bc69ec_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMi0xLTEtMA_26da5352-4584-4af3-b20e-ac8384d8bc38">P4Y5M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItMy0xLTEtMA_239f52be-7672-422b-8c25-0d0f9540b3ae"
      unitRef="cadPerShare">2.66</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItNC0xLTEtMA_6965a74a-1bc1-4ec3-8ea3-00cff2fff406"
      unitRef="shares">289730</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i243fd602ca4d4b4186f5aa8a2dad7e45_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzItNS0xLTEtMA_523d8ae7-acd8-4341-ae12-c982ea5891d6"
      unitRef="cadPerShare">2.68</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="ib597056817fd4c54bf70bc918648c2e4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmJiMDkwMDdjNDJmNDQzMGNhZDA0ZGI0OTNlYzMzOGFkXzc2OTY1ODEzOTQ0NTQ_c58f31ec-bbf0-4f9c-adad-6ac54a5b4154"
      unitRef="cadPerShare">3.02</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i34d5b6c5f2e84005a152b1904fe0c190_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMC0xLTEtMC90ZXh0cmVnaW9uOmJiMDkwMDdjNDJmNDQzMGNhZDA0ZGI0OTNlYzMzOGFkXzc2OTY1ODEzOTQ0NjI_4b52ebf3-f34f-4126-8d3c-4675bf9c18cb"
      unitRef="cadPerShare">3.90</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="id8643920cc194ebb907287f7a4b18747_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMS0xLTEtMA_fdb0e4ce-db8e-4384-a39c-2267bbb1ff81"
      unitRef="shares">1834706</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i58518506fee64ab482067aea42680848_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMi0xLTEtMA_5984111a-3735-4a99-9b6b-c771b409fdfb">P3Y10M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="id8643920cc194ebb907287f7a4b18747_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtMy0xLTEtMA_381ae3d0-2b2c-47e6-8917-0524c12c16ce"
      unitRef="cadPerShare">3.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="id8643920cc194ebb907287f7a4b18747_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtNC0xLTEtMA_03b463d0-0c5d-4880-83f8-0829f89c45ad"
      unitRef="shares">769696</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="id8643920cc194ebb907287f7a4b18747_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzMtNS0xLTEtMA_3c2d64fa-2829-4acb-b5c6-c84692b27eda"
      unitRef="cadPerShare">3.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i36557f93937d4dfb8b9c2f7b122eec39_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU3MGVmN2YyYjY3OTQ4OGU4MWY2NjFlMzkwMzg3YzJlXzc2OTY1ODEzOTQ0NTQ_4122973c-53f2-41d8-a9ee-61ad083ffe5c"
      unitRef="cadPerShare">3.91</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i0895434d6a7f4a60aa00d05659a746fb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMC0xLTEtMC90ZXh0cmVnaW9uOmU3MGVmN2YyYjY3OTQ4OGU4MWY2NjFlMzkwMzg3YzJlXzc2OTY1ODEzOTQ0NjI_55b56665-d0d2-4f53-8e0a-4d3484fde46d"
      unitRef="cadPerShare">7.41</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMS0xLTEtMA_f3688eba-9aaf-4b26-bd69-9c7d54f8f281"
      unitRef="shares">493252</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i7e98e8622faf479ca1780f0865b894c1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMi0xLTEtMA_bcdd658f-7b26-44e8-9f0b-c8677307c343">P2Y8M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtMy0xLTEtMA_bbeaf72d-cb70-46c0-8d2b-89659411727b"
      unitRef="cadPerShare">6.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtNC0xLTEtMA_0271604a-e143-4c57-b55d-46db216d228c"
      unitRef="shares">392082</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i31f893a9adab4729a2352e2afd1e63c0_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzQtNS0xLTEtMA_32b05ea9-7932-4fc1-95f1-6e59e2208dd8"
      unitRef="cadPerShare">6.02</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i88f71c7cf6714950bc9da0b9936fb3bc_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjRlNTkwODczZmM0MDQ3M2FhMWYxYTMwODU2YjJlMGVkXzc2OTY1ODEzOTQ0NTU_75572ca3-1571-4a7e-9545-729282e40e45"
      unitRef="cadPerShare">7.42</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i43b192cb3fe24ee0bb059e2280534d09_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMC0xLTEtMC90ZXh0cmVnaW9uOjRlNTkwODczZmM0MDQ3M2FhMWYxYTMwODU2YjJlMGVkXzc2OTY1ODEzOTQ0NjQ_2f375d55-d412-4441-9027-3b44327f8d29"
      unitRef="cadPerShare">52.63</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMS0xLTEtMA_4af1148d-55c0-4705-8769-f6608ca7dd1c"
      unitRef="shares">168034</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i3fc681ffda9640f2a837978353fda2e8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMi0xLTEtMA_4b921482-dfd5-456b-bba4-187ad3a38b19">P2Y3M25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtMy0xLTEtMA_d39fe179-d033-4540-9a46-e198a498223d"
      unitRef="cadPerShare">24.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtNC0xLTEtMA_29de37dd-7981-45fb-a2b3-2c0673cf76a0"
      unitRef="shares">168034</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i58548a49e4354d74a2b5d68a41fb1ecf_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzUtNS0xLTEtMA_10ef9192-ae60-4021-9d03-21f6206c0a9d"
      unitRef="cadPerShare">24.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMS0xLTEtMA_d7e467d3-5bfe-4af4-8988-9b8e1e486c92"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMi0xLTEtMA_120ad387-218d-49d0-bd3b-2cabb4d1b9c0">P3Y6M10D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtMy0xLTEtMA_6c4e9ee8-71a8-422f-98ec-d4d677386a17"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtNC0xLTEtMA_5e97b545-3e5d-48ac-80c0-d347e385e91c"
      unitRef="shares">2164551</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTpiYTQyYzI2NjliZWI0MzNjYTE3NzhjYTViZTE2YzJhMy90YWJsZXJhbmdlOmJhNDJjMjY2OWJlYjQzM2NhMTc3OGNhNWJlMTZjMmEzXzYtNS0xLTEtMA_8120a537-7755-430d-9287-fc230d0ff969"
      unitRef="cadPerShare">4.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="idc04adeb60ac4cd197686969029179ea_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1OA_25612117-0b98-4f8a-af90-0cb098b0f0ae">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0OTE_a9456ef0-df70-4569-9ab2-75812fada8b2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:348.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:181.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.02%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected hold period to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMS0xLTEtMA_b0c8d902-7aa3-4177-a404-c121eeae9ac7"
      unitRef="number">0.0034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMi0xLTEtMA_1ed2779d-1d2b-48c2-b4fd-ab6e3e97aa45"
      unitRef="number">0.0162</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzEtMy0xLTEtMA_ba099eba-784a-4369-aa0e-a0d1ad575285"
      unitRef="number">0.0202</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMS0xLTEtMA_ac07650d-375a-4135-a685-100c4eeeacec"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMi0xLTEtMA_8ac3ad05-ba7e-41fe-b731-f1c56900c279"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzItMy0xLTEtMA_21ce61de-7bff-4295-9b49-9dcc03652984"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMS0xLTEtMA_10f9145f-733b-4859-af6b-c01f9953c288"
      unitRef="number">1.1082</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMi0xLTEtMA_502208cd-f0e4-454b-b136-abb9c9c0fc0b"
      unitRef="number">0.979</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzMtMy0xLTEtMA_61a6cf84-f220-43be-ae11-fc7b5a01e2bd"
      unitRef="number">0.8115</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <oncyf:ExpectedForfeitureShareOptionsGranted
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMS0xLTEtMA_383c68d2-8816-4c30-a603-7a44a6191537"
      unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
    <oncyf:ExpectedForfeitureShareOptionsGranted
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMi0xLTEtMA_921f015e-e02e-4a88-923f-ab7fd0ff7ae8"
      unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
    <oncyf:ExpectedForfeitureShareOptionsGranted
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzQtMy0xLTEtMA_dd8dc09a-0822-4f86-94b6-e5b5dfa945a9"
      unitRef="number">0.0367</oncyf:ExpectedForfeitureShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMS0xLTEtMA_52ade50c-4051-4945-be19-716e16622044"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMi0xLTEtMA_cd1bb686-0f80-46df-bc43-362dd4593976"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzUtMy0xLTEtMA_dd0f5910-b61d-423e-9072-35e53fe9f454"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMS0xLTEtMA_e5db8d55-78c8-4a96-9f78-4ab6f480d22b"
      unitRef="cad">2.12</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMi0xLTEtMA_ca31a80a-1e4f-492e-b911-aad18996951f"
      unitRef="cad">0.87</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo2ODdlNDA3OTNhYjM0N2Q4OGQ0MmQzNzU2M2QxNWQyNC90YWJsZXJhbmdlOjY4N2U0MDc5M2FiMzQ3ZDg4ZDQyZDM3NTYzZDE1ZDI0XzYtMy0xLTEtMA_70c5c38c-ece4-4745-b183-83d0be97d61c"
      unitRef="cad">2.67</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0Nzc_fd7a1a4d-8fa0-44fc-965b-57c311174b3e">The following RSUs are outstanding at December&#160;31:&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:199.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154,923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;         (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35).&lt;/span&gt;&lt;/div&gt; The following PSUs are outstanding at December&#160;31:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:204.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMS0xLTEtMA_c3324679-bd9f-49cb-a4ab-a91c96738ae7"
      unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5a75edaede244932b30bf68f09001b73_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMi0xLTEtMA_b2ebdf1c-3027-48e0-9037-54afe7d2419f"
      unitRef="shares">260755</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibda3a9497dd94381bf80f0a2b9616cad_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzEtMy0xLTEtMA_c568a241-4824-404d-833e-d2ea93e58e69"
      unitRef="shares">190407</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMS0xLTEtMA_ece2965d-790d-403d-96dc-f9dad5a59315"
      unitRef="shares">154923</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMi0xLTEtMA_f5e69ee6-2166-4eb1-b76b-41a6ec8a507b"
      unitRef="shares">270098</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzItMy0xLTEtMA_10efeb50-1415-46df-88fd-f43625971324"
      unitRef="shares">102855</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMS0xLTEtMA_e549ad42-eb29-4bdd-a87e-ebaf0528b125"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMi0xLTEtMA_07eb41f3-64cd-4760-a24b-9cb6723961cf"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzMtMy0xLTEtMA_684fa783-c16a-4cf1-b67e-f62e471bb36e"
      unitRef="shares">4210</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i1546fe6ef3e2423b95f5332d83ed167f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMS0xLTEtMA_fe658722-3b0c-4e02-95aa-ea47280fe25f"
      unitRef="shares">229962</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5bd4a9de891f4c6096a0e8f642dcc1e4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMi0xLTEtMA_d5008b85-ed60-4e83-bc79-1df128c275a5"
      unitRef="shares">321196</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ic5661766048540b6a4217ef7021adea7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzQtMy0xLTEtMA_6cd620c0-7ddb-4a17-aa17-861a40ed0f64"
      unitRef="shares">28297</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i9be04968d7ac45418925f2727fd67f7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMS0xLTEtMA_76674d6d-e511-4d6e-9a5b-b7fe2e6f7c04"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMi0xLTEtMA_6f1c2d09-e31a-43bf-88a5-ded17613b90d"
      unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5a75edaede244932b30bf68f09001b73_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTo4N2VkZDNhMTA4NzM0NTBhOGZlYzg0YWEzOGNkZmQ0MC90YWJsZXJhbmdlOjg3ZWRkM2ExMDg3MzQ1MGE4ZmVjODRhYTM4Y2RmZDQwXzUtMy0xLTEtMA_d5ca453c-ac0d-4997-88cd-b05f1c91b58b"
      unitRef="shares">260755</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i9be04968d7ac45418925f2727fd67f7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1Njc_d1f35bdb-7a82-43a5-8241-6c47f3ae3d2c"
      unitRef="cad">2.41</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i26c471998cb54e5198f60c7e8a879104_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1ODI_84cba693-7e36-4c27-9bb3-233d8e43f343"
      unitRef="cad">0.80</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i5a75edaede244932b30bf68f09001b73_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE1OTI_bd6af722-7a71-4321-b956-c0f720be4174"
      unitRef="cad">3.35</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4MTE_f833a0c3-a387-4267-ae26-956ad3274438">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iff34051430c94f87baaf766281ba7412_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMS0xLTEtMA_61d2f9e5-7adb-43cc-bf44-c25cd4a35a41"
      unitRef="shares">61051</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMi0xLTEtMA_f16a240d-1865-49a3-844d-5f740c84b488"
      unitRef="shares">63156</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i2899ca476be7407391ff311c63456837_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzEtMy0xLTEtMA_09ffe0a5-623e-4ec0-a3d5-2aa8ff83417a"
      unitRef="shares">94734</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMS0xLTEtMA_f6218389-da80-4563-abd7-fbe719b8aec2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMi0xLTEtMA_bcd147c5-68bf-44e8-a7fe-185fa2d99de4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzMtMy0xLTEtMA_acb80aa0-1f7e-421e-b9e0-520aef35e4c7"
      unitRef="shares">31578</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5bc329880974490ba642d02fc3ec0cc2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMS0xLTEtMA_c49202f4-0c64-4cc4-a62d-e476c30ff94b"
      unitRef="shares">4210</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="iad24391fa93f4704a6b1f5acc893ae25_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMi0xLTEtMA_401934e3-e0f1-45fb-95b9-4c2a3585c15f"
      unitRef="shares">2105</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ie2dfad94253547bf935ed53ca62fb801_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzQtMy0xLTEtMA_8fa7104f-8efe-4920-8133-8659dd7dc07b"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i67bdbb4f6a5e46ceb26e20c137bccd91_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMS0xLTEtMA_c2394d95-fa70-42e0-b862-664d3be31d4c"
      unitRef="shares">56841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iff34051430c94f87baaf766281ba7412_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMi0xLTEtMA_cda7d3d8-eb60-4f07-9bfe-14ec72c5d1f7"
      unitRef="shares">61051</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4398b37a6f344c62bb88aaaa6d3d3d9f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90YWJsZTowMTNiZTM4OWE1NTk0YmE2YTk2MWUyNzZjN2ZkZmVlMS90YWJsZXJhbmdlOjAxM2JlMzg5YTU1OTRiYTZhOTYxZTI3NmM3ZmRmZWUxXzUtMy0xLTEtMA_131935d9-08dd-4f2b-a0fc-4d05d159ebaf"
      unitRef="shares">63156</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="ie5fe69759d8547afa04be2fd7beb55b4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzIyODI_6c0dcd9e-a33c-40db-8a72-b6faff294189"
      unitRef="shares">4616698</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NTQ_41eda25e-a1b3-4899-8edc-c0858a81091b"
      unitRef="cad">2558974</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NjM_c8c35165-622b-48cf-a46e-049a1d385757"
      unitRef="cad">1470153</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzI0NzI_8418b651-c1a3-4129-b4c2-896365a7cfb1"
      unitRef="cad">1415833</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzQxNQ_362f7d5f-7466-4b23-bcd9-2dcbee1ff7e1">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2020 of 40,338,789 (2019 - 22,137,990; 2018 - 16,016,366). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE4OA_b699c798-4092-4168-8a8c-be31ebbce2c5"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE4OA_cbd5b67f-10ad-4a47-8d21-fd68013d5cc5"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE5Nw_52da9c68-ff2c-439a-a459-0d9c2e4f6434"
      unitRef="shares">22137990</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzE5Nw_a5a1ce02-c5f5-4447-8d8d-fb50605bba93"
      unitRef="shares">22137990</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzIwNg_817edb81-9af4-49ec-aa91-752a02aeaf95"
      unitRef="shares">16016366</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzgvZnJhZzpmZGMwYTA1NzBlN2U0ZTE5ODJhMmJjMDliMTgyN2VjNS90ZXh0cmVnaW9uOmZkYzBhMDU3MGU3ZTRlMTk4MmEyYmMwOWIxODI3ZWM1XzIwNg_cc4b8b70-3a1c-4afa-b993-6aa5a2e73f3b"
      unitRef="shares">16016366</ifrs-full:WeightedAverageShares>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzEyMTY_1e4eb6aa-1670-4df7-8c2a-852f96d8646c">Contract Liability and Receivable&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at December 31, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:175.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:78.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzEyMTk_517fb237-b74f-4842-9a12-c76cb47d4bd0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at December 31, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:175.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:78.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized in the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730,287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <oncyf:ContractLiabilityRecognitionPeriod
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90ZXh0cmVnaW9uOmIzYjcwN2MwYjBkNDRmNmM5NTg3YTc0MThiMGNmYjI4XzExOTQ_b0d7db65-19ae-4a15-96ba-9eb980cf5b8e"
      unitRef="year">5</oncyf:ContractLiabilityRecognitionPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzEtMS0xLTEtMA_4e56abb0-34ce-494c-9aee-c7522931f004"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzEtMi0xLTEtMA_ec7c380d-8d59-4928-88f8-28e7343aedb5"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzItMS0xLTEtMA_9006e707-3c2a-49b6-a5c7-82d45c2d56dd"
      unitRef="cad">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzItMi0xLTEtMA_d6c4dd76-5ede-4388-905a-6a59ef92b3a1"
      unitRef="cad">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzMtMS0xLTEtMA_d78fbd04-0311-4e03-8b63-62c1da319382"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzMtMi0xLTEtMA_33d4103e-aa25-4a9c-987e-16d37ad9f9e6"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzQtMS0xLTEtMA_cfba1e94-3be9-4d23-96c5-0e7aeac03680"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzQtMi0xLTEtMA_aa940519-3a31-4667-a502-975076bd28e2"
      unitRef="usd">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzYtMS0xLTEtMA_6d29287f-2f93-4c3e-9d17-cab3fbd6fcdf"
      unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzYtMi0xLTEtMA_44a19391-a3e3-4f6a-a1aa-889d79f8836d"
      unitRef="cad">0</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzctMS0xLTEtMA_d8ae2179-a57a-41c7-b4e8-750ec0ba34ea"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzctMi0xLTEtMA_d6bd36ab-a51d-4583-92a2-9ffb5a5cfd35"
      unitRef="cad">6730287</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzgtMS0xLTEtMA_187df005-bb22-48bd-9374-72f34a1b40a0"
      unitRef="cad">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODEvZnJhZzpiM2I3MDdjMGIwZDQ0ZjZjOTU4N2E3NDE4YjBjZmIyOC90YWJsZToxYWVhZmM0ZmE5OTE0MjQ5YTBlODdiYTRmYzQ0NzRiMC90YWJsZXJhbmdlOjFhZWFmYzRmYTk5MTQyNDlhMGU4N2JhNGZjNDQ3NGIwXzgtMi0xLTEtMA_9462f62c-9bd3-4961-85c1-547a00f9c9cc"
      unitRef="cad">6730287</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzEyMjM_61b57c0e-2a72-4a20-862a-c8faecbff16c">Commitments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are committed to payments totaling $9,360,653 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our commitments include the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December 31, 2020, we recorded nil (December&#160;31, 2019 - US$1,500,000) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$97,381 (December&#160;31, 2019 - US$652,306) in other liabilities representing future trial costs to be incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under a clinical trial agreement entered into with the Alberta Cancer Board (&#x201c;ACB&#x201d;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <oncyf:PurchaseObligation1
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY2_b339a7dc-a367-4bba-b0b3-c3aa17faead0"
      unitRef="cad">9360653</oncyf:PurchaseObligation1>
    <oncyf:PurchaseObligationCommitmentTerm
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzc2OTY1ODEzOTU4NDM_c12d854b-66a3-4feb-ac59-5b5b3d934367">P2Y</oncyf:PurchaseObligationCommitmentTerm>
    <ifrs-full:OtherReceivables
      contextRef="ia0330059b7334744a4426087fd12ceff_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzUwMQ_7214e03c-59d2-4969-b89c-582ebc3296f8"
      unitRef="usd">0</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="i5fd64c7e97d84e4588d426a71091008b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzUxMA_fb012471-a522-40b5-be2c-80c964e39663"
      unitRef="usd">1500000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="ia0330059b7334744a4426087fd12ceff_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY2Mw_0a8e0225-e942-441c-879d-358bf4b9e386"
      unitRef="cad">97381</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i5fd64c7e97d84e4588d426a71091008b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzY3Mg_bfa69cc3-2388-4420-97b8-35148c0b5625"
      unitRef="cad">652306</ifrs-full:OtherCurrentLiabilities>
    <oncyf:FundedandRoyaltyRepayment
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzk1Mg_17b93d0a-d6fe-4ea3-87ed-dcaa4f6e3b3d"
      unitRef="cad">400000</oncyf:FundedandRoyaltyRepayment>
    <oncyf:OverheadRepayment
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1Xzk4NQ_1932423c-7d5e-4942-9555-d17cfb6b2383"
      unitRef="cad">100000</oncyf:OverheadRepayment>
    <oncyf:AnnualContingentPaymentGrossSalesPercent
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzExMTY_f3c5d176-b90f-4568-ba4d-f185a8164ab4"
      unitRef="number">0.05</oncyf:AnnualContingentPaymentGrossSalesPercent>
    <oncyf:AnnualContingentPayment
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODQvZnJhZzplMmQ3MGZhM2EwZWM0NWY3YjdhZjhiZjNkMmI1MjA5NS90ZXh0cmVnaW9uOmUyZDcwZmEzYTBlYzQ1ZjdiN2FmOGJmM2QyYjUyMDk1XzExNjU_cb357b3d-1909-4418-a27f-7ad20ac1c864"
      unitRef="cad">100000</oncyf:AnnualContingentPayment>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzIwNTc_dd60c969-3304-4434-b1b0-060dfec5c8c1">Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assumption Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 1999, we entered into an agreement that assumed certain obligations (the &#x201c;Assumption Agreement&#x201d;) in connection with a Share Purchase Agreement (the &#x201c;Share Purchase Agreement&#x201d;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2019 - 10.75%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2019 - 2.15%) of Net Sales received for such products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BRI &#x201c;Work in Kind&#x201d; Contribution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#x201c;BRI&#x201d;).&#160;The terms of this agreement include a &#x201c;work in kind&#x201d; contribution from BRI.&#160;In exchange for this &#x201c;work in kind&#x201d; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of 0.5% of Sales Revenue or $20,000 per year until December 31, 2028.</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzM4MQ_39c0bb2b-3b59-4e12-90ec-5ab4f1a5a05c"
      unitRef="cad">1000000.0</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue
      contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzM5Ng_229f07c1-4903-470c-849a-a16c4d71aca7">P90D</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage
      contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzExMDU_0519be78-5368-40aa-97b3-a3d1f4bdc1d1"
      unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage
      contextRef="iedf7891a1e984661bf760a99c195c570_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzExMTQ_f8ebb128-33b2-49eb-9b2e-4aa9c275029e"
      unitRef="number">0.1075</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage
      contextRef="ifc6e7737a72349bba2b7d231800c02d4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzEzNzU_0b35968f-4341-4291-ba89-5fd665f50cb0"
      unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
    <oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage
      contextRef="iedf7891a1e984661bf760a99c195c570_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzEzODQ_bc5a34b0-f6dc-4271-9d55-eb00347b6baa"
      unitRef="number">0.0215</oncyf:CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage>
    <oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzE4NDE_a204041a-15c7-44d2-a32c-8801e605a9a4"
      unitRef="number">0.005</oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue>
    <oncyf:ContingentRoyaltyPaymentAnnualMaximum
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTAvZnJhZzo4ZmY1NmZhOTBkNzU0MjdmYTQ1NmU2MzFjYWRkNjNkNS90ZXh0cmVnaW9uOjhmZjU2ZmE5MGQ3NTQyN2ZhNDU2ZTYzMWNhZGQ2M2Q1XzE4NjQ_a39681db-40dd-441a-9022-46eb738bbe65"
      unitRef="cad">20000</oncyf:ContingentRoyaltyPaymentAnnualMaximum>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNjc_0210a72d-b816-4721-8b4f-7190dabc4706">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:437.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:235.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22,505,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,122,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,489,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,401,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,777,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,452,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign jurisdiction tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,237,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,088,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,312,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;614,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(838,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Alberta rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to opening tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax benefits deemed not probable to &lt;br/&gt;  be recovered&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,161,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment in respect to prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2020, we have the following non-capital losses for income tax purposes in Canada:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,809,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78,994,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:142.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,304,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#x2019; taxable income of approximately $27,660,000.&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:459.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:256.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,487,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,625,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,664,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,362,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,406,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,068,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,927,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,949,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;689,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,541,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,712,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,712,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNzI_a36ebb1c-36c8-4477-93ed-e303d85e54b5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:437.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:235.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22,505,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,122,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,489,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,401,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,777,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,452,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign jurisdiction tax rate difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,237,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,088,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,312,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;614,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(838,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,341,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Alberta rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,758,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment to opening tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax benefits deemed not probable to &lt;br/&gt;  be recovered&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,161,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment in respect to prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
    <ifrs-full:AccountingProfit
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMS0xLTEtMA_69584d96-7537-4b10-9231-05aacd455a8d"
      unitRef="cad">-22505057</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMi0xLTEtMA_7b6db189-df81-4393-882a-e45c19f2f784"
      unitRef="cad">-33122888</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEtMy0xLTEtMA_a9992191-0a1f-4a15-b500-3e53ceb6b305"
      unitRef="cad">-16489183</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMS0xLTEtMA_bec4509f-4c49-449b-b4a8-a9903624f83b"
      unitRef="number">0.2400</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMi0xLTEtMA_59e4e482-6979-40f5-bdc9-7e4a1b9c990d"
      unitRef="number">0.2650</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzItMy0xLTEtMA_1cd95616-4820-4086-9ccf-1f11fef08c6e"
      unitRef="number">0.2700</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMS0xLTEtMA_e7024e37-15db-434e-a245-017a71eef2b6"
      unitRef="cad">-5401214</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMi0xLTEtMA_81470e7b-826c-4558-9f81-73934171fb2c"
      unitRef="cad">-8777565</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzMtMy0xLTEtMA_bbcf544a-e709-44cb-be25-a6c4b3bf99d5"
      unitRef="cad">-4452079</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMS0xLTEtMA_bf192926-83b5-4471-bb56-b6ba82259deb"
      unitRef="cad">3237898</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMi0xLTEtMA_1111fe22-e60e-493c-839d-77ded6aa028e"
      unitRef="cad">3088811</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzQtMy0xLTEtMA_e36d2c06-7ceb-4dde-a7ff-1330d41ea409"
      unitRef="cad">3312963</ifrs-full:TaxEffectOfForeignTaxRates>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMS0xLTEtMA_7b7b28c6-b01d-4bc4-9751-0a1dce0480e4"
      unitRef="cad">-614154</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMi0xLTEtMA_6c007329-6b4a-4092-af08-4adf7618c0a6"
      unitRef="cad">-389591</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzUtMy0xLTEtMA_4d6a8362-79b2-47bc-a120-8459e755f23d"
      unitRef="cad">-382275</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMS0xLTEtMA_936671aa-9b89-4b2c-a222-f78c60070c48"
      unitRef="cad">-838063</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMi0xLTEtMA_764a676e-98a2-4a78-ae80-740953d12134"
      unitRef="cad">3341334</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzYtMy0xLTEtMA_c1d384cf-523e-45d2-8984-633510d7f798"
      unitRef="cad">0</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMS0xLTEtMA_dc221704-38a7-4578-b142-120b6a4fb59c"
      unitRef="cad">96028</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMi0xLTEtMA_f6925983-6bc6-49e5-a07e-b18a62a9a804"
      unitRef="cad">3758175</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzctMy0xLTEtMA_18a2f997-c373-43c7-b602-c5a03ea1e8d5"
      unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <oncyf:TaxEffectOfTaxPools
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMS0xLTEtMA_e71ac777-9ba9-4a29-a798-1cc905dd84d9"
      unitRef="cad">20711</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMi0xLTEtMA_99a55f66-3150-477e-8179-786183340905"
      unitRef="cad">11973</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzgtMy0xLTEtMA_22a707b3-a297-4de7-804e-39e9c1aa5199"
      unitRef="cad">-238222</oncyf:TaxEffectOfTaxPools>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMS0xLTEtMA_466eeeae-ea54-4bec-a840-bbd3e41ae91f"
      unitRef="cad">108945</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMi0xLTEtMA_112ee8ec-705b-443e-88f6-450e2c6101d1"
      unitRef="cad">149294</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzktMy0xLTEtMA_ab548204-38dc-49ed-937c-efcf2aed7744"
      unitRef="cad">-35912</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTEtMS0xLTA_12d497fa-50a0-4997-bbce-b59234d16848"
      unitRef="cad">-2161541</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTItMS0xLTA_f105cf9d-4fc6-4389-9126-111bbec205ae"
      unitRef="cad">1961613</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEwLTMtMS0xLTA_3a2f10f1-9cbd-47f0-bfad-1220aa3b4f4a"
      unitRef="cad">-1579017</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTEtMS0xLTA_0b78bcb1-d3da-4be2-bfda-3f852cfe4846"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTItMS0xLTA_2bbda7b7-36dc-4c22-857d-45ec07dadb1f"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzExLTMtMS0xLTA_b7686fac-8e9f-4312-a640-3368f8373fd7"
      unitRef="cad">548042</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTEtMS0xLTA_ebbeed72-0c43-48f2-b518-8b93e945dbd4"
      unitRef="cad">0</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTItMS0xLTA_31871b42-30d6-4d7e-94f3-29916d5dbeb6"
      unitRef="cad">0</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEyLTMtMS0xLTA_c65739a7-50d2-46fd-b3eb-0a7949392196"
      unitRef="cad">0</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTEtMS0xLTA_2b2e06eb-bead-4bcc-87b1-be84e77759d2"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTItMS0xLTA_b2fdaf92-4933-4e28-9adb-46d15784f2dc"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTplMTU4ODZiNTBjZTQ0OTRlYTY5MzI2YzZkMmRkYTRkZS90YWJsZXJhbmdlOmUxNTg4NmI1MGNlNDQ5NGVhNjkzMjZjNmQyZGRhNGRlXzEzLTMtMS0xLTA_912daa62-1a78-4dfa-87ff-370b7e72bc24"
      unitRef="cad">548042</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzEwNjQ_6cb98a82-fb44-4534-80a4-b9d5af0ea114">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2020, we have the following non-capital losses for income tax purposes in Canada:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,809,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,873,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,430,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,812,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,056,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78,994,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:142.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,304,980&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:459.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:256.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:64.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,487,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,625,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,664,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,362,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,338,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,406,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,068,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,222,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undepreciated capital costs in excess of book value of property and equipment and intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,927,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,949,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;689,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,541,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,712,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,712,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i36ad307898ce427b8790187e5e3b200c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEtMS0xLTEtMA_bcac7bd7-61b5-4772-9542-a8a4d92b8453"
      unitRef="cad">9809000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i54d89438e9834962b588ec713f9cd690_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzItMS0xLTEtMA_3f7a276b-bb8b-4cac-8e7e-958acb5b959c"
      unitRef="cad">12170000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ifd3f0138f46c4695ad37fbc8f2fdd536_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzMtMS0xLTEtMA_c872ed86-4293-4883-9a72-7cee7ca89082"
      unitRef="cad">4009000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ibf141931e3d34eaa866f4acef645b42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzQtMS0xLTEtMA_bd88a448-dd86-460c-9725-84ca27e04507"
      unitRef="cad">4774000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ifed0ad348c7d44b8a47c4217a6d28e36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzUtMS0xLTEtMA_0e3a98ef-33e7-4ad7-9b36-179b09163c4f"
      unitRef="cad">4343000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i38a469cc0b8945629f3b38ad881e0e5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzYtMS0xLTEtMA_e77586d1-4b80-41af-aa08-835c04d3b9c7"
      unitRef="cad">2873000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ia09469d6bdcf47b6bcfcf25aee7cb4b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzctMS0xLTEtMA_2da74d0c-f55f-4fd6-829f-5c70735a2b76"
      unitRef="cad">2457000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i39ac27a554b240599f9bd777a1fc6041_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzgtMS0xLTEtMA_1b43d2d5-3200-43ee-8629-87dcf9dd0afc"
      unitRef="cad">2472000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i7ca105778fa3488ab4fcac5815684208_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzktMS0xLTEtMA_490539bc-bf00-4487-8c2a-328c1c8add6a"
      unitRef="cad">3125000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i8eca0e1194124e76a337dbb158229685_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEwLTEtMS0xLTA_867a4364-a569-462e-ac7d-b9983e8f0d6c"
      unitRef="cad">6430000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="if6b678dac805480d81678cec8ff97f34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzExLTEtMS0xLTA_8cd0769e-19e9-48b7-a672-c2d8bc024fe6"
      unitRef="cad">4812000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="id2a1e703d63441b4bd16a9d814bd0759_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEyLTEtMS0xLTA_b3551c9c-0e4a-403e-89a7-02f6395c2c16"
      unitRef="cad">5056000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i60114d1ecfaa437a904d6c5f10744623_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzEzLTEtMS0xLTA_4d7e2810-1925-4853-ad23-533f01ca3c09"
      unitRef="cad">6864000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i060c05e904e543c0b502d08304c1d52c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzE0LTEtMS0xLTI4NjQ_a25f2361-55cf-465a-a977-3e9ddfe83077"
      unitRef="cad">9800000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ibd0824dc040346089bbc41d9b1bc5c4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5N2MyNzJiZjAwNTI0ZTBjYTk5ZTIyMDcyZWJjYTI4Ny90YWJsZXJhbmdlOjk3YzI3MmJmMDA1MjRlMGNhOTllMjIwNzJlYmNhMjg3XzE0LTEtMS0xLTA_4635772b-6aec-4f84-bff5-555de198c3fd"
      unitRef="cad">78994000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i12e526825a3a4c41ad8c2653148296cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzItMS0xLTEtMA_aca6f729-c45a-4758-ac2c-82f04699d9d4"
      unitRef="cad">471000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i7656abe4911c4cfdb005eaabc3cad80c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzMtMS0xLTEtMA_2d2f8250-cd21-4093-a9ba-9d0dbf2b2863"
      unitRef="cad">465000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i0965b8657ffb499a9cb5db812656c63f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzQtMS0xLTEtMA_e42defd8-1cfe-477a-af9a-25b9e9ffe6bc"
      unitRef="cad">361000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="id63c5c00c60c4df1a2140b12e0626f97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzUtMS0xLTEtMA_ca7a4165-c81e-47eb-ac4d-548fabfd0c90"
      unitRef="cad">228000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i23653b0174744934a761bcc2fb2c6c28_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzYtMS0xLTEtMA_810a4653-95a9-4ed6-8b4a-5c95cc645879"
      unitRef="cad">271000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i157e9a3c5d344966b0455389eb83448b_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzctMS0xLTEtMA_90b50cd3-b8ca-46a0-965d-5d1a713566aa"
      unitRef="cad">520000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="iaa85527afb2a4cf99bce5e48d4143c65_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzgtMS0xLTEtMA_a037ece9-36f9-4074-b468-ad02adf79a5f"
      unitRef="cad">596000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i10628d338fe649f8be7f5a4c729aff30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzktMS0xLTEtMA_c945de69-8512-4fc8-8542-2c9d538fdf19"
      unitRef="cad">622000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i94e7b2e1b5084522b265069419c11268_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEwLTEtMS0xLTA_3cd5af40-f4d0-44ee-b8ed-24ee886fef1a"
      unitRef="cad">173000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i4a4b9c9d6c38474ebcd1343720d274a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzExLTEtMS0xLTA_a26614d1-59e7-43ac-81af-6a0e65a9246e"
      unitRef="cad">91000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i6adeb07951ec41eb8fba6df6d47342b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEyLTEtMS0xLTA_f0acff0f-90f4-4edc-8d7b-ddf4549361e7"
      unitRef="cad">114000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="id0637845ec63458e85e2cbae28f8f5d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzEzLTEtMS0xLTA_f4c5ca7e-d7b6-4840-9804-1676913d8084"
      unitRef="cad">381000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i7c77b28bdcf1403cb5d35cd988bdcfe7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE0LTEtMS0xLTA_77597496-fb75-4790-88ec-eb2442f271ae"
      unitRef="cad">487000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie9ad5f87e7304d85bd63633afc56fe8a_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE1LTEtMS0xLTA_aa9a1785-88c1-41bd-a84d-14aff2768f67"
      unitRef="cad">270000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i871337f4238f4abd9e90092d1f02384e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE2LTEtMS0xLTA_d3b0b3d8-02ee-4d52-8b0f-3df7553b4099"
      unitRef="cad">183000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="iababe61944e54b2c9ceccc57bf2faecf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE3LTEtMS0xLTA_fee26d29-f493-40a4-b946-3c348013e523"
      unitRef="cad">41000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie482d3a1b82148c1bd56712a715af083_I20201231"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE4LTEtMS0xLTA_470204be-70ca-4595-9599-a19957e8497c"
      unitRef="cad">980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i7801864cfd79494a9a797845cc05d6ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE5LTEtMS0xLTA_ce696c45-cfaa-45c0-aa93-2fc16f41a70d"
      unitRef="cad">22000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="iab3c42e6c6fd41feb4b54f0b9082e910_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzE5LTEtMS0xLTI4NzI_bbdd883e-23a5-473a-ab10-451e20e64437"
      unitRef="cad">8000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo2Y2I5MjA5MTE4YTU0YTMwOTE5Y2M1ZDk5M2FkYTVlOC90YWJsZXJhbmdlOjZjYjkyMDkxMThhNTRhMzA5MTljYzVkOTkzYWRhNWU4XzIwLTEtMS0xLTA_7fa0316a-f6df-480c-abe3-830162d9748f"
      unitRef="cad">5304980</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90ZXh0cmVnaW9uOmI3YTM3OTFjYTcyMzQ2YzM4ZTVjNTQ4ODE2NTg3YTgwXzYzMg_00386e26-d806-47ef-b6f5-16086e17f29f"
      unitRef="cad">27660000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i79faad7289cd45f58106ae2fdd652ec1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMS0xLTEtMA_7075a683-f2ed-4c92-a115-dd39ec36a996"
      unitRef="cad">21487804</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i56e6aac06972419c9ec828611697e6f7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMi0xLTEtMA_d6d91640-0c2d-4208-83f1-ad78b3036026"
      unitRef="cad">19625642</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i8378abfb369e439497cb8d7d53a35bf7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzEtMy0xLTEtMA_47be8576-b5b3-4836-a4f9-093ede8375b8"
      unitRef="cad">20664345</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ie32b7f20cab1430f8f4b1b34c8c0f1af_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMS0xLTEtMA_4291c6c1-9f75-4916-a145-1a6c815a75bf"
      unitRef="cad">6362152</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="if898df29e89b4ec3a60df1b042af3863_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMi0xLTEtMA_af3544fc-e4de-4eb4-9cbf-ba161a1b5a0e"
      unitRef="cad">6338542</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ic5cacf4383b8479f8cf65a36c967cae1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzItMy0xLTEtMA_2e74ef8f-d211-4bcc-8c7b-19f92e207756"
      unitRef="cad">7406169</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i9020465658f74f4fbde6469e191a8c40_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMS0xLTEtMA_46a97c42-8d28-43ca-bb9b-859cd3533730"
      unitRef="cad">4068105</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i1a02e778e8c84e928734637cf208bd4f_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMi0xLTEtMA_36566421-b9b8-49ed-914a-abe2034943d0"
      unitRef="cad">4222016</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ibf277f3b07e54dbb8e328eacdafdddbd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzMtMy0xLTEtMA_6b184969-35e3-45ac-aadb-c7e28cc050fa"
      unitRef="cad">3988606</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i4063dfdc87384c3e85d8174c150d31b8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMS0xLTEtMA_aae4d09d-084e-442c-9bce-7896ad255b24"
      unitRef="cad">1927709</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i931661a623914b388fdfa5f4e409ccaf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMi0xLTEtMA_78b3a175-946e-4381-ba57-5328ac821e77"
      unitRef="cad">1908320</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i5b0bf7d64d344c48bd924d075e96c40f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzQtMy0xLTEtMA_1a249c03-9c9f-4256-97a4-4b257289ecef"
      unitRef="cad">1949611</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i658b28d872bd41568deaa26495694e07_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMS0xLTEtMA_436e6989-964f-4715-af19-04930ff67ae2"
      unitRef="cad">689193</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i878f5c4c5d6f4d41947cf6fb9d21cfdf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMi0xLTEtMA_bb8c3218-861c-4724-a2bb-2d4ac5a9e3d0"
      unitRef="cad">611072</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i7b1ca5e55ba34078871b684db87e823e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzUtMy0xLTEtMA_0963b320-63f3-4e8f-bf13-bfcd7f2701e1"
      unitRef="cad">696346</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i15589c7e1a2b491aa913407d6863f338_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMS0xLTEtMA_eaba6a38-becb-4428-8629-0589d6cee79b"
      unitRef="cad">6472</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ia16bc392d6f74d4dbbf71003e9881f32_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMi0xLTEtMA_1659df29-a6c1-4b22-ab1e-a5bddfe4dc5e"
      unitRef="cad">6474</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i17a004d3e9c7446896d6d5d1956caf96_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzYtMy0xLTEtMA_5b34631b-8668-4511-a928-5add265ca2cb"
      unitRef="cad">7598</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMS0xLTEtMA_f081910e-02b2-4afa-b36a-2306c4097303"
      unitRef="cad">34541435</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMi0xLTEtMA_655c33be-e13e-41ec-8938-4a72505a7faa"
      unitRef="cad">32712066</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTMvZnJhZzpiN2EzNzkxY2E3MjM0NmMzOGU1YzU0ODgxNjU4N2E4MC90YWJsZTo5NjI2NWEyNWI2ZjM0MDc3ODI2ZDkzNzA3ZmIwMDQzZS90YWJsZXJhbmdlOjk2MjY1YTI1YjZmMzQwNzc4MjZkOTM3MDdmYjAwNDNlXzctMy0xLTEtMA_c48bc7fd-712d-4baa-ae73-d8ae019df012"
      unitRef="cad">34712675</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzM2OTM_35f02ddc-f1c4-44ea-a4f9-d4894e4305f8">Capital Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#x2019; equity and cash and cash equivalents in the definition of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,219,574&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,148,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,752,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#x2019;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On  June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 9). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <oncyf:DisclosureOfCapitalComponentsTableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzM2ODk_61bbb545-90ca-4d09-bb95-d0c6e976f504">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,219,574&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,148,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,752,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzEtMS0xLTEtMA_64405755-bebe-4d22-9660-2f3ad1fcdd8f"
      unitRef="cad">31219574</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzEtMi0xLTEtMA_5e18efc1-06f3-4f34-b228-63e0e472463a"
      unitRef="cad">14148021</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="i15a34dc52087401598ad74c4d7ac44b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzItMS0xLTEtMA_01e77329-bb5c-44f7-b663-a35b69f809b3"
      unitRef="cad">24752993</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90YWJsZTpkNGZmODlmNDA0OTg0MjY3OGYwMDY3YzNjZDA4MTQyOS90YWJsZXJhbmdlOmQ0ZmY4OWY0MDQ5ODQyNjc4ZjAwNjdjM2NkMDgxNDI5XzItMi0xLTEtMA_46bfcb2d-5fe8-4ae5-991b-2a84cd66e9d7"
      unitRef="cad">-107894</ifrs-full:Equity>
    <oncyf:EquityAuthorized
      contextRef="i8dcb30c64a054057ae8268e11a956cf5_I20200612"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTYvZnJhZzo5MzgwMTBhZWNiYWY0NjI5YTU1ZmViZTc3ZTNmOGY1ZC90ZXh0cmVnaW9uOjkzODAxMGFlY2JhZjQ2MjlhNTVmZWJlNzdlM2Y4ZjVkXzE4NzQ_ffcbdbad-65c9-407b-9a6f-723f88f4f705"
      unitRef="cad">150000000</oncyf:EquityAuthorized>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzM3MjM_bd6f77de-6e79-439e-b837-0026866400df">Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at December&#160;31, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2020, the fair value of our warrant derivative was $531,228 (December&#160;31, 2019 - $8,508,764).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $172,000.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $20,000. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balances in foreign currencies at December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:466.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:165.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollars &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;British pounds&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;br/&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,134,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,347&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417,238)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,261,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i84b52d8638644519af44304507a14d80_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzU1NQ_70f98ff8-1cfd-4e64-a646-b7c51c6921a4"
      unitRef="cad">531228</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i269daa67eeae4597bc0a7db7539e1081_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzU2NA_d2f5d115-1d05-42e1-8533-275fce5aeba7"
      unitRef="cad">8508764</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI2NjU_0be186dd-6d22-464e-a00e-dfa967da6e67"
      unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI4MDg_c1bb2b07-9e69-4e25-960b-8c313d5aac5f"
      unitRef="cad">-172000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI4Mjk_24307a2b-2461-4303-a474-f6c46ad925b7"
      unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="i2b55163e66dd4666b3c7a1810a5c179f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI5NzQ_72654c58-d9af-4ccb-81bf-315585dc4b06"
      unitRef="cad">20000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzI5OTQ_223206ed-2e34-4b0b-a373-40bd8627031b"
      unitRef="cad">0.10</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="i82062b8fa0be4689afb6ffcce9592d43_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzMxMzA_181b7b78-c352-463e-86a2-15d98c28d7f6"
      unitRef="cad">3000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90ZXh0cmVnaW9uOmI2YWMwM2FmMGNjMTRmZmM4NjJiMDYwOTkxZDVlNDYyXzM3Mjc_0185bbf0-e51c-4627-ad82-325a29c2c81d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balances in foreign currencies at December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:466.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:165.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollars &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;British pounds&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;br/&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,134,113&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,768&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,347&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455,588)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,244)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417,238)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,261,287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMS0xLTEtMA_b824bc0b-824e-4182-a938-de6f8d76cd66"
      unitRef="usd">23134113</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMi0xLTEtMA_82002a43-e316-4753-99c5-f96ff63688af"
      unitRef="gbp">26768</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzEtMy0xLTEtMA_7a33c355-f380-4ea1-9ebe-df131285b5d9"
      unitRef="eur">37347</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMS0xLTEtMA_1f1db766-c24c-4ef9-a6e2-5d2ce70cc81e"
      unitRef="usd">455588</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMi0xLTEtMA_67cf6c86-2d49-42bf-9129-71c842dc6f70"
      unitRef="gbp">2244</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzMtMy0xLTEtMA_1687fef3-f0c3-495e-81dc-4ff6a0c9569e"
      unitRef="eur">930</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMS0xLTEtMA_7cd75859-bd8f-4441-82cb-2bcd072468dc"
      unitRef="usd">417238</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMi0xLTEtMA_d39dd597-86bd-41fa-a554-c61279f719b6"
      unitRef="gbp">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzQtMy0xLTEtMA_6ad11780-0ce6-45cd-ab35-dff76a0dc0a9"
      unitRef="eur">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="id5c5734d8c674bc1ad227ce90090ae8e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMS0xLTEtMA_d3c7e8da-d817-4845-b3c2-96ed41723c45"
      unitRef="usd">22261287</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="ic994dbffe9564855820d86ebe9bc1885_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMi0xLTEtMA_e7d9cd8a-f1d9-422e-8c0f-f149867397ed"
      unitRef="gbp">24524</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="i07f6bce4e13d4467ae5fb65bb21e367f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xOTkvZnJhZzpiNmFjMDNhZjBjYzE0ZmZjODYyYjA2MDk5MWQ1ZTQ2Mi90YWJsZTpmM2UyYmUxMzk5YTE0YzU3YmI5ODExMjUyMTY2ZTQzNy90YWJsZXJhbmdlOmYzZTJiZTEzOTlhMTRjNTdiYjk4MTEyNTIxNjZlNDM3XzUtMy0xLTEtMA_d0ce85bd-e5a7-4942-beb7-2864ac5e38db"
      unitRef="eur">36417</oncyf:BalanceHeldInForeignCurrencyNet>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEyNw_d6d17c8e-adbb-4348-9a7d-2ba97f762577">Additional Cash Flow Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:292.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,979,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,017,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,368,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,858,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(723,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,795,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:255.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189,720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <oncyf:CashFlowOperatingCapital1TableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEzMw_f697809f-bd45-4cc5-a44c-132012eceef4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:292.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,767,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,979,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,017,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,012,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,368,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,858,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(723,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,795,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
    <oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMS0xLTEtMA_ad1e0f01-44ec-4898-9747-80b59cd98aae"
      unitRef="cad">0</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
    <oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMi0xLTEtMA_475fce69-cc7d-4c7f-be27-99fa02239ad1"
      unitRef="cad">0</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
    <oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzItMy0xLTEtMA_54c8112c-8d8a-4133-a5cf-5654ff9e031a"
      unitRef="cad">4767100</oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMS0xLTEtMA_ac01a17a-b19a-4be0-929e-5427fd02c633"
      unitRef="cad">1979111</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMi0xLTEtMA_b639fd77-c26a-423b-8a56-ee64491ca1c1"
      unitRef="cad">-2017122</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzMtMy0xLTEtMA_9c0a92d8-35da-467d-a0c2-cbd125c87a7d"
      unitRef="cad">-13924</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <oncyf:IncreaseDecreaseinPrepaidExpense1
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMS0xLTEtMA_a2c99176-9624-4940-b470-d83b09c04065"
      unitRef="cad">286391</oncyf:IncreaseDecreaseinPrepaidExpense1>
    <oncyf:IncreaseDecreaseinPrepaidExpense1
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMi0xLTEtMA_a5562b41-c3e0-42fc-ad52-e5c9a2a58d9b"
      unitRef="cad">-2012605</oncyf:IncreaseDecreaseinPrepaidExpense1>
    <oncyf:IncreaseDecreaseinPrepaidExpense1
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzQtMy0xLTEtMA_fc9c798c-b5aa-416d-9986-ecebac77166c"
      unitRef="cad">475077</oncyf:IncreaseDecreaseinPrepaidExpense1>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMS0xLTEtMA_e4300af4-f24b-4dd4-9cc5-070e89b2fb69"
      unitRef="cad">-1368203</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMi0xLTEtMA_5dc05f14-a8e9-4991-99e3-0d9debfba487"
      unitRef="cad">1347365</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzUtMy0xLTEtMA_ed5838ca-afb6-432a-9b8e-ad3bde6898ef"
      unitRef="cad">-1858170</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMS0xLTEtMA_05bc28ae-9f59-4cdd-b1db-2489fe8b43ec"
      unitRef="cad">0</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
    <oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMi0xLTEtMA_7296c259-18af-4493-855b-6bd9f5841888"
      unitRef="cad">0</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
    <oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzYtMy0xLTEtMA_24b78e2c-ad65-417c-a9d7-a9b9081ec937"
      unitRef="cad">547707</oncyf:AdjustmentsforIncreaseDecreaseinContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMS0xLTEtMA_2eeb157d-abd1-498e-aca6-43ab4859eaa4"
      unitRef="cad">-723230</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMi0xLTEtMA_d6973c22-c9e1-4b45-bd21-b827b632bc26"
      unitRef="cad">807877</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzctMy0xLTEtMA_5053055a-8e10-4f10-801e-2415394d4210"
      unitRef="cad">-27982</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMS0xLTEtMA_ba93b8ad-e384-46c6-a6e1-ac8234ec3cf7"
      unitRef="cad">35710</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMi0xLTEtMA_860df08d-8f72-4636-9b95-764e6c20c907"
      unitRef="cad">78708</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzgtMy0xLTEtMA_d90b87d2-9b6e-4525-8971-cc2fd3e52780"
      unitRef="cad">14531</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMS0xLTEtMA_d2d0e86b-6ed9-4396-9ed0-e441050a9b08"
      unitRef="cad">-209779</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMi0xLTEtMA_a9c4f9db-ce28-4ad2-8e81-e31d4aac15cd"
      unitRef="cad">1795777</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTo1MDM3NjU5MDY2ODI0OTVlODZiYWRlMTJhMjg4Zjc1Yy90YWJsZXJhbmdlOjUwMzc2NTkwNjY4MjQ5NWU4NmJhZGUxMmEyODhmNzVjXzktMy0xLTEtMA_b552675b-f025-4526-82e5-482588c08b9f"
      unitRef="cad">-3904339</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90ZXh0cmVnaW9uOjg3YzljMzAzMjk4ZDQzZGRhNTg5M2Q3YjdjY2FkMWFlXzEyNA_7de16553-1728-41c9-8374-41e557e1eb20">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:255.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;189,720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,080&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
    <oncyf:ProceedsfromInterestReceived
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMS0xLTEtMA_da49ca6c-cac6-4859-bd77-76d82e14a755"
      unitRef="cad">189720</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMi0xLTEtMA_92ac1876-6ca8-42e8-ab40-e0010dd7594b"
      unitRef="cad">274094</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzEtMy0xLTEtMA_f51493af-d8f1-411c-9f42-e67af81bebc4"
      unitRef="cad">173496</oncyf:ProceedsfromInterestReceived>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMS0xLTEtMA_a7064b21-d2d5-437e-abd6-7f05507f4a6a"
      unitRef="cad">12080</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMi0xLTEtMA_1b635ede-4824-4933-95ef-67cfd2529a76"
      unitRef="cad">5448</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDIvZnJhZzo4N2M5YzMwMzI5OGQ0M2RkYTU4OTNkN2I3Y2NhZDFhZS90YWJsZTozMmRiYTNiNTczMDI0N2UwOGFiZDI5ZGVmN2IyMWNjOS90YWJsZXJhbmdlOjMyZGJhM2I1NzMwMjQ3ZTA4YWJkMjlkZWY3YjIxY2M5XzItMy0xLTEtMA_816af1a0-ed64-4be8-84f3-9b3833c8998f"
      unitRef="cad">15728</ifrs-full:IncomeTaxesPaidRefund>
    <oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDUvZnJhZzoyZjQyYjA1NzM4NzI0YzU1YTM4YjJhOWU4OGM3NTk2ZC90ZXh0cmVnaW9uOjJmNDJiMDU3Mzg3MjRjNTVhMzhiMmE5ZTg4Yzc1OTZkXzExNjU_8b12d836-dd72-4938-9008-2aa6e212405c">Indemnification of Officers and Directors&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#x2019; and officers&#x2019; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock>
    <oncyf:DisclosureOfEconomicDependenceTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDgvZnJhZzphMDVlZmRlOTI5NjU0NGYzYTRmNjJkZWM1ZDE2ZjEwOC90ZXh0cmVnaW9uOmEwNWVmZGU5Mjk2NTQ0ZjNhNGY2MmRlYzVkMTZmMTA4XzY0MQ_ff32c5fd-799e-4bca-a57c-d673a9877bdc">Economic Dependence&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
    <oncyf:ConcentrationRiskNumber
      contextRef="i32c78d9692194534851ffc8c75765b43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMDgvZnJhZzphMDVlZmRlOTI5NjU0NGYzYTRmNjJkZWM1ZDE2ZjEwOC90ZXh0cmVnaW9uOmEwNWVmZGU5Mjk2NTQ0ZjNhNGY2MmRlYzVkMTZmMTA4XzExMA_f172b17d-cb70-464f-aba0-f921ca15a36c"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90ZXh0cmVnaW9uOmMwZDFlYWMyODk4MTQyZjliNTZiMzZmYWM5YWM3MGQyXzYxNg_5f66eb49-734f-4c64-997e-522445d5f00d">Other Expenses and AdjustmentsThe following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:479.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,043,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,515,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost, warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Onerous lease contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization - lease incentive liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <oncyf:OtherExpensesAndAdjustmentsTableTextBlock
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90ZXh0cmVnaW9uOmMwZDFlYWMyODk4MTQyZjliNTZiMzZmYWM5YWM3MGQyXzYxMg_d5d1e4b5-2de2-446b-a411-f73343277732">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:479.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,043,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,515,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction cost, warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Onerous lease contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization - lease incentive liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ieacddbbb17314a6bbe19b73efcd83368_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMS0xLTEtMA_aff33383-9239-430b-adfd-28c92770bce8"
      unitRef="cad">1043373</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i4b307c503b264545a9529c655c522919_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMi0xLTEtMA_d8bed02e-3c54-49af-bd05-bf57ec318877"
      unitRef="cad">561420</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i61dbf81b2c67488eabed83aa307e45c0_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzQtMy0xLTEtMA_11ff8f95-5e5e-49d7-a39f-7075361c3baf"
      unitRef="cad">680541</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AmortisationExpense
      contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMS0xLTEtMA_5020c850-e1f0-41e1-b957-f090f782d39a"
      unitRef="cad">88957</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMi0xLTEtMA_4923512d-398c-4827-bcc0-f9d91ccba2a7"
      unitRef="cad">122982</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzctMy0xLTEtMA_e4453c85-5191-4dc4-b987-4e84bddfb874"
      unitRef="cad">95375</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMS0xLTEtMA_d3615ae9-4b4d-487e-beec-ed534be6c7e1"
      unitRef="usd">357230</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMi0xLTEtMA_56e35934-c53b-42ba-aaff-314fbc54c269"
      unitRef="usd">362592</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzgtMy0xLTEtMA_4d215bf0-5bd1-4d7c-ac24-b8bf4f6a62a5"
      unitRef="usd">0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMS0xLTEtMA_2395577a-e701-49d3-9521-c9be856ff03e"
      unitRef="cad">1515601</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMi0xLTEtMA_c6bd9120-7fa2-4b03-8a61-920f91d91163"
      unitRef="cad">908733</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzktMy0xLTEtMA_7ef64c1f-7e93-4adb-9076-94a1db907a8d"
      unitRef="cad">735292</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ia846c8c806434b23ad5a6d843024e310_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTEtMS0xLTA_6f4673f1-2a00-45bf-b3bc-c55c7eb96c2c"
      unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i640ad69a2bed48779ac6bb4eb9764cd1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTItMS0xLTA_950a45d9-fbf0-49eb-a8c5-4480a22eb22b"
      unitRef="cad">233143</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i137e70b443b146e3bd028f654a8470d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEwLTMtMS0xLTA_ed9beef2-c247-4f9f-ab2b-4b03f2c26c40"
      unitRef="cad">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTEtMS0xLTA_5c03039f-60f0-4a57-afe1-40d630315cfb"
      unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTItMS0xLTA_fd35f238-c18b-4c10-a530-035065207ca8"
      unitRef="cad">0</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzExLTMtMS0xLTA_497cc169-4e02-4938-8799-ac4e9e3d3d93"
      unitRef="cad">67588</ifrs-full:AdjustmentsForProvisions>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="i816ef472813041e7a3c82c7653c6d18d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTEtMS0xLTA_52ff1f45-cfe3-4a4e-b0aa-4ac646b38c0e"
      unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="i0da5ee5e6c464f4da0e2266e4ba1d6b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTItMS0xLTA_2a76c241-ad0a-4ba8-b657-1af6143915d3"
      unitRef="cad">0</oncyf:AdjustmentsforLeaseAmortization>
    <oncyf:AdjustmentsforLeaseAmortization
      contextRef="ifade29d1a46d4e93b73275601b99b806_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTEvZnJhZzpjMGQxZWFjMjg5ODE0MmY5YjU2YjM2ZmFjOWFjNzBkMi90YWJsZTpmMDdlYjRhYTRmYTc0ZjBmYTlhZjFiNzk3MTdmMTNhZi90YWJsZXJhbmdlOmYwN2ViNGFhNGZhNzRmMGZhOWFmMWI3OTcxN2YxM2FmXzEyLTMtMS0xLTA_4afc7dca-1e53-44e9-999a-80feaeeb48fc"
      unitRef="cad">8189</oncyf:AdjustmentsforLeaseAmortization>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90ZXh0cmVnaW9uOjU5MWQ2Nzk5NzI5ODQ5Y2RiY2FiYzI1YWI5ZGU3YTQzXzY1OQ_bcc59207-0868-4483-a4ab-b6d860027a03">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:390.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:223.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,514,527&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,786,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,680,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;495,175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,767,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90ZXh0cmVnaW9uOjU5MWQ2Nzk5NzI5ODQ5Y2RiY2FiYzI1YWI5ZGU3YTQzXzY1NQ_bd61000b-7350-407d-9987-89a4d6b3b31d">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:390.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:223.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,514,527&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,786,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,680,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;495,175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,757,723&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,123,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,767,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,910,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMS0xLTEtMA_e6271ab0-1f7d-4c8a-8071-ae8bcddfb24d"
      unitRef="cad">3514527</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMi0xLTEtMA_47a85dd2-1d1c-4aee-b12c-b332c8e02a74"
      unitRef="cad">3786667</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzEtMy0xLTEtMA_2550f1f9-d39c-4253-af20-f5e52cc633f4"
      unitRef="cad">2680621</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMS0xLTEtMA_dec8cc5a-5ad6-44f8-a09f-3c8369396ed7"
      unitRef="cad">495175</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMi0xLTEtMA_3e1fe349-6efe-4606-a263-aa0801ab3a11"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzItMy0xLTEtMA_18007caf-872c-4bb1-a94e-072f95a7d89b"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMS0xLTEtMA_03abee2a-ce0a-4fd3-9447-e6e21e519994"
      unitRef="cad">1757723</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMi0xLTEtMA_bd14bb6c-23f1-4eb1-8eb9-7180adb1a9c0"
      unitRef="cad">1123408</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzMtMy0xLTEtMA_605230cc-6223-4f2c-bcd1-adf9660d37a3"
      unitRef="cad">1067195</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMS0xLTEtMA_255799d9-41aa-435e-beb9-c3c91714b34b"
      unitRef="cad">5767425</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i8a789a0f5ae3405783e4a8565b21d2e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMi0xLTEtMA_06afb528-ac3e-466c-a579-eec707353ef8"
      unitRef="cad">4910075</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTQvZnJhZzo1OTFkNjc5OTcyOTg0OWNkYmNhYmMyNWFiOWRlN2E0My90YWJsZTo0MjQ4ZjZkYjhhYzY0YmZkOGExZjIzOGM1NTgzYzNkMy90YWJsZXJhbmdlOjQyNDhmNmRiOGFjNjRiZmQ4YTFmMjM4YzU1ODNjM2QzXzQtMy0xLTEtMA_502376c0-df31-4646-a55c-ecbf2a08fe89"
      unitRef="cad">3747816</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzM4OA_aa408f9e-32cd-453b-99cc-6d13a81cf9c5">Subsequent EventsBetween January 1, 2021 and March 4, 2021, through our June 2020 ATM equity distribution agreement, we issued 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$2.85. We received, net of commissions of US$555,096, proceeds of US$17,948,092.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU1ODI_2ac4f9cc-a616-4c79-97c0-a2558576f686"
      unitRef="shares">5685097</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU1OTM_e83a6056-0efe-44b9-ba71-f0cae6d55a43"
      unitRef="usd">18503188</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="id1dda167e3394214b8a7f2f4ef0d20bb_I20210304"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU3MzM_8b30f59c-96b3-4d56-ace8-4e94855d4027"
      unitRef="usdPerShare">2.85</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTU5NjM_83ad8d8b-90ed-4bb0-b7b4-e9f8c043bd06"
      unitRef="usd">555096</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="idd0f9dd17a334fbb893d05409188942d_D20210101-20210304"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18yMTcvZnJhZzo2NWVjYjkzOGZlZjU0OGVhODNhOTY2NDUzM2JkZjMwMS90ZXh0cmVnaW9uOjY1ZWNiOTM4ZmVmNTQ4ZWE4M2E5NjY0NTMzYmRmMzAxXzc2OTY1ODEzOTYwNDI_58f38b13-c624-4513-8646-6df1ce8490c6"
      unitRef="usd">17948092</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory
      contextRef="i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xODYzL2ZyYWc6MDBlZmViYTA0N2NjNGEzYmJlMTRkNzFhNTgwN2QxZDEvdGV4dHJlZ2lvbjowMGVmZWJhMDQ3Y2M0YTNiYmUxNGQ3MWE1ODA3ZDFkMV83MTQ2ODI1NTgwODI1_1eb7ff8f-be43-4740-adb0-3bc6288ae77b">Comparative FiguresReclassification was made to prior period's figure to conform to the current period's presentation.</ifrs-full:DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231599064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">46,166,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232916776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,219,574<span></span>
</td>
<td class="nump">$ 14,148,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">89,661<span></span>
</td>
<td class="nump">2,068,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,427,200<span></span>
</td>
<td class="nump">2,713,591<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">33,736,435<span></span>
</td>
<td class="nump">18,930,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">236,664<span></span>
</td>
<td class="nump">296,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">372,468<span></span>
</td>
<td class="nump">430,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">609,132<span></span>
</td>
<td class="nump">727,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">34,345,567<span></span>
</td>
<td class="nump">19,657,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,805,015<span></span>
</td>
<td class="nump">3,173,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">123,985<span></span>
</td>
<td class="nump">847,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">248,885<span></span>
</td>
<td class="nump">339,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">531,228<span></span>
</td>
<td class="nump">8,508,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,709,113<span></span>
</td>
<td class="nump">12,869,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">153,174<span></span>
</td>
<td class="nump">166,429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">6,883,461<span></span>
</td>
<td class="nump">6,896,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,592,574<span></span>
</td>
<td class="nump">19,765,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2020 &#8211; 46,166,980 December&#160;31, 2019 &#8211; 32,198,453</a></td>
<td class="nump">356,824,172<span></span>
</td>
<td class="nump">311,077,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsandRightsOutstanding', window );">Warrants</a></td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus</a></td>
<td class="nump">31,022,356<span></span>
</td>
<td class="nump">29,338,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">400,225<span></span>
</td>
<td class="nump">464,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(367,111,330)<span></span>
</td>
<td class="num">(344,606,273)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity (deficit)</a></td>
<td class="nump">24,752,993<span></span>
</td>
<td class="num">(107,894)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity (deficit)</a></td>
<td class="nump">$ 34,345,567<span></span>
</td>
<td class="nump">$ 19,657,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsandRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsandRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212306312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued (shares)</a></td>
<td class="nump">32,198,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232131464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,944,510<span></span>
</td>
<td class="nump">$ 10,817,997<span></span>
</td>
<td class="nump">$ 10,027,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating</a></td>
<td class="nump">12,514,496<span></span>
</td>
<td class="nump">9,558,641<span></span>
</td>
<td class="nump">7,244,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(25,459,006)<span></span>
</td>
<td class="num">(20,376,638)<span></span>
</td>
<td class="num">(17,272,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="nump">3,491,928<span></span>
</td>
<td class="num">(12,608,808)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange (loss) gain</a></td>
<td class="num">(659,173)<span></span>
</td>
<td class="num">(316,719)<span></span>
</td>
<td class="nump">610,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">121,194<span></span>
</td>
<td class="nump">179,277<span></span>
</td>
<td class="nump">173,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(22,505,057)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
<td class="num">(16,489,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(548,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(22,505,057)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
<td class="num">(17,037,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(63,876)<span></span>
</td>
<td class="num">(143,403)<span></span>
</td>
<td class="nump">233,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net comprehensive loss</a></td>
<td class="num">$ (22,568,933)<span></span>
</td>
<td class="num">$ (33,266,291)<span></span>
</td>
<td class="num">$ (16,803,451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (1.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2020-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2020-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2020-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2020-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233916136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)<br></strong></div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th">
<div>At-the-market agreement </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Public Offering </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Share Purchase Agreement </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>At-the-market agreement </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>Public Offering </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Share Capital $ </div>
<div>Share Purchase Agreement </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Warrants $ </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Contributed Surplus $ </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Income $ </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Accumulated Deficit $ </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2017</a></td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="nump">$ 27,028,238<span></span>
</td>
<td class="nump">$ 373,730<span></span>
</td>
<td class="num">$ (294,446,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2017</a></td>
<td class="nump">8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,900<span></span>
</td>
<td class="nump">27,028,238<span></span>
</td>
<td class="nump">373,730<span></span>
</td>
<td class="num">(294,446,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(16,803,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,774<span></span>
</td>
<td class="num">(17,037,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="nump">123,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,010<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,010<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">1,415,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(2,366,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,366,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2018</a></td>
<td class="nump">6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">28,260,613<span></span>
</td>
<td class="nump">607,504<span></span>
</td>
<td class="num">(311,483,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2018</a></td>
<td class="nump">6,195,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">28,260,613<span></span>
</td>
<td class="nump">607,504<span></span>
</td>
<td class="num">(311,483,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(33,266,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,403)<span></span>
</td>
<td class="num">(33,122,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,476,454<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2019</a></td>
<td class="num">(107,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,077,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617,570<span></span>
</td>
<td class="nump">29,338,849<span></span>
</td>
<td class="nump">464,101<span></span>
</td>
<td class="num">(344,606,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income</a></td>
<td class="num">(22,568,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,876)<span></span>
</td>
<td class="num">(22,505,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan</a></td>
<td class="nump">241,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">6,332,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2020</a></td>
<td class="nump">$ 24,752,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,824,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 31,022,356<span></span>
</td>
<td class="nump">$ 400,225<span></span>
</td>
<td class="num">$ (367,111,330)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231821016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (22,505,057)<span></span>
</td>
<td class="num">$ (33,122,888)<span></span>
</td>
<td class="num">$ (17,037,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">88,957<span></span>
</td>
<td class="nump">122,982<span></span>
</td>
<td class="nump">95,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">357,230<span></span>
</td>
<td class="nump">362,592<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="nump">2,558,974<span></span>
</td>
<td class="nump">1,470,153<span></span>
</td>
<td class="nump">1,415,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">68,526<span></span>
</td>
<td class="nump">94,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange loss (gain)</a></td>
<td class="nump">645,078<span></span>
</td>
<td class="nump">353,189<span></span>
</td>
<td class="num">(374,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(3,491,928)<span></span>
</td>
<td class="nump">12,608,808<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital</a></td>
<td class="nump">209,779<span></span>
</td>
<td class="num">(1,795,777)<span></span>
</td>
<td class="nump">3,904,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(22,068,441)<span></span>
</td>
<td class="num">(19,906,124)<span></span>
</td>
<td class="num">(11,920,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment</a></td>
<td class="num">(29,305)<span></span>
</td>
<td class="num">(10,905)<span></span>
</td>
<td class="num">(107,466)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(29,305)<span></span>
</td>
<td class="num">(10,905)<span></span>
</td>
<td class="num">(107,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">241,922<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">123,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(460,724)<span></span>
</td>
<td class="num">(447,497)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">39,773,804<span></span>
</td>
<td class="nump">21,015,596<span></span>
</td>
<td class="nump">13,299,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase in cash</a></td>
<td class="nump">17,676,058<span></span>
</td>
<td class="nump">1,098,567<span></span>
</td>
<td class="nump">1,271,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">14,148,021<span></span>
</td>
<td class="nump">13,699,881<span></span>
</td>
<td class="nump">11,836,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(604,505)<span></span>
</td>
<td class="num">(650,427)<span></span>
</td>
<td class="nump">592,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">31,219,574<span></span>
</td>
<td class="nump">14,148,021<span></span>
</td>
<td class="nump">13,699,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember', window );">Warrant Derivative And Shares Under Warrant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">1,696,460<span></span>
</td>
<td class="nump">3,465,867<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,360,247<span></span>
</td>
<td class="nump">2,533,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">38,296,146<span></span>
</td>
<td class="nump">8,131,620<span></span>
</td>
<td class="nump">451,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,505,359<span></span>
</td>
<td class="nump">$ 10,188,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2020-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2020-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2020-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforLeaseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Lease Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforLeaseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212822936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incorporation and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Incorporation and Nature of Operations</a></td>
<td class="text">Incorporation and Nature of Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2020, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;4, 2021. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our principal place of business is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to or used in combination with existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep centers on key immunotherapy combinations. Specifically, immunotherapy combinations in which pelareorep has the potential to provoke specific innate and adaptive immune responses when combined with checkpoint blockade therapy, chemotherapy and/or targeted therapies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231891208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Financial Statement Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Financial Statement Presentation</a></td>
<td class="text">Basis of Financial Statement Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries Oncolytics Biotech (Barbados) Inc., Oncolytics Biotech (U.S.) Inc., and Oncolytics Biotech (U.K.) Ltd. and are presented in Canadian dollars, our functional currency.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of consolidation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts include the accounts of Oncolytics Biotech Inc. and our subsidiaries. Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and has the ability to affect those returns through our power to govern. Accounting policies of subsidiaries are consistent with our accounting policies and all intra-group transactions, balances, income and expenses are eliminated on consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in ownership interest of a subsidiary, without a change in control, is accounted for as an equity transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212059128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments ("IFRS 9")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss per common share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property and equipment </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"/><td style="width:47.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share-based payments </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231516616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text">Significant Judgments, Estimates and Assumptions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the global outbreak of a novel coronavirus identified as the SARS-coronavirus-2 (SARS-CoV-2) led to the associated coronavirus infectious disease 2019 (COVID-19). The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. We considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December 31, 2020, our future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates and assumptions that affect the reported amount of expenses, assets, liabilities, and the disclosure of contingent liabilities, at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant. Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, for upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress towards completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses represent a significant component of our research and development expenses and we outsource a significant portion of these activities to third-party contract research organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that have been performed by the contract research organizations. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based payments </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility, dividend yield, and forfeiture rate and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life, share price volatility and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of the warrant derivative are disclosed in Note 8.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. As well, there are no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212749240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash Equivalents</a></td>
<td class="text">Cash Equivalents <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest bearing deposits with our bank totaling $30,361,591 (December&#160;31, 2019 &#8211; $13,058,092).&#160;&#160;The current annual interest rate earned on these deposits is 0.36% (December&#160;31, 2019 &#8211; 1.17%).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212302136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:121.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:69.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,405&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,490&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,739</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212715656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between 3 to 5 years. We currently do not have leases with variable lease payments, residual value guarantees, or leases not yet commenced to which we are committed. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we entered into an office space lease for one of our subsidiaries. We recognized a $297,373 right-of-use asset and a lease liability of the same amount. The lease provided for one extension option that we were not reasonably certain to exercise at lease commencement date.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right-of-use assets               </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:280.50pt"><tr><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease liabilities                  </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:279.00pt"><tr><td style="width:1.0pt"/><td style="width:222.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.456%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231824696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Warrant Derivative</a></td>
<td class="text">Warrant Derivative<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share and one common share purchase warrant (see Note 9). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IAS 32 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative measured at fair value with subsequent changes in fair value accounted for through profit and loss. Our warrants with an exercise price of US$0.90 meet this requirement and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:385.50pt"><tr><td style="width:1.0pt"/><td style="width:192.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:93.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued, August 16, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,687,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,608,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">265,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">531,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received cash proceeds of US$1,276,532 (2019 - US$2,642,082) with respect to the warrants exercised. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions: </span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"><tr><td style="width:1.0pt"/><td style="width:202.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.57</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$3.89</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$2.38</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$4.76</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212898632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Consolidation:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"><tr><td style="width:1.0pt"/><td style="width:309.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,805,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,710,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - pre-consolidation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,396,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,268,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - post-consolidation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,988,995&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,268,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,606,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrants exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(see "&#8212; Equity Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,333,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,399,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,152,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,037,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,166,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356,824,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362">five</span> immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725;  2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726).  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrant exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212222536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:488.25pt"><tr><td style="width:1.0pt"/><td style="width:117.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,246,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.20</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,817,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(141,418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.84</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.49</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.07</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.78</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.81</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the<br/>  year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,764,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,164,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.84</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.04</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:135.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.03</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545,009&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.02</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.42 - $52.63</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-exercisable options vest annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzM1Mg_cd3e7b72-8b81-4fad-847f-5db8340cf26d">one</span> to three years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:348.00pt"><tr><td style="width:1.0pt"/><td style="width:181.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.34%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.82%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.15%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.67%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$2.12</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.67</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE0NTA_028b8dc4-7e4a-4f5f-b344-5ed3a29ae30d">three</span> year period. The following RSUs are outstanding at December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"/><td style="width:199.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,407&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">         (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also issued PSUs to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNzIvZnJhZzpjODM0ZmNhNmQxY2I0OTMyYmEyMDg4MDRlOTk0M2U5NC90ZXh0cmVnaW9uOmM4MzRmY2E2ZDFjYjQ5MzJiYTIwODgwNGU5OTQzZTk0XzE4Mjk_c9939d36-c1bf-4c0e-9451-a1e30a1ffc57">three</span> year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"><tr><td style="width:1.0pt"/><td style="width:204.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We have reserved 4,616,698 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs for the year ended December&#160;31, 2020 was $2,558,974 (2019 - $1,470,153; 2018 - $1,415,833).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212898632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the year ended December&#160;31, 2020 of 40,338,789 (2019 - 22,137,990; 2018 - 16,016,366). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212332568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability and Receivable</a></td>
<td class="text">Contract Liability and Receivable<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at December 31, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"><tr><td style="width:1.0pt"/><td style="width:175.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:78.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212339208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text">Commitments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling $9,360,653 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include the committed payments related to our collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December 31, 2020, we recorded nil (December&#160;31, 2019 - US$1,500,000) in other receivables related to an upfront payment of BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and US$97,381 (December&#160;31, 2019 - US$652,306) in other liabilities representing future trial costs to be incurred.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231304152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumption Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1999, we entered into an agreement that assumed certain obligations (the &#8220;Assumption Agreement&#8221;) in connection with a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) between SYNSORB and our former shareholders to make milestone payments and royalty payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, a milestone payment was still outstanding for $1.0 million, due within 90 days of the first receipt from an Appropriate Regulatory Authority, for marketing approval to sell pelareorep to the public or the approval of a new drug application for pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This milestone payment, when payable, will be accounted for as research and development expense and will not be deductible for income tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the milestone payment, payments may become due and payable in accordance with the Share Purchase Agreement upon realization of sales of pelareorep.&#160;&#160;If we receive royalty payments or other payments as a result of entering into partnerships or other arrangements for the development of the reovirus technology, we are obligated to pay to the founding shareholders 10.75% (2019 - 10.75%) of the royalty payments and other payments received.&#160;Alternatively, if we develop the reovirus treatment to the point where it may be marketed at a commercial level, the payments referred to in the foregoing sentence will be amended to a royalty payment of 2.15% (2019 - 2.15%) of Net Sales received for such products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRI &#8220;Work in Kind&#8221; Contribution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>We entered into an engineering and process development agreement with the Biotechnology Research Institute of the National Research Council of Canada (&#8220;BRI&#8221;).&#160;The terms of this agreement include a &#8220;work in kind&#8221; contribution from BRI.&#160;In exchange for this &#8220;work in kind&#8221; contribution, we agreed to provide a royalty, contingent upon receiving Sales Revenue at the lesser of 0.5% of Sales Revenue or $20,000 per year until December 31, 2028.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2020-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212159992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:437.25pt"><tr><td style="width:1.0pt"/><td style="width:235.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,505,057)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,489,183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,401,214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,777,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,452,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,237,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,088,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,312,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">614,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(838,063)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to <br/>  be recovered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,161,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,042&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment in respect to prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-capital losses for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.853%"><tr><td style="width:1.0%"/><td style="width:35.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,809,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,056,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,994,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:142.50pt"><tr><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,304,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, we have unclaimed scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of approximately $27,660,000.&#160;We have not recorded the potential benefits of these tax pools in these consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:459.00pt"><tr><td style="width:1.0pt"/><td style="width:256.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,487,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,625,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,664,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,362,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,406,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,068,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,927,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,949,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">689,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,541,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,712,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,712,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677211637496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text">Capital Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,219,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,752,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On  June 12, 2020, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 12, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement in June 2020 (see Note 9). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212436952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, other liabilities, accounts payable and warrant derivative.&#160;As at December&#160;31, 2020, the carrying amount of our cash and cash equivalents,&#160;other receivables, other liabilities and accounts payable approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2020, the fair value of our warrant derivative was $531,228 (December&#160;31, 2019 - $8,508,764).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalent by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar, British pound and Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2020 by approximately $172,000.&#160;&#160;The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $20,000. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2020 by approximately $3,000.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:466.50pt"><tr><td style="width:1.0pt"/><td style="width:165.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollars <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br/>&#8364;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,134,113</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,768</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,347</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,588)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,244)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,238)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,261,287</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,417</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 16. Accounts payable are all due within the current operating period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212006264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text">Additional Cash Flow Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"><tr><td style="width:1.0pt"/><td style="width:292.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,979,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,017,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,368,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,858,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(723,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795,777)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"/><td style="width:255.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189,720</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section Presentation of a statement of cash flows<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212752136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indemnification of Officers and Directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract', window );"><strong>Disclosure Of Indemnification Of Officers and Directors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock', window );">Indemnification of Officers and Directors</a></td>
<td class="text">Indemnification of Officers and Directors<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Indemnification Of Officers and Directors [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231905432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text">Economic Dependence<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturer has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212896152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Other Expenses and Adjustments</a></td>
<td class="text">Other Expenses and AdjustmentsThe following details highlight certain components of the research and development and operating expenses classified by nature. The foreign exchange (loss) gain as presented separately on the face of the consolidated statement of loss and <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive loss is also classified as a research and development expense. Remaining research and development and operating expenses include personnel costs and expenses paid to third parties.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:479.25pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,043,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,515,601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onerous lease contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization - lease incentive liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232773704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain employees of the Company.   </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:390.00pt"><tr><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,514,527</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,786,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">495,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,767,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212907032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofeventsafterreportingperiodAbstract', window );"><strong>Disclosure of events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsBetween January 1, 2021 and March 4, 2021, through our June 2020 ATM equity distribution agreement, we issued 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$2.85. We received, net of commissions of US$555,096, proceeds of US$17,948,092.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2020-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2020-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofeventsafterreportingperiodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofeventsafterreportingperiodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212006264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comparative Figures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ComparativeFiguresAbstract', window );"><strong>Comparative figures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory', window );">Comparative Figures</a></td>
<td class="text">Comparative FiguresReclassification was made to prior period's figure to conform to the current period's presentation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure, in the entity's first IFRS financial statements, of comparative information prepared under previous GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ComparativeFiguresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comparative figures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ComparativeFiguresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232138696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences).  Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled.  The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments ("IFRS 9")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent &#8216;solely payments of principal and interest&#8217; on the principal amount outstanding (the &#8216;SPPI criterion&#8217;). </span></div>Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include trade accounts payable, other liabilities and warrant derivative. The classification and measurement of trade accounts payable and other liabilities are at amortized cost. The classification and measurement of warrant derivative is at FVPL.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory', window );">Derecognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contractual rights to the cash flows from the financial asset expire, or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div>A financial liability is derecognized when our obligations specified in the contract are discharged or canceled or expired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per common share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants, if dilutive. The number of additional common shares is calculated by assuming that any outstanding &#8220;in the money&#8221; options, restricted share units, performance share units and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"/><td style="width:47.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div>We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. The financial terms of the agreements with our vendors are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods.Development costs that meet specific criteria related to technical, market and financial feasibility will be capitalized. To date, all development costs have been expensed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and includes non-refundable upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress towards completion of the performance obligation using the input method. Under the input method, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Contract receivable includes amounts billed and currently due from customers. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We perform a review of our customer&#8217;s credit risk and payment histories, including payments made subsequent to year-end.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or noncurrent based on the timing of when we expect to recognize revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based payments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the &#8220;Option Plan&#8221;) available to officers, directors, employees and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the &#8220;Board&#8221;). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided for at the discretion of the Board and the expiration of options is to be no greater than 10 years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers and employees. Under our Share Plan, performance share units and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are an award to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are an award to certain officers and employees and to non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the date of grant based on the number of PSUs/RSUs expected to vest, recognized over the term of the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212227048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"/><td style="width:47.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:121.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:69.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,405&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,490&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,739</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231500296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"/><td style="width:47.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:121.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:69.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,512&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,537&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,438&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,229&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,367&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,083&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,650&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,933&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,405&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,490&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,941&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,419&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,862</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">116,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,739</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,670&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231613192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right-of-use assets               </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:280.50pt"><tr><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">372,468</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock', window );">Lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease liabilities                  </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:279.00pt"><tr><td style="width:1.0pt"/><td style="width:222.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Spaces</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at January 1, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Total undiscounted lease liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.947%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.456%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity analysis - contractual undiscounted cash flows</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 97<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231599336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Reconciliation of change in fair value of warrant derivative</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in fair value of the warrant derivative is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:385.50pt"><tr><td style="width:1.0pt"/><td style="width:192.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:93.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued, August 16, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,687,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,608,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,508,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,636,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,491,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">265,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">531,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative was determined using the following assumptions: </span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:341.25pt"><tr><td style="width:1.0pt"/><td style="width:202.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.57</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$3.89</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$2.38</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$4.76</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.10%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.00%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212329096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:495.75pt"><tr><td style="width:1.0pt"/><td style="width:309.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:90.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount<br/>$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,805,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,710,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - pre-consolidation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,396,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,268,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, May 22, 2018 - post-consolidation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,988,995&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,268,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,606,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrants exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(see "&#8212; Equity Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,333,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,399,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,193,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to Common Stock Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,152,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,077,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(f)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,037,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,741,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,166,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356,824,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Our Canadian ATM allowed us, at our sole discretion, to determine the timing and number of shares to be sold under this ATM facility. During 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335. This sales agreement expired on March 16, 2018. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. However, in no event will shares be sold to LPC on a day the closing sale price for the common shares is less than the floor price of US$1.00 per common share; or at a price per share that is less than the volume weighted average trading pricing of the common shares on the TSX for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQyNTAxMGNjOGYyZDQ4NGQ4YjRiM2M5OTQ5ZGRiNjg3L3NlYzpkMjUwMTBjYzhmMmQ0ODRkOGI0YjNjOTk0OWRkYjY4N18xNjYvZnJhZzozN2M0NDI3ZDYyZGY0ZGVkYWRmYTgzMTE2OGI3YzVjMi90ZXh0cmVnaW9uOjM3YzQ0MjdkNjJkZjRkZWRhZGZhODMxMTY4YjdjNWMyXzc2OTY1ODE0MDkzMzU_cc7ca14f-7937-482d-8ab4-498f35b1c362">five</span> immediately preceding trading days, less the maximum applicable discount allowed by the TSX. The Agreement limits our sale of common shares to 19.99% of our total outstanding common shares as at the date that the Common Stock Purchase Agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. We reached that limit in the fourth quarter of 2019, and have not sought shareholder approval to increase the limit. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we sold nil (2019 - 2,477,665; 2018 - 678,182) common shares for gross proceeds of nil (2019 - US$4,055,725;  2018 - US$2,055,207) and issued nil (2019 - 17,278; 2018 - 119,509) commitment shares. The commitment shares were fair valued at nil (2019 - US$29,758; 2018 - US$483,690) and were recorded as share issue costs in addition to cash share issue costs of nil (2019 - $3,757; 2018 - $208,726).  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 6,741,518 (2019 - 4,425,040; 2018 - 18,002) common shares for gross proceeds of US$17,538,342 (2019 - US$6,390,691; 2018 - US$50,046) at an average price of US$2.42 (2019 - US$1.70; 2018 - US$2.85). We received, net of commissions of US$526,150 (2019 - US$191,721; 2018 - US$1,501), proceeds of US$17,012,192 (2019 - US$6,198,970; 2018 - US$48,545). In total, we incurred share issue costs (including commissions) of $856,754 (2019 - $344,834; 2018 - $135,000). This sales agreement expired on June 4, 2020. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742,016. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 8). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. We incurred transaction costs of $699,427 of which $466,284 were allocated to share issue costs and $233,143 were allocated to operating expenses, based on their relative fair values. In 2020, our share capital included fair value of $4,636,317 (2019 - 5,687,003) in addition to gross proceeds of US$1,276,532 (2019 - US$2,642,082) for the 1,418,369 (2019 - 2,935,647) warrants that were exercised (see Note 8). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.01pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2020, we sold 5,441,014 common shares for gross proceeds of US$12,628,775 at an average price of US$2.11. We received, net of commissions of US$378,863, proceeds of US$12,249,911. In total, we incurred share issue costs (including commissions) of $884,886.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of outstanding warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrant exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Exercisable into 1,730,894 common shares.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:135.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.03</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545,009&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.02</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.42 - $52.63</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212356696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at December&#160;31:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:488.25pt"><tr><td style="width:1.0pt"/><td style="width:117.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:54pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,246,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.20</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,817,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.19</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.97</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(141,418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.84</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.49</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.07</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.78</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.81</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the<br/>  year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,764,055</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of the year</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,164,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.84</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:3pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.04</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:135.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.03</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545,009&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.02</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.42 - $52.63</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div style="margin-bottom:6pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to equity warrant exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,443,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,617,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Exercisable into 1,730,894 common shares.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:135.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.54 - $1.79</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.03</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545,009&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.80 - $3.01</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.02 - $3.90</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.86</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.21</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.26</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.91 - $7.41</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.13</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.02</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$7.42 - $52.63</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.32</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options issued during the year was determined using the following weighted average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:348.00pt"><tr><td style="width:1.0pt"/><td style="width:181.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.34%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.82%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.15%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected forfeiture rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.67%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$2.12</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.87</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.67</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text">The following RSUs are outstanding at December&#160;31:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"/><td style="width:199.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,407&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,210)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,755&#160;</span></td><td style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">         (1) The weighted average fair value of the RSUs granted was $2.41 in 2020 (2019 - $0.80 ; 2018 - $3.35).</span></div> The following PSUs are outstanding at December&#160;31:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:391.50pt"><tr><td style="width:1.0pt"/><td style="width:204.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,051</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,734&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212148504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Contract liability balances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at December 31, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:333.00pt"><tr><td style="width:1.0pt"/><td style="width:175.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:78.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regional licensing agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized in the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212907032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:437.25pt"><tr><td style="width:1.0pt"/><td style="width:235.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,505,057)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,122,888)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,489,183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,401,214)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,777,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,452,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign jurisdiction tax rate difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,237,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,088,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,312,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">614,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(838,063)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,341,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Alberta rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,758,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to opening tax pools</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,711</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax benefits deemed not probable to <br/>  be recovered</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,161,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,042&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment in respect to prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-capital losses for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:24.853%"><tr><td style="width:1.0%"/><td style="width:35.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.842%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,809,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,873,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,056,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,994,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2020, we have the following non-refundable federal investment tax credits for income tax purposes in Canada:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:142.50pt"><tr><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,304,980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available, against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilized. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:459.00pt"><tr><td style="width:1.0pt"/><td style="width:256.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:64.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,487,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,625,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,664,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,362,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,338,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,406,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,068,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,927,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,949,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">689,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,541,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,712,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,712,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212152040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,219,574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,148,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,752,993</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,894)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212157800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balances in foreign currencies at December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:466.50pt"><tr><td style="width:1.0pt"/><td style="width:165.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollars <br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British pounds<br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro<br/>&#8364;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,134,113</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,768</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,347</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455,588)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,244)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,238)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,261,287</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,524</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,417</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677211650232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:473.25pt"><tr><td style="width:1.0pt"/><td style="width:292.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,979,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,017,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,012,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,368,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,858,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(723,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,710</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,795,777)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:388.50pt"><tr><td style="width:1.0pt"/><td style="width:255.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189,720</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,080</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231593896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:479.25pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,043,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Included in operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,515,601</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction cost, warrant derivative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Onerous lease contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization - lease incentive liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212156536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:390.00pt"><tr><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018<br/>$</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,514,527</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,786,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">495,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,757,723</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,767,425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,910,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677237140552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212146120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>plan</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232718824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash Equivalents And Short Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 30,361,591<span></span>
</td>
<td class="nump">$ 13,058,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CashEquivalentsInterestRate', window );">Current annual interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Short Term Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashEquivalentsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashEquivalentsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232958952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">$ 296,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">236,664<span></span>
</td>
<td class="nump">$ 296,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">1,264,367<span></span>
</td>
<td class="nump">1,257,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">28,853<span></span>
</td>
<td class="nump">7,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">15,137<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">1,278,083<span></span>
</td>
<td class="nump">1,264,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(967,599)<span></span>
</td>
<td class="num">(844,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(15,137)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">88,957<span></span>
</td>
<td class="nump">122,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(1,041,419)<span></span>
</td>
<td class="num">(967,599)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">15,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">13,862<span></span>
</td>
<td class="nump">15,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">60,378<span></span>
</td>
<td class="nump">60,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">60,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(44,708)<span></span>
</td>
<td class="num">(24,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">20,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(47,650)<span></span>
</td>
<td class="num">(44,708)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">128,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">116,604<span></span>
</td>
<td class="nump">128,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">352,955<span></span>
</td>
<td class="nump">345,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">27,719<span></span>
</td>
<td class="nump">7,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">15,137<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">365,537<span></span>
</td>
<td class="nump">352,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(224,046)<span></span>
</td>
<td class="num">(174,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(15,137)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">40,024<span></span>
</td>
<td class="nump">49,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(248,933)<span></span>
</td>
<td class="num">(224,046)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">75,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">67,033<span></span>
</td>
<td class="nump">75,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">247,438<span></span>
</td>
<td class="nump">247,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">247,438<span></span>
</td>
<td class="nump">247,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Office Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(172,417)<span></span>
</td>
<td class="num">(157,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">7,988<span></span>
</td>
<td class="nump">14,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(180,405)<span></span>
</td>
<td class="num">(172,417)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">27,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">22,739<span></span>
</td>
<td class="nump">27,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">105,229<span></span>
</td>
<td class="nump">105,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">105,229<span></span>
</td>
<td class="nump">105,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(78,170)<span></span>
</td>
<td class="num">(72,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">(82,490)<span></span>
</td>
<td class="num">(78,170)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">50,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">16,426<span></span>
</td>
<td class="nump">50,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="nump">498,367<span></span>
</td>
<td class="nump">498,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="nump">498,367<span></span>
</td>
<td class="nump">498,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), beginning balance</a></td>
<td class="num">(448,258)<span></span>
</td>
<td class="num">(414,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">33,683<span></span>
</td>
<td class="nump">33,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (amortization), ending balance</a></td>
<td class="num">$ (481,941)<span></span>
</td>
<td class="num">$ (448,258)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212125944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>renewal</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>renewal</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 372,468<span></span>
</td>
<td class="nump">$ 297,373<span></span>
</td>
<td class="nump">$ 430,713<span></span>
</td>
<td class="nump">$ 808,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfRenewals', window );">Number of extension options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfRenewals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Renewals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfRenewals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233190952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning balance</a></td>
<td class="nump">$ 430,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 808,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(357,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(362,592)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, ending balance</a></td>
<td class="nump">372,468<span></span>
</td>
<td class="nump">$ 297,373<span></span>
</td>
<td class="nump">430,713<span></span>
</td>
<td class="nump">808,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning balance</a></td>
<td class="nump">506,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(460,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447,497)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">68,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(9,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, ending balance</a></td>
<td class="nump">$ 402,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506,275<span></span>
</td>
<td class="nump">$ 882,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 44B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesfromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) from Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesfromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233956104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 458,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">286,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">172,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677237135576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276,532<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share)</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share)</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233424584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,491,928<span></span>
</td>
<td class="num">(12,608,808)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,391)<span></span>
</td>
<td class="num">(23,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, ending balance</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Issued, beginning balance (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,418,369)<span></span>
</td>
<td class="num">(2,935,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Issued, ending balance (shares)</a></td>
<td class="nump">1,684,126<span></span>
</td>
<td class="nump">265,757<span></span>
</td>
<td class="nump">1,684,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, beginning balance</a></td>
<td class="nump">$ 1,657,214<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,636,317)<span></span>
</td>
<td class="num">$ (5,687,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="nump">12,608,808<span></span>
</td>
<td class="num">(3,491,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GainsLossesfromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(70,255)<span></span>
</td>
<td class="nump">150,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, ending balance</a></td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="nump">$ 531,228<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ChangeInFairValueWarrantDerivativeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesfromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) from Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesfromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677234012984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">110.82%<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
<td class="nump">81.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FairValueofWarrantIssuedPerWarrant', window );">Fair value per warrant (usd per share) | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantIssuedUnderlyingSharePrice', window );">Underlying share price (usd per share) | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DividendYieldPercent', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DividendYieldPercent', window );">Dividend Yield, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DividendYieldPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DividendYieldPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FairValueofWarrantIssuedPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Issued, Per Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FairValueofWarrantIssuedPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantIssuedUnderlyingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued, Underlying Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantIssuedUnderlyingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677264477848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Share Consolidation Narrative (Details)<br></strong></div></th>
<th class="th">
<div>May 22, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights', window );">Number of pre-consolidation shares called by post-consolidation shares (in shares)</a></td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight', window );">Number of post-consolidation shares for each pre-consolidation share (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">0.105263157894737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Post-Consolidation Securities Called by Each Pre-Consolidation Warrant or Right</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Pre-Consolidation Securities Called by Post-Consolidation Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockholdersEquityNoteStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677234344296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
<th class="th"><div>Jun. 01, 2017</div></th>
<th class="th"><div>May 21, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="nump">$ 24,752,993<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
<td class="num">(2,366,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,894)<span></span>
</td>
<td class="nump">6,195,363<span></span>
</td>
<td class="nump">8,283,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="nump">8,476,454<span></span>
</td>
<td class="nump">620,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,418,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">$ (699,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember', window );">Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,988,995<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
<td class="nump">17,399,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="nump">$ 356,824,172<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,333,474)<span></span>
</td>
<td class="num">(1,741,640)<span></span>
</td>
<td class="num">(854,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="nump">$ 311,077,859<span></span>
</td>
<td class="nump">$ 285,193,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,297<span></span>
</td>
<td class="nump">234,172<span></span>
</td>
<td class="nump">323,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,751<span></span>
</td>
<td class="nump">$ 732,367<span></span>
</td>
<td class="nump">$ 391,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,403,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="nump">12,182,532<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,360<span></span>
</td>
<td class="nump">$ 40,037,786<span></span>
</td>
<td class="nump">$ 8,476,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,329<span></span>
</td>
<td class="nump">133,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,976<span></span>
</td>
<td class="nump">$ 385,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,606,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,314,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,332,778<span></span>
</td>
<td class="nump">$ 9,152,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,805,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,396,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,268,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,710,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677202861096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,366,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,276,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,642,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,333,474<span></span>
</td>
<td class="nump">$ 1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,684<span></span>
</td>
<td class="nump">54,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM | Pre-Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="nump">519,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember', window );">Canadian ATM | Pre-Consolidation | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,933,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public Offering | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember', window );">United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">4,425,040<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="nump">18,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,538,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,390,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 856,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,012,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,198,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,628,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 884,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,249,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementConsecutiveTradingDays', window );">Immediately preceding trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="nump">2,494,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
<td class="nump">119,509<span></span>
</td>
<td class="nump">119,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Issued Capital, Excluding Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">2,477,665<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="nump">678,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,055,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,055,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 699,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives | Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Common Stock Purchase Agreement | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_NumberofSharesOutstandingPercent', window );">Shares outstanding, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,636,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,687,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Warrants exercised (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="nump">2,935,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberofSharesOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Outstanding, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberofSharesOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementCanadianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_IssuedCapitalExcludingCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_IssuedCapitalExcludingCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231997912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Outstanding Warrants (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, beginning balance | $</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant agreement</a></td>
<td class="nump">6,332,778<span></span>
</td>
<td class="nump">9,152,869<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Issued, ending balance | $</a></td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="nump">$ 3,617,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="nump">1,730,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (shares)</a></td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Issued pursuant to equity warrant exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at the end of period (shares)</a></td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233633192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Equity Warrants Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Jun. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember', window );">Shares Public Offering, Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">16,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 11,511,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share)</a></td>
<td class="nump">$ 9.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Share Purchase Warrant Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677290533864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
<td class="nump">647,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">1,817,500<span></span>
</td>
<td class="nump">1,020,000<span></span>
</td>
<td class="nump">750,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(141,418)<span></span>
</td>
<td class="num">(12,839)<span></span>
</td>
<td class="num">(105,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(25,520)<span></span>
</td>
<td class="num">(9,575)<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="num">(133,454)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(41,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">2,164,551<span></span>
</td>
<td class="nump">1,327,845<span></span>
</td>
<td class="nump">777,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="nump">$ 8.73<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">3.19<span></span>
</td>
<td class="nump">1.42<span></span>
</td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">3.84<span></span>
</td>
<td class="nump">11.35<span></span>
</td>
<td class="nump">11.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">62.49<span></span>
</td>
<td class="nump">29.07<span></span>
</td>
<td class="nump">13.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.81<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">4.08<span></span>
</td>
<td class="nump">5.31<span></span>
</td>
<td class="nump">8.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233117112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share-based compensation</a></td>
<td class="nump">$ 2,558,974<span></span>
</td>
<td class="nump">$ 1,470,153<span></span>
</td>
<td class="nump">$ 1,415,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (shares)</a></td>
<td class="nump">4,616,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232903384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
<td class="nump">1,249,361<span></span>
</td>
<td class="nump">647,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
<td class="nump">$ 8.73<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">2,164,551<span></span>
</td>
<td class="nump">1,327,845<span></span>
</td>
<td class="nump">777,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">808,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">545,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">459,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">289,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,834,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">769,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">493,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">392,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 6.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">168,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 24.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">168,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 24.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of range of exercise prices of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 52.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677235868184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract', window );"><strong>Disclosure Of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected hold period to exercise | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">110.82%<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
<td class="nump">81.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ExpectedForfeitureShareOptionsGranted', window );">Expected forfeiture rate</a></td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
<td class="nump">3.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedForfeitureShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Forfeiture, Share Options Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedForfeitureShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233153864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">209,657<span></span>
</td>
<td class="nump">260,755<span></span>
</td>
<td class="nump">190,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">154,923<span></span>
</td>
<td class="nump">270,098<span></span>
</td>
<td class="nump">102,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(229,962)<span></span>
</td>
<td class="num">(321,196)<span></span>
</td>
<td class="num">(28,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">134,618<span></span>
</td>
<td class="nump">209,657<span></span>
</td>
<td class="nump">260,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember', window );">Performance share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">61,051<span></span>
</td>
<td class="nump">63,156<span></span>
</td>
<td class="nump">94,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(4,210)<span></span>
</td>
<td class="num">(2,105)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">56,841<span></span>
</td>
<td class="nump">61,051<span></span>
</td>
<td class="nump">63,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2020-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_PerformanceShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212660280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">40,338,789<span></span>
</td>
<td class="nump">22,137,990<span></span>
</td>
<td class="nump">16,016,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2020-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677211650232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>year</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677260501464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of the year</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Regional licensing agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized in the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of the year</a></td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liability - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
<td class="nump">6,730,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
<td class="nump">$ 6,730,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2020-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677260441624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 9,360,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 9,360,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentTerm', window );">Commitment term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 123,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_FundedandRoyaltyRepayment', window );">Repayment, maximum</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OverheadRepayment', window );">Overhead repayment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPaymentGrossSalesPercent', window );">Annual installment of gross sales of product, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AnnualContingentPayment', window );">Annual installment of annual product sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember', window );">BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 97,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 652,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AnnualContingentPaymentGrossSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Contingent Payment, Gross Sales, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AnnualContingentPaymentGrossSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FundedandRoyaltyRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded and Royalty Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FundedandRoyaltyRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OverheadRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overhead Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OverheadRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677231431800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue', window );">Royalty payment on sales revenue, percent</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum', window );">Royalty payment maximum</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember', window );">SYNSORB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Milestone payment in connection with Share Purchase Agreement</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue', window );">Payment due period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage', window );">Royalty payment due to founding shareholders, percent</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage', window );">Royalty payment on net sales due to founding shareholders, percent</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Period Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentAnnualMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Annual Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentAnnualMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Payment, Percent Of Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=oncyf_SYNSORBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212687976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (22,505,057)<span></span>
</td>
<td class="num">$ (33,122,888)<span></span>
</td>
<td class="num">$ (16,489,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (5,401,214)<span></span>
</td>
<td class="num">$ (8,777,565)<span></span>
</td>
<td class="num">$ (4,452,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Foreign jurisdiction tax rate difference</a></td>
<td class="nump">3,237,898<span></span>
</td>
<td class="nump">3,088,811<span></span>
</td>
<td class="nump">3,312,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Employee share-based compensation</a></td>
<td class="nump">614,154<span></span>
</td>
<td class="nump">389,591<span></span>
</td>
<td class="nump">382,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(838,063)<span></span>
</td>
<td class="nump">3,341,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of Alberta rate change</a></td>
<td class="nump">96,028<span></span>
</td>
<td class="nump">3,758,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Adjustment to opening tax pools</a></td>
<td class="nump">20,711<span></span>
</td>
<td class="nump">11,973<span></span>
</td>
<td class="num">(238,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Other permanent differences</a></td>
<td class="nump">108,945<span></span>
</td>
<td class="nump">149,294<span></span>
</td>
<td class="num">(35,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Change in deferred tax benefits deemed not probable to be recovered</a></td>
<td class="nump">2,161,541<span></span>
</td>
<td class="num">(1,961,613)<span></span>
</td>
<td class="nump">1,579,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">548,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment in respect to prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Net current tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 548,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 80<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677260476216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-capital Losses (Details) - Non-capital losses<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 78,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">9,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">12,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">4,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">5,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember', window );">2039</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">6,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyMember', window );">2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 9,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyFortyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyFortyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233911656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 5,304,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">27,660,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember', window );">2021 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember', window );">2022 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">465,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember', window );">2023 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">361,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember', window );">2024 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">228,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember', window );">2025 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember', window );">2026 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember', window );">2027 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember', window );">2028 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember', window );">2029 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember', window );">2030 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember', window );">2031 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember', window );">2032 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">381,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember', window );">2033 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">487,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember', window );">2034 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember', window );">2035 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember', window );">2036 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember', window );">2037 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember', window );">2038 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember', window );">2039 | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=oncyf_TwentyThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233778344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 34,541,435<span></span>
</td>
<td class="nump">$ 32,712,066<span></span>
</td>
<td class="nump">$ 34,712,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Net operating losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">21,487,804<span></span>
</td>
<td class="nump">19,625,642<span></span>
</td>
<td class="nump">20,664,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">6,362,152<span></span>
</td>
<td class="nump">6,338,542<span></span>
</td>
<td class="nump">7,406,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">4,068,105<span></span>
</td>
<td class="nump">4,222,016<span></span>
</td>
<td class="nump">3,988,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember', window );">Undepreciated capital costs in excess of book value of property and equipment and intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">1,927,709<span></span>
</td>
<td class="nump">1,908,320<span></span>
</td>
<td class="nump">1,949,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">689,193<span></span>
</td>
<td class="nump">611,072<span></span>
</td>
<td class="nump">696,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6,472<span></span>
</td>
<td class="nump">$ 6,474<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233080744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 12, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,219,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
<td class="nump">$ 11,836,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 24,752,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (107,894)<span></span>
</td>
<td class="nump">$ 6,195,363<span></span>
</td>
<td class="nump">$ 8,283,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2020-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677237051848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 531,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="nump">172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | British pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">(Increase) decrease in net loss due to change in currency value</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 531,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,508,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677232832264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,219,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,148,021<span></span>
</td>
<td class="nump">$ 13,699,881<span></span>
</td>
<td class="nump">$ 11,836,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,805,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,173,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="num">$ (531,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,508,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,134,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(455,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(417,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,261,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 26,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 24,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 37,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 36,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2020-01-01<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2020-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2020-01-01<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677260437640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable', window );">Contract receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,767,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">1,979,111<span></span>
</td>
<td class="num">(2,017,122)<span></span>
</td>
<td class="num">(13,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseinPrepaidExpense1', window );">Prepaid expenses</a></td>
<td class="nump">286,391<span></span>
</td>
<td class="num">(2,012,605)<span></span>
</td>
<td class="nump">475,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,368,203)<span></span>
</td>
<td class="nump">1,347,365<span></span>
</td>
<td class="num">(1,858,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities', window );">Contract liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">547,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="num">(723,230)<span></span>
</td>
<td class="nump">807,877<span></span>
</td>
<td class="num">(27,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet', window );">Non-cash impact of foreign exchange</a></td>
<td class="nump">35,710<span></span>
</td>
<td class="nump">78,708<span></span>
</td>
<td class="nump">14,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="nump">$ 209,779<span></span>
</td>
<td class="num">$ (1,795,777)<span></span>
</td>
<td class="nump">$ 3,904,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Decrease (Increase) in Contract Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Increase (Decrease) in Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseinPrepaidExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseinPrepaidExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677211637496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 189,720<span></span>
</td>
<td class="nump">$ 274,094<span></span>
</td>
<td class="nump">$ 173,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 12,080<span></span>
</td>
<td class="nump">$ 5,448<span></span>
</td>
<td class="nump">$ 15,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677212159992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677237074664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses and Adjustments (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share-based compensation</a></td>
<td class="nump">$ 2,558,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,415,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">357,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction cost, warrant derivative</a></td>
<td class="nump">1,741,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember', window );">Included in research and development expenses:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share-based compensation</a></td>
<td class="nump">1,043,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Non-cash share-based compensation</a></td>
<td class="nump">1,515,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">88,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Onerous lease contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_AdjustmentsforLeaseAmortization', window );">Amortization - lease incentive liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember', window );">Included in operating expenses | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsLineItems', window );"><strong>Other Expenses And Adjustments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction cost, warrant derivative</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2020-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2020-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsforLeaseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for Lease Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsforLeaseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Other Expenses And Adjustments [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677233093832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 3,514,527<span></span>
</td>
<td class="nump">$ 3,786,667<span></span>
</td>
<td class="nump">$ 2,680,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">495,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">1,757,723<span></span>
</td>
<td class="nump">1,123,408<span></span>
</td>
<td class="nump">1,067,195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 5,767,425<span></span>
</td>
<td class="nump">$ 4,910,075<span></span>
</td>
<td class="nump">$ 3,747,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139677237383208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,628,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,249,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions | 2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">5,685,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="nump">$ 18,503,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share)</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="nump">$ 555,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="nump">$ 17,948,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2020-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2020-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2020-01-01<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M77%)]B2L,(%W8SF!]3;)L0%^M^HQV5$'V3W5/VX$% \+:!MZ=2"-.'5A/"?
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M$W/Q,10<6DTM@._76:8^+O0#ZM]5QG\!4$L#!!0    ( 'IX95)"/4PEY 8
M +,A   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK5I_;]HX&/XJ%MH?
M.^D8_I78F=I*':4M:TM[H[OI_DS!E*@AX1*G;-_^G) 28CLAK*=*)8'G_6V_
M[^/ R29.7M*E$!+\7(51>MI;2KG^/!BDLZ58^>FG>"TB]<DB3E:^5+?)\R!=
M)\*?%T*K<( A= <K/XAZ9R?%>P_)V4F<R3"(Q$,"TFRU\I-?7T08;TY[J/?V
MQK?@>2GS-P9G)VO_64R%_+Y^2-3=8*=E'JQ$E 9Q!!*Q..V=H\\3S'*! O%W
M(#;IWC7(0WF*XY?\9CP_[<'<(Q&*F<Q5^.KE50Q%&.::E!__EDI[.YNYX/[U
MF_;+(G@5S).?BF$<_@CF<GG:XSTP%PL_"^6W>',MRH"<7-\L#M/B/]ALL8[3
M [,LE?&J%%8>K()H^^K_+!.Q)X!(@P N!7!7 5(*$$V H 8!6@I030 W67!*
M 4>W@!L$W%+ [6J!E0),$Z!N@P O!;CN$F\0\$H!3[? F@H'WRH']4HTV4"[
M8NO5QEZ3R%NYD5YOVFCEK>!(KWBSE;>2HZ+F@^WR+=;^A2_]LY,DWH DQRM]
M^46Q@0IYM>2#*-_K4YFH3P,E)\^&]Y/I_>WXXOQQ= &FC^KE;C1YG(+[2S"\
M/I]<C:9@/ &CO[Z/'_\!'R]&E^/A^/&/DX%4MG,-@UEIY\O6#FZR<WX!/GZP
M"0[;!;]/FP0OV@7/95\N15]UL!?5,OWG1 C5HV2S(Z-V?0_94QC,P/UB(9(@
M>F[6<]FN9[KT$P$>LF2V5#T*G!]V[*J+PJ&_#J0?@@_->JZ/TG-T_L9'J>^<
MSJ]'J3T^NS?M^G_X2>)',FU+[.V!M1]',@F>,BGF8)HEZS!KU79W8%W/9MDJ
M"_U<V[VJ4 *&\4K-^64^@%\%&$>S>"7:#$RZ&[@0BV 6R 9M ]5L=AT'[SH.
M+M33!O6C?[- _@*^5,IGGP!!?P(,$;.UE*TBMU"4DY;7,XXYX=0]&;SN[P\3
MAQEB""+"Z\@;$TE<Q#P(Z[A;FT:(.=85WED4,O6GZ9N8L#[V**4N<BMH+9UD
MET[R?Z5SJ\@YF$X3UY1.$VE/ITVC-9T6A;9TFK!#Z:2[=-+6=$Y4KPOC- 5^
M- =QL;UFM>T5%-O+EEYJ.H5<#@EUD!:EB<2$,$:U*&T*&20,8\<>I+,+TFD-
M<IRFF=K<ZRQ),]7;@(SSL%27S -,BP[J;_Q$(4(_LH7J&)YI%;HR$0AZ3,_$
MK0GK:[A:@.XN0/?8 !67FKV >%V<,)KB<DVO,7'T57IE@7D,4T<+SH3UU6*&
MS!X;V\7&.L1FXT/,:#*N.O(AK30C$X;4MG$YQW7@I0DD!%%5GCKNNIO=<5>[
M7P_;K26.[Q+'CUT4F^UPK]B-;5%PL]H4:3D8<K/!$[UM75DT,:IINC%!-4VU
MT+U=Z%YKZ 4KZN=GXGG1SE0O\_.-8 O7LX7K<$*TU7T85W,5P>I$ @\["X*\
M6LK95*;6TP:TC #BJG[K:4GO@JQ[NG=V0K\Q>[G57V1XX2+/(2[1W36!F#O(
M(]#5FN>-!9J/7X?IX]>J$ZN]AS3K=S8W(7.@/IHLN#Y!B*KR\X;AA"J"B'Z'
M(=K3BKNFU00VIM6$-J35IM.>5HN;UK2:N(-IK8@B:F>*[Z VR$*X",&NBSV=
MV]B@B!(*B1ZK52?"F'/>$&I%XE [BWLWP4$F]]*;N05"/.3ID^'6@NMKP'J4
M%8M#76B<]<F(R:LX92YUM 4W*H'ZK*58ZZ*7%J"C:KJ_+,MG#!U-C[N:_MK!
M=#V!%4M$1]/$3HP F<S.0P[FKC%[#@/KKE<D$+6SP&,F>JFJ/JH91(X^TCL
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M0@SB$DD;+/UF:<_NDVG0E"DG.O"M.YW2".NGY80E[\C47<L/Y\BW/ ELAN<
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M7_:[OI:@/-:>Y,:)A6NHFCMFMO;E#+/./ NRX"[/@ '>RNQYGCD3 S((]@,
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MIPU4Z59$WR/A&L43!&S\_8K ^- [44(X1M'211:UYY^G -A:-$=C58!,0<M
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M+&YN?PUT&#ZN*C/KFG;>YT\RQ&MC&Z/_)'Y48Q,[RF*C-$J\1\N;.9>?/M;
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MJ57M>6%R>;Z6*[Q'_\?ZUM+;9(]2JA:U4T:#Q>IB=)6<76=L'PS^5+AQ!\_
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M>#RCJY+M+U/]BS?K<(%9&D_7H?!8TSA&RP:T7QGC=R\<8'^CO?P/4$L#!!0
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MCT$-T(D#;XPW,/S4H>%[#+D0;@>8HJ@D5$-VC\N(M]A7XRYB9R^9%DDX-_2
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MSJ-#>2\36]5\!C:XR@=B%/E A(5\)Z")DX8125P*,R<),"-C'R\DO\T"N#.
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M;<59P94AP'XI93<NS '3-ZNS_P%02P,$%     @ >GAE4CP,>;>^ @    8
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M"V</9C'3C9-"T8,!VU05FOV*I&[GT20Z'#R*;>G\0;*8U;BE)W(?ZP?#NV1
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M 1DOP/<;K=UAXPT,?S<6?P-02P,$%     @ >GAE4INN??$O!   & D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULG5;;;N,V$/V5@9H6":"U93G.
MYN(8L)WL=K$--DB:[D/1!TH:66PH4DM24=ROWR%UB1-LTJ(/MD5RSIDS-]'S
M1NE[4R!:>"R%-.=!86UU.AZ;M,"2F9&J4-))KG3)+"WU9FPJC2SSH%*,XR@Z
M&I>,RV Q]WO7>C%7M15<XK4&4Y<ET]L5"M6<!Y.@W[CAF\*ZC?%B7K$-WJ*]
MJZXUK<8#2\9+E(8K"1KS\V Y.5T=.GMO\ ?'QNP\@XLD4>K>+3YEYT'D!*'
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MDPOQB_0 G?RMN+1B"WGM6AB2+7R1)&QK>6IVW(U@24L+U*!8)N2^;](0&J3
M4J4=7'(!^R]L)B?P#NYN]R;A+(K"*(H.*$^@*$?: 9$_L$0\KR234%>YIMGJ
MDP<JWPF,4F<LD$'99Z/J*F0I4\89MR7833#;:$3/Y<(B02?OP^GQY%6]1[,X
MG$9'.VH%9PD7?=_1)6"(S?557E.#89=4I\VU+B3H&J+6&K,1W%%ZJ7%?5N!)
M%'V0+ E"4-\,+H2E(&&6P9K)E/ KQ70&^[_\=!S'T=ERO?)/D[,#7X:"/6#+
MZ+-($MG6L[!2U>2BJW'MI?C]P;M5&_0Q>L\,M-HR8:GC7#5<+R<TPYE[\_*R
M+GM"RO/>85M4J$3M&L8/2T'78^N^K]W>I#4+J;!4"\-<Q6F?@:%IXSEW<Z)5
M5J=VY-\)/XB"PG6U8%+6KG<E#8<0_> YUYTJ_.;.">I Y,=06"H_A7UV +.?
MG=>-5L:\*>(,Z#6SGQP,PGV'.=<E*"K%FV _^TA6HQ^]:<<[MU6)>N/O9$,8
MTMY>7,/N<.TOV]ONR;S]SW#%](;R0$'F!(U&[V<!Z/8>;A=65?[N2Y2EF]0_
MNMJ@=@9TGBME^X5S,/P96GP'4$L#!!0    ( 'IX95*D\6N%F 0  #P*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)U6:V_C-A#\*POU@3L@]4-)
MVB27!'#N6C0H[AK$;0]%T0^TM+:(4*2.I.*XO[ZSE*PX3Q0%@EB4N+,[N[-+
MGJZ=OPD5<Z2[VMAPEE4Q-B?C<2@JKE48N88MOBR=KU7$TJ_&H?&LRF14FW$^
MF7P_KI6VV?EI>G?EST]=&XVV?.4IM'6M_.:"C5N?9=-L^^):KZHH+\;GIXU:
M\9SC[\V5QVH\H)2Z9ANTL^1Y>9;-IB<7![(_;?A#\SKL/),P63AW(XO+\BR;
M2$!LN(B"H/!SR^_9& %"&%]ZS&QP*8:[SUOTGQ)W<%FHP.^=^:S+6)UE1QF5
MO%2MB==N_3/W? X%KW FI/^T[O;FAQD5;8BN[HT10:UM]ZON^CSL&!Q-7C#(
M>X,\Q=TY2E%^4%&=GWJW)B^[@28/B6JR1G#:2E'FT>.KAET\?^]LU';%MM <
M3L<1D/)A7/3F%YUY_H+Y-*>/0*@"_6A++A\"C!'+$%"^#>@B?Q7Q Q<CVI_N
M43[))Z_@[0\$]Q/>_G\A2'_-%B%Z2.'O5Z /!NB#!'WP?W/WJKFTVTEH5,%G
M&?HIL+_E[%&XLX!F:9)\9RO/C&Z(=&EI>GQ\O$=K)JS9<TG:1D<*(A]VQ4I%
M4F*/SP7[B 8EMS!ZI00OT)M8,7W[U5&>3]X]YR=]FKY["VPJG+5]&ZUUK$C1
MO%*>Z:KU186>V(EN%_:E30/T@N.:V=+\ST_S7Z\OP* DUWJ28<,8'6)?.5.R
M#P2"M;IA-(%AM(5E:M1&T$(R\VZC3-P,+T=('KDE04]<+P"VU=0>HG^"06L5
M*$1M#/S'$(&(*D@<]/5T-!$# _9[5+:<4H"D'$^H5)OD1#@OM0\1<ZI@W41:
M>E=+069-XUWCM8I,U[QJC8K.;VC6QLIY'3=[R0?FX0U+W4G)_EMEA"YFEZ&&
M#9+@/#?R2APU+:I8$,QD-1@@#$468[#T;<+!IE3JY.$>9D2_53H\30'T5*$4
M6*F%8:PD&0LX* K70F9EPD&:1*L*)4UI+_D6@[U).>0['!6HL[Q/UM9%0<!@
M:"$>H"8(;0M7,T5U!RJ^<8%1+(A:E:5.\?8\GXEPJ'BM-D!..%(1\=@'+G*5
MD'VI;-'5*J&]*-BV2<>+,OJ?+EU(9%!P+0^[:;M<2L>E M_R$[U)/1P<^1U9
MXD^RA0-"L%*O2HU3LS;*1PM=5[K9L57>*W1_9[_L2[R;XUYLB.E6^Q9=P45E
MG7&K39H'PK%O<A0LN=EL\[E$&9.J'[35=#+ZX? ;>I-/IL?T7;]\._AYS#)U
MZ$.:?49*=)P!0ZODG#6(1Z>$]=$_"AL)C]V<ZD7MM'0A@%'!V->W[PLPD5F&
M*51C*A0:8C<"NM=9WL>Q9.\[VA!!1]GSRB7.DOU.$+VL851VF]5CFL(^'TUW
MTI)6*2N?<%&:)WEL>:<ZA18-@4X4I4/.%]>7VR'X&;<2B><7;<M^\)%,>:\7
M;=+;<R?1>.=$!^=5NK<$2IW8'>[#V^%J-.MN!/?;NWO51^57&O/>\!*F4MZ,
M?'=7Z1;1->E^L' 1MXWT6.%ZQUXVX/O2N;A=B(/APGC^+U!+ P04    " !Z
M>&527N-%6Q,'  !]#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R=
M5VUOW#82_BO$W@L2@/&*E$1)J6W 25-<@.M=4#?7#X?[P)6X7K9:4:4HK]U?
MWV>HE7:=JWW7 H:70W&&,\^\\O+@_$_#SIC 'O9M-URM=B'T;]?KH=Z9O1XN
M7&\Z?-DZO]<!I+];#[TWNHE,^W8MDT2M]]IVJ^O+N/?)7U^Z,;2V,Y\\&\;]
M7OO'=Z9UAZN56,T;W]F[7:"-]?5EK^_,K0F?^T\>U'J1TMB]Z0;K.N;-]FIU
M(]Z^R^A\// O:P[#V9J1)1OG?B+B8W.U2D@ATYHZD 2-GWOSWK0M"8(:/Q]E
MKI8KB?%\/4O_)MH.6S9Z,.]=^X-MPNYJ5:Y88[9Z;,-W[O W<[0G)WFU:X?X
MGQVFLZE:L7H<@ML?F:'!WG;3KWXXXG#&4";/,,@C@XQZ3Q=%+;_605]?>G=@
MGDY#&BVBJ9$;RMF.G'(;/+Y:\(7KCUWM]H9]KQ_,<+D.D$C[Z_K(_6[BEL]P
M"\F^=5W8#>Q#UYCFJ8 U5%GTD;,^[^2+$K\V]05+!6<RD<D+\M+%OC3*2Y^3
M9X>Z=</H#7-;9B=K@WY@_[[9#,$C*/[SPBW9<DL6;\G^((HO<E/>O1UZ79NK
M%1)K,/[>K)Z(9-_O#.N]N[<Q%Y"*9Y;@LS>U\\ ?NRS@:.VZP;6VT0%[6]OI
MKK:Z94/ !A(J#*RQVZWQ ]MZMX\L>N_&+K##SM8[)-+8-FP#R#8!>0TAFT>F
M^[Y]M-U=/$ZBQN#\XSFD'N)9</$ ,!\@ :J:I[IJ7.I:U(+A;?0Q_HF*_I7L
M[\_QO)*2YTG.D[QXS5ZE*1?8*,L2A% \*RLNRO0UNUV4>J\[W5C= 0G?NTFO
M64&9720)^PN3ZB*/O\5$WW3!UK:/F,7# /7>0-BKG&>)X%)DN*_D15'P7.58
M9SS+)4^*ZC5#A4#^=^S'T=NAL5/%6:Z<T#9=;5C*95KPLBJQ2LJ2ET)@E0K)
M*Y6R#_N^=8\&^.ZT-V^HW#2P88\2/.@H4XF,BSQC*8S.*_"6DLLB9^]WNKLC
MV-A66\_N=3O&B#]H[S4<VQAO[S550-B0ECQ1  P79X*G:<;^^J=2"OD5^[A'
M' 9BO&DWQ@<]&5!/TBO%$TF:%WG)!6Z=V6Z:'U&J*+3(_]0Q8J# _MZA0,&]
MO("A0O"J2.%.*""E?,W^B5#QK#<HKQTQGX :F$A*7F4Y$UG%997![SFO!)A.
MIJ+Z&N^/_MJ8SFPMQ;9!D#>L<X%R9J,W;8Q*R842/,\$@@9@"ZX$(,!.4?%$
M%.S]"%'0X4GDS0;.OWD&Z#)Y;K"EYC3TZ#)T2^^MBQ99U_PW^_S[#W3;^G@?
MZ6X>R,/F^>N0-X&A-IH]O++41\X.ANTT?$HI-Z45 =^Y[DVM>QN0])2(9OBB
M9K!^1%[0/K2/R:+?L@\/O46X_YE$*U;Q,@$P"26H+!@"5!3)3%<LPW+^G"8@
MBR*;20$RS=*9E("^+!8R!9GEQ4QF1!9R)G-&V9W/I&+([W2^-RT@N13+X9)1
M35 S6>%PJ68ULB3:,/$6B*5J^O('L,2@,'9-#*2M028!5MO=FSGB@6>-**38
M^YTP ZE"S*!*EJG9<)FR5"U?@)$L9R)'Q5J^*);+Y.2EO)K!0)HJ*4_^$B<'
M !=Q<I40V<E1:2E.;LK*<R<MSH>+4&U/#LK$R3M5>?3+<C6<,FF>\S3).!V
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MM=L^#3\.VV>)N*,P UF-9,R9HM\WSE*3EEAS//.=PTO2>R,%=69E4(H,#Q#
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M5Q<#.( _U<2;8&O^/+*P(=B*+PN% <*1 )XO+4QM;^B [GO9[=]02P,$%
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MKS=(G(TDSA*)L__C!/XC:+IM'4GK&NM$8"H./VG1>13=0XLM%"H19L2/DIM
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M4F9O];Y/_4/4[5D]8>_D=%*B=962U0O.\%9P1/&V1=.:P3=2&S2@E.CB8*B
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MU%XB*I4T2O"*>5-++Q\/K3H\'Y>3H;%QM\8!AVG::B:,NHZ/.-G3^LZ*IO"
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MBPA,OQ][Q>DN[*2-=K3A@MC0)P6-=R#[5FMW5GR"X2.U_ U02P,$%     @
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MF \W(5!E=%=6H#L#UYU"/T]8?[D!1I3T PK)O<I=-PBD-(BL-PJA1Y#6=EA
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M53XC],#<6]]*X-T8.JI1?P#>$>UB&M"B$INY+:5$'L8%1G2;+32&;&]!H5@
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MAEHW:B= YRNE[&'A# P? _-_ 5!+ P04    " !Z>&52OK']KE,,  !H(@
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MIFAQ='>7UDULL_;W5Y/&VF;EATM5S)1V!/@^;QJ[FS@!_87FY7\!4$L#!!0
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MG5Z<!:"[&=9MK*K]W$B4I:?OQ9+&/FJG0/>Y4G:W<0Z&'\GR-U!+ P04
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M-HS#0>W3LC^9/A1;A?8*-49O&C+GG'T--P\(Z\(5 [SLZ)YCS??@$9SRQIV
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ME'H[C]+H_>!.K&OG#Y+%;,/7>(_N87-KR$IZEDHTJ*S0"@RNYM%Y>KK,/3X
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MMI8=-7"O^"]68+T(;@-20$E;CD^J^PI#/5Y@KKCQ7]+UL3?S@.2M026&9*M
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MU7S@=!V4PA3GF;KCJQ]0&HH,7\(S:9]H5<3&.CC)I>*T!&L%E+#BC==E(K8
MP2% 4 *"8P%A"0C? OP#@'8):!\+B$J M>X6WFWBQECA85_P%1(F6K.9ALV^
M1>M\$686RKT2^BO1.#7\!3K+$IVA&RP$-I.&3L:@,,GD:=]5^@\FSDU*MLN"
M+3C Y@?HFC,UE^B*I9#N$KA:6J4OV.B[#!H9QY"T4.A_0X$7>*.+,3KY<BJ
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M;YL[_>$&PDS0]S><JU/'O.FWGX*+?P!02P,$%     @ >GAE4I]SKJ?U P
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M[<$]KLR-$*4U,-\70NC#BYV@OF.._P502P,$%     @ >GAE4M[2 "M= @
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M@/["<"PK9IW^859@# E!8AAK4Q!"%K$X1@XC=;& _FH1@J$3: -Z F-,'5
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M S_JV506MR^4J^P ]Z^4I[F@X)'G*17@PX)*DA?BX]25*D@]E)NV <V;@-!
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M1-&%)!:N0WM>(@B I!@)R?TJXHY1UA61U@]-^<ZM%4!3<?1W8Z+[;HPPB_:
M7C2V?9B?Y^Y;$RNS@Z<;0"S,(#Z$5MWULDDK0+/8@>86( 9510%L%F^&S1+8
M+ _-YLJ@VV9SW[8<8+,<P^9!95$"I>482A]7>N"P-'-X#^F[.PVJ2M;2WF[L
M;HU4\EAL*TYUV5DMLG*C:_UMO77Y2[%AUX;FY;[G:S]Y#'3PH7K071U+:APD
MY5;B\B2+E\5>V?LXR^*H.)PK?Z:2O('^_2&.L_5)/D"]H?OL?U!+ P04
M" !Z>&52 QWWGV #   &"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6R=5MN.VS80_96!D )9H*NKKX%MP+82M ]!%KMH\E#T@99&%K&4J)*TO0;Z
M\24I6;%=677R8HN7<V;.#(><V8&+5YDC*G@K6"GG3JY4]<'S9))C0:3+*RSU
M2L9%090>BJTG*X$DM:"">:'OC[R"T-)9S.S<DUC,^$XQ6N*3 +DK"B*.*V3\
M,'<"YS3Q3+>Y,A/>8E:1+;Z@^J-Z$GKDM2PI+;"4E)<@,)L[R^!#/#7[[8:O
M% _R[!N,D@WGKV;P>SIW?.,0,DR482#Z;X]K9,P0:3?^;CB=UJ0!GG^?V#]9
M[5K+ADA<<_:-IBJ?.Q,'4LS(CJEG?O@-&SU#PY=P)NTO')J]O@/)3BI>-&#M
M04'+^I^\-7$X X3#&X"P 83W J(&$-T+&#2 @8U,+<7&(2:*+&:"'T"8W9K-
M?-A@6K263TN3]A<E]"K5.+5XR8E 6.G(I?!$CCJA2L(CQ%0FC,N=7OMF0Z>7
MEWL4^B3 4NHS4IFL22!E"I\(%?"5L!T"S^!+L_(^1D4HDP\S3VD_C34O:7Q:
MU3Z%-WP*0OC,2Y5+^%BFF%X2>%I@JS(\J5R%O8PQ)BY$P:\0^J&_7L;P_MW#
M$8GH\&U]-U,P[6>*[V>:W&2ZD!NU28TL=72+^GOVOF1@4_RX.4\Q+(4@Y1;K
M=/^YW$@E= 7^U6-[T-H>6-N#&[:?J7Q]S 0BT%*A0*E $(5=IZ"?R'>CP2]=
M">J'!>XH[(+%_;#0]:]A%_*'K?QA+\_'MTK?:#K2.6<I5"@H3T%QP#<4"94(
M_\"-X[*JB8>6V-S6^T4T\_;GRO]W1]RWXT+/J-4SND^/M!=%)6B"L.>,*,JH
M.G;IZ"<, M^==&9HW0^<CMVIWYG9?MPD<(-A7VK';2C&]X5"/[894F7*Z];1
M[F>*W-&X,P(_!XM_&':A?]+JG]RG/Z5[FJ*^^8\46=HEOY_(=_W.1*Y_#A;_
M,.Q"_K25/^WE:=]!TKR#F7GW]J=WCY_>O838NJ\+YD'7^[NN"-6VQF>%&KI!
M>%7O_]VD:V=\5?)=3*/Q5=5[9QU"@6)K.RT)"=^5JGY&V]FVF5O:'N9J?J6;
MO+HG^TY3=XB?B=A2'0"&F:;TW;&^A43===4#Q2O;AVRXTEV-_<QUHXK";-#K
M&>?J-# &VM9W\2]02P,$%     @ >GAE4O!M550B!   4P\  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C0N>&ULS5??;]LV$/Y7"*,/*9!8(O7+*FP#<=1M
M?>@:)%C[,.R!MLXV44ET22IN@/WQ(RE%MB59<3L,V(M-4=]]NH^\X_&F>RZ^
MRBV 0M_SK)"ST5:IW3O'D:LMY%2.^0X*_6;-14Z5?A0;1^X$T-0:Y9E#7#=T
M<LJ*T7QJY^[%?,I+E;$"[@6299Y3\;R C.]G(SQZF7A@FZTR$\Y\NJ,;> 3U
MQ^Y>Z">G84E9#H5DO$ "UK/1+7Z7X- 86,1G!GMY-$9&RI+SK^;A0SH;N<8C
MR&"E# 75?T]P!UEFF+0?WVK24?--8W@\?F'_Q8K78I94PAW/OK!4;6>CR0BE
ML*9EIA[X_C>H!06&;\4S:7_1OL:Z([0JI>)Y;:P]R%E1_=/O]4(<&9#HC &I
M#<BE!EYMX%UJX-<&OEV92HI=AX0J.I\*OD?"H#6;&=C%M-9:/BO,OC\JH=\R
M;:?FCULJ "WTRJ7HGC[K'542W:!''5]IF0'B:_1[F2]!F-$GM=6#]]]*II[1
MAT(J458&5PDHRC+Y=NHH[92A=E:U XO* 7+& 4S01UZHK43OBQ324P)'JVDD
MD1=)"S+(F,!JC#Q\C8A+W+O;!%V]>2N-3-GCW=W%7#A^C2NYG&LRP'4BVFOV
MT;/D_AGR!]"[P59*;Z/E1&7!U!"QWQ#[EM@[YS63JXS+4MA84"!RB6B1HA4O
M4F925YIY^\V;I0VC715&B I!BPW8\9^&%C$%N?QKP*F@<2H85/NI5%)I+UBQ
MN49+V+"BT$/KX!;0,U"!KJJE[8W(BCRPY.9@?)H3-PZ#:.H\'8=&#RQTHR X
MA25=&(Y=WSVPG4@,&XGAH,1?]>*9W4Q+8:1=I"OL>A+X,?%:NKHP$KEN/&GI
MZF%SR>1(_HFNJ-$5#>K2I_4:V(\JBSJ^N"U1KR*2+N+&)]CMES-IY$P&Y7S6
M>?>#6B9=/PB)XY"T%/7@/()Q'+9T]?%-2'PF_N)&6'QYBH%.^$N3*^Z&C>>'
MN!5==UU87PXF/;#3'#P1A]U#V7,'Y7VQ%P*]<_0)A+[@H#5E CW1K 1$%<J!
MFB//GETI57"-N*U]4-4^=E3[-G6B_HW>]%:_RH_H6,'8QZW5Z$&YXW9"]H"\
ML7=N*8YN 'AP*>Y!V/MCL8(+:P<F!V[R_ZD>^% L\7"U_)?UHV8_CLH0NT%G
M4WM@'@[:^=L#B_W(\\_LZZ%P8_\_.&EKTJ&C]G5(T@.YT=*CR1E1A\*/ARO_
M3YRWN%N@3P_^6E4/3*/:U;X'=J:$X$.IQ\.U_J?/6MRMT4$XZ9XN75A/O"9]
ML)-XK>0Y1]U&#F)CNS:I4[HL5'5+;V:;SO#6]D.M^87I&&T7<Z"IVLV/5.B<
ME"B#M:9TQY'V250=7/6@^,[V-$NN=(=DAUO=]8(P /U^S;EZ>3 ?:/KH^3]0
M2P,$%     @ >GAE4HH6Q;1B @  Q04  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C4N>&ULC53;;MLP#/T5P4\ML-77.FGA&&B2#ANP D&#K0_#'A2;B85:
MDB<I2??WHR3'2R\I^F*+%,_A362QE^I1-P"&//%6Z$G0&--=AZ&N&N!47\@.
M!-ZLI>+4H*@VH>X4T-J!>!LF492'G#(1E(73+519R*UIF8"%(GK+.55_I]#*
M_22(@X/BGFT:8Q5A671T TLP/[J%0BD<6&K&06@F!5&PG@0W\?4\L_;.X">#
MO3XZ$YO)2LI'*WRK)T%D X(6*F,9*/YV,(.VM408QI^>,QA<6N#Q^<#^Q>6.
MN:RHAIEL'UAMFDDP#D@-:[IMS;W<?X4^GTO+5\E6NR_9>]L\"4BUU4;R'HP1
M<";\GS[U=3@"Q/D)0-(#DI> [ 0@[0'I1P%9#W"E#GTJK@YS:FA9*+DGREHC
MFSVX8CHTIL^$;?O2*+QEB#/E=ZDU68 B,\DY]F'94 7D; Z&LE:?D\]$6XTN
M0H/>+":L>N:I9TY.,,<)N9/"-)K<BAKJYP0AACG$FAQBG2;O,LZANB!I_(DD
M41*]$=#LP_#XZ@WX_./P\3O9I$/E4\>7GN"[I4HPL=&DP^J[(I-?=*6-PE'X
M_0Y_-O!GCC\[P?_@GCS4A.Y X003L>4K="77I/*]]ITEN RTH:+&8,B9UYV_
MU6[O[M*YL]MD5V91FHY'8RSF[K@-KPV3)$Y'5U?1<\/Y:\,XC^(\S?/!T*<>
M'CUP#FKC%H7&/+;"^/<S:(===.-&\(5^BCO*KY3_-'[!W5&U84*3%M9(&5V,
M,"SEEX87C.S<&*VDP:%TQP;W+"AK@/=K*<U!L Z&S5W^ U!+ P04    " !Z
M>&52-4VZ=BP"  "&!   &0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q]
M5$V/FS 0_2L6IU9J8T*2[6I%D/*Q52MUJRBK;@]5#P8&L-;8U#8A^?<=&T*S
M4I,+>.R9]]Z,9QQW2K^:"L"28RVD60:5M<T#I2:KH&9FHAJ0>%(H73.+IBZI
M:32PW ?5@D9A>$=KQF60Q'YOIY-8M59P"3M-3%O73)_6(%2W#*;!>6//R\JZ
M#9K$#2OA&>R/9J?1HB-*SFN0ABM)-!3+8#5]6,^=OW=XX="9BS5QF:1*O3KC
M:[X,0B<(!&36(3#\'6 #0C@@E/%GP Q&2A=XN3ZC?_:Y8RXI,[!1XB?/;;4,
M[@.20\%:8?>J^P)#/@N'EREA_)=TO>_=+"!9:ZRJAV!44'/9_]EQJ,-%P/3^
M2D T!$1>=T_D56Z994FL54>T\T8TM_"I^F@4QZ6[E&>K\91CG$TV2EJ-I2'?
M.$NYX/9$F,S)'C+@!Y8*(!_)=Z8U<\4C[[9@&1?F?4PMDCL(F@U$ZYXHND(T
MC<@3<E6&/,H<\K< %%6/TJ.S]'5T$W$+V83,IA](%$;A"9B^@3D;RS'SF+-K
MF-QD0IE6 U$%-MT!9 NDT*HFV5 I@S=DJ^%N0!OR:Y4:?_+[AH#Y*&#N!<RO
M"'@\-MBOD"-WIDK)?>LVH+G*_U?S'FSAP=S\'9)%3 ^7_/2B-U!NZ2? 8#:M
MM'V;C+OCD*WZWOKGWD_H$],EEX8(*# TG'Q"7MUW?6]8U?A.2Y7%VOAEA0\%
M:.> YX52]FPX@O'I2?X"4$L#!!0    ( 'IX95)ZO\*V4@,  %H,   9
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M88[-/R@+P.=+*<U^8E]0_SLQ^@Y02P,$%     @ >GAE4D&QA%IY P  = P
M !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULO5=M;]HP$/XK5K1)G;0U
ML?,"5(!$@6F3-JUJ]_)AV@<3#K#FQ,QVH/WWLYTT0!LRF*;Q 6SG[KGG'MN7
MH[\5\J=: 6ATG_%<#;R5UNLKWU?I"C*J+L4:<O-D(61&M9G*I:_6$NC<.67<
M)T&0^!EEN3?LN[4;.>R+0G.6PXU$JL@R*A^N@8OMP,/>X\(M6ZZT7?"'_35=
MPAWH+^L;:69^C3)G&>2*B1Q)6 R\$;Z:XL0Z.(NO#+9J;XQL*C,A?MK)^_G
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MH:T_(*V!>;X00C].;(#ZC\;P-U!+ P04    " !Z>&52>YH4"_T"  !B"0
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M8&9E4Y\V+UI4=<6V$AKJO_IQ"S4]DT8 WZ^%T,<7TT'W7X+Y_U!+ P04
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M0!7Q5\+V1><:Z:FL./^F;V[7LY&K%;&4Q5)34/7OB2U8FFHFI>-[33IJQM3
M[O4+^U4U>369%2W8@J=?D[7<SD;1"*W9AI:IO.?[&U9/R-=\,4^+ZB_:'V+#
M<(3BLI \J\%*09;DA__T1YV(#@"# 8!K !X*(#6 # 5X-< ;"O!K@#\4$-2
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MZ0#U?L.Y?+G17Y;-SR?S_P!02P,$%     @ >GAE4BK<+N'  P  JPL  !D
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M=<H7EEAR2J(B*$LM9-N>E9$D'XQ'Q;5[/AZQE4R3G-YS(%991OCS%4W9YG(
M!]L+'Y-%+/4%:SQ:D@5]H/+S\IZK,ZMFB9*,YB)A.>!T?CF8P(M;5 04B"\)
MW8B=8Z"E/#+V39_<19<#6V=$4QI*34'4WYI>TS353"J/[Q7IH!Y3!^X>;]EG
MA7@EYI$(>LW2KTDDX\M!,  1G9-5*C^RS1^T$H0U7\A24?R"38EU_0$(5T*R
MK I6&61)7OZ3I^I![ 0HH>8 5 6@4P.<*L Y-<"M MQ3 W 5@$\-\*H []0
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M(%6AWO#S[] $%!J^E!?2_J)S_6ZL5TPKJ7C9@/6XI*R^DD]-(GH S3,,\!N
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M>GZ$8U10-6^</FSE+S@B!9LUL^[-1E2S6OFS69X[*1.V7Y'!/U!+ P04
M" !Z>&52EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
M4$L#!!0    ( 'IX95+CK?2Y,@8  +\U   /    >&PO=V]R:V)O;VLN>&UL
MQ9O;<MLV$$!_!:.G=J:N+%Z53)P9U9(;=5S)8RGI8P<F(0L-2:@ :<?Y^BZH
MR%[*]$Y?UGY2>!%R!)![=@'XP[VQ7V^,^2J^E47ES@;;NMZ]'PY=ME6E=+^:
MG:K@RL;84M9P:&^';F>5S-U6J;HLAL'I:3(LI:X&'S\<VKJR0WQ@:I75VE1P
MTI_XHM6]>[KN#\6==OI&%[I^.!NT_R[40)2ZTJ7^KO*SP>E N*VY_V2L_FZJ
M6A:KS)JB.!N,]A>^*%OK[-GIE8=<RQO7GJGES;4$D+-!<@H-;K1U=7M'V[X$
MQCL%-^^/FMI<Z*)6=BIK];LUS4Y7M[X9^!5#]#/:?CA\[COQO?T_W6@V&YVI
MJ<F:4E7UOA^M*CQ@Y;9ZYP:BDJ4Z&YR;.V7][X'_8)[O?UL-4*BG['L-%^P\
M;_$849:+U?)R/IVL9U.Q6L/'G[/%>B66%^)BOI@@R(" #-X0\N\ 088$9/AF
MD)?+U0I!1@1D]&:0YY\F"P09$Y#QVT%.5I\09$) )KR0\RHS=F=L>T7(*A<+
M63=6";,1RYU"D"D!F?)"_B:==I[H0E>RRK0LQ,JC^*^)*QR"Q@3DF!=RU92E
MM \><Z5O*PU?DX WR3+35+5&D.\(R'?,D(CLCR:_];>[7\3,U1H:P\,].J6B
M^2GSJR/=5LS^;?2=+#PAYB(MPZP92!EV(/2']D7Q?#O_!4Q'Z67$[)=+)9WJ
M]!7ED1&S2/Z2UOK';*HL#*-/83 9)8\1LSU66PD![ESN-.1K&(J2Q8C9%GLH
MB'0J%U?RH3Q^["E'C)@E<6F<$U?*BG-3EJ")EA7#46X8,<OA'-)N"SFRN-1R
MGZFW;^>URA0\=S<8D[+#B%D/ONMT_6Q8*1>,F&7@>PYJ!P5&[82-@ K] 7/H
M]PE)J<1:?NLR46$_X*XN]J%"3+7+"N,@/>J@D24%<\Q_RHCFE:MM<_R !90"
M F8%3/)<^Y- UQK]HC#WJ!,Q)N6#@-D'\RI7Y3XM:K-@G_JVW[7.AQ*,21DB
M8#;$+#.5*74&1H56<GAM.SU("2)@%L2RWH(=9M^@"<A VO@[R?]IW+-X%U"F
M")A-<>U/MGKU*=P:LA,GV_F?#B$EB8"]AKAQZM_&ES6SN^.NHU01L*NBW$G;
M9G%0A-T>1<"0$D;(+ RR[NK.JE ."9D=0F.&&)/R2<CLD_X*1_RTEL#A?L:8
MY"05LUGVI4XO%F62D-DDSVN>7D3*(N&KU!F'C*:/CA))R"R2OBJH%Y+R2/B6
M%4<WXE R"9EE@C/IWCZDA!)R"^5Y2MW'&%%FB9C-TIM;]U)28HF8Q4(FV9VG
M,:+$$C&+A4X1!<:DQ!(QB^7E'+$=>(Q)KG]P3V&1V42$,2G91-RR(3%CC$E9
M)V*VSO%TLS@1"V_RO<"G&)/R3L3LG9=RLZFJI2YP0AY1WHF8O?,C-^OVX1ZQ
M$S0I_43,^GEDO-:WV_K$;$X:I\3$.57[V(07$"D#Q<P&>L1<&R_+SU4.<=TO
M)T&$@FL8DU)0S*R@GK07CS[&I!04,RNH%Q.R-@.2+W2G-RD%Q:^^< *83Y$4
M8U(*BE]S%<43[H_A+E/HO-.;Y"+\J]8[@ EMYDW1+G##-8Q)*2A^E<+G!<Q.
M%A=3"HJ9%?0,\TGPRZ8S7153"HJYY]&.,+TLP9L_WJP.)F6AF'LUOJ_:?1I[
MO$.$LE#"/</6CWD(\!B3LE#"/<-&]6;G%4HH"R7,%GH!\U"Q84S*0@FSA>C>
MQ/.5"66AA-E"O4O3O?EF0EDHX=X+1DX9=7J3W S&70B1F+BL3"@+)>P3<(]K
MZ?U#3;DG85_H1ZOJ_7B4<Q)FYW1F!4\$U)2> =X<:$W,<>634LY)7W$;0#?/
M6)CJ),.8E'-29N?0F'AG8DHY)V5VSC$F2BX_5YV%^)1R3LJ]][AO4KCG!4HI
MXZ3,QNF?%7Y,AS F99R4V3@O8?X8>XQ)&2=E-@X]>XW%F)(;D)F-0V-B,::4
M>U)F]_1L$>E_@2@#I<P&(E<".GGZF#+0F-E U$H ="G&I PT9M]7<+1EI'?
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MX^7<<KO\=?FU<W)?KCC7]Q7#\U]02P,$%     @ >GAE4A(!8E A @  ("\
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M;%!+ 0(4 Q0    ( 'IX95(N-B E[@   "L"   1              "  :\
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M2P$"% ,4    " !Z>&52[=J=% @"  #P P  &               @('L$0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ >GAE4L^US>H(
M!0  8Q$  !@              ("!*A0  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( 'IX95)"/4PEY 8  +,A   8              "
M@6@9  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !Z>&52
M'T5!<QT'   P'0  &               @(&"(   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ >GAE4L9NNM^\!   0 H  !@
M     ("!U2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M 'IX95+ SF(\0@0  .<)   8              " @<<L  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !Z>&52>7@F@$ 7  #81@  &
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M970Q,RYX;6Q02P$"% ,4    " !Z>&52* +5#=8&  #3#P  &0
M    @($"80  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M 'IX95+\[M]910P  '4C   9              " @0]H  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ >GAE4F B@#F9!P  OQ(  !D
M             ("!BW0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !Z>&52/ QYM[X"    !@  &0              @(%;?   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( 'IX95*:;O:4K ,
M 'H(   9              " @5!_  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ >GAE4INN??$O!   & D  !D              ("!
M,X,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !Z>&52
MI/%KA9@$   \"@  &0              @(&9AP  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( 'IX95)>XT5;$P<  'T/   9
M      " @6B,  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ >GAE4OX#:=\J"   P1(  !D              ("!LI,  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !Z>&52&_06\RD'   [$P
M&0              @($3G   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( 'IX95*SBDM?8@,  "('   9              " @7.C  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ >GAE4O\(R\T!
M!   &PD  !D              ("!#*<  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !Z>&52@I8*0_$"  #%!@  &0
M@(%$JP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'IX
M95(F\/I0M ,  $((   9              " @6RN  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ >GAE4B#<U4DJ P  L 8  !D
M         ("!5[(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !Z>&52CJS[094"  !^!0  &0              @(&XM0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( 'IX95+#>A K#P(  +P$
M   9              " @82X  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ >GAE4ES^9X;Z%@  ;T@  !D              ("!RKH
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !Z>&52Y2Y9
M2E@$  !7"@  &0              @('[T0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( 'IX95)%^[1;800  &,*   9
M  " @8K6  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M>GAE4ASWUB>& P  20D  !D              ("!(ML  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !Z>&525],;O+\#   8"   &0
M            @('?W@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( 'IX95*^L?VN4PP  &@B   9              " @=7B  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ >GAE4A*Z-ZC6!@
MW!0  !D              ("!7^\  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !Z>&52E[4V1,0"  !4!@  &0              @(%L
M]@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( 'IX95('
MMCL[WP8  %,/   9              " @6?Y  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ >GAE4I^V1*!D @  [@0  !D
M     ("!?0 ! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'IX95)Q/<UUGP(  "H(   9              "
M@>H/ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ >GAE
M4NV?DT,U @  %04  !D              ("!P!(! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !Z>&522K.YLF<"  #M!0  &0
M        @($L%0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( 'IX95);&E(I8P@  -\]   9              " @<H7 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ >GAE4BV^MH + P  E H
M !D              ("!9" ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " !Z>&52#HA<7<X#  "1#0  &0              @(&F(P$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( 'IX95)WW748
MCP(  %@(   9              " @:LG 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ >GAE4OH+MXN: P  %@X  !D
M ("!<2H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !Z
M>&52GW.NI_4#  #1#P  &0              @(%"+@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( 'IX95*,*YO>X ,  &\.   9
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M970U."YX;6Q02P$"% ,4    " !Z>&52\D!V=/T"   ^"0  &0
M    @(&^3P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M 'IX95(XFLFO<@0  #<2   9              " @?)2 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ >GAE4M)6:S1: P  4 T  !D
M             ("!FU<! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " !Z>&52!2&BT_4&  #<+0  &0              @($L6P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( 'IX95(#'?>?8 ,
M  8+   9              " @5AB 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ >GAE4O!M550B!   4P\  !D              ("!
M[V4! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " !Z>&52
MBA;%M&("  #%!0  &0              @(%(:@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( 'IX95(U3;IV+ (  (8$   9
M      " @>%L 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ >GAE4GJ_PK92 P  6@P  !D              ("!1&\! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !Z>&520;&$6GD#  !T#
M&0              @('-<@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( 'IX95)[FA0+_0(  &()   9              " @7UV 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ >GAE4K %X26]
M!   ,1   !D              ("!L7D! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " !Z>&52X(2R6^H#  "2%P  &0
M@(&E?@$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( 'IX
M95+2Q?- X00  %DD   9              " @<:" 0!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ >GAE4J8/^XT.!   VQ   !D
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M=#<W+GAM;%!+ 0(4 Q0    ( 'IX95(CW]KRA (  (H&   9
M  " @=B; 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
M>GAE4ADXPLP8 @  J00  !D              ("!DYX! 'AL+W=O<FMS:&5E
M=',O<VAE970W.2YX;6Q02P$"% ,4    " !Z>&52GS+Q[GL$  #[$@  &0
M            @('BH $ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4
M Q0    ( 'IX95)M8.$R\P(  #4(   9              " @92E 0!X;"]W
M;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ >GAE4J3JRVJR P
M*@T  !D              ("!OJ@! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX
M;6Q02P$"% ,4    " !Z>&52CR%E7H0"  !2#@  #0              @ &G
MK $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( 'IX95*7BKL<P    !,"   +
M              "  5:O 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'IX95+C
MK?2Y,@8  +\U   /              "  3^P 0!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " !Z>&529LT1.G0"  !M,   &@              @ &>M@$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !Z>&52$@%B
M4"$"   @+P  $P              @ %*N0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     6@!: *T8  "<NP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>330</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Incorporation and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations</Role>
      <ShortName>Incorporation and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Financial Statement Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation</Role>
      <ShortName>Basis of Financial Statement Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109105 - Disclosure - Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalents</Role>
      <ShortName>Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Warrant Derivative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivative</Role>
      <ShortName>Warrant Derivative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</Role>
      <ShortName>Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Contract Liability and Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable</Role>
      <ShortName>Contract Liability and Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144113 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2146114 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2148115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2154116 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2157117 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2161118 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2165119 - Disclosure - Indemnification of Officers and Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors</Role>
      <ShortName>Indemnification of Officers and Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2166120 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2168121 - Disclosure - Other Expenses and Adjustments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments</Role>
      <ShortName>Other Expenses and Adjustments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2171122 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2174123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2176124 - Disclosure - Comparative Figures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComparativeFigures</Role>
      <ShortName>Comparative Figures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Warrant Derivative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables</Role>
      <ShortName>Warrant Derivative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/WarrantDerivative</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedPayments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Contract Liability and Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables</Role>
      <ShortName>Contract Liability and Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2355309 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2369312 - Disclosure - Other Expenses and Adjustments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables</Role>
      <ShortName>Other Expenses and Adjustments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2372313 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Cash Equivalents - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails</Role>
      <ShortName>Cash Equivalents - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Warrant Derivative - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails</Role>
      <ShortName>Warrant Derivative - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails</Role>
      <ShortName>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails</Role>
      <ShortName>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Share Capital - Share Consolidation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails</Role>
      <ShortName>Share Capital - Share Consolidation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails</Role>
      <ShortName>Share Capital - Equity Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Share Based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails</Role>
      <ShortName>Share Based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails</Role>
      <ShortName>Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails</Role>
      <ShortName>Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails</Role>
      <ShortName>Share Based Payments - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Contract Liability and Receivable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails</Role>
      <ShortName>Contract Liability and Receivable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails</Role>
      <ShortName>Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Commitments</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Contingencies</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails</Role>
      <ShortName>Income Taxes - Summary of Non-capital Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails</Role>
      <ShortName>Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2459431 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463433 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2464434 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2467435 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2470436 - Disclosure - Other Expenses and Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails</Role>
      <ShortName>Other Expenses and Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2473437 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="oncyf-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2475438 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="oncyf-20201231.htm">oncyf-20201231.htm</File>
    <File>ex121ceocertification2020.htm</File>
    <File>ex122cfocertification2020.htm</File>
    <File>ex131ceocertification2020.htm</File>
    <File>ex132cfocertification2020.htm</File>
    <File>ex151-2020mda.htm</File>
    <File>ex152ey2020consent.htm</File>
    <File>ex21exdescriptionofsecurit.htm</File>
    <File>ex412employmentagreementth.htm</File>
    <File>ex413mattcoffeyamendment-e.htm</File>
    <File>ex414kirklookamendment-emp.htm</File>
    <File>ex415allisonhagermanamendm.htm</File>
    <File>ex416andrewdeguttadauroame.htm</File>
    <File>ex417thomasheinemanamendme.htm</File>
    <File>ex80subsidiaries2020.htm</File>
    <File>oncyf-20201231.xsd</File>
    <File>oncyf-20201231_cal.xml</File>
    <File>oncyf-20201231_def.xml</File>
    <File>oncyf-20201231_lab.xml</File>
    <File>oncyf-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>oncyf-20201231_g1.jpg</File>
    <File>oncyf-20201231_g2.jpg</File>
    <File>oncyf-20201231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "oncyf-20201231.htm": {
   "axisCustom": 3,
   "axisStandard": 18,
   "contextCount": 330,
   "dts": {
    "calculationLink": {
     "local": [
      "oncyf-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oncyf-20201231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "oncyf-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oncyf-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/labels/doc_full_ifrs-en_2020-03-16.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oncyf-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_5/ref_ifrs_5_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/sic_29/ref_sic_29_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_2/ref_ias_2_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_40/ref_ias_40_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_12/ref_ias_12_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_7/ref_ifrs_7_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_20/ref_ias_20_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_21/ref_ias_21_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_33/ref_ias_33_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_37/ref_ias_37_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifric_2/ref_ifric_2_2020-03-16.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_38/ref_ias_38_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_1/ref_ifrs_1_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_34/ref_ias_34_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_13/ref_ifrs_13_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_4/ref_ifrs_4_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_14/ref_ifrs_14_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_1/ref_ias_1_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_23/ref_ias_23_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_3/ref_ifrs_3_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_16/ref_ifrs_16_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_27/ref_ias_27_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_29/ref_ias_29_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_36/ref_ias_36_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifric_5/ref_ifric_5_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_24/ref_ias_24_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_8/ref_ifrs_8_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_15/ref_ifrs_15_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_7/ref_ias_7_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_16/ref_ias_16_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_6/ref_ifrs_6_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_12/ref_ifrs_12_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_17/ref_ifrs_17_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_41/ref_ias_41_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_26/ref_ias_26_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_10/ref_ias_10_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_19/ref_ias_19_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ias_8/ref_ias_8_2020-03-16.xml",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/linkbases/ifrs_2/ref_ifrs_2_2020-03-16.xml"
     ]
    },
    "schema": {
     "local": [
      "oncyf-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 466,
   "entityCount": 1,
   "hidden": {
    "http://www.oncolyticsbiotech.com/20201231": 7,
    "http://xbrl.sec.gov/dei/2020-01-31": 16,
    "total": 23
   },
   "keyCustom": 75,
   "keyStandard": 268,
   "memberCustom": 54,
   "memberStandard": 27,
   "nsprefix": "oncyf",
   "nsuri": "http://www.oncolyticsbiotech.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityCommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.oncolyticsbiotech.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityCommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Significant Judgments, Estimates and Assumptions",
     "role": "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions",
     "shortName": "Significant Judgments, Estimates and Assumptions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109105 - Disclosure - Cash Equivalents",
     "role": "http://www.oncolyticsbiotech.com/role/CashEquivalents",
     "shortName": "Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111106 - Disclosure - Property and Equipment",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - Leases",
     "role": "http://www.oncolyticsbiotech.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Warrant Derivative",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivative",
     "shortName": "Warrant Derivative",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - Share Capital",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Share Based Payments",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPayments",
     "shortName": "Share Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Loss Per Common Share",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Contract Liability and Receivable",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable",
     "shortName": "Contract Liability and Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144113 - Disclosure - Commitments",
     "role": "http://www.oncolyticsbiotech.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:OtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146114 - Disclosure - Contingencies",
     "role": "http://www.oncolyticsbiotech.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148115 - Disclosure - Income Taxes",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154116 - Disclosure - Capital Disclosures",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosures",
     "shortName": "Capital Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157117 - Disclosure - Financial Instruments",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161118 - Disclosure - Additional Cash Flow Disclosures",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures",
     "shortName": "Additional Cash Flow Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165119 - Disclosure - Indemnification of Officers and Directors",
     "role": "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors",
     "shortName": "Indemnification of Officers and Directors",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166120 - Disclosure - Economic Dependence",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependence",
     "shortName": "Economic Dependence",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168121 - Disclosure - Other Expenses and Adjustments",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments",
     "shortName": "Other Expenses and Adjustments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171122 - Disclosure - Related Party Transactions",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174123 - Disclosure - Subsequent Events",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176124 - Disclosure - Comparative Figures",
     "role": "http://www.oncolyticsbiotech.com/role/ComparativeFigures",
     "shortName": "Comparative Figures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Leases (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Warrant Derivative (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables",
     "shortName": "Warrant Derivative (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Share Capital (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Share Based Payments (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables",
     "shortName": "Share Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Contract Liability and Receivable (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables",
     "shortName": "Contract Liability and Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355309 - Disclosure - Capital Disclosures (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables",
     "shortName": "Capital Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - Additional Cash Flow Disclosures (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables",
     "shortName": "Additional Cash Flow Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369312 - Disclosure - Other Expenses and Adjustments (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables",
     "shortName": "Other Expenses and Adjustments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372313 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "iacdf4b3e43034c8187484f366189cec0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "iacdf4b3e43034c8187484f366189cec0_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:NumberOfStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Cash Equivalents - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails",
     "shortName": "Cash Equivalents - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i56533e258a8349e2b1036c892d892ccf_I20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i6977c19ac3804e89bd0cdabd80283dd4_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "oncyf:OperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i69e26aa497764738a8d24ee240e72834_I20171231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i094c62fa747f4899aeca008f52c1fa6b_D20180101-20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:ComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
     "shortName": "Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "oncyf:ForeignExchangeImpactRightofUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails",
     "shortName": "Leases - Total Undiscounted Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromWarrantExercises1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Warrant Derivative - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
     "shortName": "Warrant Derivative - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
     "shortName": "Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ie9a03d97a08a4ebb88012eb7ec4b6e7f_I20190816",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:ClassOfWarrantOrRightOutstanding1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails",
     "shortName": "Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i7073102f39754418a48b29815277781f_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "oncyf:FairValueofWarrantIssuedPerWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "idded585e6408411a94c46d5d947389d3_I20180522",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Share Capital - Share Consolidation Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails",
     "shortName": "Share Capital - Share Consolidation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "idded585e6408411a94c46d5d947389d3_I20180522",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Share Capital - Schedule of Share Capital (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
     "shortName": "Share Capital - Schedule of Share Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "id116bfc88a7a4ec58b8bfbf759879dbb_I20180522",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ShareIssueRelatedCost",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
     "shortName": "Share Capital - Schedule of Share Capital Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i86af6651ee84454ba8d1a822e9eb52bf_I20160225",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:SharePurchaseAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
     "shortName": "Share Capital - Summary of Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i65287d01f32c419ba89f7f594cd47caf_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Share Capital - Equity Warrants Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
     "shortName": "Share Capital - Equity Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "idb6460278d1448e2b4b9ff8f0c4e83a2_D20170601-20170601",
      "decimals": "0",
      "lang": "en-US",
      "name": "oncyf:GrossProceedsFromIssueOfOrdinaryShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails",
     "shortName": "Share Based Payments - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Share Based Payments - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
     "shortName": "Share Based Payments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ie5fe69759d8547afa04be2fd7beb55b4_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
     "shortName": "Share Based Payments - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
     "shortName": "Share Based Payments - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "4",
      "lang": "en-US",
      "name": "oncyf:ExpectedForfeitureShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i26c471998cb54e5198f60c7e8a879104_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Share Based Payments - Schedule of Number of Other Equity Instruments (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails",
     "shortName": "Share Based Payments - Schedule of Number of Other Equity Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ibda3a9497dd94381bf80f0a2b9616cad_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Loss Per Common Share (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails",
     "shortName": "Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "year",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Contract Liability and Receivable - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails",
     "shortName": "Contract Liability and Receivable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "year",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i1afa8a6f863e4e829b7dcc1eaedc3459_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails",
     "shortName": "Contract Liability and Receivable - Schedule of Contract Revenues and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ie3e8ac6adebf420fa8476e0aab04dfcd_I20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligation1",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Commitments (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligationCommitmentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Contingencies (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContingentRoyaltyPaymentPercentOfSalesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Incorporation and Nature of Operations",
     "role": "http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations",
     "shortName": "Incorporation and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ibd0824dc040346089bbc41d9b1bc5c4b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Income Taxes - Summary of Non-capital Losses (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
     "shortName": "Income Taxes - Summary of Non-capital Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ibd0824dc040346089bbc41d9b1bc5c4b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
     "shortName": "Income Taxes - Summary of Non-refundable Federal Investment Tax Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i94c4154f7c3c4d08a75ec8aa31d51d68_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - Capital Disclosures (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
     "shortName": "Capital Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8dcb30c64a054057ae8268e11a956cf5_I20200612",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:EquityAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentDerivativeFinancialLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459431 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ie5bd22e322e440f6a91f0451248c5c0b_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i15a34dc52087401598ad74c4d7ac44b7_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
     "shortName": "Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "id5c5734d8c674bc1ad227ce90090ae8e_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463433 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
     "shortName": "Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:AdjustmentsforDecreaseIncreaseinContractReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464434 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails",
     "shortName": "Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i32c78d9692194534851ffc8c75765b43_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467435 - Disclosure - Economic Dependence (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails",
     "shortName": "Economic Dependence (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i32c78d9692194534851ffc8c75765b43_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Financial Statement Presentation",
     "role": "http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation",
     "shortName": "Basis of Financial Statement Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470436 - Disclosure - Other Expenses and Adjustments (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
     "shortName": "Other Expenses and Adjustments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "ieacddbbb17314a6bbe19b73efcd83368_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473437 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i6aa444cf957a4e6bb4ee14ed2895c9d4_D20180101-20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475438 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "idd0f9dd17a334fbb893d05409188942d_D20210101-20210304",
      "decimals": "0",
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20201231.htm",
      "contextRef": "i8d53aa072e45455b906a17681d63d1c6_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 85,
   "tag": {
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pounds"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "U.S. dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r52",
      "r59",
      "r77",
      "r81",
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]",
        "terseLabel": "Accumulated Other Comprehensive Income $"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Contributed surplus"
       }
      }
     },
     "localname": "AdditionalPaidinCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares (diluted) (shares)"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for current tax of prior periods",
        "terseLabel": "Adjustment in respect to prior periods"
       }
      }
     },
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation - property and equipment"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other operating payables",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Onerous lease contract"
       }
      }
     },
     "localname": "AdjustmentsForProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Unrealized foreign exchange loss (gain)"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r21",
      "r130",
      "r141",
      "r142",
      "r163",
      "r173",
      "r176",
      "r186",
      "r188",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r61",
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationExpense": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation expense",
        "terseLabel": "Depreciation - property and equipment"
       }
      }
     },
     "localname": "AmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]",
        "terseLabel": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Statutory Canadian corporate tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r19",
      "r117",
      "r118",
      "r119",
      "r182",
      "r184"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicAndDilutedEarningsLossPerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic and diluted earnings (loss) per share",
        "terseLabel": "Basic and diluted loss per common share (cad per share)"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r155",
      "r171",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r52",
      "r56",
      "r77",
      "r78",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r160",
      "r166",
      "r167",
      "r196",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r56",
      "r78",
      "r80",
      "r82",
      "r83",
      "r160",
      "r166",
      "r167",
      "r196",
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r97",
      "r115"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalents": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "auth_ref": [
      "r92",
      "r99"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Payment of lease liabilities",
        "negatedTerseLabel": "Payment of lease liabilities"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]",
        "terseLabel": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]",
        "terseLabel": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Milestone payment in connection with Share Purchase Agreement"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r3",
      "r32",
      "r105",
      "r108",
      "r109",
      "r114"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Net loss and other comprehensive income",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "periodEndLabel": "Balance, end of the year",
        "periodStartLabel": "Balance, beginning of the year",
        "totalLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]",
        "terseLabel": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [member]",
        "terseLabel": "Counterparties [member]"
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r179",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r22",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "verboseLabel": "Contract liability - current"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "negatedLabel": "Warrant derivative",
        "terseLabel": "Warrant derivative"
       }
      }
     },
     "localname": "CurrentDerivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r23",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "totalLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "totalLabel": "Net current tax expense"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through performance obligation being satisfied, contract liabilities",
        "terseLabel": "Revenue recognized in the year"
       }
      }
     },
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "terseLabel": "Unrecognized deferred tax asset"
       }
      }
     },
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation expense",
        "terseLabel": "Depreciation - right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for deferred income tax [text block]",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for derecognition of financial instruments [text block]",
        "terseLabel": "Derecognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of financial assets [text block]",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share based payments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected share price volatility",
        "verboseLabel": "Expected share price volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Expected hold period to exercise",
        "verboseLabel": "Expected hold period to exercise"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Significant Judgments, Estimates and Assumptions"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "Basis of Financial Statement Presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/BasisofFinancialStatementPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Additional Cash Flow Disclosures"
       }
      }
     },
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Schedule of share capital"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure, in the entity's first IFRS financial statements, of comparative information prepared under previous GAAP."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of comparative information prepared under previous GAAP [text block]",
        "terseLabel": "Comparative Figures"
       }
      }
     },
     "localname": "DisclosureOfComparativeInformationPreparedUnderPreviousGAAPExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComparativeFigures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [line items]",
        "terseLabel": "Disclosure of contingent liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [table]",
        "terseLabel": "Disclosure of contingent liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of depreciation rates",
        "verboseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [text block]",
        "terseLabel": "Reconciliation of change in fair value of warrant derivative"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]",
        "terseLabel": "Disclosure of fair value measurement of liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]",
        "terseLabel": "Disclosure of fair value measurement of liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]",
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Warrant Derivative"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivative"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Incorporation and Nature of Operations"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncorporationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Disclosure weighted average assumptions and fair value of options"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [text block]",
        "terseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [line items]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [table]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Schedule of number of other equity instruments"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of stock options and weighted average exercise prices of share options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Schedule of weighted average remaining contractual life and outstanding stock options by exercise price",
        "verboseLabel": "Summary of outstanding warrants"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]",
        "terseLabel": "Capital Disclosures"
       }
      }
     },
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Other Expenses and Adjustments"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Disclosure of other provisions [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]",
        "terseLabel": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Schedule of stock options outstanding and exercisable by range of exercise price"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [line items]",
        "terseLabel": "Disclosure of range of exercise prices of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the range of exercise prices of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [table]",
        "terseLabel": "Disclosure of range of exercise prices of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Contract Liability and Receivable"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Share Capital"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share Based Payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "terseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Impact of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r19",
      "r26",
      "r104",
      "r107",
      "r117",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity",
        "periodStartLabel": "Equity",
        "terseLabel": "Shareholders\u2019 equity (deficit)",
        "totalLabel": "Total shareholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and shareholders' equity (deficit)"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "Liabilities And Shareholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price (cad per share)"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "ExpenseByNatureAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Non-cash share-based compensation"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Contract liability balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fixtures and fittings [member]",
        "terseLabel": "Office Furniture"
       }
      }
     },
     "localname": "FixturesAndFittingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "negatedTerseLabel": "Change in fair value of warrant derivative",
        "terseLabel": "Change in fair value of warrant derivative",
        "verboseLabel": "Change in fair value"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r62",
      "r99"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "verboseLabel": "Foreign exchange (loss) gain"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r52",
      "r77",
      "r81",
      "r84",
      "r160",
      "r167",
      "r168",
      "r169",
      "r196",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r140",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "verboseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r33",
      "r40",
      "r44",
      "r45",
      "r70",
      "r116",
      "r181"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "terseLabel": "Cash taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "totalLabel": "Increase in cash"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in number of shares outstanding",
        "terseLabel": "Issued pursuant to equity warrant exercised (shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTerseLabel": "Net change in non-cash working capital",
        "negatedTotalLabel": "Change in non-cash working capital related to operating activities"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Issued pursuant to stock option plan"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Issued pursuant to warrant agreement"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on cash and cash equivalents",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issued",
        "verboseLabel": "Issued shares"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital \u00a0\u00a0Authorized: unlimited \u00a0\u00a0Issued: December\u00a031, 2020 \u2013 46,166,980 December\u00a031, 2019 \u2013 32,198,453"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital $",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Compensation of key management personnel"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee compensation and benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, termination benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r173",
      "r175",
      "r178",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r172",
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "One to five years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Lease liabilities, ending balance",
        "periodStartLabel": "Lease liabilities, beginning balance"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      },
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r61",
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r19",
      "r117",
      "r118",
      "r119",
      "r182",
      "r185"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]",
        "terseLabel": "Liabilities [member]"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Major ordinary share transactions [member]",
        "terseLabel": "Share transactions"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r21",
      "r130",
      "r141",
      "r142",
      "r163",
      "r170",
      "r173",
      "r186",
      "r188",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r22",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liability",
        "verboseLabel": "Contract liability - non-current"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r23",
      "r109",
      "r113"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r20",
      "r141",
      "r142",
      "r173",
      "r178",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r156",
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedTerseLabel": "Vested during the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited during the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r147",
      "r152",
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)",
        "terseLabel": "Number Outstanding (shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (shares)",
        "verboseLabel": "Number Exercisable (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Exercised during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Expired during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "periodEndLabel": "Share capital issued ending (shares)",
        "periodStartLabel": "Share capital issued, beginning (shares)",
        "terseLabel": "Share capital issued (shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares outstanding at the end of period (shares)",
        "periodStartLabel": "Number of shares outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office equipment and furniture",
        "verboseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive (loss) income items that may be reclassified to net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r24",
      "r35"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]",
        "terseLabel": "Other provisions [member]"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "terseLabel": "Payments for share issue costs"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]",
        "terseLabel": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r4",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated [member]",
        "terseLabel": "Pre-Consolidation"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Net proceeds from issue of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from share issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r31",
      "r89",
      "r105",
      "r108",
      "r109",
      "r182",
      "r183",
      "r187",
      "r195"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the year",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r161",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r34",
      "r71"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss before the following"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r16",
      "r56"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property and equipment (amortization), ending balance",
        "periodStartLabel": "Property and equipment (amortization), beginning balance",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r57",
      "r74",
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r155",
      "r171",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r155",
      "r171",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [member]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in property, plant and equipment [abstract]",
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Reserve of share-based payments"
       }
      }
     },
     "localname": "ReserveOfSharebasedPaymentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r4",
      "r14",
      "r101",
      "r102",
      "r103",
      "r187"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]",
        "terseLabel": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r26",
      "r36"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r8",
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit $"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r4",
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]",
        "terseLabel": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Regional licensing agreement"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use assets, ending balance",
        "periodStartLabel": "Right-of-use assets, beginning balance",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedTerseLabel": "Share issue costs",
        "terseLabel": "Share issue related cost",
        "verboseLabel": "Transaction cost, warrant derivative"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Contributed Surplus $"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issue under options and contracts for sale of shares",
        "terseLabel": "Common shares reserved for issuance (shares)"
       }
      }
     },
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]",
        "terseLabel": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]",
        "terseLabel": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]",
        "terseLabel": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect from change in tax rate",
        "terseLabel": "Impact of Alberta rate change"
       }
      }
     },
     "localname": "TaxEffectFromChangeInTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "terseLabel": "Foreign jurisdiction tax rate difference"
       }
      }
     },
     "localname": "TaxEffectOfForeignTaxRates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Anticipated tax recovery"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r155",
      "r171",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r189",
      "r190",
      "r191",
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r162",
      "r164",
      "r165",
      "r189",
      "r190",
      "r191",
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits for which no deferred tax asset recognised",
        "terseLabel": "Unused tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits [member]",
        "terseLabel": "Non-refundable federal investment tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Non-capital losses"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (cad per share)",
        "verboseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Exercised during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Expired during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "Forfeited during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, beginning of the year (cad per share)",
        "periodStartLabel": "Outstanding, beginning of the year (cad per share)",
        "terseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, share options granted",
        "terseLabel": "Weighted average fair value of options (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16",
        "terseLabel": "Weighted average rate"
       }
      }
     },
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "verboseLabel": "Weighted Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares (basic) (shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Shares Under At-the-market Agreement, United States",
        "label": "2020 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2020 United States ATM"
       }
      }
     },
     "localname": "A2020SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_AdjustmentsforDecreaseIncreaseinContractReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for Decrease (Increase) in Contract Receivable",
        "label": "Adjustments for Decrease (Increase) in Contract Receivable",
        "terseLabel": "Contract receivable"
       }
      }
     },
     "localname": "AdjustmentsforDecreaseIncreaseinContractReceivable",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AdjustmentsforIncreaseDecreaseinContractLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for Increase (Decrease) in Contract Liabilities",
        "label": "Adjustments for Increase (Decrease) in Contract Liabilities",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "AdjustmentsforIncreaseDecreaseinContractLiabilities",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AdjustmentsforLeaseAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for Lease Amortization",
        "label": "Adjustments for Lease Amortization",
        "terseLabel": "Amortization - lease incentive liability"
       }
      }
     },
     "localname": "AdjustmentsforLeaseAmortization",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AnnualContingentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Contingent Payment",
        "label": "Annual Contingent Payment",
        "terseLabel": "Annual installment of annual product sales"
       }
      }
     },
     "localname": "AnnualContingentPayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AnnualContingentPaymentGrossSalesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Contingent Payment, Gross Sales, Percent",
        "label": "Annual Contingent Payment, Gross Sales, Percent",
        "terseLabel": "Annual installment of gross sales of product, percent"
       }
      }
     },
     "localname": "AnnualContingentPaymentGrossSalesPercent",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_BalanceHeldInForeignCurrencyNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Held In Foreign Currency, Net",
        "label": "Balance Held In Foreign Currency, Net",
        "terseLabel": "Balances in foreign currencies"
       }
      }
     },
     "localname": "BalanceHeldInForeignCurrencyNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Short Term Investments [Abstract]",
        "label": "Cash Equivalents And Short Term Investments [Abstract]",
        "terseLabel": "Cash Equivalents And Short Term Investments [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_CashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Short Term Investments [Text Block]",
        "label": "Cash Equivalents And Short Term Investments [Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_CashEquivalentsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Interest Rate",
        "label": "Cash Equivalents, Interest Rate",
        "terseLabel": "Current annual interest rate"
       }
      }
     },
     "localname": "CashEquivalentsInterestRate",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CashEquivalentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CashFlowOperatingCapital1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Operating Capital1 [Table Text Block]",
        "label": "Cash Flow, Operating Capital1 [Table Text Block]",
        "terseLabel": "Net change in non-cash working capital"
       }
      }
     },
     "localname": "CashFlowOperatingCapital1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ChangeInFairValueWarrantDerivativeRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Warrant Derivative",
        "label": "Change In Fair Value Warrant Derivative [Roll Forward]",
        "terseLabel": "Fair Value of Warrant Derivative $"
       }
      }
     },
     "localname": "ChangeInFairValueWarrantDerivativeRollForward",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Post-Consolidation Securities Called by Each Pre-Consolidation Warrant or Right",
        "label": "Class of Warrant or Right, Number of Post-Consolidation Securities Called by Each Pre-Consolidation Warrant or Right",
        "terseLabel": "Number of post-consolidation shares for each pre-consolidation share (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfPostConsolidationSecuritiesCalledByEachPreConsolidationWarrantOrRight",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Pre-Consolidation Securities Called by Post-Consolidation Warrants or Rights",
        "label": "Class of Warrant or Right, Number of Pre-Consolidation Securities Called by Post-Consolidation Warrants or Rights",
        "terseLabel": "Number of pre-consolidation shares called by post-consolidation shares (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfPreConsolidationSecuritiesCalledByPostConsolidationWarrantsOrRights",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassOfWarrantOrRightOutstanding1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding1",
        "label": "Class Of Warrant Or Right, Outstanding1",
        "periodEndLabel": "Issued, ending balance (shares)",
        "periodStartLabel": "Issued, beginning balance (shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "terseLabel": "Exercise price (usd per share)"
       }
      }
     },
     "localname": "ClassofWarrantorRightExercisePriceofWarrantsorRights2",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "terseLabel": "Number of common shares issuable per warrant (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "terseLabel": "Warrants exercisable into common shares (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Warrants Exercised",
        "label": "Class of Warrant or Right, Number of Warrants Exercised",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Warrants exercised (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Warrants Exercised",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "negatedLabel": "Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassofWarrantorRightWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "BRACELET-1 collaboration agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_CommitmentSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment Shares",
        "label": "Commitment Shares [Member]",
        "terseLabel": "Commitment Shares"
       }
      }
     },
     "localname": "CommitmentSharesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_CommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments [Abstract]",
        "label": "Commitments [Abstract]",
        "terseLabel": "Commitments [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_CommitmentsAndContingencies1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies1",
        "label": "Commitments And Contingencies1",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Period Due",
        "label": "Commitments Made By Entity, Related Party Transactions, Period Due",
        "terseLabel": "Payment due period"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsPeriodDue",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage",
        "label": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Net Sales, Percentage",
        "terseLabel": "Royalty payment on net sales due to founding shareholders, percent"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentNetSalesPercentage",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Received, Percentage",
        "label": "Commitments Made By Entity, Related Party Transactions, Royalty Payment Received,Percentage",
        "terseLabel": "Royalty payment due to founding shareholders, percent"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactionsRoyaltyPaymentReceivedPercentage",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_CommonSharePurchaseWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Share Purchase Warrant Per Unit",
        "label": "Common Share Purchase Warrant Per Unit",
        "terseLabel": "Common share purchase warrant per unit (shares)"
       }
      }
     },
     "localname": "CommonSharePurchaseWarrantPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_CommonSharesPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Per Unit",
        "label": "Common Shares Per Unit",
        "terseLabel": "Common shares per unit (shares)"
       }
      }
     },
     "localname": "CommonSharesPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ComparativeFiguresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comparative figures [Abstract]",
        "label": "Comparative figures [Abstract]"
       }
      }
     },
     "localname": "ComparativeFiguresAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRisk1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk1 [Table]",
        "label": "Concentration Risk1 [Table]",
        "terseLabel": "Concentration Risk1 [Table]"
       }
      }
     },
     "localname": "ConcentrationRisk1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number",
        "label": "Concentration Risk, Number",
        "terseLabel": "Concentration, number"
       }
      }
     },
     "localname": "ConcentrationRiskNumber",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_ConcentrationRiskType1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Axis]",
        "terseLabel": "Concentration Risk Type1 [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskType1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Domain]",
        "terseLabel": "Concentration Risk Type1 [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ConcentrationRiskType1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Concentration Risk Type1 [Table]",
        "label": "Concentration Risk Type1 [Line Items]",
        "terseLabel": "Concentration Risk Type1 [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskType1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies [Abstract]",
        "label": "Contingencies [Abstract]",
        "terseLabel": "Contingencies [Abstract]"
       }
      }
     },
     "localname": "ContingenciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_ContingentRoyaltyPaymentAnnualMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Payment, Annual Maximum",
        "label": "Contingent Royalty Payment, Annual Maximum",
        "terseLabel": "Royalty payment maximum"
       }
      }
     },
     "localname": "ContingentRoyaltyPaymentAnnualMaximum",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ContingentRoyaltyPaymentPercentOfSalesRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Royalty Payment, Percent Of Sales Revenue",
        "label": "Contingent Royalty Payment, Percent Of Sales Revenue",
        "terseLabel": "Royalty payment on sales revenue, percent"
       }
      }
     },
     "localname": "ContingentRoyaltyPaymentPercentOfSalesRevenue",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_ContractLiabilityRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Liability, Recognition Period",
        "label": "Contract Liability, Recognition Period",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "ContractLiabilityRecognitionPeriod",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityandReceivableNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]"
       }
      }
     },
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Currency1 [Table]",
        "label": "Currency1 [Line Items]",
        "terseLabel": "Currency1 [Line Items]"
       }
      }
     },
     "localname": "Currency1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency1 [Table]",
        "label": "Currency1 [Table]",
        "terseLabel": "Currency1 [Table]"
       }
      }
     },
     "localname": "Currency1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfCapitalComponentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Capital Components [Table Text Block]",
        "label": "Disclosure Of Capital Components [Table Text Block]",
        "verboseLabel": "Schedule of capital components"
       }
      }
     },
     "localname": "DisclosureOfCapitalComponentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Abstract]",
        "label": "Disclosure Of Economic Dependence [Abstract]",
        "terseLabel": "Disclosure Of Economic Dependence [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Text Block]",
        "label": "Disclosure Of Economic Dependence [Text Block]",
        "terseLabel": "Economic Dependence"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependence"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "terseLabel": "Disclosure Of Indemnification Of Officers and Directors [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "terseLabel": "Indemnification of Officers and Directors"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "label": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "terseLabel": "Disclosure Of Notes And Other Explanatory Information [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfSharebasedPaymentArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "label": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "terseLabel": "Disclosure Of Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "terseLabel": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "localname": "DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofeventsafterreportingperiodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of events after reporting period [Abstract]",
        "label": "Disclosure of events after reporting period [Abstract]",
        "terseLabel": "Disclosure of events after reporting period [Abstract]"
       }
      }
     },
     "localname": "DisclosureofeventsafterreportingperiodAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofincometaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of income tax [Abstract]",
        "label": "Disclosure of income tax [Abstract]",
        "terseLabel": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "localname": "DisclosureofincometaxAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrelatedpartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of related party [Abstract]",
        "label": "Disclosure of related party [Abstract]",
        "terseLabel": "Disclosure of related party [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrelatedpartyAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from contracts with customers [Abstract]",
        "label": "Disclosure of revenue from contracts with customers [Abstract]",
        "terseLabel": "Disclosure of revenue from contracts with customers [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrevenuefromcontractswithcustomersAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofsharebasedpaymentarrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share-based payment arrangement [Abstract]",
        "label": "Disclosure of share-based payment arrangement [Abstract]",
        "terseLabel": "Disclosure of share-based payment arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureofsharebasedpaymentarrangementAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DividendYieldPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield, Percent",
        "label": "Dividend Yield, Percent",
        "terseLabel": "Dividend Yield, Percent",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "DividendYieldPercent",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_EquityAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Authorized",
        "label": "Equity Authorized",
        "terseLabel": "Base Shelf securities authorized"
       }
      }
     },
     "localname": "EquityAuthorized",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$7.42 - $52.63"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$3.91 - $7.41"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$0.54 - $1.79"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$3.02 - $3.90"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$1.80 - $3.01"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExpectedForfeitureShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Forfeiture, Share Options Granted",
        "label": "Expected Forfeiture, Share Options Granted",
        "terseLabel": "Expected forfeiture rate"
       }
      }
     },
     "localname": "ExpectedForfeitureShareOptionsGranted",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_FairValueofWarrantIssuedPerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrant Issued, Per Warrant",
        "label": "Fair Value of Warrant Issued, Per Warrant",
        "terseLabel": "Fair value per warrant (usd per share)"
       }
      }
     },
     "localname": "FairValueofWarrantIssuedPerWarrant",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_ForeignExchangeImpactRightofUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Impact, Right-of-Use Assets",
        "label": "Foreign Exchange Impact, Right-of-Use Assets",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "ForeignExchangeImpactRightofUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_FundedandRoyaltyRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded and Royalty Repayment",
        "label": "Funded and Royalty Repayment",
        "terseLabel": "Repayment, maximum"
       }
      }
     },
     "localname": "FundedandRoyaltyRepayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GainsLossesfromForeignExchangeImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (Losses) from Foreign Exchange Impact",
        "label": "Gains (Losses) from Foreign Exchange Impact",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "GainsLossesfromForeignExchangeImpact",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GrossProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds From Issue Of Ordinary Shares",
        "label": "Gross Proceeds From Issue Of Ordinary Shares",
        "terseLabel": "Gross proceeds from common shares"
       }
      }
     },
     "localname": "GrossProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncomeStatementLocation1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "terseLabel": "Income Statement Location1 [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_IncomeStatementLocation1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Domain]",
        "terseLabel": "Income Statement Location1 [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "terseLabel": "Non-cash impact of foreign exchange"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "label": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "terseLabel": "Issued pursuant to incentive share award plan"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughIncentiveShareAwardsEquity",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncreaseDecreaseinPrepaidExpense1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense1",
        "label": "Increase (Decrease) in Prepaid Expense1",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseinPrepaidExpense1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_InvestmentTaxCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Tax Credits [Member]",
        "label": "Investment Tax Credits [Member]",
        "terseLabel": "Investment tax credits"
       }
      }
     },
     "localname": "InvestmentTaxCreditsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IssueOfEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity, Shares",
        "label": "Issue Of Equity, Shares",
        "terseLabel": "Issued (shares)"
       }
      }
     },
     "localname": "IssueOfEquityShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_IssuedCapitalExcludingCommitmentSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued Capital, Excluding Commitment Shares",
        "label": "Issued Capital, Excluding Commitment Shares [Member]",
        "terseLabel": "Issued Capital, Excluding Commitment Shares"
       }
      }
     },
     "localname": "IssuedCapitalExcludingCommitmentSharesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "label": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "terseLabel": "Maximum option expiration term"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]",
        "terseLabel": "Medical equipment"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_NumberOfRenewals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Renewals",
        "label": "Number Of Renewals",
        "terseLabel": "Number of extension options"
       }
      }
     },
     "localname": "NumberOfRenewals",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_NumberOfStockOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stock Option Plans",
        "label": "Number Of Stock Option Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "localname": "NumberOfStockOptionPlans",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_NumberOfWarrantsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding [Roll Forward]",
        "terseLabel": "Number of Warrants Outstanding"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandingRollForward",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_NumberofSharesOutstandingPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares Outstanding, Percent",
        "label": "Number of Shares Outstanding, Percent",
        "terseLabel": "Shares outstanding, percent"
       }
      }
     },
     "localname": "NumberofSharesOutstandingPercent",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_OperatingExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses [Member]",
        "label": "Operating Expenses [Member]",
        "terseLabel": "Included in operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Remaining Lease Term",
        "label": "Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Line Items]",
        "terseLabel": "Other Expenses And Adjustments [Line Items]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsLineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Table]",
        "terseLabel": "Other Expenses And Adjustments [Table]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTable",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table Text Block]",
        "label": "Other Expenses And Adjustments [Table Text Block]",
        "terseLabel": "Other expenses and adjustments"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_OverheadRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overhead Repayment",
        "label": "Overhead Repayment",
        "terseLabel": "Overhead repayment"
       }
      }
     },
     "localname": "OverheadRepayment",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PerformanceShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Units [Member]",
        "label": "Performance Share Units [Member]",
        "terseLabel": "Performance share units"
       }
      }
     },
     "localname": "PerformanceShareUnitsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ProceedsfromInterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Interest Received",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash interest received"
       }
      }
     },
     "localname": "ProceedsfromInterestReceived",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ProceedsfromWarrantExercises1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Warrant Exercises1",
        "label": "Proceeds from Warrant Exercises1",
        "terseLabel": "Gross proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsfromWarrantExercises1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]",
        "label": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]",
        "terseLabel": "Undepreciated capital costs in excess of book value of property and equipment and intellectual property"
       }
      }
     },
     "localname": "PropertyPlantEquipmentAndIntellectualPropertyRelatedTemporaryDifferencesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_PropertyPlantandEquipmentAnnualDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Annual Depreciation Rate",
        "label": "Property, Plant and Equipment, Annual Depreciation Rate",
        "terseLabel": "Annual depreciation rate"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentAnnualDepreciationRate",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_PurchaseObligation1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation1",
        "label": "Purchase Obligation1",
        "terseLabel": "Commitment for payment"
       }
      }
     },
     "localname": "PurchaseObligation1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PurchaseObligationCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Commitment Term",
        "label": "Purchase Obligation, Commitment Term",
        "terseLabel": "Commitment term"
       }
      }
     },
     "localname": "PurchaseObligationCommitmentTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development [Member]",
        "terseLabel": "Included in research and development expenses:"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_RestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units [Member]",
        "label": "Restricted Share Units [Member]",
        "terseLabel": "Restricted share units"
       }
      }
     },
     "localname": "RestrictedShareUnitsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SYNSORBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SYNSORB [Member]",
        "label": "SYNSORB [Member]",
        "terseLabel": "SYNSORB"
       }
      }
     },
     "localname": "SYNSORBMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "terseLabel": "Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SaleOfStockAxis",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_SaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Domain]",
        "terseLabel": "Sale Of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockDomain",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Foreign Currency Held [Table Text Block]",
        "label": "Schedule Of Foreign Currency Held [Table Text Block]",
        "terseLabel": "Schedule of balances in foreign currencies"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyHeldTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "label": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "terseLabel": "Other cash flow disclosures"
       }
      }
     },
     "localname": "ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "label": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount",
        "terseLabel": "Impact of increase in value of currency, amount"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "negatedTerseLabel": "(Increase) decrease in net loss due to change in currency value"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ShareIssueCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Costs [Member]",
        "label": "Share Issue Costs [Member]",
        "terseLabel": "Share issue costs"
       }
      }
     },
     "localname": "ShareIssueCostsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ShareIssueRelatedCostCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Related Cost, Commissions",
        "label": "Share Issue Related Cost, Commissions",
        "terseLabel": "Share issue related cost, commissions"
       }
      }
     },
     "localname": "ShareIssueRelatedCostCommissions",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Amount",
        "label": "Share Purchase Agreement, Amount",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Consecutive Trading Days",
        "label": "Share Purchase Agreement, Consecutive Trading Days",
        "terseLabel": "Immediately preceding trading days"
       }
      }
     },
     "localname": "SharePurchaseAgreementConsecutiveTradingDays",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharePurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Term",
        "label": "Share Purchase Agreement, Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "SharePurchaseAgreementTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharesIssuedPricePerShare1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Price Per Share1",
        "label": "Shares Issued, Price Per Share1",
        "terseLabel": "Purchase price (cad and usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesIssuedWarrantPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Warrant Price Per Share",
        "label": "Shares Issued, Warrant Price Per Share",
        "terseLabel": "Purchase price (cad per share)"
       }
      }
     },
     "localname": "SharesIssuedWarrantPricePerShare",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesPublicOfferingEquityWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Equity Warrants",
        "label": "Shares Public Offering, Equity Warrants [Member]",
        "terseLabel": "Shares Public Offering, Equity Warrants",
        "verboseLabel": "Equity Warrants"
       }
      }
     },
     "localname": "SharesPublicOfferingEquityWarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering [Member]",
        "label": "Shares Public Offering [Member]",
        "terseLabel": "Public Offering",
        "verboseLabel": "Public offering"
       }
      }
     },
     "localname": "SharesPublicOfferingMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesPublicOfferingWarrantDerivativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Warrant Derivatives",
        "label": "Shares Public Offering, Warrant Derivatives [Member]",
        "terseLabel": "Shares Under Warrant Derivative Agreement",
        "verboseLabel": "Warrant Derivatives"
       }
      }
     },
     "localname": "SharesPublicOfferingWarrantDerivativesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementCanadianMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement, Canadian [Member]",
        "label": "Shares Under At-the-market Agreement, Canadian [Member]",
        "terseLabel": "Canadian ATM"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementCanadianMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement [Member]",
        "label": "Shares Under At-the-market Agreement [Member]",
        "terseLabel": "At-the-market agreement"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement, United States [Member]",
        "label": "Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "United States ATM"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Common Stock Purchase Agreement [Member]",
        "label": "Shares Under Common Stock Purchase Agreement [Member]",
        "verboseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "SharesUnderCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Incentive Award Plan [Member]",
        "label": "Shares Under Incentive Award Plan [Member]",
        "terseLabel": "Incentive award plan"
       }
      }
     },
     "localname": "SharesUnderIncentiveAwardPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderSharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Share Purchase Agreement [Member]",
        "label": "Shares Under Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement"
       }
      }
     },
     "localname": "SharesUnderSharePurchaseAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Stock Option Plan [Member]",
        "label": "Shares Under Stock Option Plan [Member]",
        "terseLabel": "Stock option plan"
       }
      }
     },
     "localname": "SharesUnderStockOptionPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderWarrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Warrant Agreement [Member]",
        "label": "Shares Under Warrant Agreement [Member]",
        "verboseLabel": "Equity Warrants"
       }
      }
     },
     "localname": "SharesUnderWarrantAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "label": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "terseLabel": "Significant Judgments, Estimates And Assumptions [Abstract]"
       }
      }
     },
     "localname": "SignificantJudgmentsEstimatesAndAssumptionsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Statement1 [Table]",
        "label": "Statement1 [Line Items]",
        "terseLabel": "Statement1 [Line Items]"
       }
      }
     },
     "localname": "Statement1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement1 [Table]",
        "label": "Statement1 [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "Statement1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_StockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalShareConsolidationNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oncyf_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Abstract]",
        "label": "Summary Of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "oncyf_SupplierConcentrationRisk1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Concentration Risk1 [Member]",
        "label": "Supplier Concentration Risk1 [Member]",
        "terseLabel": "Toll manufacturer"
       }
      }
     },
     "localname": "SupplierConcentrationRisk1Member",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "label": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "terseLabel": "Change in fair value of warrant derivative"
       }
      }
     },
     "localname": "TaxEffectOfChangeinFairValueOfWarrantDerivative",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Stock Based Compensation",
        "label": "Tax Effect Of Stock Based Compensation",
        "negatedTerseLabel": "Employee share-based compensation"
       }
      }
     },
     "localname": "TaxEffectOfStockBasedCompensation",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfTaxPools": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Tax Pools",
        "label": "Tax Effect Of Tax Pools",
        "terseLabel": "Adjustment to opening tax pools"
       }
      }
     },
     "localname": "TaxEffectOfTaxPools",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TwentyFortyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Forty",
        "label": "Twenty Forty [Member]",
        "terseLabel": "2040"
       }
      }
     },
     "localname": "TwentyFortyMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Eight [Member]",
        "label": "Twenty Thirty Eight [Member]",
        "terseLabel": "2038"
       }
      }
     },
     "localname": "TwentyThirtyEightMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Five [Member]",
        "label": "Twenty Thirty Five [Member]",
        "terseLabel": "2035"
       }
      }
     },
     "localname": "TwentyThirtyFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Four [Member]",
        "label": "Twenty Thirty Four [Member]",
        "terseLabel": "2034"
       }
      }
     },
     "localname": "TwentyThirtyFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty [Member]",
        "label": "Twenty Thirty [Member]",
        "terseLabel": "2030"
       }
      }
     },
     "localname": "TwentyThirtyMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Nine [Member]",
        "label": "Twenty Thirty Nine [Member]",
        "terseLabel": "2039"
       }
      }
     },
     "localname": "TwentyThirtyNineMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty One [Member]",
        "label": "Twenty Thirty One [Member]",
        "terseLabel": "2031"
       }
      }
     },
     "localname": "TwentyThirtyOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Seven [Member]",
        "label": "Twenty Thirty Seven [Member]",
        "terseLabel": "2037"
       }
      }
     },
     "localname": "TwentyThirtySevenMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Six [Member]",
        "label": "Twenty Thirty Six [Member]",
        "terseLabel": "2036"
       }
      }
     },
     "localname": "TwentyThirtySixMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Three [Member]",
        "label": "Twenty Thirty Three [Member]",
        "terseLabel": "2033"
       }
      }
     },
     "localname": "TwentyThirtyThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyThirtyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Thirty Two [Member]",
        "label": "Twenty Thirty Two [Member]",
        "terseLabel": "2032"
       }
      }
     },
     "localname": "TwentyThirtyTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Eight [Member]",
        "label": "Twenty Twenty Eight [Member]",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "TwentyTwentyEightMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Five [Member]",
        "label": "Twenty Twenty Five [Member]",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "TwentyTwentyFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Four [Member]",
        "label": "Twenty Twenty Four [Member]",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TwentyTwentyFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Nine [Member]",
        "label": "Twenty Twenty Nine [Member]",
        "terseLabel": "2029"
       }
      }
     },
     "localname": "TwentyTwentyNineMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty One [Member]",
        "label": "Twenty Twenty One [Member]",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "TwentyTwentyOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Seven [Member]",
        "label": "Twenty Twenty Seven [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "TwentyTwentySevenMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Six [Member]",
        "label": "Twenty Twenty Six [Member]",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "TwentyTwentySixMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNoncapitalLossesDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Three [Member]",
        "label": "Twenty Twenty Three [Member]",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TwentyTwentyThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty Twenty Two [Member]",
        "label": "Twenty Twenty Two [Member]",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "TwentyTwentyTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "label": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "terseLabel": "Unclaimed scientific research and experimental development expenditures",
        "verboseLabel": "Scientific research and experimental development"
       }
      }
     },
     "localname": "UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesSummaryofNonrefundableFederalInvestmentTaxCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedCapitalLossCarryForwardNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Capital Loss Carry Forward, Net [Member]",
        "label": "Unused Capital Loss Carry Forward, Net [Member]",
        "terseLabel": "Net capital losses carried forward"
       }
      }
     },
     "localname": "UnusedCapitalLossCarryForwardNetMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedNetOperatingLossCarryForwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Net Operating Loss Carry Forwards [Member]",
        "label": "Unused Net Operating Loss Carry Forwards [Member]",
        "terseLabel": "Net operating losses carried forward"
       }
      }
     },
     "localname": "UnusedNetOperatingLossCarryForwardsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "negatedTerseLabel": "Change in deferred tax benefits deemed not probable to be recovered"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Derivative And Shares Under Warrant Agreement",
        "label": "Warrant Derivative And Shares Under Warrant Agreement [Member]",
        "terseLabel": "Warrant Derivative And Shares Under Warrant Agreement"
       }
      }
     },
     "localname": "WarrantDerivativeAndSharesUnderWarrantAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantIssuedUnderlyingSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued, Underlying Share Price",
        "label": "Warrant Issued, Underlying Share Price",
        "terseLabel": "Underlying share price (usd per share)"
       }
      }
     },
     "localname": "WarrantIssuedUnderlyingSharePrice",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_WarrantsAndRightsOutstanding1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Outstanding1",
        "label": "Warrants And Rights Outstanding1",
        "periodEndLabel": "Issued, ending balance",
        "periodStartLabel": "Issued, beginning balance"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants $",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYDEFICIT",
      "http://www.oncolyticsbiotech.com/role/OtherExpensesandAdjustmentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantsandRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsandRightsOutstanding",
     "nsuri": "http://www.oncolyticsbiotech.com/20201231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r1": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r10": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r100": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "Presentation of a statement of cash flows",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2020-01-01"
  },
  "r101": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r102": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r103": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2020-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r104": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r105": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r106": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r107": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r108": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r109": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r11": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r110": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r111": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r112": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r113": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r114": {
   "Clause": "ix",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r115": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r116": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r117": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r118": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r119": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r12": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r120": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r121": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r122": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r123": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2020-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r124": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r125": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r126": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r127": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r128": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r129": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r13": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "134",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r130": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r131": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2020-01-01"
  },
  "r132": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2020-01-01"
  },
  "r133": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r134": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r135": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r136": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r137": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r138": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r139": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r14": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r140": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r141": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r142": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r143": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2020-01-01"
  },
  "r144": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2020-01-01"
  },
  "r145": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2020-01-01"
  },
  "r146": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r147": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r148": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r149": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r15": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r150": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r151": {
   "Clause": "v",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r152": {
   "Clause": "vi",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r153": {
   "Clause": "vii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r154": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r155": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r156": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r157": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r158": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r159": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r16": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r160": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2020-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r161": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r162": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r163": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r164": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r165": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r166": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r167": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r168": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r169": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r17": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r170": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r171": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r172": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r173": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r174": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r175": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r176": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r177": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2020-01-01"
  },
  "r178": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r179": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2020-01-01"
  },
  "r18": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r180": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2020-01-01"
  },
  "r181": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r182": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r183": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r184": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r185": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r186": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r187": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r188": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r189": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r19": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r190": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r191": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r192": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r193": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r194": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective 2021-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r195": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r196": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2020-01-01"
  },
  "r197": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r198": {
   "IssueDate": "2020-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2021-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2020-01-01"
  },
  "r199": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r2": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r20": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r200": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r201": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r202": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r21": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r22": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r23": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r24": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r25": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r26": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r27": {
   "Clause": "iv",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r28": {
   "Clause": "vii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r29": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r3": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r30": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r31": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r32": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r33": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r34": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r35": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r36": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2020-01-01"
  },
  "r37": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r38": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r39": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2020-01-01"
  },
  "r4": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r40": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r41": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r42": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r43": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r44": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r45": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r46": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r47": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r48": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2020-01-01"
  },
  "r49": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r50": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r51": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r52": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r53": {
   "Clause": "i",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r54": {
   "Clause": "ii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r55": {
   "Clause": "vii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r56": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r57": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r58": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r59": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r60": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2020-01-01"
  },
  "r61": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r62": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2020-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r63": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r64": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r65": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r66": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r67": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r68": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r69": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2020-01-01"
  },
  "r7": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r70": {
   "Clause": "viii",
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2020-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r71": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2020-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2020-01-01"
  },
  "r72": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r73": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2020-01-01"
  },
  "r74": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2020-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r75": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2020-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r76": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2020-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r77": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r78": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r79": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2020-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r8": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r80": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r81": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r82": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2020-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r83": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r84": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2020-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r85": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r86": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r87": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r88": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r89": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r9": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r90": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r91": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r92": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r93": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r94": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r95": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r96": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r97": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r98": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2020-01-01"
  },
  "r99": {
   "IssueDate": "2020-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2020-01-01"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001129928-21-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-21-000013-xbrl.zip
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MU:IPVTV^\WE.>0T?"_G/EL[^ %!+ P04    " !Z>&52==A-0IH$  "4$P
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MR:+24+&_*6)">,7MLH1\@'X2QNDF!*_10-#C=R>3HXD/7KU:^QCQ<]$\'4>
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M&:@F(?PJ@\G#8!B%$>U@+IS($,$0GGLK7#$=B(BY5M,BMM4 \ "8 ,#))(R
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MWK.^$P*(@[D"N .8(X![J]0A@!_0K?23T(U*V$D"7W@A.3- 4(D,BZSO9F(
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MUX<1P-P VSLVPF!]X.(1P1_C[.KS[^>Y;,@C"<B]T8:!<Z!76+#YQ-9-G!\
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M[C@(Z<Y=,%[.L\@L9D5$GILGE"S)-"T?3<DO"KZK#W4 JI0=0>0)VB\S:Y6
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M]9V0*QGH"!F!9A0")[D361EH2;FCU&2HNDMF@6><B$W;O&&!.@3;?]+91]W
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M;J[^Z2$NNQD0JC2K*LVJ2K/:<9K5D\=+#K%SZ'K)585&7L!8K[V[5BO"VMU
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MC30F%ZR7E]8^K&&;S=XQM7VI>EMMPVILE 5[[&WU D#<;)K]]K:QF!-N'W;
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M1%$2**3C/KI+&1-@&7]9!;^3O?F%YI3!FMKCQ=:4F4>\>/.D'Y7OG?3X/=N
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M3MOLMKOT/LOL]%JFA0.^8KPF*UJ\KN1R_04N]U0^]$-QE+^73MMWWR1[._L
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M;ZXO+M]]>'>K7KD6'E9_(W@\N(>G.BR3 ]!&XLD60/FV'CSG4Q7'++C77M8
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MZNO>6@[ZD,8NTU*9=Q2-/,;[@S;>14)?"\R('#V4_35QAL9 B,#PXAB34$-
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MQ>)KC_=W\(JG/_RD!6UMS;K6]QK!]Y1/Y8XAU,]E'24P0$^K!6635[XY7$@
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M7!Q;K(#6T.!L.-F9I*=O,(F-)))@F1JV:._H]X+T.E)IRV>V1 FX6JW;+C5
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MA.&:Z]D7A&$T^Y D'-HJZZ]7%#8F<O\'1.&Z*SJD%*94B7FE*#Q[ **P,;F
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M?H1I1XP&U5P>@V@\WV)U%.RTDR1P9"&;CM"*,9'L23)R=3KE:)#Y3%KMH)+
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M%1?"\C\&P0SY>2P1\"!?%@#/9H9KP;Z<*5OSFPM)_+<W>I-8EK+@5,,O++P
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MO:6T4QO44P? +EW/&]HH8=\R:59D("J#\Y00$PC[?OZ$^"\2!YXGCS,IC8F
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M6#J8O<)S75HNWS[^\(Y%9])F.>LLPG@3HQ&R?A"T+4#K#=SL?][]<MFQU N
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MGIR>&#ZPLZ,S^*/W=K>LH\9L\3<\#0><F\'\P4:.>GUZ\W6)?8[+J:6%)UC
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MU D/Z0'SQ*]!'L1F(TH@;:TS,-4])6MT+#>2)W6W1AFS@7U1MKD0@-K]1V<
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MXL>6L)4A<D5-.L(C![! R"#O4P5, @-!Z)V0,:B0$(VR^T&BJ\1Q3C^A#;_
MRH],M+/^O4TQ T6ORVJD[">H#172%1&B?M2=W]N\\T ::-=CU#,_=V5E7P=R
M&"4-UR3FAGVK-;NW7S<.BS58X+/&$E_III/=LX?95P& I9GDC@%H(%@QIY-4
M4/T@0+7^I/42!0KFMZVT8-X#[L;!^S2K90E3MYRC[4+4D@MA18FC)(=A)XJ/
M2Z_O $X]/85PR[FJN#H&]PB86IAB((>CBNB?7%7&3YUDLS;#PJML878D(9J(
ML5P7"7R3:I,VMFX;R!!67GWB9)BN*LR"PO_!I[6D/]=HOLM%X&%$8)\^1F#O
M/P*[B:J$=8F<X8QOEPW6;;IBD:CKN@@YK4*WD^W.[TS;CYI38"G<4/FD/<+%
M3.\FF?DV^*^%!"_6C)1K2\D!&QCFUZ#_$5*?)#JGNA!X:5.%CGJ0,L[&X?/B
MZR9BZ9DN':MI@'C"9'45JE,J1-D=8F>\G#'/U=R2?9F6NO:Y$P_V[Y!M;/,6
M#]=.=L2 G$XU':%Q .+%2FFT@6TC$,QM:+*^R\JK2\:;<K"/ZJ139"_SP6FN
M H8LH7S5ZS=ASTLAU?PB6K(-G/.NP21U:(2=QFYZ#!;%*<#IRQL= BD]11.$
M@P*K@K<#>CRN61,!A!9+\ V8%S>(+K!'%W9ZNUWF,_+>0"&>EQF6-R(LBLC0
M=<J.R+];)*FK#7]6P*/(Z!+/#&L\H#:30-U![X+[8[3H)@8\MWO2=;9QCSG?
MU3JK(AT>'9R"7__.[>M<G9F4:=-JG)>DJ+/"BVU-*#;X><4DR0NM#7C-N[&I
M-;W4H_^2EGF;5R]&?G#%"/#YM?E^0R(DOS_<=JLNM,\$1::]Y@94:FMZ&^C0
MU\'O)%SJ0>,[(+&OP@ZB7H+$C64# :RV3&B^PIB3-PE3.B^K!>+)8.<C#%PW
M3<[@(T=M5PE7W8</']_3R9O!H%45+;]$IC9OAYW;65,71%?BS5 XCQ0OZ\!D
MOP+!01ML(<%C.OZU4__[&'BF_+^%;IK^0)ZFG>A5*=_V&#)].YK,B;R\(,GS
MOS!<E7= R1L[/R <,F7+&G;&C#WOKWW /&:M_"DA=OHB<,/"Y V4 BHC1X9?
MFL=.QP(?/![3>BR;;C<P_!&6/C92_B@S#;9!.UA^AXV6BW/0OW1/-N20Y2C)
MT0\VX3+\!.92@ESP;TUY11NS-]\9?@ P'E-7>V$K K!(HZQFJLC^8THE%EA2
MM)"_@DMCL#NJ&='F@)%<(FAJDJ6^[B.5JA*I+#@O\_.!WL[1SM1 #V2*X#EX
M/N>Y=>0[Q2+.3UP:L@V$4OMPWX%9KS2>_&[.;6U.K3"]29\]D7P!3?T##_<]
M>PSW/8;[?E01'$7D1 :JCG)A4DB"9P)YCGXVH+RFGMS]*A@KSM&L] *BYJ1T
M!C=J*X_Q\19.QTV<A&S7=S>=?[Q5GGYZI:=?E'X"#=-3<KSZGF3'T?:]S>!V
M'@D#_%KBY5Z:6:5X_%-Q,!5"WC#;7*]MI&H/ST[BVW\A$\!86](LV>G-7. U
ML)>7>W  F7C;D81FMJD-DP&Z."Z[(82#[2^*423#F.I2XGTXFQ$,^-]AG(?7
M5SI'AL7<E=I8ZD1A*&'!-'&OL$F4I4_S.*QF2)9;PGI(@]1F9?;/3<*7>]A#
M6+X"(U)0=])!J==ZJKV<IK+;.!C>H"XU$T5>?_)IY\B0>*<[]((2=VL*6[-F
M]L4^$]IU2#E\-]$<S95NVJK0WM(,L%HBOW3),/5EA:8Z+?1F[N;U4*C?1$LQ
M-Y=EU.P$7:_L^#@,\;R[-B,>);?72-JHZ\'P)!6LT6IS[\ZFG'%6AX9+GX4,
M[ZY9.;U^6.ZM_![E_1E!AZ_-4ZG<[X#ILJ\$7Z0&.(HQ0HSZSI_(@5ZC8N75
MG=#+8"MW]Y"!)F[>Q'X%H3+"!\RU"[1+^Q9%I<$8DS(A*V\.8\Z%]-;B#T[M
MUQ%VRGI3ZO4J-+X&\1JB9I /K(FFZKI,L%I$NJL,+<75T[^V7^%ET[]5!TG"
M1A7W7P3C 3DQ6<MZJ$%OXM^6Q1-+>F JXHW9(4@%)7?@^![<Y[\.GN_',/S-
MG)DU!O.KO>@C$5?:T^U#FV]9XU*?HXQ64*J3'.D+_(<"&5D!B]QE9/%S\CVK
MX'8ASP^=WO+Y8^#Q*Z[T7J-BOMN+/AB"G#?D.+VCC;.5+9*'2[0FJ^@\JYHV
M!,$P9(;)+10ZFW5394ECO.-4$RY:".B7B@!8S"*,29U4@^<81R:S,6TK;]9B
M.':J51<"F3'+(OH":IDUC,I.9,3@)355FUA,=ED0($PNLUWAO $[MWB;CK3#
M?6Q)WFQ7XWKLJ".<9S:$PDEAYC\C,%98=\C"A:PI1H2<GVFNX689=/0M5(;]
M(DHPXV:8S]44D^"4-X:/&/$%7F&5,9(0_IJJA!)^)#!(ZYISXL^ ZD%G8P<:
M='>Q0>1U.O;()3CT;IN>:&>B"2Y,[5(;.)(/#_;CZ.#@Q<OH?\"QA>\:>.@Q
M7$^6ZMN]W_;B_EW.#M]&!_]ZN0N?--(-@=S9Z'B>Z6GTDT4;"[V5\2/D%3JU
MAT/\+D@1@+R\\BH*WH9P8)22E[C3I"P_#88B')=N4!-I;B:F1>^9J&7J4IXB
M81!+BT>]&S\5Y47AWZ<?V U?M CYF>)KW&VYP6V_UFB#@[WH[]@!] \F8.Y5
M&_P&:TM4)6UM*X2CBQ+!.=A&K+*=91:J3EJ\/IIISZ)EZ#WGJZ8:BW(*CD@6
MND4J%?XQ&[?GJ',P#:&V:ED/]Z(W:-0OD?H?-]9&#OXJC\4$=&>(L9"V?E)Q
M+B1^:R*7N;JPVN4]8G.DO;0HP6U:2K"Q#WXX.3H[/6$U_2M8'L_BZ'#_X"5\
M]?1V^&0&3.=KWRDA[_%:-WH87MR+K\R+PQ?(TO_[3?8BT8=J\C)Y_MW!X3/X
M_RIYE3Q_J28OIGKZ?++_]/\]^^:./+_;<O "6;V?_7OTZ^G;D].3Z.CM2?3A
M].,9[N3HS=OCT[=G;_YY&GW\^>C#:73TV]&'D^C]+T=O-U(SK??W&/4/FM7R
M8E+(L( GK\"PJJ/76=EH,(W>%,G>R'VT/#-SQ Y:R$FJTG+)A=9PTL',H!EN
M.)&C(X09\_DW[GSY'!@C3!0?^K9]IXG_EU,^!S&#]<&%#+RYHU#U((+?M=2$
M3[&^DN[8N]1T9[@;,^'@;L)(>]$($B)% %NFM)R[[:H8Q%:D.'E%5,_,7E7?
M'>OA'Q6$]0B9^]^UA'JT3<94TR"D(L+F:MDT@^V9.MKDTK9!T4$;E,0R9]<6
MQ!RTL;PK\L0[6H?)2.NPK,I%B>7+%P7,\CQ;HG"''=8&XBZ&8^6&"R4 *%U@
M9 PC9UX<1/C^$?-O8SIT(Z[/K<Z]AL1=_N)E:UJ_+]3G;-$N; ]<(QKPH$1B
M+Q0@FDY5-HAN<9I_FZ0G&4EZIF72(K^Z)3P?BM'!_RU-.3VQ*=F@X=([5UDV
M,,R./.5/J##(IR9BF-8V';*'8QRR)QJFE_GUMNB<_0W#<GZ CJ&#'B6DQ^II
M^C![7R^T0ML/Z0J9P @,Y+ND(/Z:#N/1/(;7N4H^/7D'NIL+_$;S'DA\:M,
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MN'Y>FS# %S4=&GMU1@'14 =<B<& ^\4-<94?>8G4HFP%\FPP5<J0)!CF@O5
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ME:CF#TI4!R,S8TLMU6#:*%$_ENYCSZ<$.-#8&"Y"/ $VD<5"3R("OB3:OLM
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MP[5@5\SU\1B4D!V3N/6IB =_Z=,-VX(]OU:/!PZ*&:R1K)[O7H[ ?@SP;VF
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M8?W158WF&/^R0^CA%=!TPS/=]LJ^-9?Z8(ZU@]\JB^N.RRF&+:Y3F]DZ9J2
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M@XK^8*Z*:O3>CT#FDI$^*D*B8%1EQAJ4NPYZM6^JTFUI+S<, N5;<>7"2BM
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MZHX1TR>$K2R\TC*_E84>\]JUPF]EL9W[<B !>Y@C >O[Y+<[!J$.=R4G?*@
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M;$'% P/75^!',RZZG!%=-J'Y&6'IW[0H9TNJSBLQ9V04#2%DG<L9H^5%KJC
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MKN#:X#FF?EETQQ? 1]$C.%@%ZD^:.>1BUJ*A:*<;4.0:W1/IY&X)$->#2@T
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MRWW5W_/ZMV+_]\S\%]S1_P%02P,$%     @ >GAE4L9:X:-""@  5C@  !X
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M*!9<C63*->I# :UH><K5A&A!_ 2T!GHVDM^JNA<OD%[_E@Q1(&_[UQTT4E=
ME>,Q23&'R?*H,-$)#6#LGD4TT@IG:0J;>=:NP376K2QOA"N,%,=">.;K/0T2
M.@K8ZCEY<XID+N.Q-O-4@G[&6>2:#&4ZX>X$/1 V8^ $U+V+Q#1@WIAY><*U
M<4X\V$-O\<&TQ51]/2V(J8?T%@+FZ\9Q+=--JHC"WC6Q2+SVE<(W5T10J1=/
M:\AS%T-(+)DVJME=?JFTH/R4Y[M$VJ=(&(>;317-1R5Q')AO8.D  ,8*)S0(
M$,!#(@"2Z7S^E .D;P.%_ -4>8#V=G S'?; $?H"A5EBS"P(P9()O<^*'*(
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ML]1D>4S[ 'V4\9_;81 PADI#30R*@6@(#JE,#(4O%NN4K6&4+HEQ*>37&&G
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M_Q3/I?Y,E?Q ]/YWO<LIV[_K,7]A=/Q_4$L#!!0    ( 'IX95(>I@1SZ@(
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MYBEL[OZAMEZ]?+^]OODN/WG<B4]>VLWU/[NO7VV<;+]ZJ3>?//VP]81_'V[
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MF]E/<J&XTO:%6'1]DNWH67Z-$"H+ &U)SP77:=;Z!1WU!R-6T#LC'*TBJ>O
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M#EYA#01'PX8 8D$;DH'8(<X0O:@#GL8Z5U ;Q1:ZR8!\O&*261_08>?XL"G
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M8V"4H6YZ E+EP.H&57)1H4O93N.J%8V_)Y*ZQ,P?68B<(;$>@PHE 443LK.
MR5N#SF3M%Q>C*V+?,3*/\*@SPNZG5N'I<'A,>7KR1RM/?AY^8&3W )1B.7:0
M$")(9SS_I$ NYKBX_+A]C+Z'HL^X1SO=SJA#PXO/,_WNIK"" @J=@T/AD;5&
M])Y]18J.V(VTY,KBLF)I(4F1_49OC(LH(,08!6(*@,&%D"DT;!7+N6$S_S4F
M18X0@R<'@L &%44ID>JB^R%*F>QY%.!60-[,Z7=W"V0"QT@Z2U8[,%!0N5#+
MA"!89,&D1@TKS%=)SFP%G>BTR.@RY03LZK+W6P+8;$A:CK@;NJS#7&5K3N,)
MPFDI5-'!&0".,L%'%;PTJJYV()LUBV..LO5CV:OS',<IX> +*?YZZN;Y?190
MXPU9$!ZD9'69JI36W++V(4\R!UX8I6X;WIMI*M\6IJW4##25*RYDGPD4&PPG
MDX\9K!:Q"*NB#I-Z#]<0@M]97/ZQV1<T&O2'1Y1J(+=V5&\XJ]R_=.H%,40C
MNFJ _/F WG7ZQ\/NZ4Z])-^JC7.S*V]%4>H<#@I1@ 830IU@R?)DHS!Q,C;.
MLC,-!*H0K2ATL[3!RUZFP=IHQ%V"@[<T6ML?$,UV6ETCZ'O)Q?;7CY4F6G(F
MF^602F2#CE'60BOMLRG!B!#)L;-=RHKK*[[-DF\!2S8IY"B]9]TJ/$D229+V
MU5J'O.+;3'3K^-SV425@+6-;T?R.:9YT2EHJI8%=B%+(^RS )$I.!/;)S;G[
MO6)W<VGV6=@RDSU*I+2Q).^QKDR<C(\^EEB<"55#QGAW@=L",6<6X,PBIC1)
MQI*+5F0*F%HU6ZU6E%%KZ64P4^MEE&XW8/?I1;1>EP<4;]\T,#'T]4S#S)87
ME2:GZ(2.UD$!]$4;1SHKKZ"@CRL.S99#M7Q_='I'PR1S850.-@2LID(#@&!*
M.:F5*RDX*UVQ*T;-P:=N)).4D3'9;(/Q#I)B=T,$6Y"\-BI "BLFS81)3WNI
MOB![MN]QD)>53-&[Z$"80ME#]L);0:&(+)S1 2<[%ZS(],-D>M0_/.SWQE<\
M/QZD QS2==.IC:15<&!U@9)954$V%(1-7BAG"@,O@U_1:E[9^6;2B4,Z7Q+K
M)&= 61<-D?8QDI?>)_N3F[Q&0JJLK(8F"F,3)".00&5;YU!QV)ZF&\RMD/PF
MDI=2*#-;CX8E"1D1$.Q1UEW";<A!%@E9B8A>-+/*<N'4]YV[F'.I]-2!:A$:
M2S?9NKB1URD&C 3)"C6M1EN1J<DNYEQH987.;#<T$8?!0,770D>;0[$EZZQQ
M1:NFNIASH1-$"G4I2A6-!73,(PH>P B3@I<VK^C4J%&#N7#(6(O!J6@I:A#@
MT*N@<XQH(4G4#9V<LK@<FL>LZCEH)I7(H3-6:U9(V:!)WFCOE7/>)/&3:Z9&
M0HJ:&$*A/&&! M8[E*!,K.F,H+!9RZ8M1O [N]DS2@@O,+"D*0TR%B] 8[':
M6N4HJ8;.GEDD+7[W(W7SF;XC@C9*0C2@,Q0EO/&06)USV!OK9A@K)C4RC3*G
M'6^5$2+4548*!R@%?9(^UWF7P9$KVJW(U-!X=SYT2EDF#XY-72B JF!47DDK
M$(+3IJRL7,-CE3EM$LN.&*"4 HH <#F2CQFCC1Y*U%[^W*QJ)*3D@M2^F*)5
M!!<+YD Q.8I:@\^>&C4'>2%BE5GN=60Y,K%&$M5<)7N5/DOT2A%C9%2<K%!C
MA5)FT<#Y$7O\"'N8.[?AYET(*&U;J+8R,P I.(D: %VQ!,:*  FELIB+D-Y^
M-GUO$47I#M"Z@3@W8N+)]\]OFI7F+LZ&Y$D5;S2DE (X<-H)@RD1.;7B76.A
M=;&.=>H,B008XP/'@8K_4)0$)DH-@';!O?>5.ELTSI.R=:IFA. Y8C44%(!R
MUK+/8\E+G'+>UF*VZ1^+QOE%&R5E'-G-,=?#\=*E/X"C-+&PUBK.U"WJ-&"(
M=1-!UF,@;#R?/+F"[QL.ZB>(_,BBBLX%9X)!01I,S%YY9U*FNJRQ4).-.!F1
MH%P#$9E#<=1ED$);N5F Q+Z;EC[9: R$X#S$K$TVVG%@H<^C" :IO4+K1S3B
M1;R^H1$O7OHCM=#LL2E!1@K6B(QJM+5R1$E6D"2E7V#Y:X(3]P-L^N8SW.7V
M1K>B53(*R$%'96L9OO?>"9^RUT4&ER+:!FB5[]ZQ:!$8UDA])762F7\$3Q$$
MJ*#9&=<^ZA*\C9/970N>Y5\$Y7$MY3EYHDN*<^,D=8\SNY?UX3JC^BB3)U[&
MX0<VC,%I@BAKIJ/.(F2+2 J2*PF\=0VH?EMQK2%E>5!K=5*4A<,?H! C))5*
MDF@D)6]] [)J*ZXU))NE9':FI!1RW7B$C2=0#(!"()%2(%8V=-9<^QFLI4TZ
M",L6,[D$)>N0);(N*T$Z*650*VO9;%;-QR[F8FV.TN6L!4BMHLT0"SAEJ01S
M'B2N[&)36347"V@#D*C[6&<%@-($X>L6;=YK_E7*=!Q "@5-)=-5PX<O>YT1
MY?$HW>UN)\) B;:"&>2(( 5!&J%N&@_9>1\ K-'1L9\,1DX7PZM M5>(_: <
M7L+L&W)X\=(?VK0<@]0&JX\ .EAO$BMY9/>A 'C1A%WFFP'O?%S" ";9$D )
MQM6;$%7,+BMA5;;H#2V12SAGZ9W/G&,,)AJ=BS$ .FI4J)S*)B8.)9642^2;
MS5TYS\%),E85;0/*Z &$<\$7PB2C, 6)/"YN]?7BHGHKE=C"9*>E\10ILJX%
MED+/KJRV.GBR:8&WP6L"4#.<WLOVSV6MLO<I0RB:39\MK!^==MEP[+&X"X\U
M JC9+4*6&868H["%51]:=EL*6%= 1I0Y@S[?(=2VS_YH(&(_P^;,GWI)%_<"
M_KJ7=.G2'QFQ=B(E",GJ*$ IAT+5W8+)2JMS5+#BTO7K(9[V4O^0=LY*D9_U
M)]7*\N+S;#,V?+2WOW%RQ'??A>M]]Z3R5B43(5B9'"!XU*$(XX/TY++0TYEQ
MPLIF%;*NU:>^9$YV#VAS;@Z:L&TYBR+7G(*E0D66&(%*XJ!)&; B1J?0B;,!
M-T:KO8)M)KF.B\!]/==QZ=(?*18)BFKY6@2?08I:C22@3A$H14)QMNFIK,7#
M> [K8#AVSNO,R:(*)"H!*6A?JV<9=15-0R/B^4-[*V%QCI9U+,?"60)X4A%B
M*,47D8"\QLF M!-VDIX:_]$HV.:^F8T;SP*Y5E;JDTM_: H/.2=UD>SE@'0N
M"%%<4M9K(ZUS;K)M\PK,FX7.G^#S(SD.#(6 T.I:-$DBL! :%KX2)4?/C=]6
M^^XVCI_AAM71:671NF*$ @RUTE 9ZXQ52GF?1 ,2]0L!SOQS\MKJ(E3Q$&T
M2QZ%+)K%3(EBE(*\N!G$A0#P5I*%@HI6H6 0)D/2TC,<;)B2)IN)H.DK:MXA
M)K/+M%NCO,M5.%0"&2+Z4%C]!4@97,*RN)[Z@F$R0W]<08QU3TLG8X'H,2@3
M?$)5ES\/\<)^7^IL:^];W\+V.W3^Q9UBOS'EZ>*E/[)BKZ$BC+ >ZSALM@@1
M#;]7C6Z\Q-P$+E^8)/?QX-_[HU'_<+N,3\YNL&'<'(O-Q@D-4F=(SP>=1,/'
M_<'V\:B2MY;YCT5JL@+LI8&(2_>,&]KN?>O1%D6^HI(YAFRPF A@E2>CK70J
M2F')3D87&\F3W?[1BB0S(DG03(^ZK#3I&@HHUBDBR!",#EIF'1I#DI\0.U+9
M)DDE%QG!%!N$2@A07%8N8$X-2#$W"L0%2#A[IP.ZE%WV( '0%" K3 F !50C
M%L!LKNG??=]OB&9P!9+T%B5Z#Y[]Z9(,ASPJ@XPBDFHL3Q;?]#>') ITR79L
M,S)$J.M_&D2/*F-V! L\>K7"CL$R0CNEM)&0/3MKP05=:B"=;*"?V?3?"HCS
M-_W1!">,]=*5#,E +$[$%)@(X),B^ FE]6! LS8#/^*7+(INT)!-M,D411S,
M"8/2<,P?!!02B7^OF'(;3+FV9[(H-,FL.710(C$G@&(,PBGOBD.(TCMP*YHL
M,GK&&^F-L(7( M9R(V$=$H*R7K#/_S,[ +<#X_Q= &V-<85=/>TRY!)]#$D5
M%Z521*E!N;I&1O^/^\>#AB@'X8,!=@,LN@)H!:(0F9U'$]"!G2QGT BBW"5X
M/YT#H&7Q06/ S/;#J8 <3"I26+(DJ]-/Z"<V2,0=!4_>*E6P@ L)I?.B"&]-
M] %2LW:W:@**\S?_WA<GDTO%.@G!U.@_HX@A:%;I.J;&R&LSS7_G75,4.V@.
M]U6*NI "(A&C,(&4\L*P4R":ZR<N?O:_02SA"!(\0B#0!K(#5-%DRT=DB9)2
M(TKB?EKP=$G6RU(R!@NB*/3:!>>UT7Q(T<\<_M\.BO,W_Q)M*5(60R$ ZH@V
MJU##N2(P!->$55KGFVR?/X0Y"<!,D2/R!"G+X*RWH=;M!.D"8?,AO,T@>/[X
M2</B1I:*9L=*Z1A,,;JNWZ(I2^N:M5'U[NG1>3%YQ"'EYWA:&UFK1>3[XTF>
MES1MW?*-E6R=]5EOJ1- EW)2K[()G S!IVB C R^6)$<>?0N2 %-F+ZQF-C>
MRLP.@\Y01LHLDA"TBEK$8GT1@?LV.MV$&5 +#]?L)D?%C!H#!)=S .UE+#5M
MQ;%'L-*FR>2%19\.NO!PS6ZFJ(D9,&3R019(5@2+@E@A@LHI28(&K-BYZ+C-
M?]W.9*R5SEH!WH"(%D%)1\4))=E;1=>HZ< - 'DN,X5#) '!^NPX]C @?5"F
M**=<R>RYND:D>Q83V]O)SL6D5?!><(@/07"TSRI7J)(T)9&26NI0XSD-2G]P
MB+U$RQUKE*)!& E:I #%NXA86!$K]HO0@6S$5/$%!?=6@@W0P4?MT#)N[ ZI
M&+U'_F>SYO^%LHS!QMWC-;MH0_D0$H*SD1P(I]F++5K*9#48Z[5;QFCC[O&:
M7;B!64$%"8,NX 2@C;(83*D6JI R2QUNS,'JS2?>()4+<OBOC#;@8@G:4#8Z
MH54E<IRQU/'&/%">SYY*+N88H5@T!#915):42%*[F%(.<AD#CCO7O;.<36X*
MV>!,R)ZE$@L*B*1*=I&B,;$1$XRNC]>%<2P:TN =77%74Y!#H;40)D2G-7"X
MB #*"L^1O52)2B-"^_/%C9X/^N\ZPT^'^1_UNUV,_<%X>>];W-#\=F+YDBTD
M1Z'.VB<PWF<&")T400KA8Q.BO(7#9X9174F6G..PSBD-(4:LVW(P&EZ()%1N
MPJYC%X#J'_.K#8[8Q'^RJ<+.WM;.]HN_+V,>A7)Q/DB4%#Q8*V-QME;%)!E,
M,I/:F,;$#7-&<#XQ@;:8M6 0?2)0+GK'<'E'AG1DV6M$<?,FCHX'_$@7(=M]
MSZV<3G[N=$YF5[>Z2X='K&\'I^N=NCPPL<OYLG?,SLLNGCSK5UV]ULOG1QX-
M*'<^]WT^N:,I]A2RKX/'+.RLKZV*;%$IU46@0\JV&1.<O\D5>D>]%5MF8=VS
M+D)J7S@(!1L,ZQE78JIK]N=LFK$,WK?8LM7YYGI7*[)<ARRQ2)!!2])9 R%Z
M:PL@!U$6. 16C3!#<X!O-E0^Z Q&IPTA2J$L6). 3RY#7;T67*IE$[4JVU,S
MM$JSB=*<=1HUL\.&E$2=FFFL"D5'/I:]ER3(-"(_\RTTOKWJTF(3<U&X@B(P
M5[*-.15PT<944E$&B5R*$!NQ*LLWN3+;Y7A^8K;H@$DY- :B F%"*"%FYQS*
MDJR 9HRQ--H*-6G)@(12&.=\0?9;/$8H"9/QTE@/2O@566Z=+,V98.HIH2 I
M T@%Y"QJ[7*,TGBE@O6-6!ST6W"L\G$SBH5LM,YG3%X8\")[R1\3)5]*<$4W
M8N3XFUQ9Y>-FM>Z@0DE.Z&PU@&2?-DN+@4G#?PEG&K$Z1;/-T$9G_Z I8^>6
M 81<UZ- !.TP",AU;5,I7-W31#>!+=_"8Y6]G=6Z=U8D88@Y0@9T$M$(E877
M I+,IAG9VR^3Y7'_V^G1%4^NE>5G4BBHJS$(73?-"C$FD#E$&9-)T(CU$7]B
M^*0BHZQ7!C4" X?9)V6-EN Y-DF-V !MMO!-S]^)"S'^V9SDN[/&8B0(4B9(
M)4?!%@(Q)IV8-\M16++ R??K,7-1R")"73_3&E=*A! PI&AR])*UBTU6-WVD
M9NIS+G#VO5ETX1"6_04A$ON=D(M$)4%$-D_"*EM"TP=KIE[G+%=._IG9HC3[
M*%%(5VOT@P9TEOW-I$I4R2;U$^;?[]QM:5 "7AI' 5F_9,ULL38*,$;[0-'S
M =^(&*7!!;'-4BV(WACED%4)1T0EA)C($/@,$G2RC1BM:;AJN<X P:+01;)_
MXK/6OI"%4'PD5PP3IVX"4(IN1 %UP^G2I!Q\ ')1D8Q&>#!*10Z'A T@0V)H
M;2,<ER974#?+%@%"#"EDF[1G3Y=BRE*#=DIDY0!_PO&]NU0N3:JAMG4M9.&"
MD91 LF-;ZJ+6Q69P&EC+K)ARZTQI3AXW"ZL=FQ\:+][CR1M2*2(I7WPQN1&E
MC@TNHFZ6#7+)L<?B:Q&U!*%K%E>;E(,?'Z*F)^86OXJZ672A@-D4[\AI =F;
MF*VV6F-)QA;RV 2Z--P0-:B.VCNIM2N@ZIQ2C#E0$"*H+(O@0T KMMP^6YJ3
MQ\6(D:P,4&N2HDHA44K)N%A4P89LL]3@0NJ&&2+P*FN4T2L)/LF8C752H9,&
MB_"-J'9LN&II4A[7>2&]K54M+D  #%@W 0.3DC#94B-T2\/ITJ0\+D:=0)%-
MMF20A2)$ T7$(+RB(!N1]F]R+76S;%&HI97,#Y>8-5GXNL].\HA:9B-S,[+^
M/S-^I%5T18F$L2XP7SA8B3)J2#Z)(G'9C<-$-;SLI2YRRWDG=28/E.IZGSA(
M!WSGQDGMS_I4V%UGN]_M']4/]7"/6SH>-*8DVH6"F)WR(64PQ7@I+-;56[,U
MBE(CLJ,S +N>VZ+1-O<<CCJ]_7K;(QP,ZMR)]SC(38'36+*(2=C@5!UF#:QY
ME;=2\@&RQ35AQ="FPSG#!4:]=AYCB=K6W9;K[F<I^NRRT:A-G,*YZ.N<-QW.
MV>TJ47SPN:A /D2@I-&*7&04H+!H;_5/(IT+;%EG*+O))$P%M-?1 YM9GXHU
MJ&T*UB4D^9/([B*#/3O)#FS$P1IK?'%0H,1,%EAILS2C3]"("/F'P7[:>T?#
M4?W>QL4\$H4BYSSYY(&X:YT&JUWB,,C'#.6GT,QWC=\,E6TLRKFBHW!D(,?H
M.8CUA"DC1S(YYI]"V=XY?K/3GR"LSB4GECL/29,WV4L'21J1M8S+GC.:;@(S
MZ'.7C4Z?=[D7-_YSW!E;0[[I*?=4MTMI=(S=LXM>4!='W-+G7]H4G1NTM%:B
M53I(B-K[D@N: @0BI(0_A\YM N:SW'0]"@Y;LX4Z.2D!V]:@H*[>0\&RF]2,
M?1!_"LQGI]O9*8[*9^\4>U)US<!,B,I",#8 B4;4U/TPYN,]HIX.A\?TJ#]L
MC%OLG2\F03+9%F#P K!+;$L,6<G$ZOJG4-%W"-T,-:V+,J$A8R)J$,Y[)Z/U
M[!M[1UYI^BDT[5U"-SN%*8WQ(3F2J"($B1ADA3!;;W71^N=PAB?G'N%19X3=
M3Q.^6]28T@EI8])!L0)UK$$Y-"U."J$I>"^+;L9&W4W&<H8J53H4@CU78N$$
ML#[8;+/)DAT9#E>"_2E4ZERQG)V.]3E%+9(%% :$<<A&T7J2$BN:93KQ75BI
M;AO+FVHF8;D39M$#$(W*;%*\!3 R8 '0 HQP*"'[1J2LG]5!@^%V>8R=P9_8
M/:9_<(-U<.'TTUJ<\97JJBL;8DB4#1G1.B(D,,'%)-#EZ(P.)(6733 DBP[7
M#&T%F9B5(LW_ 8ABV8<K+%Q2@:\K/\5&;0TZW1WY16?X]K,BMT?'@VI%3NO)
M'ZV?' Y&Y^U-OB=-/SU\N;,^2\SGO_.HBL9(J\G:G,%:&W5BQ>NE0).D"V5%
MD)L1Y,G?GR\70;P25D5?4$2JSB:6:$M)B8+A< +TBB W(\C&RQ?+19!<=RC6
M[*HEZR FB6QP7!K/*13LSB[P=,*[T_.S<L6.>YU)K^_'H_/>/"0<'@_H]\ZP
M7W?P^ZB"/IXZ^USOOQ+$% +DR*$8AQW@C6&I9Y^<(@5&U"_R=BEWIXMG#B(=
M#[X(XKF:N &(PA4;$P%)G0$L!Y.&E;6)44G2UBUPQ?S=Z<O;F:J *><8HW1:
M MH828;H-)64O=;6-\!&GI5NI/XA[8S8%-3[GO43COBTO)AYN5 X=Z%8;O;Q
MT/PM&T0M7#)"1V7!@,%@5$C6L,%3*LA0895A"NMB!KV+#2L'NM>%]=.8^ =@
MM9(MG9=UU5H'WA-&8C%%9+ )."@>P^K/8%W(1.J"P^JO#ZN?7: B+15PRDLM
M0))#G;Q*SAJ=;)8^+Y42/I^#,"Y2OI6M+^:O?T5&0V2H[GL/!3(*4LI:@H@R
MV^B72O_>,:+S4;T%,ZF0)8+-0$&SDZ2<L4+&$*(7=JE4[UTC.A>MBQYL\HFQ
M PU1:<P&;?:@A0+24C1&Z^Y@E[;+SJB?WEX$\14.!AP5_/"*# M+F_FH=@L"
MLPVHV/<"[US Q&$34 S.0LJR,:K]9Z7-?.R'U(Z<B  Z2K"D8Q;*%VN U9 3
M&1IC/WY:VLS%2.4L2LA9<DR@H<3H@\ZUWB)([P.H26@@SXR4%!Q -(HV:U4W
MCXL,AR][F09KH]T#VL3!6QJM[0]HC/[+7F=$>4R&&2XOM-7O87YS/!PSZ!U_
MS7"MC&CP@H[Z@WKL^1BD3X=:-O%-?[ ]R)T>#D['S[W+M!]BJO2\;7LGKV_O
M^#K=%C +!LJ<45I'6C/A)$2/KJ@"5$16(DYV0UD1;]F(=R';_ F7KIMM?M Y
M><B]VS\>)!I./AX01U'U>7+GW>^_\8^S?:D-:["4?%'L4D'V$:*NXSJL^:+U
M[M_5%'Z\9S@Z[3*)#CN]]@'51< >@KKOS-'HK^\[>73P4 KQ_]Z[=&E]H#9V
M._N]AXE?FNK@Q? (>[__%@</N.G)W^??\.63GSW$EUH^.Y_ZW?[@X7^+\;^_
M%NZ;=L'#3O?TX?_997(,6UOTOO6B?XB]__/KD/%L#[DWR^3"8><#\<OP>XT_
MOI^\J^-VNIT>G;V[5/5M7VX]W=U8;^WLKNUN['SV0HOVM#L;CUZ^>+K[=&.G
MM;:UWMKXUZ-_K&T]V6@]VM[<?+JS\W1[Z_JO\-?QD4ZO*HJ'ZKYB'LSIK5[A
M\(#E=]3O_=I:O__H?DNQI0XW8->W3MX=C/Y:+_QX^\4FOV3[\1>?]! '^RRF
ML3\:]0\?5A&='AGUCQY.D!IA[-+9];$_8 71YA?HXM&0'I[]\=?<&1YU\925
MS_@QQC?]]1VQPDS8G?8%MSG5 "'<]T97)3!B;3/*9\U/]</]L7YX,,I7G-/W
M6>%\\;2X+[]\ZU>:56?/,]-6/=]HOWSZ8K,/QATQZ0SNU K7W^[I>V<W'&%F
MR[+_4!V=M"2C]+F4?=[7UR?=*VZZ-C^\KGS!IW0;:_3^.<VF;WNS%^E2&?W0
M:WRGLKCZ9?[GOQFZOS;SC3[3!N,W>K'QY.G.[HNU75;?$T.TN;&UVWK^\L7.
MRS7^8W>[Q7I_?%:J7^)?6MLO6K_L\Z_'K=U_;+0NV(1S>[#V:+>>ED'#I9ZZ
MDLWA>[MLHIVNYS'<=:=^0I,%-.CCQ]Q^L4"/>"V!F[ASRZ(:3YJI2'X6U;BV
MM?5R[5GKQ<;S[1=?T(BZJD-I?LD_HA#/WNOLRV'B87VU\T3MNGO7ZN?OO?3[
MU?75$G:NL.>!Y>/^H%4Z0WZ:UBGAH$4<>>2?U#JM4QIG&"82J^6OK9I5^;*.
M_82?JO'\;!I@*SN]"F$6RDZ/\Z#E='%,-0<P6SM/QS;YULWU<AC$*0UJQJK:
MQM$!M48U-=VIF>G6)#O<*H/^8>O?_*\UZH]__Z06<Q7/K>S$RDXTYXVN%H^=
M?VP\>U9'*YZO;>VM[,2-[40=BV[U2ZMN^#1J#>@_QYT!OPC;CLZP-3R@;I=?
M]Y"?\91/UF'1AY]WRX/Q&,!"**BK1T<F[_M]/Q=(^U[]<H_ZAX>=81W:YF"X
M2ZW><8T#'[:$D&WM35U?XSN'A#YG\<(-$@5_/X@;C;M\$OCJK\2]T[>;]@^+
M=6O8[W9RZPS3+T>P-Y:(>0\SJF_:#_6Y_;C=)[B:[=M;C[:?[>T^?;33^OO3
M[=V-1_]H/=UZ='_%\<7G^!TZ.V.J_+)Q@FG4ZN'AV,*]H/W.L(9#HQ:R:3NB
M5(N9<JO3:W5&PU8ZP $_ZU]N+(/S%MUKFHGG@_Z[3B^-NV*MRQ9BA+^V'F$/
M,ZZ$9R4\GPG//X\'G6'NC(O:*F>8._U!76YM<F# _]_'7N?#^//G4M,HV=@Y
M[K 7K*3XM26E=:W_K:6"X_*AUJ,!#>NS_=K:NO_J/@M,=Q\'I[]^%*%=Q;'%
MO]Q*AE8R])D,K>7,]!E6\3GBJ"IUCK#;HA-*QZ/.NZJ)2R?1L.'"\[^=P=O6
MLW[_[<(_Z6V*^:*\XRYU'[9^ :'_TK).M)UVB__,&^U#[/!C=WJE___UV<YT
M3UF%#>^GE6>RTJJ?:]4M=NA9(*E+1P?]'O\YX4\+>_D!^R6/,0T[AQ\S(?5X
MZX(F?C1-9SWB;ZKQP7,:#&?AP4S'SVX<%5R^[ZY[<X>-T: SZG"+@W& 1 ..
MB8Z.!\/C&BF-^BV^8NSR32H%N0/KL-):NI (7%CA]/*^<?Y[A%.%^]+;V1<?
MJ_M.FYDW"W#?N3"+ZN-IQ]<<_Q5:8WJVPOAEE;)H*?"K1T)V.Z/N)/&-Z:"5
MNC@<7F-8Y.?IG@'6IVWMG![&?G=6/3.8?,,R=]S6--LTIA6=I /L[?.!7NO]
M08>/?-2QWQY=NKXUOQU:?G5 ?QY]6T<ZN"<G4P5_;?7ZK2,<M-[5)96OS] [
M[L0%I.CVUJ.]N^JOGT+BAQG_TYKN(M":3%R]QB#I$ON)^Y?\Q%9KB]WT&?O7
M<WS_PD'&1)OS&PZHU1FV<#HX7DUF/_+C3K*D5W;/N +A8O=,!M6^TD=W_:[7
M'_B>+R9/>YF5P(C&73D-]KAC^\>C.BUZ[+\,Q[;BW"!/N_WC4-#__+=7TOUU
M./$ )U>FJ20SS&EB<89URGH=-9K>G[K](9U]F);5I?Z[L4C$T_%1[/6.N8UI
MS40+[*_2VE^#%^=M3IZ,&\51ZSK5VXT3F7-XN$O2 7$/<ACXMM69=-O@XW#<
M6(#>4[?;?MOKO^?G).2(O [-U=VN!K_63LI4.KW):-V+8_;<09@S "Z()LO3
M_=8>_W'#(>H?KQ53EVK%YM'=K&7G]-K_\]_*Z._0%XTA<IF40TV$>4S7WIF
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M9DG_?-V6YU@T-M"NO\'_G/$ J3<..?N2T[S'[Y]\__V?4WS$#"Y>N.(X>3O
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MQ*T)_"]*J_NPRO")SKT#H^D <E/09HF30@*]3$8)JY-O?^BNUI5F-$%1=OE
MVEVOQMJXHZV 5RG8"S$)"OX"/<\%/1^(= YKMT"'<2 MCN[0[W-]**[@8[-
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M>E^RR3@[P*-GR./+"E"I<+T]SUZ&7CQ:6K%?(1;5#!GC> U,C>MIFIOOR[7
M$"9]'_A+ T?+R+%QO$U2E+M!9NR0_KJUXP778(A(U"FE(K%I-C+\^*#6/NFZ
M@YKZ@+"M;9100K6D)XFL_F'5/^FJ@[]\5NJ0R[8DN^ =8U)=AP7_I LNY2?1
M*K&5."SU)UOJIQY+-H9Q7HHS^B,VCCRY9XTCA[-RT[-")Z2$J^(#GGS[ _=B
MB G6SS:NQ<P=M52&XG>@",@*[/?-",&R-!-=*2KAY#PW31><Y:DRY2CAH"2T
MJ>(_LTT9)W>P-$Z 'G]1@X]9: >R5)ZDM=U_\4*[=;"EO3RC[L1]QUN\X$9
MQ!90S^"FRFH&<2%[R1@,(RD3[%'$\6].&P8W0D,E:10? LZ&^E+=71%KBI"2
M^*F1G:3Z)'@IM:L3XQUJGJ"2;^I_J!C]LEY6 T\[.Z?T ?Z4:5A0YHBT!OYZ
MG"#J1U*&U(41$@P%O@E(SEKA#S-M[,I4?G5Y461U5W5Q4ES$PN*&X0Z_I[B8
M"OI"Q_I)8U*'J4]\F*1H+NHH&SEFS/!0#$%UT(?_< T\;8%!#?Y6>Z<8V[*F
M=??]OUDEL#AFE2"D[[FK!S<#3MHG>-D5C$X>:Y#BN?D9],G7C]+D\:.3[X1I
MR17(L9&\H2PEK-R[EH?.7& #"KP!23%\7F47#%&DF7"6N:E?@8!@#IM[DVDZ
MA5QUV69K=]&T[[EC''03'28IE< N*N+(:"^JKZ$V+-K!H.5)']+A4MP2"$7R
M>H72=#*226SOQN*+7CTOVWQ88U-,CJ>4XP(D-- '0J!2Y]Q[T[6,%1<4>CY3
M> 1F0'A,^,)?9+ W?O'%L],@KPR0Q:7&C]T'D +B$>'WET[PX^0W4CR,@26:
M#KA>)>O!Q!'OW4RJWEJ69N;%8I@4/<9XIU-:;$*GK5U[AB]0N;.R$QO&S"=2
M?HZ>G<O0:IIPMSHYYHJD03H4!K1>K9DR:5<<8UYE3,)>G]'K0T!/_BP :[_%
M\QPQI:IR3SDD2'1E61DZ]D7@L"RPZHQ;*61@89@U[1F>:ASK&"AL^,KX%="4
MCB7<]ONCNZ'[_D.R EMR+KW]D?&#$U\WVG3F#:".:/9887F(EVQ<XOG==.<I
MPT$T)10_IVN6""O&9\/NBP!0MJ0#9&+]PJ 6T73DJ$XV7QB[9;?J\3?X?[=C
M#DBP7M:,T<T\"Y:N+8H1.EFH[H7^)QU1/+!4$,V(-" 7$!*574\R,B=J-&D9
M=FOE\O>;IJ2SORH7)>W:@Y=/7W8/4X3L5UE'?C6K$/@>C3@CX$S?;))^6--
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M \/[:N@1*=1%6MH^Y7F#2I^"5BP!\9L'72.JES)(/]/IX4V_0#PX2!#I(<=
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M8G:4LG7$P60KN)QFO% 4[N^>-OQEX'IO0DEE'J5WY^SS#7V8U[NT=>N\TTX
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MK _H%$P*5]D9/T1YL_O?^.Y\B(5*DYRGJNFTH8!0,PQ"4-:M>X (?3<]6%$
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M95-0$"(@8#Y(1!$F9Q!<Y*W2]885P/Z0K47XC.WTQ)V@D[V]L7;5N811B,[
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MIH9CM1"GR$N"%N5]AEJ09526-FN&/.Y%5FT6/-'+9V5]1OF$_%4@2BO6K.K
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MV'_9[(GI_2I#XX]0CQ*C934RUJ$CQ7)D+$MC<@HS,;Y7USIIRN@JK(51F2;
MM1-9>C./:_$4Z0^P)[K2B')85C<F:LR-';MOL<55)T9*@NZT2$H.3JKAQ<(1
M3@6,H>%'L<9Z383Z11@MU=N]J^]C(KR=O'F7%^_\GXQ#PYQ8]^%;WA#4)XDS
MI5/H4*@$KLJ83X(QP/)BU!5D/X:DY;=(J))QA:-;RXCP$ TVH>.S_UO-.Y86
MFRY[8]U?=\=@Z'O<"#>=,Z*%V&FN8^8#XX$9C#;!<N"5@]]732P[F]'X<"E
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M&YMD."'AI.:>+;>)+<S3"I+$"B=$& 3+EOB(O(K@PK:R<9M9D@HVN4"+>'$
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MB!Q7&;,@DZ\*YA(5O81!(JSFZ!<F%#E,' YR_(+KX\KWIOJ+!P/LU\UEVM%
M.%)+;R+D]V40Q=K'III(MM4R;:L1#?($RS5%U80\VE!%^<+U* TL\?B2[\V]
M66;%+9GA8BS^N7&'$^((DRIH0TY-]=D3 \:X!B7]<$R1]=F%<$&*(%W"?8U
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M-H&WQD _)QU7(&$'*?V)$4C#KFH"WZLT^R[PP0B<[XC</'A:F*4P.B)>MB2
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MP;A +I#C?I1.-D]^T?H2*7=WR(MMWL9^N2/C[D*"/K]&<1P% ^]3S3N-T-W
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MGY E=CDT2YW$2HUZ*8,^",;>!3J6X+M1FZ4P37K@VA;,98WA0I47<L4<<&E
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MFM;F7MP^$!%6&_S"25JZ.1SL8IZ-QO)L3%(B44QF>3B6AV.JL\@#GXQYM,M
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M'66YQNQ&F8O^=A+QE'UWL;@\]WV<2]6<L7@#A!XQYU$R4MX(_AM[<(D.HH1
MOYVQIR(Z$L,@@PG G((P!#U,F&[SNB0MT"2@!<P9N [?46EO&G&V6$)[;M<2
MSB@\%V9JY 11M02:1JR]$4;8_JBH$A'<5*,+,%A6\>APE&7PV7C,@(L YIN&
MWPG0H,*((;QTD3'"?S:@;Q'4Q<S:F^JKZ5S$4F!TCCS#.N\RTACC9%A D<;W
MT*3/<]'-_SC+P!O&NF2J%X/^R6U]23"F7TC%RAW5IULB5M9NU:J:2L=8-X*N
MYB^Y>A"ASE:+P7/W5,B#T5A84E[I"(Y<,$+%FH'NI=$'7FAD*119NFV%P]R
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MR-2W;=;"%Q,?A%>6(Q![O**Z=R_K,2]*:<CVU6,VY]C1[![D1C1CP S+V=L
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M051^?R7D]]O4Z#?.U/B,">A;ECGHJK37UGA/SK:N'B0I\"F"I]]FP3AU?@[
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M_EN>-T1(,#B7CHITG!N/IP8:Q;%=-Z0+Q%;+EF5P%W$2QF*N6H-M7=7+I-P
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M-$$!?_ 2.++'KC,X&O3AB&_PMK6LMPE;]X=/4I&\Q#64U'[[7#P+3U_VH(B
M[U3(K=%L1]3[]W_KGQ[5UX\U9IW?J"(TY!%Q3B8%)*@Y<RFQS%6=9YPG=EA4
M-'5$PQ!(*XNU20<,_%K?5ZA7MZ#/J6K8LR?"7OGQ5>(M9L$8M,==$!1ST$5!
M]%**1+ J0C[)X@7]654,(:^CZDNP"NHE$#;T%JG_2OWC-:BZ1>C=O@HB(@_]
MZ/4U& 58#2RWA*=(&<;P_+AW=$2G,DO@_R?J_E*ET>/O?LHFRU\.3BZHHJ/N
M^Y4_7OGE\: WV,J-AV?J;9_QQC\1I74AC6)@?N$,$]PALLW_>3%\H7?;&W^_
M2F*P[E[*41J/?7\Z59+EU6#QP^E76PW+>__T(IB*?2[EN.A3(91ZI/?E<U)^
M73YBS_3&H&B/]NEM^Q=[];;GA;=]E&,]I?][+=(=M0%0PDGC,)@XZIU6T D-
MC&>BTI)")BI]\5.?S$XN#M.HJO?BDP<2IYJ)GD(>5M.F?]Q1 :@PZ*@ 5#AZ
M?%ERMUAMG+CXQ*C/5J#P*?3(,VY[OWO1EKWH8-M&@3B-R^*N-4;#MSCSPD?0
M"H].J:8QV^"DH](:5!IV5%J#2A6"ZR>*'C4Z?G5\VCNY;_QJV-^Y,-.P 2O>
MU_C5K\L1WGT*=W2AK!:_;1?*NE-!OO$B;^)UP0KP<1[#[-Q]*G3A.Z3"L M<
M 1G^B @!^6NF *$NYW"C\?W$Q>Y%/4[WY#WO)_AV_3T?TQS8I4/]":L-'R+D
M=VC''Z3,NO=L^'L^IEI^M(#8\ R^7M_QW]&0]&-3K>%\=\^0]+Y1Z7XAZ7VC
MTB8AZ0WAH[J?[?;/]A*8[:S-P&RFZ^5Y6UR(U.\:TRYPWCLG0)RO.,W!^72#
MB!VS8-'\6OS6] S0' TG5I3GB:0+[J6;^>%$=1.8KC>Z8CH-QCY/ *#.I&0\
M8Y+T50<.]JHA]#7>/W7AO>/Q=WUGQL#VDS%VNRT20ONE[K10S=U.&2-AA)--
MU0Q/!(1*8FI,\$/3&\?,\P;NB[8 -R?4]_\T)KM[?'&B.@PVSNZ>#;?4G'!R
MLJ7D[MG1ME9\OJ45'Y]O*1U]L:T$^MG%0_/<@^-G=9J;GTTLR?W&^S?/2BQ1
M 22?TR;2;&50]EEMY&J"_@V4+7.@\"&:H4M6TZ.N[!3;6N]<6H6+@IOQDIIB
MERCLI3[>X,4_#OJ')2.Z8XZ'BB9B"3:S=I A!@UFB 9*V'=B0].N?T8[NHEB
MMI&$6P3)K?/6QE-H$,5V3?:@8G(^Y9D:7[2#DF=8)7GVO%:L>K,_B?/_'!5"
MC4NC/\ AZ$BQ35(\7V:GHT-'A^;2H6DBXC$#4;M$BK=)S_G@9=D,;O<&P^73
MJ5^/'C+8[.6/JDI/$GQZHVAP?.9>#(;5YV/#O:87/EK_==O4^%!-W/_]O_>,
MF_KN^<5Q,YBIG00^/NI=G#2#P \[K<TC[7_FX:TS../DZ9;JL!MO%>UK*?;#
M#<3N;7>%Q]?5$A6ONB-:HC]T^R=G&ZJ)ZIW=JA[>70H/3WL7I\T@\,-.:_-(
M^]8?\\S[_O$#='$+Y-2^]CH^O,"C>]M=X?'V>VSWTL6=3[R93WQTU P"M\TG
M-KJ8_>+[86FV0$YU?G'G%[?=WFR_US8X<0>GFR8[.K]X$VOGM'?2$ *WUR_F
M!I\'H4[NLISJ_.+.+VZ[O=E^K^WL[!ZZN/.+-XE1]RXNFD'?]KK%I(FWA=K5
M>"G5><6=5]QV:[/]/MOQP.T?;5I4U'G%F\0=>J==LG@[15M>E..0YOXI:>*S
M?952G4_<^<1MMS;;[['UAT-W>-X0IZV=)#[K'?>;0=^V.<4\_OV\RQ,_MD=\
MA%1XH#&WU7NTTVCOGQRY1QL7EG1^T481RN--NX4ZOV@MRGZ,KR5">?%XR<*"
M -B&QW$O*?64]VBG3=0_.[F'I-LUL_,99]CTCI^T9X_?]"D,SN>CJ4G!#!\@
MX%:=^\Z4:X^=<=29<ELWY?H-:3AKFRE7KOMZE DS6S/EVHR3TI&B":1H5+QG
M0\MU;3KLB-2_&/;=P>#\?L;M)DSQ%-'6O6#2C@Y;IT/3QASU>Z<7?WO>^<L/
M\5FZ!W0/>*+XXRX88_\5)-^=_^PYO\?Q]WU+CQ]U6'5;(^[>8=4-W=/SMF/5
M/9_1<1^ G"[H_230.%V915>*W[UMXWF\_3F#0=\].ADT(VNP-0H_H]]_L3DN
MSH.H>P\5?,^$S/,1U136#!]0Z=@"\;2O_G?7<; _9F;[G>!C=]!O>^%7!TZW
M-5>X(841'3A=YPUWWG"KS<WV>\/]4_?\N.W>< =.MQ]%BATX7><6=V_;4GMS
M#[RV\WOHXLXO[L#I&D#9#IRN\XH[KW@_K,WV^VS#OGMRMFF#0><5=^!T#:!L
M!T[7^<2=3[P?UF;[/;:3"_=L8YC8SB?NL.D:0-D.FZYSB#N'> ],S?:[:R?#
M#LIFVZ'I#I5PAU )=U%,=1YQYQ&WW=QLO[_6'W2XF1UNYLXYPQUT9@>=N<'(
MY'V SGQ&G(0GQLW<AQ[-#C&SB39@1XKG(L4NNP5M0\P\!:/KHG]/$*L.,;,[
MK&VD0_,0,X_..\3,[@'M>D U#P^&;0\ZOTUZSK<9W"=U?O/A6[CAG@4J__W?
MS@?]P>MF!"H[Y,Q=9Z>S^X2$=BWL_<PUV4V!)FU;\/LRO\K3K.N-Z@+T+0G0
M][O95MLF<3?;JHO4=^'I1R%%\UBP:5&O)A-C#^/U_8<X.SL9KW_( .5F/& '
M(LREF,%>VN/=/6ICLL=MC\E>1I,$[C3QG5_S+/,F7I[$>Q9%ZQ^YPWY#^BF[
MF.S.<]/0[9]LZJ5V,=E-,,%Z%UU,=CLX&7EXZPP?@)'1161WQ^)I?[BP?^R>
M#1L"J=-."M\#**$+R#X14,)3!6,?(YKP)/=HIS4T[&H MEX#<-:*6;?-HVQY
MC&;7 -=9<[N17V^;N8$=OEO"@&C>RSY.WVUG7^V']K^7V.D,K.V6]70&UA.6
M]3R5@=65]72D>.P&GC5LX;95R@Q/SMSSBWO.UVI,I<Q=Z^E.04>'KNYHIQV&
M[AZ/5'?4-J/A,@R#-(Z<W[PK/[EOEVA+M?O]6DAW3;O?2YKO8J%32[GTW@-T
MV\*AS=N2X6GOXO0Y3*_FD:*<=^H_K7^ZE\9>.T.7)X--ZXMV)W+Y?,[1X*CW
M.*'*YK^J$46#QQN*TJ7 VYD"'[C]C0<_[4X"_!EAQDY[)]L:@="P5RUGA+:4
M^_XI\T:A#_^=!-?_^ _XGY+X.1[TSD "O5[$:9 %,9#)#[TLN/9?WP23;":+
MM7_(K/CJR/S$&X&ME6?U/UER&)^>Y@,>8JZ)3.2P_W>F!?/"N_)?CA+?^_[2
MF\)B7WGAC7>;OOBI\$[S('I9HN&FK_^/_Q@E<-/"DNA_ZKY<VL2YEUS!.F1+
M< WR"1K!)U6N.JH:Y BSFV0TPPZ$WB+U7ZE_O)X$Z2+T;E\%$=&1?E1Q>N2E
MCR].B 9X^\26@T*3WE%!/12^/!NJGU9^O?*W*[\\.>D=W?>WJU=\M*T5GV]I
MQ<?GO<%65GQQMBT:7ZQ_X\?L&94#(4=JV9'<R4C9V7:!'O:!6&_B^3R.G*\S
M+_'3)M)L9?+@695Q-4'_YL13YD#A0]1WGVXB/TEGP4)1^%%7!M;E&DNKL(5P
M,UX.Z==E"GNICS=X\8^#_F%)6W?,\5#11"RQP+U(=Y A!@UFB 9*V'<__&0<
MI#[M^N<D&/M-%+.-)-PB2&Z=MU[62(KMFNQ!Q>1\RK,T\R)\IQV4/,,JR=-E
M.UJ3[1BXQX/V#D9_OJ#<:>]\[](=NU"0WJ4[GC>YZ@Y.[UG&W*4[5O;;7!SM
M6;;CX@$PXW<F.SKCI@W&#39-M!=7ZAF+.7JG]RL[V[DWU=)FP+@MC_+:G7'3
M3N.F?^1N7CS663=KR/'>\8/J.7?G33N,J,ZTV3F,J%9I?(2&VC/;IH-JZFR;
M.[M_VHW4])SS<)\6IJD)\J;#:.KLFUW":&J5VD=HIGTS<+:<F:J[F:I\CF+,
MI:]Z['Y<V4UZ?[P'[&$'^G!XX9Z<W7-<Y$YVH>\^_^XW;D\S9K9U#]BW!VPC
M\-(LE*'J@LNW0>*/LSBY7UO%KD6:=OT>VW#7F\6E=7X)G&AOYOR<Q#?W \+:
M7;_^^,0]/MD42*B1;GU[ *MVEYON4T[8X7AO0N#>QJA?C3RLS:/LQ_B:@U-G
MCS><[WEAO'??6>V"+8]2J=V%6KI02Q=JZ1ZP%P]H?ZBE;LK\E1]ZSF]QF,V\
M^4. <G=0.?:/AF[_]*(-Y3#M<6-WEYT:U!6W-0(_8X75L'=^SZ3A_:C+K]KN
M8J[_S"/?Z9\_H*[B?CJO?8/E-[$\=L$P>#0LL(X4K9JF< <QUHB?=B&6>_'%
M4X1>NR/[8%(TCS^;)K[:%;=J5.RP>\"^/6!?BR]^]^/(2R;.?R4YW#;9LX3Y
M_4:--3*EVT 3=__J+QK4I--."A_U3MJ+8/.LE/TTSF)"=GF\WJ"]C6$],$W=
M.".AF_;>4%(TZNCL>X70 R !&A._ZH[K8Y&B>0S:C:;OZJZZ![3T ?M:=_5/
M[S;RG<\!W"/>LS*9_NG '9YNZ@YW55==U557=?7T #YGO>,GQ4+=AZJK#]ZM
MX)YO:[9MXYWN?<U;/3P9W[WMKO!X^],:0[=_LFE-[J[EC9YY^/E34O<>NG?G
MT>2VA1+<>.G498P:%6OL2-'HH]/EC9:@I-WC09<V:M:>=&FC)M"B2QNU.F71
M/>#Y'["W::,@# -O[GQ9-0R]G7'^TZ%[=KKIC.,N:]1EC?8V:_2\0SM[I^V=
M,_.LE*6>_?,=&)O;N54=*1[;FNSZR[O^\@;L2==?W@1:[$.@99-85,MZF[L'
M//\#]K5.YV<_B2;.5S_X%ZQX[_K+!T,$1MPTV-+(CM7V!%MVEYWV =__^:R.
M>T1:NBJA;<=8N@*AIELV3_J /:P/Z28/[-H#=M)ZZJH9N@?L^@.VH&GYB%8L
MH#4AV&^?OEW^_NH1*C(?3JH=T<BG9V?NT>GY@W3RH_#5$^KLAZWW$>RYO>&N
M@7M\,7"/SA]F\^T7?^VB6]C1J:/3HX<9?LJ\4>C#?R?!]3_^ _Y'+<QZDS_S
M- NFMT^_\@&['<[O?IHZV0R>W?^;$]]$?I+.@H5^F;67_H__&"4__6/SWVWO
ME9?&< ]XMF7FIZ]JURE,]Q(Y[-7PM,AVLG+^*(@FX$>^>MD_)VWZ'-O7/U3O
M\?1/?UV@U$7O] S)\+.7^A,GCIP3TIKNQ> 8!,9\#I^D,R^!AP=IFL,E7@27
MY5F:P3_@+OB3#UXRGO%9XB[&?L]IQSX-&K=/GQ99$$>I<Y5X40;;D<6.-_XK
M#Q*_N%UMV8%A\W9 B5IGX2<8D?*N?,>#PX'/]:ZN$O_*RWQGY$?^-!@'7FB$
MLQ-/B[ODELX8;R4J'R=?P,?^#WA$D/KXPUAV'@_@- _#6V<2A#GR@/RX<"JG
MSLF9>WYT[ Z.![WV*H4O?IHEP1BI\!6IX/P1!5G:I'57L_6WF>],XS",;W"W
MR-QP4C^C302E[CN)>3':7B?'%W-F?CAQ1K=P60+;G_CC+$Z )5+<\"HQ_*5\
M&^_&2R9P'^\:6=2/'&^"E(#O$S]+8F^<!=<^\-8T3F@=3-4WP'AHXGG(@BM$
MB[PCL-S9"=!A$:<!_N)5XH<>WOCU33#)9F)]V3\40_/(_,0;P1.!O6M_LA07
M?J:M/+XHDL/^WUEBA.Z5_W*4^-[WE]X4%OO*"V^\V_3%3X5WF@?1RQ(--WW]
MFI-;_^72)LZ]Y K6(5N":Y!/T-H_J8K(8UR065CM)GD'L .AMTC]5^H?KR=!
MN@B]VU=!1'2D'U6X _+2PXL+H@'>/K'==J%)[Z@0#BE^V1_TCE9]O_+'J[X\
M.]W6C4]Z@Y-MW/ATV( ;5T>5A\.'E&X])"[>U#33DIZCD__EZQ^I\RO;?%NJ
M &CJ6_]?G]03FCU?_-!'/V5_*? 'F'>HT4?Y_C'"']$U$:+#C;DKKO76AU?Q
M9L[/";@>'4J((<QYWST_N>>$[2<-^>_AWAR<#=VSP<EAMR_-VI?[3??J-N=I
M!)K;']X3NWKK6[.OS1J7T94?>LYO<9C-O/F>%=?W^\?NQ?&F*G;7RNN?5U%>
MG+GGYT?K*\J.NKLZS+*=).YCX=<SBHA]A6MZC"FU%:^](UPW&+B#BX;,^6@G
MA1_D*70D[IBX"11^=B;>5[?IP3.H=M@@.@>+?KCI8)O.YMS$:0+2NH.3B\YK
M:I#4[$B\T>PK]^3L&<>;[*O7M,<@MQ?G[LEY0T!NVTGA@XLC]_CX;..D5T?=
MG;#EVT_B!R2@&J.4=M!9VF] L/[IT#UO/8;3,_M+PP&"KG7^4H,T4T?B3:9!
M]MVSHT$[_*5B.^[@N>$#[KF '6*>T],+=WB^*?<\-K&>MBAJ;S;WX.3DV#T^
M&]RWU+#;V(9N[$.R8]W>-GMO+P;N:7_3%$E3]O:>J!+-Z\+=7C=K/)T&8__I
MFUEKJ=N<-LC^1>_DZ)YMD$>ZA?*QNQ6'6[KQZ>FVNA7[ZZ^XVG@?''?=BEVW
M8M>MV+7I/5*CP"2!.TU\Y]<\R[R)ER?WJWQI:7/+J3OLGS2TN67/M^: ]J;K
MU6O8MC2[5V\+X-C/$!%]S 7L$&O=1Q@_-JF>*-FQ;UN[J3#OMG4GMO5!.<9G
MW]RU0V;KH%_M8*2M&N_NLY],XP1N,_9;!GBWL-[L 3'"STNWV2[B77.BA,-S
M%3=K$EC:^9:">6='VUKQ!C?N,,T>$BWZO)=1PL]['R4L4Z >TZR+&E:0[X.7
M@9JZ 0TUG?JW7;S0JO@Z=L\V[J+K(E,-=D:ZS>D.SKZ6^/]7D'QW?H_C[WM6
MW#\8N/VC>T8:N\KHKOB\$21^;B9N1/'Y\U:>[R+;G)RZY\?W;+A]'$(UO7IU
M%W?U,6S?;EL;MZV[>UBK<RMK94**\>[^H+A)6\\QT!U?!1D\;KQ&NN3=7WF0
MW3IOXOG"CU**Y3N?0UC9^XBR!/A!4U]U93KEG[XSSI/$C[+PEE,;V4W,"8^7
M(QKE-K;?>0'OG+[B]$86C[\[/$:,:8$Q.)/XN,1T"7UQC[%13YT.6WJ91\_\
M-9D)BCFU('4\)\WGL.);S([AEKZ)DT6<$ ^0$CI[G3J7<S^:Z.!SFGDT/&N)
M*P[P]_BC@9%NC=KBYZ XT:/_^M"9$-7 6O<I?:@3DK?.,68B^V<]9]V<8?-X
MRN(:U[D)LAGQDK=8)/$UCK.;.IB8)7$QBT/04ZD+,BAUD)E&89#._$FUJ.DY
M>/LHGX]\3.:B7,;A=U]Y?AW\OY]<PV\Q$XO3)BF)"[K33U9(+B^$%<'7X.OX
M(!)1W%<(0"])O.C*!];/THK#X1P$T3C,:71>E2@\=(+(FNT'<A:>&L69X_\
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M"W$\!WC*28S?^EZ"A WB N5=.LNU&_DX^_(:A$B;MV/-_;"4JI"?5!6),/E
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MF+4,HFMXC.II,*N@[*$)GN+]U;J+9?X<2)983>)C]AZ;YKB\6&JP7853[6K
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M.*N/X.50( 21#1JAS(1D3D>S<&NTB>>^ MKC5 >5RR\_ Z5?I6 RIYZ" ,#
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M^<S!!<21!=D$A?XE#YIW""Y@^S%7"[\HDXXJLYX*&*F\4N$:H)R"O#T)EP2
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M9Q0 0,BPHTB^\YF:8X/*<7:.A,!U')[0!"E:E:7D\L];#=STGM%J&!Z].4Q
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MXDUY)(P=NRH/L9!)JSPGF%0D/ 3>B$Q":CO.Y^[6S5"56RO0<PLYY#?]PG^
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MK?8^NEW-:?X8)WAWX;OQ')F@*"4QE(WL14^+K#N>QY #;L]%Q7D>P[R PNP
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M,30SADU8JA(O:J%]DE=[XM"SO-&**) NU8]BB9,_CJ>+:OIBUOHL120^7!G
MW0,BVGCLI=@/C57JPN#T%PDA5 )BRR0 8/YI8:GC /E+C_(2YSRVR-'*)PB5
M.^8M4EYZ%^0&OZR:<3R>09$UKP,#DJ3,XEUA>K=<T[<FI2,:HD"0I/^%E<)P
M6*+E 03B). XQQ[V=$F3ZS2&5&@&+)_<"MC#D&X]*W.7\03X;A7,LV9B^>;*
M_,W+1#O-"82*K2YC^(L\Q;\/(3_>I0S$B7).)81$&(^ ;M\P/6%CYGE>XEHF
M[;)K:!(G&NY"MS]_))4Q"]0/5N@)W:JFO!8!CH[?! H(=RGG/L=A/%2ZBV^B
M"RKHQ$44':BKC\I:!'+Q#!"==&=1\J$0*80:%LO?Q)G 4%[W$L;&NG@Y%<#"
M?D)%"X-ZANK8!'H<2UM;X'(PF38A(Y6#"V.)-'3K2"8(5 %=LU-T\%;!N*7N
M'U'M/O"NY5"*?NVE^2U=6X"#I_N3[W!>_%#3"ISS)<>4R;D0FD-/0CH_O.<+
M,'C$&2T]TLT;9TG/?,3]VM_K?[JXW#M0.3@,Q\!GN O7"36IQ TIJ15X>>W'
M!["5#'R?@=\@:9*)\(VSBSL35Z6\Q2&ASR&N_@SJ848,FP8:OR+,<S1"2!VX
MQ*5Z#;D54MY3'8N>$,'_/9T2S&G9@3(8YM*8#/ !-0S8QPD!&H:252 .DL*M
MO,IIUIR; ELK:0N\BQM;!_D);4SB*6ZH:!_.5$J<DT_@N'@S%RPDGQO?F]%C
MHCJ05]J,"LWGW,#*Z>@6W;='!=$#&K?4OES<YM.B;<]L(B8!NQ?0.UTTB(6:
MGR2M=B$L3DL@%4%).V]I1Q4I*D7IMC+6%D6!==M]J'PD@3=CWIP8MW_(6LQ)
M'48?(L  -@#KC=B2<>JX4 6TP>*]Z^DH;S*%K-.DD#W/SI[6JOG3NJS(==1^
MAB9-V$66FX 3WF^E[C6KLQDS2(^I($1D_):A*J9NZH?TPJ(L^(.M Y2)'-&Z
M=(G/Q+0":KJ!K)!PQ/G-A_;;%&,3D7()JE2"5NMY>N5-9%D)7QX LA:E-\GJ
M@PD9+>53ZHW);9+^4)7]H_/+\P,0P%4%68,_7#%LC_R!DJ/M8V&[+UZ53_4*
M*G682%07[9'ZR*V_I>,6!KWD5(";7NSG;I:C8B5@+X4RW/_QQM?O 6.-[LC)
MR1>5*W8 ;H?>D.L95;8#J=4HW<MTS %>>&WUHDM)J$_A HP9N8I:1;P<KK0!
M(#PEV6PJ@Z8KB/(NV6L%]3R:#W?.U-Z\NI6N=*#"Q&:G=E%0VQ=&;9)^_HE2
M6Y,[\J2E EU@6ZK/U9Q(7.59HM2*"2KY6=M!A"5DXU&.O."^TNH8A6NX3DRH
MZT,O+(X9K@)5]$J\N;4QF\TK(6()&%F=+I(Q8=]XZYY7FE#+_)9@=9$2%(<!
M9FWU\LT6JV(LAA0@3D7>)$8*S8C^KTM#-*)1WPW)#6=PHW"O&#K>F&^#F_AW
MU#3^05C#F+D'U <NX7!IGL<CX^F=+8BGMQ51!O'_7?0N>Q>_]X[__\TGX,>5
MIW3T;3B8KCB8[M?C_@ ;V?0'@UY/^=0_ZYX=08U [U]?>A>#[3VN39LG1#&8
M.WF(<6X 4,(  XHHA!KENB_J3I*-/D8;EZI$72I*1QX4 -!GQJKRAW<W(<J7
MF$XK4:DQ[">I-U0^IM!["KP7)X0*-?K"?Z8SNI*4H_VBA<90JG'X0G(1;"K"
M/*\P']3\"IWN>I9"3G<.XXZ1$+NMV_OAP;YY(*9_YF6A]Q_ER+N&C#/EU$M_
M$#8H"YWH7:U5A_/^/-!\G=8V\.-'P8]'Y\=89M,;_-H_VOY<HXV99\%]F,?#
MW?VLA6^87&/" &6Y$#UB/:I(!"SVM"3XIBZ-O$GF:BDK1FHLO_;87)L=D;3D
M1^N6D8<KJ^&8OQ&=55@#)8B^D5O>(*'2EJ >259^]<[A\2I;B,2[,<Q6-@$\
M:M"'.8(XRPHK4::DVT=Q%E!BOR->JK >ES5N< "QBT.,1%T!9A""WMUZ@*>=
MB;L)@W>9'/)[W$M?.E^VT]Z&:^M(7%M?+OI4:_Q"U<;NT='YU[-!]VR@?.KQ
MXF90_?M'.Y ZN\&5#TQI_$1X(L(EI) $6Y^8>BQSJ;@*@5&S19R*JS=UPU47
M>"DQP>!&1"CRZR>B._=NX8:4&V!":)7_99I<XZ]U$=4IY@SD0>HT)*E&-V[D
M76?DG?CA?<AZ3KV+)[A\?.C]#33AID*)#TG?(F*Y3@M#NS!\2O\?BO'YQX<Z
M?O;+-)S_T.V(1VL_7OKLT@\M_5!?]]FG')CN*9S?W_=:>^*+8G<G] X7W_P%
M=RZ/K@N"X[M:.PPTY;U*0772..D' 2%1)#R0[W3%N&\J]XYA7O^$4>9IJ4H.
MC Q?7O1C'@$P6<XG;V"UAKO":I^-S"+\W[)- ]_W1FT9 )FO12#WKW4#">2_
MFZ6^I+SEURA<NW3#%(1O5\32EVRG:$0R?[&^O&:C%_H::!T+=]5\PNW0E9I-
M26$^KT1B];MB=ARU8^L5-;Q\]S\);>!VZ*MO1G,X>Q\,1U=UW=B"PWGK%_,2
MD:-A.BWTNUA7]-2L?$L(&)V'YOL'$G#]23^K &FV>%O$P/U&S<:)@8'W\]%Z
MQQ92IME2[9:YWN7U"LK#-NZP376W#=GAE], N&+#78,/,DHV3C1T1R->__=8
M[> AN[(EY/VHJ^V!5/(2VD5S1*][1"N(J%\P&K!2@.8%4:@71J9J<W1Q7B$4
MCV)6^3LL=(9OR3&KS8]$;5!D<(4X((AO%H"'A(SK-(D(%FY!CCV/#"HI1-!X
MYNQ<J$S%6!EVGAL2GC(F2E-9@FUM<0\V>Q<OX 6TF/$?0#$YJXC%LEQX9H:]
M!1@RR16@=L"O44S7=)5!9BYK3,?+ 8H:OI3<Q'2OH*857*3Q6)I*4UPJ%Y<Z
M37'I\^RL7*<B5<%!/]'9*"^L]BC+T6_FI>B4'P!A9SK+<BIG6!73*62N,%*$
M:'<EA05[O>/@6+M-X.O(FC=>&B?%:"^14;2UUXQVP?U>S77SY-=-R:=87#L%
M6@*3\>P[TOV3%UV(SP3E,R E 9$AW4"I)/WQS^PNJMQ 4F<;!GA5@*L,">NC
M*J?+^,D-652KT7 0<!"XC!J^>=(42>Z$*[AE2O^2DNDLG<A0*O0:R8(8,E6C
M. #<(^*EP9"!EI ;,DJNL=:9/UC@]\!H\G6$+WNRKM3;2,/@VV! ] TE/VEF
M?>XO0KG+[8UP%E3- 4Z80T_@*80D"]+8KY//F22@567^ L>1A53B$GRG\ZGG
MBH*HC- 03Q P,3Q*V^R&S'>; 2SF)AA+NJ>6'BMA+(IZ/%:HG1TJ-6_)"P,0
MY.JN O553 $ \R-ZY4ZT1\Z"P9!"F01=$=81Y$-E0_B;7UIY#N55W1U*A +J
M9.C%Z8+**E6Y'2;*>)8)5:%XK;RV/*F\^A96PT"'GU!*4<:$,"R,/*<4GL$,
M=?Y+2I+H4#FKV29<<HH[-8S]>)HC9#Y@ZP0Z4V6+$#8&7%<,<NJ:F@RI6% ^
M.; P)G>E5:N+-C;?541A0: 9+R.\OD1EVTGGD%$)G"&8*,,3J]?K\BV()PJ6
MD# / 3T&;%*?C.EDQG%&\,O%LHL!:FGYQ;/UW6W(UC\^5'K_ZIU^85V?/EV<
MGV+?IY/^Y:!_]EFY''3/CKL7Q_2C\XMJ86B3N[_Y+<D<<QNHL'>H?/EZ<?1K
ME_43Z_WV%3J-\99C_=ZE\O$;DF7_\O)K[P+K1[J?/O5/^MU![SA_M*''S>S"
MLBJIWM>B<R-(]5->E?MK]^PS)<DSY:+WF8K+B^[9@.M&E\I1[V+0__0-1&A1
M_-30YQ;(RVWH)-K^?$AOX8LOYQ=4_BF?SW_O70!"0V_S^R8M/]3NY7'WMX>M
M3"JY:AU:$,61X7^L0UOZ$\9BW[5:K64@3UM@_R$J'Q2O!ZQW=U;T[O[/+$&?
M*ZCD*?-J\K+N6@2&0T#S1_7:;AOVOG>PWZI"-K O7H^\@($[9!S;-Y._1$T'
M5G5+?I+Q-4.*!#![F B=-'BOXAN$VP;<OC2/(98K<F7\"!VL@!@,??87RK?*
M?LC1EMD\;-/0]P/6]H%^;LL>X__,Z!E-,8JGC.)L*B'G<QC</PAN6,+0+4O^
MAI%WF\_G"\R0FQ:\<)QYU&JW'UXUO_U@1 ^2E!YIHEQ.D^!'#G&!TP"#9G3'
MPD&KOK[HK,##I&(/%[^K%"[%QZ7]"I+T&OQCU/P#Y"*&1'V= M8S-<0.E2YW
MS%Q+[3,4 "O'_H[TX"$\"/;:[3 &T!*Z.W4#*6$<17#^U(#C#A]F&3.K/4S&
M8.T%N"7T6(#8*O@B"ZD244+Y:#5%FX^!:=RXXEX4 )= =D/L^ZJ<<C?#;[,D
MG8V5BX+27ZE1%\[P'5(C/[%Q/(G'=&[_85.4F)'%A1@;\?4(MPGCR4)&F<CP
M]PDH2@H)5,T.XS3OW9+,IA!V1>KG#$L_$1P,C%+QB7B<".\$4]/O\3=BLX&B
M9PD&FI#D:];&,<[\.^#J0^5\P;<R"8^7/U*PI'BX*QX5("1U6P;.LMNDZ#\"
MX0&.:([(Z"H+F/&_PQ,^^'B2GW>J !528$CX!-PM(X O1@>M_7]R_PI#7^7[
M",-,1[EWZ@9O(&_*?&9\6@^,,KP.O0ZP^)L*U(1O) 1+X/!!OLG2654"*@R2
ML<#W%]*-GAS#%,G;&3!!NU0N-\CHJR>ON.7MJ*:$K*;BNT67]B;CY0F,D5^%
M17S:/^LIE]U/O<$WY;A_>71R?OGU8@VCI#%Z%W=K]/)NC<\#C>;>UY/QA01
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M6!SZMO:Z?N5Y=BPH:5,T>AE,DBD=<IQ?)I3 6-<?A5X=>5W'1J\&=_V_Z&K
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MIR2E7YL I JSS/9'E'<.E"O*1F^YY O3$]]:J=?F1\9*TKW':?8XCB*2DDD
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M;!'Q,W"3%$7X6(IPYBNQSACKG4(&<PE&K:!(XR 1BR&Y)$EB,MRL"&_=]+L
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M%VNH1=;0)>K*#18D.HN$HAQQ R:1<48B;SC7D1J,96RI-51B_A?L]6Q\#C-
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M>/01F6 D"MI$H@W15,JEL:8"PI5E306)#X/$/V=(Y,8J["P2FF)@3EPCF,^
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M(IB8/&P<7XW(%^"O.?!+/'Z%@#_CMYP0;85MNDX2Q'642 >,D;:8Q.08\4U
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M6O"+S8"+36 F^T;CMYW*9(U[@<^I8AW-@S;[M&YP1V0H7M6E8/?.:]:,RVS
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MX%W XBNM3G]<C+^NG<HXK-8K0Z(P?=6U<6GPJ7PZ0G/?J*J5J\,%:Y]6K7!
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M7,JE:,-*L=+<5Z^M&[@TEP[D0I,XFHR'P^;"#_#LZI*:DZ@E<)J;+$=56DL
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M3%JRR*.FQJG@/8DV!L^X,'D#$--M@%O: )_WSHZ43MP9'I$/5B#N74 Z4(]
M(42P?S@LA]IZ3%@?"]W'AJYM@'\_JA:^^F^V!!?-"495DE8M,JJ4)#L9S<DS
M2NE +3_ &[ETIU1\%5NW8-<L=@V_TLC9J0?] L8\WR*(_G1[9.=L;_N(2BH
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M.-CI\;K$FB_5?B;A.(#%.3B&V7Y[_%O=D.[)^,3576.FG7B['?%VV(XI$VK
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M8E/L?MI[?J0B)4I9A6PP$7$B'3+*@*CBT3LNC/3D]F@9.K*U&\#Q7YL:&N]
M>0>@W&F#DH,.IQSL>A,Y0SQS%UEMP&"PR4OG#6$^]R<1?<+63^K_W<'Q)XEY
M=T"\ R#NMH$HB95>*X\<LP9Q+"2RUB5PO[7Q7N(@TNT5HG9P?-@1[0Z.=P#'
MYVTX,N4U$S2!YTP5XD8E9!TV*)@4@I6)4]WQ[F\Z'.\K7MW!\0[@^*H-1Q^\
M,21PI"T&,S7;JI:3A*2-EC&2:%*I@^.F^X[W&H[N0'D'H#Q< J4*1 OK4"*Y
MMZ4T 5FE*&C+0#(Y')'!;Y;O>)LLW*V$<_H06%/4]5E3*/Z6=.[K3<P#$6\W
ML38\\T$I2YP*G'D!_ES@7#A%LG>N0RY9^5:AULFR6V=-V3Y*'BNN:4#:D9 Y
MH 2RPF9**):"51PS*K<>2](7A-[2H=FUA<=]G('_K(!5I$3+F)>:<D; M(Q2
M)B^8XPPK0SO ;A1@%Z1MT>LH?"((8P>&1U06:6W 3=<Z$N6%,=%N/692],4%
MED>'V >+6&V<!$\/L&H"-]8Y,#4CCAA4;N3<QPZQ&X78!0^XYLY@ZBQB"OX#
M?]%($TQ1DMY@*[&B3MX:7TJ'V U";)*!.(ICXHJ#5^BX3\(DXZR-F8^Z0^PF
M(;9%%^X3H\1CAJ@G.F=K< 2HU2@E;VT004C);XTMI4/LYB 6R\2X%QCL*,N%
ML=IJ3;B.ACO8$M%TB-THQ"[<6"\B-P9+Q*D"JQA,X7QD%1"6,026+'6$W!I7
M2H?8S4%L"MA'9YT7@%SFL,:.D=SJP01O0'QWB-THQ"[\6'!B8J B(JE<RLR?
M 5GI"$J") SB-I#H"U.*TGVL;RMA^VXQ>T?$Y)>,%.=Q7B0NNKMW=[_.W7_\
MOJR7G/N<C&$PGTLQSJ6'/3=XYZ]:LNX>U[]'O5$ONUD83#\,[7E6#_'JQ_X<
M5W;3U4W7G4_7K1@YFZDU;M)C17?5:Y>W3DQ,1>HDE2D[YY:&B(7A%$N,3?*%
MQE)?X)I-X2W_]Q;J?+3OD>B$%Y5KVT?@6%NKK4<,)Y.IW@ERGC"DF*28J^A\
M=M(H[W/YS7QN7>;A'75'$4(;&QG3$OQJAXW06'HBK*;&NT@[&&XH#'?F,"1&
M,,)U9H)6N9V1L<@ISU#*W,!.F&"4W'I,%.^;;R]M[W!X1^5J$FO"='":>,Z4
M=B8R+%10*6I+#.EPN*$XW)WC,&GC8:T2HL)SQ%WPR'C0B9[[ *L8;+0V)_VJ
MON*WU46AP^%MZ\,DL%)2!,TX%\IKGD"^!J]B\"313A]N*@Z?SW'(DQ+$&H:<
M=@%Q2A,RDAGDH_1<!<^D 'VH:%_3VVI U,'PEF'H0Z!8IQ <C]P+;N&.)H@8
M#);62=S!<$-A^&H.0VP]I=9%\ X!BUPQCK2)%@E*<E)Y)%& =\@)[TO:F:4;
MBD-'",XV*?$!<YE@%BBFADIL,>52N0Z'&XK#PSD.0\@)P,(AQR5&'!.*;&(:
M!<J9YBPXQ^+68\T!A^2V6HYLS''Y1I\_7L)\%C], "'E_+$7/WV(HVGL>HA<
M:BA$IIF*S'J<N"<RNV#:""Y!OTA%?2Z<):8NG/W6MDCMI>F$U2T)*](.*?/(
M$F>P6,HQ!<**!F1(<H@F+*AQ(EJ361IQG_*N1<B&0A+>T!'FB-%2<*:DB5AC
M'"FS.!B'60?)!P#)17@Y1F4\EAP)XR/B@0ND-;?(!A:\<I@(&7+R;!_,_ Z2
MFPE)1I*RH""9,(8S&XU4DG$B2$I<Q9 Z2#X 2"XBS8Y&6$XAD:,R(9Z$A3_I
M3 'CG7":)G"[MQYGSUK>5LE8!\G;3DT7X%-3KX+S@=L4C)0J]UL62CDE;>P@
M^0 @N0@Z&QD%M@1T8W0:<4$X,C:7<:HD/&>>P@;9>BSZC-\644*'R-NF*%2!
M2X,M*$?/)=>6BT2BIU08SDT0'2(? "(7\6<IN02S-2 JN$'<9;LUJ>Q92A:H
MC=Z13(7 ^I*)#I*;"4D%"M(2F11.BI,@+"6&<LTC-HEQ33I(/@!('K:B.^""
M,(61X"R?S!+P(FDBX$IR&;D+@%8"=BNE?:,W24W^K$G-71..>XX_=T2J]R>9
M:#ON')5('FN*A D*\4#!6% R@HQ*UF*FI/>F8U'=<"S>;N"YP^*]8G$1<*8D
MY/-JBU3R,N<S@X% H@9HLDS6X# -O,/BAF/Q=B/.'1;O%8N+2#.XS=)Q !\.
MD==.-*<<L60\!NG*HHT=%C<<B[<;:NZP>*]87(2877+:$V81H8X@;KA!EAF!
M)%?<>H&=2++#XH9C\7:#S!T6[Q6+B^"R=U@"&C4"+0A>HM >.4PL@@5G+DJK
MI0D=%C<<B[<;7>ZP>*]87$25'0?,.>^1]1&PR(U"L(P1>6FT%\$(HS:R(=4=
MM=P@#Z'EQDU(-,PMM=RX8F)^/-E&I #!YBG/_,)6*AT#6/M$*1&PTH&7PHV+
M1%I7N/']Y-I.NS'T^>[9D>2)2"DM"I9+<+^3199[BQAC&BLFC!3@?G/>5_@.
MN,&OEB3WS%OZ4Z$W@)/@$P V:,X)3KEME!,\>K!6A%"B0^^&HG>GC=YD6**4
M!A0%RVF:! R3F#0RADJ>*58 T%N/*>5]S&4'WQ\'OD0YKJ+ED2C)L65:!4\-
MU5X1Q@SS'7PW%+Z[;?CZ9"S#+B'-"?@5*6&DE:,H,"E#DM91JS*O#NWS;R^<
M[."[.? 5S&)J.>A?G+B21)L$6X!IXKQV)N .OAL*W^=M^)),]T&30DGENF=M
M;3ZZ@CT.BX>%TX93@*_2?:)PA]X?![W$RYS_@8TPGD?AM4PN1$$CTY208#KT
M;BAZ7[71RR67T>1T;9V5K\,8V1 3PIA*<(:%M(9FSU?WJ>A<WQ\(OBI)S@(L
MKPF<QV@,2'%'<4&RCXET\-U0^!XNN;X@<A,A%!Q>;Q&GFB#'N$0Q8B(P58;A
ML/782-47Y@YZ9-T!?'_:'/#;HB/Y*8X4.0E1>45!B@6>7-16*\NC$41:G</N
M3W/#H?I(\5L[#W4%*W<@R3ZMA.!-!#%&-$.219L+.R72#OX*GT=ED]6,9)+K
MOOGVPL[NG/^NSOF=$\YRXE,$562,#N 3:L.4B9@;WX'R 8!R9QF4,C*A'5(D
M!,1#P,@X3)'BA/%$O3 J>P>XCVG'/+^AJ.2*22(H-R)Q;@BQ2CNJ,/:"*Q5E
MZE#Y %"Y%##7))@8C$)1"(DX%PFYD"S"#"L:",M,YEN/5=_HCG=W4T')P;@!
MK6A!AG)A1,X8 5Q*%X7&B;@.E \ E$MA<*L,MSH8!! L;-@<::\BLMHI[)D-
MPC-0E7U&OSD*WH'RCNH:-6;!,AQS9W%BHTF)8V6]8=QBI4T'R@< RJ7HML(*
MG,>@<X\6AKCG$;DD,?(^.).;?E"L*FZ2;^]MVZ'RCDZ)#5BL/H+A&@2/R1H/
M!@_.AJS4'N#9H?(!H'(I:&VEQ)PHB0@'?<DE!?M5F8!$U#I$$ZBE8+]JW3>B
M(\K^_EC]-G:2GX(_Z7;#T5V%R_W)IO/53' 2E<[$V,'E0FP:#;(F5YU)T#?6
MZ^CY[16Y='1F-X#CO^XU$OTUI]P=.N\ G4OQ:*&#L%9+A'$FY-5<(&>(0%$S
M2@)6TCJ<6[_U"5NW'/[=X?)[J\E;#45W:O)>@;@4@A96!XF)0201A[BU$ID0
M"-(6"T8L>-OL]NJR.S@^A"!T!\=[A>-2\%DZ!^8IMXBS!%8K20*!)QU1"H[2
MS ;E!.G@N.%PO-WP<P?'>X7C4M@9!V&2\&"<NHCK %=D'*E I1=4&"HZ[;CQ
M3N2W!YX[)W)#T+D4?HZ$.V%]1 :4)N* 3&2$Y0CK8++EFI)4F^5$WF9.="M[
MFSX$!A-U?0:3?++^]0G3UYN8!R+G;M*)G3FK:.;O 0M28*VU$#1)RYWQR@>;
M"T%N3;IU0NV6F)E8FU6;.<DQEPI%E1D+;3[F5IH@*PFC4<6H6&X!K?I2W%;R
MR;7%R'T<@/^LT*7>ZN2IXI0+KJ1TW!H'J\V=S/5<K(/NAD)W0<(-C@))QE-D
M603HXF0 NBJ@H#T5F"<'OL+68\IUW[#;2E'IL+L!V-4X$AI8%$QHGJF[G24\
MNQLA&$F,[["[H=A=D'8+Y;P.6"#O668^4#F[C D4#;B%U&*BK -'0N,^Q]_<
M^JK#[@9AUZ0H%:C9W'/04@4 3DYKFIQ-,9/N=]C=3.PN2+XQ&,DNAH"4U[F/
MI W()$:1$!''P$$$I[3U6-,^-YW)_ -!EVJ%)2<^<J]Y9$YSKBP&&SIG"&,<
M.NAN*'07G.".$5BMI%$FGT&<<(YT]"23==(0F;3.*?!V->D;3CKL_CC8]<*0
M&#R-6C@>*-%12\)25-$Z25/G[FXJ=A<<XL9$'S3!2$3%$0A@B:R.$B7 -$]8
M&ZMS9\H^YJ3/R3<SEMP+>N^(7_R2D>(\SHL$1W?W[N[7N?N/3[!S\9'17ISU
MW'C\OO?1#D\OI]:YP5M_U:)U][C^/7[\BIN[/]U\"+D:%\_"30(R(@BE$L=6
M&LZ<T(EK+97'05B7KC@(Z0S"[]I\8?N(^T0]Y09);,$@9)XAK7UN50XFH!7)
M:&? (&1]+==YGQI ? ^_I<O2V@CD$^Z=8RSAS+^@C;*1@!=!6 S:)YYDA_S-
M0O[BY%,FY4)(#'G&4V:>S;4\#B-GJ;:<VMP@#)!/9%_B=7*I#OH_/?2I\B%R
M8C"3@0<BC>:@\8UW$9"OB.J@OUG0;QV<.JT2K!YH>1L0-R0B[4#]6^Z%%$FQ
M0 #Z4O7Q!3D/'?)_>N1'Q0- GC,>*!>16D&Y$CH&KZUBKD/^AB%_<>Q* R=:
MQ8A,2AZ!\,Y]SJ-"QB>29+)).)M;-?456P_^=LC_Z9%O+4TA1N*UB5Q1[KR4
M 6L)/H#!7G?F_H8A?W%J*R3',NB(""&@\X6(R,GH$,5:@-TF;.0>S'W9YW2]
M1UN'_)\>^4184/=>P'Y1'!-AM V*>QZ4]9QW.G_3D+\X\V6!6I6$0E28C'SO
MD0L1(YNTS4U'6,0,=#X#1U]VCOZ=57Q5#U@Y(LSS=^GYX>86A=U]6^O;GKN-
M$\C?G(V3&-6*>0<H#AS\+\NLQ4('9K7'":=+&PAU OF[=MO8/I)!\A3!%/,:
M8\2#PT@GEU"T."0FB4[%%!-]^>T=^^Y !MUCBEV'^PL,L8AEM"YPEPG69'#4
MPM^QM5&FX)/J<+]9N&_5FA&MA ''"P>7SUJM1)H+B0B.6HI N(\2<$]UW^!;
M3KWK@/_P@6\8%T$Q([T4G%'C(G'88&F<22(JT0%_LX"_.&\A6GK! D>,@O/%
M$Q;($$V1HI8QDZ@5$A2^$GU,;SEAOL/]P\<]H: XI.611\&C5,Z!KL L$&FC
M9YAVN-\LW"].6TSRR3!"D LV]]33$CGPVE  \ >CK/4I;CVFJH]%I^\[W*^6
MVW!"HC4R,1VYIU8G8ZQ3#E/IHZO*;3K<;P[N%V<M.A%ME8](JQA WS.' /"Y
MQW<DW((-IS48^@+W26?G=[A?T_>YVZJ524L&*E^#H:^"]R *8O#@ I@.]YN%
M^]9)"^7&6^-04AH<?$,]<MXEP#TUV!9ZNYQ=861?R=MJ#?C=@5^.2OXSLVX8
M'Y=WRIMY,#JU]?%1&'R\Z//R<?6J;O*?^3%3=3G\I]Y]5&""O=>)!JYYT(X[
MYHWA)@0GM3HB0FVU?G7;X)9?.D:EI;1I/(L]]4NO!OG>Z0G<QZ^42 21 _2*
M1BZX$ X<=TM@&Y @P93W\D(VRPO(*?UP/#V=Q/WT5[33.'WVZ0- V,[&D_/O
M#EA? _;#R=[GX7#OC]^/#P]^&[PY.,1[KY^1#-C=UZ_P'GWUZ?#@D.S#OWM/
M#'[SWV/L3_X9V=?F%,#']N&:P]>_'^_^\>=P[]US<GCPS_&;ISN?WAP\9V\.
M?C\&$ KX%__W\R';>WYD%39:.XDH,Q1L;,>09BZ@X&$:I8[*,%T)6-A[,6QG
M^6B\C,P*[1C'/'IK8PHF"<ZUD=Q[MM6+( 4_P-3/)J=@H5=3W0"V7MX+MFR]
M[5KX>7<ZG0W2^=;E6WT%&-4:?GF *R]$B0HL2.+@^P37.F7 =+36!)^\!V/C
M6N.[1Z58<+-_.NE]&$]F"832N#=.O6&9Z/QRT\%T-LT?C5,:^-B#X7GXYFPP
M.ZZNZLWBY&3:>QM'<6*'P_.>B[.S&$=7@E :I3PQUC,-\ZJ-"]@'ZX+&5+-P
M29^@EEJ%%_6_A-/)>;23!IWCD3]/O^R#.H4%'+TM>^5%/+&#4?.W QCI3P=.
MT)9OCUCR5)#<I@!GAB9/);+11<0I"X8%')D/6X_9*K)ZL_&5RZABI#@F*Y47
M/&'F1(BPA"(I["BG%[>7Z9;QJY;QT^[;(ZM!:T7CD<G6##=:($L509(+ZA,U
MX)D2\&?6EC'/[_11[W7L^=/)!*Q+@&D8]T;C6>_8?HP-W NH/]K)(-L0-;H_
MV/-LCD[[O4F<#L*I'59UP[VWIW8"-FN,\-5XTMPBW_(\SF";G,#/? QY"YT=
M#_QQ[RSV["26;P:S60R/>F4U>T-XW& XF W@YV4T+DN/$_@.U&OH.1@J:%NP
MN/)VZ*73&7R\,KC>Z31_-P8Q-ACY2<P?PD#!Y)J,S_(WL)?@Z=/R_VEO</)A
M./"#&5S<FQTO7C_"C?,+3*(-@SQ%,<NVP2A/QZ/> 5Q925'P)6&<$_LVUC?^
M />#H9[!$R[U+\ 1<'%R*\E<=-T@>5T/;+L:UU]Q.H65V5E,QF_-7+R $6]7
M SX8EQ7X:[$ +Z(?OQT-IEF=/84+]],.C']@A^47OFA&^.SW%R^)G'LHB/YT
M:'SU*3=5%5X1KQ5B2MGL94BDI69(.0FR%FP?JE).'UAS,/[G4>]V;)9-M"6>
MGDXRXO*^[6?,P^Z+&<>#$4@"&$[;CJAA#!JA-Q[%8F4 A*>G#B3- .10K(36
MI-J5G^$NMO>_+D78Z?1[Y$J^R.\^3J?3N V8FTTWR'&_;U1XFN\!#OOG_8-7
M8O>=/W(6S .3.%(V@E,0DT?@)V!$=0PX61R\Q]D15WVFUBN<>L7K1>.$8'9!
M?,/TP@[*FV"XI#G.\\[)@GP*:].S)UE75/*Z5A.3\<=!@-V3-]JEVP?T8CS+
M*WSK6ZB8.;"-SL:3,(VC94MGK^B%_?2B>GRW?YK] W\^2MPZFKQ$G&6:I$ "
M<A3,6)4=",:%!%&[]1ADQ_K>@16,X+W "H\_E(6>'=M9%DAM-3\=9^5^WO-Q
M,K/9&AC#[^+$#_)^F]7;I[%ELB+M!="*CWHK\OO"J,J=2?3N=P_B=[56Y +4
MYH?Q=) WQB^3.(0=\C'^>C8(L^,F)MWZ51T_Q(N?6#<=#T]GE_^D-4!?M.UW
MTOR_(R)7<-'Z[_$\B?L#&*C( ?K>(YM@N+_8X9D]GV[]9^FMP.YN;F_R\V_Z
M]M=?U3N:-'JMD.7^WI/]OPX/=IZ\[/VVLW_P[,G_Z>WL/7FT\>/>@[&^[!WL
M]Y[L[[W<_VOGZ?;!LZ>]WW?VMO>>[&S_U7MY !_L/ML[>+GV*M_)+EUE$5JW
MP2_?.%>%"+\<\KO/:/3S4W#*![,B9'9&E1$"8]UVX]/9JJGZD\>LSXXR.TK.
M\D;$$HVXS?7WW'%D([:6,4HI5ZLQZ._E=)4[_@(K"W[X-;;[BS73>=I;_N=2
M$7-B)V]!^-::**NO^I-\=E6T675:A7+ARR^*5K4X)68T5V+EK O>?F@_3.,O
MS1]^#8,I;+GS7P:C,N+RH]53+7A*+>RIQH\$KFX_:1_"U;K@$5ZB65OZDE+V
M2(G+O[_RQU=^*>CU;WQQ^1+EWT+<]BT4B5=4,57:9*.J(O>K4,'+<N2P=!Y[
M1XW R$-H!'95S=>?%G33Y+QW>Q5?7YB6'R_K([*HK9<V1)<XQ<EJKF36!P[S
MD'PA1B>ZBQDMZ>$JV6,L]CX?GN]1&,/)X=GAYYSLL<WWG^Z]>_-'3@)YG_4P
MC/'/][M/5I(]WKUG>^]VV)NGPY,W[WY[M_ON^:?=IV_Y+MU[7Y) #GX?[CU]
M+V#\9__]W%1PP?^WCSR+GCJL4 C4Y#,1CIRR%'%/*#$L&29S P.L^YC>0?.1
MJT7&=^=1?D@B[&G\, '$5+9U_/0ACJ:7T],^=!Z ;V_+JJW2QN(D;&0<"Z59
MY%8+*1PE@<;2)IF8VG7XUCRU]MITTNN;I-?.0GI]]O0H$2=-T@XYC6UN64Z0
M$]'G+'7%M*.PK.!U,$G[PJPS?S[X-JP/24#]/I[ 7[-L\L=V]#;F@V18AV^Q
MLCH9]049=?V6%=5Q2KU&S^HEVBDK5$NL5YW$^BJ)M;LLL1RGQ"=!D2%)(NYR
M,A'-8LL9Q;P/@A"Z]9CPOJ+K9?/7%U@7"XCO;E']2.[B[5"$W&AB'HB0V[ R
M@<[D^B8!]GQ9@&$E@PS:H!A=IEU5OL@NY#W'47$L30"3BS/<5^2;>\W>5&QT
M%ME-Q!@,-2_*]">SP6Z0 _55)TQ?*Z?FZW$P[D36K7F)S\^.@I16L>@0(0:\
M1*H5TEX0I)VR4J0<F;PBD>KKHEP;(YBZ6-9#E%$W\A/O4TAUL:R[D%+;1PKV
MJI+>(O J/.(L.*0#9L@K!0X_\<QAL_68"=6G[%L<PRZ2U46R[KW3^=T+J"Y^
M=0_QJ^VCI*WF)&J$!16(1Y,0_)TCJRQWL)2)%]+'OB3KT?8?PXZZJE+]P86W
M[JUQX"W,VL:)Q0=!1MZ9:+<5^]H^LD3RY#U&W!J&.*P-,E3EUF.&4ZM-$(:#
MB:9HGU] C/'P*,AO1]3= AW'O$RDS5OP#50%=Y!/7-D?U\TE7JT</<@O>@#C
M^&TX]N\?*#*_H73IT][30PYC)/OP_>[!X5&PD82@,)(QXXT3!5 C$06:X\M,
MD"C$ \TM7J_;7OOG%I.+?[UP)NXDWUB91_BK\XWI(]KE&W?YQEV^<9=OO&GY
MQJO*^@<QH3\,]CZ_/7_S[MGG-T\//Q^^V\4POK/#=\?#W8,7<+_=\\.3;":_
MHKN#57*Y';;_],^3W8.]]WOO]@:[GU^\WWOZVV#_CU>?]OZ &?C\Y^#P77B_
M=W!XOI)O3$.20HN$G$P4]+H52#-+$#::>>.H59E34FLPH9GJ\HTW6(3]7;''
MS/FNVA9-=U:S&7G'3^ST>/]TEH;CL]_'DXK_K9->-Y)>BS.:O:?/SHZB92)*
MXL ;"0YQ&2ER-EKDDXGP-Z(Y85N/.5=];M;E5W=*<X^HW"G4.=-9<X#< V#>
MCJ3Z.<YL[E-0-6OUK%JJ_5%G<WV3U-I=EEI:.N,,H\@2X1$8QB)W3B:(:YUD
M8,9QJ;<>&][7Y+:,KHV17 _0M+K-\^7.JKJ;2HD_[& T_6L\!8LJ3<8G%QX\
M=T+K1D+K^8K0<A1S9SF*)(&IE2)#FAJ-HM.,8NQ9\KGM".MS_0-6=OU(<:Z[
MZ*7ZTT6Z[J-0HK.ZODF O5H68#Y$[86V2 H=08 EBXPD% DNF<4,$\LRWS"6
M?:JZVOJ-%F/?5"CQ<$VP32V4*,S,F<O\&";Z[3&\;17;:HFN[<D@LUK_GFVS
MP<B.//QE&][B8R?8OB4(MOOYU:<C&XBE/%'DD^2(<Y!N)G&#G-0:/L918G]K
MY10;:I\])/%UZZ'ZAQL V]BRBBY4?YM2:OM(2J]P) H16#+$A93(4>>1UC9$
M"2(K);?UF$O<5Y3_>'7V#TD\W5V@_@>TO+ZSF.H"]7<5J >9Q3W&6EJ/, X*
M<:\],D%$9%4B-%IF:=);CZ7N"RH[L^J[8[0K [M_BZH+TW]WD;54$L&\\["*
M/#<#)X@;[)##1"#*M3-$&JQ4V'IL^LR0'\_(ZDK!NE*P!U0*UIEJMQ3=SW+/
M*JLS_Y$U)"(>2<KU*:"VG%0NN=+1$=Q+3/M8K#='[TK!?N12L(M;2^S:V>ED
M,#O?'MGA^70PW4_+73KK(-U/WE9B]^Q(2.$MMQ)YY03B2BKD:)!(N*2-)(P)
MO-;:>"-[^>6^P+-Q;J4)>*J;<,:PUGW-+JG8"I[S+BN#:?X^C8?#\=GTEZ^O
M"[NH\<U=%($I_<AP]3^7UX#]SV656%(_8IQ?^C5^1"[][JK;4O.("WFMV]:F
MX;)!(V]JT"Q+P(=F[S52JF=K,=5#12YFS76ZNI.]G1[W<L3ZPG*OZ\_CE\ZN
MOS")FV?X76TO7S@_W\*=NKF;[&(3)/?7S0T%1Z5O:6ZO?"?,J1OO-7QSZ#=$
M&71D7@J1705L'5@F20?L/:$VAMOP&OZ8C*?3']5U&.Z>[)(W[P[/#^F+DUUP
M'6"<@_V#W]^]^>,97/_G8/?IL\^[?[PY7F.1.'EU?OCYGY.]=W_"M8?GF6;P
MD.Z(W==[[P_!IMD]V8%WV#U[<_)LG>@K,1=9-FW 8> D@!,AE4 J>IVB4%&1
MG->H95_@==?AEOE3;SDSZ(>.]^Z#L)J->VGPL1):/]O9^0T$$Q9,NP"6(&:4
M.\VT<5%@+'04/E%B.L&T&8)IZ?C))8]CYD;%^0R*4\^1]L0A\+FXU *\7L>W
M'A-%^QAO($OJ#WU&OCN>Q,ID^D;Q\U,<B1/!I:4Q][32G#FI/7=6.<*-QS@2
M?"WQ\SE.Q@$\G$[RW(7D63I%BEI$%ZU%)J2(N,,1.0$64I)1,AFBBM3ER*6F
MA/ZZ>2??7UO<<6$T]<J ZD/S] Z^'/ZZA5J0;Y_''U$$WOV!4B<'OUT.+I\J
M):\E$QQAAAW(02V1U08CP4 ,QB"$XW+K,1>Z+VZ-7_4V9=%=G>_\9Z5W^!?Z
MC;<"XS5\>.%&&T]+%<<ODS@LK'QUS+K&5NM7]63@Q4^L@Q<_G5W^D[OO+'^]
M0X??42[A;L]&^[]YP!4HJ< $>Z\3#5SSH!UWS!O#30A@+ZDCV$I;S:^.Y^D2
M'^Q;4,V3:-\CF^ E?['#,WL^W?K/\FG$8-0,RN11WW3.OK"F=S_5]$M1WNI\
M9^_)_E^'!SM/7O9^V]D_>/;D__1V]IX\VOAQ[\%87_8.]GM/]O=>[O^U\W3[
MX-G3WN\[>]M[3W:V_^J]/( /=I_M';Q<>Y7OLZ?7PNGK!(F7;YP[&[N\WF2/
M9[&G?^G=ZUES7?%DARV]O$'GRN^VYXKYS;OG^,V[WTYV/[\8'-)7>/_@SY/#
MDU=\[V3WT_[35VS_CW\&<!^R_W+U7/G-R=Y34,Q_''[>^P,4+8QI]^0-*/>W
M]/#S,P[*G[]YO0-C?B7^^WGG,RCP(YF[@8)-A#P!Q<HC3<@0(9%QG'N:+*<X
M5E84Z)D8MK,1))6D("N9R%6WVG";J\\9$\0&'B1?XR!];2<3.\K'N9/!QZ)D
MUI79M;?NBM:K5NV+(]K0P_!1;_OT+0RA1V15!-[O?3B=3#-);HZJVFS-@J%Q
M-AG,9G$$W[DAX&2<$CQO]+;?N]3VG1[;238[ER#EI3,JM_R)1G!0<"9&Z:TE
MDHI HO<U(80F$C5_:-O!.WN_7SO%=&<Z/07,/?N_I^#.O*P'LRDV\+U#[3T_
M4BHH%9E!/E**.'8:.4XH8L0YL#=4]"3G1O4E[ %U08%@6=II[RQ.8C8W0TZ/
ML'FS^./L.GZ89)K1<>J]>OF_KBI0_3M.RFJL[ P5!-&6&).I0@@-8/!02[W*
MW(,>!&Y51W_AAFBO>K709>W#WWE$S>/(3[SXSW .(WOMA)04.6HRQ6."/QDI
MP2Y5WGGE==1JZS%^I-<S@GL?0,GG-<S8Z[W-[B4L]]C'&*;76/';E0'7[SI2
M_."_ZW'FBN-:).Q/P#FRDTXH/&-[VT?"1QV<#BAHKT']9CJJ)!T*63APF[P)
M;NLQZRM.^YBL%[@\ZCVS_KC:'H.1'YZ&&&ZH%1Q 76IKJ$F>1R=,4));\+F%
M52(P?07V6UL!5*#/V^$,/.-I'"WOA2?CDY/QJ%IQ$ FO8#P_\\*+O;,CE9CB
MS#ED9>Z^I[A'+BJ-K"<J:.E3]'KK\7@4U^6!+[/9*XL))L)-U]LZ>"ZG%.0]
M/-5RV&E*@*M+HHG*!=>M]VT;VI]@O1V+T3JL$:-$(!ZL0M89CB(+"28_4)W4
M==9[KO'/:J/Z7],8>\6A,O^NI<'5/XBY <,0Q,3L./:.P92(.2-S<=W-=M,W
M6 [7WDU#.YV.4^U%C">E>PMX#N#\CM/+Z'-N'OAR3^P0WLJ=YRE8OO9GMCYV
M/^\^/[*1$YM I<-.BX@3KI#&R2/*!5:<"R4(OY:PF667)'Z*$S_X=J/SZP01
MO<;F>%:/L-B@\R^G];=3^C/O!P;[P7F'L302A:08XC* OX\S?R^FR8404S(Q
M6Z-FO:<B+.QL,%QV6RE_='EWCAO5'FRBD_XJ>^"]G=]?O.R9WAT7J4QOUC5E
M'M+J[8RFL\EIJ97X3G4T94#%'-G9?MEC]"%,U2^]OT&CP9]**.E[3ER_4<_@
MX@]FQQ>(V1!'XQ-XB7Q</!B![P]Z;Q)!!N8,F%DO#')0:-K+!;WEUUG+G_]_
M\,'IJ" 7WGS^BRS+9Y-8[I4K+>#F362N=Q)MCI>6 $.R@TGOHQV>QFI4TU,W
MC?_W--/F5+7"TSR4UE76-R?:V5>=54Q4V5M-@UG9&T-P"A_U<A'(E]ZW4RL/
M2:V\/]][?H1=9%Y8AA11X-.PE)!S@2%"'.8Q24-\NDRMG,0X@PTSF/8FL,,&
MDUC(F?*6.0,KU7[,VZ) M39<6YL.=@I\LK!PI]6>KG;[K)55 ?LG_Q1V2SFP
M+=M_"MB/#1%4F@N)YHSS46][NG9W0$^S64-_=31V5C[)=\^WG._J_"KYB[RO
M<J=H>#9, "KE(HLAG@V&PYZ+"U\>\#4&M%3VE[<?LL#KV>%X]+8"3K[E/!I4
MP)\_:9[ZJ+>S-CGQTP>8WFK<\Q$TSL%B)&4E/H)(*1-> ?GJV<O8+J\)-B,L
MUG$<3;- J2!_<)PCEW#3T7A1(E.30U3K!<M[.IS5J]E(D@&\9Y%4Y2%9J+0$
MSX7[8/XJ+9D&/SN#X:S. 4B3^3K>E@5SKR=:\.[_Y%??K61VGJ/]U!UOS8^W
M7AU9PZ+W-""IA$-<LX@LY19A!R8NQ49+B=>.MQ)L/D<(#T9RJY@QT6-G%!,:
MW"A,'T2=Y3;@"5[+PTZHSLEJ=#2L+*/K(>>AE5HR+1Z)K^RW1\Q=]=LS[*YN
MS)ON@E_;R(^QKI'?=:H7JWA31DIC]H$5.P/]-\HO<6F^Y@\W#UGG]/YII,8%
M)_M9)?ZO^^]T^(4DX%H8;U3B:G5.VE]- ;@3'O@?+;?WPEAT-!:S8)3%VO+H
MG-9@1$6GHN=.1I6N%XN^ZE"SN(7[C>>W7SE^+3GP\"/-3:+OX6?X_O.?)V]>
M/SL_S&?8[]Z*_:?;Y,T!C._U,[+[]*TX_/SG^[TU^IA_WNT=O&5@F T/#_Y\
MMWOP_/S_9^_+G]I*LG3_%05OYD55A)+*Y>3FFD>$V[BJZ2A$N8S;C7\A<C7"
M;"-!V?BO?R>O)!!(8*T@X,Y$4V;1U=7-LWQG^\[.YA?8WOSW4>OWK6][NQ^^
M[FP>'>+]\UMK$$7F+ K*24#+2*"0_'G&-9'<A8QPV7$G[VN16# Y_*):>6L5
MGGAOZ4SZ.WE+PL!SOSZ)O8Q-K;GS:&[[>H&I8!02#\2JTMV24B3.:$NHXXDS
MH$(ZC)-84TG=Q.^?BN:^5.[A09XSOK!ARKM9.\>W4_KDDY%2>T?!>N^I<\&"
ML]K:F"S[P7ZMJ7''727P@5F[.K;:E$UERH:WF6Z)JE,S,P0?.G @D(,EUE-+
MC&!.&L4-XH^U#=ZT0C85K,@^TY>LG*- 8D[-G!Q1C-7+6A_GUL?VD#ZRR -W
M7A*FK41P@5^LDYK8G%1I5+ AZ;4-U$6CQW(P//FM=T\).KP9DUY^88PP_8G\
MQZ/^>/Z/>!K2G>C!6Y,TT 08G7B:LT^4)FX]ZQ?=JIA2+V!C\Q"Q^LY)3Q6V
M3JZJ=#OY.DWZ]!O?']8G;-_T"<%0R-)1DH-"G\!X85BWA9K'*HC1>PF(T1AO
M*FJ:AIK5(^9Y<4%EO;]Y=N=0!PI+"A3F]P[/>_?&D_ -[V[Z!JZ8=\)KXJ(*
M!*(!4@) 0K..(C/A75ERIFF3R]$%LT\^6'AJ&S;J%=G+KXL&T&CF=.$-TR A
M.ZXMH%D#JUR9E1^_);NNBSZ>2?MP,R69M=/1ZD2R5Y1 4D"<B(RPG*C),5)#
M>_45 TTV_QJT!UF;7:OO9*G,F72WKHD^DM8. Q&+VJH 0].@P!*0S!$?\8N&
MP%U@-E.OUS9,4V*,JM72JZ*K U5^'+VN8KM6716="&R@L1(THK]*,8"-VD>>
M+:@H$U, )O]@G6%=%5T18W:#GC\HQY37C A6:"I<*8>Z; @>HU'666Y"8<%N
M C--H48)^NN:Z*.G.N;4R[HF^MC:>-UNE;7 8Y*:1,$E <50&[VA1$H'>+2)
M:\6K1DFAFH*M2(?" U5$5Q$YC"N*SD7Q_ 1-55T5?6;>8/+$=UT??<CZ*/H'
M1&J**<:)B0D(6.V)3S&1G$T6G"ME,R^D8F!9$Z';\]M!_<3\0UT:K4NCJY9W
M?+!PH2Z(+K$@6IA'I1,Q*4&2"9P DXQ8$P+16CCNN$W)EM!=TJ9>V&:]E?$'
M2UXM\[C.9/R [MC2Z:UEJ_5&F7L?X90,B+2$XSP+JR4 ,PZ,Y]8PR;76AN7Q
M2V7JZNHJ5%?1/M)L1* >2%*.(5CVEGB%L-D"T\FBD;0<[2-7LJGE:"KED3C#
M^H#I2:ZVJ8W/;,9G%*/-9GGJVO#CUH;1YC@--&1J2;8JH\UADI@L!<D*XW,1
M#"B:US8D^FX^)CRO;<XRUFF-LAF5VU%C =]D#*:37N:AJ:&V3BI$V"S,>AW$
MB>V_4^QQLLV^5F F;K-9;-)@HT")%?OV:5!3ZCY]FS0'J3QO?0_[!B)#:^*)
M11^ A@4H,5)& F7E V3%C5.E3LNU:DHQNBVO\5/I)FJ0:4_?:6,=S;*0@%.I
MRTHA9Z22GK/(DUW8O&5]^N-//_"RJ'%G\^WWG=WP%3W8/JH^ ^T-L87H&Z33
M!$^%DB@<-4'B 14N3MY49;&$&96$GWOTDACNG*50+2,:8HCK-A;.F[B*''H?
M4^.BFZH/_H\C]&WD?3@X/<+KEPI>CU7O^#2FH_)T$M[H<>'\O"[Q5:27A6H2
M'R!:V+]/RX+% ;>F=X58L\](^N;T&#]>8>N]0;=^T.Z>GW:*4QM^,=Y M^++
M[;]C;*"C^9+.&V>N>,#V62'DZK2[7QHNEN=76"%[MU)^2'(GE5+D><*CQ;\K
MMSQ\.Q_6WZ\W-E.YUH#7<[=3T4M>-GPZ"0?ES2I*SNI'E^UT%*NK7!/YNC/T
M(]]Z3Z-PN>+#*%?JI&/7/JD(/5/GN%1#4\Y%MOJ,J?AI*DZQZX<[H$R]>H1'
M[5Q<5I\)MMO[Y=5CP'?YC'=0R S+I6[(:X^SM7\9/*[>S31.KP'M @E Q^PG
M^Q&EY&HJP.Z-YSL18>17U\5ORPGCU2+J3W7@A:BUXI LW[EN]^+XK#R<[JN[
M'_J]E))L+%'>LC@E@0WH&Z?FE$2PLZZ70OVHU)(X):>Y\/@D+8>:4W*24'_R
M).US_^BW1GMJQL@["L77%K@LA>N;WYFD9LZGLX(B->/FPYER:+>V!5RUL%RU
M/?9W(*9.__LG'YOTLV6'K>]'[4^_[_%/FWMR[^,V;>WN?=WYB'^+][SS^]OO
M>\<8IVQ^^+9]>3M;MBUV/O[KRZ?#3U]:AT<'>]_?,;P7^6DWX-^_A;W=5OO3
MYI>OK=VWWV_Q0FJ;(L:SD5!1VEDB=\3P$$B&'(-F&@\M8E"[?D]Z_L6HQGB[
M,9MJS#9Z5*O&TE7C.I',6%0:HB .0PH"B1;54)R B3PX'EU68FU#K)O1RO[B
M'>X3)*6H=CL=79:HI+\MKZQV>3DP;#;#,&=O$!];9>J9A>L#J=ZXVK13&XBI
M#,2-P1V#-B (I4F261' 8R,N!$JBS0:<-GAF>FV#KXN[RTS/20L6ZA[G(QFL
MM6#96G#M)A'(,XIG3X0K/1[)&&(L,P0X5=0SZVU2:QNPKD='YY<6ESZQT/.O
M\;GC>0#VJAJ)*?LR3JJ!T\6Z2!BS^"EU0Z==I4UW<CF-W_ PMOIG\1<>164J
M=GIYU=^++1D:LB.\-AH3&(WM8=?)F5086TITF!&-AL]H-!(H$JSTDEF0L4Q1
MT'4VNLWNOY^C6DS94CY6+>;TF;5:/)9:7/M2M%8A># DQJ(614$\XYE(9G*V
M@I9ETE4V9C3D_._'B#E7T9F^'50BR_KUDLIMGU95R4%5_3E"[RF]ZF5R"_:I
M5<?UO>:C9R7^:.=[C4:-OR>Q&>^&7:GW"+PA>>*-=6@SM":&:T8"^E-NM:1&
MY&(SQNR%+7+P'-5A2F\Z1AT6L7ZB5H>'4X=K%VIHX,8$1]!Y4E2'@(H!(1(M
M@\@\&L\SFU0=7G!(>N5%AU*W0XU2SQ&#/X'0=' J_[XZB!J!SVT^;DPL11]L
M =L8DZ98FGP-AJ@IDVRSY$D[19-?V[!TG=:1Z:I$IK56+$<KKIUJ@AR4C9$H
M*U$U0C $3\X1*M'8*2-U3G0RK5AD8'IS\N7)-R!=N=S8_KL=TTGL-0#/ ]#G
M>$(OW17?GB'&FPYE>N(K/M)N.KE98-KLG]A>.; _4Z<\O"N#(VI[,X&]V;M1
M607.;,R1.$$1Q$<*:&\")Y(KFX6,45FT-ZWVT4(+JT]56U; 1=?:\N#:<NV=
M;=9)&N%)3 Z]LV&"N)1-&4Q*&/'2 . FT)8[YCB'!R[&_60!0TE]N84RB'!V
MVFV7"[_JI*-JZJ$_*- 7ZJ%7]?647K_$>538B_.[7S)NJN$Q9C]^(\S<?!K#
M7\L-]W2 2]0X1%N91S 0C0<O@K7HSJ)71N\SI=8&KSJX E5G[G,BOI/<%^(R
M?LA7[NBKN^RN_7)S!J1],K@I6^YZVF<V^:#9DAXU_Q%HJ![U3NO-SA][NUMO
MWC?^L;6S^_;-/QM;K3?K*W_?+;S7]XW=G<:;G=;[G3^V-E_OOMUL_+;5>MUZ
ML_7ZC\;[7?S!]MO6[ON1C_(X,CTR<#$Z?G2WX-PWWUT>V,(/04UV"*?GJ6%?
M-?[GQCS[ J:S1^+9=C<<G78O,&K-5?#ZQIVUS]W17PGO_.]46")VS@]2Y^W_
M7F!X.RC!8L1PY$[<^6GG\M&]YE[?:YY^;W'T>IM; CW@)7I"^NGW?W_9^_C7
M\=[NY^_;NV\Y7D/L??_WX7;[UE3NX3;^_!W=/HSH 8LG_.O+IX]_'7SZ_=/!
MSN;VM^W=/;S?>-CZN'WYG^_A6VMS#_ >&=X[18^Z'UC.T1D@6OE<]M8%8J@J
M'(V)!A&C48KU4 \ZKQ1?%Z1B74H.;:H$K0$A$-K6C.XRZZP%_DNN-1+BDK-B
M%SH7:6VC.IM&_W!&: Y^/*OXX_>[>7\.(VPG<P1M#2 "=BZRK(R)2:*0L;3V
MH$KSPS"M4IK7%^<'IQU\07RU(J;IP\E1^[A=0NL>]BTCEB>G9::W/_ S/!G<
MG<)L/< G&O^,^W)X>E)%*)6 C3[LE1MYW3EI;+O+!N?56)JI2#+PT9\=I6IR
M^*!\-_2)RC&=7G1NGLY@K-N[;KOBTIB.4"S&%*6120$UP)BS$$I.(%K0PM@H
MJKD+0R7GP^$-FX SK+<;82?_B<9[^%.\3^&B@_@T==^XHZ,4_W'YYVGW_,:?
M#+B ^E=:)7[>AS;K6U]W7N]S#TYP%HB*%"TY!$T<5XY$$R,WT:'Q*^G&]=$5
M<XVS3B(WA>BF]&",VD@N'#R(V-#)8^+[1>JVP(S*U%O\3+<E[^;%7K!0W<8*
M6_N!*A&4U21;9E'">"(N2$<003"5(H@@,&0^/4EC) P/XQX1:_Q4K-/:& .]
M]O-Z8W 9=W35ZMM%*XA_6B6D2O+W].O)@!'D)+FJ&?AK8<88\ETW1'J],<0<
MAA;]-'QIG/9*'\U",7*.T.2ZD%O$O%N1/YRE3B6<)R'=^%UU-UWTET>N<W39
MY[G U_O+,1:Z4_YSF]WA(<%RI3>I>Q,UU[CX6M;W]DW6D!%'DJ2%0%E/FOB4
M<DD/02@)/H2?MW&GX%SJB'986 4"#\I;9W2DS@A;=GW>QL43DTO(!^26 "L'
M_!!3<TL(:I=$ 6'I"ESXCC+<3-P2DZ;-[^2>4,\W-3^^D/7^9IQQ#]F'6!HK
MPTQ,($]Y>GO\4?0@UHL;9;^#WOH8/]]Y%>?^UR15^WG,Q1-?HOP/=U204W-D
MC[*>9[/$RUC$.I[I.VL;RTX5;BEH%HR/H 3UF2KNA955A*5G8_J^AHZ#B*IG
M@7L#H4\^,.J5'D_I]L=/1RW^0>X=!KFWBZ_GVWSGXY;<WOQ"6X=;W[</CPY;
MNUM?1TJ/A^^^?3K^(#[M'K5;WX\.MK^_PVOOX76^?,7/Q+</MR]W/FZS[</7
MWQ%@WICCBHS+Y!&M1^D+,X(GSD=-I+(\@J<@&5_;8,":&!PW-1_E0IQM"<)J
MK$]^45H[AB)[)I6=A)#T6F%[!8]:1:=5T:'N@)@Y]Y$2*V69*0N)^&@S,4)+
MC.VX\X JRC5K:D:;; Q9P2JJZ$(0R8];;^_%'8]1SZATM.>W&F<7G>Y%H8@\
M/VVLO>X1?6Y7=*5KC9]>[V[_7#&$GE\V,&P^[[3]18_X\W,GI4(_NA2J<[4N
M)_@(8[H\BIP04;WZ]O-VW50NL+;QD_OY5MGX92P?G Y))4>S5SPGB_Y7@+0V
M)%;RU\I3B2:Z:N4R@U:NDK2>>7E*)8@[N6>DW_=OIC;54YCJS\-H*C%C(Q-H
MI3,-!%P6Q&67211 L\J*N82F6C+;E&,:K>OUGRN!BN94O^G@T0T%K%5O6M6[
M1DG N=9&><1&A0=1)4>,DHE$RY5V(N9$*:J>%$TE5TGU%IF9>4KYEUY]K5W$
M'S]C][P[3]KE"1JD>J'GTA_Q-"N?<^(A*2N\9PF2%";*;"6U/FFN;<X+-?J5
M[%>6_Z^"GE-\@PI0&_^IC/^78>,O/$3(T2'N2IP :"">.4FRD& #HT&(N+8A
M1%.(T9:3R1<Z+W^!YX.&ORL2^0YW/#1*W7^>;9Q/T$Q-%QQ:EZ,,-GIF#*)3
M:A)+-+ D3,GEV5@'ARMDI-Y^K0Q4%2"^WH\T<)8U)]'Y8JJ4(<YJ11Q&%9X;
MK37/:QN:-6D='*Z&!H[BA#G5KPX.'U+UMJY43] ,TJE 0O88'>J@B4U<$FXL
M!!^-5M8A0#!-KN9>\[VBP>&L;0XK!R&N*O?#K>@-,MHYO)1"_G.K"HX%&4&$
M(!CGHE2 <T[&1 HRI*"I30KD5;=T7<M_9"OW[0; 4(X:[0S1FFD"2GKBE!($
M39RCC&GE6=D% KPIK&KRY1?S5ZV>_]R4=Q2?S*:Y=4G_033U&H\$X"EDH(2'
M4BWR(A$\%$:H")DKP:-,4&KZ' &)>8BVFU4LZS]_Q#(RB3)/ZN/%6+WQ UZ,
M*9^#,4X[2$$:;WSV64M;(C/OQP]XU9#EX0WAY3!D\=Q B.")#)IC8.8ML1I-
MH@A)^P@R,= %LC2M,4UK1[.WLP5G*X-87IKNCB*6V12W1BP/HJC7B,7JD(VS
MAGCK2D1A*,$CRP1_!$9$Q2.S"T4L#Z6IJU" 7Z5&Q+,+?]0.C5,,'CKX69Y@
MDZ&?I\GPZ9:[I\-+,C"?8Q8\R0S26!]+ MLS+P0SS,I^(EMR426R9YO;J.M(
M"S+%WX<QDY564.H\H2$9 DIC\"B2(APQE$XZ $2/F*DI!1ICO:AV\+KG9,'
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MG"-!11\\0T^CU=J&@*;@<[<MUFF>)=6WYE._&B0\I.I=@P0:*2(ZIP@U+!*
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MMHV.XU>?UC9883&:O[UJ6I/RJ&0?STISQS!]S*>V=;[\,1HB*Y7E@4<!G&%
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MX<2"#"I;X!2/'K&RY_BND5/%HW)&IKIP\C 2<+BUK[0+ME O<4L# 5-F8(-
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MJ25@0@G8#?LJZ\QL-"0R6SQ(3,10)ZM4M/48F<I2DD*C/;8;[N<?[Y6JEHE
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M&2U$R:D L";&4_<7F1?#$#BG=-3=LTL2EYW28BV59-H$PB5&UA!D($9[2Y2
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MBGA-*;$2/+=*)I/4(@'*#";E(;(A+T:'QZPR<(A,G,I&B03)<.MU#($EEV+
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M&W =^/SNQCK>_93O(3^3^OGVIX\_9H6CO=")D>B1<PDCGHQ'%J 420L+P0I
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MIWN"!FL\F'5*U"/.C 6W21B$@_%@H$ERQN]MX,\YJQ5\WS*[5ECB<Z=G+Y)
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MF,!B=M5JKH_LH,MWCW9(XVCW8+OY_D?C_!NN'X:CG>9G^-LW6C__>+@#GVN
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M1%SO]^-@J^-[T?;A[\/_KI=]J$F%E/=K\G1:HF3I#P'%H8$;E2P2V&* 2J/
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M4G7,^>V14E@R!:9>]))QH:,6D7IG(]5))Q$>N9=&C5)/AE)+]<82]\);%1%
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MF'AX2QV+018J';77/!JJ%>.2*9\HUB[P5-LEZPH3<[N$@1B0G!($V  P86)
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M2&ZS,SK*=2;AN[G[#CQS-#D%36!<9/;NQU!D2?,9!H=/JS8^G;[O3D*LNO3
MVV64+\;#3I7C>#BTO4;^)6L6^;TF"4:8#.&IC>)*[N/7 'ZZ8CQWT)F]W2_#
MV+7Y9:8=;Z8ZU<)=4Y&&Y[=8!^)K,K[]EMLDR7-3Q1M$Y97U6?CWZ-+W>FH/
M(W+#:$^033#=7VSWS)Z/-OYGN2M1IS\;WN3GW_?M[][0[HD6C=Y)5NZU7N_]
M 8K7Z_?%K[M[[9W7_REV6Z]?K?R\6S#7]T5[KWB]UWJ_]\?N]E9[9[MXL]O:
M:KW>W?JC>-^&"\V=5OO]M5?Y46W#?.RY."P8:119HRANF=A-A/,UT;2>HL8&
M8+ .8'()1],D\5M3OG/M7GA8?NG\';@\CJ7^/N]S-P/54<[*.!IT0?^^[)F8
MD\JG^>4E7%_^DC_X#+97?SQK=I>/&6!BY?J"@)A*D]OYX5O-RRXMUL=60@=]
M?YZ6%-"IJO/ZLE%;VY9VZ9?QK]V!/_D9E<SMDT^2..=@<9'!WJ*<-)WK2 D4
ML)?1*)D$YE>5QB?I+F?,*T+I_[Z]N=S_OJUAFL*OM)*W?HQ?D5L_^]JPA+XR
MY/9;'S0LN].PTT/1IP[,A#VHN[S57=Z>M\O;O6G[";J;_3C"?WV;F%VQ?F:]
M3@C=6)_)9V=6WK.M?L@_=N8;MD+>Z>]3("KO].E)Z[>#WMYVM]?:WL)[[4/<
M/-YG\)VSYO8^V[]H'1]L;_%F^^WYWE7O-,SKH+?/]^ YS>VW8F\;WO/8@Y*Q
M==8Z#L=-VCII9H_X]JZXTJ%,<HZ%$@*YZ"+H'I0B(R5&-#$;2/(AY&[T8!!0
M8AKBAK#"M3UE?TS/]R6/_ER8L1:GY#5F/ YFS,^]120Z)D\0ECGQ*C&.'*4:
MP2;BF!,F);,;FX0W"-<-3!]<".*Y^/9[=?WEH[8U5HG>W^Z8^&=V.OC.^%\/
MR=&ZST*M'-BMA8*T4^Y6#6[W K>E9D,X%YQB-+M@A$><)X6<E SE9GK2)(V-
M8V!1\882M&'6NTS$]^'7D^I$+P$I;MZ;?SZ'7C2"U_S_-U"-&<^ &9V%1@ N
M>4<#$BGF\+\HD#'$(6HU]T'*:$*N88=50YOK%M0UD;H*_+H<O7,U&N''GE.M
M2PS QUB$0=$?C(LC^SD6MG\.S.K&Q6!\%(?%^ AF-![:D _S/6SS>%2<VO/2
MK9_=4F>QNNUT,,Z](LLRQ?ED[; ,#'#P?N41VZBH#LS[A_E@OSRO'_1.NW%V
M/)0#!)9Z3"ZTE2Q+&\/=PS@8QM,[G:@NK^C=3Y!_[$[L+D1?Y 69GIDU\B)'
MF%@OATGD#])D/!E>1DP , [+0(Q1CJPXA36RPS*RHG"3<!BK M"VZ$VZXPXZ
MAR4N RK@:G]BN]WS#,(PRN<.O$3YS=/3X0#LSS), Q[VZ\ .PZNB#7LV'0_F
M OO?&1WE, VX7-VQ'*"1!\V?34YAH_-LR@>7A:FG;S*:DD%Y7CD:#:;5KL\Z
MXZ/\R2@N#%<]_NH;S$>:+LCTAO/"=G.$RFRH1>*\MF3E42FLG!W!PS,QPBOG
MI*C1:$9[Y59,AL/\YTU1)KD6]Y4'Y@ZI/K\-? B3A@D.![T9V<]68VJ[C"ZG
M/3V#_;5:9> 36QW>?H;]M#D,MLAU\JH-SJO=#]-]@S]@LTK:B9<EOZ??'65'
M?RC^.['#<1S"=D_YK]K6>QR=KR+'_*<S&@^&>4.ZYPV@@GZ6*"7MY4TKB03V
M]G0(9#*$IT^7*, "@,0ZK/8JUQW,JYNW.HND#$DEC/5Z0 [E*7A%)8M7BM,)
M(!703'%FAT.;"0F0<@SD/LCUV>/0=S(!9R8=]+,(RP\=+ \ZW>[F?-N&\7 "
M.)<G.@"U:S"<\L@T$@M>XB1FDAV/8^]T!J;.=LOIYV\"/Y3@D<JWJL*K+M]H
M:B.71%HNSXQX9ZM1$OHM852 YW%X.8?\5M6XHT:Y-B4,?+:=KG6=;G[*PI%_
M]9K P,-J1?J#S&"38472Y;+EG1O!S+J .L#GI;2I1@,Q ^\X&57!:5/.O8%N
M7XP0V.L7Q>^3?BP(K<);2O@'\"G9/&_1Z"@'Q675N40M^#MVR^+_HPPZL%3_
MS+NQ\6O^['W^;.-?U2H#!G0[:8;.(0>-=-QD)H(GIWFE_W&?.G/!.X:]Y!:+
M[)^W8 -('0FQ.4T\B<I5@"6AB_K_;NO-'13_*BJC4OJW)F-XY9R[NO;J__<'
M8>SPUL7;3PDT^.!L0%)X@SA6#AFPP)"B+&F=>%)8@ XO< .H-/]_38\O.7,1
MAAK%:.)&?M@Y+?=[&'V$7^'R#-D:!5!+)H,99;V/( Y+N0R4E?M1=$I5\34
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MN!T2:K9<";:4UG+.?3)"61ZE<SQ&PF.@V@AO B_94L_84G]_E$K-FT_/F_/
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MSYVW,O>^BZ>YGE'_$+2#SB"L4@*_G^D#M/7QK^/]XQ.0XP?=@^,/>.^WOXY
M)A_MM?=I:_O#19/^?G)PW#QKOK^:P+]/#CZV.GOM)C_H_=5KM4%'^+C#FW1'
MM([W<:O=O-COO>LU+[:^_'W1Y'M;GT [ \%M(F+4!\1SPWECLH\S$&8U ;W-
MBZME4+35B6AN8U""@[!W@*F<8N.#3(YZ<S7A__W$C>)_)[GL1+43WZQ^\BVZ
M_09:7KOMAD*J/TA6W5R^Y9LKNCDM/U'\;N'&X7E1H0(I$V*;=NB/"EY=:13C
M(U"C#H_*(B&_3_JQ@H^M=K. 3<A51D)G-!YVW*3*J#T<QE)=;A1GL>CD=BRA
MN%6_+YMKCZZH^"'@!#*4*,L83\YIPP(6'!NBM>&T*E)*9OQ*,,/\^\J3E<UB
M@)W+UW@_G<K*Z///S;^>PGB@J^]<[+6SSK[[B5K/4^9>*XE$W(.=;A3HZY8*
MH86226J9G892BP8VU[.R<JYU#[:[VN6R&@VHY*-1<3H<@#(>RNHN'][_XU;R
MF(RNFG_/1AN_Y8G^.9UG[DPZ)9:](1@ P#$UN2R32[OY*6IF)182X3+4E3N#
MG%4$)>QME$$(R_.!EFX(S!KDAJ+<A1T# !46S"=0DH%*.C[>@41 ]):[<954
M2 B62!49 \H@W&FK$DT\)APH=N[3[DT4LMMZLTP(U4:7NQ_^S#.:/8[4FU]M
M/FM>-#]IQW 2QB,C'4,\ !E8'S7BT7 M1."8@C5$7^GK/KVRR-00%%2P)T.C
MZ,=QWO2,'2 ^<JVD%8:)&YN.O9Y/O::1BD;@<Z 19H,&.QD9'$..ML7(*<=1
M-$E[S'-GN"Q/1)8FU]T]C=46&W-3H98:=R.*_;,6*!E")Z8=8<A+RL%B@-]T
M=@7*D @ "#?8 U$0U0 < ;JXWH[ZU0WNLD?0Y!]6,93HW.3^Z:S^^]C'_+GM
MX[)8W[#T#^[V*\:!7?ES&.%J#!_Z(0[AC\^=P63TV];6GRMC-'_9V]Z_^(,>
MG.]_]+*Y_6L7Z+FSW]["+=HZ;OVV W3\>[?9?G?2NGASU&H?GK7HVR\'VSN?
MPV]_\?"?W[L'M/O9'0_.FK_]U3OX^/M1<_LMVZ=-O-]N=?9['[[ 7%GSXP[0
M_Q8[V'YSTOQ+LV;[+05E.SO8S_+/3R0ZE9).R$4.DE1Q4+@#0"5SP"%:VZB4
MNVI" ZZJ&)T/H(9S[(7C3&-/J2,I7Y173>B%'2K>= YAUQY20O2'>;5NMGZ_
MN1B;[Z+O6A#0J>.K^\[LJ.C9$(OQ(*N=N6QFZ<_Y_\!J*9<G?P!/RL2<?\TE
M*?UD.)R6OJR^>0JK"!?*$6\ I=L+5_Z,'G9RNX?]?]P@G,./HW&ON_G_ %!+
M P04    " !Z>&52]R.@$] :  "7,0$ $@   &]N8WEF+3(P,C Q,C,Q+GAS
M9.U=6W/C-K)^SZ_@\=.>JM58E.C;5"9;&E\2;7DLK^7);)Y2$ E*.$,1"B^V
ME5]_<"'%"T@0I*0ELW0JY;$E](=+-QJ-1J/QXS_>UH[V CT?8??3B?YA>*)!
MU\06<I>?3KX^WPTN3_[QTP\__/@_@\&_/S_=:S?8#-?0#;1K#X( 6MHK"E;:
M-POZWS7;PVOM&_:^HQ<P&/S$B*[Q9NNAY2K01L.1GO_6^VA9E_;%8F$.+B[
MV<"PAL9@85T.!V=@;.MP 2_/[='?EQ\MW31'5[H]N!I9QL 87]H#H),?EV=G
MUAF\7%Q!:\% W_R/OKF":Z"1CKG^QS?_T\DJ"#8?3T]?7U\_O(X_8&]Y.AH.
M]=-_?[F?LZ(G45D'N=\SI=\6GA.7'Y_2KQ? AW%Q[)I;.U.>?(*=;8!,?X%P
M ,W5!Q.O"?%HJ(_&>DQ'49&D'N3Z 7#-73TN=MUP74Q@!=YIL-W 4U)H0$I!
M#YD[NFJB+ $M8 4[FG2KSD[YER<:" (/+<( WF%O?0-M$#J$)'3_"(&#; 0M
M(D .I"*2*9#Z.@#>$@8/8 W]#3!AG1'\Z0=-HRQ&ZPWV LT5,&S@+UB;?2]@
M9(.A/J!#SX7B'IL@8)*>[J- = J=P*=_#1*(#V^^=7):V8"4D.E75U>G;U1J
M2JL7F<_*#^BO WU4K]HR*5*OF_PUB.D.T89DQM1K0TRW9QN*)X=*4]*4#YR0
MMN6*MD4_WZ\MS=K1M!$,"MF>S_ "\(9=O-Y&4X.,[?DI_7)@AXXCGR12#$K^
M.RV1_#8PL?=[4J1.<P6=HR@],0$=I;,Z%?K0_+#$+Z=FZ'ED]=M6:@Y?2KG[
MJ[[ZR(!:$-5O24Q$?RFM'[@N#A@*_23Z;+-!KHWY!^0C.@D_QC/Q"=KQ(B&L
MD@7JCOWS$7BFAYT*W7BZ\? &>@&"?GJ%90 K#Y(%EJVS@W@-^-T!BP^D*7$9
MH8:L/J%?GQ(2Z-PG78EIZ=3Z=.(3;CB0#TZG>VX"IV[/"8D9.HS3?_W^6]"N
MVW]"@ESTW]']C0?K=I^0^,02:\)_2O],OM>0]>GD&I,MPHE&/_OZ-%6PV%CM
MG"J&C8$3EOPT)&8X^5\;)-N*@<:H?CS-E\VAA#ZT9NY/[/=\+R/BJ(B$,#<[
ME.FR4E5(%GT8CZ)L;&</\]G]]&;R?'LS?R8_O]P^/,]G=W?3A\G#]71R_SB;
M3Y^GLX?ZXZ^,+.&1SG@T(HR9DQ&&,9-2T%J"K<WNM!VZ%L._,U,<\D= +(1@
M!0GC@',\SF:KD;.9JHU]V*S]+5/;_[ZS_>Y^-I]/'FZN9U\>GVY_N7V83W^]
MI9\=C.&E%<A9/1X.#7564T"-U*)EJF$?O_/X[OJ7R<//M_/IP^V_ODZ??[NY
MO9M>3Y\/QN$2>#E_#;(!4N=O5(4V?=!X)=K?HFK>YS!AP&3^"YEGWPXW:1-$
M.1?/AL/S&EPDJ!J#[1'3IF3T/;*79LT KO4 @M"#V)X1RYI]YM?FF@*DA&TC
M?:CKW*1%ONE@G]"2/S*@&D'5.*R&;2T![A'C/@,?^=B^0V2(302<G9 _IKI5
MFW=JJ'+VT?_S[&.XE%<[Y-2L3&/WB(/S<+T&WA;;<[1TD4U,/C>8F"8.W0"Y
MRT?L()-L;6NS4!%6SL.QSDS9# \C8,K%%+268&LQ^#L3<Z-]9&8J,74T-$:B
M7E5G*MF=1+_UR:A18\ S6#A'XVX$+N/M>'@VWH^WO))WSN8'GQYP6Z%#S)<;
M2/I+5BY:_1-9NOP;& #D'(OK"A7+),(8GAM[200I'+6 EDZW06.-(%L<WHQW
MF<FS[@%XU!Y]@<>5$*$:N3Q<&*)95DL>=O7UD_7)^/PSM);4</5O_0"MZ60@
M^Y&)[X?K3;,=4QULN=UVJ3._5);)*<[NX/^N[2I@NZE4%3UBZC7P5[=_A.@%
M.'10ZCLH<O1RYESIS*F480Y%T%(0_1W\O;5F%9Y4/9)Y(^YX\LSIO1)\Y">N
M6Z(QZ+!LJ"JIS:="$.G,(?\Q1UZ&.3$,4U\[H)XSH^%&1 (EW7;H9.<A&!7%
MC.GC%J-H6)MJ-QF67+.-#=$F*.-1#W7:/01^@RD3D<GU%EE6+O)#SPE[-\ -
M-5.&6*Z+SL;B"L[)^ZA[>,_W-JI*8.0:Y]P0#=V($WVWH/@P/-$+'=@F(&3?
M!0.ZQV-?W".P0 ZB(6W[,:Q&!7)67ABBY;5C):ME@.T!J4?C%;$%A1704G7U
MF-7/. #.5]<B TA]*C#+A^U^;%8$E[/XTBA;I,@OK 8M746.N]M>\O8;56+4
M //(WI JL]H,%!'DIL25/KS,<RG"T!*0/K.@H851AB,U-D;#L6A4B^SHH^$A
MC.?>-D@UHE3!C71#9>KTWC01AOD)FH0K1,FSAF'[>@7<)43N'4#>K\ )(;8%
MFH/Q>)_*Y>(P,H972N*0;0(]).&-T)"KT69HK!WT\Z*9_RY!+W!WD)4Z7OA*
MP!$-<O[L //[W%P1!'_&OGOTD(G<Y1=L0<?&7@37V!0^<G/D4C8F>W\E*4N=
MP:6:I=%V44$C+=-8T[2H;1IOG!:U3F/-TTC[8OA^6MOS%?#@-=B@H,%U@ RQ
MU ZC)P6"]F#D6D3?TS%O&@(C0L@-K[.QZ%O(C'\?;:[T*/+?B0K!#K)8N_:/
M1Z@'+U>,YX8NQJ5D&+C[.UU+SXVS# MVH4'I3P_"7"FRG*\7AB[&E^3YF@HI
MRDW:=YX6C/P=QH&+]XDUJU^%G,N7ABX&!BMS>5?9.[]C4W06!C1?",T7M*^]
M6Q=?SNDK0Q=#B?*<3FS75#WOAFC,!7JR&FSCX3CH.EP!+>7M>&CH%4;40.,5
M)+Q\7W_A9T"H'\%VW2A8K !"NM48T["78BXQ%"V&Z34;]MEW% %)=Q_CT5@\
M#BMB26\W(9DA35D< 3:_<\<%/8O\!NG)(;0F+] #2WC[!CT3^9"Z-/:T=0Y8
MOUR%C@U=31)R]A!M2.3"X8>E<5NTJ#%:W!J--^==W:X/$AZJ "GGN&'HPCEI
M"<??UTJ5B9@R&6E4&Q=[JC87VR?J9\=V9F(>6R\T;(Y<:,X,73A[JJTFTK8U
M"]A+VJ8MMAIK':7*:HYWV6,CFPQ]3NNGO.UD4%/G2M&P'T[>]FZ"7,;.#;W$
M)2W(6*J,L.ZD3Q^HE&6/N&)9?!>JK 9Y"-<+Z!&.!2OH\3W3U/4#+^2</X+.
M4JM1+C(7QDAI:Y%32[QJ)@ZT\GB/F*J^E_)QCWW_$7K7>+W&+AO&^O%<(H1\
M<WBIBVYT"J(1%(W#<([VF@^-P^M*D>3SZLH8J7&EE_/D&KN!!\Q@%SM(EIDG
M:$+T0DV9!ND1I7#2^6,,=?&X(@9,!3?2A3#!?.=5-! -O2Y*H%(/C*&/Q6C5
M2K[UT1TC'^O];UO6@Y>J38-&9=5G:M_WV7(6) 9C7.X)OD W9#?*#W#1X+"U
MR^5C;(S$R[D*\I&V77?EXX;PJPH]OZ1 ;1(4-#O02-/*%UM#%T^-4]3]'._F
M$T^ D,^>,Z)?):/?4[EG^4V@VR@M5Y9:+OOGNGB.GJ'OZZCOL_ ((/(9<&&,
MQ,P;:9A>S@&:4W--K.ZW!C,@32N7_TM=C#7@U!HC[^> -]Q B0CRW=+56+SZ
MDA[\/FZ,4F/XZ.$71%]NL[&7^KBI9E)'EJJKLZ$Q$LZ6,UQC"1PX/HO\S[*T
MWZIL%_GV0#C%HYFH!^X@7*W$EO-5-T:"[R+'UU1$':EC$%6B\5K>69L,OP?M
MT+6H\KJ#%O2 ,W5?H!_PS#5OUQZT4',3^Q!URD6!AM+6$X6D<BVJ74NJIT1:
MU(#>2\G.]?"5<,S$2Q?]":T;:$./#! IPC,5'$(VZM4DEXBQ,1).<?,2D7)G
MI&O4XBJ9&$2)&/HH!?&%A=T8-LDB)T!([=LS0Q<#P>(HVA1*K[G0]+B@#$AJ
M])Z=C<4K>@4<Z:/M*XYH\VR+94AR-7=NC(7(@T+F]%!]W<6/(Z0"*FHSIA!$
MKL(N=#&R<0>3CN[H.2\:JC$)E%R178[%"P"%?.FC*BL:U;U/-95 Y0KNRA@+
M(2#%3.O[^6718"<F]6?@T&>T?>3>80^BI7O-'P7>PW.\=X52SI\/C;%PBEW&
M^;0I'U?,\HKPJK6D[EZ*QL2R&!1P: [F.P>_[F/3R]&D:^.YKHL!W D>3Q%-
M$7MJZTN'MN%ZJ8(I73C/1V,Q.+**:7U<0Z4C_0 #GN]HZCY@EQ;XAKWOR%WN
MF7#@()7*-?'8& OQ!I7\)\LQ#.(43U.7.=U8R:@%O<Y5(&4:"P8O^/PH$E)5
MF5PR:"Q1 \G@X>XE>J.'XC!U+;CFKXI01&S/;/([]&ATUPWRH!E@KXEK5055
MOEZ?Z>)EF!PNN[\0(;,@L!UVCSAX:Y(!7B/S!FX@&1YB?]9F5P&$G#?GNGCK
M) ;1$I1><Z&ISBQ'DBO$"V,LA&<4\*276H[?L'HC8^#S=YBL_PO]AL&2,BSY
MK+G4Q3LET?6K"(Z_X)0 OK-H#V]=-:)\[W$U%B^6R-G5QYV'9)2;:D %2*DJ
MO!@:8^$DKXIS/=2*3Y"T@%Y,]8+MLP=<'Y@4N3[#2H&D^O!"U\7+(A&4QK"T
M--@[8YHJP@HXJ1:\&(W%B/]R)O51 Y8-;U/U5X4GUWUC8RP< <KXU4.]-P\7
M/OPC)!VX?6F6 "P/(-=SABY>>DH@-([1X_%O_KIN,8Y\@IP98S&12YX;O9P7
MUWB] ?P8\PXMFP5=B1#RN7&N%UYIBD&T".6_DPL_GK[Y'\%F@UP;TT_XWZZ+
M>=O91^03Z$ 6&DIY1,9^:__^_$K^WCZO$%TB7O$72+-YG&A@X;.;D9]. B^$
M)YH+UO#324EA%SD.7:OCPF\+ST$?-]!#V*)-_'1BA1YKQXGFD_D1H""D?_WL
MX7#SZ8071P%<GV@!*^YBUPW7'RV\!LB=DB\HRLEI>2]8_@3_JVM!;Q(0\WP-
MO.\PF"P]R$I> Q=8"+CRWM4$:;_7$U(>.+M+2T&4H854X/MS0&RG1^B9D#['
MFG38!HZ_Z[$Z0'5GD4OS406J?24=W7!PE9Y&1^"W;R8_""*SV@RB!\V^Q@^:
ME793D;H.0_EW"WY*_^G$9&'6BGWGGZRQ2]8%;ZLDWH07,YZ8;/*&_%(!SA<[
M@(A:P4<+D>;0>R53H1.D%41R:LY0]NMCZ!%ND,&/IY?RW)23MS\KB]OW#+UU
MJ8#*2 [>(?Y)3*32(QYR/B=+"?OF'O,S$UTFBW*:#@EF8B_,;-%A_@S?@L\.
MF5"EO%.F/Y9D!G$5*KV-'_E])(HK2+\;S)<"TG /FOQQHR?"NM)>U\8Y?._K
MK2 5B_M>ED%W=$^L0V8+!RU93<FE?JD&JB;L@![*>',G&6\NL98AA2C51VJT
M1^JDNC9*91>+61)E6R>FV%<7E=MR"I2'-N*BSK')H=(YGBIPELZP2O5'N>%6
M3G"<KB W@$OHU=0G9*DCWY$MYN05>!9MH+(V*2=M7Y=,?3^$5ORTP)OIA#39
M;*(6>#?D7:V'T8$^%US>K.BAA*+]_GP!;V@=KJD&G\4)9'^F.@%:9%/$1G^1
MRB@ZH?IBR4!*Y^0^D!U80XCA8D)H^;:'UY%^C%,D^[K,W)%1[;%SM.#BB!O'
MR&'#?CZ094[)O2.4;E^.:<IA5L'$<? K8)$LV1NU1)-Z]!'J&\C_G:SIT]3E
M'-T#L;M^@OAA%CF;\Z7:9^\U9NL@K^0)^=_YPB^Q=4K*'TG!U+ +4DFTB)69
M22A4+HQRHAJVSG_8+94D](MB;^?A9L.+9:Z!ZNPHMWHOW1RP$YOKM"L@%U\Z
M*XQ;G43#4#93]P!L?R<3<7!&Z@1!$JVO*@O*])U@?:13N;W+3'MG2]K,MV/T
MY872?BI0'LMWPNI0XJ4#?'\6/ZX]\YCO/-Z</>;>_IQ#,_18]LQKX#C0^KQ]
MQ'Z0*1*O0!%2^0;P^!6WO2=.^2%L[-U'AH87H#\CAI8=W531==8FY7N^QW#A
M()/H,$@5BLJ&N9BB?>,E4=+81LSK'1 +4EFS%Q*UK[WIQ,/QQ,-\NF3>NME]
MZ4??^B/Y-*Z/=J1#1V6U-T=+ON"ZP3]#:\DFVRVI9@T"[D-,7D>IXG<CJ-:E
M@&R%;LE\,X.9S>_ (7?W(,U.*R<OUY?ROS9.9Y57R8EYW1/V#AOU8MQ-E6S+
M*-H7X91/XPZ'GKH')%VZ_54F5H]$5W#]F'H K'QC64'562%D#O\5=H@U[/,'
MA1YP -FG\XV#J%'W0K[BIXL(EV\HZ^(<25XWH:*A338]M)TOP(F< ?,5,>JH
MLS5Q-/MJFZ=:.)W81.VB!?3*X[S"HJTKFR)#-?LH<WU#MYB^?864,=_8<X.5
MX8-2DB[VJ'K!D-.TWR?!4TH)I($[,HJ.ANTHN<;J1?+4A>R&_OSM83Y[^ERA
M8[*%VA?1K"<C/FV)3U^0FSP6D[P*IN0448/J[%8C2O>TY0[/TNF:*W68*;K:
MTM"J< 'WF:)I8_IYY<$:IX^9XNV+:#KZ-!N*HAZU6DS7?M]NT NRH&O]AJ!C
M506,%Q=N.[;O&M/Z,:]",:1/3M,^6W(6_-0-(!&E0!J4*:5IGTDYNZ)"KY45
M[Y""2Q_;5OM(Q*+M[U>2"P,W3#(5;A;$!=N?(NG;2.KWECHTQ7=>P2>\!4ZP
MC9R#D5XEXTVOX$1/T\EB(>J@M'R11\TQ43F;:J*T/M'2QST>9P4-)3,C>]1_
M1<'*)*8K7L,Z40&UP%H?A#G=]07$@@BV$Q<X6Q_Y=]BC5/[,_L)"ZJFB?R*V
M.G9)2^GQK8](B^/L?_3;7X&':"]X-%:YX^\8=1UI!&MM"HI.TN+7W_,'X(OM
M+3!7V;*2(*0#0+=]FE[8A]AW%OMJK'I#4$#>V3WCSV3I\?G#0%0E%%Y\+.V]
M&G%WHQ]3-M878,'/VUNR,@;;LB08V>7R 0;I&Z]@*5MQ#UQ/ZZ9YI/-V9[+"
MB>P3V2T1>:"7%$K7Y'H@K:]&:9MPCM[4#<A4X?9MR"A/^"]D.S[-Y2C?$E$K
ME>%*NN9'@T>.:$]""<BOCQ@[Y=%CA64[J[O39IV_NT:QX6H#)-<HZIB':CBM
MST6IZ;'G\BV!.5:_E<V5M,MS3BUY=0]IIGC[>B@>75 0:% 9G5!,U-G@!'J+
MU.37G6Q(X#W(_+S9NU"EG5:D;MLFX$%R-"CY&OM*Y]9BX?;%<C(:CH:9V]O/
M*_@E>WN;WHV%%@LHJ.AF4[3VQR%]M/FO$%![E9ED4_H6[9K[P!<X#%@<\3W9
M]"*';?848_4/!=^)4]0XO/P)NO 52,P+L6#KMY+3=JKR?3^A=/ORFBB4:%=U
MS2+YR;[+IX$#Y3RI)NRL_<<5"[\'$M_<IU$ECU'$LKS/4L*V ZF_D/78!,XN
M28A<+,M*=T0L<_%9PC:W08Q7.4;[?4[EE?!KY*!(RK;M$\S?XT7NHP<W %E1
M-I!RCZ@"9<>U"3-3(J[0P[OF6;=40-H7UH((P^K DPJB]GN52;:4RK1DT1-^
MQR';B1 X<:%HW7N&ZPWVB+#<(*ID:"ZJ"L5TZ%K:'[?B4,;*V.)*LO;])=BC
MPQYD#&S7V@5%S^SIW=.<WLMP$%4VU=$)3?%:'XK=]> XMY-<R$N+MR^MV>!%
M<>V)@Q=3^R?%0$A%K,ZN92P?:9R"Y<[#:V;KSNR99R&78/!EJOQ<2Y&\L_V7
MY"Z3QE!5TW4HF(K?<YB$P0I[Z$^9 TTHV%E/X>P%>BL(K">XJ;@G6%"RL[V*
M_1Z[R_2)UU;AG%"5NO65I68\1/[^\L$"+0J V]Y2Q1<D%0/O,@7;7VC3QRBS
M.CFQ9EURD8D9.R7IRXK*=E:_I+W)LGQRM=+G* *UKG6JUNQJ9WP-A$[XVS/W
M/A1?(,@7;G\Z9H,RV>9X0R.!Z@5S%M&U+I+R)#SY%#MB%AX:*9C/U9,%:YC_
MYS!5M[V8IB6 ::DHT=43]*'WPJ8PG]+,[HTO==21JR:HK4M=^E0C<YQ1OLS)
M2-H^ B'C3KI.#_X9"76-5[@J9!3MZ[MZ>8"[F_'WH('B/$9V1H\):.P9\%PB
M[)+#RO]$W=V-UTT?/ZO:X?G"[0M0VLBDR442S?JV(>,(R 9OFXF#4+=9:\&U
MKK CKQI?4"I<<H5E6P_'*WZ&A1H/Q+"@Q[+/'J!^BANPK8A 4 ;I0$;LFN'L
MCZQM-](;:4T!_WJCD0WNYWD%8'PS^FB7"(KJ:3M@D+2%:26R<JA:.%*2]C5[
MV<U*GM,MRH-?^UYFCKJSAPY)AB7I&8-0K$-'"KO#/A9W^ 0IX^._I*_A5!-V
M0%/%R;)G=N[^!KW443/AMA)&)[Q%NWPGU<?X!25;-Y+DKX75,0YEU*UW,VVM
M*V==%$JWOP1\=>G;JP\P2#0"V8)= \_;1@=5%4M<#8#V>TM]0X 8KF3+<0-?
MH(,5@C7E-.WW*3UE(A<8C6,A"Z&Z1[T61B>T)'LV =&HO7P6E8J OTJZ]CF:
MN8NI?&E*+-Z!GB3W$UE@Y6=Z/$4E"Q*[GU=<?;.QC+*[?I^[D*Q7%KWTQ0WC
MZN@("45G3S&%F&Z6I6073QM]K1B(VQ"L?1$O/,!12EVL0-GVR4UC=OXE6)>/
M&GQ>$>CE*I<6X@ZY9#HAX/!7M%,!A;+KYP?![NS6.9-%G$S6&CG'4Z7;EX#,
M0U35,<2%A5O?BI0]1"U/>%9%U3YSYN%Z3>21& #)TQ(3TZ29BLC(/&('J7"M
M+DKK[$R;<[=T25"W_C+%.\# 7412VG!+A24MMF+0$MTQLA^_0I]QB#6XXDC\
M8)5TP.M5D'"[4L/*:=J7!+%]E<>A4I+V>Y2>=NJI?\7B[?=DE\YH%[ ;Q9?L
M3+?R78L":=MA*>DP(;HY#GQ@!_09U U]2\Q=\I;4"3920>G**L)^JJ\B8O'V
MY;/XLIK<N)'3M-^G3(J-8 7731-V- !JO_?<91SY&?/>8K+Q47$X5U.WW\_B
M0(FJO)Y2HLXZ@_+W[;9/T,3$X*;5<.M*>HY<17HLNPR:: T<-:$U'8#69#:1
M_0+9.Y"=1.ID@$:C>_35#_J*;W)*P(+4+98#J?(8Y4#P[8M])HF78M[!?.'V
M>Y%ZJ7EW$H)MOFNFSFE^_> S=*&-@@;//S< [<3!2^8H4]7U(Y1NG[\E#KHI
M,QQ(2YD>9GO$Z%VUNJX^&5)WCRYVM_2889'R1C]6/)Q13=AZ_%9T09JF_MV]
M'!'%F95?+),2M>Z@_?&4=-4WJ>'WTP__#U!+ P04    " !Z>&52T\HA\50;
M  #D(P$ %@   &]N8WEF+3(P,C Q,C,Q7V-A;"YX;6S=75M78S>6?L^O8&I>
M1RG=+UF=]"(4-<U,!9B"='J>O'2%,S$^]+&I%/WK1[*Y&+"-[2,)5]9*J((R
MTM[?_K2UM;4E_>6O7Z^&>U]\-V[:T8_OT/?PW9X?V=8UHXL?W_UZ_A'(=W_]
MZ;OO_O)O /SCY\^?]CZT]N;*CR9[!YW7$^_V_F@FEWN_.3_^?2]T[=7>;VWW
M>_-% _#3])<.VNO;KKFXG.QAB-'S?^U^<$X&88P%0F@&J(,4&"<A8)H$Y(V7
M/.#_N/C!(6NQ0@$H["B@1 :@4?PB&7/,2Z.\,]-&A\WH]Q_2%Z/'?B\J-QI/
MO_WQW>5D<OW#^_=__/'']U]--_R^[2[>8PC)^_M/O[O[^-<7G_^#3#^-E%+O
MI__Z\-%QL^B#L5GT_A^_?#JSE_Y*@V8TGNB131V,FQ_&TQ]^:JV>3#%_5:Z]
MI9](WX'[CX'T(X P(.C[KV/W[J?O]O9F<'3MT'_V82_]^>OGHR==MM'8P]M)
M8\>F:2?>7GYOVZOWZ9/O#]K(BRCSM(W)[;7_\=VXN;H>^ON?778^_/@NMG ;
M8N<8(CSK^M]GO_G^40*KA_9F.%7X4_S^[O=3+SV$\5\G?N2\F^]H6U5/CL].
M/AU]V#\__'!V'K_^<GA\?G;R\>/1\?[QP='^I].3LZ/SHY/C[>!8N_6\D&VG
MU .L299[:8:M??*A8:)O^V"0H39^./WIH G=&(2;X7!P'&6[Z;KH+/;'8S\9
M#Y 4'''B 9'6 >J) %HX ;#41!L=,&3T*9AWBDY9GQJ>4G^BO[:C]NKV?0(9
M),[S]],.TR<>_P9LVPT>/S*UQ'+A9M#W4?>T:Z]]-[D]'>K8Z,@=_O.FN4ZN
M<B"5-1QR!J*SBS[.<@0,009 ([D+"'&!22V]ETKY%( Y]NUW=J_MG._B]/!N
M[P^?G/G=3#$367?V!2V?^JF[3[P?WUQ=3=L$S<1?W?]^FC:R<F?2EK'-C M1
MF?YD^9Q0;,/-V-_I!YUQE& ,N,$ASH-2Q+D-1_VX$=PS@53 M3CR7+AUJ(&_
M56KTLD1&1GQJM&F&S:3QXP'!G" 1"/!2XTA*J8&!A@,O)*+>$.Z)JT6&.;GZ
M*WDP,]R\KE#*H!5WP&$;X>;8 8FQ!EHJ!V,<%8*O1OR7XNV65]R6(R]9W],0
M&7G_.)R?:">4H\X+8 SV<1!Z'H51#&!BK=8Z*,)U_5!A0V+4\XGYB-'?',6Y
MH2%2T>5#P(-'@$:'#Q2/6K) E<,*2LC\#G&CG^('[6C2:?L$ ,0EQY1S(#R.
M $AM0 Q63%P;L\"B_AH)41^ !9+NEO?LSZ95PZ6OH<H,&Z_'?EXB+U) 1#C0
M5,,8*VD-I,06<,>5YE II-["KSX3<[><:UG>]#)11M*D)='D=H 145K) $)(
M48#D 1B*!(#"&N@0EM)5\RTSD?JK=C0>WWAWH*^;B1X.B!.:8QL#&QX[I9XZ
M8+".W1L!E?'02<QK:?A$LMWREEOPX27-MT>^-[.G>;C!;[KKXI)_K$=NNM ;
MG]Q,4C(VY;<'<7%(O3)QS1BXBA&O3D,840!9P"KJ;0)^QO4%R;W7^]DM;];#
MKIDAS>B\]IUKDO9Z>*J;*,@]XS33%.FHI0I6I@DXQL+.IF2/]7&)[SCRU4+%
M)3*NPP[R+; CKS5RDL/:FZL$JG<GDTO?';17UYV_]*-Q\\4?C6Q[Y0><.*>0
M@<!X22-O"06&, :"599X)Q$D]8CRNKSKD(9^8Z3);*6<R5H_T<W(NT/=C:*3
MBW&]@S$6<QPP[J,<RL0I#0H.++)>*&9$G.BJ)6N?";<.-=BW18U>^&?DP<&3
MM#-A*"!-!$ 21F^&( >1A0)@08A%AN+@6.7$9:ZMK ,]OMP?N?1',N 7/8R-
MCP<,(14HLX!&'=.2AP,9E =!8XOB_]PX64WCA2+N5@B]/5\6)&S[FR3C2)AY
MZ)EZG[WU41XSC&M78[B3WB"@O7>SW*,VB@ AM;,("<E,M6ETB8R[%8WGI$@.
MH^3WEJ>=OXY1X.'7ZSB51VF$)<8@H8!A"L5E@J) *80 "UP&Z)6+4WQEM_E,
MQ-V*R+,ZD?XFR9YQBDYM/OM%O>7$L]BY829.[2ZD#2@(*%$L*.1Y9&S=_--3
M ;,EVB1S,691&GCG/* 0ZNBY&0%&BB 8=M3A:GN\BQ)M;SUY]F;'2_IO@7RA
M#7[JI6(B3MLR3M. .LJ YB$Z9Q.@E)8SZ:LM('8V[UZ  =O:(%,V,JYIKYI)
MJCL:IUBN'4WB<L:/;!0'#8*+RUOL190"T;3'2H%D" /,9 SD-#9.A36SD:OZ
MV:W9+9N-,P.</PZ:5Y IYJW543<K(N$4B9(@*H!@VECK% I\9VI>ME'YO-/.
M1P/,1Z2G^G86C@:LB+5>@B#$M#Z! (U4C&,\@\;',,3C:@'@*D%W:SKLR:*7
MKC";C0HM*^<U#<9*@Z,D 84HCA9QE2LX P(%ZHR$W-2CS!(9=VOJS,Z6')8I
MX%.?[YT3SHWBQ #,G8TS>:I]XE("H;$*#E$2YY':CG6+VH;JJ\M\1,EAF?Q$
M^>"[YDM$Y(O_V(QTC ?T\$G 06*\QQT&B-$8&0@1 P[C"'"!,X&58)+!RK19
M+?%N[?^4(E%&J^7<3IQE8AS42!*+ 6&0Q]Y=G!V#UP!1RZ&!%EI=C3/9\OY/
M<DV<!.4LQ8!C&@TIHR%U7"VGDWH6P;A6@A73_<LW.-XZ,MN"#TL9OP7R1>H&
M[^2PA ABC0-8^KC\,L8#[0D"1B.B!%?!ULO5KCZP]=8!5Q82],+_&0_^\OXY
M+I_B]_4.2I[JI,>ECZWHX5,9<Y^:?-K5VQRA7*%NA6.JGT[.SO://QR<_'+Z
M^?!OA\=G1W\_3#_+BOO23JH@OIZ*V<ZNGG9M:":?VO'X9Q_:SI_KKW%1[#6F
M,,+%;#H$00.0CG-@$/620\T$JG9\=8%\_?W_?^IF-$YM^O')Z.!2CR[\T>BC
M;KJ_Z^&-/PF/\5CT=-(%'QU<7.FIN/!SV -#X\+/:\9L9)/ N%KUPP9R[U;H
MT)=E+Z>04B;,&&4\$?'PJYT*^:$)P4<7:M,/SSL]&L_,\MG;]F+4C+T[&LW0
M.NG2[PX@,10Q[@ W),$D/5 RQ& )8Z)B>!1H,&_"OVTUVJUXIC SJY@](V>/
M1I,HYG@RJT.,(VMQ-0[7!G)L" @L[<X'RX 4V "N1'".(B3J59&N)_)N9:/R
MLZZ X3+2ZE'?CQ&-DVO?Z;1AM6^C@Y[E..+23\) &<"!I:U)+*/B<4&@N(:<
M6R5MJ'98Y55I=RLKE9],><U5A$>#N/@DU$(-%.4I*88#T!9"$(3S.LWW%%;;
M6GP4*Z>*C];$ E-LK052!SK='08F4 >@H18YZVR,8G8F(-^=6',CCJP:!=M9
M(NNTG+QZ%."NE&VVX7\3Q^3=X&Q'*9E&)3*> H&1CF-2,* )3'>]! E=L%S*
M:A5EZPB\82 (OA7>9#=6U8DX.(0]#7'2H!S%<-,&8(PWP'K,K5%!8URM8FO#
MB7B[(R]C'Y%-L=('_\4/V^EM27>6&VC(N&#"@Q"4256H!DC+$" Q<D*1%QBR
M:H>$5TJZH0NN-Y9RT&S109E<5LM9U'&OYKT<<>6&F4_9!FE02I+3Z$:T  A:
MQ2#D/HI6K9KCF7 [ZWS+$*:7;7)NTR\X[$>0@1!B# 2* E".%=!&6J"85U C
M;CFO=FO>JT<P>T;M/A 5L+$@&!E G$;CDL13%8W*F%/08,[?(+6\6P%L7XZL
MBF0W,D#V@K>7BAW[R4F8ADJK\V0#;:@Q7+NTS#1I0:N 9"0=W:!26ZRB:Z\V
M$_=59K<RH/GI5M78;[L=?/"W_>/_/#P[.C[\GU^/SO_WP^''HX.C\ZS;D4NZ
MJ+(9N8YZ%;9]#_;/_O;QT\EO>?=Y'UNM@^5B);+MY*94[\=A^\<T@OIUNJ-P
M5TWV)(YBG#%#@@&:I4.2/$X%*H90T<MQ9 *Q4M4[=[:>R%D"$.N]FW9S^-5W
MMAG[DW!R/5N*,\*")(P#3H6-H:"&0'$5X@SIA;3&Q!:K;6:LE'3'PI3\?%L8
MN62R7-XDRH-0Z>*GJ/#9I>Z2LA!Y@ST#U*#X1: HD*,.".*C.[)Q<4%J7H"]
M6,H="S]JTVA[B^5<!T:M3VXF(2K^L>VF1>0Q-E<D$($P0(:E:\,(!-)8"3 6
M@5&;CB[;FJ[YN8 ;[J&6SAE484YO0V4FS3.%YS+*1LN@F8Q2B%0E'A0',D7.
MS >F$67!V&K3V$I)\R84%"+>6@^\B8)0QS70*H1TP3U'4OG@2+4QL[,)A6R\
M69U:V, 46:_$^[^;\>PH;!RA'WQ<==IF!O;([5^UW:093[]]2/U9%(()$'!A
M>7IB!P,E-$GE8(K%60!B6VWG>%/A=W[NSD:LHF;-2+]YR5X^L8!I$$)X8$T*
M4!U#0"JB@*&>::XC[+B:=UHEZ&Y51Y6D539S%?-@T\ TO7/E3O7M](<#HX02
M$BL@K71IG>-BD&H-< 19#*E'TE:[0N4U87>K-JJ>A^IIM@(UG'>.\63TXHRJ
M<,X;9C6@*EWI;4G4VR,%N)9$T(",IJ$6GUZ5=K?N>2Q)J+R&*^:@?AUU7@]3
MS7+\)J+^4.0\*WJ>UC\/H$,!*XX!1-/[D7U<5UMH@>1T6CYCXLKZ;5S6.N*O
MPSG^I^!<8=,6(V%<=WQIQE, 9' 6(JJ!8LBGFF89)VS)XC+$,1@7ZA35*[-8
M)N0ZA!)_0D)M::9,UU#-R1+NDC>SE<._[O89+0^(V_1ND)O>C$6 %C"J*P,T
MF@EA[+-JA*4W4;W2U3KVE]^P_?/C7>H@UBMGQ2(YL0M! )>*@RCC%!B?;ES6
MA$=YJ7&B6JB=^;B?>M/4;#8'4\J:><NUNT3^#W[VY]%H^ASTZ.+^@0 ;6/Q/
M&,!D>OH&HN@+,8SK3H:-)18ZPZL=ZGM-V+5RF?#/P:VLABN;^3\:18(_JY&T
M*BA%4F1&;-K,$A1H! 5 A#E!X]H!DGK7[:TE<H:]@)LNAJAI5WCIV[<'0ST>
M-Z'Q;G^\"#:&A= I7XAENF4_7;4?)Z/(&0>]US0&)[[::.ROSHZ5@A>@[H)=
MB+HD*#I5+#FY*85D(9T\TC0="(;4IC>E!" L2N<$QB94.Y>QKM"EMSPMH>E-
M#0-$.HA%J=(@O30(;$0#(B*(9F_I[S8[ZE1O/[ (YQ9OG>>Q7?V9E&@NO;<<
M!.5TE Z&N&9!\5ONE=(BG7)]R\WT+=U^O9W!MZ-87VN6Y=JB A7HG="*"Z"M
M2$\=\%2J8B&P GLLB0P25@L_MJG(?.OMPK?C6E]KUJE=3\7WW74[<[QZY([U
MY*;S;9B;GI[(LV99]1K-9JVKWE2-C'7I/^MQ,V[#P^6<9Q,=.3E[8&0<_YBE
M^+8!<;V6L^*XA3(9H3Q+P[J[;<-9<S&*X;A-8;JU[<WT!OO3=MBD.^RWPG+-
MIK."N8TZU=&L@.I;HKLC*)_/+M,OA_'YW&W]=1%>I%IU?,_LI7<WP^CQG]3P
M1.<U_I#>31R6Q'Z-SM_ +IM"4MUFQ^D)Y92*+V^A%UV]@3U6JYL3_4<I_NO&
M74QWW [CJN<JF3[&1OOC&#Y?;Q_;;=)^7IRW52SG*<1G2:QM %R8",MVPG"5
M@.6 R#*87VNS)%#5AN=]$EK/Y9^W0FMA0UDA>EW4PKCT")M6-%<<H\(AT:(N
M^PR[5>T5QZKT<+L[G;8-+O,'VW)!L$B<[-KV&#9/&BB@>>&A,>LDRV2TI*D"
MF%2;>F;=/3_9$$?C\UKB_KAMT$D!1+=5,?](;"=Z^.O(->/I<L _%>.V/\YK
M=E!B)&^A6D9\?TN#9OYUI*U ?-E*5J1>$;(D'#WF@&5ME86F\,SPHK\LD\3K
MK98%K=K4\:+G=#G]R,:A/M6G#;-BR^:QV+(-+WXG*])]!"AKE&S0E+3?0])J
M+FN2-BZ;](#/ST-M?S^SE_$WQ[/[5$Z[)NUE_M(Z/PQM=]=<KT"AL$AE;5P0
MOIRIP'3N\+Y4=ZM<WWP#>9-Y2T4KI'^?+9B7S13#HO1VREQ7L[]'XK;#QDWE
MSY.2WZR+8DANJEXIE!_V8>9_F@W@E:V7PW9]I:K"^K%M)Z.V[Z[?YMU4!GJU
MFJ40OY_R3FXFXTE<4L<)+4<<L&D?Y;#>5,%"0*?<Z.3VON?L/OF5YHO!NXE:
MN9']^<DM%%LC^+29_$BM$+,H(GUCHT6-%4:G1ISTI,,Y3SQI[>]WUTQ&+_';
MM)+5N_TOOM,7_OXFRA3R9YB',LI0V"(9 2IJR'P.=76SA>%^0P>ZV-)SLV;:
MX)M9.8U2<_LY)4#:\,3R-4;&EB*]R4#) 5]1JW]HQG;8CF\Z_VQ SZ5 HN1S
M6:X[S?):NK<8A:V;%Z9*X_CXYLKX+HJ2;N>?!6I'H_&DNYFI5&BHKM=KM=&X
M!0@Y-PS;\?AT^C3"53N:BKG=MN#+9O)N_KTB9E%$>NV7+FVM,#ZEB9.>D.NT
MG3QLO4;O\ME;WWQ)L\=VA7BKF\Q;A[>!^-50Z[$@6JOAB@@67BBM[CQ/6>AF
M753$MEH,OEJ,QRGL_G.?_1<_NIE616<JZ\DK044;]0(GWP,LSV1,IT&Y093I
MH(#@5J1K+1@PR'G !?0><Q]TO6>K%LB7X8SS3=>EVS46Z&XAQ($Q#AAD'E .
M,3"$.J #9CK^''E4[UV[I6+NUM4,?3FTX-AR'@-E/!9_',?Y<J$8-I!H#X&7
M% *JG012&@.LL]H@:YWQJA9K5DJZ6Q<NY"=./C/5.>:>PO%FLGWV?_[W,\]=
M2P3+&CP\]-$O GC13"DH:H13S>C"C[8^^?RTA>SAS!+A2D'0-S!\T5 Y0$I3
MX^&!]BV),?_[V:^X6"A8&>5[K(!?ME(*B,)KV[F>'NXJ#FTW]^,^ V?]UDO!
MMXE2^59"L[AA^M3K]"K[6<_IX98GMT,_?BY=W->TW:F/7UV,3(4@7A "+*86
M4 A#>GJ6 B(]QT81XVR]*Y%Z*I-MC?5<@H%%UE%K D!,\?0N>@S=A0N *8,\
MP5Q96BU47B+CCJVN:O)RZ5*LEQV+7:B_1.>!5L1&E3$(P:0W-J$$QCH!,!=,
M:68I86_TD,,2B7=L7?:VE,MOXYSWXRT9#Q)I)IE2<46I-*!84:!X(( YYSWA
MU#M7[QW,=?S:-LJ_8,1D__IZV-A9/O]KNL1E0#7WFB@(L"$44!8"T,E"G"MM
M(;0.Z6J7T:\A[S?A[#=BU\L!E=ML&8=3$BT$;R<GX>[UECN!Q@,M@D0.JSBV
M393(6@64]1A8%*#&)F#/94TB+1;SF_#<&?B3P4B]:3-=K,Q+,ZU3FE9-'+17
M2=\I2@/LC300QW6-2U-#" IHB3TPV"F.(YO)\Q>M%RR#UNQLPVM%B]]<GI$
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M1]!C9Y"M=C'*5AKLUE47.T#,OE:N2LGIFP]F[H610= V,&HB/($Y0+'3P*#
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M\?LK2)]O?U:,N%(H$MG)0KGJ1&-B/FO/2IT!0G$.FSJKAZ-YNJHS+%%;-.W
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M9!93XJR(9)4%<M_L8(E&#[XS6]=ZT4;X?7=F4]$7*6)@QN0:E^+(P.O"C,H
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M/>I!CRG!S5%?Y7PTP'V<_/&V4SEJIGFOZG*PAA[ ]4/256VEY#H@$['FJ+C
M"7]0K'!3O#(AICQ<'/<!Z6BSE/A'H:)M*.X\2>@6UN4$3B=7N;\*'1<Q"Y94
M;:F7 S ?'3".)7LADN70M(K?'<,<+V.Z7Z:F?8BY\]2A36 ?_YA>I2>0NH<$
MBDG P'302"9%% REX%Y"]F13[,W_CV&>*?_[B7F ]_\C47F=_4^+876OL#A2
M35X;+&;-F<E!9E5KT(2FE:CO'.BYZL">HNZ\.\(FM-?3B]G5^A2DQ507)"EK
MJRD9:,:),ZLUCP&$D0=L ]?C/%,=V%/0G;=&V()L_/5*.;WGR0J#K"155G<]
M8D3+1-$A*2DUUTWSA>\:Y[FJP'Z"[OVD=66GK$FFP1D=88S&Q\"DL32)6#+S
MA02$RDD5=!%VN,NY'<RGB^(SMP[B[\I%X%8:$[ECTIK,= DD.U,4T\K&R(5W
M;GVQ[;/B3%/8QX[$#*&IVXK,]$)K+^E4^TMK=;SHDT=NBV&N6*@%G,A)R9',
M$R&<S,E@4D<IV;?'7(X3"SF.B@Y)^S:K]!%%->B=M#JEPH*2D5[,VC6(DQLF
ME4T<:K=Y/5AF\..-:O2N9-V$+MJ0_9".@YO@?HRABR%%&'G.P L3KEZZB<DR
MT-XQI8SPF0. >K#1R\-$=_]1I%0T?R. D2=*QDFIBI8AD#="HD$-2:O.3WR[
M/+%$8Y*4@ARRH)9!4& @>68J8PK!!"'$_G[JCA/+;D_<#$_<:1V9A^SH!7>!
M^>0T4PF4RUK0)/S^,]AUXM;I>5$('@&=8P"UNZ_P58F"9PH3]\:B@U+VGL*N
M\Z).CSL"9@E).$:^/%GKTI+-14L#$T8I+Y/"7)IV>6Y^W+'W$KC<T(Q#E230
M]LG!U?L:R+R4DI7B:6N-I/S#^8T/K'3>D4R2UK3TDC5]JS90$S3/NW!>*[[N
M+I^VC[ '*)P7;="9=-HONZ[3BLP@"\^BX46C!!X2/!WJ6Q3.ZY#Y-C(>K'!>
MDCY$;A2#X.N%/D%[6BB</ <R^'Q1(LC!"@,_R,)Y;4AK5#BOC<2'*9R'G N_
MK-:ER#S3T406R6ED0F0H,B6=]& O_\,KG'>0 APDZYV+P%"U':[-I;5DU)/Y
M_.+\1[>?US">_0/.+G!:+JVE;NLY' RCWQH.W4IIK6Y#"))4(J/TTFGG,)#_
M$1.8P"5FA6Y+W88NQ=5#F9"K7MJGB\\X6[77>S.9+V87*_ ]50)I-NI0Q3[V
MD,&:7H@4@]?!VFRT3EE&6[!D5U"2Q0+*W%G/H]GP#Z,IE"B)7"R(+ DE:_,%
MP0)H8!:=T)9GX/91="[H,&[\HTC#5OH:W]\=\6R<0"68LY(,7!,* UDB \VY
M%;P6AAYLW^]H3L>.. ^CYW?4[1A0)7HQ3J\F<A/]UCG]G4#3UC;R1127E6)D
M5M=JC5R2W 1G2=6\R9*T+H.=<+4%_]RUM1>2>W&=[WZ_7D]G!<<$])ZW*T@5
ML!9+4+X:_UD!B\[6%#$5M!9%AN%B3)W,Z+DK\'#JT&OMC.W3N#H9SZ>SVG3P
MWNF4&%*2R3-M?:S%"C7S,=>0E7.:)X>)#Y8+U.G,_M3RH=6CEY(:7=E(.7J
MFK07R29BNM0#O!H5)+\K@#0%RG#'9;V8S?L(=^VHX<?APLGB5X2JQG68E[#
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M";(+L1V:9['QH-Z$V"2 7#Q8GF2]0F;)",\Q""C*I80J:LW%:.L3NW2TKOW
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M$N!5YEF*TZZK^R,;<R+V3ZZDN8OP?Y0TCUC2?)#V-*T-[4/]R94TDR-F/>C
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M;+>'L7DKA6\KO0F5*H]62$Z.<JFIEM( K5( XU'I4'(.!L.A)M DB:<C\#8
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M;G# *(J)Z">KB-LEY!FJ21,^'FO*P-=''TA5YHLW2-;4S2'Y?^M][Z)(7<]
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M+U,BRE_4-]Z\7-+9(OH,*F08=&XXUZM2,B,>J@+69&E'H0'*:>@> ;X% 1_
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M>GO4[JKJRY;F%/M8?4D345W\6NF8E\]"*H#B0):Z7<9  &Q+-I:!Z6PM/FO
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M*V=_M>6^W'J%488==?Z6&@R2@6^J-N#WW!8Y*NVLO.29RE0-VDT/RI:S%;=
M XGAMOWMN7\APSD\ID3<['33K?TI*UJXTO)%!JN("_97] /M6 H8IV%79;-I
M[U?TH=6TQVCM]LFT'H.1!3/<G_6,243XTF?]M3?,5OF1[''!<M>,-C-W_/9L
M/'I^BP[V:*]PFLW23KI@Z6HIX;MYWEVNOT-Y8+1_/J09N;MQVL#^9BWF$0[
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M>(XP7LJ-B)3]>2'<$RB&5ZTD?;U7SRC1%%VN\UX2*4K2!$G\8S&TO>C 1/J
MK(1VR3<R46+KPS:)3HIE2+#(/>Q.J.0F>1PO=6Z3GW.L +)H+ZVT-?.B9ZL9
M^OY. ]7OL+GALS%)OC\7*H@<G,WBB0L]V5SS$Q@GS_,7PW%3UL45IZ I_-7O
M0/'*$6%H_N^)D\G@MK6\7])4M^([;_Y;?7N5B7K6C7/9+ID@$S0.Q]'7=;5O
MBQO/Q:.B7?]*+%HM3RAF]_*C.,;/B^\?,[Y?Z%<H%>EO-/";]7Z:/--OPE2:
MS12\20%1E]IF7@QBEV041&GWM?(J&1@O\'HWC-A&(ZM];_Q45EOS=?_26A/$
M3H>SK>L'LN U[$+QBHR4##Y1N!_'A-=U9)R+&C2V1?T%5?#7W6QQ_WO'%,)W
M4ZA9TAB\)N!E_&%1V+I&_B\;D;"@6I3"N?ZJ_8&-0FN#YL?E$[6RZ6!4=<U&
M7G_<(R!.1FSF3K)$W0'KJL06CW<Y2HP9CW9LX@CM)9:2%+K_O@[J=/WR^K.4
M@-4F@;EI_P/+%)"VJ5;]GF9_-Y$[7?Y5N**W*NG8:[NQC:@/6L0LN=YYG'%.
MMP,4XK 5<X=^RW"3^=@'-L<N\FY8!W+GJK&&A;?<6)V8U#I ].C]BZ\1+TF'
M-&W^M&$7US@:2J3G9I:;&QF5!55^X[7-H)53"O,_P"^]PXW%U_T2&<3^>PA+
M$6L^VW<7QB_UJL+"/]351)I?-TVU.5F1]Z_)R%R=^!\H!RW:]@?MP!KG]143
M>F)IJXM.3>\ EK^I]U 6RNI'P K9EI6[R^['-B$W'E$!H$P>29IIYL.SV0LX
MT^2[CNE+;DDBA2SU\F.61(*JL$G1]Q1/*H9E1EB6 ,S AM =5I\YA4F.HG&Z
M.[B=3ZS[O'I')O?O'3T?**%N[HLXQ5HP_7T>T#)V<E.UR%Q=8Z:#W?DJ0<GQ
M(BAN/V6B'+^G=DCTA;H*GJX2PL"FIYK8;L$XK$UEV_IC?%IP6;46$6@V45\_
M;3RJ;%M;1D92#QT:T6[/:+)BW.W[H_Y5<W\2U)$=3\4Q2!/^2C)2Z2]NK_#"
M[JI_"14M\[/-*M-SS=<G=+,IUA(*"B5)UB<5W8Z@4!CPXN9S[$"&@5/@%)M[
MU8TV5/[EBD:M]1E^*FA)PP;T)G9T]B2X51L8<G)FU/:C\:>'2NI#4L"N:OQ<
M*S7%Y)^ZUU:F"VP2:(23PI)'%N"JO[6!4:HF6N(5N^CJ.<J.-^":1>,EB#.S
MI'[R$GV_CPHE[[H#XQR4)>@YA9D9]3Q]A;KZPG:.@;%4RS7@!-N7+T#L]!,<
MX.3O,-"6%'YYZ*JGVM4VX\,MNH8%[X@29Y(9\)7N74_$9>JJ0&H?7V\\ F)-
M0+"\@3CLJ3MYERZS4-9?1W,J?+WK]Q6SS\8&' 3?])??* 8/GS'V-%L2WVGS
MY7T8%WZ+Y\J7''KREY(V55$F4N7$PX@[.WZS([B?L\>^T8;K3-=T\-(BJ;1T
M-4'ZG^?1K\O5AEO9%?^D_G-G@R8+>E3E1BMC@H+ZU\X!@I^8J6R_"US\D@7W
MRFM>G^T=?0[PVJ"=)/=GD-;3G;Z8,M69KGDF4EB"=AW#!<BAHDNNZ/'43W2&
M=U'=&9Y1]>91]E?[&QJV_X)QJ+"IF&YGAWF^O:U_=5*%^\]P^1& T0$B2;RC
M*$(U*$1I2OL49P3=>GN..@?74WRG2&(5BC;+CDQ1%H,'NWG=%R1S;'YHV"OV
MSK88OZMQI6EJKX[VYI(RUS+)NCY\!.#LAOH<&(+GUCA_GD3X52TY/0+\<3I#
MM&_M0\<J@_]%QTLQEHRZZ0.':HJ5&<AM,EN: 2%KF][TXE9#<C=:@WXJ4%12
MX*U+GEC_KI%/3'\W""$S^6^^8#RN#]0_>^5#=4>Q0A^:\SIVB3W_!? 29Y@1
M#8ZLO.)&*G_VOA6OEE+<@H,<6IO#!<^7)8;2VK#HLH4SRG#N!8%_BUS6;-P"
MN!.=+^8-4-_S_=>N3) .<8W S_!Y@F)X+\%5 I?*)OH)IJ=@1#ISN& 5"3/%
M]IF28 G%N^I"./78L<7B[[*U4=$P_?!X&\G!3M?2W:=IVYF,D$5JT=L,&.J&
M]<FS5;GQ(DSVM*>.YS;5-:X@&]W>"0]C4</5X,ECK-MGIG?LR/2K<J*\F$9_
ME]EZU4JP@5;#N@,ME7-X( "-)3<*UNTFN\BN/Q5*<2<[U4%1:>[8)E/JP+O:
MZ'UC\J*ZIDO.QD^OW9K;%4":[0"Y(0[1-1VOD=@,.+&;7(,HI72+C%8'ET0Y
MQ+\;!@V:\!\-<<UIS<U;9"":=RT;$R0'9PR;#4X/"X6WF2ET2D"ASEX#,C1)
M_33DKB'>OPZI7MDF#C*O[ QX9:8T_$W[_%%0BT1^=-M":2TW<'Y>%TJ3LA=5
M^6^I[?SWQ>O_@ZFWCHK"^Z)'QP!42J1;!$%IZ1X1B0%)Z92.H7-H:6D! 0$I
M*8EA!&;HD.[N9H;N&7*  =[G^W[OK??^N'_=O\Y=ZYR]]SKG[%NJIA%0O33A
M;R:&?U&Y?Q%\^POADK@P [4O7IG;/2PRN$*IM+3S5C+6&LT7$USOKG)FK&^R
MH;GB)M2PD7L7I%'W &:A>T X\"E\61"$OLN"@FOV.[NH3QW,[&,D#9S>&^&%
MMPM9USIG*BPG-;Y_UP.6H_NUU+JU38 ^7KN,#>*2%X2X=#:VPFLGN#^WP,55
M?+X8Z,PAM;^7//@VPB^.JL.QW'!A3WN#R#$RT!)LT-5LAX^;_NI"/VT"TM;;
MVJY#A'_\<#"RYP'-L$N )1:*A%%""% DJ<@Y+T*: &M4%C-9MPWZRG41#UY_
MBN3@>"69@6$N^R-%%C.!J>L)QL>I8:B[_Z,$<KH3%5+.GK'E])-%M]7J MT*
MV(TXB>]6KVM;40\8UL7S!CZ7.E$C=^]<CL2R@D.NZ[[A9(OM6RDGI%0JEDWL
MTA::,:I?6.RZ8M.2^+M56Y6><E&N)OV3T@U?K5&/I^^97:&'CSD+FWB (L6]
MZ(U>L$N 9=Y1#'<4YGTO>CIRA*_JM]W._&(72'/&3&YT#[!:!2^8)'[%2>:M
M[@;/UU&/NKDYR1C*XE5$NX[GRT5K=E0B6]0VNW*?MW+.8_6Z9 30L'@8G \!
MB5E7FLUK2N]0U*BM4JK(?/PWIP<D-?<ZAOW]4UMK:\G$T?I7,E62)Y6Y:.#0
MU3$(B[=NQKSL0-7(%XY85EA7;1#1LV<L_6PK1G"I1?5/\1Y@_1>T9H4QM2W?
M23<D@7K8!H+=;'UMN>2DF\=_;H;*BUE92Y4_?/+RA&NY50SG%87RZ6RCLX^\
MU&B>^B]Y"9V<V-,&)(4::D-[5*SL6>-CV$(RGL@V,63/5ZI?)&"*HKKO 0L$
MW3*O)X/&+XC=+P_Y;_-%/BFFQ:@0Y;B3!IT-6[ZM.^;;5]_?\+W-;J(8X5QN
MS=V2MI<M^5I/J*[B5)))7$%U$?LBYEK][NFKM>#V#W?,?/_/'KHH")AJ]O%_
MNTN%J_]1_^?_7YO)/.[N\2WS1L!0^GO%C]1,X,.R?9+-89#3@U,@%+\G="$J
MH>;8\WRY8P91=;LJ3#S%<*.A$R,B$OI*#*J$?"A1D,L]SEZZ223\4#*1A-LP
M..1))!+JC(B-#EKU_/EB;A?]F&_3-E% ,<#*O4GV0B8$:?9-0JV@,-AB5^3"
ME''<T4E]WDFG3NK?KW.VM*2?R2H,N3\SUW"!MVGW  "\Q4;,T$"HB;C.1PMT
MEP@@IWJ7RK!1XPE(5AK5-/5QPE1O=Q@271HZ@K8=JIY C8FO9'OT&/B&1_Q.
M/UIL<BEZK+\[3?WTL<71[R.3@(E+U\1N$'U*%S6=SF1+_,R5!S[R5UF&F,X5
MJ/UX;+8*(JD*'Y/B YN[7'A-9IE[I3BH2GIR;5F&[('^;;5*8EE0@<*>-CK)
M^S=*0X<>%(??-GJ7YKHVXN<YQ%@93\U,@D:!\*@0KV \D^ .(Y0_O7 \+RL5
M_VX/N.\BM*JGC()%KGVY_I<S0^;YVSL4)\A4O4V.9OCSH@<SRK/1*HC-R"B>
M:@7U9OK#T"S^_,&(8(U4Y.=?H<&&O#*/.]TOTND"G&OKWD&[T*-O,R4_K/K$
M;6^U;SP(.Z^X!T0NX.=C2LP:9[RD#57ZCBH_:4AOA+C1$1>P_OI%N?;PO>GY
MF6@[V,CE"5;A5+W^!O_*UM^K(=4@TR[]YQ+?RO(H8#UOV.^<?\!3?*OE4)JD
MUQ94"F:#U2VY VNZ([.*(.V.7DJ'GV8*MD^T030<J>L%#P%L9$FC?M<=S/-U
M_UHE;X#1:2,T+I6L^@4JH*_?5,><H]4)I)5ZWDOO;ZL_@:B Q@+4 ]WP:O;U
M!/F!]E.T55MO1\E*]_S<(8!UJ!_L7WGP\P#:6=MI.OIHEE;N:D.35!9?;@.*
MP"6KKVXKK=Z%CE?6](+Q[.N#PJ5=.&\L8R$VMY/I%5JFX9F<UT5BS>Y"J=;6
MI(;29<62.\N7#R+!$;?R05ZF.W6F#+.5%2XL=GS<-OZ^ZU)7[BR=1/]=-4!&
M.Y)P9FU-TX<;'Y.I\95L4[;>/P<<^.>B8</W@$6^;D/2N.#_D)U\!>)-SI1+
MWVDW\OE+0WTD18Q]Z/F##5U6J?^"WY(.2(8?<P:*WK6H2P";U=4XJ</PBU:(
MN2K/46$[?=<PA-7* ID,6*.KNX7SK@C)-2RP, ,>E(R%'*<,U?D^_Y,!V?28
M<B<="UO2V*C]\GOES[])R\6KZ=AZ@X)AXQNZ#AE#5UJ:/'$U&P47L9BI,8OD
M+?WU>+8T YI7K][:N/L!_J>?3=AK""*#D69R#%2S!%W68_V\C#HRO@%#V9NT
MSWQ9/OS^^V4CF9\3UGE,)AKJ9<\G,WH1D;;@#WJN=G'R.$TD/H--/5/T0;2>
MJ6Q%8,72ZS?RRZ;]N_Z^^P7'6'J%.%:M=Z5 KX5#L-7EI IBVBRH1?FSXH;:
M>!^4X9MR]=^% 44-1<M#3>/6R42'W3MVHQ5(F-Z4,#@:?MY8I?+$Q=$B62]7
M'>04@CBEG7I*BWP_U)Y1[3['0=D+<NO=56!^7C:YI7M:TY*K$\R"0D_D?TX&
M+7IY#2R95J4V"=L@P,,I1J+'#DBG<AW'S\%"QNJ1T 3+\?\*\"KC;AMQD/0.
MW0542,/^.G@A4R^-5<@7#"J0MP*DZ?KHL(Y=Z_FL,2\ .[^#T%%Z4Q6>\21\
MC[$AV[,!HH7V'PB-MJUO5V!TL)54:C*XXQ63,@VFI6JKK28Q,JNGC3S_KY$T
MU6V6^A3[B9?=1O+4MXKB'\FLUDYK+&\\OB)!?7V539VKU<G[K4SH>77JG7T4
MD!H2B),MW!FU%_=%Q=O:)!C\.T$E131G/>BS$.=*2IK;+J=S-KT\;\.1C[VZ
MS8/S$*)$.P<#Y;J"R%LG/%N\;S3K6R>":UT,NYUYZ%:'TL 7O@^;!)HZ7V07
MB;X =0NNS?;> TAP(EC;M661R2XF0L14$//PG]?[*_< )R&_)I"@Q-*BG.-X
MMV=UCRZ[2JI"!R!([NMQY#W@F12!2 2::M [JF(9LJ]GE&W ZVD4XN-/T\8O
MQ.5J9N7:4_XWS[C/_=]:G*]/>^*\A4L"5(C.M,6%!"$\W$65Z6[OXZ.<8YB.
MOP49ZW9(C/\SHJ;$=OA(B.;DL_VIZ>#=L\,]OZAVOI@[_/$[BGG]/28A!")+
M$UT)_;VTL%=GF,6;ZN-9QV3\?$&6%D&5GRDJV&<=V(7+^],CDX_QZ6R</=B^
MX/G<3>5C& &+A KY2_)PKFO5-#;:6<>GC5P,R(,YP@$;2PI]!Q]J":DHNW#B
MMS^"D5^P_NT>=7&>JESZV.C7PZTA14N&2Y+J0H)"KVU2*0J?# 'TQ&D=GP-X
MM.R U6TX=KKM\,, T75B:N,:C$+S'2WXN-K8L-<\(*FB4*!/5.HUC<! RWMQ
M':GGE8;*JLO'P8UW9M.)JK<E;7;+!+U!E)B4';^2B*/_"!WMLJ&J2\F;Z8VI
M@PD.DOSU'#E[A[&0S4=/6*92-2@P6ZL/<;;F]NC3GA5Z%W+%M1:SKN OR9-Z
M/T<9!.0?)PO-N*L\A"=59*V[?DCE 1 G$*NZW CLB)K25<T2=).25D8%EC$^
MX&VKYON4N_"2E08';8JC9S0;'>$/VH+\":(/ZKO.[0(R[.50.?G-]'8;!L%D
M(AL=Z:Q7\GY#HC^SG7Z(X('.]TRG]O<__DX)*OA0<+!.8M04G-K<G##:8P8W
MS>##<=O!CRD<?*C]TL.%3*@8U03=G%=>3O$X\\B,^R30JB@R_/3E/_@C.&C1
M&IAT4B*5MLW1XL<=3" E<0^H\8Y%>6%>_\/8E%>NV!,6$4L8L&;J%]2]=:XF
M33*&SPN0PZ,T )P@G\1@6R4<1Q$DZT"&9_S\UNS?22_IM[,;L 'J!G\WG BC
MO/:Z0U&0VUF/AOL)49LP_H\B-3J^O1G%Q)61%7M*2[445OP6(Q3'P:\<,HQM
M;#/0=IV8PQC#'.IYDZVH55U;G2-D';)^:AFC!U#:)8=7  !/"@')@L;!"7?4
MQ@&\TY[[](M_V-N:)Z#"DM]8M>C51<FBM0A&#1X[T8N(T6.FZ CCE08MB=[@
M_X)&E&8N/=FCIA$:YI;SR&[6]NX+&*C_?K7T.>)O^ 0A"= '_<<JL+@P[0O^
MFP0@_YA S:.79:,EFY>Z*1WDPF2LB'?Z1J]/OI:8_"JA&'LVWD_Q()?;_^>4
MK3HOU\?V$3=U[3QY?T(RP+!9[^-@$DZF'[\=M;@LFF<R'!SF+(7=Z'U+FXM>
M?:W*9:SNL5_1$[HI/IG*+$PG;MK_E-28#)=+.%=;JLLD=E#.\?0B$@'T9[[W
M W;R)1#GV^MF<D3#ZP-TD%D6'[VK_ZK$"G-PL_P(BQA1Z\&3W84G@Q&8NH-U
MY"H35F*].Y?8ZRFO9WVA_M;?AH%16U:B;T5:H.@$D@F#@H" RB><4LJOGQ!0
M+M^-KE*Q8=4Q=/3%#3<R664*GK=*[VX7/VR8__+1=H6=?=XW%0'B:?VRCOYW
M@Z"JO1$\ 8-;*BMP(YD>39JEM2M1N<U:ALL@BC_C_?04GN:(I*C'9',Q-YUW
M3_/7XHU,L2#*PN^ID\?"]L>O;-@"LECCDL[M^ICJA;> Y&V6YYC9+GKZ4@1+
MOO1IC_/F#9>4*!F#^5A85P3D\:8QP&,6:!_P#NNY2MK,>A'(OB<MJC)AH1W]
M>[.V;(T4UE8J?)7.@#'AMM%DD*$'#5>"2XX6BQ=J+^KDH8DN?/\&(D Z689<
M"K=&$]?>N)&!_37H)F+(&_UB_,%6Z(!)_L4Y[2T8F;B8=?>TQ./W/K4I-];+
M@>]+EN">(3$<DD:P=[+(AV&1^ADUU)SZV%5F'AM<'MSQ<99:47M&I&>.Q%D*
MP2UQV<-5.^E4X86E634SJHB-BC'G14D++ 4%2N^C('H"0VC*P%H27DU#Y;WQ
M]/+C>6CK:2Z_<>(\RM;?V[#X'@ 41'>H]L7]_$^+&"AUOF64992]@!7> ]9R
M5OA5U3M:Q= Y)2Q.,B-"LP<6Y@VZ&V$.ZW.B&4]E6O5A-<%VI"',!*ULINJB
M,6?2$OM:SD"X4S$8W"\#(QVZ!Z"E9F,#)+ $:Z0 R)Z=%*$U2KQD1L1P]*()
MT>A4AGK_+4M!8* PC>UK2R3X#->9P$]3P?!'C5C;>U(A1=7+;$.-^DU7P]N%
M\3L7OHS3D3KT@/JWMF<LF2O6!M!S-_JG8=2O?[OJD&G7B/8)  Z-_Z.A=^0[
MP&?G?[S::!R42XL'7D>!GE#M8693;\=?7X2%G>(QE=!27G)TM\V5:,\$/:N,
M10+)98OVBM>65L1UY:>TCX;\)[>T\;ZN'^/U/Z:[<EZ]>]J&ZG.>;Y8OW?%C
MS$Q)#Y7S%9K;TWFO>0\(Y+_^W.\1)_27ER9.JSC%OMLH2\\;9G-TCO4RF12!
MJ8Z475!<;197WDK5ZIJ,YN!,4-'-/NN,<KKU\1;@W4^AK\7U-5S_ )<U\/W7
MI?=Y#GSJ&+EVG?S7U*/NJ+\YG043KD!2-%Q:/,JV;#SV&1O- 8]^U;KMZTJ)
MDT:>#Y(5[ON9=2R6-Y@]9)OF<>2S%+_)+[B2\VY/;H&X13*GIS_]X!'N"%>1
M7V8_=C%BF(NKK'CM=VH\<75[C*L,6+6E_O&[-13+O+9OE#M_Q.C 3!H@/HUX
MVFS$F^WCAEH\KTF0E(='OJ^J42=#9O>_;?@J+:$GBY&[L$:[A &MLST,(SM.
MU3"FZ<%$<77ID094M.Q*T\_YCA8$*M1\G:/<&/02(9(==R)8Q%H:&A;E:30,
M5IF +>JG\D!#;J1.NOYN;HH]H[5\H)VC)-8/"WX[\L9&V]J,U%]!3:+< 1IT
M.RI(&Y7*T2_JW,9:A$U"=_Z3,(MHED>U<'31#67R],8($Q-T4NE>J'"9<&O*
M<VL-"B446=SN:'FGL]KW&MOA;&]C"K!ZR'@;@V99-K^Z2.NZ2-Q*K'Z%RZ=D
M-JW;[[V2(RLJ,OJ@%VGRW@!+>TPB R3%%'T/B (B"6;RTU7KQKT,CG,&MI;:
M/5Q\V-RZ7[K/F9]TY;[=\64$U^>BS.)D."&"-P[;2NB*>*\*@UT]/YRA*MRO
MLLBO=.M]C7*0C:0&E6MYF]V*45N9V\)O1%')N<N_0RG-FQ<RL1C"#C^.*"]H
MD J,#"RG4#M]!#^+56G^$!&_633=/,$EC]"_4M/5XG>;!5<"+>GIV^BPHNHU
M&,;S^+:8\U(AWS:$.5RTMNN##74L):(K?\WUR56&B?YSC^_@+&PL9KW'E Q#
MM""&^"^:<"]U4FS8C0+&DT>$'BBI4\M'DV.2H6C%_OYA"//(*I_P<,DA;<4"
M9%!A!@YE;6]E:AJKW&C[:D]'(9(T[+J/V/A!E#Z IF:AQFI_?JV @ >2OL=Z
MH)G_M7)@@)W+6HS@+L.Z<)PLJ@L]4D#<D\T(7<V12L=[.*28Q*G\P*GC8_O:
M+QU!]*K25+/PNE$P\:IQ/!4I^<ZU4;RZ4AUU_G;.T;O-3Y6'#';D>>9;&\Z/
M["H).E8ISF%/L?Z@R;.;/X?(L?,B#&7*DQ_]Q'N%=LQN>X!H&:UWWP/!*J:W
MOX6A'YQ ^0CT10I)>;!UZ=+B[H+#8L>L2")WDA(UQV/X!-7V5A\# (]5\5GZ
MZG7;%6-=?+#-*JF]$XK+C!1;O7=]VG['BD ?07E+2J"I6?31FR&\YEY)BX.*
MT771#W\%=":\786['*P7X/"Q]EYN&]B_^R"4XEA7YN'/"=Q4Y*MC-_N'-1EK
MWO].:2-'OYO'_G*5H;S]?<X%I'>@7BB@CP=V!;%4SR+ZH)9*Q?7^_B7U3"K/
M/]IZ)G_YDJ  H9P)FF"F;B;'L';2A=G7_MTS99D2%FY&3%F@+R^X[&>NDHHB
MU<\RFB^2LL4>Z'RR"O6QR&!NT0*U )%M:SGD'J5I67-ZDZMHQ;;<NV=DZ*NV
M@]?_]X[LE:[UJ\_[9MKW@':&$>!:WO]K .BE*(NZ!X3\KY<JTK.F/8Y7-K%X
MX/QV;*"S]HV$ZIO637+>S?8RL'_=L<ZW(ZF3=Q,A1W)"\OO,NOA4E=_:4RNR
MG5\JMCQ@#</N5RX98"4['ZZ@5&M/34!"S]26KI($T@X@QA[[)F;A,E1U,<WD
MOU<-(%FJ4SPNK&G[!UG+,H-O>RR]OE :AS0]F[]=\0_]K(N5+PO0$4F3X,VY
MCEB.#Z^;-.JE_GE,+E&Y)JTHMHUP SXM:![[L%O-EJS0.:PT]RZ%^/M3,^2Z
M&'"B26!>WH(\"5-?"JM04V^2ID>FMTN:D:FX\'0<I3AOV@06?'$7?3" "7VR
M'Y=SOI-#=9O@953>?PZ2Z:5*9(!M2'W&MR@?6;U,S*L AJ_0)JQV40GL:2P9
M*1)U905L^WU]_SF!7Q'#8$EYX=,Y&ETK(X(-%,HTB\"I%"]P7FGT=5H,32AH
M][7+CA!P]5N0E@("A>S6MI+3XEN(2J<*=&1 !KN3UPU;P40RC-C?BZ!JL"1E
M;=W"*8A]K6K^L20-_GZ:V.CF(N4JEJ-3E E8FV%55R^1W3(7:Z5OR:%@8937
MXY?@[S^M2MJCMZ!0Y(*DJC%B0]3;O=C?BM"FXAA.TF86M+=,*.!@8W [(SU8
M+=S/$<7HIKNY%$'G$-7^#6T0BK*^3=:D/@)[SCBE1]Y&ORX6$$HG(Q-;![6@
M@+OUR9(@>]56:R>JF<FA ;1>>[:E&KPV!U, KXG #?I::9BB^)>8;[:EWY^?
M599W+AB75IB8(=H;ZI)4X,EQL0E!\KVPDW:8TST@0KC<9*?<%GH;O]XH7V?O
M%&+OC>MU=4$"+('J0?Q2\FOEI ^6=J\]OS=GJA:VFI*U0;I.ZT.N<AVNXN3E
M@_U&;A&+HPV]6K_-&+-OP'49B<C$*)]:4]KZV5>(Q!N@QN='R5W)A;<'GC0[
MTOLG/A<M&"W(XL5O3&T^<;EA3V/6 IM3_-S7)SX,7CR;1QPK;;8!8-@2Q$-M
M(D#\@BOQH,5T=BAFD^+)[\ K'>?UER32Q$$6P>VZ;;;!6,U<.![T9.6V*L#:
M\;HS+OA/TJ:U-5.9\I'9^[EMRFU),[D"CA\ZOHJ-8U?>(R/[NE,L-?!(E=CR
MR$4&S;B:G+9!CCFBZ29ISO/SXHF[7J_;PN2?AM,6//QNT]X)'@=<9LB2,.<
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MK<W;37[ 2-M#+? /]7;,<Z;6O4D/="W-""N8=2*1H1P1^+1-8$:M5@/_K.'
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M[C;UCD0Y#C9P<*MF[/TYID,AJWO23>=5$?UY[#R,W:N5  V+E6&!9*+421;
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M33%LQA"$X#Y#^TL$C'?NY$<7#G%U8)5O :C?HB!+EW=LCJ4O*V4I-W(IO)J
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ME$YR10%2;P;1F09]F8=+P1T.5F&Z"">9X0%5O*%0KF_,2Z(NT  3X"%1&?#
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M0>9&-(-]2>.%1YG!,GR(G)'1&V7:F;V1MX6\6NO>KPBI!W0T6JW>__O#ID>
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MP3@GOWZXK4CU/6O%]Q=7#;&T:\A:*>SF?<DRL-I"M@%#C/4$5P^M?&GP_P"
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M;)C%&H'=>$?B)X/_ .$.TO2_&7AN\U:3PW<33Z1=VAB9HEFDBEEC9)04R6B
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M6]O(%^A8$_G7P[97GE.._%?4O[#'BW^V_AYXT\,LP62&>TUR#)^\HW6LH_\
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M(A"#KRDJ..#BLWP?^R[-J_A3PWXFNM5CTOPSJ&D2:UK6J36I:+18UNYK5(E
M.9YY6BQ'&-I9FQPJLP6AQ4^16?-?KM_PVNGWW[GL7QOMKCQY\<;C4/$&F>'9
M/#.H>![R[T6]2PLXH[RXC\/QD,KQ@,[13J @;.QEVK@C%>;^.].\+Q_"IO'5
MG;^'8;WXC6=AH=GIOR+'H=]$P75;GRQS"I$,11P!@7S[>5X\A@TV3Q/XFATW
M2K6ZOKF^N5M[*!(<W%RS-B-=JY^<DC@$\GJ>M=5KG[,'C'2-8TO3VT5;N[UV
MX>RL_L%[;WL<T\>#)"9(79$>,$%E=AM')XYH+]C&-ES6M^2_K4]R_:"^'?\
MP@_PGO\ 6!H^@MK/@SQ38FUNK;P]I]C8_P!G.DZ.T$:RR2W=B95AVS72DLS
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M$]:_9TT?^U;3Q:=/TW2M8\:6NE1OX;L;^&*X2:4W$8N&CAE_=RSI 6*(P/\
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M=US(@P%248">8F""5&3GG)KKOV<OCVOP6\67&EZA"C:7KEW;R?:'D*"PFC)
MD_W64E2001P<\8JU\>?AQ'X-\:OXSTRY\3:A;W]\AM]2O9%E5C]YHMP(.Y !
MD[3D@<\U]=E.*3L^NQ_/O%65RR['NHU>G)N2]'O]S_K4U-3ETCP5-?:29E9;
M^-9(9_(^4;AS%\PX(/<=#T-'AW7-;\'Z?%:WFE0S6,S^;#]I1_\ 2HN R!Q^
M'7E3@BO;O@W?:/\ %#PI:MJ]K::E>>4\-SYMNK1PJY+!X\#DGIS@@@^E<%\6
M/ MKX0\=06<\XMK=0K-!]H"R!#TVGD98="1SCO7UDJDG!0<=>OY:%8K#5*5&
M+@N:+UO;NMDM?Z^X\X\4"SU+4-UG:W7V6^(\R.[E\YAV=B0 0 -O'M7L.F:;
M8R:%8WFG7$EO;VX6&=9[A50*!\I09/WCCDY_ UE>$4\%>#_$M[>/JTVH--;%
M8K:>W/?(VDJ0"S$XSP,XR0*;K]WX;UGPK;M8*RW4<QF\J%-O#$DPEN5X& 3R
M%.>M>A^[BX4)*VG5?UJ>Y@Z>'PZA0FTN97LTM?\ )G-_M-> KCQ7\,]2U31;
MRP:?2E0W5C%&TKPP*54.93PV6(.5;@YXP#CPGX8^';JY\36%[/YTVTA)(Q&6
M)4G:2!WX/08STKZ&V^#-4O9+G73K;+">;19Y+B6YC7D)V4*6 SD@9  %=9IE
MAINK3Z?J7@_0]/T?28Y#,89HRMU+@J 2"25.><)D=>3R1XU>-2%=TY7MW?Y>
M9\_C,%6^NNGSZ.W=NU^GDET]3/T[5;#P7\*5T[39(].:Z,L?F7-MYEP2=@W*
MN3LW!<+\IZ$[A4W[/'A34++5[&X6/5)K/3YO-6&WLDALHERK&YN[K;G$?S$(
M26(R1Q4<WPZOOBG\2;'3XY+JQ3Y5CS#S*2Q!2/GF/&!O..^ <X%']OS5(? O
M]D^$]!O+FWMVM"-42%ML=^%(V,V/X=WF #H<9YXKYS,,5&G>P97E,\TS%48>
M[&.EUY:MV_ST>AX#\8_$&DZ[\3?$5YHW_((NM3N9;+C;NA:1BIQVR.<=LUS5
ME.)G^[BJ\\#N^=O%3V(*,%V\5\KU/Z$C'E2BAU[#YBMQ6//;M&6K>O;I0@7%
M9MS;-=J=HH*D9R$R,%R?IV-?3O\ P23LO*_;[\ M_P!A'_TVW5?.ECIVP_,M
M?3'_  2C54_;W\!?]Q#_ --UU0T<N,7^SS_PO\CY0UN-KJ  =*P?[/9I3C^)
M2.:[*&R^T0<C%0C159^-I-!M8]^\!?MC:=8_%'QA?ZAH^H7OAOQ!&;K3[;>@
MN=+U$:<;);A3G;M9&D210?F0H>J"J_AW]J+^Q_A_X'\(W<&H:EX-T?2[O2_$
M.C-(JP:FMS=22M-%_=FC4Q&-VY22(8^4G/BD5BT*\5;$+>50O,B.'I]OZ2M^
MI9^%_P 0(_@U\;M%\36MO+J5KH6HBXCAG(AEN8064@E<A)"A/(R%;D9 KT?X
M4?%#P/\ !'Q[H>J>$[7Q9JD-J]W'?MJGV:%Q;W%NUOY<,2^9&945V;S9.'(5
M2@7->(ZXQ6X^45>\,3L7'I0QRIQD]?0^AIOV@]%7Q!8VMUJ'BS5?#D>D:MIL
M\CZ7IUA+;O?P"$RP6UOMC)4*F[?(2^T8V8 /#S?'_P .^&9? =RMWXTTF_\
M#.C7GAZYET^WLYD>WEGGECE,<Q9)U83[);:155@O#]*Y.=T\HYK@O&;"[NN#
MWX%(F6'A:R_K?_,Z/XQ>.-!^)GQ)M+[PWI TJT@T^&UN7%E#8'4[A"Q>Z-M
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MXGDDF8* !GK6WXDL)?&.M+\+_"]Q'#:V_P"_\5:N.8XU0C='GNB'@C^.3"]
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M2OLKJRZ)J^ZOZKX@O/!=S;R&'^TEQE4>VA=PON00<XK@9HK7[0LEO=QWT);
M9 5<>Q4\BO.-+^&6O:*6OH&FBCC4RM.CG&T?>8>H7N1TJW=>9#=-)#K"27$B
MY9R^ Q_E^-=5+-<;A6G7=XRVNGJNZT_'J:UN$\GQ=25/!8A-QWM9V?9V>C\M
MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\ >/1:=XW^#7P_\"!ENM0FCN%QEEN@
MSC_@.*\Y_99T+Q=\8;J'POX=UM;+69L_NY)1Y4ZYY8>C 9Y''M7!_M[^$?\
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M"WI7/FR6*:@&R"PTICR0:?<^'ED.[%=5I?AN7^S&O+CRK&QC&7NKN000J/\
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M@A@HTZL*RDY=-/\ -W7R'3QZ:;5[Q_K[SZ@LOB OAG2F66;[9(PWK-,RKO\
MH!@#Z<TU?B='JEI&C+:B1(O-&(U/?CMFO 6UGQ%XA^ DVHQVMTMY:ZQ:V-K&
M4(DN&ERI3!Y[ X]J] T#X!ZU?>&+?_A(-8TSP]JD"J2L):YN(FY)W;"%W9[9
M]J\VGEM&JI5*]54[;:/7R273T1M3S%IK2^S>MCV#PO\ %_4O&]C+8S1,OV,9
MQN(PH[_3ZUV%AXPM;)(5\[[1<2?*$5R$KQJUT^QTFVOH[7Q$L5[=1JCS>1L
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MIUJEC)I+:9KK16GAF^TVTDNKHW:F,2_;VWY7F50ZE05)4IN .>XTGP7:^+?
M&/$DA-G,=D2 ;WNAU89]!Z]JM?#KX9Z#\&=#NF\-Z'J%K9ZDWF2-/<-(&;!&
M]5;Y5;:2 R@-COBO$S6M.N_;.;]I>[_X/]?(]7+\11HRE'$TE.G)-:M)K:SB
M];--:Z.\6TFKZ?&_@;]J#P\8/$'A'Q9'K#'5+Q5N9M(DQ+%/;F5-K L@E@)=
M_D#C)5#R!@^S7'A!?BSJ-G>K:RZ3H=KIUO8P+<'=-]F@C"AI#_>(&< X PN3
MBO0-?M?#MI&UFN@6-GSO'[B)8^><@ =>]2V?B70Y? VL-<3M;S6-NZ[">)8S
MUV^XZ^XKU,5C_KV(56%-4Y64='I9;>7H8?6J\<&L/.JY4X-S4+=6DFUU>B(+
MW[+\0_ 4.@Q^+K'P]IMN<V^EZJ0+7405\O=YAR8YU'*MT['BNP_9T^#L6KS:
M]8^+M%NGO;-U07DLY:'[-&ZK!)(00RL/D4/CD9.2-QKX.^+4-_XPU&3^UKZ:
MR\/^9Y45K$=MS=)[MTC4C'0%CGH.M>R_"7]KJQTW0],\)^*-8OM/TU+:/3],
MU*U=F;18U/R?:F.6FB'<#E03]X9%=.7\00IRC1K/79-;?-_KMW//S?PMS2M1
MGF."A?[7)]IJUVXK_P!M=F^B>B?UYX^^!%OX1\;:UXHT.U_L_6-854U/4GN4
MD:W12C2M$NT#Y_*3.7*@ X45=L_$&GZ'9VVH1ZI?:Y)J-J?L,-H3/]K3(W"+
M'RA1W.>Q'/2N(O/"GB2S\,S:IX?UN&_LKB5':STN]^WZ?J-OM4O*F<J<N""J
MXR"00#P?9/A+\7XM7U^&.2PL[CP^J8A\C3=OV8 *7"*,;0#S@=/PKZO!SIX>
M#C2C9-MNW5O<_,\=FV-Q=12QM24Y12BKO51BK*/HCROQXWQE^&/PU;6O!%Y'
M=^*M9NHE:&]M1>RVVGK%*[K:6P!5V>=84RJL$0DG;DLOL$'QMO'T6QT_5-%B
MC\6?V= ^JS6EJ?LL-V8\2*O)V\]%).#D9/6N=^/7A?1=4\5V^N:;K/VK7EM9
M;:!K?=M%N<DN_7:RAB/EY).!G.!PMU^V?X#^!M[JVA^(;.^MI- "K-JMO827
M4;W&Q7*$*^25) )*G!'M7F8S&4L+6^LXJMRQG:*3:2OY>>AZ>%^L9G@HY;@<
M(I5(-S<XINI).R47OHGLDOE>[>'_ ,%%_P!J2U_81_9SLO'Q\ :5XR\27VH1
MZ)I<5_B.W6YG65Q)/@;FBC$;':,,Q(&5!)KXKO\ _@IG\3_CO\/)-(\8:]:V
M>E:@5>YL--L(K%+H=1"S+\S1#^Z6(/&<UB_\%3/VZ-+_ &Z-4\)>'_"^DZI;
M^$_!MY/J$=QJ( NM5NY4$9D\M21'&B#"@DL=S$XX%9?P*_9>_P"$V\.6[:E?
M7LEUJBK]@L+"'S')\U5/F'&Z-?OY.T@[>#R*\;$?7,TQ#PV7^]&VNMKKK\NA
M^S9!D>5<&Y/'-N*X*%2<ER\T>>47T2M?EE;WG:S775:9X\2Z+KC+Y-O-<71<
M?*O*H,]<]AWKJK'QGIVEIY>HZ7]LTR[P+NVDC/EF3/+ <8/N"#Q7(W5@/#.H
M7EA;PQVMM;DB25'!,Q&5"CN0?3MDYZ5=L_%$T^E2VFH0PW4$RC*9^= HP"#Z
M\#\J_/,5S2K\B@XN.C5W?SW_ "/WS+Y>UH*K3J.<))-.^EFKJQZ9J_PQTWX>
M^$M*U^&TF\6>#=4G%U:,'82P7:(T:+<("-R)N(V\8(4^@I?A7XKUT^+GOM#M
MO(M]4U&-[NW2Z*Q6,(! *;@2S(,!>C'<3D5L?L[^/K.+X=2>';FU2ZTJ[N@Z
M.S%9K.7&"RD9# @#*D=NU>H?!?3?!]W_ &\ND2:E-J_@V3SM5B6S81QJ$\X-
M$FW=(2HX*[@S J.>*^LCFV)Q6$A@JTKPALFM?F^OD]U>VVA^29EPKEV59CB,
MXH4_W];24KZ-;JRVCT4DDDW%2M?4S_#T?BSX=^)=0MOB!XGM=/DU2%M0TS5+
MB V.GZ?;K)%#'"\Y"@7!D=2J8R0<;FKM='_9*GU3PGJDMU)82KJ4LSZ^9[A[
M>ZT171I8;:-W5#!$4X,8&%RQSN!%?-__  5I\>:/XH_90^&:^%Y6M='\7ZQ/
MXF@@VRQ23,N=SS12_.C"60X5@ I4\<5O_%_XF^/O^"B?[-?@GQ1Y,>FCPJE_
M!K.EQ3>6=7N8HXB;J!/^6G[K<-KG<I5P"P(KW,/Q3BLNP,L+%I1ET]5:R>CZ
MIKTV/R_/N"<+F^94,WE!N5)M1E?1.+3UA>4;:232ZN[EH='X2_;%\#ZU\6_A
M'\2M0GB\%WVBVXT#6+4F2YA>*/='E954E@8I6'S#/R#K7FWQ]_;EURR_;&\9
M?\*%TO0_M'C$PZ3#K$FD_:]2UA%"#8GGDK$C2+D*B)G:I/(KP_0=1TV2U\O8
MI5"2%G(81D'!X[,.G3-&GZY-X8UM=6\+ZA%I7BC3_P#2-,NY8@8EF4@X(/!W
M+N7!X.ZO)S#BRKC:='#U(ZTURJ7E=VOY*Y['#?A[#+<3BL334I>VESN/V>:R
MUTWNTF=Q^W./B]\9O)TWX@ZM?VK6ME$]M9:7<1Q:;<J,@S%(7*,Y<,"6)"D8
M^7&*[W_@G3^W-H/PO\)2> ?C9XOU!=2TS4(=1\+ZKKB274=F!"T)3S<$QM'E
ML,Y8;92,@**^3_C1\0OC!XU\;:3K7BK1(=%5;#&CW-C;_9;2WM@V\[ K%U+M
M*'P3EA(I^[BL;Q!\7KG7+;[+JEK::U;2*BN]W -T##@LA3:V3[DUG1BN2]2S
M;WMJOO/9IX&<[^P;Y4]+KEE]SNGIOTUW/UT^,VN:?\-/ TGBVWMVU2&UTF6\
MT74(XA+I]U)=E(!'%.K[9&9561E*M^[C)!!SGP7XL7Z> /A#8_V7I^I+XB\4
M6B7%T[02&:"&6*-I!+N9D,LDZM+N14PI08#;C7@7[+W[?=OHMEX/\ _$:PB?
MX:^&I3):BRC)DM59RS;1_P MHB3@@G>H9L9^[7T1^U_\??$7Q.DCUCX,2>'O
M'&E7MJTBG1FCU/4HIU()CGLBRR1P!.C!2=W!V #/TN$S.&79>J.!;]I.3E-W
M<5:UE%V^);O7K8^-K</XC'Y\Z^<0C*A2C&-)22E[W-SRFKWY'>R:6_O7O=W^
M1O$/F7^HI#?6<ZV_FC[1YR ^8N?F&"#U!/.,UT'[0F?VBO!D-CX?L;B74KRY
MC%K:P6!C6U 0%H(P&)*M)C"XPH4XZXKW3PM\$X;KQ!)=>-M5TV37M2A@T^^\
M/6TJQ0^']1\OS70CYG:1E]#A<X)/RM7T!\*O@@WP2TJ;5+5--TF1H?W-Q%$+
MF2$;T\Y23(-KLF],JP*%@<'&#YF.S+,L'AI>VI<L:ZNFT]E_+=KY^J=[-'U6
M%EP]FV8PK_6.>MA&UR0FK*4DFN=*+>FC5D_A:LW='QOX>_9#\._L\^&[C1?$
MM\;_ %^>*(WIMX5FB@D #>0F[C"'@L!EF!Y"@5X'^T=X-T+Q3J#M_:&K1S3*
M52[AP$/^_'TR/8C-?1G[12VUYKTZ0WU[9Q>;(\L@+LS*20J,ZX;"YW$C&=O<
M9!^>_C5KVBZ/XX:SM=0DU6PC1(94$J2(LH'S;90!G)^8<=&QDD5\^\AQJPZS
M95;INR@M_756TMYGZG@>*L-5S%\.U:4N504G)V4'HK)<K<KN[:;:6ZO??YF^
M-F@:YX#\.JUDJ:IIK)Y2RVJR;XBPP \>2<DG@KD$GL:_:6[UJ;P=^PU\/=!\
M06EGI>N?\(MHMM<Z9;MN%E>P6P2=/0;<(K =) XR<5^?/P4O?!4?QU^'^IZI
M>RV.CZ=XDTZYU%9\,H@2YC+G.,8 &>1T%?HA\>O@U>:\UO>+.UG#9$PH;L8B
M\HN664ON(&\'<-S#=D=S@?H/!F*^LJ4ZC:<;*S_KRZ:'\M?2.P:P%6A0PBO"
MHI2[V:LFD^NCOK=[:G,>"/&NNWNF,OD02:1=VZPW2)"H8H@P65NH9L ,!@,*
M[F70;K4O!D,MYI-QJ_ANRAD>QLOM0B>R;."4<K]T%B0K#N2,D5R_[/VG-_PE
M%YH,DD5Q\S/;6\[0MYS,N"!Y;LRG )QDY_$UV]O::M\)Y-6LT31;R]NU2T;S
M(&D2.%B,*X'*[<Y#') Y ]/TZ,N>#<-U;3OY^3\S\#P-:I/"^TM>UE]VKT_'
MS.*\(W(\;1Q6$]]_8SV,1AM81;2327;,,["2N1QUX .>3U(/%WPJ\565Q<>7
M!'>2;59HP0JN.3\Q3(!YY!_I5WXD>'[Z+19;JXM]-+72?:&GMKAF ;D>9YCX
M9>005Y(/L:]7_9N^(WAG4?!-NNI^#TDD73VMO.6:9;6:8H4A4KM")U^9RX7<
MX;.X\=N*Q5:,%7HW\UIH]]/4]98C$57SP;IO9WV[Z*SW_K<^5?$6F7UGX?2'
M5-.O(M0DF<6LL=NRQ]<-ANA 8%?3MUKIO"GP=U+7M.CDBM0ME#*B2R$',C$$
M<#^+E2<"O8KOX1W&OWT+ZUI<'A^X\*[K6ZM+0!I+CRQYNXR*2'0KY8)X/7.6
MR3V/[,_[/,FK30ZW+)?6MK;W11+FZ?9L?86 1&W+M!ZC !'<G!KGQ6/Y</S2
ME_7D;QE7]C:<FW)_-?+I;J>'6/@"X\3Z_-H-O#<VOSQV$UV(RRV BD#R9[#S
M) J@'^%7Z5\]_$3PEK6J?M&^*-.\.^&]<U1KBY.H6\<%NS2+%-\\>2GRJ?Q'
M0U^D&L^']-^&?Q0N%5+RXL#8--?2B8I#/</(2H88^9CABHSD#/K7FOQ"_::D
MTEO[/T:QL].LP K",!G; P"2.2<#J<U^5\49Q-5J<*6K2;WMJ[6=_1;'W/AO
MDLXT\1BZCLYM1OY1NW9==6E?;1J^ECY&;]G?XM6_APLWAW7%:3#M!>W$+Y'I
MACD'COS7.7_PT\7:9=LNI>'-0TR/ 8/)"=JDCH",BOIS4OC9="SEDDDR)/FW
MO+P/I7(7'[1$.F:BWG7DEP^,BW4\,?1L]OI7S-3,L;BHJ6);E;1:NR\M;GZ/
M*%&W*Y/U;_X!Q'CW]ES2_%-CX/O?$FO:E:S6^FLSZ5:XADE#RLRN\QR57;C"
M@9YZBNI^'?PF^'/@\;]-\'^';.9?^7F>W^T7,G.23)*6).1U]:T]>\0V/QG/
MVN%8[77%B38Y;:ET%7[C#MZ CI@#I7FNN_%"WNM4?2[R9=-F@S%*KQ ,K#^'
MGU_7UK3"T:^)JK#TY6OIO9>=_7_@%QK1@[Z7[_UVV/3Y/A;\-_'6I-'_ ,(7
MX=NM0G;<\L47V>0-TW;HROY=.*R/C=\.M!^+&A>&_ 46K3^&O"?AG46U"]-@
MNZ:_<IL"!R<+C+(&(Q\Y/.*X.Y\3-%:M#9:L(9&ROEC: _\ (^]<NFN7VE+<
M"XN9FF.#Y>..#G&>^>?RKNQ&1X[!6K2::VNG>WK?;[OF$ZU-Q<9?Y?D?0'A+
MQ-H/@W3[C1_#5O#X;M+']V+6WC\N3('5FQN=CU+,3FJ.H_$FY:%;6:XN)'9^
M&ED\L#\37COCKQA<:W\/QX@L9I[?4-#V_:/+/,T .,_5">OID=A7#VO[4,U[
M/]GU""WNXW(!Y"-G^6[K6>6Y;AZ]Y8F;B_2_W_TA2S)*R;TZ=#Z@'Q:M])U&
MU$<C7EOI?^D&1^5^T'Y Z9[JK$ ]S6/KOQ9@\ W;-J2W%Y;ZI$TMI=HV$)!Y
M#>A'<?C7A]G\1[7[#(N]E;:0D9?< IY_PK8UJ;4OCC\'9-*T..2XU_3;N*X@
MAB;:TBD['&?H0?PK&6#4:GL[\T;_ (=_*YG+'1J7:6N^GET^X]-M]33Q,8KJ
M.ZAD\QB3&LGR@ 9Z]\U?UCXHS+HEY#;[8H;%4CC23B3<Q)9R/0X !';/>O/?
MA[^RE<Z*BR:YXH:TO8V ,-@ 61NX+'@D>H%>@7G[..GZM9S6\/BC7&:2,*&E
MC28+^/!-=683RJ=*U&$HS7S7GN_R-HUJSC[UE^9EV7Q+DN-(.J),UPMKC[7&
M&^8+T#*?8X!'3!S5K2_VB[&.\F&GW5A>,C[?*N&,<C#O_NX]QWJ'X0_LN:EH
M/BBZANM:MK_2+BWFA>6$&-@"A'*]CSZUK-\&? ?PWU)3I^@6VN7UKA9+[5O]
M(FF8=2"W &>@ KGPU;!TXOZQ251/1;IK_([:=6;:Z.UV^F]E\S#\>?'Z7Q)I
M=G'9;[$O(Y<%PV2N !GTZ_SJSXE\=W%Y\*O[>M2N_2VC6_5>3ACA7'X]:ZZ'
M5;&_D:&72?#\%NV#Y"6D>1]<"MC3M(\+Z/H4TMUI>FR6MY*ET;49C6X$+[@Q
M&<;=W'H<5Y;JT%72Y&HWO;?3LW^IT2J5)N7+J[>FIYAX33X@>/=)M;KP[HM]
M>0C+K+- B6S=^&?''IBO2O%/A+QMJVJ65Y>W.A::MM!'#Y7VW(R!\P7&>]5O
M$WQ]N]3FD62ZAL8F'^C!WVJZ_P"S]/TKDKSXAP2QM<74L]P8V^8I(/D_ ]:]
M3$2K9G54,)AXPMLHK6WF[I?AU.6523?LYR<E_6Q-\=?!WBZRTW2=7\/6MQJ5
MW<3_ &2\L[.3[Q(^653T'<$^XIWA/X0:EIBQWVO>(VTFX=,&ULF^T2P'T9B=
MN?4<U&G[427-S=6&E^9#:Z9IS2 RG;)-,S*#P"?E"G (]ZIZ%XIA^(_AZ\U"
MQ\[^UK.-I6M%8;;C'+$ _P 0&3CH<>M%/'8W"T'@^6,7=W;BG+T=[[?D=$JD
M.;F3;[:Z:;^9V6K:9X5ORWF76O2S84F<3(A! P3MVXY_2ICX>\*^&9(-<_LV
M?5M;\G8)[B3<-G53Y8X9_<UY#+\7K<:5(B:@L-TI998U=65/3/'X]:X7Q#\<
M9]8O82UU)&T6% C)(R./R-:5LEQF#I0Q*GI-='KJK]EOY'/4QD(OG>_]?D?0
M<7QX@\0L]LFI0QK"Y06C_))NZ'@4G&58$VX7AZ<H*"G=H%)*=\<?E1(! >F8
M2(X)HQDM(B M(*"D=#F0&*,G.0'IF(QNZ8T<;(S7]_MSG?/E7,_OOJ_K/ _*
MF+C[YQJP7) OUIIS5HN%P?M.AKD/,;^]5,6.;[BJA!WD.I[4?B3Q+V'^_Z5T
MIZJ5^/?R2:=DJA;80ROJD6N Z-O!<-PH.YMJ,K2V\%^A5'LJW R28(V7Z;/G
MZXA!O3 .GIF1D;BTFX G=5<S;[-=('P'4,^WAWY8A93N>S.ZEZ*%FY).9D8N
M#Q&5/5\="Z;=4:L^'PJ*0(=SES^0-+-OS9=,9II0 MV9R0.QHODU&JUA*F@P
M#$HP4*=HJX.#PZ3>)-K.=5'".IK-%!W&J'/7:8GH+-Z8Q?OP5O"PZ:L)QZ\Y
M8AQM W"=9N8>HO98YR.Y:\!<HZ5LF/6P- N&JG1Q:,S9YE8^T6+$X>\XS%JJ
MVC239H<0VI:?U9A'Z3Z W 4^K9\*EYW?=O[<1CYR,UKXSB7: 'MH=0WX</98
M8":TI?%E<_JHW=PQ\7&^CYK.\Z.E#ZG@135T64IO .^;][U!:..U+^^I]R]B
M=$H#K MZF_W!"TVX \LI?J]N)+^N(N#VGDB#=/<*%CXQM*/DWP%SO?*O5W*;
M"9[VF41$F,ZH2BU'T(5J3,A1#?.,L'=.O?OJN7GL[-;R((S)R9'W!;H 6KW:
MD3&?IE7AUJIZ=LS=9CW_,/74UN(+=.VL)%T'F=V]RFTRP>G=L!%9/+@E))'X
M^I+6W8ZU%Z/1N^ODYEG^^/[<+>^;OF/'VZ,\\-W)E7DM:PG)7G1\0,=\3MBY
M76C&[+2JOX;K$!5PXW(G0#FP!WF;:-,<,S%^*"OR*>")QQ:(B?><5RTL*2"?
M_2K/GRZV@$Z.H'=*HSP3T*KWL"61Y;B(ZMWS9!U3%,QA.V &2>6WT3A)S,3=
M6L(=*UYT_D8>#\LL$8;1B;3*Z_BLM9&.E0&&88CCL;T@P[IK,&->^60Y>J*]
M8M,J^7&8MIR B40Q&A>\O57$<>8%UR/46_\UP[EV_3E-(@<#\096[#D^Z4[:
MDW/X-AYP2B=> J>B^T#T-(FQ-]O$.5_?8\AG:,?1$T_:KKHL3Q83T!,L>-68
M-+_Q9O%5W>C"Z*20^O0.$- N=Q8"#=6K-AP'$<ZL?C9X$FR2O_\AW;A(MZNK
M_.ITF#$@>-J40F+_TF*:WD:8O ;()$W+\K+348!:@=%$J8H1A%992^:CT!\C
MM$P,J!O_C;+O&-BUX/5PUI!;E0EZ#7::'Q]S[KPLULJ]J3L*=+^DZT?R-B9H
MT!HX0B?;)P7QJD5,9+D^TAH/[*D4D@\%IMF+P1_1WLLM0)GM_(PM[3)QF$[R
M6>C@N4?9]&&8A_,15RF[>T$6D7>W<N-R*X;HORPR!;D',G7[6W\;\>EV-KM-
M)[?&1\*E7PVR/U^X$WL5DU!2_PMM\1*V]O"QS\'"'>-1LL0P\%^)*!YICZ=/
MOOJW*=;(MA5OH+AZ96QYHK,F(>=M'+M$G<J_RCR1"EG_1'_1.D68C^N_P>T_
M0;&Y!)=6WQ<$^A30&P4;@:+3F8/#S6<.BGLGP< &4H>"^C.<?.DJ9(\S)$2#
M$O_^*.R)V1/'NHS_$KB(788W%"\G5=4]3RLF9JX!^C9B3RAZ?XRR6[%R :HC
M(P]'?.VC0W"<K[!+'TM3#TH(JFFNGH861)$%=0;H^Z'5#U)EI2"6LON)><?W
MK[K/54;Y>%I@DJ&:23_',BA9$IUG!B_/ DBMK*JJ$QUS"'_'KG9P5=\*+^U?
M>>D""8^6+_T1\1:.:6'XF^TV:RG]G*.4N_?@>>T^(&-M@)?%3=-S!-F(]V3B
MZ]-=X.O0__ >RX<<NS7U-O/N&K.$#('LIURZ,KD.040]YE^[ZC?P'M[E\NEA
MRS#!5<'ENB;1X6L &7\N(<K6DFO@-8X2+C<L< 5JZGL>K:=]OA%B0[IY>)Y_
M _O48HHDC8_7:'IP=)8H:]#8+9.;Z^4]2MY1NXKL8PM]7,Q.[%F?G4N DLG+
M%]50X*\,@G6ZC:+M&; 6D8>L/<&V+)(5KBU!AMMBQ5T#-%.1EQ:C2,YK@'/M
MQR5.N1S+$__Z!NP<S>H9*>(AZ\#*.\(HZAM,"AK_96>4V6K;/^!DNWRE,*OQ
MS-LKT/=OVSEB>?_/,O$!SEY_-V1;L-V\ASE9[0)P([W?2QHZ&KK:EC([VIT=
MD>@_MQ!B'A+=,/FK.4WP(K!.\17%$G+-)%3\&O#>;SN"[C2E"1K5;[Q+^4=Z
M[D_W>(VVI+2A+J_1\[-#5CRO0>Q*8V8G8WW\B(J\%;^:4\M]GF_'\VM\S']=
ME*:DH-:67 \1#]'#I>,VTT321?$3F%)_V6-KD8C\[#-1_!I*:OMH::E$^43=
M/[G +7Q<7M;UXUUG4Y>OJ.P6$9G7KS-XX+^ X>/W9GN"_!UILUQ]:U0IC-N3
MI9VFGDFQ%8KZ(C8T&QVY_-DWVWE1O*RN36FK*!/U5XFU+;HDWN?'PQ#;]F;L
MWXR2SMQ!A:<WY=EUWD8.[&-:H"%T62:Y52[&OF#+:E!@!P%IIY+MHI2[8_;Y
M@5^+(WEZ<$7%7V(M,W^3@<C;%%]\*4[%)+:KND:_XJE >SR/K&Y*)M/@&XS3
MR*VV2(@$^^RQ*]R;=!.?Q5)7:(NOMFTY.JEF'X;GY4J''YODO6+5V.MO^\QR
M*@1(!4H-8 ]1]OS3'#MHO78XW'P>(DXWBYZL3FW#DG<,]2X!3@]ODP9YZ'$T
M>ZY[@J2C_DWH'[8:P4\7N#W4_0_BG%Z\7O0]E,<-57ZN(S^&!81"Q-9XYI#;
M^8>4KZN-V UAUM+E-.F!#1DYK1YB$QYB 5)P(Y9A'&/?OG>0'*S=1^E/E?S3
MF^GC.L#>]?S3\%T=.(Z\\"Q,G#-/JWB^%+;BNN+=\HLKFITKU181I2H@WU)C
MT[VTL^%_(PY3SD]+YSOZ_%(V5*GA*KNQP\3M<'\S9B4I:6/=6T6+>L?L4U9W
M\\N?Z^*^N<N1^@]^@=9P(ABCM,^!F7'BR)F%@S =7F@B/I"Z^$,*O%<OY/-J
MS4:5G?S1^!+8W0=)%>%FQ$$:#GXVT\F-1" GM@(_;;=^H!&H1P(&V,QUDD8
M*KJW:#45*_RO ?C'"GUTK 8T'<FEO!]J3N;JPEC/1,GET_YK\QE^X//SZ'G^
M7=6MFZT&@;W60OV*$/\YUN9\)0'^[Z76KHY=;_X#9MW?9_ME2VL('B*"5X9L
M:)YS&QDV@$JB-@KN5Z BL+6N2L5[E:^ZEIT%ET] F+.9N;U+N69\!$74[T>3
M(\>B_&:@DO529L$<ZX7FZ@'_UH/:J4NR%58BD\7JAW"!"0^B@>,*H>)0?"UB
M7WL\326I,(;T*GJ *V;N$_C;59DZ$U#AO;CLG'YE,96W:%8]]:^C"O[U-)4M
ME13KB_/^" ;6;OFF8:Z9=!WEQQ]2227T4V'*+AV^:X?[O-]W@#>( FM@I;6T
MS;/!,,Z7Y@\R]7.<M*W8H1LK]X^GJGV!\2[,N N8HEE.6]E!S9SY[.$T"%\
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M-P)$AYY%>36K4YR\SZC*J>*HP]A!<RC97;O^6[77_,\]_P"">WASQEX,\6_
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M7O:R6IZ?\'?VBO$'[-?B&7P[)-J%MX<OH_+O=+DCVK)&W.P@@@AN@;TKV?\
M;S^+/B#]I[PCH>I6-Q]D\.6,(_LZTM(S#!:J%VA"F3RN-O)/0U\S)I$WB_Q+
MIUM'8K-'HR^5(S@[]0E8EI9G.XCEL 8., <5]@?LS^'/M7AFX\-ZYI\EYI\D
M9E@6([7B<+V.#P>,\?PUXU;+X4<0X82?-!VU[]?U^>]B<DS*4J5/&8Z@H5XJ
M2?=-Z-IOK9+T3:NS\^_AI\%=1\0?&BQ20^9=-YC;I"""> >>G>O5/B)^RW<6
M]G<W%U:1OE0-B+R!_>/I7TIXC_9CGN?$-O=64EKI4UG+B%PIPV3R&'^T._4<
M5M^*_".CWWAZ='O;K3=4L0$>">?#;O[Q!ZJ<#GO7T6#SI4N6C'=;KY[_ *>1
MX-7&*ABKU+ROU/S2NOA=?>!?&<<PFGM8X^('7G#$CC:>N>F/\:]J^$_QV\*P
M?&CP[<?$KPU>7G@/[3Y>O6VFN1/J$8B9$8+N!!W[&9 V<!@I&:V/B7<6'B_4
MCI][;QW5I;S*\GE.(@Q!!QGC&<'//(],YKA?C=JNB>,K6W-C&5<RE+>6.W\@
M6\2HBK$PR2>0_7)X!W'-=694)QH3KTZBC&33<&M[=OUM\[(ERH8G-L/1GAYR
M=I)5(NW(FK:N_JXWV:O&\MO2OC]\)+7PAJTGQ"^%-PVI?!?6;S;:75O(\LWA
MUF )L+^-_P!Y!*,D OE7 &UFKV+X!?%VR@\%VNZ^;=LVG:^.*\D_9C\6W7[+
MGP*\:>,I)9OW-G*MSILENMQ9ZW%Y986MS"_R21.Y12&Y ;*D'!KJ?@)X*\(_
M'WP WB/X16YL]42+[7JW@62X>XFL2HS*^FNWSW%N.3Y+?OXAQ^\4;J\#!X.%
M>$ZM%6=[.W7KIY:_\.:>(V.G@GAL#5ES**;4G>[3LDI]&U;XD]=VH]?3O&7C
MJ\\2.;>T:299@?WKL24 !))_#]<"O+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZ
MUSUW^T>N@Z]Y<"-,PS%<1(<,!D9 ]"" ?J.:WO#:ZQ\8(5^SZ=J%U;Q_.Y,&
M%7D84 <$GV_K7V^383*J655*N)LZNNCW\N5>?=>?8_/5CHRI^9K?!7QK?:A'
M-8W3-)#*!$L;_,&4\'KU!KYN^,6JWO@OXSZS9V-O,(M/OWMX)5C*[U5L=".1
M7UWX/^%5VNIK/<0"Q6Q82LKKM;"G)X[<4[0[:P\;^+M0;481=0^<TCN\2E@Q
M/3/K7S.#Q2I2=2]FMK$SP;K45)/EU/"? ?P_UKXZ:8CV]K<W$5J )YI!F.+T
M&X\#Z5[K\#_V=['198[O59&6QL742,!N64]D3NS$^E>J:39:#I/AS^SM-LVA
MA4[R.%4D]R!@$UQ/Q;\1ZYHFD27VGPM?V>D6SRK! G[X2!>&"?Q>O%5/%QQ%
M9SJS;OO>]W]YI1R^K2CS+67RT\]SI_"7AWP[9_$/Q-J.GPQ7&JW4P3=-B86F
M%&0@/3 P.*O3WDMY>M$TC22*?O%CMS7Q3\&_VE;VPT2XNI+F:.ZO+^:1I?XU
M)(%>Q>!?CM!XANA#?:E]F#C"NYY:3MD_3/XXJ%EL\9B53C9.6BULD=4<1&-J
M:EIW>[?5_,]<U[6K?2W;S',DR#@A<A/SS7F?QGLM:\3:KI/BQ=2:\L]'CECO
MK;&& ? 68 =<<@CMD'UJ3Q1XNN(#)]GF2_MY,,6&-Q]_0]>E<=IWQI@T?7%A
MW":"Z/E7$1'WE((.1^8K7%9/B\![E5:/9IW3_KS,ZF,7M%"IMT?5>GZ^1>U?
M]INZ\/6(@@U"0;1C"M[<54M/'<VM6.Z:^DO+BX4D)$X*Y*DXST/;K^E>:?&/
MP./ /FZG(DEUI=PQEMIXP6 ']UL=#VKS7P?XLNM5OOM5GI]^T.XCY(W"R'\.
M#7J9/4PV%;J5J7/=:/>WR?<\V>)5"HZ;5_,]6\7_ !4CT;_0Y@_VK(.5^[^%
M7[Z[O?BS\.KW29(Q-=&$W5KZB1!D?B1Q[YKSG7O#&L>*9(YET>^C"#'^H;@?
M3K7T-^SG\.7T/P/J^K7T_P!C\BR:*&X9 3;EE.6 /&0N2,]\5YF(IPG6<J,>
M6[;2[:W_  #!R<Y2E/:VI\4W/QD(_P")7-;37,RL""BE6B8?K^(J]<?$:9+=
M8HVN&DQM\MXSN /7H*^^O!?[.F@S>&M/N/#ND:5YRVB&6^GB62XN&(R27(XZ
MXXXK \4?!*^T1VU!+..%G.':%%^;ZX__ %4GFT4G2C=1?2^_R-,1E3@K.=WU
MMLO+Y'S1^S[K$C^+M-CE#+F=0Y[C)]*^L/A#\)M(\*:?#<1Z7IEWJMS=S[;F
MZA7[00LA P2/E_#%<GI=KI=AJUE/?:= ;BSF242[ KMM.<$^AKG=6^+&L>'O
M%4[:TS(S7,LT)5_E>$N65E(]?S%<M6I*HK4M#KP-J-&2=F^GEL?245A?>(XM
MTJ1V20L5++D'CVIR>((?"<R[;TS3P@LDIX=#CMZ5XGHG[35OK.HVL=]=>59W
M#>4V&VA6(."<>GOCMDU>\5>+MEKYUK(TUJWS!G(9E4X[YY'//H:]'#\.8C$8
M1XJBT[-^[ULNOKUMIY7>AK];;@[6-SXG?$37K;3;J[T.4ZA&KK)<0X_>1HJ@
M9"_Q+U)QR,^E96B_M*75WX=A:2*UMPS@2-;IM*9_B[X'KZ9]*\_M_BPVD>,T
M6SNFD56&\>G3D?3I7*?M-^(E^%>O0ZC:[;:QUZ)IHHU4G]ZI_>!>W<''^U[5
MR82;IUXSE%2=[ZZWMT9SUL0ITE*"5H[+R_K<]]O_ !U=V^EKJ5MJ*WT+?-M!
M^Z#R,$8/3/J*\Y^('Q0D<+?--(79AC)!P/0CTKY\\"?M"M)--"M])''DD)C@
M9ZX&.*KZU\1[K6/$"Q0[[B//S,IR!D_I7N9U4P&)<*N&I>SG]KHON6E_DO,\
M^IC.9IP3_KL>K?'CQ.TWPJO/%D+,K:(D?VEH6_UD;,$&?H2,>Q-=)_P0U^.-
M]XV_X*1_#G3LWAM9AJC,,DQC&EWC GL,D#\:VOA9\,;;Q'^SKJ$.I8AMO$=_
M;6+1,.)XPX9P#VYVC(K[$_X)W?L^>&?@M^TGX9C\,^$-'T&WS=;KB$&2>7_1
M)A\TC$L2?KBO-PN,]C*,(W3D[=M+V^96,PLIX6IB)RLN5_-V;_*US\V=4^/4
MVK>)[BUD-TLRR'S01\Y/<8ZUW_A/Q3;^9#<2R7FGWD9_=RI\A3G/((P1WYK[
M5T+]G7P)X&>35;71[6/4+QB9;UX5>XN.V-_4?1<"LO7/AGH-XTDEG$D8D!WI
M-$&#?G7BT\TA1J7H736S6A[4\'[23DZNO:U_QN<;\*-'U+Q_I\+0ZA/J"0(%
MCB0;G;'<@?EGTXZ5T\GQ">SNET&.7<VX+<2#HS?W1_LJ./KFNR^#-U;_  \,
MRZ7%;1I> QW"QH$()[C'2OBOXW?&RZ^$OQ/UK2%:3S//8I<L#E48G[H/?W-;
M5JM;'2]O4DY/;7==OD34@\-=U^R:??OZ-:?>>_\ Q1^/<?A75&M+"3:MK&$=
MOX3(3@#\R*SE\0P:Z9Y=0D^U@0J\A).U,CD@9QMS]#SVKP32/B1!XG\-*VZ2
M.<,LPE90V&!SSZUVWPCU";QMJ?V%8UDM6<,(PA'F'C SUX.*^JX?QN795AZE
M:K%2K=-+O;1)]+O?7;N8T<5S3<Y1UZ:'>^#/ #^++.W9K4*;AR$&[$<:]2[^
M@ Y_"O:_"FL^'/ .F_8=!BDGFQF:\(&Z4C@[1_"OICFN$^/4'BGX&> M L?#
M.C:5KNJ:]=)'J,,F9/LMD0P)10P+$2"/=C=A3G &6'#>(_VFO#/PI\'ZMJRW
MMIHWB33;B'2IM&UFRNH9--NI251RAC<O"^ T3@2(V\9/RD5Y^!X6S',J-/$8
M?E?M)-63UCUYI*WNQZW7EW5_GLSXXRW*Z]6CC>9.G!2NU[L[_9@[^]*^EM-F
M^CM[M+X/UCQ,(;F\N%ACN27CCN%D:1U[$(F6.<\%L D\&OG7XD_M+^ ?AK^U
M3X/\0+I\VI^5HNI:;J%\5AM+JWNX;BVBM'\N1BP:WCEU##,.8Y&"@G81Y?X,
M^--K^T2OB'4OB7-X=O/"MU]KNK;6[LSV6DV)R%$UN!=#[1>8<*JM&G*C+MM$
M9\9\.64WB"PCT77H1'H+(\4,JWLR[YW#-")P\&Q89'C.T([(NXJ)"1@_LG#?
MASEN#F_;RE*HX\MTW%-25I+39-::MOJMC^>N+O%S-<>HNC&$:<9<UG%2:<7>
M+][JGK9)*VCW/T=^#_[4'@_XTZ-+'<:MJWA^>)DB6"_A,BK(RE@(IXAMF 49
M.T' ]:POC%\-=<U+Q''+X<AM[^&;+?;K>16M[E<;@?-4XW<]#SSTKY5^%GAO
M1_A_J&BP:;K>I^&I[AIYKG3EB6VA-_"&D6V:-WD 1D!4 (?F:UPJE@1],> /
MC9J'P>\3:/:^(K6^;1?$5I;7;-)+&\,ELTCQR2F4'+R!RD8B^\GE;N02 9IX
M>X>E"3R=N,K>[!NZ>ETDW:73N_062>*5>O5A'/DIPVE-*TEJDW9-QW:TLO4S
M;'P3XZ42)/IL0\L=1.K*_P!"#7H/@3X;ZMIS+-J4]JD"#,@BD#$?C6=^T#\9
M+/X?7.H:=X?M'\:>+Q8C4-*\.V1DDGN(6Y6ZNE7FVM@NX[I2I=EV(&8XKG?!
MOQ+UJ]\%>'-2UBWM](\17\327ME' ;<*NX%&,3?-&2"1M<!CMW%5SBOSW#U,
M?# O&8F"BD^7E;M)^:B]U=6OZ]F?JM?#Y15QT<%@I2DW'FYDN:*VT<D[)M.Z
M7:W5I/C?^"C_ (LTGQQJOAGP/XA%Z=#TS3'UV2>TC:>\5Y7,8&W< ($6-)'&
M1G:3G@5\C^$/C[>3>&]:T=?%$WBW0-/N((],EMM(&F7<A<(LB(6CR\;-RT(
M1ER<YX/UI_P4+\.:YHUEX/\ BCX=N(;6ZC\K1[E)@%D5E9Y4G0%3O3RV>)L
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MO[?=*O\ :;0QF)'224F&,1INRL>!GKV%>OF^4U,N5&O3J1J*HO>72-ME?O\
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M];_\$\;[QCKHM-->XDAN&=7FFE$<88#);.,G &<+DXZUG^+_ /@G1JGP_O\
M2X[A;.;[7,(HS#-YC ]3D8XKT;P5_P %6_ -[XJT>XU[PMKVD2:0\HL[Z6UA
MU :8)4V2&,(RN-R\' )[]:]:\9?M;>&=:^!LGBSP/'JWQ.GM;A;*'0M'VJZ3
MRRHWGW"R*'@**K .Q"[&888D$98B-2=-JHVWT/:P>>5L/6BJ459[Z==;6>VU
MGTUNME=\KXM^ >D_!S]D;Q1)<Z?I^LWEW<PZ/'!>P)+$8VVR2':X*Y!5/F/
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M._X:/\3POPKJ2OKOG8=?,D^][$U](>)_@GH_Q5\-^!=(U2W6^BNYKF\*<AU
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MK0-]BOQ"9(O*4-$8CRFX=N<G]*^N_B!\!+/XA6ENNF6\-]]GD266V=CMN K
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M:%)<LY-)-MV_%ZZ;=>QZ.=\14\MR^>95TY0BKN*6MK>6WJ]%U=CL/V*OVO\
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MV6YR:U$%Y1?DS]6W;'/",I<68B\ H0X$\?T7'U_6DT?(OT,$0*;-].<#3;1
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MM=V2:6 2+H=;;?'K,; R._4W])Q)*0VU6!U_/L<]UHJB?_3TQ%GP9J6F4A/
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MEN&H+ -C0/7=T[GP_QZXB!L^?X .?]Y; <QXE"))Z]6NV.][H"'(@@R2.+@
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MU532HN!_)^X48-.VYBJL/'RF74F5X[)[T+M.$%>S)N:*"$.L;'$.$U@@T:/
MM>98;,5JBTF[3J\(%O70"=:2##BQ*+K/ YI9*@F$M$,^DOQY@*BA$AG.8.EM
ML=<9YBF>7%V]MPCE?OOW_R'JEB..N\$7#LTE%Q%J;(B_\G-=C>W46>:#&[^Q
M^2N+F9LVP+K>U' ./V]@AZD)T8V9LWV'>W6UDX[ON++%U<R[6(SG(8(QPN8K
M'I(9^K]?5-A;5.M<<CVX82]D_-ZA?R=U;"+-VFK"8_7,;:?X! 0DY6"+1XMZ
MCIRI<L@ KX6,75VE4&$=GV%YQQ\4;;W?<..[-:/O@B^[Z=4+!@_1^"$^#_Q=
MZ3ZXO"?,JM-RN4F97%RV %5JUUK5$:NO'C*1/638D2;*VY!=\*7".DBQER/S
MO2J$V3K+*_XWV5:Y'.['? \1)[/9C"ZAT4U0#A::MZ2K&(;RED$LJ^K #8A&
M,"RD9+,HJEBPV./G\':5&:H74KFVG5E KFDANF;$SZTT'G9T?U1==JCVGCWJ
MAU)ER4 /7_Q)&5* 5Y] #8=F?@_UN_PM4FQ4<'2^_&@A,1#Q1\-C*4N= @$G
MA<]F^N\_5U<XZ9KO:M;%JSXZ'\[XD.A#0QB(=1;(^F[1)'Y+4JJT/0?GM+E@
M,O'GL]A>:*M, G!2?5IGYO1@B^RO^H&L0U$E.V/,Y>>%&B<\KF'*/?F&J[2;
ME=(4U![S\D1P7U/&(5LO  R0Z;YK9>6X-]3R8_O&J:I@UB<EI9Q=<B%L!)X<
M#]&%]6JY\G86(R&:_X0N:=5U(;DF_..01]S*>M:=MJJ= K9M;/42<BJGXD$$
M5\*)N\,7>25Y3PA?PF\%^/X",GUSD)L<3=A?>S;ZND;I<PC_B!-.3\7N_H#:
MW">O@J&$U.40B5HBN(T.N*-_S</=A]-W3J4DAB?HFLJ^0A+M<7W"T1:/%/E]
M-;YO+"]*9>?+G Z?7+"R:1;0\H,IW#%!)OOVU4)-H[#%Q!\<^/G*HINUEA2N
M_T(N &1:,6V3(@FGN1Q-Q%80Y8E:O-]? 0_%=!ZW_QP\;+C\!AW,?;:"U7%F
M^2S>^JN<;X'T+716V4)GWV3DR3,^,@$2,G.R!<K?']^-9S]H]^F::,HF&U&D
MUU7O$&83DH-_[*8<C^J-)3[MNK)A.U)J+-/X3>!$&0*N/0B.=W?F*&W"#X9<
M[YXXC<__YD+!?-;8/U;L8MT+D27[+R6R('23Q.V3RJKTI905IN<=."_;-.SQ
M[C%WA4V:I\$W#H%32)L(NVHTQ0'3O)Z6$&@#;.C9I#4Y+$5.I7?TE\QN6N4?
MM61;S^KP5OJN">9@T N1BF(28T=_B"3/N.S3C5,J2@X5&F&R41WB&[\R)K?7
M'5\N=&7V'NYH*Y3YC:8DU#,/0V@Z]'TWTTU>XVRR/[UY'&S=X;>FGZ#=WZY>
M&8((9_J@,BA8L&''2J3K#"4D;6(99\I6/BA>61$*R=* &J<Y?- U7>)GJW1!
M]G.S1WL5'ZI"R2M+P'LN"RQN5$?2!L^F3D=2]UH@QGMK-.[<=#/TYC^)H[?N
MO N[_0.87C@=I]L\S]LD\H.01[)["-GF-CG3QSQW>GK^R^"M][D7/7RO4TR<
M\B^<=E3%YSTN?JZKL"'E7*@Z)V)-L?!J'%[#%6R7VJ4L^)XB6TBKY(KILA2>
M'&4M+F_-I\\N5Y2O*3=\^W;0I4N$Q,W+TL&K;]X1?/2 Z^!HX\1<S;<80OY)
M4BR=P[WSSO8D!P=O#8/X*>*;5A_>YQ)5?[Q-I,?8\MI3_CI';$PW9<KT"[UZ
M/!1#QBZ6UJPXQ++&D'KXY)=>B;AL7!M[MCJPM9PFR#%;<)K0-8T.Q7]H4[%>
M.H[[53>2H;>CN/JVXHF_#M.@,'E7A3Y8@^"PA(<?=U97$X3;@5]8PJCW?55K
M-Z$IY-Q"^:@022C1Q=^PDK,Z:?FU&09\DT82HY24<8*6==<[N%=R$ZFUD"XA
M7G.. H%;2$K'"6+IX"@,="H/KZRZ5B<8EAAXJ,9P/M D0-AI_BIEE0>??=9[
MH^RX/90-K97_M&IZH\92.?/QR8/&A+_FAB$2$-<)-31AX'/E\AT^;^7'/&&0
M%1G=*IZBL^71=@VU0/.3T*QH$-.B7B@#@A7KN^-@J!=D\SQ)1+!WY ;KNZM'
M(";("TOK#<\W9EBY@QGKJJ22_!?QY667N!583XHI+@A3(C+N9\5H2[T^\U $
MBV19ISGW4Z-W# =(%S(W10,B&.73V*;1$#4O>+TC:YOE%L\_E".]SPQ8'6\'
M6,H[400FJO=5\N-(^O9[;];WAB\ $(*2[1FD$/Z;VU$@0:[&\?VM^IJ_*BI;
MH21A;,D1<)K22FR7SQ+8^KL2""RW\5)1Z(=#HD/$)LEKVA\,XZU&*/:);Y7Y
MN*Y$)&$5V4$AFBBUQ6] %K&5"T#X.S*M!JS8/_#TXP-KQ:D"V_(+P!!T'/.V
MHV+S<',T1U91UGUC[RS4'#]0O+^TFC8@L?\PMLT+'FN JIF#^E8;/XWE?V48
ML%:GBHYS#K.;6P*_-W$YO27OL;Q!W+DUT-\G^%_8UKKR./A=3N5N7KDZ3^V?
M]:&.*W>=;BW?GJ1M;K0/F0ZM6BEX!P+31FV;:2]5QENX+^7#FN&)3[.OP:=(
M]M%_/>F8A/:G+"4D^D\JAUIQJ2X'\M5GR1< M2V'H"ZEL[*4TI,T-8<H'+N9
M0(-D4=:[=;HCO$I#!AYMCBN5LMX[+-X07TWDC.FO=4(;[^&Y!\J=_O8>:+9[
M3H<<>Y.QCH2@E@5"6AZS_E5IF1_93_!T#(J#ALJW&RNW8D:%ED[))*R\L-GX
M>>RI]GJ"HOP;O=10ZQ3XZ07@*1&A=ROME4[E?B]72<10%-<J<GVA<B>G$WAE
MUFK>1D>@B+7!>GJ^FR$'("C"E;/P)-#Y%[1R6)5&-$0H>5-9CB)<LQOA95T
M.KQZD#"%?$,(;14I[NOC[,Z5(W)<KA.I<MOT@O:7&N3?K/BA?^!575;M=\;Q
M7M+GMQTK3]8%P.1 2X]\ R?&_';"3!K2#WT[U%V]F!8?MJNR-8&^1%&&]V&.
MTS#Z/%!6CT91O/LT11@X6:V-@ :7S$#LNE9M^V5TWC39",BM\[.?_ G8Z?_G
MOUF;[E$-"6(S<K&XOJ"53;&U*L:D;<Y/H5SF/ZPRR&7G>N<W%I]V]LU!5R\
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M+@(C5?E"'3:M:CZ +$-$'UH8\68,/ &&9I1,<MYRNST2^/KUO>%,TAPY%$H
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MH8SI5<'8+*TRS\#R8&HW[8>5[1FV5X+V$SO >9PX[3(BC+UDPF<6]U_*L]J
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M$'I40.4 HG9O@,'Z<6VZ\+SY%^-#IQM7Y#Q]I<\*>LG'[7I>$/OS VX%;NL
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M 05,BGXB8@]OVHSN5>U-=M\6L*MS*K50W.T>-]?@ZJOOV\W5JK#1%^/L/H8
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M27$E1 7"3^1,AN%>PXE6QQ! &;JE7@K$+@D^1=KB(T0=X!8BF)2]8'RU>I>
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MPFLHZH .?EYV0)FPR*E?]*WRI\.VOY!7DWW)EX*4Q)L1YY)LN.46STGX,(6
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M"5-JD+0)RZ@VE\YN#W5#\ )$7X+$\'M.4_$&?=  TRNC<HC<WYWMUV#&\+2
M>6PNX-AFJA&WBH3GS>VR2!*3U:\F2^)"C.MG3!\YSWU*^5.9XK^756S9+GHM
MV?]PES9S'W&! /&WP@"88%VKWR;^P:2AJBR>F\27LIR+!8,N#@;W_BHQP@C[
M)D,WL^]UYAR@-[9__7K;,]5*T^?"IV,H3Q3E-1FP3XLB >?M'_U#/8+TG=^
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M4@R>$AVQ;^CW=^ZS%<.-PN&ORJ(P@O4E#\Z4_I8J4I'Y>Y C#8ELZP@E?B:
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MLN*[^$/T@S)!CX\?/H)@W[H>8NNEK-O!D?&0(RJ'!:OGJ ]X2@%*'D7)A7A
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MD7MRIE(^VFRL=]Z2_TFC0BU>!T5)Q8N0;A,1?K/F&8SC%73.^3^=34]  M/
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M@4-R7L5[?(*?>UB]::46K'TI]JU1\>06W=;6#S\;44D)S@@OP50)JZ;)FZY
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MUK>2'/]E7PI3=@;OA!LC!P>-TZJ77V9O&3^_N.=%XZI:L?59BUW>A\H'_UH
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M+=I9D/ZQD6W I/)_CDYF<4RUV_Z;,$BQ)./ SK0KUF]">+0PC/*6:XR1G(9
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M4/KX?F;2PN:_H9("0J6>\=]0B9Y?K_?O$N4?'T1]NE1_N)2Z\GZ3E]:?M6F
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MZ[[/-@O'Z^*:=UZGC9%81YKP5][D(IXWJHK0.J?I8]=EX#OKJRJ5=_D9DPQ
MBL?H5[WCO\=)V+ .$K4_?<<5\0:QJ69D?2<A#0=7<-O"ZH3.+=*DES#"7WMH
M*YU/G$G1.)[F;WA&;.+-+Z[!0DM7'LJTX7GYY5*5W=MO'U)+FG%#79$,V,:'
M]7 CT)HDK!-BQ,G;$/P;JN'&/# /56S;UOY[X$!J]7S?-([ Y0MSC"(ED0][
M0:X_=V?PR=U4YQMK_ [^KGSG'/0[-;]RGA$-O!/QGN[K8$1(V,+S^QZQ0L1D
MIDX4(KO+#@3ZKT:P>BP^U]'=A**D=.TEJ?O3(K0Z2!_2_)DV:E#NV28>.>U;
M9](EX(FC 0D!"VST&R(6D#AH.BN/"6I>\\MPT=Z-P"\=M(@7ZR47 G_@@=\Y
MDH:M(YF_+D$IVL^19YC.[4@XGU&C-Z@2#1=#:-0(H5SH+S;C3UJ\:M-)#*D)
M$Q>HCQT$<1SJ<CD&=$?IFZ8M4DJBXG$$2R2]?OW1K4-YN6;^ZK*]$QR!2.D.
MH$3LW<E[B_0&D,/'*N#'YWV$!O/V6493WV-46ZW$[1=!]QMB08EDN+[8NNWV
M)N@>7-C>QZJX>_EU#Z6@-4K%FMK&(O>62Q!"ZXM]2?.Y#,R!5'LQUM3"\ZPF
M?A42%XRHA3?I37@8U%#:=6)O2/EML!UHVC)%,A!&+$(Z/@=[,5MMW7RY37$?
M,*9%:)Z*#*8'L-<B1BN]S=]#JRD>3Z1:IZNW9JIRA[Q""+\,="6_RUE#1OI)
MSIX^-M4^U90->]3Q<PS\!4/8W[%ZN_<$PM7C9-<[(,^A;8*.SAY\9EM.'['T
M,S<XXFMHUL>$V7(\*R70.NCO^1&UIX'R",\G ,:]B/TZA^_)'>>TAKS5XW+D
M=S;JWB6G;K,N$K4"[,W$-S[C\PD;@Z&/9 &S4XAHQ2/@8 ]!=^"SXMM">U!7
M@M,>:9:YAB*AY)HI,I+H"T/9P\F-!XD_<^,(8ZW=7:?YCC&]^ #?R$BY-G\X
MSH!]48M$B#J(::&$WE8SI9/_(KI)V>/>4\S^"JNC#J%[Y["(>.>(+@VK[FSB
M= !?QA2[>I5%:G@P4@E,&'*--M/:G4G\06#R"]6H//H(A7J$^]HJYA!),_9L
MJX82TP]U-GJ9NZ40\ \F %5P:/0*PO5T1!IA>^?6O3F2EK7;^]T[_OAT.YS'
M</'75'GB2T .!HHY8,V<?*,E/_81!4X:U";M7.EMO:%=$\?8!GN<<@0W9!Z%
MY1:ZK6\E(7A0@M2E-ID6<D-3_8RM<A>,KF>WYRY-:._IX0.I?[A3J@EN5!UC
MCAZ6W2= $E?*FD_7=_K!B#LO5B]EW+=S8SSZ"8#]2'[O/B/ZPAR>WM/:&<;A
M$3[-55.S8 UUPLO1D'_Y]8V>MOQ+?"YI8RF&6#SR>R]X3:3$6BG^O60]5'3U
M>6GG1U_GCG'6#>:-**.VND($:R^EFVL7_\XJ@:BR><V]+^P2)-^VS'/2QVLB
M+3#U8]T^>?TJ$8_5/81WD;Q8^:U;ZM<3>/7='W3?7Z%Z2&KCY[HGTCE83[VX
MUD!8#5_YO(H9FQ>;L7=RHF\\YQ$W3_P2@@'("7$3.9GW&M3I?"'.;?]("4'H
M?O/GSE:=XB=J.J5)<N;O*%EW^-#K?RZGD"RYF,."ND53;([P&J"A1?SA]F?<
MT#8CTV1[&M*F<P_G(UJND01%.4<BK#T2Y4X&3A1\&7D40 Z*7Y_QRV;$@SEM
M:/Y558+>VYEO8Y0L]V(>YCCW\5T,;L/E1?94V(2R=*:G4F$J5LFIC\2?+SX;
M)=\?^AM4'>@"5\K$MB^7^R^W1S(9F[/>,Z34BO[@)907<Y/GOZ ]K/_,%"IA
MCI= PSBMOPY;$./]8) QI,\!=F)\Y4!3("3$-.>K&^XO">=_ O2.4]@MD)11
M2)?_;DJ>6W[UQI)P8)L,9<G"Q2_Z F_^_69:.KSRKB^/]E0[#E:V9D*MAR-H
M$#*SL;%JRT'\2S(1.XF; 66&1AA (6(OFY7_HWI\^],8UH>9L@D(I<&(<#&D
MM2Z5J2F+<0'^-G%XV ]?DFZV]?$G+<;J50&B?</1N1_?GH;[L7OZ->SXD#Z?
MU/=R[%T_4@I=T-',EDLS&=$)WCTY@FWMR)?:7AO1V/$:_I 3XY(E%A_J2E)6
M_HSN!M>$8##G8[QK[%IL"#U"Y$[)V[FWD^K>UJO\-\[Z";+_N]I\^1_?)Q$I
MLF$_N15)E5J)1\P!:6;H #5E^1:I.[X3QR/G=/=%4?([H0,3&N<:4=Z-\:"W
MSKW9]MG"\:D;.#2\*'M>S\.*7J308R1%+LBCI$Q8T_<'O"!1G7NQ^:YQE9L_
ME]B FN>UPT;^Y[6$</'GTQ .F?--\=I-YH[Q5WN^.G&V7K8^HB5R<:4^'7)0
M%2QL0A^4J<J T146>"D8CKXAV'M"B,A;[;X69VJ>/JGR8 /)<W+H@Y?2X[[X
MF,K1HQ?N-G=GDYT-2;<[>E]\OEPY3%C'7CVM&8]CFM:?> )<V.N&+NY'885Y
M28\K);*MB*,B$KIY[JD18/BLP6EN4_ALG^Z5H*]*D\='OK1T-GLV0G)\TG<'
M(4B7W5NFYX& 3KN8DWFKNSX!"MRXM2< R;R=KFG)#J14M 3V:KB&XD0CN'M(
M,UEH[#F_S,37E'Q6V,'(-]')DXWYQT:)N]_:6$--%\+H6;>-$@A6VJ@QO'NV
M\3 &UZ2'.+KQ1O^%P,' H#R:!W ']8J_'D+1K-&W/V-U8_QY'U+:E))E-9T:
MFM9:#G,O=B(*&C [X8!0];JV[K-S(,)\ZZ*N.7R8K3%:RI&WP9:%EJTN2 ]E
M'XG\%A87KJ?S]\6J40D#^/9N^&44;(PR4QJ6[SEW=G0,Z):5Z(D76IY490J1
M@VQPA;4.!JM!MG-&T-%'YR0!%^PB*'-G9;7T61OA;UF;OH./ASJ]&M+3\STZ
M#8"#?D7'+(/:LT-/@/3\?0=_X8="_IKP6Y'?303=&[28AM9'%#3%HHL:>!J9
M0W$_0H3&&5X8;9>%B8ILF."9>!^L!T9:37 V/%>ZC8_PG&^MU9"D$Q;*6H[J
M&MO (Q^0A"^6"X+U$+J;+'^*H=;D960XPJQ%KGK=2>-X_J?^-]<)4"%=Z"IZ
M.5K;T@%=86P9$['M]<G6K,'U$R"<6E1I[_!"S& CHHOXE*FW_[0QPMG>VH\B
M"J+\:EF!Y1T2;T_&C2NTB HIN0 @[7W4ZDR^C_.Y>.'U> A_S$XP#UV+*P5*
M\N\J+=P(>I1V_Z/3Q77_ &(HK=[447&H3&=&>% %VH!YLMII3]-K52?9C_E?
MU^*9<W4?<N-3=Z\,]CM3.\"?/NOF/9;RLN?8?K;+[YT=&9\X+PUSEWMA<UDA
MWS/#.UJKL@*Y_;A!,WG'?L]53V%<LPEVX;$%8A,.H3LN GB:Q0MX!O*/1I*&
M9Q,/;J&SL?ZJ7H$\?.E9.4<BKUC,6^(]RP^"A ">R!V#S0A%>X\[JOEN]TJ!
ME +CO5;'7D5',A]G +)UI$40UJ]?\MW"ZMTHQ-EKX\^]3;H"D+/[@)%/@"]<
M/<!/^5:V[$ORE79>0K2M/-_9]2Q(L,Y"7-#<T'<O$.DIQ/H#.97:;MOJ0.:!
MMQPF^B+M+WQ+2I*6V=^J)_"E<]1\OK05O'8\$U=M@S.VE.E__K;Y 4;7.. _
MSVZI-7C7+SFXJ;?EM%M>4W8O>R?KSSMC^F9Q_PE _%(OABQ6HS\V[TNX:(*:
MY*C_R68N<-S@5 P*C6KSLS5@O9:+XHN@JG\^,"%_,5[!L#4[:2D<+D' 1&5,
M.U^=D/4$8./+S+7C,\>U43F!@&_KJ:I7;'2[2P)_*-5X;]&<N6:!^ <V-;\/
M9Q7R^L\5F*=<EU9).RI-;R[U0%XV+C$C%RI_RX9VI)I9S/5I.QS: 3))4M-M
M2Z5AI06$+?GER(2UV^:4.D>(7]8+WTLI2]GVI'BX;,Y.DALG.S0/V5[(&]5%
MKX9S3";X8K(H9/JR;BZXPZ(QMGDYPBE+]-^?:RH<\1TVVC#;Y^SD1"6S%%MH
MP7:3)'TP-5&.9TAIZ49MZM",4U.KY&N?[TDIA3%U'^@<K;J,FC/TP?*^NGTE
MU,<)E0H$NBI=E#L%:Q?PT^5>B[,:V%QI6SD.@.>IARX*,+C[>:12-(\VB2D?
M%E TGL5BL/:QY:4BB1@<Z%0-&!Q(OGCE2+3971;<H,E@BF:#U/]=J.I!AHM;
MM1UH'R]^)/,$:#N0/#3+EF$JL;6=) NJ0&6+3^6S3?@HQZX7Y\(J$@G'D:>\
M;Z@9!YJQ\1E#C7=F7?9TC9X 7E.@X;MR2B^VA054T/?N%I]*./3W^$_FYT=N
M:*$X"AR(/<U.!>4+O P0GW1 :K:78QH[.G_#7KN>EH39$C/#KWK(PQK8^V7/
M],?ZA676&?EH ,C5INJMNS9,#'QMKV*#J-24_CZ!"COY4D8EILD^\L']?H9X
M1C%7\)=39K&B"7,\M^ZKSZ=0^ZA'7V084\0VT>ZZFQV;CV BJ^VK85I?E(R2
MEUN3._X-BN3C)<+F0WM2;\-/TK)DB1F2CI"+F-""2#\6TS/FYH"%))4![X9"
ME7,<(Z$1$;0*X=NNU$CFPN$X)M.>6SK^T?KME5?9+=( >VS4RN2DYNFR= ?O
M4:T[&8L!FV4D!OLT8E^H9U;X)(I90V$,JBLLB%VO4P'6Y,_(QDGF(D5<9$]N
M63 L4YW>30Q%^-0;IF7XHAC)!"V2J;G+[3NNNN'939Z6A4NLFS\.YQ.U"9'Z
MI[]EG\6OT6S';]U<=>,P7QB%^.KZP%F]CT7U7<T%IG%+;!EPRPI1W238I^;&
M2F<EJ"^P\M^BBA?H2IO3_$ERSE'W H_/$*'5O^OB:HKM=$DL"!):V)@W?[-I
M*OH'*UV25.[ DF,SJD'2Z<_9,J<-R"ZK8^134-7DI_=.PFYAJ2 +L+GML4*"
M JQA7[@ Q_X#_\>ON-^*IFE=;]I9MR(%K*F9<<,_+_J8^D[3-7<?)*G;U>\8
MXD*-6;P())L$=(^G0\TR[7B?,Q9;C//A:0B;7'M7YA\P5#CI%?EINRP:K 1Q
M2=% R^J.BJ.\Z,IX)J@Y)??)W.4I'(D90F+T'B?=J237?JXCW2;RWDYP?ID8
M;(9^4;A,6,B^$CQ%/TRIM'7=3X>]A<97Q6VMZ@\,$0Y'[(:%6H0#0+@^Z/$1
M5"=?Q+&,O ?7QF/];:D?&DCR<-+&R(^,!7@,LR.82PR$*.6&QM6E", 8TLIB
MM/?<_;B\\FQ.[XTZ@Q^?&WL?K*W&B]JB%=H[VZ\%UGW^-K]IE7QPQ$,V^Q$=
MQ99<>/^M.AQO#1=R]Q[Q;6=0.7E6>?I3,\6)-HQ+7E&,%1^#B]YUJ+L+G2FE
M"_7+%=N"-./BHOLOB$C@FYW*7BN@5/^G/.:IPXM.?&/@G!U+E;[!\&2O?R(?
MBV=1W'[<.< WR&<  Z5$78_H$]'PDD>T(QDHSV1(^YME7&WJ\EZ>W4]A(AP0
M\;9JCJN2M_PFL7"2HH=&;Z,]M-.\)O26:9 VVC<OI4;6XW5J=;!?^0!=3L^*
M VL)CRR#FYO(!&NR6DS*W*E?##_'5&E3TYRX^KENU6/_$P"]P22!]@6$FJF/
M>UG>UG'];EG^6=L R?DW;69YJJ2AS78?F?R7-IM6^\,8]^6,/"I.U#&T5C<^
M!TKX6?6)TOP/-GP[+P40U*SM?4P?0?ONZLJD&<P89,G =80QCL&T8V-6\Q5#
M=!:6"6>(M%Y=+BND_UN9$/CY='2\M[LDT;I1L79Q(E%E=1CE0M:48P$82U-V
M][7&YS?HRXVE(0%YJ:()$%Y)X+;>Q_DI,!L)L&+W_M(*92>>F207><V1%E@Y
M^A.D2T#(PUJAFL^'XH7$N:EBM9$F5#<3_T.^@+^QR-:30OE^JO*8[_D[7J7%
M4957XT"9!+0@5N.$KYB5.4(@75!T:73_(!$2I,R<V$P#65N$I ?/SJ#BYJ"K
MX-G7Z:,4CM^L#;PW-4!/]6.B((B%Y^9"X\75 !O/ N<<F%+N*FE/:<PHSF;1
MD\U 640 )DJPB=;(]_<]H(+=)*@M-B$__X(_\TQGO3B=;;(UTM;9^&0P[3AQ
MSYX&'KL.++V"$NO.9S84M7(33C=AR:&=,&ZRV-M#O[Y[%':*HHI5QPC-.WL9
MZY^"Q$R_N%O#/^WDM9EU:_Z();;.7?@(;0VHI]B@);31.3\>?+9A%7F^M,:T
M9\*VY_[UXRBZ$;EQEG6AMYG_Q@\<<2Y^=-^U>R8)A9,&6R_FZX*YJ8;Z7C^=
M@2QRBO)%W)L#H$ 9$1+(<4;7'JZX:06!8PW:;N#@';J-F29/[<#.:-_"'E>4
MT,.U?BY5 <:>"P-VFKUY7'7PK<&HPZR*J8=^'=EWIGOB1)W*NCV=SP-HO)W[
M7"W79J#6/P3<:&]LL7D$TV+Q6%U<]XPE0/NZOL<5'N4FJJ^AVQ?CKJZB<2W;
M24-6GF)##"E:8#SZJ9H@3*U+QERA7BVKI=QH98T7]U!G_10[XJK4Q% M&P?@
MR YF(I6V$=,.L?=@LQJJ,Q-8J\6_7>^'C'2ERGP!_SZP*<91M6E[5,K,BVME
M3Z?Q-!HM">NRO,?_":"0V;'];A!/,FJ=,ISUEWVP]A$IEZ[F\02*GEG<*@=#
MLJF[>B:BP).N(\8WY[IJH.XU2+_#_%SS@X*(&LG+[TUG #!S2G0-A>-NB2I1
M034S+0OTG@HQ4G7_['38?H%V;CNCZRI=H"GQ!M;4>(;40:Y)[_8=130T$=>^
MK?:AAJ\3PX01M&[R)1#/7WA#*,J;GU__^''P)>W!RW"9L\G@;15<,1SO(5-I
MF?%^MB)R]2^Y"X^=ZJV7E^.1_ :@NX,HSA/G4K^8J"W'<?9X1=[:8WF&K#)G
MITJ[WGK:GJ+HS$(KK  >&QN>%2@[QU>B*D%,S/;(--RW6FZ]\7:#F:.X@CEJ
MI-S'1TU-*%F.D$).(;"Z96L:VZO2$.FF&"PCY^[QV  Z!,HIYGA?!T6;O?*[
MF:-/#AE.&PPDT=KCO^+B<Z6Z4?%QW#T;1]F'*!(R%VV& !8YV'F VZP+/*+'
M$1IQ>'780XG'.FC/H=$GW,!!M3:P35O>P2](MMU=IW_BVR;%M+K;I%&)U_;G
M1RGFTJHK,<U-YVX\O$=8'J =40/_-N3H$6.RXMW4X[HV:LN""NG#Y&XQ0%W#
M?C,$>&-9PX3@.OW\,7Z\9X4A]UB4ER^;H]0Y]\*6:M/7ZTURH _&6FPB"L >
M;VUUP 3_<?P)@%]UK[R>/5ZW3U)F7V31ZT5 UZ!1+;/MX/8V-.0Y'<6U:MP3
M /43WL+B^O9)OW,82: %C*,[I3_O10*:O;S<ZVHZ]>O4[RJ ?Q&57AL'N[*@
M3%UKH.^Y:I$1^;A"\?<IX-[DU5F 4?Y0'LNIU_JO%919:TTBURXFF\BH^Y^A
M;E(R^^I!0DQ)(7AV77#9X-W3\5CV3W?:2U/#Y$-WM0/%)&:? ?=C@*W9&ML
M*N<86JS"V<:EU<6?SU(/U8=Y4;NEA&A[;HP.DL)1@\>D+D[F:]9D\@ML:HUM
MO2062*_K$L^69 @:X]\%CP'V?80E)-%W(<W#WE3/@&1?'VM53H$BXE/.(^!+
M7P//\?*RU'=@O1EE/T'0_=%V8(O]W!5M1"#ZB:BRI=@E_&RWV>WTZ"=+2J*J
M*V*&AA%!_P3 &$OU*=U/^SYD[1D."\S H,*-EUC00$+U0EFI-K%O+?OB%)YS
M>R#%T"Q"_\Y'+&I75->RS.YMLNUDMX\/;@5J$'Z^U<W$;4@[]_ZS (+0/ITB
MDP4608'CJKP\FXO3Y)I 6^^S$4OKIK0T";Y'7O^7T  ,;]BF#%0]VY8'N!36
MYY6XBS1S,6[V-C31SSHFJ87_UNLTX<IC.H#-^V.51XQ :VWSPU';:>-(C##>
MLTU_?#RS8GQ?@JD.(43[GT&].1T/JJ9QI%D6U2S==1,KQ/",F1-E=Y.[?-=U
M]ZGF]PKE)J;0 BM9Y_*,P:I<)]]*/I.C:EI-A/IUQ8_!V\E<P6[5R-D5\8>4
MJGN!YN86>%[K8<C[LQBKIF2;:YIL]<G;*^)M<4Y$B\]F8$BB#2^)O1&6QHN>
M^S!W[HR6 1Y%089D5:F%'ZI!MXSM\-WUZQA'YX:#(]9-PV0VK?@SM.!H6=0=
M&:0@!A0&<S'ADUA=WN)[T7P5!.6N7<\ O4\@)<,U:<C"J\IDJMTT-\585%2X
MJI2QM.^<G?XN/]O0.9,E^(3RA]?)$P#;=\Y0M"RL+5EA;/1WD^\J7+1^I?$C
M_-!7.4<PZYO2=P4D.<WM9,.@+I3%;;ID7S0E9!6TO(P.R@DG&ON#;$?IC9>%
M3?4A/NIC[N=\BZ2TP30#]:*NFP8)-/8R9Q9ZYM+SJ'1;,BU#0X/LJ@QK%G
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MGX?@;4K:"4F,J)1K5K/<1194FWG3$X9^& DKARD7W,TDA4Q.J--F?M>*O(L
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MLQ!H=+*XE<.+/$E GO+;ZRMSA('?1A3_C\ X&M*8KA/WJX0Z>>S51>XNE4U
MA)-2$'70H]"1_FK]R6 "VOW+/[-*"P8#PM+ABP,D@A0OCC*+9_CN;+GK-EU$
MFM@XY5 3R8*3T:QV*9OHKUA65@*AXQYPO- VCU/= 9T BM/KPX/U9;9NBH9\
M2Y^+=E8VD78<@Y>,\M 1ZHAG\<+D0H?^JU?L<#9_WH=:4;_U%L:[][_?<K:4
M9;HF\ Z_1#&OI4.V*\V'9_>*4\Y(-%QV+BB(*?;4.B6^+UXU%J_]5"1"\)'A
MB^<:H1MZZ5MWDUK9O@?T+HD&C^6=]LK1LCV*G=S TD";U13ZGNF:XZV,V#,Y
MI 2EG%VJ24?L&Y/Z?$[8POCE/O )$&+-N!J?-=CTA5_B@21U71P/#BO<6-88
M5)XZ/.;'>0>//#H";_(HBIB+:,O("Z&NZ4Z:U/-XFUR9/923#&J=#D9XQ#%I
M3W V['F ^=K2=-S&OM!YTC-1HLF140ZHHB9PG:J&;SWDB=//T>(@IN5GN2[F
M8#O4!N^28G7.<D<@^D$CS[;6\%',JVVBH!C&53F^)8[W(VQWK_TU%I\ #"<#
M@0B6OV^XEX[<,=QKT#_*K\8^ >":?]=2&]!?01%-"3?, 8Q/@*[@OVN%E>_L
M_(UQG@"O7_2M(O E$%E^"0]%=YU10XC!-=VX#DI;Q7+OF![C5Q.'-%+/FSN^
M)S^/290S^@48 JQY];O7=F?=TJ\%'JW62%4:_>XDJJYN\UE3Q9?A\& S6'N=
M!?53QN@2UASC30F2PD:JPENHN=)-67-H#*"#/^S>,YC@WDM'?8HSHV^C<TA"
M[<-&1Z$C1#ND04%&GG,!O>94J!P]FG\"=(LZFJ+E3'"R\N>[:W4WJ=.71W()
ME7A?X_DF:7*H8F0)(J<L./&K',^.F.\!JYY7-BDVJT4E91,Z5#B97+_+,U-7
M4W*GX59U)<;:<?#5R<N8!XYJK0I";.>JH:6O?,(Q*GE*&6YA7YH7M:KC!XB(
M/_YNEE"(WG-9!4J)<#!\:2DD?(<WJ@.>%K-C+NQ^ OB"!Y"9"P2H:C_:814V
M0&/C(#I['8'7-FP9-2X_1F6)JTV\/JJLME?V^=DP?+*M5;:V>[%>"[22BA[M
M:%I9Y0!HA^REJ5^"'UA_6_C! $W,#ZS;X*'(Z&<S!T=6.L1%%E+5UBH=PY=@
M,,\AJ>%U@6K+M.VILPEPIK9I/GIT:NLG<;LEO@L.NF@<![\ YL0CK;FV@]F-
M&*\N=ZWK*A]9'NV?+O@5/GMUW<,59LPJO71U(I[.B_2PI:NF"A.H^?*I88A*
M=Z_L:'L] :$2N)8'; CV&EUW!*Y<^'Z[R::\^#J[,QK6C*JALBM#N=9DY>SM
M9,(J9;03X8O,Q;^[8.[CAKE_+^;F%>_&DHON:NW:ACE3[P^CR9A';CP<D"MP
MU(,V>#(MU# O1Q?:+$H;ARA%/RNT0OG^)P]-JP9KJS=1)&4+%5B**7#QN^MO
M$)J4."K]2"N\XZD1*E"5G%Z;*UII2'M#6J+]Y0BD/G0V\<Q@^V'9LHFKL>%D
ME>$.\Q=;^[DD*;NF70XT.GK)45UC-QHS"J?WL))#\.0M%"QY% 7B.B+C(W2V
MW?TU.%5MCEQW(7P&*7\"\$P\4XPZ^QPF0^OR;5L@Y4!)I0%)<(68 1.<,T,5
MK% #^3-X>=K#IPN%'*$:/3^2D\!-%+HX??%*,UUX"E&O7G:DOL7&-+/K]_GV
M=_PSB42:%W4QMV9B\-&)<+?4^AMP+_9>$)LRI4<[))WPH;/H" 'EW[VJ_Y%8
M66"1K ) :6%L-2&]9YM]I '7VP,M^Z.78_L.W[/0652PRF&+A$C1I,:9[P"-
M!OF4Z_2H+60N++O1X:\ZTN #^1ZGL]V""VEYCO?O*8[>EH8RE#B!$[Q4MJ7&
M!HUS*:E"ST6ELLW.]C3 *OEB;! 1?X6K;7L#K_;[5-BN%4D<:Z5"<8N)ROC,
M3=6[ JT83//C6<7-FO S1( B*$ZXM.U[4Z\J533)?M>+P9R\W"^AK'YKIX9M
MSDD'QC \ZO>DTKJ](UE<M_4&95N7PON:J<)N0WKR](,*%S7!)@W7T>(8J^^=
MG3W<0=Z^LLB;LGDZ-KGN0U^V,BQH>X;BO>EBH\]3SBE:ONW/BM/.?&MK\(C?
M0%;@EG9I074CP_<6ZZ[L4X^STRC38)6_\),PHMU290TDN$ _TH;3RYXV>.9Q
MPI5X?( E=<N_TG$3&[:;+2W-,,?*PE']E]US7NS0XE@CXNZX$1O3_4":W$J]
M97U3!?\4CO9?LL^^9;#0%=(4X[M(H:(8=&)W.JB2^DMT)IH8XGC)M:C5Z_U*
MDJ$?E T+(:#$O<>7124P4;DG0=RMKR[8*[1/3/<\,KU8>K^=J\QWIZ<Q&G)?
MLAOYK1F=BFQH4*@FZ2HS3U.JXFPLQVDZ!9)^UF)\ZY"=<,-10B6:'#M]>+NW
M C,14Y&9[7ZK>D2^CA,XN(J1VV#T7B>>^=YDG<[%L900S7;3$!O$>=Z%U$R/
M_1PD3H,(=8;3=]%X]-F^,BCT^!A"O9B(<30.O,"+T'DK<;BZ@2/T'L1^&UW*
M>4STD4%#TI*)B?6-'+I0%SU:Z^JB^UI"> #=/6.VQG=[FTNL*$(Y)8T=MBX5
M%5VAO3$9L=O97[/=T^/%YYBU6_*OF05;&^-$F#[S&X%KWM?C)>C)8J.T50S=
MU4':-3NE)Y\ O7DL\$W=CM,-O!>&[UNV GEX##R[? &=TV!/&E9$:1[6Y.,D
M8Z$_I[F&SO+WHAIA#3F45:8]PYI>.=7>$T"JAV>2>9R9S8BU"P.W]BY*P1#5
M59DW>G?:$X# XP8B9L?HIX_V\UOF& /=PX8(,WWP:D7-1-TC24\O9D>9"G>*
M :2Z_3J0/H4\4QCJP79 ]H,A[U'1J!W'^J'87\KOVWO"]]A[;GFF\0RVGBA=
MY&2 VS6DRVH1-43^)@Y0MZFV]H>\P+'<)@1SZV)MK6E[U _6S.$O5K!W:QS?
MV&K?(9G%K!4\+62<>5V#?;H[\%FVY_K<<&%5V-Y'Z9UMMFT*ME8N* QPBR_#
MMNG.B99KS0PZYP#;2W \ 91Q[^LC6< L&CK.UC>'Q@A7^*S>+$38 X^T+;&?
MX2-#0XO9]%@9 H,AH_M8A2R>6!7XN^-MP,@*-6)Y7=%>)WQ3J66**%L>#,!"
MQD=2IW'1>J:&- APS\G:I'OXUG;E%U/ON -0%P"4"AR_\:5U88T(?N2WTS5^
M8Q 3*(QVZ<SF*=UC@<8D/M@$ZV0OB_SU76]$(Z9XK]WYA]^?%!*8[I>W\E;%
M/J](53EM)1_6Z;J]D'#([[P>-0\Q(9+G\V:OL#6O_8E.K1^)_AO'-4]B0E0"
M/CSQ.:%7%Q@+BINVTU6190*P,D[('TPO=!2?YA6Y<D4[:0C1J-6UX3-.M[Y3
M 0P6B*FJ]'1X( Y.*S3[=77$:9/\#_RE/"JQR1DLUY-18E^A).JY#0K1F4MX
MI.WHK[A&7A%4'D(<_2HX!+?EER^,_%./O&,YT9&DM5+YEAH[P/?9=4TZY@@V
MV<^>/;:7-1$4%=]3W8EAF65+ Z><XG#:/M['(>*R-:[YM-6-T:N*AX@-LJE9
ME2_"^D=42^CF0;$%V,QB>FL)QUGGE)^=]BDG/:BWIPPKL!GU,^3S6I9S=D]K
MK! >=]ISB,#NA;"!VH?O_I;/VK[/&R]4\@$S/K'&N,D_4[+8]<9I=@V249W9
MX/$_>4;C_P-_7UA?:,3 (=MPM$;$R)=WMRBZ5VM'N]!I- #(V9$?O.86TH(S
M8T'C=\&/GM1Y;SMV!S#<!>"!Y3%J.D3CBX[6%M +RB_1SS;Y3>609TCM=SE9
MB*"Q/I9F=L?IGN_6KLHMZRR/Y/'/9$MX5*(7?O-H%CM>QMCZOL=LXRQ'MC4[
M9PTO^IBV'#W9E.WK-S&RXR*-XK3#1](&G9N-@_#,K^^-$U8L3P7-A4=38ML4
MU%Z_^2*>"E1A>Z\6@VE/L[-K/O$A1CVNIY3 ,:%$IS90A/I _>/25]S7KUQ8
M>)Y7<*983U6*#?2>4Z!D)$XW.99650Y=E@[WGA4D?\BXG?'"25**N]9:YV'&
M4;!W;&FOG,K]%L1"WCB!<FWJJ@TAXOD Y9/E9V_,_G99("B\20,#4[_2B9UV
MNMA9/HMG;C1Y'>Y=@/.S^)P09#3@]>) 'F>LOR(4X\5*(O$[\P.5@&<JIJA6
M&? SEM1AF:"L%F1+:0&AJRM0VN01-:M/Z->$PT6=0CW/%"!.#]3J)B/+7FTN
MQA8Y"^]$6H_ F6C2/C.49B:;(?GY-?9TR49QN+A81?U@^HVO^B\;'B*1RE]J
MIVH#&1M@&>_!$C$R?)5L)/Y,CH'9:T8(UX#I+8P]YC']$,T&16'NA-C2O*N<
M;TVTL\1 /45F[35/P#/%E\B%3(Q12#H?PR5@%<.Q Q"K4%^H/MW<,HN3RL"G
MR*53I7CJT5$3;A?O<AAM7MQ[E\904Q#F&Q8SM6AE*88?<M>5&+B9@MB^4%V(
MY34(\ZY2VFBN0(#U=;V B-8!0/W:;M\@*)<EV>#H1%*NR/6,0]<@QPM$6F!-
MK#O4>Z?&6/76]AH7HAQU_O8"I%1$UO]^R_+VLL"XN/$HZZM[M(/GKXJITG J
M"ET*SV>0%19:55UB6_JN$O,L,VYG]BONJV+(4KPXQ/.!9W!)FRR?,!JEHKVL
M>J,(\HE"?:&G99F_;M]/5ZILJ#$5TL)E7CJ5C:HK6S;4P.'6:@ES';/W'?C<
MI<F=^8,J.\*8%=IR Q)8,68]:AG 8:ARS]/^$R&#X>/W#('UM+VJ+UB/4V1G
MBJ>WG:73Z/\0P^=W;&M/ #Q&A5O=O8BCE+]?CM>3@*L\ 2@,*D^R>YO>[-N(
M!%.5ZST(_)C=28CX2?EYSYU:R"1\.7/65CY('+@Z;6 ?W365@-P(-ACI5Y^E
M+YXN'C)1^/WI"9!/_--VMMD4J=\CB^"<6RH30G@H=:!C+H2<313(O),TGF:S
MU'BHA\Z'=*[M?3P;: PQ]V90DSGTR@P]D?SZ_4#MYQK%)XX428*EZO-H!WS\
MNW;6$4X6="! VT&C7LM-B$HKL29#&F"U7TOB"%76Q&;S/![T/6,34$23YXUG
M1GY,=X6@^>JDQ T]7IHO"*:YZA:U[NU)$HC*!DZE:FFGJ6UD7[DTM"NHLW6N
ME/5DY_@W7$;L@O '\V:JY7ZOK2JRHV)",#_:Y'[_:EBMD=4?/!6"RRHI5,8G
MDAX-"M]Z0V.W(0NQP[)WC%_9Y7?4W-HI4XMF&QJSDZ-?>F-;R@,L"7-95?@6
MY9_SVO<)<-AYIRT+=UNY[@G@K'\"?(E9KXF,BM&<9J <+72P\I;Q-G610[4&
MA)"A&,O@C6CQJ[=T8J:\;=@4.OOY!WI!5]HI:T;0A,@V$=\.!H3SAI)BT0&W
M8 :^@%R(&1I*\!\$_X$>U!6\C5^]3;R_6B=Q9-B)OMX!3XAE?P*LOT)8;\AP
M[_L:AOX2L/R.#<>&]X9(T@NAXG=13#R4!UI:(5Z^3H\4%?%[ F"0]M80('$F
M@/J\ON DO_P:'+1F@2RY'-IE*FG%9R<T,@]=+3IY J">7AI2> @_XY_#M%;'
M?@+P:V;@LR)NXJ3%JG=&5;G91[P7&8*SPN7F=$*[)$5=E;SKVIGG&#1#%E]5
M]Y- B>8^@@CQD_RR"H!QHM$UHN+.,VJ6-PE\EXX]:5NI 6/#OE;%\8L[-ZW:
MS6HBVJ%.9+@S<02R(_VZ+2D?B0O917A'K0V9O?@_S,<I%N5!B/O"(HBV8A/:
MS]59G39"%&JI^ T3"B[+7S4N>>]419*91^LB:7MEI1Q*Q;U][B*V[_+#=YI5
M6O@3M'M077\<;1 \>!-F95RZ\AD'-=G6(LK5B#%#T/16E_L/;*^"/V6]-[TL
M^D1?,3F7R%8\M2A4;:"4PRFB*UVZ%,O%Y_"1OJ@Q'>"N>9,=9[6HV(S91)59
M89LA]_L2#R<A<K7>NN\$^VCE^I;A[$/G496#+LU=DOV9IE(^<\0,]NRA8)=]
M@PDEI;ZXC?-1<5CW;QG>4 2*2;($H3\74] C"R+E?2)/8U+ETH+I)=)K2]H"
MH@^SF ][7#("OU+HQ"&SWJX\(X;QZ2.<]G7P76P<]1G/+"6]^$8Z),G+JO;7
M9R#@4,^$C6&X$C,(ULD#8VY9@%84C>QNQ"5E@JGT$I:F]1RQ= IC/GG@3!T9
MSARB"/HW#(<H?H\ *U*M3Y6C.R\P$Y[#,MD2@!;.'4$SR0&RQ(#&(9"4&\OS
MW:F@9S>Z1!LWQ)0=W1]D70K0C,LR,:K"8SY6QX$%9;6X^'H,A HP;S7)%IHX
MML[IJ_2*[H3)]W376WKNR\  92\")O[G"<ZPJD&N#+'?;RINIZ2== .^RGS)
MRMS8)69PG=K!/_!V*S"K^IR.E:0"B;$!8;NPN'.79SZJ4'PM!":-[3+FU**#
MYFA*S#Q_BNTOMSJ;E+Q9L))4A4,CB_I5WWR(-WXFP'#37FD0>=W^:C!:.)I=
MFI38O;>#::8-IT:J<H]TEL*ST,9+6I13.Z)<+%*L^Z=8OW9"/*O(=+;[R8=O
M6;9@P*U)=R<IG\3"U\4EPY*.J%-SA7>.:2^V%KWC)$6*J#9'/][CS"8EX^K^
M$@U<X\#K.^-?2:! !.KQO&F=8A2*?'/7+S1L"I=Y(T9*O FF7UCM9W<3U7CW
M(?)W/Y ']SW*#+X/ZB?^$QH6^/83((Z?&VRGX[9WV]8(FS9<07ZGRONA<+ZE
MB_W_X^HM@^)P@F_1)3A!@KL$#1[<(4#PX+ZXPRZ+!G<([@Z+A> >9'%W"9#@
M+.[N[O?WO_?6>Z]>U7R<ZOXPI[O/Z>J9\3);#*%"I^V2&#_''[W '31E&"T\
M86B='FO:;.5S;4(%<G#D6(U3Y9!=!TQ=BLZKGU/!"I"?5%)+9>-')187DR0/
M*Q$T<&KYJM;C0\3I[T/\TQ[],[E9*7CO)/;/Y7)WEA O1VJ,SW6ZRFVA?ITA
M9I4+GYD[F:FVRP=)LN.:Z<GBU;KF?LVM3SMPTL?([_GVY]27#B/C..>^PK:T
M+MZ3CPA.YU/9MIEDPNZ =Y<M^QN7Y81\V?#+ID-G#Q-DMO;WFPO7+Z"S$QZ#
MC5-UE(5X4K3"8/D;AQ_N9R8ZOASW.1LG3+?>LU7?,S].W<1&([?;[- +W,F9
M]9!27IR8B!Y08\/B\>Y[+*9.J!Y/10GB17ZW#-Y9?]26<Y$'.!O-]Z/!SE!
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M_&1,\J<>LP]1E!*XUK[*G6[D %M97'VQ?\PC\DR_U9W9E73;8)=6O0B-*6P
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M,(:4H*C^OQGRY3YD!]>+:0R$ZF+BF@'?HL?>-34\=80Z@;."KW!#="IK(L5
MD7[Q4E/5ER&Y8+UR(^DP;;-]&>=7Z@[N06YP85TS[6>> :;?L8+L?1C3=?'O
MKRO;T)L1.T!?%@QGL"KP)FD <3<3H-OHC^PP!2:F.%B+,^.&_AWN0Z5GA93]
M<-R[2VR69:X?AMS5/+DY+Z!EG0T<1<@? Q%-0)Q1'Z5DF87RGH/XG<EKAS1&
MFOBL-QJ_JZ0Z)7)=W_UZ0*B\.;J\JY(DW2_#5S[Z<X?H(N%548Q,.GK3*(7E
MPGBMEV0)D,X]X]TK\85,^C-]'N:S0@;,B%9]UR_/'2$7-Y?$23&8YW\NMU>\
M 6"HQX7B&"_1_:O$'?][J*4KHI8CN5S6XX&\59)K"%,((8+T?S=8XO@Z61<E
MK#CA>:\$_]K/NR*/NS9H[YTWV0;*#S1B7V6/$7GI1#^OI_Z?*QX:<5Y3*0PG
MS(ZS'F^ D(=<*2]"H\'I<9_P$YDGUO@0\\G^5=+_XV\R@HLCM7SP/W_U$8R"
M&^$T>"A.D@A!A)L>']*&2_XXJA3:4-DF5.9)3-4 .X%UHU[*<Y7Z*Y!D!Z]?
M#(;MYV?F/A@C,VLC 49#, BJ;CA-V68M3(8-&\5V&8)K(&1S!.2_]:E=+;5S
M5_Y4=:2D$\>5RR*)%3:N>%WJ]MZ,PC+JGXQAO&)-.<UW&O>?913]]1G;#JS2
M2JF%) .ZN7\RA:T;> LOAU1L/Q(3+=,'"'B/SHU$+4:=LW[GN*XTP:<A*M+M
MT+YF 5)4F#CDB:5'W7 B/7-TALN1Q=46'[ZW8,%_E\_5<)( F)A"01A!"O[2
MO4?@BWB.G)M59'A? YPZY9@CE;)#IQFH;]WS/>9*UYOX"]BB3\XV[]#LS<5.
MO@V[&%6H,@:U6L<72]DD0<1IV-^5]@Z6G!;P?R%!2LX.F6$5^"7*YFZZP6FE
MZE_S'+WZX6_ ANF1#AE."(0]\^2D<_JU%E"?9;V6@8J4)CCR,8(U!C?11,U_
M,@__>]XBZL:T;2?W3,U984M+TO=F&"QM$\DUT$SMY_JVC=B(4 ^BA(BGC\*_
M-X!-%[X!1V+)@YX^8ZI5"\KESA>V8(^-5+USJ75ORTO!> )?EPN/:(=3\=E2
M9<+FA!%,1''E9GJ\4@")YOW5I''G*CE=E>8J^/'$_U4N%D.C]!3V'RCVEA]O
MG:VVJ(D,84-]*_Q'7V>H%*[O:_(AR?6UC-;P2F*6!9KM/;%W@3SMQ$^,GL:[
M1UJU]74M4XQ):*<.["<[>))(H=$L.QY<L;V$P^9?MFQIDB]7:RZ&#.<L@C<W
M_:3(R3U_V.ZOF@^0O4R%4'P:^G85YSQS"Y<;4@:)Z:J&*+7/LG^OL/7H#Y,D
MF&XC9#O]=]$2+QD,6+?)3JV+2MF8%.1MBRLBE=-I$ M;W3S:^-8$S;GIF'FD
MRMH%,3M2<!NN $K+N_DM!M]]"+H#8&PGH?B*W";=ZY[?;9YD=]*>8U<X2D3L
M19BLZO<JZ/M.8=H%N[:'!"L,FR.Z2%+KV+T!"*[7J)[9YJH;!,!5P%W*=*C;
M=L4>JAHB1!L0O.ZB"[AT0J/ME+Y8.RYS7?=S'QHP)D]U8Z<52>0;"6J'N6E2
M3$ASL?60!EKD<F5[>_%]&F5Y09:M/%#*10TZ7*7L/&_\=>L=6C0>NZS'B7F1
ML8) BA2,T$,1LII%?DS)^A_'-,&1OBB5B*^RA/T[/AF>NN%O22EJ-91%T(W-
M0*S[LAWL'%R(/;M)5IPHGNC#T-$/(:BEX,[[21.O'HQ&]]\*T>]_;.=@(=PJ
M?E$'.JZR:Z0MH189&6=/0RG'LC?#JMT("NI+Q-)V=DN2MPF--T]2G.4QDA?J
M8.(KBE2IHBZ.1ZJ>PX@$FY0.NBWVG'RI966I*JPJ)TWB\!KV9LN;8B6AWC95
M49W.$ 3IQYDD._)." PTM3:BDO*89$>?U[+Y6U3&O6="Y,* 98.VDM(+,S!/
M$2,QA2-KG"JLE9);^2)DC7!RJ7CW8++(T;;QY#>&\D*(QLIOW;B'JA/L(["W
M#GNED#@,5M07-S.<)*+\;G_=HSIJ%7+(&O]O^Q-1:RQ?M"R6TG*O3-]E]KS1
M>A66J,<Z#H4G2++%;9S(\]UCO>RH!'6&+D?B67PN:_7]1W_>R0AWT)J[FVW$
MZZVLW"'+-Z;SO(16OV0@5VQS$JUZ> $VVO/1SW^O&H)5G'">7KF-H1/*K1Q\
MA]GIF[:BF(#?4T3&8OR_*XU8CL UHA[E"S=TK!4Y:;$H;X#7CN_"D! J+L.[
M<(8K+J.P3);^7TF?IJ9/^$LG@1T41R1'4V727JEBY0WI2SMT8BS#PK'<U[AS
M#5O9\AW@Q*D:4IM!SZHG+_>8*<5>#I*4#KV&< MMP<(^FRKC1ONI""+*?K"^
M<.]#6Q><,)]U^WLYL8U7B4NA.;F+09%^&$H$]JPS)'"/X.$C6^8 M^(!9PDP
M0UZ^5%O!(=5E;LWE+UH2N5\S*&],@YG_,Q#U77"AK:>-U.O*3(YE ,O4'&-S
M:THVVJ9QB7AA @JWBRQ"=<7&:>)+UZ;GLUEI455QJ(/6?B,>IP ;VCOWZ)Q2
MP ,BGNHJ#1YK3F-],Q5*AU70:17GZ:^P2WKIUV*VT:6LWPQ:",M;HCK6>9O1
M)ZK:/UK4+E6(T/YDI=%O 0*=WL65'*E-9HVSMFAO&] M^-I<5 !?IZ W5=4.
M55]ZH+0\1*Y)W=E;<?('J\T&D=7M;EOJ8JF[%92Q?R1WDZ3&8/+;OC\=*'NV
M@@Q5AU2CB56W#,0XR-,]+8WN6,U(M-BZD66L)P!JKOLB'M5;ZQT[J8%Q)*?T
M$6'P>6(!$GT!OX7N'N1P.I(A5,'J=G%JN$A':ZZ?L.^D45S4&V"C.H_;RWV2
M<K:J[K@YW>Q/."D=I@>>6+RJYH!K)\5Y9]>&-E29:H6IL44-*>T8S0E=T*('
ME7*87K? $[HZW^UM/P\LVJF*>4>LY/4+\XG>,(AJ=I@AGCYQ4*B;;WL5;69S
MAE.B@4@ *I0][DK#%N+_A:T X.*$MHUY6V,>1A7J,:(@)MS!^>(NPGPYFUQ"
MLM]Z(_SCOFA3@;>T(6-N35%/[^R*_XRI#"FNW3MHZ%V;R8_7][.^F@$4"6"/
M#_6I20KJT<Q(V_C4)%0/-#JS-;W3%0=)GE&7)-->BSNC2_,C</ZDSL(;NB3T
MLDZ<6$4LE5TCQ@DE/W;ZRRG)I^9-#702]D!)A$C2=<QKPKW-SQ<EX@K\KC,Q
M'W47^5^4X\G]Q_W99MJU+Y>*\QUV;)(>\3X;( IANF"CBN(NX^N]BM_SN%V0
M]_#H+83Z22OIM$XGZ2OQ1K5<64C'Q1&S"..A?IO_NX;8R;_DJRS[SRR6]V@A
M);\%JA%-RX% ZL#]!5%\MR4OWIOZEBF.DY.W2QBNE-+DXTQV\B3"_+%;,U"
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MJATJYX0> $J;PUHHR$#B?XK[<J135>4<#VR!6#6[:OIE,,&D$PV+?98LFOB
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M3# :IZ$R(+R8;/7-4O[-6=MV.M3/\Y:K%GR:=@M<ETW3O+[=*T(K;RV!I]J
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MJEFZ 9_+K3E*P'J_[*/[1\GPI>Z\*Z_ITGB;X?\ B3,6IZ0R&5H]PYGA7J&
M&2HQG&00R@U%^TM^R?/\,]0TO6O!IN/%O@'Q5*G]E:G:CS1;;F \J=NBE<D!
MB #@@@,"!XWX.\8?\+#\9IH?A&T34];TZX<WDUTI2TLXO*XF256#1LI8@L0<
M9XY !^T?V#OC18_ 2;7-+^('C;[59ZPD$MFLP)LK>4;A(L:!-V7R&+GER"2
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M"V=_Q!(RE8=IY^48 R!P.XZ4SX)?#VZ\2+I*WUBC75M<-<3)*A>:2%7P4 Z
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M1'_D8'\*]%_9N^*+>#?!OB3QA>G9!X==DLXR>+B<$Q6\0]]PR<=1N)Z5YO\
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M0%)!& 6(  QP.QS7A'P[^+6G^!_&UO)<7B,+B,VDMY HGDM\GHP# J""3GJ
M.AR153XF?&RP^(_CG4+&UFU0:'IMC+' ,AC,X  9UR/XF8@@$@ #')-<LL!^
M\=WH;4XT8X=TIZN^FNW7IV_IW."^(]A9_$GQ#=6&ER.+&^GPDL@".D;'+.%.
M,@'/ Y.?;-?7W[$RVWAS138:<TICTJ.-A.%.)<'!<DGC)/ KQ/P+\!]-\/\
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M(6H;F,%2,U,8MTV<4K6N\[J&PU,R;.:AD576KUU&&;IBJ;##>U).P2-[PO\
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M]#E\G#"*=5Z;^B+WP$T[['\3(YH6L8]6^PWBZ*][@6\>HF!Q:ER00 )2N">
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M#5#Q!X@OO$^LW&H:C<S7E[=-OEFE.6<_R  X ' ' KK/B9JUKXL\:3W%DO\
MHJJ(T?!'FD$DN!U ))QGL!7/W>G*%SA2:YI25SKR_!QHTDW\3W_R.>U"Y;;M
M'XU7M$+SXK9GT@2*S*.%Y/M]3VID&F>0=Q7 IN2:.ZPZX@6.$>M9>IR;!6I>
M',8K)U6 NW3@BCS8$%D?.=>U7YK?,7(SQ5'3U_?+6]':K+!URU%NHDSGR<'
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M1=W36[:G-=W<;E+*_>[E("YA57C:(*B@ D@A?F)(XZ*..QE'%*-.*=)K6_\
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MWOO^"C/QJNO!W@?QGHH\,:KJEU!=:O' T&J:C!-(TTF[:9XX%E$IBY)( 5B
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M62CI%7>LFKNR=ENSIOAW\26^+6@P^%->T63Q/J%G"[:>QO7AEN50 I!A<99
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MMXK\?7NH7_AO3[J#3[,Z/;^=<7\\VXJK*Q B"A>22021@U] :]X'U3Q[\/\
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M+<D 1D%L]L@\=NU5"FY.R/"EB:]:7O2_&R/9/B)^U1I TFWTY;"WL6*XA>V
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M[7ZFF&QV)P\E3DF[:6=_^'7]:',:A^S[K6C1><([6^A !+6DPD(YZ;>"<=>
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MDD(.3DL<%CGK@=CGRS]FSX$QZG)!\0/&&MW5[=-*USI\!?S/E+$!W9B<#IM
MQCC!KUZ]U";QKID>G:7.UHK':)&!81*O.<#)/ / ZGCK70M%S,^1]ZI+NV<O
M\3QJ5E ?$TTFV!')CM,99%SP2<C))YQT[5@7/QUNM,T%;S4-7AO8(8S*Y@<J
M"HXVA1EMPR!@CKD5%X*_:*T'XT_!S^T-)-WJ^GO?RZ5&+JP-G<)/$@=F568E
MD*L#CDCG(!&*\[TWX?VM]J5Y+JTWV6T$C- D<6 Q&=N?<YST![&MLMQ%.K36
M*I/FB]GT/7QF68O*\7/#9C3<*E-VE&6C3[,MZM^T=8_$YO*L8+F?R9 9;,L5
MN(ESRY!&"!CN".>N:])^'NI7GBC25C;2H=*EA7]Q-*F3<XYP"",DC'8<]<5X
M+XB^$T?A?Q!IVHR7DEI<W\^8?*<J\4;#D%E((!ZE>0.,BNL\.7]YHT1>QU6Z
MN&LAM_?[C)M(R-O'''0XY]Z]:%&6(I\ZZ=+:??T]#'V=3$P<Z?3OM]^Z\SV3
MQ)\6&^&MHEYJ#1WBPKLE$!S(BGH2IZ8((R.G?->7_'/XEV/QFMENEW!H(@L3
ME@SR0A>0>?O!N1CL2.E8'C?1KZ&QM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#
M?AS6]"_LJ\L;;5'UA60R&("X1N> R@$>@(P0>]>;7@E[JU.*5K66K74\A^"F
MIW6EZ)YC2-)!O/\ HTBB2.1,<YXX)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++
M<B0A4C# ,".<$?W<@C.1Q7J%U^SKX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R
M,GL<@UY?J-SJGPW\;S>&S);.M],\<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@
MZE-VDEWW\F>KD^92H5%0EK"3^YO2Z_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]
MF?LCVNGR6\]M<"X98XQ<,BK<"2( L%+@95@V"0--_&>E:2XAWW# XP685@^.
M]:UJYTQ89DOKV.,?NOWI=8_4 9P/RKR37=<N;1_,N%FCB+<;@?I7R.7Y?7Q+
MY%>;\M3]3S',55KN5.A&E&R7+&]M$DWKK=O5]>[;NW[I=?$>W$NU9T5L?+O(
MP<=L^OUKQGXF_M4ZQX;\2/I>DQ/)? &9FD8+! @/,C.. H/U).  37 ^/_C)
M:^%_"MW(S9DC0E2&/49[5\ZZA\59-3TFX:YOWMX[NY"E"29+AQPS'L%3.!V]
M 236>.P[PRY%'WMM>C\SV.&\OCF%6S>D=^QZG\4?VG?%7C)9[6SU."QBO9VG
MNI+.WBLS=R,I1F;8 S$CC+DD^@KQ#Q?XONM%NI-\ES)*>6+2%B3UR3GFOJCQ
MK^SEX;&EZ]H-MX4N;"+0]"GU6'Q0]](T]V\<2213%.8V@F+$*!@C@@G!Q\G^
M'X[+7K$W5]+Y:@#<S,,'/KWKPZ>*M#FUY5Y/?0_1)5Z&!:<8I-QB].5MQ=^5
MNS?9V3U79$GPD_:-\3_#CQ3+J>BW\UE=%&B=& E@NT88:.6-@5=6'!!!KZ#\
M"?ML:EIZI>7>E6L<UK;1VEO;V%M';PVD*DE5BB4 *H))P,YSR:XCX/\ [-NA
M^-O!>K>(+KQ%IMG86LMM%$NY1)*TDFPJC,0-Z Y,>"S@86N)^)DUK\+?%OV&
M9VF:%0T%S;MN2[7&5D0C@@@CCG!R"<\5];%YWE.&AF,(.$*GNIM)[ZI6:=KI
M73ZKJ?G^*X@X1XGQE3(ZZ]K4A:4DFX[:7NFFW%MI]4WMJ?5A\:>(/C?I$EU#
M=7EK8W"$W%[Y[*LI(P$==V!M & ![GBM#XL>%8OC%XQTKQ58>,HX=$6ZTY[A
MVU>WL#HBV=IY+D*R^>TPE42(T9(96((!P:Z;X1^$='\1? O6-+GCEM]3L4M=
M7CFA)\RXL'.)6*@8&TLI+G  )]L_!7CCXQ/KWBN_NDD\BV2XD6T@4_+!&&(4
M >PQD]2>36/$&>9EG=*G3K\L80U2BK:[-N]]?):6Z'UG!?#.7\-XFO7RV<E4
M?N7FE)<C49*UK>34M[IIW5T_:?VG/%TWQF^,WB#6--6XETS4;II("R%%=< %
M]O !<@L?K7"Q^ =6:4!4NIOLJY&':01+[#D#V ZU6\&?'EUTE;6:5%)!P[C*
MC SSP3S["O3K+XS+>^!9_P"Q--M=2U73A'?:1;0,GVFX<O&CQ.C8+ABCG(Y0
M%CUHX3X;KYO6J0K2Y5'7HY/IL^EVKN^G1.^GB<>>(DN$,#1IX6@G#X5>ZBM-
M+M=6E+W4M=[Q2M+E4\,R3:2DMU>K(0<+&[<@C^6#V/(ID.GWVG:G;S86X@C;
M<3D, !Z]2/J*P_CEXA;PAXJ>SF33;3490+NZ@L+T7<,3.2=A<8 <#!9<9![\
MUP\'Q4>SN4?[5("#@!6]>*\K,LKQ. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6
M<542?+)./1.Z3;T?1]5]Q]U_L^_ 'QK^T#K.DV6AZS>'PO?7D::J7<&XTZW.
M/,>-C][ Z C/(.3C%>!?MM^"?^%+?M,^)_"%KJ*W>GZ)<(L:13&0H&16".V/
MO -SGD$\\YKZ8_X)!_$G5?"_Q%L85GFFTO7Y?LDZ%"R(Q'RDG'RD-M].,@U\
MH_\ !0;XBZ?XO_;'^(FI6;);64VL3",!=OF;3M+D=RY4G/?([8K6-.C+"JI)
M^]S/Y:?H<.%CB*/$-6E91H^SC)6[M]7WT:LM+:E;PMXNTN>U2U>W6W/5GSU/
MH3FH-<U'3+B556V9A(2$=2>< G(/0\ UPO@55\0ZM#%!)'<7,[K%:V[@;)YF
M(5%?D84DC/-?2%UH.DZQ'\2=/_X2+P[JFN?#ZRCFO]-5);>RT>&+]RPM)S_K
MY(\KN5A\QX4@9I8'AO"XBC*O6Q*ISNU&+?Q-*]F_L+?WG=-;)6N_(XGXGS;!
MXYT,IPLZU.,8SJ3BFU3BY*/-I?GU:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDG
MG!&.E7/!_P 9]?\ A_JT:R-,UNS  <HZ9]&''Y@US.K?&6*RNXT\Q)>0H8H
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M@@C!R<\Y%3EW'$LMUPD.5VMLK:[_ ->AV9UPWA<UH?5,;%3C=/5N]UL^FO\
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M,VU9!RR,#@#/L>H-;@_9>OGU"]?P;XMM]!T&"&;4M275S(Z6EK"#YDB%06;
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M$_![Q%XOMTDLM-N'C?&'8;5Y[Y..!73? 3X%:9X<2.ZUJXMFU(DX1OG6+GC
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M->I?!*Q&@)JJLZ7]YIK?9%ABD! 60!P5;'S#@@]<[6QUKV:.1X;#X!8.?O\
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M[*7[-FE0_&WP7XBTG5VU_P -7.IQ6TZ$!9+>8'S8TE3DKDH0&'!!Q@'&>/\
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MJ*>JNK*Z>QVG[/7PBDT*[\-_VMXEN--\0^++N<Z% FFO=02K;MUN6#+M5V7
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M@C9*R@$=N!5>"#S9!W)X KW7_@J!X#7P3^WM\0HXT\N#5;R/58O0B>)')'_
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M:;:)-I'\)(^E=)\)OCAH^G^(&O[J=Y=,E@:"9;= Q=7!&"N1R.HY['Z'Y_\
M"7B;5+*^>&96N+/[C1OU0'D,I]B,9['KQ4?BW3YO#ME_;FFQ?)#('F6)=HEC
M!^8%<[0PSG( S@URY/GE"G#V5>FE*]U..COTOT:[^73J>YQ#P31KX2?L&W>+
M]UZW5MHO=-;I=^I],?M->#&\?Z7H.I+X@MX;"&W2V^RI:YDB*@$*9%0L8R!O
M&0<9QG(&=3]E77])\9Z-)H.M6NFS)!;D6\L\3'S07R\:LOW2 6()&2, $$8K
M'_97\92^//"&H2:/<V=S=R636AT^Y<*[PN"?-B&"7*D$%4YY!Q@9JQ\,OA5K
M5KX\ "Q T[^SATG2KA+JYNU6VANHV6"[4OM5P2 "G<GJ,X(]?UK+<="K04I.
MRW]&MS^/<5@YY?F?L9)M7[/5:6?S\NNQWGQ#^%FF?#^SN-1\-VUSIL=]CRX1
M.6V8)SNZY+#MG&/J:\_@^%,_B#0H;J/4M-LKBX)-M',AA7!SR'^[P1T/7C!X
MQ7O%KXU^&OQRO]6\$Z+XXTW5/$>GV37%]:V>50JA(E,,V=KF,@DH<$KSC!S7
MF&I?"?1]-O9+6P-SJDES(\,=O+=#;MQDRDHVU5 !()/OBOILISO#8JES8:IS
M6=FUKMT;/M,UR/'Y15A1QE.5.4DI>_&S<=>FCMIHUUTW-:'P%X=\):5HUCYL
M.J7'!6YBG*(6)!<Y49!7:<;B,Y. <8.9X_N]/TSQPS6FM7D5E-:EK81P&Y\A
MCN+1J&8 +\X +#!.3CH:@TSX'?V%J2VM\S6T<+K)-<:<XG\\8!50>25YP3W)
M.>,$=/XM^".GV8TV"/4(5&I+Y[K-O>:6/!8D*H(! P<'K[]*TY</&2E*=]'\
MSQE&@IZM;;:W^7_#G)Z-\,M.U>>"ZUSQ!<W6GJYD@CG<(IE?))6-1C<<  XQ
MG)'8U,MM9Z1J9,.CW#:<%9//8AY9)B,DMT7) (P,\#O@X[SP3^Q?<>,K:S_X
M1J29[6 L+BZEQ&LLK L%4#)P!CA<D@DD@5U'BWX#V_P1\.7]KJT=SK.L*T/V
M2&&(Q6SNZ97G'\/1@,<<9.:\_$9O27[NF[^6WY&53%5%"].-H=[?UVZ'B?\
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M;E^=QECX/UK2O#XMHUA6YG DN7EEV@MCA1W  [>O-9^J>'/&MWI)TZ'4;3[
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MMEJ8U33H[1+D,Q030@YRC,K8! (ZD"KOC?X2W'BIHAI.KVR30 +';W2%25&
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M"_$\E]<0:787^HV-G?'3F(^SF>WB*I#)DN-@4$*$+ $FODOXV_\ !=.3XH_
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M"NH-]IC1;!@0R><=V4+*W (SQ6AHW[!GB+3Y?M&J^*M)LRR_ZF")Y60YZ$G
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MQ5%0J J!B>N:QO!G[(UUXENUNO$.NVMMI-N6:>WT\&6ZN"!D(K,!''G^\=Q
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M"% ;!  R % ).20 =/XC_&[^P-2OWTY[#1]-9@#M1(+>*,#"H"3C:H "C/
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M;O\ 9+9&?I67K_CB,/))))F1R HST7T [5/IWQFL=$T>5%@\Z4C(4 ;NW3/
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M9R\LA(5% [D\G@ GBNX\/_$W6_B!K4/A'P?_ *3>ZDI2YDP6CMX3@.[CT /
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MG#J<8()![/XFZA>:G/H-SJU]H=_XK\2PMJ>H2Z9>F> +D+$A&T>7*55B8P
M<XQD9TQGA_+!9-_:LJZYKNR76[25GT:]YM=5LSPZ7B![7B27#T\.W%)-R>MM
M&V[*]T[QBGT=[HZ[]GC]F[PQX.\":QOUBZN;Z68L9#@3O"3\JJO0D#@=><L0
M"1CZ6^#O[,GPGTH6]_XHEN$C2,2-%?W95K=>"-V"&R> %0'WXYKY!T'Q>4N1
M;QW;13VX(6>-S'(C8Z @Y!'J#D=JW/@]I>J:OXG_ +*TN]_M"[UNZ18Q<R!7
M1@" 9'8@%%/)8D8 )/3-?F.*IU:CYDW?MW^X_3*+HTH^QI>[%]>J]&S]+-%^
M)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/. :^3?C[^UO;^,
M_&W]G:;K,B>&?M=M?V=[K$#RMHD<3R,8X8HV!)#.H 8E3'@$$J /*O\ @HM^
MV/H&G:1X;^%/@+4[>_T'PC#$+R\MC^ZU2\ )EF![H&9ROJ7=AD!2?!O 7CFZ
M^(6IP6,2QR7DC*L<;'F3) )'! QD9S^M?9\+YQC,JQEZ,%4YM+6W?2UM;K[*
M6CU5G<_/N)N',)FV!:Q-65-)MJ5]4O[W35:R;U6CNN4^Q/"WQ7TVRLKB"X^P
MW:<Q%K92UO<# !?:V3M8Y.ULD9Y)->:_'+]EKX1>+?!I\8:WJ_\ PKN"ZU!=
M-M)-+M7O#J%TRE]BVZD%2%!)VD#'0$XKSWQAX0\2>"M6EM[AOLP@N/LSR0-O
MB+D!E 8#!.#R1QGCK6]\+_BSXL^'$LVB21:3K&GWL\<XM-8LQ<VZ7 (".,D%
M7P2!@D$X!!!X\;&<.YDL:YQAR5:CNHJ\5=ZZ=.O>U]$?;Y3GV4PP4:E2I*IA
MJ:M-W3ERQT=[IJZMJW';5VW/(OC9^QCX^_9G\1WH#6_BK2;1@XN+%RTHB90R
MN8R V"I!(QD=ZX;PG\>M-M9I&O&:(60W>4ZE"3V!!Y/^-?;'QE?6K;Q7J6I7
M6KV?B"3SXQ-=VY6,2S$?.BH6R1&, @9P,$9KSKQA^RUX)_:-T*9KRTM[75BA
M/VB#$<J-V)' 89['GT(KU,P_M#*9K#9M&]TFFNW?S739:W6Z9X.4XK*,ZH/%
M9;.UG9Z.R:TLUNN^E]+-*S5_#/ W[0$?BC71<74RQ2NPVAL[-HX"XZ8 K[X_
M8C\.6U_%'XLOX$$,#A[6%_NR%3DL?;(X]:^&?AQ^SQHOP=\<MIWC*QD18@9+
M6?S3]GNU4X&#G)/3(ZCO[_5'AO\ :FL]$L([*Q2W6WC4(J+PH &  /0?K45J
MT*T4\-JOZ_$[*.7U,-S2Q>_1)[^=^QZQIFA^&/@#XU\?^(O!L?B!-9^)5^+_
M %=]2U(W4,#!R^V%" 0"S'!)) P!@<5E7OQ-O-7EW2NT[9/5B/TX&*\\U'XL
M1^(V\Z21%9N0$X ^G]<YK)G\7;R&279^HQGG\!7!1P,5[B77\6=F.SFMBY>T
MQ$W*5HJ[=W:*48J_E%)+R1Z)KOQ$E<KYKQP C&"^#]?4USL?Q9MM+F>03-=3
MC[@W?(#ZD=3CM6'JB++;'RYTG=ADL'SD$=0??@G/L.U<+J6FG1;HS;TE9UR<
M,>#].V17U&)X=>'H^T4^;:ZMW['EU,1."T/:Y/'=C\1;*&UU!%8F,*DX $L;
M')R#W&3R#P:Y'Q#KUQX!N&L;IMOF F.1>5E7LPSW]1VK@]*\5M#+\I92I#8!
M_,5W=[I$GQ6\)+8R*S/@O!,OWXF X(/H>A]17E>Q47[VQG[9U%IN&D:K;ZDH
MN5NWEDQ\RYQC@#!QP"#QZ#UK6*^?&?L]W)(Q49!D#9Z_C@^M?/4?BB71+YX?
MG_=N49UD.<@X]?45U_AGX@8EB;SF7&#UY_.OKHXG".*4J27HE^>YQU,<W[K/
M7-#1K1W621_,8%2NT@#ISG/0]OUKL/!WB&.]B>QN4W03*48'KCL1[CJ#7FVF
M^+([F%7:3SM_\_>NK\*QSW]]#Y:,6=@!CJ<^M>)B*=/F?LT[=+G/]8<GH,O=
M=NO!NM7-HL[J\3<,3PZ]5..^13OC_P#%*30/V$?&EU,RQ2:S(FFQMG!P[HIQ
M]1OKT'Q1^SC<^._'2[KI;*QM+./[9*<,Q?'"J.QQUS7B?_!7BVTGX)?LQ?#_
M ,+::TTL^O:M)<NSOEMD2%LGM]Z0=JZJ=9\OLG*UU]P4;RJK7W;_ )'R!X*N
MU%]!]G9G<L JKDEV)X'XFOI/PW%:PVL+:@EK)<Q%2V3D1MC&,]R/6OGCX-6K
M:;*VH^9YB1H1%N !WMT/X#-=?J?BLZ7I,^Z5_,<=SU)/6O"J7ORQW/KK^[:6
MQ[WK_P 1H='M?LZS+*X'S#H1QG /0\?C65H7Q&@DD++$^\D#(/6O&O WC*XU
M:.=I&=HT;9M)&.V"3WR>W/X5LZ5]H\3>((EM7X(";0W)8GMU'%>G7R6-'!?6
M*DGS.VG37];'+*HFE;_ASZ*^'8O-7U..2)6WLXV#/.37K>K>$/#K+MU2!=4D
M9?WT0.(T8]<'J2?:O/?A9H47PU\.JLTGG:G,OS$_\L0>P]\=?RK:7QM;VMW&
MN[>4R6P>K>M?.2K--^S?J=]2G%0O47HO/^OO.YT2PTSPO:_\2KP_I]G&1C=!
M %DVX[MU(Q[UG^.-4M]9T%M-O=+3RI<F*4J \!.071N""-Q((/7&<CBJ>K_'
M"V_LR"W@M5?>?+:3(18^AR20<_A]*\S\;_'#RRL3Q+&K=^N#C. <#GVQ751R
MO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\ 1[OPIK7B+4&T
M1;LOHUFJQ6.I-+@&YNH\LSK&K8*#.2,@8Z6_"^J:\VI27#3:;,VF2#[-:Q(9
MI92S@(0659 4)P5<'!.1D<5XEX?^.C:7JZW:7DUI+;MO257(Q]/Y$=^]>D?
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M81<E6CS.#NG;IHU'732^DM;*WS7J)DT[QAJ%K8/YEFL[JLK@@1H&( ;@!F
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M/\JY+6_ -QH=ZK>9-&6<,C2)OC# ]"0.5)[]N<U[=\'KWQA9Z9X9TO2;C0-
MDL5DT^_NM1GDMX[];X[I5N" 2JKL4)(HR-P7=@$5WY%X>O-,14E"LJ<;-VML
M^EE?5;]>AX?''B5/A/ 4JD*+K7E&.^ZUO=I:.UDG:UV>/R?#?P]>ZFT?V/\
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M+*\?5RO$3Y9PO&<86Y5Z--Z^=[[[:H]*\*_MTKH^C_\ $]O[:YNW_>2,UC!
M9&48#MM4EVQ@ L2<>@JA\1_^"A,C>&X9[.S^VW5UE/+6.,%,>K8&,_H.E>/:
MU\$]<O=-DO+>.VNH(3AW)*E#ZD$9 ]^E>7^)[/6/"$[2+8?O%SA^#&C>I/3
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MA%4\3*,?:7CRNWO/LE]IOI&UWT1[+K_QG\&^!=.L?%GBNWVV4TT5O/#;VSF
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M3UBSFL[Q%!?6+003(?.' 5XAM^<??W#(R"3]>?M@?L1^ /VQ]5&O76HMX?\
M'0@"PZS!$'LM151A$NX<\XQCS(\,!C(88%?.?PQ_X)&?%B_U"62ZO/A_%#:R
ML!!+KP']H,,;2&2-BL9SDD@-@$!<XHQV78F,N2G'F3TTVMYG+E&?9'B<#&I7
MFH5*;N^;1W\NDE;3\6DSS;X"?":S^+'C_3M'NMNDV\K&22ZO87:!X "6=2-N
MXJ1R!P 1R20#Z_!^R'I8\-ZGKFN>(IH/#&DE+:VDTJR%W=WI=Y DA3<%CC94
M)!. >%'/->U?!#_@COIO@FT.O_$;XHW&H^*XKZ6^5/#T#)86\3X+6>;@GS(B
M.,[$)7 R!7#_ +87A'X@?LZ:)8WG@CQ3:S>'--A^R_;+*QAM;M(6<F*"[3#+
M(J$MY;C@,Q.%)P?J9\,Y35R"5"GIBW9IOF2Z75U=;*VVCVT;;^!P/$F;5^-J
M2BT\OV:4DF^FC:O>[NFD[QZ722^2?VK_ ($QZ1J7BCP*FHI%J>E7,,\4Q7:M
M[&$W@$$$J=K@D'H1C/>N!^'G[!?Q;_X1B74+K1/LMI>&..PN&U.!#;!@':6:
M,,T@C,;*PR 2I+ $ UC?%/Q=XNUG4=0OII4O=7OI6+WMX[ORP(:1@H)=O0<#
MZXQ7J/PC_;/U2*^T'P?K%U'J%OHNEB^N]0A$-K?7BPP"U_?%5!G;RVVIG+!5
MQC.37D<.9'5P^(AA<QY5'75WU]U[-)K?JVK(_1N/,=/#8'V^4\\JJY4W&UKN
M<%9J4DVFN;2,9-NRM:]N>^+OP*U;X"Z&?L6HP^*?(FA+ZMICR16Z3OGA4P"X
M) &23@CD\X'F^I_%;Q1KD^Z:^<:K;2G*K"D<C@= AP&5U(R "">W(KW+Q?X[
MT'_A7]YH5E;K-KL<DHFCMKIWL(K5V#*6&U<R)P 58@%V.3P*\4?X?L'9I&>5
MVR=S')W=<YZY)]:Z.+*.$P>*5/!RTMTVTNGKU=[W[.ZTLD<OA[CL?F&6^WS:
MG:2;LVK2L[-7B_ATLULI*SL[MO['_8._X+4:QX22W\*?&>>YUO0R/*MO$'EF
M2_T\C^&Y7[TR=MV-X[[AT],_;.\5>)/C,]EJWP?\2:5XT\&WEHZ#3/"&I(NN
MV]W]X7$R;A*\( 8>7'@AL%@1R/SP\!_">\^/7BMM%M;W2=$N=/C:[U#5]5G^
MRV&GV:C#37,N"0%8HJ@ EBZJ 20*^[OV4/\ @EOX!_9%^(/AWXF>-O%FI>-+
M72]+G\36OB+1%5/"NF-#D+OF!::XDS@*HV@N\8VOR!\[NKS/H<71I4*W/A=[
M-N.R:2NVMK.U]$[OHF9WP _8R\3?&CX9^'[SXQZIJ":[IEU)K>F:#J-Q'#JE
MQ81/&GG7,7+E%N.%((?:<,2&P/H;3/V=+GQ+JQN+&2PL2SA#-'!%!AF.%56;
M!+$\!0<D\"O>;?5]'\:QZE_96K:?J2Z3=MI.H>0N9;*?:DS6SLRAAPR,5!(S
MC/(KE_'=_P"&]*T:9=0T1M?M]!NK75@&TV2[6TNHRY@G3:,;D^8G!(49+ "N
M"IAYU5:BN9]++S\O/_(?]OO#:U?W?>Z6BWVER_9U5WYWL>?^/]!3P/X*2&ZN
M+^1H+:[M#;F](M;TS;09)X=I,LL83]V20%)SCBOAWX[06.HZA$\EO?O'I0DF
MA6&*-B9-N V'^7A=^,@\=!G%>[?$?XIW/B_Q)!<33I_Q,H/M<,<4NY1&Q)$A
M SA2P/)R"3P37G?Q"\ V?BG1IF;=-E?G;!!R0>0.OT'3WKZ?*<BQ>3XZ-7$4
MVFM;-6\OZ:.NGB,'Q#D$Z=+$1G&JMX-32=^9IV=GNTT^_H?./QYO?"NBZ?I5
MCI3V%Q?:? S//I^^/S5?:P,NY0"ZL'!"]F!SD$5QWAG7X?'.JVFDKID-U<7K
M&.,QAFE. 23A<EL $D 9XKT3Q_\ L]:AI-Y;QRS6L]JV4A)/S;2"1@\8STY.
M<U+^SYI%QX(UO5#Y.E6:ZC9-X?:ZO(%:".&Z?$X+Y&&*@[2<D$=,9(^@I\-T
M<]S93KRY&VF^ETK7]Z_96OZ:+IY6:\28C@[A&I#+X.M[*,N57;DI2;M:-GHI
M--Q5M+ZNROZA_P $JM*M_AU\:OBCX7U;0]0L?$?B?P]:1Z/9WR):7$MQ%=B8
M)$)P,EXPQ#@$A5<CDBOI#XO_  3BO[W^TIYWTQYY-T\\I MP2"67S"< \J ,
M8."20< _$O[97BVQ7P#X#6]\:VVL^,TN9-0.L6-O.+W2K>T0Q6T#S9PTC29P
MZ$ !0>G3K/@[_P %@&TWP>=,^)GA"\UJ.2)$_M70[M8+J1D^Z\D$N868#@D%
M<]@,FO<J4:&45WE\:G,H_:TWT;5EM:]KO>S?I_-^<99FG&&&AQ)&ARSJK6FV
MU91O%24FDGS6;:T<4TG?<]Z\%V%GX8^(T2SM;PV3@,9(]82:X15(P<$! ">>
MQ S@FO<O'_PRNF^QZY<:JD/ELJPJT:0PRKDD ",E26&"O.,=N3CGO@]XF\%_
MMA?LRIXV^&LW_"31:?<FVUO0]5TF(:RDH PJ_9P65T!#!LE2'#<@<87_  FW
MBKX5>(;SP+>:5:ZKHMW<'[!IVHS$O91AW.Q'P#D $(&Z<#->U@<:G-23T_3Y
MGP-&G++*LL/BXM7T]&^CMT_JW4ZB35?$7B'Q&(_^$ENM/M+<Q+!%?6TL\!W'
M!50JL%4-U! .3D\<UR7Q0T?4M#TZXCNIHRD.0\DDB(D$@).%7<6*GL0!U Q7
M5Z5\4_AOXT\$K]EOET*_?=%ONW=IK:11@G?R&09P<@<9'O5JV^ =Y'I#:A=W
M-O(MP?W,L"AF>)EY;.2 6!P, 8'>O8P].G3DI;7>FGY,]##X*A)PJ1UN]+.Z
M^_[O^"=5\!_VJE^%'P3G\8>*K&;4=%\&O;QDV.B_:-2N9IB5AA1QD>6@Y$K8
M";MN  #6K\7K'Q-XJ\?PZC)<7-IX.^*5I#>6[HXM[RTC""4Q72*=S8&5).<D
MC#$9%9G@35=8^%O@_6-*T6VCL%O!'#(]U*DEC H8%I) V0Q [;""2!@'DZDG
MC8ZEXODN)K6'5[Z.,/=79<M#<6R$[O*,8)RA) CP< #/->']5KQS"IB5)*E:
MR5M;WO>Y]4ZV GED*2I2A7C-MS;T<+645"V^^M^OR.#\2_#&PT'2]/T^'2KF
M]>X9KZ0QI\\LIRBN5YXRO Z#8#CFO9I/A:WP6^$.N^*)_"/_  F&K6>F07=E
MH=I,(IWWS+'O,H(0($)D<#("+G(S7G/Q0_:_T^[GCAM6&A20E$^RS0$33Q,"
M"P=59HP 2."I(8\5ZIX7^-GVKP7X5*M)ING6$#3:=)-._P!KN(PQ"D%@&"N2
M0N<93:",X-<V<5,16ING%\KU6CO;]#R\/F6"ACXSKP52%-IN%W:235U)K;F6
MC:U_!G-Z'+-XCO\ X>>+KKP;8^%Y=1T.2]U#3Y%\\:5(9&V&*1E#KYHYP<$C
MJ"!SR_C(>$_"GQA\3?$#0_#=CI?CWQ=;BSU365N)"]Q& BDK&245F"("0.<>
M]>5_&+]MEM,^*VMZ'-JZWVL0WK/JNZ4ND<V,) I."1%&0#Q]YFQQURM*^+\?
MCW6;&"ZNP!>7$<)<8Q&&<*3CID9Z]:_-,XC4JRC2JOG]G97MN^K_ $^1^K</
M8B.$5;&8.#H+$MMP4G94Y-.-/?WHV2=I7UWV.]N?B!>:C*3-*TSD]9,G\1SB
MLW7O'TR1JLTT:8X"@$Y_0]A7,IXOO/%=Q\2;/4/ASK'@.W\"7\=II.JW=TSC
M7U,NPDAOE)8#S 8R<#KCC,6EV5KKNCW]W_:^EZ?9Z7:_;+^^U"<6\%HF0/G;
MG!+' XR>PYQ6>2X/#8V,JTI\D([WM?\ 'IW9])F>6XO#8Q82K%.HU%I1:E?F
M2<;<K=VTUHA[_%FSTV^9E+7$RY"!LA0?7'4CVK6TOXO?\)!8):WZ+<6S[O-C
MDY!))Y'H0.A'(KS;QUX(;P=?V\TEU9WB7L NK>YMY1/!=PM]R6-UX93SSUXQ
MBN=M/$S1SE2<$\9'J*ZL1@8TI\L9<RT::ZIGAU,15A4=.IHUI;:S[-=^CN>A
M^.[F3X<*LT3O+I=R<12@\IGHC'U[ ]_K7,Z9XKT_5UWO-(UTHR0SYP #CGC(
M(QC^M=!X967X@^'WTR1?M,%YF)X^I&>A!Z@@\@]C7SIX]NI/ ?BG4-+4QO\
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MR2W5]-+['$R^#8BGVAI7\_CRV7KGL<U]C?LP?$WS?#^DZA\ETUFZ6UT'_O#
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M@#D$@9!&:\R\/:[XPT?Q[XF\1>(+BZ\023WD3W.HNY9M75T+>>H(PI"J@,8
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M?L=:#K7AY-6UZS9XIR'MK6!BA"$#'F-U)SZ8%>U67PX\&:+!':Q>'M*CB0X
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MM"+7*I/EZZVO>^O2T6MXMML\(^-?_!'K0/C/\2I/%VH^/W\&>!=(4ZWJ.FI
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M%CN@ZRQ @D [F3;S_?JG\<?B?X=%CJFG:TOV&ZM[Q[;=RTFX$X'J#CVKY?\
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M9QTUTOKHU9G,_!3X:Z3\*+<:GJ$,9UN/39;:*=@I>W$VW=$&X!+% 2 -HV
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M#]UEN/B[I[+1L_%?$CA*M.K3J4(.51^]RK>2TZ+5OII^2/:+;_@G_K6C^/\
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M$JJR$ELD# 60G)X'&1G>'?@WILGC:\T_2/%SSV^G^5)=WEQNDG>5XA-+&RJ
M$9<G ).X#.<\'0\3:)=^(=+%K-X;O-$>^#12QRR<..1@.IPI(Y##!'!KT?X(
M:I;?#/2X_P"T(K6VMVB7RQ>W#M<7$J902*5#%QC<"Q&<\ \&ON,ASC*7DM7"
M9A&4JRNH*]U%623C=-1ZWLFVW=ZVM^9\5<'Y_0XDP^89)**PLK.I=>])W=U*
MS4I]&KN*BDHK3FO[7X2\/2Z7X=M[.^>ZO(5VJJ%WDFN&QQD COU  &.M:WBJ
MZF^%/PYU&\T/0_%7BN[FU-[]]&34GGO'EN'!=4,BL8X4P L: A=PP,9(X72=
M1\(^)O#5Y#<7^H:FVJVD]A=V<$DMJ/)E4J^V=F$B$ \%!D8ZUTS_ !3M/#_A
M[3H+18[*RL;6"QM-DY8E0!$B-,[;W?: 26.3UY)KQ,/"=9\M):VT:U:O^'];
M'T&,K0P\HU,0GR\UW&5XQDETNI*5W=K1:7NI7T.^M?)\#^/]0U_4O%%_9Z19
MZ0+=M$E\IK&P=',TE\S@;Q($RC M@ $@=,?A'_P4<_X*!2?MQ_'6ZOM#:33/
MA]HY:T\-Z4I$,9BWEGO'B4A?/N')D8X) *#)*DG]#O\ @HM^VEKG[-?P^U2^
M\-^*+.\GUZ2!M/TIM)MI&T.VM$VWQ+DMY_GR/&&\P *-ZY!(P>&_V7/@UXOU
MO49OB'X3^$=K\/\ XQ+96_@'2M \/)IOB5)IXA,9A<( ZR(KY*J608W$@$(=
M(RYE[-WCJ]_Z>G]61-&G+!3CCFE4?*DN56V2NDN6-Y*[3;O>TFIR34G^2<7B
MBVD\,VMO':B*^BF+O,/XUQT]?3\J[?7X;[0_"FFZA(K-Y@$A"]@>Q]RI_.M7
M_@HI^QU8?L%?M2ZEX(TGQ%?>)-#:QM]5L+B\MQ%<QPS%@(I" %=T*,"R@ C;
MP#D#E?#W[1WV2"VM;RQL;RW"+&ZNQ!E4#' Y ./PKGQ5"^G8^XRO-HUJ2JQV
MEKKI^9Z=KUE9_$ M':Q/=+<NI\LG#%#@9'!P .22.!SC%>B>-/V5]3_9FT3;
MI/C.QU.^MI5:_MHTD1+)2H9'CDR4:.0.I4OM9L$ 8!KQFXL8Y=*7Q)X9N9)+
M#.)H-Q$MFWH1G./QZ=.*Z"Z^.OBGXB>&FT7[;=36,CJS(S R7#* $,K  R;<
M';NSM!P,5UY'BL#@L)7AB%)U6K0::23MUO?3U4M]+:L^7XOPV>X[,<)/+*D(
MT$_WJDFY-::+[^CCMKS:(S?%WCO7/$%VD(NXWDFD"[$C):1CP!R<9))/3J:]
M ^"_[-/BOQAH#>-I%3R](A7481<WZ6]RD,4YC:4QR*=T6]< C@D$#)K@_!OP
M5U;4?$,D6JVC"WNH'CC<$-Y4C#"MC/)'4#UZ<U[Y\*/'4WAO0M#T/6KC4M3T
MCP]<JU@T,J"5+4 .8-VU<Q,Z@E3Z9&>_T'"=3#8O$7S>MRJ"NM4KO?:UKK75
M];/=:^'XDU,YP&5QCP_0524W:6C=HO1WLT[2;2LNET]&[8?Q5_:^U3P_X#\0
MQZ782-X^:VNK6YGL5@2UN#+;,L4KQS,KET,8'[L@Y'  &#P/B7X8>!_'?AS1
M?&=O.]G;>*+2&2 J_EQRR- C%PF/E969E(Z94X%<3^T3;7VI?%F^\000^?=:
MO=RRRK;P@Q(6./+"J!@!2 2>O4'.:N>#+_POH_PU3PE<V]_#H]E.+FT5[LR&
MWGR-Z1%L,(R2QY..3@#(SR<7Y_6SBISU&K1;Y;)+35]ETMIW79)+/@G@*APU
MA.7!1DI5$G--MVDE'5:M/7FUOLU9?$W-X4T"SLY[F:^19;JS=K=,KD.0,%L]
M.<BOO;_@DKX?\1?#G]G_ ,9>-K+P;J6N0>,/%5KHL4]C,D-PMA "DURF_AHX
MII6+ ')VMC)7!^>_@M\-/"/C[X7:KX[\66'B2ZT*UUC[ FG:)/';.FV))"9)
MF#!6=2 @[DDDX!(^]/VC/#EK\4/">B^%/AUXC\>?!&U^%<]K;M8Z=;>1!?6L
MENDX@*L2DF PS)EBK[PP);)^-RGV<7-R?O1V\[_H>[FF%Q3A1J2A^[JM^\WH
MN2S>B=[W<>EM=SF=)^%?Q6T3XE>+8_%'C5_%7@JY4#0[9-"":A9#?EMQ155@
M%RN.23@X'(-J7P7IUC")$AUJU8D [8@LQ4X_UJ[?D'I@ GUKYA_;9^/GQ4\-
M^*H9/!NF)KNG292;_29$N+=L\<;@"I'?D ]1BN$N/CAXKL-DEV]S<7"@%;@7
MDJW%JW4A9%(. >QX[XHQ.(>\4F?19;E\Y4U*;Z=%;\OQ/M?Q%X4TF7P_<_9[
MBWTV=G:-(K M'=. >H3<%<D=1T/;G%>/ZQ_9/AWQ$UI>6C:C/,8YFNK_ $R?
MS/-B1D3SX@5>0!6^4!B.N<UXYH/[6WCG2+1O+U!/$$,>7-K?G[41W.0<./J#
M[YJA:_'F;XN^(&:#3;BQU.;/VBR+"1+C:,@0RM\P8XX1^IP V<"JP>98B$)T
MJ,G!2W2;5^NMGK_P_<PQ60Y;C:L9X^G[2<&^7F2;5][-K\O+LC:_;-UC6OB_
MX=TVQM?"R:?X5T:Z9T;3HP3>,0,.\> T0ZX4CN<G-1_LT_$C2='^%.J:''IN
MFZ5?Z@H2[N=280(\"7(8RI=* V]8U(,8Q]T@]20[P3\<]*NO$9:ZOM6TRRGM
MP LEO+F-%(4DHQ97 9@&!((XY!P*]"\=? -OB+XCM;B[T#P[XLC5UD\PPH+D
MICGY&*.) #P&)]^*^DX7XACD>,>(JT5)-65]+.Z::;3:VZ;GQ_&WAW0XCRSZ
MK@\6Z>MW;6Z2:::32:=^NUD]3Y#^+=K9>/OB[JECX-:XOM-O-6>*SO[='2QG
M1FPIB+ ,%.22#TZ#(Q7UA^S9X&T/]CNWT;Q5J^G_ /"9_&;QY%]B^'G@7S-U
MQY"@#^TKQ,[H+7*!V=L9&U4RS<>F?##X'>&=5^+.CZCJ:76D^$_#MM(8;"6$
M()W$@,T[*I.U5!6('[TDCA%P [#Z*D\->%O$OQCN/BEXI\,6?AG5]2TN#1]'
M:&V47FH:?"TLT5H\BY*L[ Y! PK*H) %3AY5,9B9SPRNZC;4([/K=J[T5[VU
M^Y#S)T,HRVE0Q,N6%)*,JDG[VR7)%M*\I6UEIRKM)I'BMY^RKH?A.\UKXC?%
MJXL?%7C#Q%.E[?WD\0> S)$L:6]HK E88U0 X &0< 9 KY=_:?\ VL8)HI]/
MT>/R+&W!1I,!1R<':.G3CI7IG[97Q<NOVG?B=_PCLFI?V/ B.\R;F2VM(D!R
MN5VE@I&  0#D$CD _%WQQ\ 3>#;"S6:Z:^MC&7W19=I0'($D@R=H8$%3T/08
M(YX\3D..KTWC9P?LT]WN[=?3=)=UYJ_IX3C'*\IJ1RBG)?6913M':-U=16F]
MFFY/H^EF>Y?LJ_%+P[?:FEOXNMKK6-!8.WV,'"7(9#MB!RH5B^W:"P0DX;@X
MK?\ V@/!'AO4OAWHMGJWAR.%([998;>PN8)71F 4R@1E8XYB=P<'@$$KD8)^
M6OAK\4F\*I%'#+(;1'#"%FP,C(.1T/4]?6O=XO&VF>(_"]Q]GL9)))_GE8RD
M;"222!GN3GFO5_UEA0RC^S8X=.;?Q]EKT75;-WLUHU=7/E:O!^(Q7$L<\GBW
M&C:SI[J^G5Z6;NTK)QE9J5G8P[[X-> =4\$.^M>$IO#6GZ(@N!J-U>P(\J@\
M[G1F)#'U!R>!S7D;_MK3>$/%%W8^'HHX?#[&>WM=0DC#7TJS($?<6! 4XRI9
M"01Q@' [;Q-X>TWQA8OIFIK)-I=P0Q7>0T4J_=D0@\,IY&>/J*X73OV*%U/7
M?LNI>+K/3K6[!=M0GLFW;<@JA56VY..6)&#U'>L,OSVMA$U2DX.2U[-?EUZG
MK<1<)T<9*/MZ2J0@[I]8M-;=>FMOFD<GIWB071C7,CN5V?,2> , $^U?07[.
M_P +-,CD@US6H-\6A1C4+B*-6?S\@&.!EQ@NQ(.T$D], 9-2?!;_ ()_P^*/
M$]K'8:SJ&JZ=&P1)YK9;<7!&.0N2Q7TS@D8S7VYX'_8ZT/P0HNIY&GL 3T"P
MO_WF9FEY&\X)('0$]\5XE;EV;W/:PF:8?"05XZ]%V]?+_ACY?^$VC_$+6_BE
M?^--8\(ZH#=18M(_+ %M&6)5 ,YX')..22:]Z\'_ +5-Y;/JNDR)IOAS7I-+
MN(M)N];M2UK;WQ3$+RK@Y4-UX(Z5W'B26XT@F38GDQ#:-OIZ_2N-\3-HOCNT
M$-]%',,8.]?F0_7J/SKI]I"4;<ME:VG0^5Q,IRK_ %B<N9WO[UFGK>S7;RVM
MH6+3XCW5U\/_  W;>)]7T'Q!XSMH)!J^I:- (;2=B^4 VJJEE7@D #G')K7T
M'4IM>AF^SR(D-J@>>XGG6"" $@#<[$*"2< $\G@5Y)XE^%%SX/M3?:9))<V"
M?,\>27B'J#W _.LO7M4\(^/_ (97'A/QQ8ZI>:'<ZE;:FKV%]]FECFC!4!N"
M&7#$X((SSC.,$<+4Y%3PWO2V5WN_-DPQ5#%9DJF/?L:=2=Y.G%6BF[OD@FE9
M=%=6T1[3XM\23>#K^:UOK:2WF@P9-QSC(!!SD]0<@C/%8+?&.YCR(YEVG[N?
MT&:XCQWX_M_%^LB:&V2TM?)CMK:!9"ZP)%&$0%FY)VH,GOR3Z5QMSXADT2\=
M9@QC4G"DD>XP.OTS7V699#&AAXUHJVR:O?6QY&*E&+]UW72_]/\ ,]HA\2Q^
M-],>.Y">> </_$#V.:XJUUN;3M2FMYVD62)RI![^A_$5F> _$;W-[YGS1HW7
MZGO]*Z3QU81VNE6NI2)AI',#.!GD#*_A7DT(J_*<DJGN-]C>\'^*;?S':XD<
M8 5<D[0IY//;GU[5K:SJ\%S%Y<-PY*#C(.1CG /\N*\ST#6#!(/EY)_A.<UU
MFF_;]<799V%Q(W<HIPOU/05]!1S*=.DJ/*M/ZU.+VS:LD:.EZI<W^JPV>]CY
MKJB^Q) KQ3_@JW\0/M'[0FD>'X9&"Z%H<>Y0<!&D<L<GUP%_2OH_X.?"'5[K
MQUI;W%LZH)Q(VXCHO/K[5^=__!0'XBKXS_;1\?W*W"E;/4CIR8;C; HBX/U4
M]*X:,:7,O:[#P4N6OS2Z(71M7CO+956XP_.,M\V<9P1R<>W'UKTKX3VD]_-&
MR'Y3C/?GO]:^=?"FL-)?+#N7+X._H,5]/?L[WRS20_+^[0YP>Y')/XUGFV(I
MU%%48I6ZVM<^BIS5222/HGPW-_8FEQVF_:XMVN+F7J($49Y],G _$5\R?&74
M_$/@64WFG10V\,\HBCGN+E&,1W;=P3!)&&/)Q@C@\&OH+P?KS7GA3Q%<X4W$
MLD,(.>B$2,1CDX)49^E>#_M(?$#0_$OAM-!L?#M_:?:[WS+G4+J1FP@3#A3C
M$BEERI**4RP)(P:];AFBE2=7^9_@KV/R7Q&K\V+CA;V]FOO<K7_1'O'[/\UG
M\,_#%Q,^J/&=2B:YBN[F,1?:7P,I$,$ *I4Y/)!SU.*P_B3X;\.?M6>(_"6K
M:SKM_H"^$(9=-AMO(FN]+UB!YQ,6>*)T;S02X(.4<,I^4J,_/_@+XBZAX8^'
M5SI$=U<7RA&^RQ7MP[);'E0%YP %SM X()!'0CWKX&W$FJ>#]+^V6]SI=M%
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MEO+9.N.XR.OO7OG_  3Y^&5Q\8/VY_AY#I]E&^D^%;H^(-59T)BMK:V7*LP
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MX4#N<$]*^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)
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M[IR4LK<DBYG67 0,ZC8H!)"LQZ]/I?P/J_B[]GWP?;6I\./%;0Q!-\6V5$P
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MU<\^6,;CRUHW78^?=$TSXF>-?#9L8+Y/&6D_V:K6M]86HVSQ18#)(NT,)$(
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MOK?;32SZZZ>6_GB_%6=[MI9/$/B>YDFN3F;2K4E8?49.<CGM\N,#!->?:O\
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MXRNX0I5Y<U2*2;5TKVUW;_-^IV&]-2UHV=AJL=LJNJF:XF2"! 6 &2QR3D\
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M.X6SMX#K$.YY2I8H!G!PJEF.<  DD"O*EA5?1'Z33SK"1:A4E[W9:_@KE?\
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M_AO\*IO%^M6%G8I)/>.R[HPN <<DD]L8SUP!R:\BM*A"I.6&?N\SMTMKMO\
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M/,7[%#$)+:$$_*S,5 5L;L%"&X&" >?H;PU\ M'\%^$;[[7NNKB'A&<DXX(
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MW4I/5M2LG=O<\EU'XH736,-U:V4UQ!XCMX[K2XXT0>5  /F(7)W/N#$,?E!
M'()IR>&-8\3">:.PNI+J]Q^YA)98\# 'N0.I]>E?07P!_8NL?"VC6:^(-&A3
MQ7H,,-I/>W%KY,&H<%TF5E8E\;SNX&'W @X!KVC2OASHWA]FENII;Z2--XB@
MBV1Y]!CGG_\ 77E\72PDL9.A@'^Z35O/16L[N\;;-ZO=W;/4X1KXZKEE*IFB
M_>O5I7>MW>^BL_):+962/E;]G;]D/6GUQ?$FO6 2RT603".90&GDR-N1U*J2
M&)/7 '3->Q^/=72ULDA^S37#H2S[3EVR<D@=SWV]2>*[KX[?$G7?@M\(-1U+
MPAX5A\9>*IX VF>%X[@0I>!V5&!;EB0&))P!A2!CK7%^-O 6N^$],M%\06=O
M8:O=6<4UQ#:RF:"VE9071'(!8(Y(!(YQGO7P^*P#DU4>J6EO^&[GU]'%3FG!
M/EO>UFKZ;Z>5][6UZV/BVY^(MY\0/B;K.B6/A3Q$-)FM8=1N);: R/:,Y(D5
M2K<JP^=B,%.3CFMC4?%OF:7$L<TC*&P2 1G!P1CZUZ5XQ^',T$<=QI\DUE/;
MS&XFEB&W[864K(&4$ ;P3G& #S@UY;XIL&TVZ!(<Y)RNT]N>![5]#Q'C<NQ:
MI+ TG!Q5G_P=-=$O>;3:W1X_!^5YI@56_M.LJG,UR^7I_+JW[J5E]EDWPV\7
M0V'Q6G6]N%AM[N)7BWL "< $XZ\'T_.NX\:_&?0O#J21B\AED1RF(3N+@$'.
M, Y&2/>O%?%5Q:S6?[]58=LC!!/H>HS[5P/]AVB:D9HFEMWB=6&^9FP0>"!U
M./QJ,MQU&*C'$1?NV72UOG;_ "9]'*<XWG2MUM>^_P KGTU:?$G5/$6AP*-&
MNK:WO(OM4-W)@&2U+^6953[S*6PH(X+<5N?M"WSV_P 'KN]@N-<FU"86\$-C
M8W6V5U5P#+#$05,R;PQP"2 !@G /'?".]U/Q;-IZ7^J:H]O9VQMM,:QD\BVM
MF#&4O)%L(;S#PX9\' VX)-?1/AK7H]*T^*%_):>W11O "AV &3CMDC.,U]YF
M&+R_+<;AL9@9^T4;2<4VKZJVMFE=K5:M-671GY=1K9KGN QF"S2E[%R;C%NS
MLFK/2Z;:3]UZ*2LWU1\[_LN:%XQO_C;=^+?$RP^)YO#\EKHMGF4D_9RDA:8_
M*(P1D#Y\L"<DH<U]'?M%>)=2^+GPLNO OA.;PK9?%/Q-I#:GX?L/$T$=S%;I
M'+''/,5PZF2-9#M(! ;DY ->5? _X:Z#\&_%7BI?#]YJLZ>*M8DUB^BN[XW"
M?:9"2QB! V@YP1D\ <\5]!OK/ASX<3Z=XNU#2]+N_%EI9R6FCW,L2M/90N09
M"&ZA"0.,X.,GCK\_QEQG'-L5"HH*%DDK7=ENUT6[=M%TU/3X'X)7#V#E2A5E
M5YI.7O))-Z)-J[>J2YO>>E^IE_MC6'Q*^'7@CX3Z#\/YHYIH_$6AQ>)DMHHH
M(-/TZ'>][*WW2R3,(PP ) 5<#DUY7_P5,\+:Q\>/V5-5M?"6E7.M^)M(O8KW
M3(;63;< '=#-L&1OS#(X,><,.Q(%6?&OQKU3Q-J5\/[52[O;BZB1%B.Z2-7#
M%V<8QA=AQC).>@ R<#0_CA8W/B*Q6\F_T1Y#"0LAC+LP90 WW02< 9!&>:XZ
M.39A6K48N'*JOP^EDU?M>_D[WLMCUL/Q'EV"H5:RFI2PSO.RLV[NZ\[6>VEM
MWNS@_@G^U7XD^&/[0'P0^!.EHNAZ-X1\.167B.RU"<2WM[*=*$_!VD!89-H4
MJPW,7&-JU]E+\1$C/,F,U\@W&OV_ASX@PZAJVGZ'=^([.U\N+5(62YN;>V8;
M40RJH5 X3A8B5.&) ).;US\;]0\1:C'8:1;7&HZA*1Y<40) !P S'LH)Q[D@
M#DUAFV48S!9A_9UN:>FVM[]5Y=?34]#*^(,OS?+H9K2_=P=T^9I6E=WN^]W9
M]GI=GNOQ<O[K7);74-%OH=/U:RW;;B5U"NI1UV@,=I=2Y9<@CJ#P:^;/C]X4
M\+ZAH%CH_P 6K[5M=^&OB35=/TK2;/3)'>_T_609(WG9T51';M&&4[2Q82E0
MH &.X\,72M8F;6"T][<J.;A"#$<G*A>V!V ]<YZU'X@TR?3XOMFGS?9)R0\9
M4D ,.A/7H>GZ=:^IIT<9/ _4)S5D[;7VZ7UT3VLM.AST<DPE/'+.J2?-;2SM
MNEJNS:T?=;]STKX\-:^%/"L-E;K'%%90+!!&C9$<:*$4 9S@!0!GTZU\:^+/
MBC?Z?JTB6]S<0L&(PDA7'N#D5ZYXK^.=OJ2>'K.XLKG4M:O8KN+4S;6TMPEI
M$A B=RH 4A]Q,?)(.1P,GYQ^,%NUUK=PUG/YL44A7S%_BP2,CV_ET-?/YYPU
MB<#"%3$I6FNFMO72WFM=4<?#_%V%S"M5H8=OFINSOI]RO?R>ETUJ>K?!OXKZ
MHGB:QO)[J^ENK"13'+YGR%20#%(F=LD9'!R <<YXQ5[]N7X+6,.LZ/XP\&/8
M6=C>7@BU6U\TQ)I=P,[BP^\$8*Q^4$?*<>E>8_!J[DBURP6:5Q%(P\QNP7(!
M/Y5[Q!%#I^H276H21W.DZU+=VE_%(IEAD)>1#@*RD.,*1@@G&0<C!^9P>9/
MXR,I:PNKKNO*]U^#]#ZJI3J8RA5>'=IJ+L_5=4K-_)I^9\U_$/X:6)L96TW6
M7O+[3U4WJ7BBVWSARLQM@IP\,8V$N><,#@ US.G^%X_$/A^YTV[>3R;A@QPH
M+0D# =6P2"#R".X%>_>-?@QX@N_@_J;1^)8;O0FNA?SQV*-*'=41/,F9OGB5
M5128P  1D@GFO#/A-X[T[QMXJ@TK3&O[B1T$EI?M8/%:Z@H8J6B9L$KD$ D
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MUJ37?A?XN\*ZEXFO/ >J^)-*6QT_Q/9;L6BB16<!E^9?,13&67) )QUK.O\
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MQ6\@-TT>3)$H.6( SGN.GTK]L/BQ^R]I(>^6#3-+31=4VO,[VJ7!D< 8W @
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M0YL+)>]-.UNZN[:I*]M5)-V?-%HU_B[X_P!<\%:CI=GX7B6\NM*AGU>QU75
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M#I%E;N7_ +*C>VW/ 6VJ6((4L3GYRX&!Q4?@'QG;^.?"^HV]K<6W_"0++!-
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M,#/[M02Q&"!7J7Q%U+0_!'A2/^S9]1LXH/#\>B6.BK<;=-LX8S&5D6'/$@"
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M^U?3O[,?[?>K?M__  ^UOX$^-I+S3]7UBUF,?B70Y([*]>WC4O+#*-I4!U#
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MBE=:IXI\+I%-/#)?QP"XN&DE!D<NQ9=H[DHH.??%=#\(/%6A/X?M+.\GCA=
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M!P>Y&*H_$+X:ZEX,\)W7B3P7=>)[_27OKG1]2CU'P^?-@\E"P< ;OW#'(R0
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MNK!BQ< ^7&". !@\ [L&N,U_X_?$3]HBVUN.'P=X.\%:=XD00WL.FVA6XO(
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M%MK%E&_W9"N>#_GO5NZ\9I>2K-'&HN$(PZG!^A]1[&O6RK-)85>QJJ\?Q7_
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MJ/+@MXEQ$.Q;!R23UR>IJ;X\> _#>G^ =9U"^T:.^A@@\^2WZ))L(=01Z$H
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MRS#\JJO6:?/WWOR\J[)1TVNSSF/1--^&>GWNH>(M3L-'TG22?M%]<RA(D Y
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MXV] RLP/?FN%\"_!GXD7?C.^\23Q2>,/$6M?O]1D:)9IKC  ^9<
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M:!'^8J< FO;(/"\VN>!KFXFMO/6QCWY*DX X(]^*R?#OPA\/Z@_VB2>ZTQV
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M25TMDUHCWCPMX%CTW0[70-,FDO9Y55=2OS@&3 X0'HJ+_/GDFO2O G@F#0O
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M#<@FNBENK?[!%;I&BQ(@"JH]!7GX+ JFO:3UE^"]/\S3$5H49.C15NC;W?\
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M]?\ "_A73?#FG VL21QD9)VA%Z=^YK1)/X3R?8R3M(\[F^$-SHFEI)(RLV>
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MVZUKPC<LL#3?9(RX^0D\>GKFO#C6BY<K^01IMQ<V]M_3_@'F?PZG9SY<@Z'
MW?Y[5W^I:3*ZP2VK[R90K*".,\ YQD@>]='X2^&FB7;";4K&\L)RJLZ@%1SR
M#C'?TKU3X7_#SP#<^)]-CCGM7FDN$C8/=C.20""N1D^Q%%2A+FZ?><SJ04KV
M?W/_ (8Q]+L_!_P.T+P]KWQ0\4:?X4M?$=X++1X;K>TE]*,%B%4$A%W*68X
M!SP*]P!50*J_+XL^*)/#-F-)C9$54!=T8%0I'!![@C!%>3Z9\=+7]IRS\6Q_
M$WX!?V;I?PMUM?\ A%6U=&FEOY#*8BT?"\E%60B,E"N,@\9F^)OC>X\1^*;^
M6\95\^08P-HP!@ #H .U>'[:<HN<7>+T6Z>GQ;_AY'V^(P$,+[/#5XM5H)RF
MN:$H6DHRI<CC=WY6W--NSLE;5'6>%;Z.*>&:-F)EY9VP..G%1_$?4_#OB/3]
M3TG5K"P\1>'=6A6#4;"\W&&;:XD0A@059'4,K Y! -</!J#W%H8X5N+J38<1
MQJ6<@#)P.^!SZ'H>*WK6UAU[1ED\EC&\8*J@VISD8(R<$XY]O0DFOH<BX?I9
MA3FZDK6TLK?>_(\=UINJJL)-26J:T:>Z=]TT]4T8OB#Q1:V^A:;H^DV*:3HV
MD(T5G9QRO.06(+,TCDLS' &2>   ,"O/_'MI#K^C75O-'YOG1E&4KSSZCM71
MZ_INJ-;>+M#\.^)K7PGXFU;3!'H>M3Q&:+3IBXW9ZE=P5E#@'!.>U:?PQO--
M\5^$[SPQJGC2Q\:_$3X:V\>G>+[D6\D;>>\C%3O9%60H&6,D<DKS7SV,H_4<
M6\#56VSZ/JM.]CNAA<16PM7-%4YYPFN>-I.:3_Y>2=FN5R:BVY7<I+<_//Q7
MX-CT[XCWMK=R2*LVUW8DYCC#"-B3[94@GUQ7HGPP_9G\5_$RSO(])\.ZAK&D
M6<9A25;<21R  X"-QN8CJ!DC\:^B]3^ NJ:'XPU74['PO;^*]*U6Q:'4+661
M(4CB#!O,,K?*BJ1R20,=\@4GQX^"_B3XA^'_  .OA_5+CPMX1LM%MK=O#5A=
MV7-S'>.\\_VIY5'EF-E99HB3E K <5YN-Q'LX7I_$S]"R>I1Q\J5*K6C24EK
M*6J6G:Z_%I>9\P_!W]F.;4=:CTN+3+\:EYYBE@#/&T1!(*.,C:0 <DXP,U]4
M/\%KOPK'IWA/2=,MH1>7$5OJ=SLEGCG3:\B;FVD(/,P&92"1M#<8SE?&6^\+
MK\4[74IO&-]>K_9=O8W-]HX!DU&XBB"22F;@,6P QP <9!.3BRWC;Q#)/X9U
M32?&/B?P_P"&-.NG-S:W.D)=Q:XC8 1YV&<@+@%2>OL*]KAGB*M@JCKUUSW5
MDI:V/G>,N"7G670A&LZ2NI77NWM>W9^FS77L?3WPY\*6_AN>TLV6Q2^M8TCN
M?LLQ='DP"S*",A<Y SUQFOS]^-G@"SM/C1\;M0TE7&A2:[=>6&(Y? $V"."I
MF#D>@X->T?M)?M6>%_V2OAQJM]\/;&2W\;>.;B2>)I+0M*)G.'N"N29&4G"1
M@ %NP4-7QO\ %WQG\1O@GX1FM?$_A'4M.TZ>Q-\07WRSM(-Y9SR2S$DMG!!S
MD YK'FE/96N]EHBL/RTG[2K4;2C:\GJ[;OS/+OA_X;N-2\>V4MC=ZKI=Y;3F
M875G+Y$EM@?*T4@((<'T[=.]:7C[X7>+=>\':UXQ\0>+O$EGKURR^7=7UV+E
M\%BJ)+"020Z\Y&"#C (KRKP5\;?&'Q:\42:+X5AM].4VLUU-)<,6%NJ@9<%<
M=,@ '.217IGQI\57E_/96^HW?VZ6SM(E,Y41[RJ!22!@'."02,C)YYKWL)BJ
M.%P\J=6FG-IVZ]EKV>FG2_;5GQ^88.IF^,AB,+6DJ4&KV?+M=Z;7W5[J]MKV
M2'_LE:#H?@WXBP7OB^Y;QOJ]FKM;W-UN.GVC%2J1'>"H9V.!*0,'L:]@_:0^
M FG^)M+\.S+?Z3#KDT)-[!I]P)6VJ<+%<':JF9 <*X'SKN)(X!\>^#'A1M<'
MF1J\IE(=DY\O*GC(Z' )P2.,GUKUCQ!;+X2^'?VR:=/M3$Q)&I^:,=23W) [
MGV]*^APLJ,,"\'6IJ4Y]>W;:UVN_R:9RXC(Y4,SIYK#$RC3II^YNY.RUN[Z-
M[QZ;IIF'X1\$7'PC@M[[PW<S:7J\<PD2_B?_ $G@8*$\J5')*XQSSG KS7XN
MZ3JWBGQ8=5:&YN=0N0/-6-';?@DDJO(4 9. ,#DX&37M#Z@+'2K6X16%K*$2
M.9\8&1R"_0'(YR1].]</XQU32_&&NV&F_P!KVNAR%FN;B]D9E6.%!D@E2#N;
MH,<D=*UJ2J/!_4ZB?LW:R>BOTM?1/7?SU>I]-*CEU.<LUIQC[:*=Y+WI6;U3
MM>35X_#K;ET2:.%\$3W$-J;I@T=H%+)*ZD)+API56Q@D$XQGL>]>]?LQ?M/:
MM^SCX\@UO3U%]IT^V+5--=]L>H0YY&?X77DJ^,@\'()!^E-0UKP[\2?AK;:?
MI=KX9TGPA/X6%MK5P^RXTK0Y( &698L;UD<$Y88)#J?O $_!4FLV]]JL\NEP
M-:V.=L,98L=H& 23SEL9.>YKR>(N&'DL:2G54G-;:WNMWU5NBUN][:GR7!G'
MD>*YXF5/#RIJE*W-=<K3^%7TES63;]VRVN?M3\%O$GA?XZ>#K?QIX)UZ9M*E
MRDSN5@GTN4#+13C(VE0>IX(Y!((JE\<_ W@WQ$Z6.L>/O#%VSH68R:9'<(3C
MHS["#Z<FOA;_ ()/>-KA?BEXL\+O<R166OZ#)<F ?,KSP.FU@O<B-Y!]*]>^
M+WA@WNH+8Z?<))?7,P@BMURCO(Q"@$$8Y)'M7P^(ITXRYN7?S:_)K\;GZ/E>
M4O%U6ZU9QY>T8WMYMI_I<Z#XD:?>ZIX''AO3?CTFE>&(%VG3M,<6Y*CHBNQ)
M101T0"O ?'GA7PC;7"SZQ\1+G6GME*(NH:_).B \D[6;&2>3QSQQP*Q_C5\
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MIJN9)7G*3DDDKV:DV[:ZIOHS!NO&A^#WP)USXF>.#'+KGC53'X7TFY4HWE#
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M:UT]VVN_3K9>ME?0_37XI_MB^&? 7PZM_#7PZTC6M<T^PMA9VK:19,]I'M&
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M4\+$*2!M<=B/J?PKM_AMXBNKK6[;R]\MQO55C499\\8 JO\ '6"RO]=^R:A
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M"0,\"O1?^%4Z_8VVZ2334F;KYDKS'@8STP/RK*^#NN3:7X#L9IKG=>7J"YF
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M'=8V,,,D=F)\>9(7.6=O]H]2?4U\Z:7I4EY\16MX=C6^GQRW$K21NZE$7YV
M4@DJ#D#.,@9XKWSQ;\1-2^*'PT@O+JW\AXL)^Y;<@XX(QD &O"UG.C^,89I)
M[F+S!)%B/( ,B%2<=AR"2!GBN_*906,IU*S]WF5_OUN='$$:M/ 5*.#7OQB^
M5>BT2LCW+Q7\1]'^'OPVUZ;P_?OKMKIS6T<$\J"-I9I  "J9)(#') ZCGH"#
MQOPG^(VBK\1-#U3Q?%)<R13@M;R%RF\9RLRH-[(QP&"D$#D GBL'P?X_A^)I
MUCX=Z3HEA9Z7"MG)J3R //<3H24V.N"J_)DKTP<=!6)\6_ $G@W4+*+3Q-'J
M'V@QHT3$2;VX 4]<DG'7O7VV)S[+L+B8O"T^965^S];Z_P!?=\#DN3YOCL#6
M>:3<9MR2:=FGIJFKI6>RMZWZ_4O[;4FG:W\,K+6KB-$M[V_@T_0]1L+&4HFG
M+;;UDCGPJ3(6+*QD;>3TR5(KYO\ V>/A'XN^)?PWL?'NE>%+G5-%-U>PQ*ET
MD+WBP9!*KN#L5!RP4$':1W-?3/[4>LKX5^"7C".PU*;4;UK?2M)U?0!=@VGA
M9EV%2J8 <[D*#:!C<2:^?/@M^TAJ7PM\%:;H=CX:T2Y;PW;7O]C:I-++YVC-
M.Y=B(MVR3)=@"1D97((%?"YWQ=B\\FLPHTHTY1:25[I<N[;ZN]MU>VCOH?;<
M,\!T.&:"R;$8FI6I2@Y2YH-2O4BG&*C)IQAK9RB[6]^*=QT[>(O'&C6&I76H
MW&L6=K:II\*SN9#9Q+R%4'[OJ2.3W)K:T[0-NGAL=LU1_9%NKSQA\8;#PC#;
MQSWM[&TJ),_EQ3VRJSS.S'Y08@K,W?;SCBO>O'/P06#Q7H-CHVH:7K.G^+IX
MX=*O].F\V"X#S>2<' (*OD$$=JPAB)U:EJ\W*35U=W?F]==]_,]3$4:5"@Y8
M2FH0BTGRQLD[:+165TM%V6FB/MC]BS3/%GPG_P""5VCQ^&_"[^)-0\;:G<W,
MJ'4H; :? \Q!G)D!+GRXLA5!)/H.:\^\<>'/#<&D:[X=\26,.N>&_$*Q+>6K
M/Y;;H9!)%(I*LI*L,E6!!&01BOL'XF3Z;\)?!WA7P#I\=_91LC66DRVUE)-;
MP-:VY;]_(ORP(44@,QY8D8ZD?*'QV\/QW^K2S6)2:WGB2XC5"/DW(&9".HVL
M6'X5XV;3N^1OX='^?]?(.$G*-ZT[Q]I)SBU=/1V3OMHXV5NJ9X]XYT*Q^(5U
MX9T/3;.'2?#'AFV>RL$DGCFGD9B"\LIB4#+%5& H''<DFL_XH?LX^!?$GA&5
MM)TE([K2[,2O>JCRB>=I2B*S2, %QDO&$)5N> ,5TG@V#^RKI[B:*W.QB#'(
MX!('7CH17>>,-3\-W/A2>50]F]W"(HY7QOBE=E&XX7D ]">0,CO7#D_$U/+)
MU,-5P_M'57+!O3E;ZWLWK>_2S2://XXR3%8S%T,90Q$J:A+FG:[]IK=IZI=[
M[\R;35CX$UOX=:?X(UF*;[*GG6S9V>7YHR,XRN#D?45GGX+:Y\3/#L]Y:KJV
MIZ+I,(2268/+!IBN^U=H8\,2.-@/7GGI]LCX)P^&6BC>:VFCO!F*0J&,A)((
M)SG)QG.:JP?"N&W\5Z79S75XNEZ=<23%H)?)ELRT9($649"XE2.3#\ ;SCG!
M_3.$LGP5>;IXW$RA%)O>R>UUKIJM/R6Q\OQ[GF-PN&AB,KPD:U:4HQM;5+6S
M[NTK/31:MNUS\_\ 2/@UK&D:SMM8W,'F'?%+"2I;[I.W&5..XP1^%?IM^P%_
MP4;\5?LQ?#JR\.^- WB/PW;+LM&:<M/:(.2@9LG:.P.0.F!7%7/A'1W6:\>*
M0M,"Z;PHDYY+-@ ;B3R0 "<X'.!X[\7=.NK/4FN%B\C3HL?:(SE05/H!WZX_
M7BOF\PRO$1KR> F[Q;U[I?Y]G?S/I:+CB<-'ZW23C))N+=[7[-6U7=6ZV=C]
M2_"7Q:^$_P"WAH,S>&M9M]-UA01-IEZ$Y]PF>1[H0?53TKYG^-?[*UOH6H22
M1M:MIS.\;26MK%=0NRDAD#* P8$8*L 0>,5\M^#+.&-=/U:QDDL]0CF66TN8
M&(D0@Y!89 ()P<\$=\CBOT*_9F\*^'1\=?%GC#6[B&SFD\!66NWP=C';VTS-
M*L]RPSM#[;=<L1N&6(ZDUY^!A2S'FYERU(ZW6E^]UM?TL>O&K7R#"PQ<&YT)
M.WLWJXO2UI;V?FG:UM;GPUK]UH/PXUB*V5FN]3CEWE)+0Q 8^Z"K<?A@CVKT
M;X=:[J'CF?3K;0[/Q/XA&FYENK73K9EM[<D'!WEF08)Y+  <].E>!2_\%&?B
M#>^*]6FCUJ36;*_N9&1==5-3@\LL=I$4RL%)&#GC'IFM31/'?Q<_:VUE-!C\
M3>(-3L[H%%TRUG2PTX  ?((EV1 9*@*1DD@#)-88?#<U14J492E+HE_E?\CZ
M+->)'AHNOB90A3BM7V2]5&[_ .WD?2'CWP-#<^'K:S\3?%+P7H32 O+8:GJT
M%_-9YY&8K8LQQT))4#G@< X,'Q6^&?P0T*VMYOV@M+U#4+*"6VLFTWPE+<W%
ME#(<ND,[*K1AQP<,,#@'%?)OBGX!VOPTCNSJ,UNMZ-WDR6:"XM[@J2&*R @'
M# @D X((->:W5Y&+Q8XX(UD)&9"QW8]S_A656FZ=>6'KTN62W4K\R?GJK/Y7
M./ YW_:,(U\)64Z;O9Q4'%KRO&5UT?O:_>?IE^Q?XD^"]MXSN-6T/6=:\0?8
M"NHP'4=+$,VH76XJI*,[']SDE%/!9]YY49Y_]N'XN>.O%_BJZU"/PYJ,6R?S
M(7O)E1!$ 2"IW$$C&< <>E?-?[(EU8RS7^@WBQM]K_TB)VY.0O !ZCD#OUKZ
M\'B._E_9_P#L=QJ-O?13V$BYB8&ZL$VX99%P6"JI)5UR1QD8'';0J*M4CA*N
MD$[Z?KO_ %OW79B:53"4YYQAUSUG'EUW7E%*R7-U7=^[K9/XBN=/OK[Q"=1U
M1+G3IK]3<)'/$PWKN W;FY8$L"&P <\>E>K^#[H:8]J%OH9)N&5EYC '0DD<
M8/4$8]:C672[>Y\4ZM/J^GW26>D0Z?:V5[!(5GM@PW&(X#+(2,*,XR!D>F7\
M#/"5O\0(&N]02Z2-<V\*(Q3RV&,[AGG).,=/;T^SQV0TJ'LZN$E=65[K9^C;
MNGI;2W=GY;D7$6,S.6(P^/IN$D]T]T[:*R333O?6]]E;;WWP5XRU3Q[XV$U]
M;7%IHLMR[VT&FS&+[',^#+,S!F\R-Y 2$ 4)DG!&*]WTJ?4M'UC04TO3[6\@
MFU 0:I/=WQ@ETVU !$L:\&1C\W7/(48^;(^;?A=I5OX>UR1H]1U".!9 8EA4
M2QOC((*GL.!Q]<YKVK0_B;I4_@U]8E6\MYM-G%O<1OMQ)(2-@BR1G<&&.<GG
MN"*Y^(/KV88B,G%;))1OWZIWU?5K3T.+(<OP/#=.4)2O&5VW-Z?#;>/+HMTN
MZUNM#RW_ (*BZ+X7UZYT;6;+4=+C^(6G6#7%UIBR8O-3TI25,P3N86!/)SL\
MPX(0X^%II['Q1>RV]K$L<^G01B\*]':4R/&Q'J54C/L*_1OQU^R)X7\>?M(^
M'_B[XC\5>(IO"ZVYO5C@:"'1=-2UM'VO?SNX;[/*LLH5$7YFE<,VT@5^=^G?
M"VU^$'Q<\?6FG:HNM^'/$U_#JV@:F[[OMNE;&:U<' P/WCKC .(@<8(KQ8RB
MXR<MUI\]#ZK#R?/1A0?-&6K?1)\RM]ZT^]:6,[P%XSC\,^-HA<6":FA1H9X[
MNX*I+DA@!D$ @J,'&<]SP*L_!']HA?V@_BIX@\'ZKJMK+/HLSCP[93D!I4,D
MBW$2O@*[@+&ZA0 1D 9!KS.^UV^_X3+59K5) -*1KO<8RPE*.,(#T!().?0'
MBNZ_87_X)=-^T]X;BUB>+Q!'/?ZS!!!J&EV;W/V"6<R,LDDB2((;>()EY<D@
MLN!7K5,^KU,&\/B)MQ5O-ZZ+;5_COY(\+%\*T<'FE+,,#17M'>_1::N]]%==
MK;:;N^#\:_ DWPS^(^DZM9V5Y+?>:?L\,*D2R1MP\1&"2&'(&,Y (KTCX@_L
MN:_\>(K61;"XTEM/MI;C5[[5+"ZMH/#]K$F]IKLM$" 0<*L>]W/"CO7T%^QW
M\'/&FN_M937&O:8_BV_^$'A*^N=-%\OV:+5-7AGFAM+6>5@H#NR!\DY*[3G!
MS7T0^H_&3XZZ;\-]8\30WW@373K5Y+?:+;:=.ND:GHJ+&;FWO"ZF/SQ]V%RH
M\P%@N#DGYURBJD:4KW;LOFTOS9]O&M5=*I7P_(DDG).6MW&4M(VNTHQ=WLM-
MTG;S/]F7XT^,OA-^R7X;\)_ /0?^%L2^%;Z=/%/_  E0?3;BRG,@E2*WMY2"
ML9.XQ$EB@4$@,3CZ8NM/U'6?BAI&O:TVAOIJ64<BV-]8I<W>AW[%2[P70&1&
M!D,,<E0RD9JUXOTLVW@&^6S\32_#ZQTMH]1N]7M(8XXK:T@RTB.3@+&5P20>
MJJ"""17+_%3X@&/4G:U$)MKU1=0-"XDC>*0!T96'52K @CL>U>Q6P\Z$W3GV
M7;SZ;_>?"9C44Z*Q--+WI23TE=:1>LFE%MW=E'5):[J_S]\7?V8_#OPL^%?B
M2SN-'^(OB+PEXE\13W^I^%8;RTO+^1_.CB@OXKF$AHH0B/(4&Z1UD8.3P:^E
M_%MII^O6%GJ_V/[<FDR*MQ GWKB)1@ 9(R1@<$\XP2,YKR!_$MW=:G$D:NTL
MK!0L:DLY)P !U))XQU->B^ +V\AT[4DFB:)((\3^>P@6%N@#%R "3P 3DGBL
M:+A#W9OY_KV.?$XF>+VCK=M)-M:VTU;?2UVVWHFW9'CWB[Q_)J*P[)DN+RV@
M5+RYCT]+#[5,,[G%NC,L8(*C:"<[23R>/$OB!X_O-9OWB\V1<'@?X&O>/&6@
MV/BW7;J%3-I>I6[&.<"//O\ ,O4'\P1R#7G>N? "*2\7_36D);)?8,8[D<Y%
M=$*:BE'HN^OXGGUO:U*DJDDO>;>B26KZ)622Z)));)6.=^%/PMUSXE^>MI/M
MMH\!R[$(6]!P>3WQ77ZS\)[[P3&MO<Q*H*X#+SGZ&N[^%,5E\+M+\DOE,Y)&
M2SGV'-;US._Q0U&$3;-,TF$EI)I2!(ZCD@"B4IS=FV[;"IT9;RV.?^%'@.^T
M/PEKFH*B%I(/L\.XX!9NOY#DUV'PF^!'B*VTI;A94\N=0P\Z<H"#W  )Q]:Y
M7Q1\5[?7_%6E>%?#RK;Z0LZQ22EN9%!RQ)]2 >:]HL_%;6<21V\GFJJ[5&<
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M_:)?MB8G9B7R ,D]\# 'X5ROQ5^-FI^(/'LGB'5(;>"SMHXK-K33X,0Z9:H
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M /A9?A=I_@F6^M=:^"J64GBC1[N^^W7&G0W+&:W2ZF4>7)<)<N5.TX".< *
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MWAR\MQ)+'<QWL,:JZQ,\:/)&S3+@@E%(.2*^YM,\"?$CX;^+[3X:Z+H6G_\
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MCU"[N'EU#4Y7GDVYP%SA03V  K3VTJ2?+\6WI_P3GY6W&*V_/S\E^?Y]'/\
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M)48YK2_9,\-:EX+_ &8++7OB9X8D\9> =*\0#7] T@QHUT2KMYTT!RI4%E4
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M@'\0?>OF#XF_"?QCX%NI7TO5[S4;>$G^,K, #Z=&_#\JWA7I55S<O+?S_P"
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MK6\BP7:F5CN53L'<9/&3WQTKZ6\#^ %^!>MB^T.:-+QXUMKA99%DCFPX( +
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M)N,;75E)V7-K:][,[KP=KMUHVGSVLDVKM;Z9JDVFS+>V,MH+B:$*6EB5B1+
MV\!90 #@\5W>EZS97.K:3:_;M*M;S5[AHM-AO)HTEO9XE+GR%<!FDC0EB4&0
M#U&:P/@G\-KKQGJZW-[]HCT_^$RL2=H/"@]OY 5TWA?XI^'O&%]J&H7W@YM
ML_ VM2:-X<O]>L$BN[V]*&.::R#Y=48'RPXP9!N(X%?1RS;$U<,Z-:TGUDU;
M9W^^W4\V6(I5:SY8-*ST33:;5HW;M>\K7TORW[7/FO\ X*:?%;X8Z5X U#PK
MXYT[Q#XFL]-U:RLI(M#O)(MNI3VTDT4,ZQ@L8A&%))(P[@8X-=]_P3_^%7PT
M^"GPEDUSP/X7U/2?%/BA?.U:?6+H7M]"<E4 2$"WOV..YP UN-I*;0,CE@2.
M.._;!T2/X##Q?;_"W0/"]Q\1OBA,=9\507)&I7=S#;IN98;)]RR7+#:"B[=@
M<O@MBN@_827Q;X>_9JLKSXBVS6/C3Q"[WVHV^Q8UL(P2EM;)$GR0K'"J?(HX
M)8G+$U\U3J55BW-332T:[::*W?K?Y>GUV*P^&CD%.@J4HU)24N;F:YXV:?N[
M<MT[-=8IWU9!^U)^PSH'[2VFI<F6XT_Q/8L9+#5+-<7,#GG!Z^8A/53]1@\U
M^9/[07PC\0:=XG;PQ-I5TGC6"\:QN[ 6_P"]DE4 [XUQEE?(*D=003CG'[ :
MWJVL7_@OQ!I_A?7+;0?%&HV7EZ1J%RHV6THD1G&3PK-&'52W + D@<CQGX;_
M  7U(?M6_"NU\<7=UXD\5:=:ZWJ,E[<2I<R1VLD<<,%N\ZDHY#,S! [F,<9V
MX-=%:M)U8PC%Z]>B#*:D*.!JXBM6C[KLJ;;YWI?F6EN7[.][[VTO^1GB_P#8
MT\:_#[XD>%/$GBV6SEL)+L6KQQ.X.B2.#Y1E) !!; +#@$@=,9^H[SPG9^+?
MABFG3G:L8 W#JF1P2?0U]T_MD>!?A7_PS;XD\>"\?Q'H,>FW,]K;Z#*EQ-JL
MD;%&B@;# [75M_!"A&)Z5\B>#OA9XP^+?PGT#QE\/?AKXRN-%\2B9)--E19F
MLVB8 $2_(K*V<#C(*D<U.(Q475A16KM=6U5OZ_0]#(<%76"KXZM%Q@JBA)RM
M%J=G[K3L]D]+65FO(^;9/&7Q"_9FCET/0];N+/2)I6G@ @CE$#L,,\3,I,;$
M=2I![]:\P_L&>65YY0\CR,7=R=S.Q.22>I)/)-?5_P 3=/:V)T?Q1X>NM#U*
MU!#V]^#!-&1P<*X&1Z$$@^M>)7EAI_B-;B+0)%FOX&)%K(0))%7EBHR<X%:<
ML8IRM9O?S.B%IRM3=TO/1&U\$?V0(?CE\.O$>K:GXE3PEHUCBP^U+9_;+FXG
M:)I3'%%N4$B)'8DD8' R:]7N_%GC;]G70H_AGXA\0V_BK11X9MKW1-9CM!!-
MJ^EJ<PPL7'FAXNAA9B!MX]*[/_@GYIFJG]C_ ,1>(]-\)OXSFU+Q489]+99V
M6Q6&!5CVI#^\+3>8\;$$#9N4Y!P?1_\ @I1^SI<:-\/]-U;Q!X@UB/9=1VMM
M/JDJ7%Q!/=/]I:T$BJ@6&WCCD2, $YXXR0/-P]:M+%2IR5X+5:+1VT=]_+L=
M688;#PPU#%*3564Y0MS)IQ5KKE6J:=G=VOI:Z>G<_LP?M1>$?"/[$?@./Q#K
M]GI-I<:M>Z/;SW),<2S^>TJP,^-J,RN"-Q&1T-+^T'X1.N?VD;:;4H;VVT:3
M6?/:W_T!XUD">2LV[)F9F 4!2"WRYSS7A?\ P3D^#VI/\!OB1-XDTZW\2>&-
M?C;4/#VBWTL?E7=Y#.(FE42 JI8-L#''*Y/ S7;>!O#VO_M*_"FZ\076EZQH
M_B;0]4B:\\*:Q.8H9&B<&*4*I5,.G1\<E,@XZ^MA<+A\5C:?U^?)3ZM*]UU7
MEZZVW/%Q.+QV6X.M/)Z7M*J;44W9<S5T]M4F]5I?:Z/F_P")/A&\M]1GCU"Z
MN+>2$_/&Q.Z)O0C.,U0T;X]6.@Z;'H<=Q<+*IP9@2 6]SG&/PJ;XZ?$%M-^(
M&KQZE:O8ZA<7<CO;*7F6,DGY59F.5'0'/]*\RUSPC=>+M:TJW:9-%@OV<B6>
M/9P /G)48*D\=<D^U<V*R"ACL2\/AHN2<K13MK=Z>K]/R/T+_6B>"RB%;.K)
MQ@G-J[46HW;\EH]_3?0] TO]H#Q%X+EO[<7#R:67\SY"?,#-P21GD$9(Z8/<
M5L6G[8]L 8X522XV".3S)&5I%!!P1QZ8QGKDY-<G<^!H=,\$+XB\/ZCJOB&'
M28A_;,K6)5-/ X16<9!<@KE2.AZC!QYCK?BB3Q!)(MKIUM(X ^;R]S ]?3/%
M>EB<!C,DJ+"XRBK=-5?ETL]&_-*_9[GYYDO$6 XA4L9E<TX72>DK*3U:NXQO
M;1_-;71[)KO[:L%S?[I+5TF!"J"WRHHX"@8'';&/YFMC4/V@?$=UX876)-%O
MK705,D:N('6,RHP1AAA@L"PR<X )R01BO#O!'PJOOB!X@T_3X8(;J\OYEAB@
M1-@=F.,$YX'J>,#-??VA_!;Q!X)T?0_!LENVO^5:O''+;R&+3M+5P"7>)@P)
M.TQGDE@ 1@DX]O)\?EE;VGUE\G*KK;5_\!]-^VIKQ#C,WRYX=8&DJG/)*6^B
MZ[;7Z/9>ESXI7QE!XU\4IJ,<;6]TY*2X  R3T P. <].E>[^,[:WT+]GK3+6
M%)EU?Q;=R33S8PHLK8!50>N^=V)_ZX+7;>'O^"=_A_PE+J=]XF\20Z>6+/IR
MI)';IW(W*Q)(SQ@=N>M+^U-X#D\&:=IT'E_:;/0O#-K!"UOAU$MUNN3DCT\[
M&?;&<]/@<3+V^+E6BO3\%^5S]JR_-L-'"QH*6L?>?162;_"3CI]Y\,6/PNU3
M61/>PQH(6=F5G?;O!) P.I%>]> /V:-(L?"EO-?PQR7P(>65IB#&1@_)Q@$Y
MR".F*Z+3?A)J%GX9M8[S3)M/DO+8")9"GF@$ !P@)(7W('/!P:P?B/\ %"Y\
M.WC>&M2BA,]G;#;(C AR,<Y&"2>..O'>O3P<E2KNGBURRT:NMUY7\]_N/AIY
MY0Q%XX67-'5/E=]?.W7R/6O#WQ<NO%U_'H^JN^J)K$*V\MU'*_R112%BYB7:
MF9.0[%?FZXY)KS_]J#X:PWWB%['3;*V_LWY7683(H ')"KU+'O@8'%>7?#K]
MI.\T/Q2UFQ_LXF$P?:-V60GDE1T)8XP#D]CZ5]1_!WXKZ>W@S7H;RZL; W4Z
MHVJ7T$5E<2PDJ!*$8L\+;1(K*00P8D'/3IS'#8GB;/E+&8KEA3A9-JR^25E>
M]K[7L];V/RJK@</P7@98O)\$[3G?DBW?5J]V[NUKI;VOMRWMYQ\)/A=X=UK2
M;*UL?#S:]K.I3-917,4J+<V AS.ZVB!@LSO'Y@ ?)!CX(!%,^"7C;3_A=\7K
MQK>Y:]ATO4#'.6P"<.<#*D@L ,-[AAR.31^*7P>UGP]X:UKQ1H'BG3;/PUJ-
M^X@M=)F>XN$5@5 #J,A=N1@D8!P17A-KK.J_#O6]0M;RWC@CU !T>+&W<IP"
MNWID,3C\:]3B#,,!C,!1R_!T%&5%)2FG?F=DFTTW=/EB];M:I6MK[/AUEV9Y
M=FV+S7.,=*I2Q-^6DU9TU=R46FE9ISDFHV3=I.]]/LO]M3P];^!BDFERQR:?
MK$"WL97E!&Q) ]#@KTZ5\?\ A7Q]/\+O'44K#;+(?.<XSY2D9&!7L?A[XUSZ
MI\-K6UUB6WN[>.U%G#]IA,BQH7)&UAEE8?-@@8)Z\5I_##PK\-;O[3)=:-<W
M.]PS3Z@Q)N!D$A6 (7CCD 'M7FY=-TJZE-KE>FKT5[7/L<\S3ZQ1BHIRG!.[
M2UE:]NF]O76YH_"G4(?B/XAM'L]39+=\S2EP/,QQG:N0""<@$<#GK7HW[2/A
MO6]+\*Z'=>$=8ECU<ZG 8KI&\J?3PLJ*)05),B*CD.#R/E8+P15B;]FG3;_7
M;7Q1I-C'I<FYMB6A,<%RI)92.2H!#8 &,D').:\FU[QOK?B_XL2:/<1W6G6>
MERH)XSN>#3T. \I/0 ]>>3G&:^VH\11RO'PJT;5.5/\ %-6O:ZWUM^)^6Y[P
M_+BS))82NW1YVEO=KEDG>R:3VTOZV5SWS]F_2I?A]X9M]&_X2N^N-4M;V=]7
M(MHD@,HD###ON=RR, 6P 5"D9/->]^(OA!X:^-'PN\:Z7K5A#I]GXDL4>]O[
M*!$NSY1!BF9\?,8V5=NXGC('%>'Z%X<\-ZAKND>'/!NGK>W>KRHUY>@DW%SM
M 49 X7(  XX'/ %=U^W=^T9#^S#\ +C1=*:&77-4GCLKB7JSL$)P@_NKC &.
M2,GFOE\\S:IF^/GCII1;M=)=;)6ON]MV_DKV/3X3X-HY%E='**4G)IO5O:*D
MY.5MHZ.]DM]-;77SEX^_X)X_!?PIX(U!O%?Q*\:7*6,#7$T]O%!#'8(,$NR*
MCLY&0,$]^ .*XW5/^"=O@WQ9\*XM8^%GB>P\;R,^!=W4C:9K.GS)CB-U81EA
M_%%,B$]0P.*Y[]E[]ICQ5XQ\3:YX;T;1W\2:GJ2)JDH:^>S,<5MN,AGE (-H
M ^9(V #X4 YP#Q%M#XQ_8H^)6KQZY'<0RZI';Q77V:426]S*N29PZEE+$< Y
M!(R2!Q7#'!XM4Y8B5/\ =JRYEM?JO)KS[^E_9EFF"CC%@HXC]Z]>1VORZ6?=
MI^6FC6NMOT"_8M^//Q"^!WP9U#2OC3XBTNU8!++PUJ]ZV9IY"K*%G*E@40F+
MYB<'?C<37IOP"U3QU;? ^%OB':77B+QE;W<EM<0V(MH;F[MWO#''*066+:D)
M$C@')4<#.<?(/P6_:;M]7DL?[3MK;5M%U"X1#;W<(N()74;P2AR005R2!C(!
M-?5^I7'QCNG^'\?PRO+&^\)W!EN?$NH:FD-U?"Z:Z9_*F#E0+40LH!49 ! ^
M8#.,ZK]A[2*;Z::N_P S@K9*Y9@L/5=."D^=RFW&#2BW:\=5S+1I:MVM8O\
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M\9Z=I_C6XDAN+=)$ ^3 PP)[@]17H'BKPY9^,=(,<<;0ZAP0\HRQ!QP?51R
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M4:ZE+Y=C<*&2ZB<NB$=/F7/7\B.],TKX@W5UK-S9V\*:A<-)B.5#A%R,$X
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MZAY80ADCF&^'<#QN7!!^E+$95IS4=SBP^80G)*J[>NOY:_F?H#X.\76OQ/\
M[.U>^TVZU"XTDGRK"VCRFJWK *HC.,  #)R,)NS@@#/NNBV(_9J\'ZKX_P#&
MUQ9WWQ U>V\J.-"5@TRW7)2U@4DE8TR2QZNY9B<XKX>_9:_X**ZO\&?AWK>C
MWF@PW_CZVO#+%?S,7CAMG!WO$G0L"%*@84 MQQBO%?VCOVR/%GQ[\122ZIJ=
M]N5"OEABBY&>",\@_E7SE>GBO:N+W[]$N_1M]5LEO>^WM3P^'E92?N+>WQ2O
MK9=%'HVVV]K);_0GQ<_:"M/VBM?N+*Y,=W'<:E%%)>PS)&+>(1/D2;S\BL<
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M^!7P_M]-LTU"[9=D9!W,>G;I[],5B_&#X7ZMXN\?W&L6UY(HMV"V\5I/L?:
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M02*]!\,Z7X-\;^'+KQEH5U'XL\(>,VBNK&TU&(R6NF-;0"S:*&)@)+=PJ%9
M226R>]>7_&/PY?:@UNUOJ>B0>7:2+IFD(Z6C"TM5!=;>+.62)74L1TW9.232
MA6J2J<U6:<6E;U?GV[?TWXN(JT8)T,/1G3KPE+FW5E%.Z<?LRA;WG9:J3>EE
M'DO^"?WP@\4?LP:[XGM+SQ;H<_A#5;V!=(+2BSGDOIB04.[:H>4* L2EB2"1
M@#GL/VYO$L'Q.O/ 'PGOO!]MXOM/B%J,CW:SW<MK/8); -YUL\8+"X4LQ!'
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MR&P#@Y!QFN;\4ZC:Z+XF:%=-M;*:8L8182I<VZ*PVL@^9PZ,."CDY'!Z#&F
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MBT_2IOLJ^7(@3H-U%9>K^&1:WA2+5-0NDP,2+,B@_A16?O\ ]-&:P\NWX/\
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M (!R/AKQ/:Z)<VUGYJW&S#K)D < X#-UR,=,<_A7H/A_PG)XKU?SEBCVI$J
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ML>G6*SR@.ZM$JON/HRX#?H?:O!->^$VEZBZ/)$HN(SD%0!D'KGU]:]'^!O\
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M^'OQH^(>H_%WQ5X0O/"?Q'LM7OY;'PW?:B6@N!&\:#6EMG4.9&^52ZYBWKD
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M/";3*H<B"*>W!SSL.R0$CUY_&OK7XCWS>,/^"=4?BBW=&:*Y6SO-DA*QJQ4
MJ>I(90">IS[5\R>&_!_]KW\3QIN"ID\9K\WX9G#&4)RK+FL^57LVK65C[;B#
M-IT*TI9?)T_>ES<K:3=^WG>_5ZZMF&?VM/$$&8;KP8LJ$!?+BO!)!QUP)$W
M$]MQ/OWKA]9T?6OB]?0G5((].TFV8R16,"A0[-R6D;JQ)/<FOHSPU\&X]7U
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MKB]TR\-L+N!1<(JR1R0[E+ %(V4A@59<\@D'G-?\97&JZFL,22&UL6$80=,
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M9;9W@;3V1@C*X;DEB"1@#(ZCC)^<-!^ 1T,R6<(D:UMYUFF^SE'E<J-C.C@
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M(+2Y2-_,(LT(#2AB!L,8V<CD 5^O'C#Q?9Z7X7UC4-0^V&YMTW"UNU\ILD'
MV\G'!/3V.:\+*\ODI-U8ZIV3M9_/T_ ]GB?-*6)JI8!N-.?O2BI7CS/=JSM;
MKTZ.QE?%W]CWX8?'Z\:^\1>"_#/B"1HMHDOM,B9]O;#;0PQVYKY7^)?_  3*
M^"/PYO9IF^&>ARVDF]HQ#+<,UL"/X8]Y0Y/4XX]*^FM!^,T3Z%;0VHD94C5Y
MFFRL<"DX /7KV'IVK-^.'BZS;P=.T8^V7TC%44(=H4#C Y)!/)Z'I7K5,).G
M.,*D=7T/D.>K3FH7_$^6/"4>A^"?#ZZ5H)CM/+F:*WM(K=,P* ,D*H"H/<<D
M]2<YKI;B*VNHK&YFTQM3EM9Q)/(TGE2"'/KCKG!P!V_&M;4]!T/P$WABZNO#
MNM^*->\7R26XN]*ODM+:PA2>.'R@[ B6X!<,$(.0,<#D9OC[X8IX!\6:UI-I
MJ5S(^FW3PI<>9\\FTC!(R<Y!PPQU!Q7MX/,L/B95<'2?OTM]';7L]-O4^HS+
M*\3A\!0KXA-1K\W(TTW[KL[J[<>RYDO(M2W^FV>L+=:3&\-NS$O#(/,C.#R&
MPV01V///&>M4_'WB#^V]:TY;>5E/D')5CNB#.#@-U!7 ; Z$^M5_^%=ZTVE&
MY71=;U&Q:(N;BWC..21G(Y(4\D@>Q.*YF7PO=76H&1;^\CG9HUBDAB\N.VC8
MX8,O))XP<CWQ2Q52G-<C?,XZ7Z_/_@GS\*B@O8S;DU>S::T[>=ON/0C^TUJ_
MA[3+E;I--M]7EE$&J:K!I\4%Y>*"=B2RJ S!N&.<9/7)KYB_;K^'<4GB/3_B
M!;0M_9'B_,&K&'&T7:@9DQV9AA\=R'/>O>/BG\-[R]^$FMR:H(['6H]MQ:7"
MMQ?@ *S;>",AE/)ZY(XKS*/P+J/BO]G_ %+PW?7=O<_V/+'=NL<H=-PS$0#R
M"0'SP3P,^F?B,5A*<:,H0BEUT[G7E.<8BCF$*]2;;T3NV].B]$?*?COX(0Z7
MX8N?$"S+J-G!,+2Z6-0DMO*P)C<#H58 C/JKCJ*[+]EFY\,_#Z]N+VQAC77[
M\%=-N=1!9S*H8J$"@H69MJ>6^0>W/%:WA'PEK4FHG3H)+AY(6-C=69&8]0M@
MLDPC(QC<VUL$]#R#FI-/^,/@+X,^/[/4O#'A/Q#KNJZJRFPL[Y@D-@^#\D2*
M"6<,6PQ!(S@$5Y679D\%B88M14N6^C]+?+U_/8_8.),GIYQE<L)";A&I9W6Z
M5]?7JFNOEN:?Q9^!D/PM\(2>(/[!T'[1K\<8DO98&C:RF9"TA*9PLI+$8 "C
M ZG@5= N(= _8ZU\0!(M3\6W<&@Z<FW<[Q;T>Y<=P652"?0 #H*]$\70ZG%\
M/=4N_BPEA;KJMQ'?:1X<MKLI]C<9R\K %B!N)*@DLQ/0#B3P[X*TGXJ7'@W2
M?#4=Q-I^BS2^7),I11+,%^7D=2023[XS7FXS,)8_&NHU9-W:6V][??NSU<%@
M*.6</2P].3DX04;R>KZ?E=VZ+38K?!SP#I\WP[U'P9XAT&QUWP]KRV[75K/,
M\#&6%R\;K(I!!5B3SD'O7J/B#P5<>)=<^SPZ=#9V&F6,-A;V=BC21VD*#Y%+
M88L#R23WR:[S_A52_#]8R]NLE]#@[2 <-CG'8CTK(^/FL?%CP3H'A6W^&YA\
M->$;[3K:XO=1MXKB34;C4FO&2:*,0HV^1(_*(CD&TINP"<X]FCGV&RV+Q'L.
M:H].:]KK?7^NQ\CPSA,5G->&21K*$&W)*3?+S62NHI.\K=E>R?0Y&U\++HYM
MVMPFPH/,78<Q$=03TY]AUSG'>UXHU>;4&@&GL\<T+ K(C;61ASD'(.1ZU[AX
MM^!=]XK\4:=_:UQ;V.I3Z;;/K,=G"(U>\*?O6"=(]W!*]B2,53\7? !'0+B_
M#-)\$PA+.XFEZ9WX)SW-88[-)X^JJ]2/+IHNR/F<1^[J2H)IV;5UL[/=/L>;
M_!G4KR[^(-A<:M=WEY]HD6WD>YE:1MIX !8DC!Y%=AXI\)>$-4^*.H^,-#T+
MP[!\1KA)+3_A( '!O2J^26*;@GGA5VY(SCD"L_79(?"&C2WWEJC!=MKD?-+*
M. 4'7 ZDGC->'Z1\8]+^&NIW-O?+->F]D,UP'D+Y<\EASP<]Q7%*C2JKEGY-
M:=CV,']>ITW5P]1TTU*+:ERWC+>+U5T];IZ-/4V_$?A_Q-X?9[6:"3Y>,@>G
M2L;P[\--=\3:C)+,S0J!U=3D^F#7H&C_ +0_AO6($\G5IHEP/W=T!* .^#P>
M*UM/\1VNJW1EL=?T%@YX25G4#Z@ X_.NC#59TI\]-V:/'EEF(C[\5=>1S/AC
M]GN:UE22>9I(S@[.?+)R3R.I'Y5WWA[P1:Z/(1)#;*53!)4<CZ]>M5]1UCQ%
M96#R1ZQX8:- 2!;K)*WTZ5Y-J/QJO[>\OY;I]2N)K6-I&C\GRE"C@8//7\Z[
M<1CL77CR5&VNV@Z>%K2^([^YT-[O6IELEACAC!::5L!(E'4D]AC\37/_ !6\
M16^G:2VGVEQNMY<&:8 J]ZW7D=1&#T'?J:Y'PO\ %O4/']K_  VT .Y8$R4C
M_P!ICU9O<_@*U_"7A6+Q1K;S2,TS)C)<YY]ATKR7=OWCTZ=6EA(\U-\T_P $
M<II/PANO%MJ][*LR0,2-^3V[ >U4M7^&%UHB'[-,^%Z?-R*^H?!?AV"*P2WV
M?(JX_$\UA_$/P79I WEJ@D]!6;Q'*['FU:DY+GE)W/F9_$WB32CY*F:0+W#G
MFBO1[[PLRW+#:#SZ45O[KUL8K%5UHIO[SV)];FUA9/\ 2/*$;;D!ZHP.0?SI
M-2^)\$T"I<2JHVX.6R(R<DY).0,GH?Y51\1^$[[PY(9IHWFLY,DR1 G!]_3'
MO7(VVB_\)WXD%G;6DC*W#.R$$YX//7!KU,CSJ6 <J<HW@]=.G^=SNIXJI"5F
MCKU\+K%"TVFK'%@B1I(B<. ,G(Y!R3U ],5TOA&VU"\#??;: #FN[^"?[+DT
ML*?:#)#&BX4S,S$^V,\C_P"M7J$/[/?_  C-M),;B-HE8%=HP3Z@BN;/LXHX
MRHJE"#5E9M]?N[&OUBC*:5[,\\^$GPW76M<D:^39;VZF28NORXQD@^O%>6:E
M\<I/#OQ6UC2FBMXO#-M-Y=C/.Y>1Q@$ #@D9/'ITKW3]ICQLOP:^#$JV(1=8
MUH[$"]0I& ,=:^$?&'P,\;2[M7F$E^]Q^\9HGWO'GG 7J,>PKSZ7LXQO+=[#
MJ8B59W:?+'33OU_X<^S?!'BO3C DTM]IEO XW$"8H<_0C(K;U/XQ^&O#ZA4\
M20Q'J0%WX]P3@9_"OSWT[6-6M6,-U-<"6,X(D)R,>W8UH27\MZFUW9_?))JI
M2=]+?U]QY]3V/-S)/\/U3/LC7/VAO#J7;7"ZG<:A>KQ&SRC8#V( X%>8>(M0
MD^+/B.'5I+MKNXM9% YR8PIR!7@QL=L."74,/4\UTGPHU2Z\&:Y!-;W$C1;P
M'B8_?'I[UG)<RMI\O^'.[#XBG47LW>_2[6GHDDCWVXO;B^<Y9D,(R,BG[8]<
M$4R[#<JOE&(X^<DY!!]0?S]JZ#0+*S\;:2+NWVB8#YXCW[\>E<SXR\/R6$WF
M6+>5(O!7_$5.$J3P]53ANMCEJRE&5A/$_C"7PWI]NGV1XWV-O5=GWB>23S@8
M&" >O'0UD6'Q"FUBS%N+:-974!W<%N#U 7(!R>,^GY5F_8M6\470M_+:21FQ
MG' )Z_K7LOP>_9VM[:..XU:16V?,8UX+GT)]/IUKZ2KQ9C5'DARKS2U_%L/K
M4_A/-+/0&GD!F5XU. -W^-=GX0\.-#<HJAFR?E.#C\Z][T7P1HETHCDLK7RT
MX4"(9_/J:YWXA:SI/A!6B5(X+2R4R2LG'R@9V@^M?)RAS+0>']^?LXK4\!_;
M5T35(O&/A37[>XM]-L=#LDE>:9@3*Y8_NU4<DX')/'-.^&7QE\*^)HPL-O<0
MWCG=(LC'+D=P,X(^E>7_ !E^)FI?'KQ[)+<'R=/@;9:VR_<BC P"?4D#)_*L
M?5?#4FG)');C88L?<)R0._U%>H[<L:?96$ZT6W&HON/K6?Q/X3\4QQ1W:6T<
ML8"@LY0^E,F^&?@^X/G*( 6'!\[*O[8S_2OF/P[\3;ZR=8I!Y\:X!W_-FNXT
M3XVZ;:,IFL'612 =K'!'J!V^E9Z[6)C@:,_>IU/D_P#@_P"9]0?"?P3H?AZ9
MY[>.UBN)<9\LY)'89ZUZ?::G;0QCYD4*.QKXUT#]H^W^WA(M+RA/#,S@X^O2
MLGXN_M%^// =S#-IZ6<^EWI_=@1DM'GL3GDUG&T&VU=F<LHGB*BA3FG\U_F?
M6OC_ %2#6UNH8V7B$J.>7;KCZ<5X_!\)?[3G34(KQ09599(F7(ZXQG.00:\0
M_P"%H^*M3L?M6L:Q)8^<-PAM@ X![9[5U?@;]H5;'RXH+MEEV!72\'$K#C<#
MTR>_2CDT]XZY86=.G[*FU?3\#L+W58_ \4VGZA:--&ZD!S]W:<C/3.?3ICM7
MAGCR>.WUIKFS\QX.42-VW +G.TC'KSGUKWN7XH1>)-.:/5-,M[B-OXH&VDCU
M /&?H17.OX;\'W]T9$>2!^OE7"'\LC(-=6'Q56BG&C4<4][-HX.6I%^^CQ6Q
MT&;QS=".WT]VG;A1&N2?H.M=7XL_8=_X:*^&GA[PWK5SK7AJ;POJ=QJ%G+%%
M(]I>K.(PZ3QI(C,5,:E<DJ02",'CZ!^%>A:9:;3;+8QY/_+-QNQ[]^:[;Q'K
M"Z'9*\*QAASN<@ #W->3BJ2K+V;V._)\TQ.78R&,P4N6I'9V3W5GHTT[IM6:
M/(_&/[.]M;QZ8A\NTTK1=.@TNQA9MT\D<0(!(!(&2<!<G P,G%?%OQD^%FC:
MC^T3K?AR:Z2SM7AMY+F=E,D=FY?RF+!>3@2(3CGCC)K[/^)/QC?2+=M0+0SW
M3$I9Q-P';IOQUVKU]S7R+XOTR^T+Q;JVK0V2:Q-K5G):W7F.5?<TD<HD5NFX
M-&I&01C(QR"'*E^[Y*?38[Z?/*%2M7E[T]V^K;NW]^IY?\0_A6WP+\563Z;X
MI:]M93)&[Z>'2.5&4H>,997 (/&3G)YP:6T7Q1XEDN?[&\"ZV;>2-?(N/L;+
M!&JY)&YP%(.>1W["O2O%G[4'Q2UW[,%TW2K+['"MO"\:>6T*   !E 8].>1D
MUQ>L:A\0?'>Q-0U>%(T)<*(1+@GJ07+$$^N:]K"9MCXT%2:O;9M[:WV_(\FC
MEV"I.<HN,7+XK)MO1+HK=%U_$S)?A+KVC>%_[+_X2:'S;Z5IIM*MKUY[A"[
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M.9BLU^T&:U2.X1F\UU8JNP$@D$D@8]QS['%8OBWXDW%AJS1K X03=<J%"@X
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M.73(\I@<C![$>WI4%O:-XD\8+:JN(H?NKVSTSBOJ/X:>%;70=%@AC51%&@W
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M.*C)(;"Y]ST %>4^,/C%'I5D\EK=8N "LUU@8 /&R(=B>['GTK)\6>([Z_\
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M4K,Z#6?$<GB2[D@2?R;:W<)L5B [9Y)/7/MZ'(STJOX3NKB#QCIUO)^]@DN
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MN5D;*@\C/7ZUYY>^#[GSY&TF[FC.3@!B#^%>G7\%KJ=R@DF8;ON[P2"HST&
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MI+Y#9-MQ#T76)+0G)I2]3\0W:_O4-OS;EQ5&'1?$**#Q7<ZMW6]DJD:F$:(
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M;C0UA:<W"?EIT ]S]ZWHH2:7+FAC_\4\6TR^M^T\"SYQU5NLX\I'?N3+IVM
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M:?/6SG<%=?^V0:3H8YWJWDW$WPNF%;JTDF[G)? =^9(VG5.&^J-08=!.;1S
M3[U:33H<XAA4#P\\49W83F!NSP.VZ!%57I%^<=;T-.RFN("*GF+%DV_IMW!:
M]W)0>7%$]QY$D;Z_ /Z D6\G_;ZT.K4?5K[WY>>0Q&K4RTF1?6<2"W\]O65K
M \VF_?C@KRA$@NK &I,J5_-A=]NEL+OD6[,8)F%$0A#E*,<I4J6I*J'5F_AA
MP%&W:+)(2XV^[MHOB=W^8?_MEZH8C[8K1?5 _FH/&H4-BOW?W6.3L;!)"#O7
M2"*(,VN@GE=W'I09BV)J009GY&S  G2<M>H@Q_4(!1SY+J6D:FYQ<;L,4P!
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M?1A;=KZ.@#XY4B]4-SQ^:C*'U6E^ J4W9NED-'FSQ_[)%'"R09_[^,/Q4\]
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M[N053]YCOS<F@(YR^62NVUUK"2*(7/PG@-C]:P  V4&52:#0S;Y)*?SY<#/
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M5*&[E4U'*"378W VV$G6JC=&A-> ,>^'@A,"S$-;)4]2FB(ZQ$_!8BJQRM<
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MJY$P+=^4+TWPO[@4FVL [8K.);B]R9E-0=8Z]OC&3[.=/6#DN$ZTKY2&(1*
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MI.#6),_*W^9*Z;Q1XGC0PB>Q]+FJ$6B393"][6(BBI"<J8NJ[V:,9>5^HE)
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MSB;:\UC<%].T#8_A@OMPR3:]/AI<3L( >PDPJ.*_CP"T:R5D<5T#Y'9L>9>
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MV;!2DIP'@K>:63D[&6[J@("#C9.=<(PK</??\@GX,Z);\M\U(-?XSAB,1,&
MX&N6R@;^H>W3$(.V#9N [) \V8TY!Q]);>%48^30<<K>O8)]W/MBP:BE'4C
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M$Z0>*W;X'70[FLIVFV$DXE^,Z1#ESS(7GLX4(ZII98.#[^6&32J?7S_P$:+
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M]?$Q9X^UA('M?]0*9>WZ)#+S?@PE#56AW$TWP\S7F<Y$3A\I6(KL"%*Y9O5
M_FVWTL+O1P"A6B4&IWU06\+7YQH=O"ZOOM&=&F=L<4L^CQB[NRFFH8Q?4^DY
M- WX";P>\3_^PZ3,BI4I5E9.IE0TOMR=;<]>[FO:BG) [[5,K_N<0O8H(WH3
MHCQ)).,$]F=NOV*;H+ B%\]L \OY,-8B;^A2H5^/B>9>X)UBE"FG,Q;7L+G
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MZ?@]9_K9$SEYZ8"GK[ Y;F;UR7SU8#\=_]2-Q-\5-*SB6$*0_NZ#<%7F%.9
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MAPH$E?MR^+][!(6T'HA-BSR4W5W@>OK/G]M@^IQ$C?W7O\YP-PG^WMN=N<M
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M,<\J84V8CRF^A_E3CG;5&ZWJ'^;H#57,O9ZG]0W_  1>_P"4;'PR_P"P>?\
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M",@/N0#&#QR"/I1IT_4KVEOA_4J-X/UN]M&ACT_P?>V:YB,%Q:L.0<8+J2,
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M>Q(&,]:JW%M'%J,EJVM>)+N1@IAF,J- 2<$F)E&05!ZD 'H,\T[%<UWT*B>
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M/*@7&<*@(+<\#.!227UY91&TNK..:WDY#J"DJ2=<E>FW/H<@>HIH<9-?\/\
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M>7WR1@G'L <]<XYJ=?Z9/M?ZN<['X;TO4]*NE@TI UMB3[.\;1%H0<A0<C#
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M%!HS7%QJ.@V-WIR-&JZA?Q*ULP') 9L XYR!SZU^68\ 6_B$;=2U3Q5J7/\
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M .AFBI/^"+PQ_P $U_AC_P!@\_\ H;45^I8/^!#T7Y'\-\2?\C;$_P#7R?\
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MGE$(BD\@ODC=U'''O4]G9:/<VC)="QN(5PR%B"A7L5[9]AS5=8M,/(TB07#
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MT3>^'HB/QG*#/V-S/[-*?VT;U;=NL@TL?2SW+85Z8TUW2(+6&M>=R=*V^.7
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MEF5HJ.%9#0R.7K,$'"[OF"*! @O/Z]LC41UF_*75W: [//?45%?Z4K'XT1U
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M8H2P-[!L="2H3>'M+2JZ]J7$-J'QL>/I#-3BVC6;)O4:%R^1<WE_6*T1#4C
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M?J?@!M>XF2,@<ET:;;5LU<1XYVNX/+A*USU->[H1\ 0=B-LXG76=0+C$.8
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M#%N9N)OS_-<&%G(MP?AE)9)A+Q(TP=K(_.EE($@I923N"$$!T)#F-123]S)
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M23TN\0C<N498SRN24'&]Q=-9+&WT=;W*/ /&C$(0\KT.3S.UH7A9.#BA&#]
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M!E.X@5&+I5$QL+6$U"GP?MI=(+T3:=<-()']U2%XJ>/=\D""&=$DNS-"$!6
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M&;/_[4WFY,P7FU7!CT[+#](:SH#E>BC_@[\M+)BOP^'5/G[G_BB6AZ]FQ<V
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M3JP0.@D+O4)4QKHC(R/$8="NZ;GKSTAY*:7SCSA_WS9=+Y[KEFY,R/6^K[K
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M<VXC!,L/'V_IO&5$(J4*&&4?^]0.J,O)_MO0C:(-T*>F356AH;(Q!JAF[E"
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M5&'^=HT^338Y!;UUZK=T8UB:,#=O']B,]GQQ=ON=A9;<L[#O&7:_Z.LISW1
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MG7MD4K$^G^9<Z*(E69W(@#,!KRR?>8O%/QZ=^XJU$+*"/ZI7D7X6'>32-,*
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M3=1T3\?WOR,9!JXY;1Z1RU<3L;VPPEO_T?U94=ES(,!PQ>0+,R;XXF2X=EE
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MT%U_*<I]4U29G]^ZS!*^$]W6$;!9$IFP2,B, HI%IIRW& $JI/HKQ23$RLB
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MMF^^'4G:B?EX7(R/^7KD\5WY_)WX*I;UWO'ZOQ6B4N/</EQ]+^H%IC@C6<Y
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MW?H-O*(V&.TI[Z>Y"_N,E],&(WSY9MKPX5WB*H\2K&0EOHIR(S0.3%>"5YY
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M&'-CFU8';6MO3TS:A@SM&[5WA/RD)L078EY1?.#"F3*6[^7PS&:>5L*!\88
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MH=SQX9V(@<>"V9*4[?#JX6C#P2:D;#OU#AG<\EFOC1P>8W\A0BB"* *2L0Q
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MRGZ>\9WFN.T1VL8M_:8U",J5XL56A^8#36;K-O6J'K=MT0 4?;.BBV@3D^,
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M@%!$,L[*6!*+P.>%6:;&IP=B1HV<T;>O%K=_KF-J$I,< 2G?SJ=?D&S"A2.
M%2@<Z *:9:2O!XR>2-ZEIP-&ZGH4.(S$]7UX#)OU5](0\.>5>";M1'NMG+^H
MKXPXL7_20E+""P&492UT/V4!RCA-05%(SC)!,89X]D.LZ-+-:+47R>9EV!?,
MW[O0Z*#MHJW@T5;R2&E6;U['(<:KP]JYV*Y^UR.HZ4HWR_*\4Z8YQ]^N4KW5
M)XCEZHYM2,/50<H;VJWNF%XW6P>,:\?47%2S]]V>W5W37_#W:OP9H24C4)0
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MQS*E26J9#G5VGJD1VD;(B+121HO#HL!U]$9'[]@OSO68S\--U#92Y!(#O8D
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M,MK2LMN"F%*Q=Y@]TZ^2/WK:*A ];S30M]2V*KQM>-EX(1S(=A",O@G63;C
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MW@(?=]:@]\6] '9\L]S/)*ZNZ%YVN_)YNWI#7\E/W5ZK6J[:MCLS@42*4B*
M@#(!:GO. 4TS#"B)!9*(BR+!=BZIT;Q3VXIW0NL+U6KD9WW/6FW&SUKFJ.UK
M8AT\-%L"4X=U=& ][Y?[%U]T3(]U):_T*4[3'] $60<GU@HGW\ZLF3"!G5HK
MA$Z=6[O'G2J KI?LGYWEJZLJK5__6*Y%\],OS_-J_6ZY4!Y0K7NV:GM@)H7
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MVGM^RSNY1DRHO*CMZ7LL24T;4=4S;<-%,5_7^E_'71=/!PWR<E[49?,N7OZ
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M;!;8$!'_%:[P]F62C3&H<ZG$S^J[_YW48EL#[*M8/<U0A@HNH0 \+:5.694
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MXG4]5F$\BG.AE=U[^G&YVK6!V/QY*,"#8*+ZH:]#U;,DHYCH>TN"YKIK0UJ
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MCG,\+@X;Y%7O4VKS6O=^SL7X:KO9W;VLOR]7U?\KE)F5\@)B+D&1PQ0@R5-
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M1HW$G6:?&CNT4D9\3\QHI>2TV<=M%\#$YO$(JV=JV4C^-FID;T[BM]*_C3K
M]Q6('CP#;F-7>00^D-DU]@)8&F>. /;8;K:C!C3M'!4^M/Q<!W'L',N$;G+0
MC%;5__RJ1H%W/ZMZQE,(699E("TH5.8A+$%),N7C8I2KC2&%R*8:]^6)IK8-
M'$@::5&C1M;HFY;6MEGJ)71-B'\<S#QS?!BX+!O,C@!;N"ZS3O#9-YOMP:2_
MX^RE <*VG>U1XZ3W;-_G75A3WQ-?56PM>%,(1U_0VZ2(,90JY# &<986BBM%
M"DJ6,N59TX0I^H09-"I=VS?1U%AS)VG7P^E%RVKS]E\!U80LQX'*,UGNH=36
MIVK$=,IIO *7#5F. UL@LG2%SY(L^S'I(<LK P0DRWXU#LG2X/.CU +727]Z
MEK\OY^K[,J_6K_N]M/Y#G],(/I,D%I+E*: (8H!8075-1-T)"Q$,,UX64IBE
MO \1P^8E")/AOA&[H]EGM6(B^K'585 Y<+.52?,THW&!=:4!M3(R%:#D*0*X
M%!BB/(\SB 949Q]]78*<:]]\54PCT7ZQ]GW&MH%Y!^W;HYZ1CZW0WHJO6T$6
MM.BZF62W++9NA5U/D76[L=PWKEVPY2 N<[<7EYGQ(DV5:1\#CBD#B$@!2$$1
MX+',<$9HQJEE!3>C>:=&@@=QQ*[T@#WSF0!N3G8CP^B9W_;E?:MVD4WT]GD;
MO14;J<<E. N8_'.:B3#!:<P"H7/,9?/XT.9B]]ON3\J()I1@Q40YS)6I5N1
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M*_+=3N61(_0<45NT?AW-=X+:$L,9/$U981A*OB,K%M XL,%EW7U3P9F9 _/
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M[=0[9&W+9UV8_([_]TN]UE^M6NVO[P5;"5*+3XOVSVJQR6G?M9Z;L2R3L>X
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M>(=D2!EA%2Q=ZKHTM\J=,L+H2B*5V?/>;IJT-UAS2"3)) *2B (@DC) &2*
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M";,S5SK=QAEV*K*4BF>5MTJDXHV5>-:WIA:/[?WU7:E6P2G.( 40EU"9MJ4
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M]NONTECTZVPZS1YX\V2X=.6IYT$6W#ELO6SC 1%+;0^O1,UV9,U:8:-(]2R
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MD7,80'U7G=X@)5Y+]CZ^%%[.DR"DYOS#G8_,Y"<1V.?GTX^'L>YBOIR\6Q5
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MKCM[N/61J\Z>5'&_YNSIQV-W+J]SVEPOKQ\?[7:IK=?$__S,EWK"<Z:JG)?
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MG8L78?D[KL\^+G&S/Z[,F+!",,P*6"RT'SC6"P42CPG$#1:E>))-8=!DP9%
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M<WH -ZU8U&=71AQO0FF>;W3M?/7RW?LZ)6DV)<KP!Y8U^H0R0#:UCI_[FJ5
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MJ_/-[VHB'TGFUT7&65DLKZ77:M):NR1UG,;6H?S&D-A&P8>(16N0H;9ZB=F
M*R:"Y\YS:W3DHNFT]1-,;).!"XLR$+O!P*94R07'H!1K6<!H7!GGF^JI)[;M
M [M6$MOVT?0H$HP>S)A!M#:K3<TEI_\PEL%AL/0?9:2,Q974VZ2@/U%BVUX
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MD+:_2/98;D[X,7\?4#Y^E]P]#D[*-FY.DL.2KG9\3'=V<A>=8["6*F<M@DB
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M)&R5LS'9Q$R>B\)9YM@.3^K<9ERS,96&$-;$B7NM:[4MV2AK(CBAR01V=40
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M#@&\"8ZKP!C*R5*,>E,Q]RM:$PD>TV#@?.%^,WQ*Y8S1!$BF=L%@*4 4O#Y
M%$=WO_$^^:8!WT8FP41H&P;E/43?!,X/*-N348PM&H,!ONV88&J+6^8R9,&E
M*SZ(8,-4"'YRAV>)S3X8>83.TP76!.Y.OL]^N>WLSC43B)C H21CC-D,'I&!
M,](:Z5AE[MFD,/]RU)R[B8;@S&9PS(22)D[( 7'D//SS\R)]_FUU6-'Z.Z;5
MI^6"_O$%%TH+7BL*2U4#*G+PLB;'&5/J@/@8Y&1MW7OL?VZM/A?<7E/R@\O^
MG%K8WJ\1HKU>+W-5+#\C@2%<OEM^PUUEV)T01JB*.FK=2:JE^G-B@BHJ7D>1
M:<Q0)*H:[]3@K>9@39$RA:RM;Z0A[D"W7$SH?1WYPH4+=/8<G;UB)1@,/"0Z
M\L@FJQ#XJU=1'0.NT:JHCA%X$];$@_(,*143@07(Y"F#2L'7'E+$T<)U8DZY
MI"<KA_X+5E$=!8Z7JZB.D503.'L^>HY84VUC E8T641%D$7$LB&E7Z*+KDC!
M)HLIG$<5U5'"/Z**ZAA)-/+ZM/OQ+H]7,25]U@Q\+:!5IK;T9);,:Z:U2S%*
M;8]\C7RXP-PX&$AXS]9(].-D4V"XR^/-J#6GG4+@TM08@X+ ?  ;<E')E'I8
M>H#AN(SH65(5A@%#/TZV!89[.;R>A5 B>=U99[6/KV8D;#M10O(.HPA]X'!D
M1O0LF0H# :(G-YN"Q+TLWI B"LX-66!9@,I:@"O.00Z6D0/!4^!'9D0?K-!N
M*=4P@.C)R[;P<)?%ZS)ZLJLL%!=(S>F<ZHA%!A)-*3%(ZWV?&NPC,Z)G*:@:
M" _]>-D4'N[2>+V1D6N)D(P@GJ!5!&F4I/&"]#8;[M*1%54]2O)GJ:@:!@W]
M.-D6&.YE\.K,.-L.=(VDUY0D']XGU" <(QK0&>1'5EOV*LF?I:)J($#TY&93
MD+B?P"LC>=^:(40G<WU>IU^Q6DSNZNL*.N\3ZP&)8_.A9ZFI&@82?;G9%"3N
M9?!:S9T*L0"K!>5*Y5)C?!:T]C41U&G32TD<F0X]2U'5,(#HR<M6\/"@PX!D
M1>:4P-K:=83<9G#2<&*(24$)7;3N4Y[??#G5R4#HR\2F0' 72@L,,>E$YHYA
M-9??,?#!UR&RO)A:'7:T3NC1IF&>.JIAH-"/E4VAX2Z6YJ+.11()/#!RE+EF
M$)(CK<995,$1??G(/CX]^C3,4T$U#!KZL;(M--P+I 5?HBY. ^K:BTA$"\&9
M "ZB%RPSLH-[X>'(L.0\%50#(:(G.YO"Q+U8FE969LXSR%PS@46H@S-=A'KC
M:0Q,17GDPT6?3@WS%%,-@XB>S&P+$'?!-*F\+45:<)@9T9 S!!\LD*M,QI&0
M5KH)6C7P\XQ,GL+,I@!Q%T\CXR<R<I"!;>M$9?69/2)(JZ,HRHM@^BB((WLU
MG&=H\@16MH6&>\&TX'(,J0Y4SI%T7/:)+CVRAJ1. 9';Y&6?UCY']VHXS]CD
M2>QL"A/WHVG&Q,*)>-"A$!$V<H@A1\@L>KKT.+>'TSK'Z=5PGL')D]C9%";N
M!=148<[S5">#6K&+N3M&IA 3,F.0J3#1>1CP";T:SC,Z>0HSFTC![%\W:X6I
M9;,:DK6>2#6VYGK$^IH7G,PL"]YVX?)?J%+_M"3B:3!POG"_*9N5UKB@/!CA
MZTL4*8N0R4_0UBIA/ 9O1=. ;R-;=2*T#5JI?XSHF\#Y,W0$CD:C1DB<G)OZ
M6$8VK BU_5C2*F;FIJOE^ NALP]*GB_C["^RV4W,OR_392 ;*W],"V+WHBS2
M[R1!VM%G8EN=U+=>U*K#</DC>5:7JZ_U-]L!?D0Q78*W1!MDFA<#U@8ZZ:@]
M.*,%F5%12<X9CZ6K33K0EN8V%*;&Y7SR;$)_#EC<':WBD9<,T>@ZQS<(B#IH
M0*QY;XQKF?A4.O=_.DX,:CC/A)(F3L@A*9W:#@CKZ?)B#G0*Y&_GZ""@29!3
M$J@\\TI/UMVM#P%S6R=S >Y58V5PZ9]5TXGT&?/U):[*WY?K';G_!_,A(P9K
M-7'<:N,UF#B!ZBF&\Q9GBZ6S+PLG?-L2P?%0ITW[:'B(S(N_UG!>%9.VA8XQ
MYCI&4;, P:*N*7)*%IUL2).U\_FKMY4X!ERCM94X1N!-F S](S].)FNM)BHS
M)S/-(X>H.-EJ@4L9G=?.3&9#CQMK;MEXZ &[ 6/-QV#@?.%^X[)C)E:2.99]
MJ-._3:UZB!IT)B[$*'2)KFG GW$T[WBT#1MK/D+T#03\*@V_X=7[K[@FP2X_
M5?+>AO6Z-C#_=UC?/K4:%96LS74#JU/3/"NUQUV (F1(08J<1->ZR<Z+GB7\
M^L!@-;Y,&H#:,+'()),SR0<@ZCT=;^,@UGHB&:Q5*1@?.J=6_T]L^2283B_/
MWB#^ANNX&@3&3[5>W%/""U=H>(*$A;P*%!&B- :RD)&3R65941V1^?PJ<P=N
MYP';0%R?70E^6*_H7%Q]_W 9Z##\]_5B>RJ(8^^65WAYB>GJ.ES>_*/?\7*;
M]/28XS>T1\?JC#JRY1W6$GQ?2_"9@YRET\*5VDNL(^*&W=G</5+F0>F,TIT=
MV1\_DVC>;3;7^':UN>6EE4P70<H]HZIOWMQ"],Y"<ES)I$QALFN-PY,+S-U[
M91Z<G<[KV>&RX\G;\'5!!L*A?4NV[TU9!_H46"&[5BA?9S4;")HL!!=B$MPX
M@[Y[(D&7%>=NWS*GRS&H-)H(X0SXWJ;)Q."1^(J:;9/7/$07.*20>20];;F=
M+/5JXC2 ]O-G3XMISH22-DX(YNMTM2 F/F6(//\L_&YS_V'8:)&X):8;5]O$
M!5()2+\M63*32Y*&3?=T-0!!<\>=Y@+DXY,Q-3J:3QO8WY%W$NJ7#_#$9X9]
MZ']MGR>^X-]!Y"-M$ZN;\[Z\_1R6GW#S;EE=GZOOMZ^M(97$(D.HN8*@@I*[
MKL.IMI!T.J,L<BKU\/IVA[4ZWL?_(K=O\0TW'U:7B[38'E=R >GX[&:]_!J6
MX=-B^6DOL)_^_$K.8UWB^P6=#*>4RB 9>7U*>;+GK">#/EA54'BNW62/2 /1
M-+=F'1BM+]L24\G^#)7FUFP;2G7N/S:V GUJSU.J4:FCX9HQ",40,+=5BB(F
MD.3U!^^Y>M13YAS5Z&'Z#BVPD\3;%5D@2UIR)X@_B/4_T/_PKXN<$GF>*@''
M.GK.) G!Q0!9>E<?>[FUQP\@>G79,]!DQP#F83Q@+/8/^'XSG:XZ)>_S^:^-
MK:W&R-L\"GV%4"!B1+"I5OOIFJ"<>)TQP&**D3.=ROFKJ[LUWH9-??BL/]5/
M?PN7];!<:(9(M[4 P>ND/HX&G"O5G, B,1O'PV1L>'J+9Z#)CL'28YML ,DT
M$:O9,>5"Y%PR)X,P%U/;)28#7C$.3CF,+CNI#P?NC8>HW9;FCB*.CJ >G)_]
MA67/@.NKSZMUS>R_L$D;$Y4!FY&!BLF"E\J#)ZS;E#5/LFMZPN&WYTY*& D
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M7,1L'!=: 681Z&S4ND+RT0"CCLR1;8SF %'CQ?YZ4=!H5*0GD!X]7(XOU2;
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M:6]N,C R,"YH=&U02P$"% ,4    " !Z>&52==A-0IH$  "4$P  '0
M        @ $_$   97@Q,S%C96]C97)T:69I8V%T:6]N,C R,"YH=&U02P$"
M% ,4    " !Z>&52K0"N>84$   I$@  '0              @ $4%0  97@Q
M,S)C9F]C97)T:69I8V%T:6]N,C R,"YH=&U02P$"% ,4    " !Z>&52S'9I
M*0VN  #*^ 4 $0              @ '4&0  97@Q-3$M,C R,&UD82YH=&U0
M2P$"% ,4    " !Z>&52%HF^AT(%  "P%@  %@              @ $0R
M97@Q-3)E>3(P,C!C;VYS96YT+FAT;5!+ 0(4 Q0    ( 'IX95(DO@0GP 0
M ,0+   >              "  8;-  !E>#(Q97AD97-C<FEP=&EO;F]F<V5C
M=7)I="YH=&U02P$"% ,4    " !Z>&52QY#Y$!B&  !RS0, '@
M    @ &"T@  97@T,3)E;7!L;WEM96YT86=R965M96YT=&@N:'1M4$L! A0#
M%     @ >GAE4H]H;BCN"0  Y34  !X              ( !UE@! &5X-#$S
M;6%T=&-O9F9E>6%M96YD;65N="UE+FAT;5!+ 0(4 Q0    ( 'IX95+["<)
M&PH  & W   >              "  0!C 0!E>#0Q-&MI<FML;V]K86UE;F1M
M96YT+65M<"YH=&U02P$"% ,4    " !Z>&52QEKAHT(*  !6.   '@
M        @ %7;0$ 97@T,35A;&QI<V]N:&%G97)M86YA;65N9&TN:'1M4$L!
M A0#%     @ >GAE4KOJ-\MF"@  G30  !X              ( !U7<! &5X
M-#$V86YD<F5W9&5G=71T861A=7)O86UE+FAT;5!+ 0(4 Q0    ( 'IX95*A
MTWJ'3PH  +PT   >              "  7>" 0!E>#0Q-W1H;VUA<VAE:6YE
M;6%N86UE;F1M92YH=&U02P$"% ,4    " !Z>&52'J8$<^H"  "H#0  &
M            @ $"C0$ 97@X,'-U8G-I9&EA<FEE<S(P,C N:'1M4$L! A0#
M%     @ >GAE4BT24VTGE0, ;Y@C !(              ( !(I ! &]N8WEF
M+3(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( 'IX95+W(Z 3T!H  )<Q 0 2
M          "  7DE!0!O;F-Y9BTR,#(P,3(S,2YX<V102P$"% ,4    " !Z
M>&52T\HA\50;  #D(P$ %@              @ %Y0 4 ;VYC>68M,C R,#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( 'IX95)696&Q"VD  /5Q!  6
M      "  0%<!0!O;F-Y9BTR,#(P,3(S,5]D968N>&UL4$L! A0#%     @
M>GAE4K*T;7:G00( AD(" !4              ( !0,4% &]N8WEF+3(P,C Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( 'IX95))YD4$O-0& #L'!P 5
M      "  1H'" !O;F-Y9BTR,#(P,3(S,5]G,BYJ<&=02P$"% ,4    " !Z
M>&52V5W"2SEM  #U=   %0              @ $)W X ;VYC>68M,C R,#$R
M,S%?9S,N:G!G4$L! A0#%     @ >GAE4F>9/VG-X   'ZH) !8
M     ( !=4D/ &]N8WEF+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !Z
M>&52#A)2-@B6  #DY 8 %@              @ %V*A  ;VYC>68M,C R,#$R
@,S%?<')E+GAM;%!+!08     %P 7 &(&  "RP!     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
